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Preface 
Cardiovascular disease in general and atherosclerosis in particular have been a topic of
great interest for decades. During the later half of the past century, we noted great 
advances in defining steps involved in the biosynthesis of cholesterol to the discovery 
of lipoproteins. The latter led to the identification of key cell types which are involved
in the uptake of the lipoproteins and specific cell membrane receptors that determine 
their entry. The lipid clinics played a major role in identifying the risk factors,
particularly in identifying high plasma cholesterol and low HDL cholesterol, in the 
etiology of the disease. 
On the one hand, drugs such as statins, life style modulation in the form of reduced fat 
intake, decreased smoking, and increased physical activity, continue to show marked
impact on the incidence of cardiovascular diseases. While on the other hand, the
emerging understanding of the roles of chronic inflammation, diet, increases in the
incidence of diabetes, and the environment, are factors that we need to be concerned 
about in the future.  
Although prevention is always better than cure, the beneficial roles of HDL are still 
only partly uncovered. In addition to promoting reverse cholesterol transport, it 
appears to influence inflammatory and oxidative pathways. The latter poses 
paradoxical and conflicting implications. While most non-clinical studies seem to 
stress its importance, the use of antioxidants in human clinical trials has not been 
encouraging to propose antioxidants as a therapeutic means. Caution should be
exercised in making judgments as inflammatory and oxidative stress seem to go hand 
in hand. 
This monograph will bring out the state-of-the-art advances in the dynamics of 
cholesterol transport and will address several important issues that pertain to 
oxidative stress and inflammation. The book is divided into three major sections; the
first section deals with the pathophysiology of atherosclerosis with emphasis on 
epigenetics and nutrigenomics. The second section discusses cholesterol influx-efflux
pathways and inflammation and immune mechanisms of atherosclerosis. The last
section discusses oxidative stress and vascular mechanisms involved in cardiovascular 
disease development. The book will offer insights into the roles of specific cytokines,
inflammation, and oxidative stress in atherosclerosis and is intended for new
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researchers who are curious about atherosclerosis as well as for established senior 
researchers and clinicians who would be interested in novel findings that may link 
various aspects of the disease.  
 
Dr. Sampath Parthasarathy 
Florida Hospital Endowed Chair in  






researchers who are curious about atherosclerosis as well as for established senior 
researchers and clinicians who would be interested in novel findings that may link 
various aspects of the disease.  
 
Dr. Sampath Parthasarathy 
Florida Hospital Endowed Chair in  





Atherosclerosis-Models and Concepts 
Part 1 
Atherosclerosis-Models and Concepts 
 1 
Mouse Models of Experimental  
Atherosclerosis as a Tool for Checking a 
Putative Anti-Atherogenic Action of Drugs 
Jacek Jawien 
Jagiellonian University School of Medicine, Chair of Pharmacology, Krakow,  
Poland 
1. Introduction 
Studies concerning the pathogenesis of atherosclerosis entered a new phase at the turn of 
the 21st century. The 20th century was the age of cholesterol and lipoproteins, which has 
been concluded in a number of clinical studies carried out on a large scale, and they 
demonstrated unequivocally that normalization of hypercholesterolemia significantly 
decreased the incidence and mortality of coronary artery disease (Prevention of 
cardiovascular events and death with pravastatin in patients with coronary heart disease 
and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin 
in Ischaemic Disease (LIPID) Study Group. 1998; Scandinavian Simvastatin Survival Study 
Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart 
disease: The Scandinavian Simvastatin Survival Study (4S). 1994)  Nearly to the end of the 
nineties, atherosclerosis had been assumed to develop as the so-called chronic response to 
injury (response-to-injury hypothesis) that resulted in the loss of endothelial cells which line 
the inner side of the vessels (Ross & Glomset, 1976).  
Atherosclerosis had been considered first of all a degenerative disease (Ross et al., 1977; 
Ross et al. 1984; Ross, 1986). However, approximately 20 years ago, the trials started to focus 
to a large extent on another pathogenetic mechanism of atherosclerosis, not considered so 
far – the inflammatory process. 
2. The first indications  
In 1986, with the use of monoclonal antibodies, the small cells with round nucleus present in 
the atheromatous plaque, known before as “small monocytes”, were demonstrated to be T 
lymphocytes (Jonasson et al., 1986). Several years later it was shown that these lymphocytes 
“recognize” as antigens the oxidized molecules of low-density lipoproteins (LDL) – oxLDL 
(Stemme et al., 1995). Moreover, the correlation between atherosclerosis and the presence of 
at least two types of infectious microorganisms: Chlamydia pneumoniae and Herpes simplex 
virus were observed (Thom et al., 1991; Hendrix et al., 1990). It raised the question if the 
inflammatory process participate in atherosclerosis. Speculations of this kind were initially 
received with great scepticism because there was no spectacular and unequivocal evidence 
of a significant role of inflammation in atherosclerosis. 
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This evidence was delivered by a new technique – gene targeting, for the invention of which 
Mario R. Capecchi (Italy), Martin J. Evans (United Kingdom) and Oliver Smithies (USA) 
received the Nobel Prize in Physiology or Medicine in 2007.  
3. Additional evidence for the presence of inflammation in atherosclerosis 
The newest model of atherosclerosis (described precisely at the end of the paper) enabled 
the investigators to create apoE-knockout mice, an ideal animal model to test the influence 
of singular proteins participating in the inflammatory response on the development of 
atherosclerosis. These studies showed, for example, that the absence of only one cytokine – 
interferon γ (IFN-γ), reduced atherosclerosis even by 60% (Gupta et al., 1997). 
The overexpression of adhesive molecules (vascular adhesion molecule 1 and intercellular 
adhesion molecule 1) at sites with atheromatous changes was also observed in 
apoE‑knockout mice (Nakashima et al., 1998). Monocyte chemotactic protein was shown to 
play an important part in the progression of atheromatous lesions (Aiello et al., 1999; Ni et 
al., 2001). Moreover, it was observed that interleukin-18 knockout decreased atherosclerosis 
by 35% (Elhage et al., 2003; Tenger et al., 2005). 
Inhibition of CD40 signaling reduced atherosclerosis (Mach et al., 1998). This was explained 
by the fact that ligation of CD40 molecule (tumor necrosis factor α [TNF-α] receptor 
superfamily member) – found in the atheromatous plaque, on endothelial cells, vascular 
smooth muscle cells, antigen-presenting cells, platelets – with CD40L activates a number of 
transcription factors: NF-κB, AP-1, STAT-1 or Egr-1. Therefore, it influences, for example, 
the endothelial cell, which, in consequence, acquires proinflammatory and 
proatherosclerotic phenotype leading to the expression of adhesive molecules and tissue 
factor on its surface. It creates new possibilities of therapeutic approach, consisting in 
inhibition of the CD40–CD40L pathway (Welt et al., 2004; Alber et al., 2006;  Tousoulis, et al. 
2007). In mice the effect of CD40 is also antagonized by transforming growth factor β 
(Robertson et al., 2003). 
Finally, in apoE-knockout mice with severe combined immunodeficiency (SCID) 
atherosclerosis was reduced by 70% in comparison to the control group, due to a 
significantly lower number of lymphocytes in mice with SCID. It was demonstrated that 
transfer of T cells to these mice aggravated atherosclerosis even by 164% (Zhou et al., 
2000). 
4. Atherosclerosis as an inflammatory process 
These and other facts made the investigators realize unequivocally that inflammation was 
essential for atherogenesis. Therefore, in 1999, just before his death, Russell Ross (the author 
of the previous theory of atherosclerosis as a chronic response to injury) officially 
proclaimed that atherosclerosis was an inflammatory disease (Ross, 1999). 
Whereas the deposition of atheromatous lipids and the accumulation of foam cells – 
macrophages filled with such lipids – in intima is the main morphological hallmark of 
atherosclerosis, the more subtle changes in the environment of the arterial wall, stimulated 
by the influx of inflammatory cells and local release of cytokines and other inflammatory 
mediators are currently recognized as the crucial causative factors of atherogenesis (Glass & 
Witztum, 2001; Binder et al., 2002). 
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Inflammation occurs in response to a factor that destabilizes the local homeostasis. The 
factors that cause Toll-like receptor dependent macrophage activation in the arterial wall 
include oxLDL, heat shock protein 60 (HSP60) and bacterial toxins (Hansson, 2005). 
The first stage of atherogenesis consists in endothelial dysfunction (Ross, 1999). It 
involves first of all the regions of arterial bifurcations where the blood flow is not 
laminar. Hence, these localizations are prone to develop atherosclerosis. In such places 
LDL is stored in the subendothelial space. Low‑density lipoprotein accumulation is 
increased if serum LDL level is elevated. Low‑density lipoprotein is transported by 
passive diffusion and its accumulation in the vascular wall seems to depend on the 
interaction between apolipoprotein B of the LDL molecule and proteoglycans of the 
matrix (Boren et al., 1998). 
There is evidence that unchanged LDL are “collected” by the macrophages too slowly to 
activate their transformation into foam cells. Therefore, it has been suggested that LDL 
molecule is “modified” in the vascular wall. The most significant modification is lipid 
oxidation, resulting in the formation of so-called “minimally oxidized” LDL (Gaut & 
Heinecke, 2001). The generation of these “aliens” for the body molecules leads to the 
development of inflammatory response, with participation of monocytes and lymphocytes 
in the first place (Fredrikson et al., 2003; Pentikäinen et al., 2000). The inflammation is 
triggered by accumulation of the minimally oxidized LDLs in the subendothelial space, thus 
stimulating the endothelial cells to produce a number of proinflammatory molecules (Lusis, 
2000). 
Before the “minimally oxidized” LDL have been phagocytised by the macrophages, they 
have to be modified into “highly oxidized” LDL. The scavenger receptors are responsible for 
the rapid uptake of the modified LDL (Suzuki et al., 1997).  
During the following phase macrophages “present the antigen” to T lymphocytes. This 
antigen may be a fragment of oxidized LDL “digested” by the macrophages, HSP60, β2-
glycoprotein I or the fragments of bacterial antigens (Hansson, 2001). The interaction 
between the immunological cells requires the presence of CD40 receptor on the surface of 
macrophages and its ligand CD40L on the surface of T lymphocytes (Schonbeck et al., 2000; 
Phipps et al., 2000). It is currently believed that the immunological response of Th1 type and 
its mediators: IFN-γ, TNF-α, interleukin-1, interleukin-12 as well as interleukin-18 accelerate 
atherosclerosis, whereas the response of Treg type and its mediators: interleukin-10 and 
TGF-β inhibit the development of atherosclerosis (Daugherty & Rateri, 2002; Laurat et al., 
2001; Pinderski et al., 2002). Therefore, there has arisen an idea of vaccination as a future 
treatment against atherogenesis (Hansson, 2002). 
The next phase of atherogenesis is the development of fibrous atheroma. The deposition of 
extracellular cholesterol and its esters is then intensified as well as the migration of smooth 
muscle cells from media to intima, proliferation of these cells and finally production of the 
extracellular matrix by the smooth muscles cells. 
A stable atheromatous plaque is most commonly covered with a fairly thick fibrous layer, 
protecting the lipid nucleus from contact with the blood. In an unstable plaque there is a big 
lipid nucleus with a fairly thin fibrous layer. In atheromatous plaque, changed as described 
above, the proinflammatory factors produced by T lymphocytes (such as IFN-γ) seem to 
play a crucial role. They decrease production of the extracellular matrix by smooth muscles 
and at the same time increase production of the metalloproteinases by macrophages 
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Inflammation occurs in response to a factor that destabilizes the local homeostasis. The 
factors that cause Toll-like receptor dependent macrophage activation in the arterial wall 
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and at the same time increase production of the metalloproteinases by macrophages 





5. Is atherosclerosis an autoimmunological disease? 
The role of HSP60 as an initiator of atherogenesis is currently intensively investigated. Its 
“molecular mimicry” with HSP of Chlamydia has been observed (Wick et al., 1995). 
Moreover, the anti-oxLDL antibodies resemble antiphospholipid antibodies, therefore the 
concept of atherosclerosis as an autoimmunological disease has been established (Hansson, 
2001;  Kobayashi K et al., 2007; Wick G et al., 2001). The investigators also emphasize a high 
pathogenetic similarity of atherosclerosis to rheumatoid arthritis ( Shoenfeld et al., 2001). 
6. The new experimental model of atherosclerosis 
Since 1992 the mouse has become an excellent object for the studies on atherosclerosis, 
replacing the previous animal models. (Paigen et al., 1994; Moghadasian, 2002; Jawien et al., 
2004). 
Then, the first line of mice with a switched off gene for apolipoprotein E (apoE-knockout) 
was developed almost contemporaneously in two laboratories in the United States. 
(Piedrahita  et al., 1992; Plump et al., 1992). 
These mice were soon described as “reliable and useful, the best animal model of 
atherosclerosis in present times” (Meir & Leitersdorf, 2004). 
During the generation of apoE-knockout mice (known also as apoE null or apoE deficient 
mice) the normal gene coding apolipoprotein E is replaced by a mutated gene which does 
not produce this molecule. Such mice are called apoE knockout because they have a 
knockout, switched-off, null or inactivated gene coding apolipoprotein E. For clarity, in the 
following sections of this paper we will use the most popular name: apoE-knockout mice. 
The year 1992, in which apoE-knockout mice were invented by a homological exchange of 
genes, was a real breakthrough year in the studies on the pathogenesis of atherosclerosis 
(Savla, 2002). 
The apoE-knockout mice were formed by homological recombination of embryonic stem 
cells. The changed cells were implanted into the blastocyst of a mouse of C57BL/6J strain 
which were subsequently implanted into the uterus. The offspring was a “chimera” that was 
next crossbred with a mouse of C57BL/6J strain (wild type), which led to the formation of 
apoE-knockout, homozygous mice in the second generation (Capecchi, 2001). 
The inactivation of the gene coding apoE resulted in the formation of mice with a phenotype 
with a complete suppression of apoE, but with preservation of fertility and vitality (Breslow, 
1996). 
The apoE-knockout mice, in contrast to all of other animal models, develop atherosclerosis 
spontaneously, without high-cholesterol diet (Hansson et al., 2002). 
The generation of such a model changed the nature of the studies on the pathogenesis of 
atherosclerosis and enabled the investigators to formulate a new definition of 
atherosclerosis as a chronic inflammation (Savla, 2002). 
In a number of reports on atherogenesis published so far there has been a tendency to 
consider this process as the effect of dyslipidemia or inflammation alone. It is an erroneous 
dichotomy. It should be emphasized that atherosclerosis results from both lipid disorders 
and enhanced inflammation. Therefore, atherosclerosis is a chronic inflammatory disease, in 
most cases initiated and aggravated by hypercholesterolemia. In the review published in 
Nature Medicine hypercholesterolemia and inflammation were described as “partners in 
crime” (Steinberg, 2002). 
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The inflammatory concept of atherosclerosis has been formulated just in the recent years. 
However, it is currently an unquestionable achievement of science which also have specific 
therapeutic implications (Fan & Watanabe, 2003; Libby, 2000; Libby, 2002; Libby P et al., 
2002; Jawien et al., 2006; Alpert & Thygesen, 2007). 
7. Animal models of atherosclerosis 
Atherosclerotic cardiovascular disease, the major cause of death in Western society, results 
from complex interactions among multiple genetic and environmental factors.  
Numerous animal species have been used to study the pathogenesis and potential treatment 
of the lesions of atherosclerosis. The first evidence of experimental atherosclerosis came into 
view as early as in 1908 when Ignatowski (Ignatowski, 1908) reported thickening of the 
intima with formation of large clear cells in the aorta of rabbits fed with a diet rich in animal 
proteins (meat, milk, eggs). The most useful animal models have thus far been restricted to 
relatively large animals, such as nonhuman primates, swine, and rabbits. Hamsters and 
pigeons have been used occasionally but present problems peculiar to their species. Rats 
and dogs are not good models for atherosclerosis because they do not develop spontaneous 
lesions and require heavy modifications of diet to produce vascular lesion. Despite the fact 
that rabbits do not develop spontaneous atherosclerosis, they are useful because they are 
highly responsive to cholesterol manipulation and develop lesions in a fairly short time 
(Drobnik et al., 2000). 
The lesions are much more fatty and macrophage-rich (inflammatory) than the human 
lesions and plasma cholesterol levels are extraordinarily high (very dissimilar to humans). 
Pigs and monkeys are better suited to model human atherosclerotic lesions. However, 
nowadays monkeys are not widely used due to obvious species - specific concerns (risk of 
extinction) and cost. The pig is a very good model - when fed with cholesterol, they reach 
plasma levels and atherosclerotic lesions that are quite similar to those seen in humans. 
Problems with the pig model are costs, the difficulties involved in maintaining the colonies 
and in their handling.  
What has been traditionally lacking was a small, genetically reproducible, murine model of 
atherosclerosis. Such a model could help to overcome the many problems and deficiencies 
of larger animals and, in particular, would permit studies of possible therapies that require 
relatively large numbers of animals.  
Until 1992, the majority of atherosclerotic research focused on mechanisms in rabbits, with a 
lesser number of studies in pigs and nonhuman primates. These large animal models have 
provided invaluable insight. The use of pig models of the disease initially revealed that 
monocyte infiltration was one of the primary cellular events in the atherogenic process 
(Gerrity, 1981).  
Studies in monkeys and rabbits have been pivotal in defining the cellular events in the 
initiation and development of lesions (Faggiotto & Ross, 1984; Rosenfeld et al., 1987). In 
recent years, there has been an explosion in the number of in vivo studies that is largely 
attributable to the use of mouse models to study atherogenic mechanisms. 
8. Mouse as a model of atherosclerosis 
Mice are highly resistant to atherosclerosis. The only exception in mice is the C57BL/6 
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lesions in the C57BL/6 differ from the human condition in the histologic nature and location 
and are possibly attributed to a chronic inflammatory state rather than a genetic 
predisposition. 
The earliest mouse model of atherosclerosis was the diet - induced model that was first 
characterized during the 1960s in Wissler's laboratory. Special diet contained 30% fat, 5% 
cholesterol, and 2% cholic acid led to atherosclerosis in C57BL/6 mice. However, this was a 
very toxic diet on which the mice lost weight and often got sick with morbid respiratory 
infections. Paigen et al. modified this diet by blending it one part to three parts with a 10% 
fat diet to yield what is called the "Paigen diet" which consists of 15% fat, 1.25% cholesterol, 
and 0.5% cholic acid (Paigen et al., 1985). 
Although there were many uses of this model, there were also many disadvantages. The 
lesions are very small in mice at 4 to 5 months of age, in order of 200 to 1 000 square microns 
in the aortic root. The lesions are largely confined to the aortic root, and they usually do not 
develop beyond the early foam-cell, fatty-streak stage. The diet is also unphysiological with 
regard to its extremely high cholesterol content, 1.25%, and the presence of cholic acid. In 
addition, Lusis et al. have shown that this diet is in itself inflammatory, as leads to the 
induction of hepatic NF-kB activation and the expression of acute phase reactants, such as 
serum amyloid A (Liao et al., 1993). 
Paigen et al. colleagues also developed assays that are widely used to quantify 
atherosclerosis in the mouse model. The most standard assay is the measurement of the 
cross-sectional lesion area in the aortic root (Paigen et al., 1987). 
In this assay, freshly perfused and isolated hearts are fixed in formalin, embedded in gelatin, 
frozen, and cut into thin sections at anatomically defined sites in the aortic sinus and valve 
region. These sections are stained for lipids, and the lesion area is measured microscopically. 
Although this model has been widely employed and is of significant use in the study of 
atherosclerosis, the pathology of the lesions are not ideally suited as a model for human 
atherosclerosis. This shortcoming led many investigators to downplay the role of the mouse 
as a good model of atherosclerosis. Lesion formation in the diet - induced model is largely 
limited to the aortic root after feeding the Paigen - diet for periods of 14 weeks to 9 months. 
The lesions are quite small, only several hundred to a few thousand square micrometers, 
and they consist almost entirely of macrophage foam cells with little evidence for smooth 
muscle cell involvement. Thus, this model is largely limited to the fatty streak stage and 
does not progress to resemble human intermediate lesions.  
For many years the mouse was not used as an experimental model for atherosclerosis 
research because of the beliefs that mice could not survive on high - fat atherogenic diets, 
that lesions were not reproducible, that most mice did not get lesions, and that lesion 
pathology did not resemble atherosclerosis in humans. However, the use of lower - fat diets 
solved the survival problem; the use of inbred strains rather than random - bred mice solved 
the reproducibility problem; the use of susceptible strains resulted in most mice getting 
lesions; and longer experimental times showed that lesions with fibrous caps were 
produced. 
The following is a list of questions that can be used to judge the usefulness of animal models 
of atherosclerosis: 1) What is the nature of the experimental lesions and their similarity to 
human lesions; 2) is the plasma lipoprotein profile and metabolism similar to metabolism in 
humans; 3) what is the time frame necessary for lesions to form, and how long does it take 
to breed the animals for the studies; 4) what is the cost of acquiring and maintaining the 
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animals; 5) what is the ability to perform in vivo manipulations and imaging; and 6) what is 
the ability of the model to take advantage of classical and molecular genetic approaches ? 
The mouse as a model meets many of these criteria, but first it is important to acknowledge 
many important differences between mice and humans. The average lifespan of a mouse is 
about 2 years, compared to about 75 years in humans. Mice weigh much less, about 30 
grams for the adult. The lipid profile in the mouse is very different from that in humans, 
who carry about 75% of their plasma cholesterol on LDL. Mice carry most of their 
cholesterol on high-density lipoprotein (HDL), which we know in humans is protective 
against atherosclerosis. Thus, mice fed their normal low-fat chow diet do not get 
atherosclerosis, while it is a common disease in humans. One difference, which is an 
advantage of all animal models, is the ability to control the environment and diet in mouse 
studies, which is impossible for long-term human studies. Human genetic studies are 
limited in range to various types of association studies. With mice, on the other hand, many 
additional kinds of genetic experiments are possible, including breeding and genetic 
engineering. 
There are many advantages of using mice for experimental atherosclerosis research, 
including their relative ease and thriftiness to acquire and maintain. Their generation time is 
short, at about 9 weeks, 3 weeks for gestation and about 6 weeks until sexual maturity. It is 
easy to breed very large cohorts for experimental studies, and mice can develop 
atherosclerosis in a very short timeframe, as discussed below. Classical genetics in the 
mouse is very well established and is aided immensely by the availability of hundreds of 
inbred strains. Moreover, in 2002, The Mouse Genome Sequencing Consortium published 
the culmination of international efforts - a high quality sequence and analysis of the genome 
of the C57BL/6J mouse strain (Waterson et al., 2002). 
With the coming of age of molecular genetics, it is now possible to add exogenous 
transgenes into mice, which can also be done in many other species. However, uniquely in 
mice, it is also possible to knock out or replace endogenous genes; this is one of the main 
advantages of working in the mouse model. The major disadvantage of the mouse model is 
their small size, which makes it difficult but not impossible to perform surgical 
manipulations and in vivo imaging. But there have been recent advances in these techniques 
that have overcome many of the size limitations, such as the ability to perform imaging of 
abdominal atherosclerotic lesions in living mice, cardiac catheterization to determine 
cardiovascular function in free-ranging mice, and surgical ligature of coronary arteries 
giving rise to myocardial ischemia. 
9. Apolipoprotein E–knockout mice: A breakthrough 
It has been a longstanding goal of many investigators around the world to create better 
mouse models for lipoprotein disorders and atherosclerosis and to identify genes that may 
modify atherogenesis and lesion progression. In 1992 apoE - deficient mice were generated 
by inactivating the apoE gene by targeting (Piedrahita et al., 1992). 
They inactivated the apoE gene in mouse embryonic stem (ES) cells by homologous 
recombination. Two targeting plasmids were used, pJPB63 and pNMC109, both containing a 
neomycin-resistance gene that replaced a part of the apoE gene and disrupted its stucture. ES 
cell colonies targeted after electroporation with plasmids were identified by the polymerase 
chain reaction (PCR) followed by genomic Southern analysis. Chimeric mice were generated 
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disrupted apoE gene to their progeny. Mice homozygous for the disrupted gene were 
produced from the heterozygotes. The facts that homozygous animals have been born at the 
expected frequency and that they appeared to be healthy were important. They demonstrated 
that lack of apoE was compatible with normal development, and they also provided another 
tool for studies of the phenotypic consequences of apoE deficiency. At the same time another 
group created also apoE - deficient mice (Plump et al., 1992). 
Mice homozygous or heterozygous for the disrupted apoE gene appeared healthy. No 
difference in their body weights compared to normal mice was observed. However, 
significant phenotypic differences between normal animals and the homozygous mutants 
were observed in their lipid and lipoprotein profiles. The apoE-knockout mice had 
markedly increased total plasma cholesterol levels, which were five times those of normal 
litter mates. These levels were unaffected by the age or sex of the animals. Although the 
total plasma cholesterol levels were greatly elevated in the mutants, the high density 
lipoprotein (HDL) cholesterol levels were only 45% the normal level. The triglyceride levels 
were 68% higher than those of normal animals. (These apoE-deficient mice have had a 
dramatic shift in plasma lipoproteins from HDL, the major lipoprotein in control mice, to 
cholesterol - enriched remnants of chylomicrons and VLDL. 
Mice naturally have high levels of HDL and low levels of LDL, in contrast to humans who 
are high in LDL and low in HDL. In addition, mice apparently lack the cholesteryl ester 
transfer protein, en enzyme that transfers cholesterol ester from HDL to VLDL and LDL. 
Despite these differences, apoE - deficient mice have phenotypes remarkably similar to 
those of apoE - deficient humans. 
A chronological analysis of atherosclerosis in the apoE - deficient mouse has shown that the 
sequential events involved in lesion formation in this model are strikingly similar to those in 
well - established larger animal models of atherosclerosis and in humans (Nakashima et al., 
1994). Animals as young as 5-6 weeks of age have monocytic adhesions to the endothelial 
surface of the aorta that can be appreciated readily with electron microscopy (EM). EM also 
has demonstrated transendothelial migration of blood monocytes in similarly aged mice. By 
6-10 weeks of age, most apoE - deficient mice have developed fatty - streak lesions 
comprised primarily of foam cells with migrating smooth muscle cells. These fatty - streak 
lesions rapidly progress to advanced lesions, which are heterogeneous but are typically 
comprised of a necrotic core surrounded by proliferating smooth muscle cells and varying 
amounts of extracellular matrix, including collagen and elastin.  
These lesions have well - formed fibrous caps made up of smooth muscle cells and 
extracellular matrix that often have groups of foam cells at their shoulders. It is not 
uncommon for the inflammatory lesion to erode deep into the medial wall of the aorta, and 
some of these animals develop aortic aneurysms. Many of the lesions found in older mice 
develop calcified foci (Reddick et al., 1994). 
Other characteristics of the lesions in the apoE - deficient mouse, such as indications of 
oxidative change, merit attention as well (Palinski et al., 1994). 
The atherosclerotic lesions in this mouse contain oxidation - specific epitopes. In young 
lesions these epitopes are predominantly localized in macrophage - rich areas, whereas in 
advanced lesions they are localized in necrotic regions. In addition, high titers of antibodies 
against the oxidized epitopes are present in the plasma of the apoE - deficient mice. 
The complexity of lesions in the apoE - deficient mouse, together with the benefits of using 
the mouse as a model of human disease, makes it a desirable system in which to study both 
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environmental and genetic determinants of atherosclerosis. Initial studies examined the 
effects of grossly different diets on susceptibility to atherosclerosis in this animal. These 
studies confirmed the validity of this mouse as a model of human atherosclerotic disease 
and laid the groundwork for future dietary studies. 
Hayek et al. developed a more physiological than Paigen diet - "western-type" diet for 
mouse studies, which is similar in composition to an average American diet of several years 
ago, consisting of 21% fat by weight, 0.15% cholesterol, and no cholic acid. When fed this 
diet, wild-type mice have a two-fold elevation in plasma cholesterol, while apoE-deficient 
mice have over a three-fold elevation, to about 2 000 mg/dl, again, mostly in βVLDL, but 
there is also an increase in LDL (Plump et al., 1992).  
The post-prandial clearance of intestinally derived lipoproteins is dramatically impaired in 
apoE - deficient mice. The apoE - deficient mouse responds appropriately to a human - like 
western - type diet (Nakashima et al., 1994). On this diet, lesion formation is greatly 
accelerated and lesion size is increased. In 10-week old animals fed this diet for only 5 
weeks, lesions are 3-4 times the size of those observed in mice fed a low - fat diet. In 
addition, monocytic adhesions and advanced lesions develop at a significantly earlier age. 
The results of this dietary challenge demonstrate that the mouse model responds in an 
appropriate manner, i.e. increased fat leads to increased plasma cholesterol, which in turn 
leads to increased atherosclerosis. Moreover, the data suggest that in addition to its 
histological similarity to humans, the mouse model exhibits a response to environmental 
cues resembling that of humans. 
Lesions in the apoE-deficient mouse, as in humans, tend to develop at vascular branch 
points and progress from foam cell stage to the fibroproliferative stage with well-defined 
fibrous caps and necrotic lipid cores, although plaque rupture has not been observed in 
apoE - deficient mice or in any other mouse model. Progression of lesions appears to occur 
at a faster rate than in humans atherosclerosis; the rapidity of lesion progression can be 
advantageous in many experimental situations. 
The genetic background has a major effect on atherosclerosis susceptibility in strains of apoE 
- deficient mice. For example, lesions from 16-week chow diet C57BL/6 apoE-KO were 
relatively larger than from FVB apoE-KO mice and in contrast to FVB mice there was 
evidence of early development of fibrous caps in these mice. In older mice, fibrous plaques 
from C57BL/6 apoE-KO mice were larger in size and had larger necrotic cores compared 
with FVB apoE-KO mice. Comparing humans and apoE - deficient mice, lesion progression 
and cell types are similar, as is the presence of oxidized lipoproteins. The major difference of 
this mouse model, as is the presence of oxidized lipoproteins. The major difference of this 
mouse model, as is the case for most of the other models of experimental atherosclerosis, is 
that plaque rupture is not observed, whereas plaque rupture is fairly common in humans 
and can lead to heart attacks. One potential reason for the lack of plaque rupture in mice is 
that the diameter of the aorta is less than 1 mm, which is even smaller than the diameter of 
the major coronary arteries in humans. As the vessel diameter decreases, the surface tension 
increases exponentially; thus, in the mouse there may be so much surface tension that 
plaque rupture would not be likely to occur. 
ApoE-knockout mice are considered to be one of the most relevant models for 
atherosclerosis since they are hypercholesterolemic and develop spontaneous arterial lesions 





disrupted apoE gene to their progeny. Mice homozygous for the disrupted gene were 
produced from the heterozygotes. The facts that homozygous animals have been born at the 
expected frequency and that they appeared to be healthy were important. They demonstrated 
that lack of apoE was compatible with normal development, and they also provided another 
tool for studies of the phenotypic consequences of apoE deficiency. At the same time another 
group created also apoE - deficient mice (Plump et al., 1992). 
Mice homozygous or heterozygous for the disrupted apoE gene appeared healthy. No 
difference in their body weights compared to normal mice was observed. However, 
significant phenotypic differences between normal animals and the homozygous mutants 
were observed in their lipid and lipoprotein profiles. The apoE-knockout mice had 
markedly increased total plasma cholesterol levels, which were five times those of normal 
litter mates. These levels were unaffected by the age or sex of the animals. Although the 
total plasma cholesterol levels were greatly elevated in the mutants, the high density 
lipoprotein (HDL) cholesterol levels were only 45% the normal level. The triglyceride levels 
were 68% higher than those of normal animals. (These apoE-deficient mice have had a 
dramatic shift in plasma lipoproteins from HDL, the major lipoprotein in control mice, to 
cholesterol - enriched remnants of chylomicrons and VLDL. 
Mice naturally have high levels of HDL and low levels of LDL, in contrast to humans who 
are high in LDL and low in HDL. In addition, mice apparently lack the cholesteryl ester 
transfer protein, en enzyme that transfers cholesterol ester from HDL to VLDL and LDL. 
Despite these differences, apoE - deficient mice have phenotypes remarkably similar to 
those of apoE - deficient humans. 
A chronological analysis of atherosclerosis in the apoE - deficient mouse has shown that the 
sequential events involved in lesion formation in this model are strikingly similar to those in 
well - established larger animal models of atherosclerosis and in humans (Nakashima et al., 
1994). Animals as young as 5-6 weeks of age have monocytic adhesions to the endothelial 
surface of the aorta that can be appreciated readily with electron microscopy (EM). EM also 
has demonstrated transendothelial migration of blood monocytes in similarly aged mice. By 
6-10 weeks of age, most apoE - deficient mice have developed fatty - streak lesions 
comprised primarily of foam cells with migrating smooth muscle cells. These fatty - streak 
lesions rapidly progress to advanced lesions, which are heterogeneous but are typically 
comprised of a necrotic core surrounded by proliferating smooth muscle cells and varying 
amounts of extracellular matrix, including collagen and elastin.  
These lesions have well - formed fibrous caps made up of smooth muscle cells and 
extracellular matrix that often have groups of foam cells at their shoulders. It is not 
uncommon for the inflammatory lesion to erode deep into the medial wall of the aorta, and 
some of these animals develop aortic aneurysms. Many of the lesions found in older mice 
develop calcified foci (Reddick et al., 1994). 
Other characteristics of the lesions in the apoE - deficient mouse, such as indications of 
oxidative change, merit attention as well (Palinski et al., 1994). 
The atherosclerotic lesions in this mouse contain oxidation - specific epitopes. In young 
lesions these epitopes are predominantly localized in macrophage - rich areas, whereas in 
advanced lesions they are localized in necrotic regions. In addition, high titers of antibodies 
against the oxidized epitopes are present in the plasma of the apoE - deficient mice. 
The complexity of lesions in the apoE - deficient mouse, together with the benefits of using 
the mouse as a model of human disease, makes it a desirable system in which to study both 
Mouse Models of Experimental Atherosclerosis as a  
Tool for Checking a Putative Anti-Atherogenic Action of Drugs 
 
11 
environmental and genetic determinants of atherosclerosis. Initial studies examined the 
effects of grossly different diets on susceptibility to atherosclerosis in this animal. These 
studies confirmed the validity of this mouse as a model of human atherosclerotic disease 
and laid the groundwork for future dietary studies. 
Hayek et al. developed a more physiological than Paigen diet - "western-type" diet for 
mouse studies, which is similar in composition to an average American diet of several years 
ago, consisting of 21% fat by weight, 0.15% cholesterol, and no cholic acid. When fed this 
diet, wild-type mice have a two-fold elevation in plasma cholesterol, while apoE-deficient 
mice have over a three-fold elevation, to about 2 000 mg/dl, again, mostly in βVLDL, but 
there is also an increase in LDL (Plump et al., 1992).  
The post-prandial clearance of intestinally derived lipoproteins is dramatically impaired in 
apoE - deficient mice. The apoE - deficient mouse responds appropriately to a human - like 
western - type diet (Nakashima et al., 1994). On this diet, lesion formation is greatly 
accelerated and lesion size is increased. In 10-week old animals fed this diet for only 5 
weeks, lesions are 3-4 times the size of those observed in mice fed a low - fat diet. In 
addition, monocytic adhesions and advanced lesions develop at a significantly earlier age. 
The results of this dietary challenge demonstrate that the mouse model responds in an 
appropriate manner, i.e. increased fat leads to increased plasma cholesterol, which in turn 
leads to increased atherosclerosis. Moreover, the data suggest that in addition to its 
histological similarity to humans, the mouse model exhibits a response to environmental 
cues resembling that of humans. 
Lesions in the apoE-deficient mouse, as in humans, tend to develop at vascular branch 
points and progress from foam cell stage to the fibroproliferative stage with well-defined 
fibrous caps and necrotic lipid cores, although plaque rupture has not been observed in 
apoE - deficient mice or in any other mouse model. Progression of lesions appears to occur 
at a faster rate than in humans atherosclerosis; the rapidity of lesion progression can be 
advantageous in many experimental situations. 
The genetic background has a major effect on atherosclerosis susceptibility in strains of apoE 
- deficient mice. For example, lesions from 16-week chow diet C57BL/6 apoE-KO were 
relatively larger than from FVB apoE-KO mice and in contrast to FVB mice there was 
evidence of early development of fibrous caps in these mice. In older mice, fibrous plaques 
from C57BL/6 apoE-KO mice were larger in size and had larger necrotic cores compared 
with FVB apoE-KO mice. Comparing humans and apoE - deficient mice, lesion progression 
and cell types are similar, as is the presence of oxidized lipoproteins. The major difference of 
this mouse model, as is the presence of oxidized lipoproteins. The major difference of this 
mouse model, as is the case for most of the other models of experimental atherosclerosis, is 
that plaque rupture is not observed, whereas plaque rupture is fairly common in humans 
and can lead to heart attacks. One potential reason for the lack of plaque rupture in mice is 
that the diameter of the aorta is less than 1 mm, which is even smaller than the diameter of 
the major coronary arteries in humans. As the vessel diameter decreases, the surface tension 
increases exponentially; thus, in the mouse there may be so much surface tension that 
plaque rupture would not be likely to occur. 
ApoE-knockout mice are considered to be one of the most relevant models for 
atherosclerosis since they are hypercholesterolemic and develop spontaneous arterial lesions 





Heterozygous apoE-deficient mice do not exhibit elevated plasma cholesterol levels on the 
chow or Western-type diet, suggesting that when mice are fed a physiological diet, a 50% 
decrease in apoE is not sufficient to influence fasting plasma lipids (Van Ree et al., 1994).  
The apoE-deficient mouse contained the entire spectrum of lesions observed during 
atherogenesis and was the first mouse model to develop lesions similar to those of humans. 
This model provided opportunity to study the pathogenesis and therapy of atherosclerosis 
in a small, genetically defined animal. 
In 1995 Kashyap et al. (Kashyap et al., 1995) described the successful correction of apoE 
deficiency in apoE-deficient mice by using an alternative approach involving systemic 
delivery to mouse liver of recombinant adenovirus vectors expressing human apoE. Thus, 
the single genetic lesion causing apoE absence and severe hypercholesterolemia is sufficient 
to convert the mouse from a species that is highly resistant to one that is highly susceptible 
to atherosclerosis (Breslow, 1994). 
The method of measure atherosclerosis by using the aortic root atherosclerosis assay was 
originally developed by Paigen et al. (Paigen et al., 1987). The aortic root cross sectioning 
assay is widely used in murine studies of atherosclerosis, allows for coincident inspection of 
lesion histology, and is amenable in studies using large numbers of mice. Alternative 
measures of atherosclerosis, such as the en face method, correlate with aortic root 
measurements. However, these methods are less amenable for studies using large numbers 
of mice and do not allow for inspection of lesion histology. 
10. LDL receptor deficient mice 
Gene targeting in embryonic stem cells has recently been used to create LDL receptor - 
knockout (LDLR-KO) mice, a model of familial hypercholesterolemia. LDL receptor - 
deficient mice was made in 1993 by Ishibashi et al. (Ishibashi et al.1993). These mice have a 
more modest lipoprotein abnormality than the apoE - deficient mice, with increases in LDL 
and VLDL cholesterol leading to a total plasma cholesterol of about 250 mg/dl on a chow 
diet. On this diet, and at that level of plasma cholesterol, LDL receptor - deficient mice do 
not get atherosclerosis. However, this is a very diet-responsive model. After these mice are 
fed the Paigen diet, their plasma cholesterol levels soar to about 1 500 mg/dl, and large 
atherosclerotic lesions form (Ishibashi et al., 1994). It has also been shown that feeding the 
less toxic western-type diet also leads to the development of large lesions, with plasma 
cholesterol levels of about 400 mg/dl. The lesion pathology in this model is not as well 
characterized as in the apoE - deficient model, but it does appear similar in that the lesions 
can progress beyond the foam - cell fatty-streak stage to the fibro-proliferative intermediate 
stage. 
11. Other mouse models 
Overexpression of human apoA-I in apoE - deficient mice increased HDL cholesterol levels 
twofold and substantially decreased fatty streak and advanced fibroproliferative lesion 
formation (Paszty et al. 1994; Plump et al., 1994). 
By 4 months of age, all but 3-5% of apoE - deficient mice have had detectable fatty streaks 
that vary considerably in size; some are barely detectable, whereas others occlude as much 
as 8% of the aortic lumen. In apoE - deficient mice that overexpress human apoA-I, more 
than 50% of animals have no lesions by 4 months of age, and the animals that do develop 
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atherosclerosis have lesions that are barley detectable. By 8 months of age, apoE - deficient 
mice have lesions that are highly organized and that occlude on average 25% of the aortic 
lumen. Those apoE - deficient mice that overexpress human apoA-I have mainly immature 
fatty - streak lesion that occlude on average only 5% of the aortic lumen. Collectively, these 
data suggest that overexpression of apoA-I can diminish lesion size and slow the initiation 
of fatty streak formation. 
More recently, apoE and LDL-receptor (LDLr) double – knockout (apoE/LDLr-DKO) mice 
have been created (Ishibashi et al., 1994), representing a new mouse model that develops 
severe hyperlipidaemia and atherosclerosis (Bonthu et al., 1997). 
It has been reported that, even on a regular chow diet, the progression of atherosclerosis is 
usually more marked in apoE/LDLr-DKO mice than in mice deficient for apoE alone 
(Witting et al., 1999).  
Thus,  the apoE/LDLr-DKO mouse is a suitable model in which to study the anti-
atherosclerotic effect of compounds without having to feed the animals an atherogenic diet. 
To study the contribution of endothelial nitric oxide synthase (eNOS) to lesion formation 
Kuhlencordt et al. (Kuhlencordt et al., 2001). created apoE / eNOS double - knockout mice. 
It has occured that chronic deficiency of eNOS increases atherosclerosis in apoE-KO mouse 
model. Furthermore, in the absence of eNOS, peripheral coronary disease, chronic 
myocardial ischemia, heart failure, and an array of vascular complications develop that have 
not been observed in apoE-KO animals. 
Recently, Veniant et al. (Veniant et al., 2000) managed to even up the cholesterol levels in 
chow-fed apoE-KO mice and LDLR-KO mice. They did so by making both mouse models 
homozygous for the apolipoprotein B-100 allele, which ameliorates the hypercholesterolemia 
in the setting of apoE deficiency but worsens it in the setting of LDLR deficiency. Moreover, 
the LDLR-KO Apob100/100 mice developed extensive atherosclerosis even on a chow diet. So 
far this model seems to be the best as concerns the development of atherosclerosis in mice. 
Therefore, gene - targeted mouse models has changed the face of atherosclerotic research 
(Savla U, 2002) and helped in creation of the new theory of atherosclerosis - as an 
inflammatory disease (Ross, 1999) 
12. The experimental use of gene targeted mice 
The apoE - deficient mouse model of atherosclerosis can then be used to: 1) identify 
atherosclerosis susceptibility modifying genes, by the candidate-gene and gene-mapping 
methods; 2) identify the role of various cell types in atherogenesis; 3) identify environmental 
factors affecting atherogenesis; and 4) assess therapies that might block atherogenesis or 
lesion progression. 
ApoE-deficient mice have also been used to look for environmental and drug effects on 
atherosclerosis and to test novel therapies. One of the first observations was paradoxical 
effects of probucol on atherogenesis in both apoE-KO (Moghadasian et al., 1999) and LDL 
receptor deficient (Bird et al., 1998) mice. Probucol with strong antioxidant and cholesterol - 
lowering effects increased atherogenesis in apoE-KO mice by 3 folds (Moghadasian et al., 
1999). Several other compounds reduced the extent and severity of atherosclerotic lesions 
without affecting plasma cholesterol levels in apoE–KO mice. For example, administration 
of antioxidant N,N'-diphenyl 1,4 - phenylenediamine (DPPD) to apoE-KO mice resulted in a 
significant decrease in atherosclerosis without reducing plasma cholesterol levels (Tangirala 
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A marked reduction in atherosclerosis by dietary vitamin E was accompanied by no change 
in plasma cholesterol levels in apoE-KO mice (Pratico et al., 1998). 
Likewise, antiatherogenic effects of the angiotensin - converting enzyme inhibitors (Hayek 
et al. 1998; Keidar et al. 2000; Hayek et al. 1999) or the angiotensin II receptor antagonist 
(Keidar et al. 1997)  in apoE-KO mice were independent of plasma cholesterol lowering 
effects. 
Since inflammation plays an important role in atherogenesis, during recent years it has 
become apparent that the 5-lipoxygenase (5-LO) pathway may take significant part in 
modifying the pathogenesis of atherosclerosis. Enzymes associated with the 5-LO pathway 
are abundantly expressed in arterial walls of patients afflicted with various lesion stages of 
atherosclerosis of the aorta and of coronary arteries. These data raised the possibility that 
antileukotriene drugs may be an effective treatment regimen in atherosclerosis (Mehrabian 
et al., 2002). 
Of special interest for atherosclerosis is the arachidonate 5-LO which was originally 
identified in polymorphonuclear leukocytes, but which over-expression was recently 
demonstrated in macrophages, dendritic cells, foam cells, mast cells and neutrophils within 
atherosclerotic vessels. This enzyme generates an unstable epoxide intermediate compound 
leukotriene A4 (LTA4), which is an important precursor of LTB4, LTC4 and other cysteinyl 
leukotrienes. Initial observations and the use of drugs affecting the 5-LO metabolism were 
mainly connected with asthma and other inflammatory diseases (De Caterina & Zampolli, 
2004). 
However, a growing understanding of the role of inflammation in atherosclerosis has 
brought attention to the potential role of leukotrienes and their metabolism. In 2002 
Mehrabian et al. identified the 5-LO as a crucial enzyme, contributing to atherosclerosis 
susceptibility in mice (Mehrabian et al., 2002; Spanbroek et al., 2003). 
This observation, after a long pause (De Caterina R et al., 1988) has again focused the 
attention of researchers on the role of leukotrienes in the pathogenesis of atherosclerotic 
plaque (Radmark, 2003; Zhao & Funk, 2004; Zhao et al., 2004; Kuhn et al., 2005; Kuhn H, 
2005; Lotzer et al., 2005;  Back & Hansson, 2006; Radmark & Samuelsson, 2007). Therefore, 
the speculations have been risen that anti-asthmatic drugs could have beneficial effects on 
atherogenesis (Spanbroek &  Habenicht, 2003; Wickelgren, 2004; Funk, 2005; Back, 2006). 
Indeed, it has been recently demonstrated that the 5-LO substantially contribute to 
atherosclerosis in both mouse models and humans (Mehrabian & Allayee, 2003; Dwyer et 
al., 2004). Later Aiello et al. showed that LTB4 receptor antagonism reduced monocytic foam 
cells in mice (Aiello et al., 2002). Lotzer et al. pointed that macrophage-derived LTs 
differentially activate cysLT2-Rs via paracrine stimulation and cysLT1-Rs via autocrine and 
paracrine stimulation, during inflammation and atherogenesis (Lotzer et al., 2003). 
Therefore, a hypothesis has been formulated that leukotriene-inhibiting drugs developed to 
treat asthma might protect the heart. There are numerous potential targets that could be 
useful in the intervention in leukotriene metabolism in atherosclerosis. Interestingly, the 18 
kDa microsomal protein - five lipoxygenase activating protein (FLAP) was found to be 
critical for the regulation of 5-LO activity and biosynthesis of leukotrienes. The role of FLAP 
in atherosclerosis was additionally confirmed in humans by Helgadottir et al. (Helgadottir 
et al., 2004) who showed that genetic polymorphisms of FLAP are associated with 
myocardial infarction and stroke by increasing leukotriene production and inflammation in 
the arterial wall. 
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The 5-LO is abundantly expressed in atherosclerotic lesions of apoE and LDLR deficient 
mice, appearing to co-localize with a subset of macrophages but not with all macrophage-
staining regions. Indeed, the results of our studies showed that the inhibition of FLAP by 
MK-886 or BAYx1005 can significantly prevent the development of atherosclerosis in gene-
targeted apoE/LDLR-DKO mice ( Jawien et al., 2006; Jawien et al., 2007). 
Moreover, this study showed that cysteinyl leukotriene receptor blocker montelukast 
decreases atherosclerosis in apoE/LDLR-double knockout mice (Jawien et al., 2008). These 
results derived also from our numerous studies, concerned with atherosclerotic mice 
(Elhage et al., 2004; Elhage et al., 2005; Guzik et al., 2005; Jawien et al., 2005; Jawien et al., 
2007). 
The findings of the study concerning MK-886 were confirmed by Back et al. on their model 
of transgenic apoE-/- mice with the dominant negative transforming growth factor β type II 
receptor, which displays aggravated atherosclerosis (Back et al, 2007). 
Colin D. Funk's research team questioned the hypothesis concerning leukotrienes, 5-LO and 
their role in atherogenesis in gene-targeted mice, stating that in mouse plaques there is no 5-
LO overexpression detectable (Cao et al., 2008). 
Finally, Poeckel & Funk in 2010, they tried to explain the whole complicated phenomenon. 
13. Limitations of animal models 
Animal models potentially bear the risk of compensatory mechanisms due to genetic 
modification of the target gene that render the results difficult to interpret. Another caveat is 
species differences between mice and humans. For instance, 5-LO expression in intimal 
atherosclerotic lesions varies between mice and humans; also, 5-LO and 12/15-LO appear to 
be differentially regulated in inflammatory cells of mice and humans with the murine 
12/15-LO producing mainly 12-HPETE, while its human counterpart primarily synthesizes 
15-HPETE. Notably, both products may have opposing effects in inflammation (Conrad DJ, 
1999). 
Moreover, atherogenesis in mice differs in several facets from the human pathology. Thus, T 
cells, whose presence in all stages of atherosclerotic lesions is acknowledged, are 
underrepresented in murine models of atherosclerosis (Daugherty & Hansson, as cited in 
Dean & Kelly, 2000; Roselaar et al., 1996). 
Despite these shortcomings, animal models afford an invaluable means to study the effects 
of directed genetic overexpression, deletion or pharmacological inhibition of key enzymes of 
the LT cascade in a physiological setting that cannot be achieved in humans. 
5-LO/LT pathway shows important disparities between murine and human atherosclerosis. 
Advanced human plaques show differences in 5-LO expression compared with mouse 
lesions. In human lesions, 5-LO (+) cells were identified in macrophages, DCs, mast cells, 
and neutrophils (Spanbroek et al, 2003) and notably, these 5-LO (+) cells are present in the 
neointimal region, whereas in mice, they are restricted to the adventitial layer (Zhao et al., 
2004). With increasing age, these adventitial macrophages form clusters with T cells, 
independent of the severity of atherosclerosis. Intimal inflammatory reactions are connected 
to distinct adventitial inflammation responses, whereby B lymphocytes, plasma cells, and T 
cells conglomerate with macrophages. 5-LO (+) cells accumulate around new blood vessels, 
a common feature between mice and humans.  
In human atherosclerotic plaque specimens, the quantity of 5-LO (+) cells even increased 
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Moreover, the elevated 5-LO activity was found to be associated with BLT1-mediated matrix 
metalloproteinase release from T cells, promoting plaque instability (Cipollone et al., 2005). 
Human lesions demonstrate detectable expression levels for all major components of the LT 
cascade, i.e., FLAP, LTA4 hydrolase, and LTC4 synthase, as well as BLT1/BLT2 and 
CysLT1/CysLT2 receptors. 
Taken together, in advanced human atherosclerosis, a role for 5-LO is likely, which is 
distinct from its role in early atherogenesis. This presence of the 5-LO/LT pathway in 
advanced lesions is not found in mouse models, which might be due to: (i) rapid 
progression of atheroma growth in mice vs. slower, often interrupted progression in 
humans (i.e., initial fatty streaks might remain dormant for many years in humans, until 
certain factors promote the progression of some lesions into an advanced state) (Libby, 2006; 
Libby & Sasiela, 2006)  (ii) advanced human plaques display a higher degree of instability 
and risk to rupture than murine plaques; (iii) temporal dissociation in the Th1/Th2 'balance' 
at distinct lesion stages between mice and humans (Kus et al., 2009; Toton-Zuranska et al., 
2010; Smith et al. 2010). 
14. Future directions 
During the last few years there has been a resurgent focus on the 5-LO/LT pathway as a 
potential target in coronary vascular disease (CVD). The complexity of the 5-LO/LT 
pathway participation in mechanisms contributing to CVD is evident based on the many 
studies (Poeckel & Funk, 2010). Limitations of these studies often result from the 'snapshot' 
punctual nature of analysing a single time point in CVD pathogenesis that makes it difficult 
to gain systematic insight into 5-LO-driven or -independent processes. 
Murine and human CVD etiology differ with respect to the 5-LO/LT pathway, and even 
within murine studies, the nature of the applied model (for atherosclerosis, abdominal aortic 
aneurysm (AAA), or ischemia/reperfusion injury) influences the conclusions. Whereas a 
role for 5-LO-derived LTs in early stages of murine and human atherosclerosis, AAA, and 
reperfusion injury is cogent based on their effects in chemotaxis and induction of pro-
inflammatory responses, the 5-LO pathway appears to play a distinct role in advanced 
human atherosclerosis, but not in advanced murine disease. Targeting specific leukotriene G 
protein-coupled receptors rather than upstream targets involved in LT synthesis may be a 
superior strategy for future CVD therapeutic interventions, based on extensive past 
experience with other pathways (e.g., via angiotensin II and adrenergic receptors), although 
this remains to be determined. Conditional knockouts and comprehensive translational 
studies should serve better than the traditional, simplistic 'one model' approach to 
understand the complex effects exerted by 5-LO products. Understanding the cytokine 
milieu during distinct stages of CVD progression will be crucial to elucidate how the 
expression of members of the 5-LO/LT pathway is regulated. There is little doubt that 5-LO 
plays important roles in many facets of CVD, but the challenge for future studies will be to 
clearly dissect these activities in a temporal and cell- and tissue- specific context in order to 
provide a solid basis for potential therapeutic interventions.  
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1. Introduction 
Avian models of human atherosclerosis such as the chicken, turkey, quail, and pigeon are not 
currently in widespread use, but have a longer and richer history than most mammalian 
models of cardiovascular disease.  In 1874, the first angioplasty surgery of the aortic wall was 
performed in birds (Roberts & Strauss, 1965). Spontaneous (non-induced) atherosclerosis in 
the chicken was first described in 1914 (Roberts & Strauss, 1965), and it has been repeatedly 
observed that avian lesions bear close resemblance to their human counterparts (Clarkson et 
al., 1959; Herndon et al., 1962; Cornhill et al., 1980b; Qin & Nishimura, 1998). The pigeon 
(Columba livia) is especially suited for genetic studies of atherosclerosis because susceptible and 
resistant strains exist in the natural population (Herndon et al., 1962; St. Clair, 1983) 
eliminating the need to construct an artificial phenotype through genetic or dietary 
manipulation. In fact, it has been suggested that the White Carneau (WC) pigeon may be one 
of the most appropriate models of early human lesions (Cornhill et al., 1980b; St. Clair, 1998; 
Moghadasian et al., 2001). This review is comprised of background information on human 
atherosclerosis, a description of other animal models and details of the pigeon model. 
Atherosclerosis is the most common form of heart disease, a general term encompassing a 
variety of pathologies affecting the heart and circulatory system. More specifically, 
atherosclerosis is a disease of the blood vessel itself, and is most likely to develop at branch 
points and other regions of low shear stress along the arterial tree, such as the celiac 
bifurcation of the aorta, and in coronary and carotid arteries (Bassiouny et al., 1994; Kjaernes 
et al., 1981). The disease is a chronic and multifactorial result of both environmental and 
genetic factors, as well as their interactions (Breslow, 2000; Moghadasian et al., 2001). It 
remains the number one cause of morbidity and mortality in the United States and other 
developed countries (Gurr, 1992; Wagner, 1978). 
Arterial lesions begin to develop during childhood as lipid-filled foam cells making up 
“fatty streaks” (Napoli et al., 2002; Stary, 1989), and slowly progress into complex plaques 
consisting of multiple cell types, intra- and extracellular cholesterol esters, calcium deposits, 
proteoglycans, and extensive connective tissue. The final and terminating atherosclerotic 
event is blood vessel occlusion, often caused by plaque rupture, which can lead to a heart 
attack, stroke, or embolism, depending on the location of the affected artery. However, not 
all fatty streaks progress to advanced lesions (Getz, 2000), and their progression/regression 
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of the most appropriate models of early human lesions (Cornhill et al., 1980b; St. Clair, 1998; 
Moghadasian et al., 2001). This review is comprised of background information on human 
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remains the number one cause of morbidity and mortality in the United States and other 
developed countries (Gurr, 1992; Wagner, 1978). 
Arterial lesions begin to develop during childhood as lipid-filled foam cells making up 
“fatty streaks” (Napoli et al., 2002; Stary, 1989), and slowly progress into complex plaques 
consisting of multiple cell types, intra- and extracellular cholesterol esters, calcium deposits, 
proteoglycans, and extensive connective tissue. The final and terminating atherosclerotic 
event is blood vessel occlusion, often caused by plaque rupture, which can lead to a heart 
attack, stroke, or embolism, depending on the location of the affected artery. However, not 
all fatty streaks progress to advanced lesions (Getz, 2000), and their progression/regression 





Clinical symptoms do not usually appear until later in life (Munro & Cotran, 1988; Stary, 
1989). Therefore, research and intervention strategies have focused on delaying the 
progression of plaque formation rather than preventing the appearance of foam cells or fatty 
streaks. There is a strong familial component to all forms of heart disease, and many genetic 
disorders have been identified that contribute to lesion progression and the probability of 
plaque rupture in the general population. However, little is known about the specific genes 
that determine predisposition to the disease, nor how these genes interact with each other 
and the environment to initiate atherosclerotic foam cell formation in any one individual.  
2. Human atherogenesis 
2.1 The observed beginning: Foam cells and lesion development 
In human lesions, early foam cells originate primarily from vascular smooth muscle cells 
(VSMC) [Wissler et al., 1996]. They are the first cell type to appear in susceptible regions of 
the aorta (Balis et al., 1964; Ross & Glomset, 1973), and the most abundant cell type in 
developing fatty streaks (Gabbiani et al., 1984; Katsuda & Okada, 1994; Mosse et al., 1985, 
1986; Wissler et al., 1996;). Early electron microscopy studies noted that VSMC were often 
filled with lipid when there was no lipid in either existing macrophages or in the 
extracellular space, but the reverse was never observed. 
Since those observations, multiple investigators have reported that abnormal VSMC 
accumulation in susceptible aortic regions precedes the actual lipid accumulation (Mosse et 
al., 1985; Ross & Glomset, 1973). Atherosclerotic foam cells can be derived from both VSMC 
and macrophages (Adelman & St. Clair, 1988; Wissler et al., 1996), depending on their 
physical location (Strong et al., 1999) and the cause of initiation. For example, plaques that 
develop along the descending thoracic aorta have more macrophages than VSMC, whereas 
plaques along the abdominal aorta and coronary arteries are comprised mostly of VSMC, 
with very few macrophages. Human thoracic plaques are very rare, and those that do 
progress are usually secondary to other chronic conditions such as hypertension and 
hyperlipidemia (Wissler et al., 1996).  
Although VSMC are the first cell type to accumulate lipid and initiate the fatty streak 
(Doran et al., 2008), much emphasis is placed on macrophage foam cells rather than 
myogenic foam cells. Macrophage-derived foam cells are quick to develop into lesions and 
are easy to induce with a high-fat and/or high-cholesterol diet (Knowles & Maeda, 2000; Xu, 
2004; Zhang et al., 1992), in common animal models of human atherosclerosis, especially 
transgenic mice. Unlike VSMC, which can alternate between contractile and synthetic 
phenotypes, macrophage cells do not change during the disease progression, and so are 
easier to identify in the laboratory under controlled conditions.  
Greater emphasis on macrophage-derived foam cells is problematic because the pathogenic 
lipid accumulation mechanism appears to be dissimilar for the two cell types. Also, rather 
than being a primary initiative event in humans, the arrival of macrophages appears to be a 
secondary response, as they are far more common in advanced plaques than in early lesions 
(Balis et al., 1964; Nakashima et al., 2007; Stary, 1989; Wissler et al., 1996; Zhang et al., 1992;). 
2.2 Atherogenesis risk factors 
Major physiological conditions such as high blood cholesterol, high blood pressure, 
diabetes, a skewed lipoprotein profile, heredity, advanced age, and maleness can increase an 
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individual’s chance of developing atherosclerosis. Collectively, these risk factors, along with 
lifestyle patterns such as physical inactivity, smoking, obesity, and stress have been 
statistically correlated with specific stages of lesion development, plaque stability, and 
overall disease outcome in the general population. Although genotype clearly influences 
many quantitative traits such as LDL/HDL levels, blood pressure, and adiposity (Gibbons 
et al., 2004), progress has been made on minimizing the effects of the controllable risk factors 
in order to disrupt, delay, reverse, or otherwise deter plaque rupture and aortic occlusion in 
high risk individuals. 
Despite moderate success, especially in the realm of cholesterol-lowering drugs, unknown 
genetic factors continue to influence both the age of onset as well as the frequency/severity 
of clinical symptoms (Funke & Assmann, 1999). Unfortunately, by the time most people 
manifest clinical symptoms, it is too late to implement preventative measures because the 
disease is well into the progressive stage. Early identification of susceptible individuals 
allows timely therapeutic treatment. Less than 50% of the mortality risk from coronary heart 
disease can be explained by currently recognized risk factors (Ridker, 2000), even with early 
diagnosis. 
In order to understand events in the at-risk population that remain unidentified under 
current screening methods, the specific contributions of heredity, diet, and lifestyle 
influences on atherogenesis and progression must be determined. Towards this end, 
research emphasis has recently shifted towards identifying cardiovascular disease markers 
that may be detectable prior to the manifestation of clinical symptoms.  Markers are simply 
variations in alleles that are known to associate with a specific disease phenotype. Markers 
do not necessarily cause the disease, but can be used to improve diagnosis and risk 
assessment (Gibbons et al., 2004). Inflammatory markers such as C-reactive protein (CRP) 
factors [Tsimikas et al., 2006; Ridker, 2000] plus markers of oxidative damage such as 
myeloperoxidase (Shao et al., 2006) and paraoxanase (Visvikis-Siest & Marteau, 2006) have 
already increased clinicians’ predictive power. As more markers of atherosclerosis are 
correlated with disease progression and outcome, the genetic variation contributing to 
predisposition and initial manifestation will become clear.  
Until the genetic basis for susceptibility to atherosclerosis is understood, correlation of 
various risk factors with specific metabolic or pathological features will be difficult to assess, 
and efforts for prevention will remain equivocal. Understanding the inheritance 
mechanisms for atherosclerosis is an important step towards reducing the morbidity and 
mortality from the disease by customizing intervention strategies for individuals based 
upon unique genotypes and environmental risk exposures.  
3. Genetic defects in human atherogenesis 
The relative risk for atherosclerosis is clearly higher in individuals with a familial history 
compared with those having a susceptible lipid profile  (Funk & Assmann, 1999; Ordovas & 
Shen, 2002; Palinski & Napoli, 2002).  Many studies have explored the relationship, or 
concordance, between heredity and atherosclerosis. Heritability for early-onset coronary 
heart disease has been estimated at 0.63 (Galton & Ferns, 1989). The relationship becomes 
even clearer after analyzing concordance in twin studies. Twins fertilized from one egg 
(monozygotic) have a concordance rate of 0.83, whereas twins that arose from two separate 
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3. Genetic defects in human atherogenesis 
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These concordance values suggest an intimate relationship between the genotype of an 
individual and the incidence of heart disease. The fact that the concordance rate in 
monozygotic twins is less than 1.0 (indicating 100% correlation) most likely reflects the 
attenuating environmental effects on atherosclerosis initiation and progression. This gap in 
causality underscores the importance of understanding the genetic profile of a client before 
attempting intervention, because even among those sharing the same set of alleles, the 
atherosclerosis phenotype will vary depending on individual exposures. 
Genetic research on human atherosclerosis has focused primarily on the role of cholesterol 
metabolism.  It is estimated that several hundred genes (Ordovas & Shen, 2002) are involved 
in the absorption, conversion, transport, deposition, excretion, and biosynthesis, of 
cholesterol and other lipid substrates in the body (Knowles & Maeda, 2000; Stein et al., 
2002). Very few of these genes have been characterized. A defect in any of these pathways 
may contribute to atherosclerotic susceptibility, because the net result can be a significant 
increase in plasma lipoprotein concentration, especially LDL, and/or the inappropriate 
deposition of cholesterol in peripheral tissues such as skin, tendons, and arteries (Garcia et 
al., 2001). 
Blood lipid homeostasis and cellular cholesterol metabolism are highly regulated (Attie, 
2001). Genetic defects have been found to impact overall cholesterol metabolism at many 
steps. In humans, most plasma cholesterol is in the form of LDL, having a half-life of 
about 2.5 days (Goldstein & Brown, 2001). Some of the cholesterol component of LDL is 
transferred to HDL via the action of cholesterol ester transfer protein (CETP). However, 
as much as 70% of LDL is removed from the blood by LDL receptors (LDLR) in the liver 
(Garcia et al., 2001). A variety of single gene defects have been identified that increase 
the incidence of atherosclerosis by influencing the LDLR activity (Funke & Assmann, 
1999).  
Probably the most studied of these LDLR defects is familial hypercholesterolemia (FH), an 
autosomal dominant Mendelian disorder (Brown et al., 1981; Funke & Assmann, 1999; 
Goldstein & Brown, 2001).  This mutation renders the hepatic receptors nonfunctional, so 
that they are unable to clear circulating LDL from the blood. A second type of 
hypercholesterolemia, autosomal recessive hypercholesterolemia (ARH), also impacts the 
LDLR (Garcia et al., 2001; Goldstein & Brown, 2001). ARH is similar to FH, in that both of 
these hereditary defects result in chronically elevated blood cholesterol. This imbalance has 
the potential to change the physiology of the arterial wall, making it exceptionally 
vulnerable to atherogenesis.  However, unlike FH, the LDLR in ARH, are believed to be 
functional, but their altered location in the liver makes them inaccessible to circulating LDL. 
Brown and Goldstein also identified a single gene defect known as familial ligand defective 
apoB-100, the primary human LDL (Fielding et al., 2000) apoprotein. This inherited defect 
lies in the composition and binding capacity of the apoB-100 to the LDLR, decreasing the 
ability of the LDL to be picked up by the LDLR (Goldstein & Brown, 2001; Gurr, 1992). In 
the healthy human aorta, LDL particles are thought to be incorporated into SMC by receptor 
mediator endocytosis. Chemically modified or oxidized LDL enters via scavenger receptors. 
Once inside the cell, the LDL cholesterol esters (CE) are transported to the lysosomes where 
they are hydrolyzed by lysosomal acid lipase (LAL), also known as acid cholesterol ester 
hydrolase (ACEH). This enzyme breaks each CE into its free fatty acid (usually linoleate), 
and free cholesterol. There are several known LAL gene mutations that result in the 
abnormal accumulation of cholesterol esters in the lysosome. 
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Two of the more common lysosomal storage disease phenotypes of a LAL mutation are 
Wolman’s Disease (Kuriyama et al., 1990; Lohse et al., 1999) and cholesterol ester storage 
disease (CESD). Both are inherited as an autosomal recessive trait, although Wolman’s 
disease is usually fatal within the first year of life, and so not directly related to 
atherogenesis in the general population. However, individuals with CESD do demonstrate 
premature atherosclerosis, in addition to accumulating CE and triglycerides (TG) in the 
liver, adrenal glands and intestines (Pagani et al., 1996). Niemann-Pick Type C is a third 
form of lysosomal storage disease that directly impacts cholesterol metabolism at the 
cellular level (Blanchette-Mackie et al., 1988). In this condition, the CE is successfully 
hydrolyzed by ACEH, but the released cholesterol component is unable to leave the 
lysosome to travel to the endoplasmic reticulum, causing the accumulation of free 
cholesterol in the lysosome. 
Lysosomes are also responsible for the degradation of glycosaminoglycan (GAG) chains 
after the core proteoglycan has been broken down by extracellular proteases such as matrix 
metallopeptidases (MMP) and disintigrins (ADAMs) [Arndt et al, 2002; Seals & 
Courtneidge, 2003). There is an extensive repertoire of catalytic lysosomal enzymes, and 
their functions have been revealed mostly by observing the consequences of their absence 
(Santamarina-Fojo et al., 2001). Defective enzymes lead to a wide variety of diseased 
phenotypes known as mucopolysaccharidoses (MP) ranging from the mild Schie Disease to 
the severe Hurler Disease, which results in childhood mortality. In these two examples, 
GAGs are not properly degraded, and so will accumulate in the lysosomes and in the 
extracellular space. GAGs in the ECM will attract LDL that has entered the intima by 
binding to apoB-100 as previously described, where the cholesterol is most likely 
endocytosed by macrophages and SMC within the developing plaque. 
Once in the cytoplasm, cholesterol that is not needed for routine cellular functions is 
esterified by acyl CoA: cholesterol acyltransferase (ACAT) and stored in vacuoles. 
Intracellular CE remains trapped in the cytoplasm until hydrolyzed by neutral cholesterol 
ester hydrolase (NCEH). This enzyme releases the free cholesterol so it can be removed by 
HDL and transported to the liver. A pair of ATP binding cassette proteins has been 
identified that are believed to control this efflux of cellular cholesterol. One of these, 
ABCP–1 is defective in Tangier Disease (Faber et al., 2002), an inherited condition where 
cholesterol is unable to exit the cell via reverse cholesterol transport. There is a moderate 
risk of atherogenesis associated with Tangier Disease, which is increased in the presence 
of additional risk factors (Tall et al., 2001) 
Research is directed towards a range of HDL-associated apoproteins. Genetic factors 
account for approximately 50% of the variance of HDL composition and plasma 
concentration in the general population (Tall et al., 2001). The primary apoprotein in HDL is 
apoA1, followed by apoA2, apoC, and apoE (Fielding, 2000). ApoE is an important ligand 
for receptor-mediated clearance of HDL from arterial cells (Moghadasian et al., 2001; Stein et 
al., 2002), whose role is of great interest to investigators of atherosclerotic resistance because 
most patients with familial dysbetalipoproteinemia (FD) are homozygous for the E2 isoform 
of apoE (Johns Hopkins University, 2011). Although this defect has been shown to be 
relevant in some animal models, especially apoE null mice (Smith et al., 2006; Zhang et al., 
1992), only 1-4% of humans with the E2/E2 apoE phenotype actually develop FD (Johns 
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these genetically susceptible individuals, but may not be relevant to the more common 
forms of atherosclerosis in the overall population.  
Any of the currently identified monogneic defects that directly or indirectly influence 
cholesterol metabolism and/or the inflammatory response will increase the likelihood of 
atherosclerotic events. However, individual genes do not work in a vacuum, and additional 
genetic and/or environmental factors are often required to determine the overall 
susceptibility or resistance to disease. Nuclear hormone receptors and other types of 
transcription factors are under investigation to determine how they exert their regulatory 
effects (Cohen & Zannis, 2001; Desvergne al., 2006). For example, although the binding 
capacity of apoB-100 is genetically determined (Goldstein & Brown, 2001), the specific 
number of hepatic LDLR being expressed at any given time is dependent on dietary and 
hormonal factors (Gurr, 1992). In a hypothetical situation, the apoB domain of LDL may be 
functional (non-mutated), but without the adequate expression of the LDLR to bind 
circulating LDL, the end result could still be high blood cholesterol. 
Clinical studies have demonstrated that not all individuals afflicted with FH will develop 
early onset atherosclerosis. Of those manifesting the heterozygous form of the disease, 
where circulating LDL levels tend to range between 300-400 mg/dL, only 50% will actually 
develop cardiovascular disease (Stein et al, 2002). Even though there are both hyper- and 
hypo- responders to the effects of dietary cholesterol on serum levels, some individuals 
demonstrate relative resistance to atherogenesis, even in the face of hypercholesterolemia. 
Equal emphasis should be placed on the search for genes that contribute to individual 
susceptibility and those that confer resistance. 
The ultimate sequence of atherosclerotic events is a result of the combined effects of many 
genes, regulatory factors, and environmental exposures (Hartman et al., 2001). This 
synergistic influence on phenotype may give the appearance of a polygenic or multifactorial 
effect (Funke & Assmann, 1999; Goldstein & Brown, 2001), even when a monogenic 
abnormality has been clearly implicated. These interactions have made it difficult to 
establish a universally accepted mechanism of atherogenesis (Peltonen & McKusick, 2001), 
because the sample sizes needed to test these gene-gene and gene-environment interactions 
are much larger than those needed for simpler genotype-phenotype associations (Ordovas & 
Shen, 2002). 
Pathways that trigger atherosclerosis in the general population have yet to be elucidated 
(Visvikis-Siest & Marteau, 2006). Most genomic scale experiments have compared either 
full-blown plaques against non-affected aortic segments (Archacki et al., 2003; Forcheron et 
al., 2005; Hiltunen et al., 2002; Shanahan et al., 1997), or they have analyzed differences 
between ruptured and unruptured plaques (Adams et al., 2006; Faber et al., 2001; 
Papaspyridonos et al., 2006). In both types of comparisons, differentially expressed genes 
have been identified that illuminate plaque development and mortality risk. However, 
genes responsible for initiating foam cell formation could not be discriminated from those 
involved in later events. This gap is not an oversight by the investigators, but rather reflects 
the limited availability of human tissue samples at early stages of atherosclerosis for 
relevant comparative studies. One of the major limitations of elucidating the sequence of 
events that occur during atherogenesis is that an investigator can “observe and study a 
single site in the arterial vasculature” only once (Ross & Glomset, 1973).  For this and other 
reasons, most atherogenic research requires animal and in-vitro models of the human 
disease.  
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4. Animal models of atherogenesis 
4.1 Mammals 
No animal model of human disease can fully encompass the unique complexity of molecular 
machinery and the wide range of expressed clinical phenotypes. However, many important 
metabolic pathways have been explained by the judicious use of animal models (Hartman et 
al., 2001). Therefore, the most appropriate choice of a disease model for genetic inquiry will 
ultimately depend on the specific hypothesis or research question being investigated. 
There are some general guidelines to follow when choosing an animal model of human 
disease. The phenotype should resemble the human physiological condition as closely as 
possible in both the normal and diseased state (Moghadasian et al., 2001). There are 
additional practical issues to consider such as the size of the animal and housing 
requirements, generation times, and the specific cost of overall maintenance, including food, 
daily care, and experimental treatment (Moghadasian et al., 2001; Suckling, & Jackson, 1993). 
These concerns become especially important with the development of transgenic models, in 
that the associated investment costs are much higher than with traditional animal studies. 
Several animal models are used currently to investigate various clinical manifestations and 
genetic mechanisms of human atherosclerosis.  Mice (regular laboratory and transgenic), 
rabbits, and hamsters, are the most common models but miniature swine, primates, rats, 
dogs, and pigeons are also employed. These models have been used to elucidate the role of 
specific molecules in atherogenesis, lesion progression, thrombosis, and plaque rupture by 
direct hypothesis testing. Selected disease characteristics in animal models with their 
relationship to the human atherosclerosis are presented in Table 1.  
Animal lipid metabolism studies become complicated because the majority of circulating 
cholesterol is in HDL (Suckling & Jackson, 1993) for most species except humans who utilize 
LDL (Garcia et al., 2001). For example, a decrease in plasma HDL has been associated with a 
reduced risk of atherosclerosis in mice (Breslow, 2000). It does make sense that relatively 
low levels of HDL decreased the clinical atherosclerosis incidence because HDL 
(Moghadasian et al., 2001) is 70% of mouse total cholesterol. 
However, in humans, decreased HDL levels are associated with an increased risk of 
atherosclerosis. Despite this marked inconsistency, the successful extrapolation of animal 
studies to human atherosclerosis is exemplified by the fact that it was impossible to raise 
circulating LDL levels, and thus increase atherosclerosis risk in experimental models, 
without LDLR that were compromised, either genetically or in response to dietary overload 
(Brown et al., 1981; Goldstein & Brown, 2001). Subsequently, over 600 human LDLR gene 
mutations similar to FH that trigger varying degrees of hypercholesterolemia have been 
identified (Goldstein & Brown, 2001). In addition, hamsters, rabbits and primates have 
repeatedly shown reduced functional capacity of hepatic receptors in response to a high fat 
(Suckling & Jackson, 1993) diet. Individual LDLR activity varied in response to dietary fat 
and cholesterol because primates, like humans, dogs, and rabbits can be hypo- or hyper- 
responsive to diet (Goldstein & Brown, 2001; Moghadasian et al., 2001; Overturf et al., 1990; 
Stein et al., 2002), with some individuals demonstrating unique resistance.  
In newborn humans and many animal species, hepatic LDLR have a maximum operative 
capacity when circulating LDL levels are approximately 0.25 mg/dL (Khosla & Sundram, 
1996). Approximately 60% of plasma LDL in hamsters is removed by hepatic receptors. The 
clearance rate in hamsters is much faster than that of humans, with the hamster LDLR 
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(Suckling & Jackson, 1993). However, the fact that hamsters and humans share a common 
LDL clearance mechanism makes the hamster a suitable model for this aspect of cholesterol 
metabolism.  
Hamsters and humans also share CETP molecules (Suckling & Jackson, 1993) that transfer 
the cholesterol component of LDL to HDL, a key step in reverse cholesterol transport. These 
homologous features are in direct contrast to the mouse, which, despite being fed a high-fat 
high-cholesterol diet (Pitman et al., 1998) and its evolutionary relationship to hamsters, does 
not develop advanced atherosclerotic plaques resembling those in humans unless animals 
with sensitized genetic backgrounds (Xu, 2004) are used. 
 
 Hamster Mouse Pig Rabbit Pigeon Human 
  Normal Transgenic  Normal WHHL/MI   
Lipoprotein 
Profiles         
Predominant LDL HDL HDL LDL HDL HDL HDL LDL 
CETP + - - - + + + + 
LDLR + + - + + - - + 
ApoE + + - + + + - + 
ApoB100 + + + + + + + + 
ApoB-48 + + + + + + - + 
Lesions/Foam 
Cells         
Primary 










Primary Cell   
Macrophage + + + - + + - - 
SMC - - - + + + + + 
Characteristics         
Spontaneous - - - + - - + + 
Diet-induced + + + + + + + + 
Thrombosis - - + + - + + + 
Myocardial 
infarction - - + - - +/- + + 
Genome size 
(Gbp) 3.55 3.45 3.45 3.10 3.47 3.47 1.47 3.40 
Wild-type diet  
Omnivore + + + + - - + + 
Herbivore - - - - + + - - 
Table 1. Comparison of selected characteristics of atherosclerosis between animal models 
and humans. 
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The mouse is technically advantageous because of its small size, short generation time, large 
litters, and the availability of many inbred strains (Breslow, 2000). However, laboratory mice 
fed on a chow diet do not develop spontaneous atherosclerotic lesions. Atherosclerosis must 
be experimentally induced by feeding a diet containing 15% fat, 1.25% cholesterol, and 0.5% 
cholic acid. These non-physiological conditions create serious limitations for comparison 
with human studies.  The most important factor may be the presence of cholate in the diet. 
Cholate is enough, in and of itself, to induce a chronic inflammatory state in mice (Breslow, 
2000; Shi et al., 2003) confounding the true atherogenic role of inflammation. This is further 
exacerbated by the fact that some mice are more sensitive to inflammatory cues (Rader & 
Pure, 2000) so that some genetic differences between susceptible and resistant mouse strains 
pertain to the diet used, rather than the atherogenic process as it is observed on Western 
diets (Breslow, 2000).  
These and other genetic differences that exist between mouse strains can cause significant 
problems when interpreting and comparing the results of gene expression studies 
(Sigmund, 2000). For example, just because a specific inflammatory marker was identified in 
an atherosclerotic plaque and not in a healthy aorta does not mean that inflammation is 
causing the disease. Indeed, the molecule could be there to accelerate the cascade; but it 
could also be there in an attempt to reverse the pathology, or may even be responding to a 
cellular signal not specific to plaque progression (Knowles & Maeda, 2000) such as cholate. 
This is true even with transgenic mice because the foundation stock may be different. Also, 
because gene insertion is random, knock-in models do not by definition contain the gene of 
interest at the same locus. Therefore, simple transgenics may not be sufficient to prove the 
role of any given trait because of positional insertion effects on both absolute gene 
expression and copy number variation (Warden & Fisler, 1997). Delineating the specific 
function of a candidate gene is difficult, if not impossible, without being able to precisely 
correlate the phenotype to the initiating mechanism of foam cell formation. The heterogenic 
background of the mice combined with the variable responses to the atherogenic diet 
confound the interpretation. 
Despite these often overlooked limitations of extrapolating mouse studies to the human 
disease, research using transgenic mice has enhanced the concept that atherosclerosis is not 
a simple lipid disorder. New atherogenic theories must be explored to explain the 
occurrence of atherosclerotic heart disease in individuals displaying no dyslipidemia. Most 
of the more than twenty unique quantitative trait loci (QTL) identified in mice (Smith et al., 
2006) do not influence plasma lipid levels or blood pressure (Allayee et al., 2003; Colinayo et 
al., 2003). This finding has been especially interesting because these QTL were identified in 
hypothesis-driven experiments exploring cholesterol metabolism in LDLR and/or apoE 
knockout mice. Many of these studies have demonstrated the strong genetic influence in the 
arterial wall on the susceptible and resistant phenotypic differences between mouse strains 
(Lusis et al., 2004). For example the major mouse QTL, Ath29 on chromosome 9, in the BXH 
ApoE(-/-) cross fed a chow diet was associated with early lesion development but not with 
risk factors including circulating lipids (Wang et al., 2007).  
Knockout models theoretically mirror homozygous recessive forms of inherited disease 
because of the loss of gene function (Knowles & Maeda, 2000). As in familial 
hypercholesterolemia (FH), LDLR null mice experience a 2X increase in plasma cholesterol 
levels, even on a regular diet, that is further exacerbated on the high-fat, high-cholesterol 
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the mutation’s impact on plasma cholesterol is greater than in the LDLR negative mice, with 
4-5 times the normal amount of circulating lipoproteins (Knowles & Maeda, 2000; Zhang et 
al., 1992;). However, preliminary studies revealed no relationship between these elevated 
lipid levels and lesion size in apoE null mice (Zhang et al., 1994). Only 2% of the 
homozygous apoE2 null mice developed aortic lesions at all, and the contribution of this 
mutation to the overall human disease burden has been questioned (Visvikis-Siest & 
Marteau, 2006). Subsequent studies have shown contradictory results, as the nature of the 
lesion appears to be dependent on the parental strain used in the experiment rather than the 
particular knockout gene (Allayee et al., 2003; Getz, 2000; Sigmund, 2000; Smith et al., 2006).  
The largest effect in these hyper-cholesterolemic models resulted from the macrophage 
colony stimulation factor (MCSF) impact on lesion progression (Knowles & Maeda, 2000). 
MCSF has been reported in advanced human atheromas, and this finding in mice lends 
experimental support to the role of the inflammatory response in atherosclerosis. However, 
the role of this molecule in atherogenesis per se is difficult to elucidate in the mouse, 
because of its chronically inflamed state.  
Although not yet yielding consistent results applicable to human therapeutics (Yutzey & 
Robbins, 2007), transgenic mouse research has reinforced the importance of genetic 
background in determining atherosclerotic susceptibility or resistance in an individual. 
These studies have also suggested that the mechanism of foam cell formation varied among 
individuals under discrete experimental and/or environmental stimuli. The importance of 
the specific initiating mechanisms on the developing phenotype has been further 
demonstrated in rabbit models of atherosclerosis. 
Rabbits, like hamsters, have CETP and do develop atherosclerotic foam cells when induced 
by an unnatural diet (Suckling & Jackson, 1993). Unlike the other animal models described 
in Table 1, rabbits are vegetarian, and so cholesterol is not a normal component of their 
wild-type diet. The Watanabe Heritable Hyperlipidemic (WHHL) rabbit was developed 
through selective breeding, and does not have LDLR (Watanabe et al., 1985;). WHHL rabbits 
get lesions along the aortic arch within six months, but do not experience thrombosis or 
myocardial infarction. However, these advanced atherosclerotic phenomena are observed in 
a sub-strain, the WHHLMI rabbit. This rabbit does get a heart attack similar to one of the 
human atherosclerotic (Shiomi et al., 2003) endpoints.  
One of the important contributions of the rabbit model to understanding human disease was 
the observation that rabbit foam cells can be derived from smooth muscle cells (SMC) or 
macrophages, depending on the specific dietary perturbation (Weigensberg et al, 1985). This 
is in direct contrast to the mouse, where the predominant cell type in early lesions is always 
the macrophage, regardless of diet and genetic strain (Lusis, 2000). Rabbit myogenic foam 
cells are biochemically and morphologically distinct from macrophage derived foam cells, 
and both types of early lesions are structurally different from those produced by catheter 
injury (Weigensberg et al, 1985). Recognizing that different types of foam cells develop in 
response to different initiating mechanisms should help unravel the controversy of foam cell 
origin. In all probability, the predominant cell type in early atherogenesis is dependent on 
the pathological stimulus, and the specific model under study. 
A second revelation from rabbit research has been that both macrophages and SMC express 
receptors for the MCSF protein (Inaba et al., 1992). The proto oncogene c-fms3 induces SMC 
migration and proliferation, as well as macrophage recruitment to the atherosclerosis-prone 
regions of the aorta (Mozes et al., 1998). This is important for atherogenesis investigations 
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because the ratio of SMC to macrophages, both found in human lesions, changes as the 
disease progresses. The fact that both cell types share an activation mechanism means that 
the presence of MCSF in an experimental sample does not by definition mean that only 
macrophages will be recruited. This simple fact is not evident from the plethora of mouse 
studies, and is further evidence that multiple models are needed to grasp the complexity of 
human atherosclerosis, especially at the initiation stage. 
Swine are unique among the other mammals depicted in Table 1 because, although they are 
LDL carriers like the hamster (Julien et al., 1981), and most lesions develop in the aortic arch, 
they also develop spontaneous lesions in the abdominal aorta. The initial foam cells are 
derived from intimal SMC (Scott et al., 1985), and appear similar to those found in early 
stages of the human disease. Unfortunately, these lesions do not progress to advanced 
atheromas without being induced by a 4% (w/w) cholesterol diet (Moghadasian et al., 2001). 
Even after 90 days on a hyperlipidemic diet, less than 5% of the cells are monocytes (Scott et 
al., 1985). Swine could adequately model the gradual transition from a myogenic fatty streak 
to an advanced lesion with activated macrophage cells, reflecting the inflammatory response 
in humans over time.  
4.2 Pigeons  
The WC pigeon is unique among non-primate models in that it develops naturally occurring 
(spontaneous) atherosclerosis at both the celiac bifurcation of the aorta and in the coronary 
arteries (Clarkson et al., 1959; Prichard et al., 1964). Foam cells develop into fatty streaks 
which progress into mature plaques in the absence of elevated plasma cholesterol and other 
traditional risk factors (Wagner, 1978; Wagner et al., 1979). These non-induced 
atherosclerotic lesions are morphologically and ultrastructurally similar to those seen in 
humans and occur at parallel anatomical sites along the arterial tree (Cornhill et al., 1980a, 
1980b; Hadjiisky, et al., 1991; Kjaernes et al., 1981). Multiple studies have clearly 
demonstrated that susceptibility in the WC resides at the level of the arterial wall (St. Clair 
et al., 1986; Wagner et al., 1973, 1979;). Lesion site specificity, severity, and disease 
progression as a function of age are also highly predictable (Cooke & Smith, 1968; Santerre 
et al., 1972). 
Show Racer pigeons (SR) are resistant to atherosclerosis, while consuming the same 
cholesterol-free diet. This susceptibility difference occurs despite similar plasma cholesterol 
and lipoprotein concentrations in both WC and SR (Barakat & St. Clair, 1985). WC pigeons 
are one of the few animal models to develop severe atherosclerosis while consuming a 
cholesterol free diet, and comparing results with the resistant SR enables pathological 
changes associated with the disease to be distinguished from changes due to the natural 
pigeon aging process. Virtually all WC and SR differences occur at the arterial tissue level as 
there are few system level differences (Fronek & Alexander, 1981). 
Both pigeon breeds are hypercholesterolemic compared to humans, and, like mice and 
rabbits, they are primarily HDL carriers. However, pigeons are unique in that for the first 
three days of life, cholesterol is circulated in the form of LDL, after which time the 
lipoprotein profile switches to HDL (unpublished data) for the remainder of the pigeon’s 
life. Neither breed has apoE (Randolph et al., 1984) or LDLR (Randolph & St. Clair, 1984; St. 
Clair et al., 1986), so the effect of these variables in other models of the human disease is not 
a factor in the pigeon pathology. Combined unpublished data gathered from several 
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plasma cholesterol concentration in pigeons ranges from 201 mg/dL in the SR to 242 mg/dL 
in the WC (+/- 16 mg/dL in both groups). Although these values are borderline significant, 
they do not change during disease progression, nor does it appear that blood cholesterol 
induces WC foam cell development. This fact is further supported in wild mourning doves, 
a close relative of the pigeon, that have 258 mg/dL average plasma cholesterol but do not 
get atherosclerosis (Schulz et al., 2000). Sterol balance studies have revealed that the WC 
excretes less neutral sterols than the SR breed (Siekert et al., 1975; Subbiah & Connelly, 
1976), but this difference had much greater impact in diet-induced atherosclerosis than in 
the susceptible phenotype of the WC to the naturally occurring form of the disease (Hulcher 
& Margolis, 1982). 
The most widely studied spontaneous atherosclerotic lesion in susceptible pigeons occurs at 
the celiac bifurcation of the aorta, and by three years of age reaches a size to be easily visible 
on gross examination (Nicolosi et al., 1972; Santerre et al., 1972). Early pathological and 
metabolic changes are apparent microscopically in this site by six months of age (Cooke & 
Smith, 1968). In contrast, diet-induced lesions in the WC aorta occur at various and 
unpredictable sites along the descending (Gosselin, 1979; Jerome & Lewis, 1985; Wagner, 
1978) and abdominal aortas, and are pathologically very different from non-induced lesions. 
Foam cells in spontaneous lesions consist primarily of modified SMC (Cooke & Smith, 1968; 
St. Clair, 1983) while cholesterol-induced foam cells are mostly composed of macrophages 
(Denholm & Lewis, 1987; Gosselin, 1979; Jerome & Lewis, 1984; St. Clair, 1983). 
As with mice, diet-induced lesions develop more rapidly in the pigeon than their 
spontaneous counterparts (Jerome & Lewis, 1984; Xu, 2004), but different atherogenic 
mechanisms appear to be involved (Santerre et al., 1972; St. Clair, 1983). One of the primary 
diet induction effects is to shift the physiological lipoprotein profile from HDL to LDL 
(Jones et al., 1991; Langelier et al., 1976). In fact, 1% diet supplementation with cholesterol 
causes such a rapid onset of atherosclerotic foam cells in both breeds that it becomes 
unfeasible to detect the influence of intrinsic factors (Lofland, 1966) contributing to either 
WC susceptibility or SR resistance. Therefore, the spontaneous lesion model is best suited 
for genetic studies to identify candidate genes for susceptibility or resistance as the 
introduction of an artificial diet confounds the interpretation of the earliest events occurring 
in atherogenesis.  
Since 1959, many studies have been performed to systematically characterize the initiating 
factor in lesion development in the susceptible WC pigeon. However, the mechanism(s) 
leading to WC foam cell development is not known, and few studies have been conducted 
in the spontaneous model to identify the gene(s) or gene product(s) that are specific to 
initiation. Clarkson and associates (1959) observed that age and heredity were the biggest 
factors in atherosclerotic susceptibility. Diet, exercise, and gender were not primary factors 
in the WC pathology.  
Further studies of age and heredity effects demonstrated that genetics play a larger role in 
lesion development than the normal aging process (Goodman & Herndon; 1963). The 
authors hypothesized that inheritance was a polygenic trait. Wagner and co-workers (1973) 
compared susceptibility to lesion development between the WC and SR celiac bifurcation of 
the aorta. The authors found a greater number of advanced lesions in the WC than in the SR, 
and concluded that the genetic control conferring susceptibility or resistance in the pigeon 
appeared to be at the level of the artery. Supplementary experiments by that group showed 
that blood cholesterol, triacylglycerol, and glucose levels were not different between the two 
 
Spontaneous Atherosclerosis in Pigeons: A Good Model of Human Disease 
 
37 
breeds (Wagner, 1978), and that elevated blood pressure is actually a consequence of pigeon 
atherosclerosis, rather than being an initiating factor (Wagner et al., 1979). The latter study 
provided initial indications that although diet is not the primary factor contributing to 
atherosclerotic susceptibility in the pigeon, it can impact the severity of a lesion once 
formed; thus indicating a role in progression. 
A range of metabolic differences between the arterial wall of WC and SR pigeons have been 
identified. In vivo, differences in the WC susceptible foci include increased 
glycosaminoglycans, especially chondroitin-6-sulfate (Curwen & Smith, 1977), greater lipid 
content, predominantly in the form of cholesterol esters (Hajjar et al., 1980b; Nicolosi et al., 
1972), lower oxidative metabolism(Hajjar et al., 1980a; Santerre et al., 1974), relative hypoxia 
(Hajjar et al., 1988), decreased acid cholesterol hydrolase (Sweetland et al., 1999), and neutral 
cholesterol ester hydrolase (Fastnacht, 1993) activities, increased glycolysis (Zemplenyi & 
Rosenstein, 1975), decreased tricarboxylic acid cycle activity (Zemplenyi & Rosenstein, 
1975), and the increased synthesis of prostaglandin E2, which also decreased cholesterol 
ester hydrolase activity (Subbiah et al., 1980). Although these studies did not distinguish the 
primary or underlying problem from secondary effects, increases in non-esterified fatty 
acids (NEFA) and in chondroitin-6-sulfate (C6S) seem to precede many of the other 
observed differences. The role of excess NEFA and C6S in pigeon atherogenesis is not yet 
clear, although the presence of C6S in the susceptible pigeon by six weeks of age does 
support the response to retention theory. Both human and pigeon smooth muscle cells 
synthesize C6S as part of the ECM (Edwards et al., 1995; Wight, 1985), where it has been 
observed to complex with plasma LDL entering the vascular wall (Nakashima et al., 2007; 
Tovar et al., 1998; Wagner et al., 1989; Wight, 1980).  
Human atherosclerosis is considered to be a multifactorial disease, with many genes and 
environmental factors contributing to the specific phenotype and ultimate endpoint. In 
pigeons, where individual lifestyle choices are not a factor, the numbers and types of genes 
contributing to baseline susceptibility and resistance may be easier to elucidate. Preliminary 
crossbreeding studies indicated a polygenic mechanism of inheritance (Goodman & 
Herndon, 1963) with resistance being the dominant trait. However, the authors noted that 
each breed responded differently to dietary manipulation (Herndon et al., 1962), so it is 
possible that the genetic differences observed may have reflected the confounding influence 
of diet, rather than the spontaneous expression profile. 
Pigeons are not as well suited for traditional inheritance studies as mammalian species 
because the birds mate for life, and do not reach sexual maturity until seven months of age 
(Brannigan, 1973). Although excess cholesterol esters can be detected biochemically at 12 
weeks, three years are required in order to definitively characterize the complete 
atherosclerotic phenotype. However, the pigeon genome is approximately half the size of its 
counterpart mammalian models, and comparative genomic studies are facilitated by the 
published chicken (Gallus gallus) genome, which is similar in size (Hillier et al., 2004) to the 
pigeon. 
A 15-year cross breeding study at the University of New Hampshire examined grossly 
visible lesions (or lack thereof) at three years of age in the celiac foci of susceptible WC, 
resistant SR, and in F1, F2, and backcross progeny. The results supported autosomal 
recessive inheritance of susceptibility to spontaneous atherosclerosis in the pigeon (Smith et 
al., 2001). This finding contrasted earlier results (Herndon et al., 1962) that indicated a 
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breeds (Wagner, 1978), and that elevated blood pressure is actually a consequence of pigeon 
atherosclerosis, rather than being an initiating factor (Wagner et al., 1979). The latter study 
provided initial indications that although diet is not the primary factor contributing to 
atherosclerotic susceptibility in the pigeon, it can impact the severity of a lesion once 
formed; thus indicating a role in progression. 
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Rosenstein, 1975), decreased tricarboxylic acid cycle activity (Zemplenyi & Rosenstein, 
1975), and the increased synthesis of prostaglandin E2, which also decreased cholesterol 
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Herndon, 1963) with resistance being the dominant trait. However, the authors noted that 
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possible that the genetic differences observed may have reflected the confounding influence 
of diet, rather than the spontaneous expression profile. 
Pigeons are not as well suited for traditional inheritance studies as mammalian species 
because the birds mate for life, and do not reach sexual maturity until seven months of age 
(Brannigan, 1973). Although excess cholesterol esters can be detected biochemically at 12 
weeks, three years are required in order to definitively characterize the complete 
atherosclerotic phenotype. However, the pigeon genome is approximately half the size of its 
counterpart mammalian models, and comparative genomic studies are facilitated by the 
published chicken (Gallus gallus) genome, which is similar in size (Hillier et al., 2004) to the 
pigeon. 
A 15-year cross breeding study at the University of New Hampshire examined grossly 
visible lesions (or lack thereof) at three years of age in the celiac foci of susceptible WC, 
resistant SR, and in F1, F2, and backcross progeny. The results supported autosomal 
recessive inheritance of susceptibility to spontaneous atherosclerosis in the pigeon (Smith et 
al., 2001). This finding contrasted earlier results (Herndon et al., 1962) that indicated a 





experiments through the backcross generations and did not use a cholesterol-supplemented 
diet (Smith et al., 2001). In addition, and probably of greater importance to the experimental 
results, all pigeons consumed the same cholesterol-free diet. Parallel investigation of the 
smooth muscle cells cultured from several tissues of the WC, SR, and F1 pigeons 
demonstrated that lipid accumulation observed at the celiac bifurcation is a constitutive 
property of WC (Smith et al., 2001).  
The finding that spontaneous atherosclerosis in the susceptible WC appears to be the 
result of a single gene, and not the net result of many interacting genes, as is thought to 
be the case in humans, makes the pigeon model a simplest case system. Identification of 
the gene responsible for predisposition, and an understanding of how this gene 
influences the described metabolic and morphological changes could reveal an initiating 
mechanistic pathway that remains undetected in more confounded models of 
atherogenesis. 
Experiments have demonstrated that the SMC monolayers grown in vitro accumulate 
lipid and synthesize proteoglycans in the same manner as aortic cells in vivo (Cooke & 
Smith, 1968; Smith et al., 1965; Wight, 1980; Wight et al., 1977) but at an accelerated rate. A 
comparison of the maturation and degeneration of pigeon aortic cells in vivo and in vitro 
is presented in Table 2. In culture, foam cell development is evident in WC SMC by 8-10 
days, where several weeks are needed in order to observe the same phenomena in vivo. 
Other differences in the WC SMC include more esterified cholesterol present in lipid 
vacuoles, less arachidonate, and decreased mitochondrial metabolism. Although it has 
been demonstrated that the act of culturing aortic cells can change the SMC phenotype 
from contractile to synthetic (Worth et al., 2001), this has not been observed in primary 
cultures, where the lack of sub-culture minimizes potential genetic alterations. WC aortic 
cells obtained in vitro demonstrate a similar degenerative progression as those cells 
observed in the celiac bifurcation (Cooke & Smith, 1968; Wight et al., 1977), offering 
further evidence that the gene expression profile is comparable between the two model 
systems. 
In vitro, there is no signal communication between SMC and endothelial cells, monocytes, 
hormones, neurotransmitters, other humoral factors, and whole body feedback systems 
(Shanahan & Weissberg, 1998; Thyberg et al., 1990). The only source of interaction is 
between the SMC and the media components, resulting in cell growth and ECM synthesis. 
This makes it possible to observe the intrinsic characteristics of WC and SR aortic cell 
development in a controlled, time-compressed setting, while limiting the number of genes 
under investigation to those specific to aortic SMC. Interestingly, although only the SMC of 
the WC celiac and coronary bifurcations are susceptible to atherogenesis in vivo, SMC taken 
from other WC tissue such as the gizzard or small intestine exhibit features in vitro similar 
to atherogenesis in aortic cells. This is not the case in the SR, where neither SMC from the 
celiac foci, nor SMC from any other tissue undergo phenotype modification when cultured 
under identical conditions.  
The aforementioned experiments provide additional evidence that the genetic defect 
predisposing the WC to atherosclerosis is conditionally expressed in SMC. Factors that 
stimulate the expression of atherogenic genes at the celiac bifurcation in vivo appear to be 
present in vitro, as the cultured WC cells undergo degeneration parallel to their 
counterparts in aortic tissue (Cooke & Smith, 1968; Wight et al., 1977). Genetic factors 
denoting resistance in the SR remain expressed in both experimental environments.  
 




Table 2. Maturation and degeneration of pigeon aortic cells. 
Anderson (2008) analyzed differential gene expression in vitro at day seven of cellular 
growth. Ninety-one genes were uniquely expressed in the susceptible WC cells compared to 
101 genes exclusive to the resistant SR. There was a marked difference in energy metabolism 
between the two breeds. The SR VSMC expressed genes related to oxidative 
phosphorylation such as cytochrome B, cyctochrome C oxidase subunit I, NADH 
dehydrogenase subunit 4, ubiquinone, and ATP synthase subunit 4B. This was in direct 
contrast to the glycolytic genes expressed by the WC which included enolase, glucose 
phosphate isomerase, and lactate dehydrogenase subunit B.  
In addition, genes expressed by the SR were indicative of a contractile VSMC phenotype 
whereas susceptible WC pigeons expressed genes that reflected a synthetic phenotype. 
Spondin, decorin, vimentin and beta actin were upregulated in the WC. Myosin heavy 
chain, myosin light chain kinase, tropomyosin, and alpha actin were expressed in the SR. 
The resistant SR appeared to develop and maintain an extracellular matrix with structural 
integrity, whereas the susceptible WC was already expressing proteases and immune 
signals.  
Although many genes were different between the two breeds, the compressed time frame 
made it difficult to determine what happens first: changes in energy metabolism or changes 
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sequence of events and determine the single gene responsible for atherogenesis in the WC 
pigeon.  
Analysis of SMC soluble proteins from WC and SR pigeons revealed differential expression 
between the two breeds. Eight discrete zones of molecular weight versus pI were identified, 
five which included only proteins unique to susceptible cells and three which included 
proteins unique to resistant cells. Eighty-eight differentially-expressed proteins were found 
in susceptible cells with 41 located in unique zones. Resistant cells had 29 of 82 
differentially-expressed proteins in unique zones. Some annotated proteins, including 
smooth muscle myosin phosphatase, myosin heavy chain, fatty acid binding protein, 
ribophorin, heat shock protein, TNF alpha-inducing factor, and lumican, corresponded to 
genes identified previously or to current hypotheses to explain atherogenesis (Smith et al., 
2008).   
Additional research to identify the causative gene for spontaneous atherosclerosis will be 
facilitated by pigeon genome sequencing. Comparative studies between the resistant versus 
susceptible breeds may reveal sequence variation contributing to the disease. The pigeon 
remains an important model to study the genetic role at the site of lesion development that 
is associated with human atherosclerosis. 
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1. Introduction
Mathematical Medicine is a relatively new and expanding area of Applied Mathematics
research with a growing number of mathematicians, experimentalist, biomedical engineers,
and research physicians involved in collaborative efforts on a global scale. Mathematical
models are playing an increasing role in our understanding of such complex biological
processes as the onset, progression, and mitigation of various diseases. The cardiovascular
system is particularly intricate, and the formulation and analysis of mathematical models
presents a myriad of challenges to the investigator. (See (Quarteroni, 2001) for a survey on
the subject.) Mathematical studies of the cardiovascular system have included continuum
mechanical models of vascular soft tissue (Holzapfel et al., 2000; Humphery & Rajagopal,
2002; Taylor & Humphrey, 2009), fluid dynamical models of the interaction between
blood flow and vessel walls (Baek et al., 2007; Quarteroni, 2001; Veneziani, 1998), and
mathematical models, such as that of the present work, of biochemical characteristics of the
vasculature (Ibragimov et al., 2005; Neumann et al., 1990; Saidel et al., 1987). The disease
of atherosclerosis, and its initiation atherogenesis, involves a complex interplay between
mechanical, genetic, pathogenic, and biochemical processes. A comprehensive view of
atherosclerosis will ultimately require integration of these various modeling perspectives.
Herein, we focus on the inflammatory component of atherogenesis, in particular the role of
immune cells–primarily macrophages–in the presence of oxidatively modified low density
lipoproteins (LDL cholesterol) within the intimal layer of large muscular arteries. We present
a mathematical model of the key inflammatory spiral that characterizes the initiation of
atherosclerosis, and perform some analyses of this model.
It is well accepted that atherosclerosis is marked by chronic inflammation (Creager &
Braunwald , eds.; Fan & Watanabe, 2003; Ross, 1995; 1999; Wilson , ed.). Changes in the
permeability of the endothelial layer and subsequent deposition of lipids in the intima cause
an up-regulation of chemoattractants such as monocyte chemotactic protein 1, interleukin-8
and macrophage colony-stimulating factor that are secreted by the endothelial and other
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1. Introduction
Mathematical Medicine is a relatively new and expanding area of Applied Mathematics
research with a growing number of mathematicians, experimentalist, biomedical engineers,
and research physicians involved in collaborative efforts on a global scale. Mathematical
models are playing an increasing role in our understanding of such complex biological
processes as the onset, progression, and mitigation of various diseases. The cardiovascular
system is particularly intricate, and the formulation and analysis of mathematical models
presents a myriad of challenges to the investigator. (See (Quarteroni, 2001) for a survey on
the subject.) Mathematical studies of the cardiovascular system have included continuum
mechanical models of vascular soft tissue (Holzapfel et al., 2000; Humphery & Rajagopal,
2002; Taylor & Humphrey, 2009), fluid dynamical models of the interaction between
blood flow and vessel walls (Baek et al., 2007; Quarteroni, 2001; Veneziani, 1998), and
mathematical models, such as that of the present work, of biochemical characteristics of the
vasculature (Ibragimov et al., 2005; Neumann et al., 1990; Saidel et al., 1987). The disease
of atherosclerosis, and its initiation atherogenesis, involves a complex interplay between
mechanical, genetic, pathogenic, and biochemical processes. A comprehensive view of
atherosclerosis will ultimately require integration of these various modeling perspectives.
Herein, we focus on the inflammatory component of atherogenesis, in particular the role of
immune cells–primarily macrophages–in the presence of oxidatively modified low density
lipoproteins (LDL cholesterol) within the intimal layer of large muscular arteries. We present
a mathematical model of the key inflammatory spiral that characterizes the initiation of
atherosclerosis, and perform some analyses of this model.
It is well accepted that atherosclerosis is marked by chronic inflammation (Creager &
Braunwald , eds.; Fan & Watanabe, 2003; Ross, 1995; 1999; Wilson , ed.). Changes in the
permeability of the endothelial layer and subsequent deposition of lipids in the intima cause
an up-regulation of chemoattractants such as monocyte chemotactic protein 1, interleukin-8
and macrophage colony-stimulating factor that are secreted by the endothelial and other
cells. In addition, LDL molecules become trapped in the subendothelial intima where they
3
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are subject to oxidative modification by reactive oxygen species. Macrophages begin to
accumulate in the region where they assume a pro-inflammatory phenotype. The stimulation
of macrophages may be due to the presence of inflammatory extra-cellular matrix fragments.
In addition, oxidized LDL is recognized by a macrophage scavenger receptor with some
degree of interindividual variation (Boullier et al., 2001; Martín-Fuentes et al., 2007; Mosser
& Edwards, 2008; Podrez et al., 2002). Macrophages attempting to internalize these particles
may become engorged with cholesterol and transform into foam cells. In this state, these
immune cells are incapable of performing the customary immune function and become part
of a developing atherosclerotic lesion. The immune response is mediated by those chemical
signals emitted by endothelial cell, immune cells, and immune cell derived foam cells. The
corruption 1 of the immune process caused by ingestion of oxidized LDL can trigger an
inflammatory response which results in increased immune cell migration to the site, possible
further corruption, and ultimately accumulation of debris (necrotic, apoptotic, and lipid laden
cells) characterizing plaque onset. This inflammatory spiral facilitated by chemotaxis, the
process modeled herein, is a hallmark of atherogenesis.
It will become evident that our model incorporates many parameters characterizing such
things as the rate at which macrophages move within the intimal tissue (independent of and in
response to chemokines), rates of phenotype changes for macrophages, rates of phagocytosis
and uptake of lipids by immune cells, degratation rates of various chemicals, chemical
reaction rates and so forth. Some of these have value ranges that are known in vitro or in vivo,
but many are unknown. The analytical techniques employed at present are linear stability
studies. This allows us to obtain criteria based on the relative values of parameters and to
interpret these criteria in terms of the propensity for a lesion to initiate—or not. These criteria
will take the form of various inequalities in section 4.
In the next section, we lay out the disease paradigm and the assumptions upon which the
mathematical model is constructed. This is followed by a presentation of the general model
in the form of a system of nonlinear, primarily parabolic partial differential equations with
mixed third type boundary conditions. In section 4, we perform stability analyses of the model
under two different assumptions regarding the source of inflammatory components. Two
stability theorems are given along with a bio-medical interpretation of the criteria derived.
Also included is a discussion of the existence of unstable equilibria with a focus on the role
of an antioxidant presence and the competing processes of macrophage motility (unrelated to
chemotaxis) and chemotaxis. The chapter closes with a brief conclusion.
2. The disease paradigm and model basis
The large muscular arteries most vulnerable to atherosclerotic lesions can be considered
as thick walled tubes consisting of three distinct layers. The outermost layer, called the
adventitia, provides structural integrity through a strong collagen network. The middle
layer, the media, provides flexibility and adaptability through layers of smooth muscle cells
enmeshed in an elastin and collagen network. And the thin, innermost layer, called the intima,
is where the atherosclerotic lesions begin to develop. A monolayer of endothelial cells forms
an interface between the intima and the lumen through which blood flows. These endothelial
cells are highly active in the circulatory process providing a smooth surface for fluid flow,
1 The term "corruption" refers to the formation of foam cells due to the failure of the scavenger receptor
to down regulate in response to excess cellular cholesterol content (Steinberg, 2002), and to the ability
of C-reactive protein and oxLDL to increase the inflammatory properties of monocytes (Zhang & Wahl,
2006).
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secreting anticoagulant, procoagulant, and inflammatory factors and regulating the exchange
of cells and molecules between the blood and arterial wall. Insult to the endothelium and
so called endothelial dysfunction is a precursor to atherosclerosis. A number of pathological
conditions, genetic factors, and behavioral practices may result in endothelial dysfunction
(Davignon & Ganz, 2004). This process appears to be characterized by a change in the
permeability of the endothelial layer that allows lipids to migrate into the subendothelial layer
followed by an influx of the cells that comprise the immune response. Following endothelial
dysfunction and migration of lipoproteins and immune cells, we identify two significant
steps to atherogenesis. These are oxidative modification of LDL, and the initiation of an
inflammatory spiral.
2.1 Lipoprotein oxidation
Lipoproteins are micellar particles which contain regulatory proteins that direct the blood
trafficking of cholesterol and other lipids to various cells in the body.. There are four major
classes of lipoprotein–chylomicrons, very low-density lipoproteins (VLDL), low-density
lipoproteins, and high-density lipoproteins (HDL)—but the bulk of cholesterol is contained
in the latter two. Low density lipoproteins consist of a lipid core, a surface protein and a
number of antioxidant defenses. LDLs deposit cholesterol in the tissues for cell metabolism.
High density lipoproteins contain most of the remaining cholesterol in the body. These
particles take excess lipids from tissues and return them to the liver for processing—the
process referred to as reverse transport. Elevated plasma levels of LDL indicate a high risk
of disease primarily because of their susceptibility to becoming trapped within the intima and
subsequently attacked by radical oxygen species. The inflammation of atherosclerotic lesions
occurs in areas of intimal thickening enriched by deposits of oxidized LDL.
The modification of LDL is a complicated process that has been the subject of several studies,
and the reader is directed to the articles (Parthasarathy et al., 1992; Steinberg, 1997) and the
review (Young & McEneny, 2001) and the references therein for a more complete and detailed
description. Cobbold, Sherratt and Maxwell provided a mathematical model of the in vitro
cascade of oxidation of LDL cholesterol in 2002 formulated according to a linear chemical
reaction process (Cobbold et al., 2002). This model is adapted and included in the present
model of atherogenesis. In brief, the mechanics of the process can be described as follows: In
the tissue, where the concentration of reactive oxygen species (ROS) may be relatively high
and external antioxidant defenses low, each interaction of an ROS and an LDL molecule will
result in oxidizing one of the vitamin E molecules on the lipid surface. It is also possible that
an oxidized vitamin E molecule (α-tocopherol radical) may be reduced back to a vitamin E
molecule by an antioxidant present (Niki et al., 1984; Watanabe et al., 1999). If, through a
finite sequence of oxidation of vitamin E molecules, an LDL molecule losses all of its innate
defense against free radical attack, it is susceptible to peroxidation of its lipid core. Once fully
modified, the oxidized LDL is both attractive to macrophages and unable to leave the intima
(unlike oxidized HDL particles (Tall, 1998)).
2.2 The inflammatory response
Accompanying the permeability changes to the endothelium and the influx of lipids is
the immune response. Various white blood cells (monocytes, T-lymphocytes, neutrophils)
migrate into tissues in response to chemical signals. Once in the subendothelial intima,
monocytes differentiate into macrophages. Under normal healthy conditions, these immune
cells aid in the degradation of apoptotic cells as well as the removal of foreign agents such
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are subject to oxidative modification by reactive oxygen species. Macrophages begin to
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and uptake of lipids by immune cells, degratation rates of various chemicals, chemical
reaction rates and so forth. Some of these have value ranges that are known in vitro or in vivo,
but many are unknown. The analytical techniques employed at present are linear stability
studies. This allows us to obtain criteria based on the relative values of parameters and to
interpret these criteria in terms of the propensity for a lesion to initiate—or not. These criteria
will take the form of various inequalities in section 4.
In the next section, we lay out the disease paradigm and the assumptions upon which the
mathematical model is constructed. This is followed by a presentation of the general model
in the form of a system of nonlinear, primarily parabolic partial differential equations with
mixed third type boundary conditions. In section 4, we perform stability analyses of the model
under two different assumptions regarding the source of inflammatory components. Two
stability theorems are given along with a bio-medical interpretation of the criteria derived.
Also included is a discussion of the existence of unstable equilibria with a focus on the role
of an antioxidant presence and the competing processes of macrophage motility (unrelated to
chemotaxis) and chemotaxis. The chapter closes with a brief conclusion.
2. The disease paradigm and model basis
The large muscular arteries most vulnerable to atherosclerotic lesions can be considered
as thick walled tubes consisting of three distinct layers. The outermost layer, called the
adventitia, provides structural integrity through a strong collagen network. The middle
layer, the media, provides flexibility and adaptability through layers of smooth muscle cells
enmeshed in an elastin and collagen network. And the thin, innermost layer, called the intima,
is where the atherosclerotic lesions begin to develop. A monolayer of endothelial cells forms
an interface between the intima and the lumen through which blood flows. These endothelial
cells are highly active in the circulatory process providing a smooth surface for fluid flow,
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conditions, genetic factors, and behavioral practices may result in endothelial dysfunction
(Davignon & Ganz, 2004). This process appears to be characterized by a change in the
permeability of the endothelial layer that allows lipids to migrate into the subendothelial layer
followed by an influx of the cells that comprise the immune response. Following endothelial
dysfunction and migration of lipoproteins and immune cells, we identify two significant
steps to atherogenesis. These are oxidative modification of LDL, and the initiation of an
inflammatory spiral.
2.1 Lipoprotein oxidation
Lipoproteins are micellar particles which contain regulatory proteins that direct the blood
trafficking of cholesterol and other lipids to various cells in the body.. There are four major
classes of lipoprotein–chylomicrons, very low-density lipoproteins (VLDL), low-density
lipoproteins, and high-density lipoproteins (HDL)—but the bulk of cholesterol is contained
in the latter two. Low density lipoproteins consist of a lipid core, a surface protein and a
number of antioxidant defenses. LDLs deposit cholesterol in the tissues for cell metabolism.
High density lipoproteins contain most of the remaining cholesterol in the body. These
particles take excess lipids from tissues and return them to the liver for processing—the
process referred to as reverse transport. Elevated plasma levels of LDL indicate a high risk
of disease primarily because of their susceptibility to becoming trapped within the intima and
subsequently attacked by radical oxygen species. The inflammation of atherosclerotic lesions
occurs in areas of intimal thickening enriched by deposits of oxidized LDL.
The modification of LDL is a complicated process that has been the subject of several studies,
and the reader is directed to the articles (Parthasarathy et al., 1992; Steinberg, 1997) and the
review (Young & McEneny, 2001) and the references therein for a more complete and detailed
description. Cobbold, Sherratt and Maxwell provided a mathematical model of the in vitro
cascade of oxidation of LDL cholesterol in 2002 formulated according to a linear chemical
reaction process (Cobbold et al., 2002). This model is adapted and included in the present
model of atherogenesis. In brief, the mechanics of the process can be described as follows: In
the tissue, where the concentration of reactive oxygen species (ROS) may be relatively high
and external antioxidant defenses low, each interaction of an ROS and an LDL molecule will
result in oxidizing one of the vitamin E molecules on the lipid surface. It is also possible that
an oxidized vitamin E molecule (α-tocopherol radical) may be reduced back to a vitamin E
molecule by an antioxidant present (Niki et al., 1984; Watanabe et al., 1999). If, through a
finite sequence of oxidation of vitamin E molecules, an LDL molecule losses all of its innate
defense against free radical attack, it is susceptible to peroxidation of its lipid core. Once fully
modified, the oxidized LDL is both attractive to macrophages and unable to leave the intima
(unlike oxidized HDL particles (Tall, 1998)).
2.2 The inflammatory response
Accompanying the permeability changes to the endothelium and the influx of lipids is
the immune response. Various white blood cells (monocytes, T-lymphocytes, neutrophils)
migrate into tissues in response to chemical signals. Once in the subendothelial intima,
monocytes differentiate into macrophages. Under normal healthy conditions, these immune
cells aid in the degradation of apoptotic cells as well as the removal of foreign agents such
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as bacteria or viruses through phagocytosis. As stated, macrophages have a high affinity
for oxidized LDL. However, attempts to take up the modified lipids by the process of
phagocytosis are unsuccessful, and the lipid laden macrophages transform into foam cells
(Goldstein et al., 1977; Podrez et al., 2002; Steinberg, 1997). Unable to perform their normal
immune function, these lipid-laden cells signal other immune cells to the site precipitating
accumulation of fatty tissue and the progression toward plaque growth. Additional chemical
signals secreted by the foam cells and endothelial cells summon more immune cells to the
site. Additional macrophages migrate to the localized site of inflammation. The chemical
mediators of inflammation can increase binding of oxidized LDL to cells in the arterial wall
(Hajjar & Haberland, 1997). Hence, the new macrophages become engorged with oxidized
LDL and the cycle of chemical signaling continues.
The role of macrophages in initiation of an atherosclerotic lesion is complicated and far
from singular. 2 In addition to foam cells, apoptotic macrophages are regularly found in
lesions. Apoptosis of cells (macrophage and others) within a plaque is found to have both
stabilizing as well as destabilizing affects (Cui et al., 2007; Tabas, 2004). Phagocytosis of
apoptotic cells (not necessarily macrophages) may induce resistance to foam cell formation
among macrophages. This occurs when during phagocytosis, the macrophage takes in high
levels of membrane-derived cholesterol as opposed to lipoprotein-derived cholesterol. In Cui
et al. , the authors report that ingestion of apoptotic cells induced a survival response in the
macrophages in their experiments (Cui et al., 2007). It is also known that macrophages appear
in different phenotypes that are non-static in the sense that they may change types—a process
that is reversible (Kadl et al., 2010; Mosser & Edwards, 2008; Stout et al., 2005), and that
the different types serve opposing functions (e.g. inflammatory versus anti-inflammatory).
Moreover, the sources of additional immune cells include transport across the endothelium
as well as migration via the vasa vasorum that provides blood to the artery wall. The
mathematical model is constructed to allow for the diverse functions of the immune cells.
(For a mathematical study similar to that presented here that focuses primarily on the
competing role of inflammatory and anti-inflammatory macrophages, we direct you to the
article (Ibragimov et al., 2008).)
3. The mathematical model
We begin by identifying the key chemical and cellular species involved in atherogenesis. For
each species, an evolution equation is derived through the classical approach of imposing
a mass balance in an arbitrary control volume and subsequent reduction to a pointwise
statement. We do not consider here the volume of a lesion but rather the concentration of
each species at any point.
Our model consists of five classes of generalized species–two cellular and three chemical–that
have critical roles in the initiation of an atherosclerotic lesion. These classes are labeled and
denoted as follows:
I Immune cells: These are primarily monocyte derived macrophages but may include other
white blood cells (T-cells and perhaps neutrophils).
D Debris: This is the bulk of a forming lesion consisting of apoptotic cells, macrophage
derived foam cells, and potentially necrotic tissue . Our use of the term debris is
unconventional in the sense that we do not intend to suggest that these are inert cells
2 The reader is directed to the article Mosser & Edwards (2008) for an excellent review of the array of
macrophage phenotypes and functions.
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or simply a byproduct of some process and merely occupy space. As will be seen in the
mathematics to follow, this species type plays a pivotal role in the inflammatory feedback.
C Chemoattractant: This chemical species represents any of a number of cytokines
and chemotactic molecules including macrophage colony stimulating factor, monocyte
chemotactic protein-1, and various interleukin proteins. Any chemical that is used in the
regulation of the immune response primarily through inducing chemotaxis is included in
this species type.
L & Lox Low density lipoproteins: The LDL species consists of two major sub-types, those
in a native (un-oxidized) state, and those molecules that have undergone full peroxidation
of the lipid core.
R Reactive oxygen species: These are free radical molecules that induce oxidative damage to
the lipoproteins present. This species is a byproduct of various metabolic processes within
the arterial wall.
Also included in the model are several input parameters. Of particular interest are the
parameters Aox, that is a level of antioxidants such as vitamins C, E, and beta-carotene, and
LB representing the serum concentration of LDL.
Each of the representative variables here is a vector with each component representing a
specific member of the class. For example,
I = (I1, I2, . . . , INI )T
where each component Ii, i = 1, . . . , NI may be a different specific white blood cell, a different
phenotype, or may represent cells in different roles. We allow for I to have NI components,
D to have ND, C to have NC, L to have NL + 13, and each of Lox and R are scalar valued.
If we isolate any representative variable u from this list, we construct an equation of the form
∂u
∂t
= −∇ · Ju + Qu
that equates the evolution of the concentration of species u to a spatial flux field Ju and any
net source Qu due to cellular interactions, chemical secretion or uptake, chemical reactions,
and the like. The flux fields and source terms are outline below for each variable.
3.1 Governing equations




















bikIkIi − ciIiLox − d1iIi , (3.1)
3 The model of LDL oxidation presented by Cobbold, Sherratt and Maxwell includes LDL molecules in
a fully native state containing NL vitamin E molecules. Studies show the number of such antioxidant
defenses is on average 6 per LDL molecule but may vary from 3 to 15 (Esterbauer et al., 1992; Stocker,
1999). We then consider Li to contain i vitamin E molecules where L0 represents LDL molecules
completely depleted of native vitamin E that has yet to undergo full oxidation of its core.
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The role of macrophages in initiation of an atherosclerotic lesion is complicated and far
from singular. 2 In addition to foam cells, apoptotic macrophages are regularly found in
lesions. Apoptosis of cells (macrophage and others) within a plaque is found to have both
stabilizing as well as destabilizing affects (Cui et al., 2007; Tabas, 2004). Phagocytosis of
apoptotic cells (not necessarily macrophages) may induce resistance to foam cell formation
among macrophages. This occurs when during phagocytosis, the macrophage takes in high
levels of membrane-derived cholesterol as opposed to lipoprotein-derived cholesterol. In Cui
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in different phenotypes that are non-static in the sense that they may change types—a process
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the different types serve opposing functions (e.g. inflammatory versus anti-inflammatory).
Moreover, the sources of additional immune cells include transport across the endothelium
as well as migration via the vasa vasorum that provides blood to the artery wall. The
mathematical model is constructed to allow for the diverse functions of the immune cells.
(For a mathematical study similar to that presented here that focuses primarily on the
competing role of inflammatory and anti-inflammatory macrophages, we direct you to the
article (Ibragimov et al., 2008).)
3. The mathematical model
We begin by identifying the key chemical and cellular species involved in atherogenesis. For
each species, an evolution equation is derived through the classical approach of imposing
a mass balance in an arbitrary control volume and subsequent reduction to a pointwise
statement. We do not consider here the volume of a lesion but rather the concentration of
each species at any point.
Our model consists of five classes of generalized species–two cellular and three chemical–that
have critical roles in the initiation of an atherosclerotic lesion. These classes are labeled and
denoted as follows:
I Immune cells: These are primarily monocyte derived macrophages but may include other
white blood cells (T-cells and perhaps neutrophils).
D Debris: This is the bulk of a forming lesion consisting of apoptotic cells, macrophage
derived foam cells, and potentially necrotic tissue . Our use of the term debris is
unconventional in the sense that we do not intend to suggest that these are inert cells
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or simply a byproduct of some process and merely occupy space. As will be seen in the
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C Chemoattractant: This chemical species represents any of a number of cytokines
and chemotactic molecules including macrophage colony stimulating factor, monocyte
chemotactic protein-1, and various interleukin proteins. Any chemical that is used in the
regulation of the immune response primarily through inducing chemotaxis is included in
this species type.
L & Lox Low density lipoproteins: The LDL species consists of two major sub-types, those
in a native (un-oxidized) state, and those molecules that have undergone full peroxidation
of the lipid core.
R Reactive oxygen species: These are free radical molecules that induce oxidative damage to
the lipoproteins present. This species is a byproduct of various metabolic processes within
the arterial wall.
Also included in the model are several input parameters. Of particular interest are the
parameters Aox, that is a level of antioxidants such as vitamins C, E, and beta-carotene, and
LB representing the serum concentration of LDL.
Each of the representative variables here is a vector with each component representing a
specific member of the class. For example,
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where each component Ii, i = 1, . . . , NI may be a different specific white blood cell, a different
phenotype, or may represent cells in different roles. We allow for I to have NI components,
D to have ND, C to have NC, L to have NL + 13, and each of Lox and R are scalar valued.
If we isolate any representative variable u from this list, we construct an equation of the form
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that equates the evolution of the concentration of species u to a spatial flux field Ju and any
net source Qu due to cellular interactions, chemical secretion or uptake, chemical reactions,
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kRRLk − kRoRL0 − hAoxR+ pR. (3.8)
The various parameters appearing in (3.1)–(3.8) require explanation; a succint description
of each is given in table 1. Each species is subject to diffusion, or diffusive motility in the
case of immune cells, and this is reflected in the flux terms μu∇2u (u represents any of the
various state variables I–R) with the coefficient μ with a subscript a measure of the motility
or diffusive capability of the respective species.
χik chemotactic sensitivity of immune species i to chemical stimulant k
aik , âik binding of immune cells to the lesion for removal
bik measure of subspecies interaction for immune cells
ci , fi rates of foam cell formation
dni cell turn over or chemical degradation rate
pik rate of chemical attractant production due to the lesion presence
eik uptake of chemoattractant during chemotaxis
kR, kR0 , kA rate of oxidation, peroxidation, and reverse (anti-oxidation), respectively
dni cell turn over or chemical degradation rate
pik rate of chemical attractant production due to the lesion presence
eik uptake of chemoattractant during chemotaxis
τi , h efficiency factors
pR production of free-radicals due to normal metabolism
Table 1. Bio-physiological Interpretation of Parameters
The terms χik(Ck, Ii)∇Ck are the contribution to the flux field for macrophages due to
chemotaxis. The coefficient χik(Ck, Ii) is the chemo-tactic sensitivity of immune cell i to
chemoattractant k. This is the classic Keller-Segal model of chemotaxis (Keller & Segel, 1971).
The dependence of χik on the immune cells is generally taken to be linear, however there is
no present need to specify a particular form for these functions. Each of the immune cells,
debris, chemoattractants, and native LDL species may undergo natural turnover or chemical
degradation represented by the last terms in equations (3.1)–(3.6).
The immune cell equations contain three significant cross interaction terms. The terms aikDkIi
capture binding of macrophages with debris—in particular, these and the analogous terms
âikIkDi in (3.2), account for phagocytosis of debris by healthy macrophages and removal for
future processing in the liver. We also allow for inter-species interactions via the terms bikIkIi
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in (3.1). This accounts, for example, for potential change of phenotype of macrophages during
the inflammatory process. Recent studies have demonstrated that such changes may occur
(reversibly) in vitro and in animal models (Kadl et al., 2010; Stout et al., 2005). Finally, the
formation of foam cells through binding with oxidized LDL appears in equations (3.1) and
(3.7) in the removal terms ciIiLox and fkIkLox. This foam cell formation appears as a source
term in equation (3.2) as τi ∑
NI
k=1(ck + fk)IkLox, where 0 ≤ τi ≤ 1, ∑NDi=1 τi = 1. The parameter
τi allows us to catagorize different contributions to the lesion—different types of debris.
The equation for the chemoattractants includes (in addition to those terms already mentioned)
a source term reflecting production of these chemicals in response to the presence of
debris pikDkCi. The removal terms eikIkCi represent the reduction of the chemoattractant
concentration by binding with macrophages during chemotaxis.
As stated, the equations governing the lipid oxidation reactions (3.4)–(3.8) are a modification
of the model of lipoprotein oxidation presented by Cobbold, Sherratt and Maxwell in 2002
(Cobbold et al., 2002). The chemical kinetics are assumed to be a linear reaction model in
which an LDL molecule containing i vitamin E particles reacts with a reactive oxygen species,
with reaction rate kR to produce an LDL molecule with i − 1 vitamin E molecules. This
model also allows for the reverse oxidation reaction in that an LDL molecule with i < NL
vitamin E molecules may react with the antioxidant species Aox, with reaction rate kA, to
produce an LDL molecule with i + 1 vitamin E defenses. Any LDL molecule that has been
completely depleted of its native antioxidant defenses contributes to the concentration L0.
A subsequent reaction of an L0 molecule with an ROS (with reaction rate kR0 ) results in
peroxidation of the lipid core and a fully modified LDL particle. The ROS is depleted through
these reactions and through direct reaction with the anti-oxidant species–the latter occurring
with the rate of reaction h appearing in equation (3.8). The primary source of ROS is as a
byproduct of metabolic processes within the intima. The term pR represents this source. The
reader is encouraged to see (Cobbold et al., 2002) for a detailed construction of the model.
The modifications of Cobbold-Sherratt-Maxwell model presented here are two fold. First,
we allow for spatial variation through a standard Fickian diffusion. More significant to the
study of atherogenesis, we include the uptake of modified LDL by macrophages leading to
foam cell formation and subsequent inflammation. The terms fkIkLox represent removal of
oxidized LDL through macrophage binding and the contribution to the forming lesion as seen
in (3.2), (3.7) and (3.8).
3.2 Domain and boundary conditions
The system (3.1)–(3.8) can be considered in two or three spatial dimensions. In (Ibragimov
et al., 2005), the current authors performed numerical simulations of a simplified model
accounting only for immune cells, debris, chemoattractant, and later smooth muscle cells
(a species not considered here as we are interested only with the earliest onset of cellular
aggregation). Such simulations were performed in a two dimensional annular domain,
and demonstrated the ability of the model to produce such features as localization of
immune cells during inflammation and localized aggregation. The subsequent focus has
been on illuminating the interplay of the various parameters by considering the initiation
of inflammation as due to an instability in an equilibrium state. The general spatial regime
considered is a deformed annulus (in two dimensions) or a deformed annular tube (in three
spatial dimensions). In either case, the mathematical domain Ω is intended to represent
the tunica intima, the innermost subendothelial layer of an arterial wall. The annulus, or
annular tube, has an inner and outer boundary denoted by ΓI and ΓO, respectively. The inner
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The terms χik(Ck, Ii)∇Ck are the contribution to the flux field for macrophages due to
chemotaxis. The coefficient χik(Ck, Ii) is the chemo-tactic sensitivity of immune cell i to
chemoattractant k. This is the classic Keller-Segal model of chemotaxis (Keller & Segel, 1971).
The dependence of χik on the immune cells is generally taken to be linear, however there is
no present need to specify a particular form for these functions. Each of the immune cells,
debris, chemoattractants, and native LDL species may undergo natural turnover or chemical
degradation represented by the last terms in equations (3.1)–(3.6).
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âikIkDi in (3.2), account for phagocytosis of debris by healthy macrophages and removal for
future processing in the liver. We also allow for inter-species interactions via the terms bikIkIi
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in (3.1). This accounts, for example, for potential change of phenotype of macrophages during
the inflammatory process. Recent studies have demonstrated that such changes may occur
(reversibly) in vitro and in animal models (Kadl et al., 2010; Stout et al., 2005). Finally, the
formation of foam cells through binding with oxidized LDL appears in equations (3.1) and
(3.7) in the removal terms ciIiLox and fkIkLox. This foam cell formation appears as a source
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NI
k=1(ck + fk)IkLox, where 0 ≤ τi ≤ 1, ∑NDi=1 τi = 1. The parameter
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with reaction rate kR to produce an LDL molecule with i − 1 vitamin E molecules. This
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vitamin E molecules may react with the antioxidant species Aox, with reaction rate kA, to
produce an LDL molecule with i + 1 vitamin E defenses. Any LDL molecule that has been
completely depleted of its native antioxidant defenses contributes to the concentration L0.
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these reactions and through direct reaction with the anti-oxidant species–the latter occurring
with the rate of reaction h appearing in equation (3.8). The primary source of ROS is as a
byproduct of metabolic processes within the intima. The term pR represents this source. The
reader is encouraged to see (Cobbold et al., 2002) for a detailed construction of the model.
The modifications of Cobbold-Sherratt-Maxwell model presented here are two fold. First,
we allow for spatial variation through a standard Fickian diffusion. More significant to the
study of atherogenesis, we include the uptake of modified LDL by macrophages leading to
foam cell formation and subsequent inflammation. The terms fkIkLox represent removal of
oxidized LDL through macrophage binding and the contribution to the forming lesion as seen
in (3.2), (3.7) and (3.8).
3.2 Domain and boundary conditions
The system (3.1)–(3.8) can be considered in two or three spatial dimensions. In (Ibragimov
et al., 2005), the current authors performed numerical simulations of a simplified model
accounting only for immune cells, debris, chemoattractant, and later smooth muscle cells
(a species not considered here as we are interested only with the earliest onset of cellular
aggregation). Such simulations were performed in a two dimensional annular domain,
and demonstrated the ability of the model to produce such features as localization of
immune cells during inflammation and localized aggregation. The subsequent focus has
been on illuminating the interplay of the various parameters by considering the initiation
of inflammation as due to an instability in an equilibrium state. The general spatial regime
considered is a deformed annulus (in two dimensions) or a deformed annular tube (in three
spatial dimensions). In either case, the mathematical domain Ω is intended to represent
the tunica intima, the innermost subendothelial layer of an arterial wall. The annulus, or
annular tube, has an inner and outer boundary denoted by ΓI and ΓO, respectively. The inner
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boundary ΓI corresponds to the monolayer of endothelial cells that form the interface between
the arterial wall and the lumen, while the boundary ΓO represents the inner elastic lamina that
separates the intima from the media. In the following analyses, we will assume that there is
no transport of any species across the boundary ΓO. While there may well be some transport
across this elastic lamina—in particular of free radicals due to metabolic processes within the
media—we will assume here that any such contribution is negligible relative to production,
consumption, and inter-species reactions within the intima.
Influx through the inner boundary ΓI is for some species a significant source in the model. In
particular, the chemoattractant and native LDL are subject to a third type boundary condition
on ΓI modeling transport in response to a chemical potential across the endothelial cells. This








= αL(LNL −LB). (3.10)
Here, n is the outward unit normal to ΓI , C∗ is a baseline level of chemoattractant present at
the endothelium, and LB is the serum level of LDL. The parameters αC,i are assumed to be
non-negative. However, the sign of αL is not specified so that (3.10) may correspond with
either forward transport of native LDL into the subendothelial intima or reverse transport
of native LDL into the blood. We assume here that LDL in the blood stream is fully native
(has undergone no free radical attack) so that only native LDL is capable of either forward or
reverse transport.
The immune cells are also subject to transport across the endothelium. The mechanism here
is a chemo-tactic sensitivity regulated by the level of chemoattractant at the endothelium. The
boundary condition is therefore a mixed third type condition with the flux of immune cells





Each function αI,i(C), i = 1, . . . , NI is a nonnegative monotone function of the vector C of
chemoattractants 4.
The remaining boundary conditions are
∂Υ
∂n
= 0, Υ = D,Li,Lox,R i = 0, . . . , NL − 1, on ΓI
∂Υ
∂n
= 0, Υ = I , C,D,L,Lox,R on ΓO. (3.12)
This is the mathematical representation of the previous statement that no transport of any
species across the inner elastic lamina separating the intima and the media is considered
significant relative to the interactions within the intima, and that only fully native LDL,
4 We can state the boundary condition for the immune cells in the more general form
JIi · n = −ᾱI,i(C)
where JIi = −
(
μIi∇Ii − ∑Nck=1 χik(Ck , Ii)∇Ck
)
is the flux field for the ith immune cell species, and ᾱI,i
is a corresponding reformulation of the right hand side of (3.11).
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immune cells and chemoattractant enter into the system via the endothelial layer. We may
further consider the completely homogeneous Neumann conditions under the conditions that
αC,i = αL = αI,i = 0. This closed system requires a modification of (3.1) to include a source
term. This may be interpreted as modeling the vasa vasorum as the sole source of immune
cells contributing to the inflammatory process. In reality, supply both via the vasa vasorum
and via transport across the endothelium occur simultaneously. Study of the two extreme
cases considered here is done to illuminate both the biological and mathematical differences
these two delivery mechanisms make in the modeling and analysis.
4. Mathematical analysis of the model
There are several approaches to analyzing a particular mathematical model including
numerical simulations, asymptotic and perturbation methods, and stability analyses. As
suggested, the last of these, stability analyses, is particularly applicable under the present
circumstances since we do not have experimental data from which to glean relevant
ranges for many of the parameters. A classical approach to mathematical models of
biological phenomena—especially those characterized by pattern formation, morphogenesis,
and aggregation (Keller & Segel, 1971; Murray, 2002; Turing, 1952), is to consider significant
state changes as resulting from a mathematical instability. This will result in the criteria based
on relative parameter ranges. The inequalities will depend not only on the relationships
between parameter ranges, but also on the source of inflammatory factors, and on the size
of the domain (intimal thickness).
We present stability analyses of the system (3.1)–(3.8) under some specified conditions. The
system considered throughout this section will be simplified to account for one of each of the
species types I ,D, C, one native LDL species (which may be considered an averaging over
each of Li), an oxidized LDL species, and free-radicals. The system of equations is
∂I
∂t
= μI∇2I −∇ · (χ(I , C)∇C)− d1I − cILox − aID + Mφ0 (4.1)
∂D
∂t
= μD∇2D + ĉILox − âID − d2D (4.2)
∂C
∂t
= μC∇2C + pD − eCI − d3C (4.3)
∂L
∂t
= μL∇2L− kRLR+ kA AoxrLox − d4L (4.4)
∂Lox
∂t
= μLox∇2Lox + kR0LR− AoxrLox − fILox (4.5)
∂R
∂t
= μR∇2R− kRLR− hAoxR+ pR. (4.6)
The modification to (3.1) appearing in (4.1) includes the source term of macrophages via the
vasa vasorum as previously indicated (which may be set to zero if appropriate.) Since we are
considering only one native LDL species, we also modify the equations to allow for reverse
oxidation of oxidized LDL and allow for an efficiency factor r for such reactions. Subscripts
have been eliminated where they are no longer needed. For ease of notation ĉ = c + f .
Our analysis of (4.1)–(4.6) consists of a linear stability analysis using an energy estimate—i.e.
Lyapunov functional—-approach. That is, we consider certain equilibrium solutions of this
system as characterizing a healthy state free from certain inflammatory markers. We then ask
whether such equilibria are linearly, asymptotically stable.
57lumi ating Atherogenesis Thr ugh Mathematical Modeling
8 Will-be-set-by-IN-TECH
boundary ΓI corresponds to the monolayer of endothelial cells that form the interface between
the arterial wall and the lumen, while the boundary ΓO represents the inner elastic lamina that
separates the intima from the media. In the following analyses, we will assume that there is
no transport of any species across the boundary ΓO. While there may well be some transport
across this elastic lamina—in particular of free radicals due to metabolic processes within the
media—we will assume here that any such contribution is negligible relative to production,
consumption, and inter-species reactions within the intima.
Influx through the inner boundary ΓI is for some species a significant source in the model. In
particular, the chemoattractant and native LDL are subject to a third type boundary condition
on ΓI modeling transport in response to a chemical potential across the endothelial cells. This








= αL(LNL −LB). (3.10)
Here, n is the outward unit normal to ΓI , C∗ is a baseline level of chemoattractant present at
the endothelium, and LB is the serum level of LDL. The parameters αC,i are assumed to be
non-negative. However, the sign of αL is not specified so that (3.10) may correspond with
either forward transport of native LDL into the subendothelial intima or reverse transport
of native LDL into the blood. We assume here that LDL in the blood stream is fully native
(has undergone no free radical attack) so that only native LDL is capable of either forward or
reverse transport.
The immune cells are also subject to transport across the endothelium. The mechanism here
is a chemo-tactic sensitivity regulated by the level of chemoattractant at the endothelium. The
boundary condition is therefore a mixed third type condition with the flux of immune cells





Each function αI,i(C), i = 1, . . . , NI is a nonnegative monotone function of the vector C of
chemoattractants 4.
The remaining boundary conditions are
∂Υ
∂n
= 0, Υ = D,Li,Lox,R i = 0, . . . , NL − 1, on ΓI
∂Υ
∂n
= 0, Υ = I , C,D,L,Lox,R on ΓO. (3.12)
This is the mathematical representation of the previous statement that no transport of any
species across the inner elastic lamina separating the intima and the media is considered
significant relative to the interactions within the intima, and that only fully native LDL,
4 We can state the boundary condition for the immune cells in the more general form
JIi · n = −ᾱI,i(C)
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immune cells and chemoattractant enter into the system via the endothelial layer. We may
further consider the completely homogeneous Neumann conditions under the conditions that
αC,i = αL = αI,i = 0. This closed system requires a modification of (3.1) to include a source
term. This may be interpreted as modeling the vasa vasorum as the sole source of immune
cells contributing to the inflammatory process. In reality, supply both via the vasa vasorum
and via transport across the endothelium occur simultaneously. Study of the two extreme
cases considered here is done to illuminate both the biological and mathematical differences
these two delivery mechanisms make in the modeling and analysis.
4. Mathematical analysis of the model
There are several approaches to analyzing a particular mathematical model including
numerical simulations, asymptotic and perturbation methods, and stability analyses. As
suggested, the last of these, stability analyses, is particularly applicable under the present
circumstances since we do not have experimental data from which to glean relevant
ranges for many of the parameters. A classical approach to mathematical models of
biological phenomena—especially those characterized by pattern formation, morphogenesis,
and aggregation (Keller & Segel, 1971; Murray, 2002; Turing, 1952), is to consider significant
state changes as resulting from a mathematical instability. This will result in the criteria based
on relative parameter ranges. The inequalities will depend not only on the relationships
between parameter ranges, but also on the source of inflammatory factors, and on the size
of the domain (intimal thickness).
We present stability analyses of the system (3.1)–(3.8) under some specified conditions. The
system considered throughout this section will be simplified to account for one of each of the
species types I ,D, C, one native LDL species (which may be considered an averaging over
each of Li), an oxidized LDL species, and free-radicals. The system of equations is
∂I
∂t
= μI∇2I −∇ · (χ(I , C)∇C)− d1I − cILox − aID + Mφ0 (4.1)
∂D
∂t
= μD∇2D + ĉILox − âID − d2D (4.2)
∂C
∂t
= μC∇2C + pD − eCI − d3C (4.3)
∂L
∂t
= μL∇2L− kRLR+ kA AoxrLox − d4L (4.4)
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∂t
= μLox∇2Lox + kR0LR− AoxrLox − fILox (4.5)
∂R
∂t
= μR∇2R− kRLR− hAoxR+ pR. (4.6)
The modification to (3.1) appearing in (4.1) includes the source term of macrophages via the
vasa vasorum as previously indicated (which may be set to zero if appropriate.) Since we are
considering only one native LDL species, we also modify the equations to allow for reverse
oxidation of oxidized LDL and allow for an efficiency factor r for such reactions. Subscripts
have been eliminated where they are no longer needed. For ease of notation ĉ = c + f .
Our analysis of (4.1)–(4.6) consists of a linear stability analysis using an energy estimate—i.e.
Lyapunov functional—-approach. That is, we consider certain equilibrium solutions of this
system as characterizing a healthy state free from certain inflammatory markers. We then ask
whether such equilibria are linearly, asymptotically stable.
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4.1 Stability with zero transport across the endothelium
We consider a uniform, healthy equilibrium solution of (4.1)–(4.6) subject to the boundary
conditions (3.9), (3.10), (3.11), and (3.12) in the special case that αC = αL = αI = 0. We label
this equilibrium solution (Ie,De, Ce,Le,Loxe,Re), and introduce the perturbation variables
u, v, w, z, y, s which are defined by
I = Ie + u, D = De + v, C = Ce + w,
L = Le + z, Lox = Loxe + y, and R = Re + s.
Substituting the assumed form for I–R into (4.1)–(4.6) and keeping only terms that are linear
in the perturbation variables results in the system of equations
∂u
∂t
= μI∇2u −∇ · (χ∇w)− Au − Bu − Cu − Dv − Ey (4.7)
∂v
∂t
= μD∇2v + Fu − Gu − Hv − Iv + Jy (4.8)
∂w
∂t
= μC∇2w − Ku + Lv − Mw − Nw (4.9)
∂z
∂t
= μL∇2z − P1z + P2y − P3s (4.10)
∂y
∂t
= μLox∇2y − Q1u + Q2z − Q3y − Q4y + Q5s (4.11)
∂s
∂t
= μR∇2s − R1z − R2s − R3s (4.12)


















= 0 on ΓI ∪ ΓO. (4.13)
The various parameters appearing here are the rates at equilibrium given by
A = d1, B = cLoxe, C = aDe, D = aIe, E = cIe,
F = c15Loxe, G = âDe, H = âIe, I = d2, J = ĉIe,
K = eCe, L = p, M = eIe, N = d3, P1 = kRRe + d4, P2 = kA Aoxr,
P3 = kRLe, Q1 = fLoxe, Q2 = kR0Re, Q3 = Aoxr, Q4 = fIe,
Q5 = kR0Le, R1 = kRRe, R2 = kRLe, R3 = hAox,
and χ = χ(Ie, Ce). Each of these constants is assumed to be nonnegative, and due to balance
of mass F = B + Q1, J = E + Q4, Q2 = (P1 − d4) + R1, and Q5 = P3 + R2.
Let U = (u, v, w, z, y, s). Before proceeding, we define stability in the following way:
Definition 4.1. The equilibrium state is called asymptotically stable if every solution of the linearized
initial boundary value problem (4.7)–(4.13) for the perturbation variables vanishes at infinity in the
sense that there exists a positive functional
F (U) = Φ(t) such that lim
t→∞ Φ(t) = 0.
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Our study of (4.7)–(4.13) requires the construction of an appropriate functional F , and
this construction gives rise to the inequalities involving the parameters including intimal
thickness. In the interest of brevity, much of the computational details are omitted here. The
main results are stated with a discussion.
We begin by assuming that the product terms uv and uw are nonnegative within Ω. Physically,
this can be interpreted as saying that an increase in debris (v > 0) and an increase in
chemoattractant (w > 0) results in an increase in immune cells (u > 0). Likewise a decrease
in debris and chemoattractant (v < 0, w < 0) is met with a decrease in immune cells (u < 0).
This is a rather minor and biologically reasonable condition. However it can be dropped, and
a weaker stability theorem obtained (Ibragimov et al., 2010a).





−(A + B + C) −D 0 0 −E 0
F − G −(H + I) 0 0 J 0
−K L −(M + N) 0 0 0
0 0 0 −P1 P2 −P3
Q1 0 0 Q2 −(Q3 + Q4) Q5
0 0 0 −R1 0 −(R2 + R3)
⎤
⎥⎥⎥⎥⎥⎦
We will assume that the eigenvalues of Λ have negative real part. (The implication of this and
other imposed conditions will be discussed later.) In the following construction, this ensures
that integrals of the form
�
Ω Ui → 0 as t → ∞ for Ui = u, v, w, z, y, or s. This follows from
Green’s theorem and the homogeneous Neumann boundary conditions. This constraint does
not guarantee stability of the system or even point-wise boundedness of each Ui. We will also
assume here that μD = 0 which is consistent with the immobile nature of the lesion core.
A sequence of inequalities is obtained by multiplying (4.7) by u (4.8) by v, and so forth and
integrating over the domain Ω to secure bounds on the rate of change of the total energy of
the perturbations. In so doing, we introduce consideration of the geometry and size of the













Here, |Ω| is the volume of the domain, and the parameter Cp is dependent on the geometry
of the domain 5.
For ease of notation, we set
A1 = A + B + C, G1 = G − F, H1 = H + I, and M1 = M + N.
And in addition to the condition imposed upon the matrix Λ, suppose that













[Condition 4.1.4] L < 1, [Condition 4.1.5] G1 > 0, and [Condition 4.1.6] J < 1.
5 When an L2 norm is considered, Cp is related to the inverse of the first positive eigenfrequency of a free
membrane (Acosta & Durán, 2003).
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Following a systematic construction of integral inequalities from the equations (4.7)–(4.12) we
























































Cuu2 + Cvv2 + Cww2 + Czz2 + Cyy2 + Css2+
Cuv(uv) + Cuw(uw) + C∇u|∇u|2 + C∇w|∇w|2
]
. (4.14)
The coefficients on the right hand side of the inequality (4.14) are





)− D+E+Q12 , Cs = R2 + R3 + μRCp − P3+Q5+R12 ,
Cv = H1 − D+J+L2 − χL2μC D −
χM1 L
2KμC D
, Cuv = G1,
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We are now able to state our first major result.
Theorem 4.1. The equilibrium solution (Ie,De, Ce,Le,Loxe,Re) of (4.1)–(4.6) subject to the
homogeneous Neumann boundary conditions is asymptotically stable provided
(i)
∫
Ω uv > 0 and
∫
Ω uw > 0
(ii) all eigenvalues of Λ have negative real part,
(iii)Conditions 4.1.1–4.1.6 hold, and
(iv)M = min{Cu, Cv, Cw, Cz, Cy, Cs, Cuv, Cuw, C∇u, C∇w} > 0
The proof requires a definition of the functional as the obvious modification of the left hand
side of (4.14). Of interest are the physical interpretations of the sufficiency conditions stated
here. The meaning of the conditions on the products uv and uw has already been given. It
can also be noted that each of the coefficients appearing in the array (4.15) is written as a
positive term minus a non-negative term to highlight the relationships necessary between the
parameters to guarantee stability.
The condition on the matrix Λ—that its eigenvalues have negative real part—has distinct
bio-medical interpretation. Parameters E, J, and Q1 are the rates of foam cell production by
binding of macrophages to oxidized LDL. If these are large, then they are a source to the lesion.
If each of these is small (conditions 4.1.1 and 4.1.6), then to leading order Λ is block diagonal.
The parameters Q2 and R1 are the oxidation rates of LDL. If Q2 << 1 and R1 << 1–so
that Cz, Cs > 0, then the eigenvalues of the lower 3 × 3 block has negative eigenvalues −P1,
−(Q3 + Q4), and −(R2 + R3). A healthy system would be dominated by the antioxidant
reactions which correspond to large values of P1, Q3, Q4, R2, and R3. If in addition L << 1
(condition 4.1.4), then the production of chemoattractant due to the presence of the lesion is
small, and the eigenvalues of the upper 3 × 3 block are to leading order
−M1, −12 (H1 + A1)±
√
(H1 + A1)2 − 4(A1H1 − DG1).
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Large M1 indicates a fast degradation of chemoattractant and sufficient uptake of chemokines
by macrophages to minimize immune cell migration (reduce inflammation.) The parameters
D and G1 are large (condition 4.1.5) when the uncorrupted, healthy immune function
dominates through normal phagocytosis of lesion debris. Similarly, large values for A1 (due
to dependence on A and C) and large H1 correspond to degradation of the lesion and clearing
by macrophages. The sufficient condition for stability is the inequality
√
(H1 − A1)2 + 4DG1 < H1 + A1.
Several of the requirements for stability rest on the interplay between chemotactic effects and
diffusion/motility. This is typical of systems characterized by chemotaxis. Conditions 4.1.2
and 4.1.3 as well as the positivity of each parameter in the array (4.15) provide a minimal
requirement of the diffusivity of the intimal layer and the motility of macrophages—motility
unrelated to chemotaxis—to guarantee that a perturbation off of the healthy equilibrium state
decays.
4.2 Stability with transport of macrophages and LDL across the endothelium
We again consider the simplified system (4.1)–(4.6) and perturb off of a healthy equilibrium
solutions (Ie, . . . ,Re). However, we consider the boundary conditions (3.9), (3.10), (3.11), and
(3.12) with αC > 0, αL �= 0, and the form of αI appearing in (3.11) as
αI(C) = α0I (C − C∗) (4.16)
where C∗ is a base line serum level of chemoattractant and α0I is a positive constant. If the level
of chemotaxis inducing agents at the endothelial interface is greater than an average level in
the blood stream, then macrophages (or monocytes which differentiate) will enter into the
subendothelial intima.
The perturbation variables, u, . . . , s are defined in the same manner as in 4.1, and the linearized
system (4.7)–(4.12) is again studied. However, the boundary conditions on ΓI for the variables
u, w, and z (corresponding to immune cells, chemoattractant, and native LDL, respectively) in
the present analysis are nonhomogeneous and must be derived from (3.9), (3.10), and (3.11).
It should be noted that the existence of a spatially uniform equilibrium requires
Ce = C∗ and Le = LB





= α0I (Ce + w − C∗) so that μI
∂u
∂n





= −αCw, and μL dzdn = −αLz on ΓI . (4.18)
The additional boundary conditions on both ΓI and on ΓO remain as in section 4.1.
The approach applied previously must be modified here to account for the effect of the
boundary terms on the total energy of each perturbation variable. In addition to the Poincaré
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Following a systematic construction of integral inequalities from the equations (4.7)–(4.12) we
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Theorem 4.1. The equilibrium solution (Ie,De, Ce,Le,Loxe,Re) of (4.1)–(4.6) subject to the
homogeneous Neumann boundary conditions is asymptotically stable provided
(i)
∫
Ω uv > 0 and
∫
Ω uw > 0
(ii) all eigenvalues of Λ have negative real part,
(iii)Conditions 4.1.1–4.1.6 hold, and
(iv)M = min{Cu, Cv, Cw, Cz, Cy, Cs, Cuv, Cuw, C∇u, C∇w} > 0
The proof requires a definition of the functional as the obvious modification of the left hand
side of (4.14). Of interest are the physical interpretations of the sufficiency conditions stated
here. The meaning of the conditions on the products uv and uw has already been given. It
can also be noted that each of the coefficients appearing in the array (4.15) is written as a
positive term minus a non-negative term to highlight the relationships necessary between the
parameters to guarantee stability.
The condition on the matrix Λ—that its eigenvalues have negative real part—has distinct
bio-medical interpretation. Parameters E, J, and Q1 are the rates of foam cell production by
binding of macrophages to oxidized LDL. If these are large, then they are a source to the lesion.
If each of these is small (conditions 4.1.1 and 4.1.6), then to leading order Λ is block diagonal.
The parameters Q2 and R1 are the oxidation rates of LDL. If Q2 << 1 and R1 << 1–so
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We note that these inequalities also depend on the geometry of the domain through the
constants C1, C2, and C3. The consideration of best estimates for these constants has received
much attention (Acosta & Durán, 2003; Mazya, 1985). For the tubular domain considered
herein, the present authors provide estimates of the constants appearing in each of these
inequalities (including the Poincaré inequality) in (Ibragimov et al., 2010b).
The procedure is similar to that used in 4.1, and we obtain a set of inequalities relating the
parameters of the system that provide sufficient conditions under which the perturbations
will decay. Again, much of the computational details are omitted (the interested reader is
referred to (Ibragimov et al., 2010a) and to (Ibragimov et al., 2008; 2010b) for similar results).
Instead, we highlight a number of inequalities in light of the bio-medical significance and state
the primary result.
To facilitate the analysis, we assume that the decrease of oxidized LDL due to attempted
phagocytosis by macrophages is negligible compared the increase and decreases resulting
from the chemical reactions with free-radical and antioxidant species. (This is to say that
uptake by macrophages is a minor effect on the oxidized LDL concentration, not that foam cell
formation is negligible especially as it relates to debris growth or decay.) This is equivalent to
the previous case where Q1 is small and corresponds to f = 0 so that c = ĉ, Q1 = Q4 = 0.
Here, we no longer consider the transition matrix because we cannot impose any physically
reasonable constraints to guarantee that the integrals
(∫
Ω y
)2 and (∫Ω s
)2 can be ignored






Ω s are the average values of the
total perturbations of oxidized LDL and free radicals, respectively, over the entire domain.)
Instead, these are treated in the same manner as each of the perturbation variables.
The competing effects of diffusion (cellular motility) and chemotaxis are prominent in the
result in section 4.1, and the same is true when considering boundary transport. In the present
case, however, the sufficient conditions require the diffusion to overcome both chemotaxis
within the intima as well as that across the endothelial layer. In particular, stability will rest
on the conditions








≡ μ̄I ≥ 0
and
[Condition 4.2.2] μC − χ2 ≡ μ̄C > 0.
The latter condition arose in the previous result, however the former relates the impact
of chemotaxis at the boundary through the parameters α0I and αC on the net motility of
macrophages within the intima. A direct comparison with C∇u appearing in (4.15) reveals
the additional requirement on this motility to overcome chemotactic effects when boundary
transport is accounted for.
The diffusion and degradation of chemoattractant are also required to be significantly













(C3 is the constant from the Friedrich inequality.) The function C(ᾱ, μ̄C) is nondecreasing in
ᾱ and μ̄C independently, and will increase if both of these increase. The condition Cw > 0 in
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theorem 1 will be replaced by
M1 + C(ᾱ, μ̄C)C2 − L2 > 0.
Recall that M1 is the rate at which the chemoattractant is reduced within the intima due to
natural degradation and through uptake by macrophages during chemotaxis. The added
source of chemoattractant from the endothelial boundary is reflected in the new requirement
on the size of this parameter.
Of particular interest are the two cases of LDL transport—forward and reverse—that can be
admitted by allowing αL to be either positive or negative. When αL < 0, LDL enters into the
intima through the endothelial layer. Stability in this case will require




The second in condition 4.2.3(-) gives a specific requirement on the removal rate of LDL
(P1), especially due to chemical degradation, relative to influx across the endothelial layer
(αL), the oxidation kinetics within the intima (
P2+P3+R1+Q2
2 ), and the size of the intima (|Ω|).
This particular inequality indicates that intimal thickening is destabilizing mathematically.
The role of diffuse intimal thickening (DIT) as a precursor to, and in the early stages of,
atherosclerosis has been the subject of a number of studies (Nakashima et al., 2008). Those
arteries that are prone to atherosclerotic lesions such as the abdominal aorta, carotid, and
coronary arteries are observed to express DIT whereas arteries known to be resistant to
atherosclerosis do not (Nakashima et al., 2002). Accumulation of oxidized LDL relative to
native LDL in the deep region of DIT in human coronary arteries has been observed (Fukuchi
et al., 2002).
The stability requirement on the degradation of LDL in the case of reverse transport is
significantly weaker provided the rate of diffusion of LDL and the rate at which LDL leaves
the intima through the endothelial boundary are sufficiently high. Let
φ0 =
P2 + P3 + R1 + Q2 + (R1 + Q2)|Ω|
2
.
Then φ0 is a measure of the total oxidation rate of LDL and depends on the thickness of the
intima. If LDL is transported from the intima back to the blood stream, then stability will
require
[Condition 4.2.3(+)] μL > φ0/C2, αL > φ0C3/C2, and P1 > 0, if αL > 0.
If conditions 4.2.1, 4.2.2, and the appropriate version of 4.2.3 (- or +) hold, and we follow the
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The coefficients appearing on the right hand side are defined by
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P3+R1+Q5
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Cv = H1 − J+L2 , C� y = Q3 − Q2+Q52 ,
Cw = M1 + C(ᾱ, μ̄C)C − L2 , C� s = R2 + R3 − R1+Q52 ,
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P1, αL > 0
P1 − |αL|C1 − P2+P3+R1+Q22 − (R1+Q2)|Ω|2 , αL < 0.
Provided
[Condition 4.2.4] min{Cu, Cv, Cw, Cz, Cy, Cs, C� y, C� s} > 0,









Cw, and βy =
�
Cy.
The primary result of the current anaylsis is
Theorem 4.2. The equilibrium solution (Ie,De, Ce,Le,Loxe,Re) of (4.1)–(4.6) subject to the
nonhomogeneous Neumann boundary conditions (3.9), (3.10), (3.11) and (4.16) is asymptotically
stable provided conditions 4.2.1–4.2.4 hold and
βuβv ≥ D + G1, βuβw ≥ K, and βuβy ≥ E.
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establishing asymptotic stability for this case.
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4.3 Instability of the equilibrium solution
The theorems obtained in sections 4.1 and 4.2 establish sufficient conditions under which
the uniform healthy state is guaranteed to be stable to small perturbations. It is not readily
clear whether the inequalities derived are tight—in the sense that they are nearly necessary
conditions. One can ask the degree to which these conditions must be violated to result in the
existence of a perturbation that will blow up.
The existence of perturbations that blow up, in particular spatially nonhomogeneous
perturbations, is typically addressed through construction of an explicit example. The
classical approach is adopt the ansatz for the perturbation variables
u(x, t) = eσtū(x), v(x, t) = eσt v̄(x), . . . , s(x, t) = eσt s̄(x). (4.21)
Expressing the perturbation as U as in definition 4.1, this gives U(x, t) = eσtŪ(x), and the
system (4.7)–(4.12) can be written in the vector/matrix formulation as
σŪ = ∇ · (Me∇Ū) + ΛŪ. (4.22)
The diffusion-chemotaxis coefficient matrix Me has the diffusion coefficients on the main
diagonal, χ(Ie, Ce) in the first row and third column, and zeroes everywhere else. When
considering the case without boundary transport, using the fact that Me and Λ are constant
matrices, the ansatz can be further refined to seek solutions of the form
Ū = φλ(x)�ξ.
Here �ξ is a constant vector and φλ an eigenfunction of the Laplacian on Ω,
−∇2φλ = λφλ,
subject to the completely homogeneous Neumann boundary conditions (4.13). The
system (4.7)–(4.12) reduces to the algebraic equation in σ, λ, and �ξ
σ�ξ = (Λ − λMe)�ξ. (4.23)
Solutions to (4.23) for which the real part of σ is positive will grow; this is the classic Turing
instability problem (Turing, 1952). For the Turing stability problem, one considers the case for
which Λ has only negative eigenvalues and Mse, the symmetric part of Me, has only positive
eigenvalues. (This latter condition will hold if and only if χ(Ie, Ce) < 2√μIμC, and this
inequality follows from the conditions C∇u > 0 and C∇w > 0 appearing in theorem 4.1.)
For any domain Ω, the first eigenpair is λ0 = 0 and φ0 = constant, and it is well known that
there is an enumerable set of positive eigenvalues 0 < λ1 < λ2 < · · · and corresponding
eigenfunctions {φλn} that form an orthonormal basis for L2(Ω). In the case that Λ has
only negative eigenvalues, an instability must come from one of the larger eigenvalues.
Unfortunately, finding these eigenvalues explicitly for a general domain is not possible. For
an annulus (R2), or an annular cylinder (R3), they can be found by separation of variables.
The corresponding eigenmodes in these cases are nonaxisymmetric suggesting that lesion
initiation should also be nonaxisymmetric—this is consistent with clinical observations.
For the present case with no transport of any species across the endothelial layer, we can study
the effect of the antioxidant level on the stability of the healthy state. If Mφ0 in equation (4.1)
is replaced with Mφ0C (to make the source explicitly dependent on the chemoattractant), or
if Mφ0 = 0, then the equilibrium solution is (Ie,De, Ce,Le,Loxe,Re) = (0, 0, 0,Le,Loxe,Re).
65lumi ating Atherogenesis Thr ugh Mathematical Modeling
16 Will-be-set-by-IN-TECH
The coefficients appearing on the right hand side are defined by








Cp + R2 + R3 −
P3+R1+Q5
2 ,
Cv = H1 − J+L2 , C� y = Q3 − Q2+Q52 ,
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u(x, t) = eσtū(x), v(x, t) = eσt v̄(x), . . . , s(x, t) = eσt s̄(x). (4.21)
Expressing the perturbation as U as in definition 4.1, this gives U(x, t) = eσtŪ(x), and the
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We can, after some lengthy calculations, show that in the limiting cases as Aox → 0+ and
Aox → ∞ (Ibragimov et al., 2010b)
Loxe ∝ A−1ox , and Re ∝ pR, as Aox → 0+
and
Loxe ∝ A−2ox , and Re ∝ A−1ox , as Aox → ∞.
The latter result demonstrates that the antioxidants strongly control free radical production
and LDL oxidation. When studying the spectrum of Λ − λMe, this asymptotic result shows
that for Aox sufficiently large, the lower 3 × 3 block corresponding to the lipid chemistry
produces no eigenvalues with positive real part. The question of most interest is what
conditions are required for stability (or produce an instability) for the full system in the
case that the lipid chemistry alone is stable. If (Le,Loxe,Re) is a stable equilibrium for
the lipid equations in isolation, what effect does the antioxidant level have on the stability
of the equilibrium (0, 0, 0,Le,Loxe,Re)? In the limit as the antioxidant level vanishes, the
equilibrium will be unstable whenever






The critical and competing roles of diffusion and chemotaxis are prominent in this criterion
providing an unstable equilibrium. For any positive eigenvalue λ and diffusive capacity of
the chemoattractant μC, if the chemotactic sensitivity χ(0, 0) is large enough, the perturbation
will grow away from the healthy equilibrium to some other state.
An analysis like the above can be employed with any variation of the system (3.1)–(3.8)
provided the boundary conditions considered are completely homogeneous of Neumann
type. For example, in (Ibragimov et al., 2008) the present authors consider a system
characterized by two distinct macrophage phenotypes each subject to diffusion, chemotaxis,
the potential to change phenotypes, but for which only one subspecies was subject to foam cell
formation. We showed that the stability result provided therein—that analogous to theorem
4.1 here—was strongly dependent on the dominance of diffusion over chemotaxis. As is seen
here, for any set of other parameter values, the chemotactic sensitivity coefficient can always
be taken sufficiently large to produce an unstable equilibrium.
The question of unstable equilibria for the case with boundary transport can likewise be
considered. Not surprisingly this presents a far more complicated situation mathematically.
Even if we only consider constant equilibria, the special approach based on the ansatz (4.21)
and the spectral analysis above does not yield any instability examples. Moreover, the coupled
boundary conditions provide a Laplacian that is not self-adjoint and does not allow us the
option to expand all of the perturbation variables using any single family of eigenfunctions.
Nevertheless, a careful construction within the appropriate mathematical framework will
provide conditions for which an unstable equilibrium exists. The effect of antioxidant
concentration on stability can be analyzed. The reader is encouraged to see (Ibragimov et
al., 2010b) for a construction in this case.
5. Conclusion
The purpose of this work is twofold. We have formulated a mathematical model
of the inflammatory process that characterizes atherogenesis. This model given in
equations (3.1)–(3.8) is presented in general terms to provide a framework for the ongoing
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modeling process. With this in mind, adaptations are easily included as our understanding
of this complex medical process increases. We believe that mathematical modeling provides a
useful tool to meet the goals of medical research on atherogenesis—identifying vulnerability
to disease, development of treatments, and promotion of preventative interventions.
Computer simulation (in silico analysis) requires a model consistent with and able to capture
the characteristics of disease as observed in vivo.
Here, we have also studied the model by performing stability analyses under two different
assumptions regarding the supply of inflammatory components—macrophages, chemotactic
chemokines, and LDL. Taking the vasa vasorum as the sole source of these species, we arrive
at a distinct set of inequality conditions on the system parameters that will guarantee that
perturbations off of the healthy equilibrium state will decay. Bio-medically, the perturbations
are interpreted as the start of inflammation, and the starting equilibrium as a disease-free
state. A stable equilibrium is then seen as representing a cellular configuration that is
robust—where a lesion is unlikely to develop in the short term. An unstable one suggests that
(bio-chemically) the location is vulnerable to atherogenesis and the potential for development
of a fibrofatty lesion or latter fibrous plaque. In addition to the positive stability criteria
obtained using the energy estimate, we offer a negative result in the form of construction
of an instability example. This latter condition highlights the inflammation mitigating effects
of antioxidant presence and the significant interplay between chemotaxis and diffusion when
the antioxidant level becomes negligible.
We also raise this same stability question under the assumption that the supply of
inflammatory components is from influx from the blood flow via the endothelial interface.
We again produce several inequalities that when satisfied by the system parameters ensure
that the equilibrium solution is linearly asymptotically stable to small perturbations. Of
particular interest in this latter case is the stabilizing effect of reverse transport of native LDL
from the intima back to the blood stream. That reverse transport of LDL is stabilizing is not
surprising given the corruptive nature of oxidized LDL on macrophage function. Our finding
further supports the development of treatment modalities aimed at not only reducing serum
LDL levels but at facilitating reverse transport of cholesterol (Superko, 2006). Although the
conditions are numerous, clinical values of the various parameters can be easily compared in
light of the various inequalities derived and presented in theorems 4.1 and 4.2.
The availability of clinical values for several parameters is lacking. Moreover, the parameters
appearing in table 1 need not be constant, and determination of appropriate functional forms
is an important and difficult task. This will require a process of "fine tuning" through
collaboration with clinicians and experimental scientists.
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1. Introduction 
Atherosclerosis constitutes a primarily destructive phenomenon inherently arising from 
dynamics of pathobiologic effect within the intima of elastic and muscular arteries. It is 
significant to view the development of elevated intimal lesions within dimensions of 
ongoing further injury to the endothelium. 
Considerable interactivity evolves within plaques in consequence to neovascularization in 
particular. The outline evolution of individual atherosclerotic plaques would considerably 
modulate the dynamics of migration of smooth muscle cells to the intima and as a 
consequence of various agonists such as hypoxia, growth factors and coagulation-
anticoagulation-fibrinolysis systems. Also, insulin appears to exert toxicity on the vascular 
wall and possibly promote atherogenesis (Nandish et al., 2011). 
2. System pathways of injury 
System pathways constitute a representative sequence of events that depend on dysfunctional 
activation of endothelial cells. It is within scope of parameters of permeability and loss of 
endothelial cells that a full plethora of forms of injury converge as intimal cell proliferation and 
as deposition of protein matrix proteoglycans. Oxidative stress and chronic inflammation 
promote diabetes, hypertension and atherosclerosis (Sewon et al., 2011). 
The individual roles played by various agonist actions in the definition of the atherosclerotic 
plaque would evolve within the specificity of focal injury to the intima in particular. The 
convergence of such injuries appears a constitutive attribute of the variable expression of 
sequence prototypes in lesion demarcation. 
Developmental parameters of modelling include the delineation of individual pathogenic 
events in terms that integrally reconstitute the modified anatomy of the individual 
atherosclerotic plaque. In this regard, Ghrelin improves endothelial function, lowers blood 
pressure and regulates atherosclerosis (Zhang et al., 2011). 
Significance in terms of complicated plaques as constitutive pathways in modelling of 
plaques includes the essential interactivity of endothelium with smooth muscle cell trophic 
effect. Macrophages in particular implicate a series of converging events that sequentially 
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1. Introduction 
Atherosclerosis constitutes a primarily destructive phenomenon inherently arising from 
dynamics of pathobiologic effect within the intima of elastic and muscular arteries. It is 
significant to view the development of elevated intimal lesions within dimensions of 
ongoing further injury to the endothelium. 
Considerable interactivity evolves within plaques in consequence to neovascularization in 
particular. The outline evolution of individual atherosclerotic plaques would considerably 
modulate the dynamics of migration of smooth muscle cells to the intima and as a 
consequence of various agonists such as hypoxia, growth factors and coagulation-
anticoagulation-fibrinolysis systems. Also, insulin appears to exert toxicity on the vascular 
wall and possibly promote atherogenesis (Nandish et al., 2011). 
2. System pathways of injury 
System pathways constitute a representative sequence of events that depend on dysfunctional 
activation of endothelial cells. It is within scope of parameters of permeability and loss of 
endothelial cells that a full plethora of forms of injury converge as intimal cell proliferation and 
as deposition of protein matrix proteoglycans. Oxidative stress and chronic inflammation 
promote diabetes, hypertension and atherosclerosis (Sewon et al., 2011). 
The individual roles played by various agonist actions in the definition of the atherosclerotic 
plaque would evolve within the specificity of focal injury to the intima in particular. The 
convergence of such injuries appears a constitutive attribute of the variable expression of 
sequence prototypes in lesion demarcation. 
Developmental parameters of modelling include the delineation of individual pathogenic 
events in terms that integrally reconstitute the modified anatomy of the individual 
atherosclerotic plaque. In this regard, Ghrelin improves endothelial function, lowers blood 
pressure and regulates atherosclerosis (Zhang et al., 2011). 
Significance in terms of complicated plaques as constitutive pathways in modelling of 
plaques includes the essential interactivity of endothelium with smooth muscle cell trophic 
effect. Macrophages in particular implicate a series of converging events that sequentially 
re-define in repetitive form the dynamics of atherogenesis. Dyslipidemmia increases lipid 





Growth factors are instrumental in terms of the emerging morphologic features of the early 
atherosclerotic plaque and as derivative phenomena of endothelial injury and permeability. 
The constitutive parameters of re-distribution of trophic effect particularly interact with 
neovascularization within the plaque core. 
Developmental sequences of multifactorial type in atherogenesis are particularly prone to a 
staged outline evolution that permeates the intima and sustains injury to the endothelium. 
Such significant interactivity contributes to outline emergence of new sequences in trophic 
effect and as proliferation and migration of smooth muscle cells. 
The macrophage is central to such interactivity and operates primarily in chemotaxis and 
trophism, and also in terms that dominantly influence in significant fashion the attributes of 
lipid foam cells. Plant-derived alpha-linolenic acid, for example, restricts plaque T-cell 
proliferation, differentiation and inflammatory activity (Winnik et al., 2011). 
3. Focality of inflammation 
The inflammatory infiltrates include a representative response to injury as atherogenesis 
further compounds injury to the vascular intima. The role of endothelium is implicated as 
dysfunctional response with increased permeability to monocytes in particular. 
Proteoglycans retain lipoproteins subendothelially (Anggraeni et al., (2011). 
Such recruitment of novel forms of injury includes the transforming ability of protein matrix 
proteoglycans as integral constitution of the injurious agents. It is within the dimensional 
redistribution of such injury that the endothelium plays a prominent role in sequence 
selectivity and in modulation of parameters of redefinition of activated dysfunctional states 
of inflammatory cells within the plaque. 
The focality of injury is particularly significant within the neovascularized core of the 
individual plaque and as parameters in the growth and maturation of smooth muscle cells. 
Reparative processes allow for a sequential remodelling within such system pathways as 
coagulation and cellular migration within the vascular intima. 
The variability of delineation of injurious agents indicates an activation of new parameters 
as the plaque evolves. The overall confines further extend parameters in plaque modelling 
that permits responsive elements in the creation of multiple sequence pathways that evolve 
in their own right; for example, deletion of microsomal prostaglandin E2 synthase-1 retards 
atherogenesis (Wang et al., 2011). 
4. The individual smooth muscle cell/macrophage 
The secretory dynamics of smooth muscle cells and of macrophages attribute a central 
pathogenic role to foam cells within the intima. Both smooth muscle cells and macrophages 
are recognized source for foam cells that, in turn, predominate in the mature atheromatous 
plaque. On the other hand, the matrix proteoglycans are also central players in re-defining 
attributes of the injured endothelium. 
The reactivity of macrophages within the protein matrix that accumulate within the intima 
allows for the emergence of multiple converging agonists that characterize endothelial cell 
activation. The development of subsequent new forms of injury transforms such endothelial 
dysfunctionality as parameters of maturation of the plaque. Interleukin 18 is involved in 
plaque destabilization and regulates the innate immune response (Yamaoka-Tojo et al., 
2011). 
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The central core of the plaque is one dominated by influences exerted by transformations in 
terms of neovascularization and as compounded maturation leading to lipid core formation 
within the plaque. Insulin resistance and cardiovascular pathology may share a common 
genetic background (Bacci et al., 2011). 
It is highly significant to view the trophic attributes of injury to the endothelium as source of 
the evolutionary traits of emerging atherosclerotic plaques; indeed, Insulin-like growth 
factor-1 stabilizes the atherosclerotic plaque by altering smooth muscle phenotype (von der 
Thusen et al., 2011). Stages in sequence pathway maturation are central to the outline 
demarcation of individual plaques in a manner that depends integrally on dynamics of 
neovascularization of the plaque core. 
Hemodynamic shear stress contributes to a redistribution of actin microfilaments within 
endothelial cells in a manner that modulates dysfunctional issues of activated 
endothelium. 
5. Cellular proliferative kinetics 
A proliferative smooth muscle cellular response is further significant in the maturation of 
the atherosclerotic plaque within such sequence steps as redefined injury to the 
endothelium. 
Stages in preparation for subsequent events in the outline of the atherogenesis process 
would include the delivery of injurious agents to the intima. The sequence pathways are 
significant parametric factors in defining the dimensions of the endothelial participation in 
atherogenesis. Endoplasmic reticulum stress and the unfolded protein response characterize 
endothelial susceptibility to atherogenesis (Civelek et al., 2011). 
It is further to the evolving forms of agonist action that atherogenesis modifies in repeatedly 
staged sequence the pathways of dysfunctional activation of the endothelium. 
6. Low-density lipoproteins 
Neovascularization proves to be a centrally operative agonist in the modified development 
of atheroma formation and deposition. The added parameters of consequence appear to 
implicate a primarily evolutionary role for hypoxia and ischemia as plaque re-definition, 
both morphologically and in dysfunctional forms of endothelial activation. 
The inflammatory nature of the intimal deposits elicits a responsive panorama that 
implicates derivative attributes of low density lipoproteins and cholesterol and as extended 
participation of the neovascularization of the plaque. MicroRNA-29a targets lipoprotein 
lipase in oxidized low density lipoprotein and modulates cytokines and scavenger receptors 
(Chen et al., 2011) 
Hypoxia is itself essential for the formation of new vessels within the plaque with the 
production of growth factors and would additionally contribute to the intimal thickening as 
further evidence for staged representation of injury to the intima. 
Directional re-orientation of active dysfunctional states of endothelial cells compounds 
hypoxia and ischemia within the vascular intima. By-products of matrix proteoglycans and 
of lipid metabolism indicate the essential staging events in plaque maturation and as 
derivative phenomenon to further atherogenesis. Chemokines produced by endothelial cells 
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derivative phenomenon to further atherogenesis. Chemokines produced by endothelial cells 






7. Intimal remodeling 
It is as remodelling of the injury to the intima that hypoxia and ischemia further modulate 
the migration of smooth muscle cells within the intima. The increased permeability of the 
endothelium is significant as a redefined series of further injuries to the underlying intima. 
The orientational redistribution of the agonists in atherogenesis redefine a central plaque 
contribution to increasing profiles of further hypoxia/ischemia and as evidential 
remounting of parameters of sequence effect. The multi-factorial injurious events are 
converging agonists in hypoxic/ischemic core regions of the individual atherosclerotic 
plaque. In such manner, the multi-staged evolution of plaques correlates with interactive 
dynamics of further injury within the intima. 
Dynamics of action of oxidized lipids correlate closely with emerging new roles for agonist 
action in developing plaques. The interaction of variably participating agonists contrast with 
the intimal emergence of incremental hypoxia/ischemia in terms of increasing matrix 
proteoglycan deposition and cellular proliferation of smooth muscle cells in particular. 
Atherosclerosis affecting different topographic sites correlate with the type of 
hyperlipidemia (Van Craeyveld et al., 2011). 
The platelet/coagulation systems are incremental sequence events as trophic influence in 
staged convergence of multiple agonists in intimal injury. 
Distributional parameters are particularly significant in the dimensional targeting of the 
intima in terms of the vasa vasorum supplying the arterial wall. 
Component systems of sequential impact would contribute to the emergence of positive 
feedback effect in agonist action. The endothelial cells participate by the production of 
various agents such as growth factors, in particular Platelet-Derived Growth Factor. The 
semblance of such influence dominantly re-characterizes the atherosclerotic plaque that 
trophically redefines the form of hypoxic/ischemic injury to the intima. miRNA –mediated 
epigenetic regulation may be implicated in atherogenesis, involving oxidized low-density 
lipoproteins (Chen et al., 2011). 
8. Hemodynamics 
Hemodynamics within the neovascularized core of the plaque allows for a developmental 
evolution in terms of so-called complications such as hemorrhage and rupture of the plaque 
and as staged representation of the endothelial cell injury. Consequential pathways of 
significance would confirm the agonist nature of hypoxia/ischemia in terms of further 
emergence of intimal deposition and of cellular proliferation and migration. 
A response to injury permits role redefinition as emerging parameters in pathogenesis of the 
deposition of proteoglycans within the vascular intima. Matrix metalloproteinases 
participate in plaque destabilization and rupture. Their overexpression is an independent 
factor in the pathogenesis of acute coronary syndromes (Kulach et al., 2010). A proliferative 
response in particular illustrates the nature of the vascular wall injury that incrementally 
progresses as gradients of hypoxia and ischemia within the vessel wall. 
9. Gradient parameters 
Consequential involvement of the lipid deposition phenomenon integrally permits the 
establishment of gradient parameters of hypoxia/ischemia within the operative fields of 
emerging neovascularization in the plaque core. 
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Procedural and technical specificity of individual plaques illustrate dynamic turnover 
within plaques in terms particularly of agonists and cellular parameters in redefinition of 
atherogenesis. In this regard, Interferon-alpha upregulates expression of scavenger-A in 
monocytes/macrophages with foam cell formation (Li et al., 2011). 
The specificity of the inflammatory response is sequentially consequent to the inter-
changeability of agonist-induced parameters in creating a microenvironment of hypoxia and 
ischemia centered on the intima. 
10. Cellular endothelial injury 
The contributing roles of endothelium especially in cases of trauma to the vessel wall 
would indicate the prototypical attributes in lesion emergence and of subsequent 
maturation of the atherogenesis phenomenon. Atherogenesis is contributory phenomenon 
to an ongoing migratory involvement of the intima. This is well-testified by smooth 
muscle cells that synthesize and secrete matrix proteoglycans, and oxidative stress also 
induces production of superoxide by endothelial cells with nitric oxide synthase 
uncoupling (Zweier et al., 2011). 
Significant participation in atherogenesis involves mirror-imaged targeting of multiple 
component systems within the vessel wall that developmentally integrate as regions of 
hypoxia and ischemia, including the thioredoxin system that correlates with cellular apoptosis 
in endothelial cell lines in hypoxic stress (Park et al., 2011). Neovascularization proves a 
permissive phenomenon in development of gradients of ischemia that redefine the individual 
plaque as compounding parameters of progression to further injury to the vascular wall. 
Permissive dynamics are characteristic of oxidation of lipids and particularly of low-density 
lipoproteins and as evolution of deposition within the intima. Targeting of subsets of cells 
indicates a selectivity process of progression within sequential pathways of incremental 
further injury to the vessel wall. Disrupted endoplasmic reticulum equilibrium engages the 
unfolded protein response in such cells as monocytes (Carroll et al., 2011). 
11. Vulnerability issues 
System reproduction indicates vulnerability selectivity in the evolution of atheromatous 
plaques in terms ranging from cell kinetics to proliferative migration of smooth muscle cells 
directed to the intima and a sensitivity of endothelial cells to responsive pathway generation 
and trophic factor production. The macrophage system is especially representative of novel 
pathway events that induce a sequential series of models in manipulative further 
compromise of viability of the endothelial cells. 
Within such scopes of pathogenic representation, there would emerge a parametric 
remodelling based on aberrant reconstitution of injury as further projected by responses to 
injury to the intima and endothelium. Within such context, the unfolded protein response is 
implicated in all stages of atherogenesis and plaque progression (Lhotak et al., 2011). 
12. Pathway activation 
The operative essentiality of the intimal involvement in atheroma formation calls into 
operation the developmental dimensions of both endothelium and also of medial smooth 
muscle cells. The sequence attributes of multiple different pathways contribute to the 
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foam cell systems. Mast cells, macrophages and neutrophils release TNF-alpha, IFN-gamma 
and IL-6 with expression of adhesion molecules and leukocyte recruitment (Zhang et al., 
2011). Synthetic and contractile phenotypes of the individual smooth muscle cell indicate 
specialized forms of series determination in reconstitution of the damaged or injured 
subintima and also modelled parametric fashioning of the overlying endothelium. 
Hemodynamics of blood flow localizes such injured endothelium as representative and 
constitutive foci of persistent pathway activation that delivers dysfunctional attributes to the 
multi-components of the early atheromatous plaque. 
13. Eventual sequence emergence 
Contrasting sequentiality is triggered by an aberrant selectivity for trophic effect 
reproduction in terms of ongoing creation of hypoxia/ischemic gradients across both the 
endothelium lining the vascular lumen and also within critical regions of operative effect in 
the involved vascular intima. Such representation calls into evidence gradient pathways of 
projected reproduction that specifically induce focality of involvement of the plaque within 
systems of cascade effect. A complex interaction of genetic and environmental factors 
operates (Chyu & Shah, 2011) 
The platelet and coagulation systems conclusively demonstrate a participating series of roles 
culminating in organization of adherent thrombus within the plaque as incorporated 
dynamics of trophic potential.  
Incremental attributes of further compromise of the viability of the intima are demonstrable 
as evidential pathways of increasing impact in terms of enhanced intimal thickness. In this 
regard, cells proliferate in atherosclerotic lesions and also in vascular tissue bordering the 
plaque (Zettler et al., 2010). 
Scope of representative projection is conclusively constituted by the end-stage plaque with a 
central atheromatous core that consists of cholesterol lipid, lipoprotein and oxidized 
molecular entities of variable derivation. Increasing representation of inflammatory 
dynamics is largely dependent on initiating events within the foci of intima underlying 
dysfunctionally activated endothelium. The dynamics of spread and of replication of 
individual endothelial cells constitutes a further pathway model for gradient creation 
between flowing blood and vascular wall intima. Pancoronary arterial instability implicates 
multifocal disease in acute coronary syndromes (Puri et al., 2011). 
14. Concluding remarks 
Re-distribution and retargeting events are primary modelling systems in sequence pathways 
and as multi-staged involvement of the intima of arterial vessel walls. The intimal thickness 
and remodelling of pathways allow for incremental redistribution of agonists that target 
differential systems such as endothelium and smooth muscle cells. Macrophages are 
constitutive systemic parameters that focally re-orientate the targeting dynamics of hypoxia 
and ischemia in intimal lesion creation. Oxidation-specific epitopes present on apoptotic 
cells induce the selection of Pattern Recognition Receptors and damage-associated 
molecular patterns that may be targeted by innate immunity (Miller et al., 2011). 
Only in terms of ensuing neovascularization of the individual atherosclerotic plaque can 
system specificity in atherogenesis permit the emergence of converging pathways of injury 
and attempted reconstitution of the vessel wall and endothelium. 
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Macrophages induce transformational events within micro-environmental conditions of 
propagated susceptibility patterns that relate in particular to selective sites of vascular 
involvement such as near-arterial branch points of exit. It is such representation that 
illustrates the evolving vulnerability of focal sites of intima and endothelium in the 
generation of multiple atheromatous plaques; these subsequently promote self-involvement 
in dynamic transformation to the so-called complicated plaque. 
Regional pathways of spread and further expansion contrast with the maturation of plaque 
morphology within such systems as macrophage and endothelial cell activation, with the 
creation of the synthetic/secretory phenotype of the individual smooth muscle cell within 
the intima. 
Distributional dynamics in generation of the atheromatous plaque are developmental issues 
as indicated by activation of the proto-oncogenes c-fos and c-myc. The considerable 
heterogeneity of component cell subpopulations within any atheromatous plaque also 
permits the emergence of monoclonal groups of smooth muscle cells that trophically sustain 
growth of the plaque within dimensional confines of the involved intima and of injured 
overlying endothelium. 
Hypoxia-ischemia is a powerful component series of systems in evolution of the 
susceptibility pattern determination of plaque localization and remodelling, as well-typified 
by the marked eventual thickening of the involved intima.  
Gradient generation is a key mechanistic system in generation of projected effects of 
hypoxia-ischemia that coordinate the convergence of injurious agonists in terms of trophic 
and destructive elements within the intima of the arterial wall. 
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foam cell systems. Mast cells, macrophages and neutrophils release TNF-alpha, IFN-gamma 
and IL-6 with expression of adhesion molecules and leukocyte recruitment (Zhang et al., 
2011). Synthetic and contractile phenotypes of the individual smooth muscle cell indicate 
specialized forms of series determination in reconstitution of the damaged or injured 
subintima and also modelled parametric fashioning of the overlying endothelium. 
Hemodynamics of blood flow localizes such injured endothelium as representative and 
constitutive foci of persistent pathway activation that delivers dysfunctional attributes to the 
multi-components of the early atheromatous plaque. 
13. Eventual sequence emergence 
Contrasting sequentiality is triggered by an aberrant selectivity for trophic effect 
reproduction in terms of ongoing creation of hypoxia/ischemic gradients across both the 
endothelium lining the vascular lumen and also within critical regions of operative effect in 
the involved vascular intima. Such representation calls into evidence gradient pathways of 
projected reproduction that specifically induce focality of involvement of the plaque within 
systems of cascade effect. A complex interaction of genetic and environmental factors 
operates (Chyu & Shah, 2011) 
The platelet and coagulation systems conclusively demonstrate a participating series of roles 
culminating in organization of adherent thrombus within the plaque as incorporated 
dynamics of trophic potential.  
Incremental attributes of further compromise of the viability of the intima are demonstrable 
as evidential pathways of increasing impact in terms of enhanced intimal thickness. In this 
regard, cells proliferate in atherosclerotic lesions and also in vascular tissue bordering the 
plaque (Zettler et al., 2010). 
Scope of representative projection is conclusively constituted by the end-stage plaque with a 
central atheromatous core that consists of cholesterol lipid, lipoprotein and oxidized 
molecular entities of variable derivation. Increasing representation of inflammatory 
dynamics is largely dependent on initiating events within the foci of intima underlying 
dysfunctionally activated endothelium. The dynamics of spread and of replication of 
individual endothelial cells constitutes a further pathway model for gradient creation 
between flowing blood and vascular wall intima. Pancoronary arterial instability implicates 
multifocal disease in acute coronary syndromes (Puri et al., 2011). 
14. Concluding remarks 
Re-distribution and retargeting events are primary modelling systems in sequence pathways 
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cells induce the selection of Pattern Recognition Receptors and damage-associated 
molecular patterns that may be targeted by innate immunity (Miller et al., 2011). 
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Parametric Determination of Hypoxic Ischemia in Evolution of Atherogenesis 
 
77 
Macrophages induce transformational events within micro-environmental conditions of 
propagated susceptibility patterns that relate in particular to selective sites of vascular 
involvement such as near-arterial branch points of exit. It is such representation that 
illustrates the evolving vulnerability of focal sites of intima and endothelium in the 
generation of multiple atheromatous plaques; these subsequently promote self-involvement 
in dynamic transformation to the so-called complicated plaque. 
Regional pathways of spread and further expansion contrast with the maturation of plaque 
morphology within such systems as macrophage and endothelial cell activation, with the 
creation of the synthetic/secretory phenotype of the individual smooth muscle cell within 
the intima. 
Distributional dynamics in generation of the atheromatous plaque are developmental issues 
as indicated by activation of the proto-oncogenes c-fos and c-myc. The considerable 
heterogeneity of component cell subpopulations within any atheromatous plaque also 
permits the emergence of monoclonal groups of smooth muscle cells that trophically sustain 
growth of the plaque within dimensional confines of the involved intima and of injured 
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Hypoxia-ischemia is a powerful component series of systems in evolution of the 
susceptibility pattern determination of plaque localization and remodelling, as well-typified 
by the marked eventual thickening of the involved intima.  
Gradient generation is a key mechanistic system in generation of projected effects of 
hypoxia-ischemia that coordinate the convergence of injurious agonists in terms of trophic 
and destructive elements within the intima of the arterial wall. 
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1. Introduction 
Atherosclerosis and restenosis, complex pathologies of blood vessels, are multifactorial 
diseases triggered by the inflammatory response to injury of endothelium. Remodeling of 
the injured vessel, proliferation and migration of vascular smooth muscle cells (VSMC) and 
elaboration and accumulation of extracellular matrix proteins are main traits of these 
diseases (Dzau et al., 2002; Libby, 2002; Pons et al., 2009; Ranganna et al., 2006; Ross, 1995;). 
Despite the substantial progress in understanding the etiology and the clinical management 
of atherosclerosis and restenosis, they are still life threatening diseases. Precise reasons are 
not still fully transparent. Different cell types; distinct cellular pathways and processes; and 
multiple genes within each participating cell types that are vulnerable to both genetic and 
environmental risk factors participate in the pathogenesis of atherosclerosis and restenosis. 
Recently, it is recognized that besides the genetic control epigenetic mechanisms regulate 
development and maintenance of organisms or their interaction with surrounding 
environment through the coordination of a set of reversible modifications that turn parts of 
the genome ‘off’ and ‘on’ at strategic times and at specific sites causing changes in gene 
expression with no changes in DNA sequences (Ekstrom, 2009; Pons et al., 2009; Ranganna 
et al., 2006; Turunen, 2009). The two well-known epigenetic mechanisms, DNA methylation 
and histone modifications change the chromatin structure and dynamics that alter gene 
functions by influencing gene expressions. Dysregulation of epigenetic processes has been 
linked to human diseases, which influences many aspects of cell biology including cell 
growth, cell cycle control, proliferation, differentiation, and cell death. Reversing the 
dysregulation of epigenetic mechanisms may offer effective treatment strategy for many 
diseases including cardiovascular disease due to atherosclerosis and restenosis. This review 
presents the current advancement in the epigenetics of VSMC proliferation and potential 
use of histone epigenetic modifiers in the intervention of atherosclerosis and restenosis.  
2. Overview of pathogenesis of atherosclerosis  
Atherosclerosis, a disease of medium to large arterial vessels, accounts for over 55% of all 
deaths in western countries. It is typically asymptomatic for decades but ultimately result in 
life-threatening pathological outcomes like myocardial infarction and stroke, both with 
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presents the current advancement in the epigenetics of VSMC proliferation and potential 
use of histone epigenetic modifiers in the intervention of atherosclerosis and restenosis.  
2. Overview of pathogenesis of atherosclerosis  
Atherosclerosis, a disease of medium to large arterial vessels, accounts for over 55% of all 
deaths in western countries. It is typically asymptomatic for decades but ultimately result in 
life-threatening pathological outcomes like myocardial infarction and stroke, both with 





Atherosclerosis is a complex progressive disease in which intimal thickening of the arterial 
wall promotes luminal stenosis by vascular remodeling, accumulation of cellular and 
extracellular substances and VSMC proliferation and migration. Integrity of arterial wall is 
crucial for the regulation of vascular tone, control inflammation, thrombosis, and 
angiogenesis, enhance regional blood flow, and inhibit cancer metastasis. Arterial wall is 
composed of three tunics that surround a central lumen through which blood flows. The 
innermost layer is the tunica intima composed of endothelial cells that form a smooth lining 
that minimizes interaction with circulating cellular and non-cellular components as blood 
moves through the vessel. The middle layer, tunic media, is composed of vascular smooth 
muscle cells (VSMC) and layers of flexible proteins, which enables the lumen to contract and 
dilate to regulate blood flow in the body. The outer layer, tunica adventitia is a protective 
layer of connective tissue that anchors the blood vessel to surrounding structures.  
Under normal conditions, a delicate balance between proliferation and apoptosis of local 
vascular cell types maintains the thickness of arterial vessel wall. A number of regulatory 
factors produced by the endothelial cells are responsible for the homeostatic balance by 
controlling vessel tone, coagulation state, leukocyte trafficking, and cellular proliferative 
response. Any damage to the vessel wall by mechanical, biochemical, or immunological 
insults triggers endothelial dysfunction or denudation of endothelial layer overwhelming 
the normal homeostatic balance, thus, upsets the normal vascular tone setting the stage for 
the activation of proinflammatory and immune response. Escalating evidence indicates that 
inflammatory or atherogenic stimuli promote ROS generation in endothelial milieu causing 
oxidative stress (Freeman & Crapo, 1982; Kehrer, 1993; Kunsch & Medford, 1999; 
Madamanchi et al., 2005). Inflammatory response fueled by the oxidative stress is also 
linked to oxidation of lipoproteins. LDL molecules that enter the subendothelial space are 
oxidized to form oxidized LDL (OxLDL) by different mechanisms including enzymatic and 
nonenzymatic pathways, which are taken up by macrophages via scavenger receptors to 
become foam cells. Besides stimulating proinflammatory and proatherogenic effects, OxLDL 
also appears to elicit highly immunogenic response resulting in the generation of 
autoantibodies that appears to be of pathogenic significance (Hansson, 2009; Klingenberg, 
R., & Hansson, G.K. 2009; Steinberg & Witztum, 2010; Witztum, 1997). Moreover, elevated 
levels of ROS appear to function as second-messenger molecules transmitting the 
extracellular signals to nucleus via redox-sensitive signaling pathways to turn on the 
expression of atherogenic gene products such as adhesion molecules and inflammatory 
cytokines. Expression of these gene products elicit changes in the vessel wall promoting 
inflammation, infiltration of monocytes and T cells, proliferation, migration and activation 
of VSMC and matrix alteration (Freeman & Crapo, 1982; Hansson, 2007; Kehrer, 1993; 
Klingenberg & Hansson, 2009; Kunsch & Medford, 1999; Madamanchi et al., 2005; Steinberg 
& Witztum, 2010; Witztum, 1997). These processes involve synthesis and release of a host of 
regulatory molecules, both by cellular components in the blood and vascular cells of the 
arterial wall triggering autocrine, paracrine, and endocrine type of interactions between cells 
and the molecules they produce. Outcome of these complex interactions leads to migration 
of VSMCs from their normal residence in the arterial media to the intima where they change 
their phenotype from a contractile to a proliferative type (Libby, 2002; March et al., 1999; 
Ross, 1995). This phenotypic change, in conjunction with excessive production and 
accumulation of extracellular matrix proteins, is the main contributor to vascular 
remodeling.  
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2.1 Vascular remodeling in atherosclerosis and restenosis 
Atherosclerosis and restenosis both are multifactorial vascular occlusive processes but 
exhibit certain similarities and differences in the origin and progression of their 
development (Dzau et al., 2002; Pons et al., 2009). Inflammatory response of activated 
endothelial cells to injury or insults elicits both these processes. Activation of endothelial 
cells leads to a cascade of events, which promotes vascular remodeling by changing the size, 
structure and composition of vessel wall. Moreover, both processes involve proliferation, 
migration and activation of VSMC and modulation of extracellular matrix by elaborating 
and accumulating extracellular matrix proteins. Although they share some of the risk factors 
such as hypertension and diabetes, there is a consensus that atherosclerosis develops in 
response to elevated low-density lipoproteins (LDL) and cigarette smoke. On the other 
hand, VSMC proliferation is the primary pathophysiological mechanism in restenosis, 
which is largely due to transcending wound healing response to clinical procedures such as 
balloon angioplasty, stent placement and vein graft surgery [Dzau et al., 2002; Pons et al., 
2009]. While restenosis appears to be insensitive to circulating lipids, accumulation of 
oxidized LDL is the characteristic feature of atherosclerosis. Additionally, while 
development and progression of atherosclerosis is a gradual process, the restenotic process 
is a relatively a rapid process caused by surgical revascularization procedures such as 
angioplasty and stent placement. Despite substantial progress in understanding the etiology 
and the clinical management of atherosclerosis and restenosis, they are still life-threatening 
diseases. Possible reasons are multiple factors, different cellular pathways and processes, 
and multiple genes are contributory to these complex vascular disease processes. 
2.2 VSMC proliferation 
VSMC are highly specialized cells, which play vital roles in the regulation of blood pressure, 
blood flow and in many pathological states. In mature individuals, the typical function of 
arterial VSMC is contraction and maintenance of vascular tone. As such, VSMC in adult 
artery exhibit contractile or differentiated phenotype displaying quiescent proliferation 
state, decreased synthetic activity and expression of proteins unique to contractile 
phenotype like contractile proteins, ion channels and signaling proteins. However, VSMC 
retain their remarkable plasticity to undergo reversible phenotypic change in response to 
alterations in the local environment like during development, physiological conditions like 
pregnancy or in response to vascular injury. This remarkable flexible persona of VSMC 
makes them vulnerable to phenotypic modification from contractile to proliferative, 
synthetic, or de-differentiated phenotype in conjunction with vessel remodeling by altering 
cell number and composition of vessel wall (Pons et al., 2009; Ross, 1993).  
VSMC proliferation is also the primary pathophysiological mechanism in different clinical 
pathologies such as postangioplasty restenosis, in-stent restenosis, vein bypass graft failure 
and transplant vasculopathy (Dzau et al., 2002; Holmes, 2003). The clinical procedures 
performed to clear the occluded vessel fortuitously become precursors for restenosis in 30-
40% of the patients, mainly due to proliferation and activation of VSMC. While entry into 
cell cycle followed by proliferation of VSMC contributes to the formation of neointima, 
activation of VSMC induces expression of proinflammatory cytokines, adhesion molecules, 
chemoattractants, proteolytic enzymes and other molecules not usually present in normal, 
quiescent, contractile VSMC of the medial layer (Kleemann et al., 2008; Li et al., 1993; 
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state, decreased synthetic activity and expression of proteins unique to contractile 
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retain their remarkable plasticity to undergo reversible phenotypic change in response to 
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pregnancy or in response to vascular injury. This remarkable flexible persona of VSMC 
makes them vulnerable to phenotypic modification from contractile to proliferative, 
synthetic, or de-differentiated phenotype in conjunction with vessel remodeling by altering 
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VSMC proliferation is also the primary pathophysiological mechanism in different clinical 
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inflammatory response, and in turn, increases further proliferation of VSMC and elaboration 
of vessel remodeling.  
2.3 Antiproliferative therapeutics to target VSMC proliferation  
The current therapies used for atherosclerosis aim to minimize the risk factors that promote 
atherosclerosis, such as reducing elevated levels of cholesterol or enhancing the blood flow 
by surgical intervention of an already occluded vessel. Ironically, the surgical procedures 
performed to clear the occluded vessel become a precursor for restenosis, mainly due to 
VSMC proliferation, in significant number of patients (Dzau et al., 2002; Ferns et al., 1991). 
Because proliferation of VSMC is the hallmark of atherosclerosis and clinical conditions such 
as arterial stenosis, transplant vasculopathy, and bypass graft failure, the suitable 
therapeutic approach is to develop strategies that inhibit or block VSMC proliferation. Based 
on the current understanding of the molecular basis of vascular proliferative diseases, there 
is an abundance of potential therapeutic possibilities. Accordingly, a number of agents are 
tested for antiproliferative activity including heparins, cytostatic agents, inhibitors of 
angiotensin converting enzyme, and antagonists to growth factors (Dzau et al., 2002; Ferns 
et al., 1991; Gershlick, 2002; Stephen et al., 2005; Toshiro et al., 2005). Although some of these 
agents have shown promise in animal models, they failed to elicit any protection in human 
clinical studies (Gershlick, 2002). Species differences, potential toxicity, and lack of potency 
are possible culprits. Furthermore, the probability of successfully treating a multifactorial 
disease by targeting a single factor is unlikely. Additionally, all vascular cell types secrete 
growth factors and cytokines that activate signaling pathways that are redundant and thus 
prevent the success of targeting one or two factors.  
2.4 Cell cycle as the therapeutic target  
Based on the current knowledge of cell cycle mechanisms, it appears that targeting specific 
parts of the cell cycle is a better strategy to inhibit or block the development of vascular 
proliferative diseases such as arterial restenosis; in-stent-stenosis and vein bypass graft 
failure. Moreover, cell cycle is the final common pathway where all the growth regulatory 
signals converge, and thus, makes a rational target of antiproliferative therapeutics to inhibit 
vascular proliferative diseases. Some of the experimental studies indeed reveal that 
inhibition of cell cycle progression emerges as an important therapeutic target for 
prevention of vascular proliferative diseases (Dzau et al., 2002; Ranganna et al., 2006; Von 
der Leyen & Dzau, 2001). Different approaches such as pharmacological agents, irradiation, 
and gene therapy have been used for arresting VSMC proliferation. These approaches 
inhibit proliferation by cytostatic or cytotoxic mechanism. However, cytostatic mechanism 
of cell cycle arrest is desired over cytotoxic mechanism to avoid unintended damage to the 
vessel wall due to cytotoxic treatment. Three different approaches have been tried for 
arresting VSMC proliferation by targeting cell cycle, which include: 1) brachytherapy, 2) 
gene therapy, and 3) pharmacotherapy.  
2.4.1. Brachytherapy 
Endovascular radiotherapy is a promising method for effective antiproliferative treatment of 
restenosis (Teirstein & King, 2003; Waksman, 2000). Radiotherapy directed at restenosis has 
two objectives, one to treat restenosis by killing the cells that re-occluded and to prevent 
further restenosis by inhibiting tissue growth. Brachytherapy with either beta or gamma 
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radiation sources are used to diminish restenosis in patients with post-angioplasty 
restenosis or with in-stent restenosis. The rationale for using radiation for treating restenosis 
is that uncontrolled proliferation of VSMC is similar to neoplastic cells that can be targeted 
for radiation therapy just as transformed cells in cancer tissue. Brachytherapy-induced DNA 
damage of VSMC can result in arrest of VSMC at the G1 checkpoint or induction of 
apoptosis through p53 induced p21Cip1 upregulation. A key feature of brachytherapy is 
that the irradiation only affects a precise localized area around the radiation sources. 
Exposure to radiation of healthy tissues further away from the sources is therefore, reduced. 
In addition, brachytherapy is associated with a low risk of serious adverse side effects. More 
than a dozen randomized trials established its safety and efficacy. However, it exhibits two 
radiotherapy-related problems, arterial narrowing adjacent to the edge of the target site and 
unexpected late coronary thrombo-occlusive events (Raizner, 2000). 
2.4.2 Gene therapy 
Gene therapy techniques provide a unique opportunity to genetically engineer vessels and 
grafts to become impervious to atherosclerosis and neointimal formation that contributes to 
arterial restenosis, in-stent restenosis and vein graft failure (Dzau et al., 2002; Khanna, 2008; 
Kishore & Losordo, 2007; Gaffney et al., 2007; Melo et al., 2005; Von der Leyen & Dzau, 
2001). Gene therapy approach has potential not only against monogenic diseases, but also 
against complex diseases where multiple genes are involved in the disease pathogenesis like 
in cardiovascular diseases and cancer. One of the key challenges of the gene therapy is 
appropriate vector for the delivery of functional gene or a concoction of genes in multigenic 
diseases as in cardiovascular diseases. Besides the choice of vector, other parameters such 
as, appropriate gene targets and efficient methods of vector delivery for a specific target 
have to be optimized. Vectors can be either viral or non-viral. The ideal vector is the one, 
which is nonpathogenic, less immunogenic, more efficient, and enhanced tissue specificity.  
Delivery of therapeutic genes to the cardiovascular tissues is challenging. To facilitate local 
gene delivery to lesions in the vasculature catheter-based vector delivery has been tried 
using a variety of balloon catheters in animal models and human trials (Khanna, 2008; 
Kishore & Losordo, 2007; Gaffney et al., 2007; Melo et al., 2005). Stents are ideal gear for 
localized gene delivery to the vascular wall because of their widespread use, safety and 
permanent scaffold structure. Stents can be coated with genetically engineered cells or 
plasmid or adenoviral vectors carrying therapeutic genes (Khanna, 2008; Kishore & Losordo, 
2007; Gaffney et al., 2007; Melo et al., 2005). Experimental studies have demonstrated 
usefulness of gene therapy in treating atherosclerosis and restenosis in various animal 
models and in some clinical trials. It can be used to transfer exogenous genes to express 
functional gene products to overcome defective or downregulated endogenous gene 
expressions through vector-based delivery system. It also can be used to knockdown or 
suppress the expression of gene products that contribute to pathogenesis of disease by one 
of the several methods of gene silencing. These include antisense oligonucleotides (ODNs), 
short segments of RNA with enzymatic activity (ribozymes) and small interfering RNAs 
[siRNA] (Dzau et al., 2002; J.M. Li et al., 2010; Banno, et al., 2006).  
A number of studies have shown that gene therapies can be targeted for reducing 
cholesterol levels, inflammation and thrombosis (Feldman & Isner, 1995); for upregulating 
apo-A1 and downregulating chemoattractant protein-1 (MCP1)receptor expression 
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(Qian, 1999); targeting vascular redox biology through heme oxygenase-1, superoxide 
dismutase, catalase and glutathione peroxidase antioxidant gene therapy to attenuate 
oxidative stress (Van Assche, 2011); and lipid-lowering gene therapy to reduce plasma LDL 
levels (Grossman et al., 1995). Furthermore, neointimal hyperplasia that contributes to 
pathogenesis of arterial stenosis, in-stent stenosis and vein graft failure is also a good target 
for gene therapy. A number of potential therapeutic genes, which are key to the 
development of neointimal hyperplasia, have been identified. The ones that are promising 
for gene therapy include tissue inhibitors of matrix metalloproteinases (Akowuah et al., 
2005; Gaffney et al., 2007; Khanna, 2008); NOS (Cooney, 2006; Dzau et al., 2002; Khanna, 
2008; Kishore & Losordo, 2007; Gaffney et al., 2007; Melo et al., 2005; Von der Leyen & Dzau, 
2001) and p53 (Gaffney et al., 2007). Importantly, delivery of antiproliferative genes such as 
those coding for p21Cip1, p27Kip1, and iNOS are used to inhibit stenosis and neointimal 
hyperplasia (Dzau et al., 2002; Von der Leyen & Dzau, 2001]. Conversely, silencing the genes 
that contribute to proliferation via antisense ODNs (Dzau et al., 2002; Khanna, 2008; Kishore 
& Losordo, 2007; Gaffney et al., 2007; Melo et al., 2005) or siRNA approach is also effective 
in preventing in-stent and graft neointimal hyperplasia (Banno, et al., 2006; F. Li et al., 2005; 
J.M. Li et al., 2010; Matsumae et al., 2008). Antisense ODNs–based inhibition of cell 
proliferation-related genes such as PCNA, c-myc, c-myb or different cyclin-dependent 
kinases (cdks) have been successfully carried out in experimental models of vascular lesion 
formation (Braun-Dullaeus et al., 1998; Dzau et al., 2002; Morishita et al., 1993; Simons et al., 
1994).  
RNA interference (RNAi) technology is becoming popular approach to alter gene 
expressions to interrogate their role in pathogenesis of disease, which has utility in the 
inhibition of VSMC proliferation and neointimal hyperplasia (Banno, et al., 2006; F. Li et al., 
2005; J.M. Li et al., 2010; Matsumae et al., 2008). To determine whether Angiotensin II (ANG 
II)-induced neointimal thickening is mediated via cytoplasmic phospholipase A2 (cPLA2) - 
and phospholipase D2 (PLD2)-activated Akt, injured carotid arteries were exposed to a 
retrovirus containing cPLA2 siRNA or PLD2 siRNA to test whether their knockdown will 
result in the reduction of ANG II-induced neointimal thickening (F. Li et al., 2005). SiRNA-
mediated downregulation of cPLA2 and PLD2 resulted in the reduction of ANG II-induced 
neointimal thickening. The involvement of CCN1, an extracellular matrix-associated 
protein, in the development of neointimal hyperplasia is confirmed by siRNA-mediated 
knockdown approach (Matsumae et al., 2008). The atheroprotective role of midkine (MK), a 
heparin-binding growth factor, is corroborated by the use of MK-siRNA (Banno, et al., 2006). 
NADPH oxidase has a critical role in the development of neointimal hyperplasia and 
restenosis due to its contribution to oxidative stress, which is blocked by siRNA specific to 
NOX2 gene Cybb, an important component of NADPH oxidase (J.M. Li, et al., 2010). 
Several experimental gene transfer and gene silencing strategies are evaluated as potential 
treatments for cardiovascular disease, which resulted in Phase I, and Phase I to Phase III 
clinical studies for inducible iNOS (Tzeng, 1996; Von der Leyen & Dzau, 2001) and 
transcription factor E2F, respectively (Dzau et al., 2002; McCarthy, 2001; Mann et al., 1999). 
E2F, a transcription factor that leads to upregulation of up to 12 cell-cycle genes is an ideal 
target for cell-cycle blockade. A double-stranded E2F decoy ODN that bears the consensus 
E2F-binding site (cis-elements) was designed as an agent for prevention of vein graft 
disease. In rabbits, treatment of vein grafts with E2F decoy ODN resulted in inhibition of 
neointimal hyperplasia and graft atherosclerosis for up to 6 months. This led to phase I 
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PREVENT trial for human vascular bypass grafts, which resulted in about 75% reduction in 
VSMC proliferation and fewer graft occlusions. Similar gene manipulation approach was 
used for coronary bypass grafts in PREVENT II trial. Although the phase 1 trial (PREVENT 
Trial) showed promising results, later studies were less positive including the phase III, 
multicentre, randomized double-blinded, placebo-controlled trial of 3014 patients 
undergoing primary coronary artery bypass graft surgery with at least two planned 
saphenous grafts (Alexander et al., 2005; Conte et al., 2005, 2006). Although appears to be 
promising, the use of gene therapy in the treatment of vascular proliferative diseases is still 
in infancy. Various feasibility and efficacy issues as well as design and delivery of the genes 
have to be addressed taking into account the complexity of the pathological processes 
leading to atherosclerosis and restenosis. 
2.4.3 Pharmacotherapy 
A number of pharmacological agents have been used to target injury-induced VSMC 
proliferation that contributes to neointimal growth in balloon-injured arteries. Among these 
rapamycin or sirolimus, a cytostatic agent, arrests VSMC proliferation and migration in vitro 
and reduces neointimal growth in animal models of balloon-injury (Dzau et al., 2002; Guerin 
et al., 2005). Its action appears to be mediated through the inhibition of mammalian target of 
rapamycin (mTOR). One of the downstream events induced by the inhibition of mTOR is 
induction of p27Kip1, an inhibitor of cyclin-dependent kinases (cdk), causes cells to arrest in 
G1 phase of the cell cycle. In doing so, it inhibits cell proliferation. Paclitaxel, a derivative of 
Taxol, is another promising agent for proliferation arrest, which by collapsing the mitotic 
spindle formation causes mitotic arrest (Jordan et al., 1993). It prevents neointima formation 
in animal models, and its clinical effect in the blockade of restenosis is investigated in 
several human trials (the ELUTES, TAXUS and ASPECT trials) via local delivery through 
stents coated with paclitaxel (Finn et al., 2007; Wilson et al., 2007). 
2.4.4 Immunotherapy 
Over the past several years, accumulating data have identified involvement of several 
antigens in the initiation of immune response during atherosclerosis. These include 
exogenous infectious microbial pathogens like, cytomegalovirus and chlamydia pneumonia 
and endogenous proteins such as oxLDL, heat shock proteins (HSPs) and β2-glycoprotein-1b 
(Habets et al., 2010). Among these, the epitopes recognized on oxLDL are important because 
of the role of oxLDL in the pathogenesis of atherosclerosis ((Hansson, 1997; 2007; Steinberg 
& Witztum, 2010; Witztum, 1997). In addition to its proinflammatory and proatherogenic 
effects, and participation in the formation of foam cells, oxLDL is also immunogenic due to 
the presence of several neoepitopes. A number of neoepitopes generated during the 
oxidation of LDL are highly immunogenic and cause the generation of autoantibodies, 
which are detected in atherosclerotic lesions. Since the different epitopes of oxLDL induce 
atherogenic immune response, it may be possible to inhibit proatherogenic effects of oxLDL 
by modulating the immune response towards oxLDL through the immunization against 
oxLDL. Several antigens have been identified and investigated for immunization against 
atherosclerosis in animal models. Immunization against oxLDL show reduction in 
atherosclerosis in several animal models (Habets et al., 2010). This discovery of 
atheroprotective immunity has resulted in the emergence of immunotherapy approach 
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oxLDL offers protection against atherosclerosis, which appears to operate both through 
cellular and humoral immunity (Zhou, 2001). The increased titers of T cell-dependent IgG 
antibodies to oxLDL (Habets et al., 2010; Zhou, 2001) and natural IgM antibodies to 
phosphocholine (Binder et al., 2004) are also in agreement with the atheroprotection. 
Furthermore, two recent studies report promising immunotherapeutic approach for the 
prevention of atherosclerosis. In one study, LDL-receptor deficient mice were vaccinated 
with oxLDL-pulsed mature dendritic cells to determine the effect on atherosclerosis (Habets 
et al., 2010). In the second immunotherapy study, tolerogenic apo-B100-loaded dendritic 
cells in combination with immunosuppressive cytokine interleukin-10 were injected 
intravenously to hypercholesterolemic mice. This immunotherapy significantly prevented 
atherosclerosis by reducing autoimmune response against LDL ( Hermansson et al., 2011) 
Although, these studies are encouraging and promising from a clinical perspective to 
translate these promising outcomes to the clinics, antigens that can be easily manufactured 
under good manufacturing practice conditions and that have a reproducible quality are 
necessary. However, several clinical studies are currently underway to evaluate the 
therapeutic implications of immunotherapy.  
3. Epigenetics and vascular proliferative diseases 
Advancement in technological innovations during the past 25 years has resulted in far-
reaching in-depth comprehension of the biology and the etiology of vascular diseases, and 
thus influencing the perception of the pathophysiology of vascular proliferative diseases 
like atherosclerosis and restenosis. In spite of the substantial understanding of the 
etiology and the clinical management of these vascular proliferative diseases, they are still 
life threatening diseases and reasons are not fully evident. Based on the recent finding of 
the role of epigenetics in human diseases, it is proper to expect that epigenetic 
mechanisms enforces an additional layer of gene regulation that alters chromatin 
structure, and dynamics in the pathogenesis of vascular proliferative diseases (Ekstrom, 
2009; Pons et al., 2009; Ranganna et al., 2006; Turunen, 2009). Epigenetic mechanisms are 
essential for the functioning of genomes to regulate normal development and 
maintenance of organisms, and to facilitate their interaction with surrounding 
environment. Compilation of the past 10 to 20 years of studies has resulted in the 
identification of three highly interrelated epigenetic mechanisms that alter the chromatin 
structure and accessibility. These include, DNA methylation, histone posttranslational 
modifications and non-coding RNA (ncRNA) expression based mechanisms, each of these 
mechanisms is essential for regulation of gene expression. Therefore, it is anticipated that 
the genetic and environmental factors that are relevant to the development of vascular 
proliferative diseases by their effect on inflammation, VSMC proliferation and vessel 
remodeling, is regulated by epigenetic mechanisms through the modification of 
chromatin structure, dynamics and accessibility (Ekstrom, 2009; Pons et al., 2009; 
Ranganna et al., 2006; Turunen, 2009). Although there is an outbreak of interest and 
enthusiasm in linking altered epigenetic mechanisms to human pathologies particularly 
cancers, it is relatively unexplored area regarding cardiovascular diseases. Moreover, 
deregulation of epigenetic processes are linked to changes in many aspects of cell biology 
including cell growth, cell cycle control, and cell death by altering the expression and in 
turn functions of target genes without changing their primary gene structure. Because 
VSMC proliferation is the hallmark of vascular proliferative diseases, understanding the 
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epigenetics of VSMC proliferation and in particular their susceptibility to perturbation by 
the epigenetic modifiers may offer novel insights into disease pathogenesis and epigenetic 
therapeutic approaches. Therefore, it is appropriate to review the current knowledge of 
epigenetics in the regulation of VSMC proliferation.  
3.1 VSMC epigenetics 
Curiosity in epigenetics has surged during past decade even though the principle 
question it aims to address has been there for decades. That is, how a multicellular 
organism maintain drastically different gene expression profile in different cell types of 
the organism, while all the different cell types of the organism have exactly the same 
DNA. This is where epigenetics come into picture. Epigenetics refers to the inheritance of 
gene function/activity/expression that may be stable over long periods, last through 
several cell divisions or inherit through several generations, all without any change in 
their primary DNA (Ng & Gurdon, 2008; Probst, 2009). The three interrelated epigenetic 
mechanisms, which involve: methylation of DNA at CpG dinucleotides at specific 
position in the DNA molecule suppress expression of nearby genes (Esteller, 2008); 
posttranslational modifications of histones alters chromatin structure and changes 
promoter accessibility (Kouzarides, 2007); and small RNA molecules generated from non-
coding RNAs (ncRNAs) inhibit gene expression (Mattick et al., 2009). All these 
mechanisms involved in epigenetic regulation contribute to epigenome. This review 
focuses on the role of posttranslational modifications of histones in the regulation of 
VSMC proliferation, and on the epigenetic regulators of histone modifications as potential 
candidates for drug targeting in the treatment and management of vascular proliferative 
disease.  
3.2 Chromatin structure 
Chromatin is a nucleoprotein complex consisting of repeating units of nucleosomal core 
particles. It offers a dynamic platform for all DNA-mediated processes within the nucleus. 
The nucleosomal core particles are the basic units of chromatin consisting of 147 base pair 
(bp) of DNA that wraps almost twice around two copies of each of the four core histone 
proteins, H3, H4, H2A and H2B. Each nucleosome is separated by 10-16 bp long linkers 
DNA, which gives an appearance of a bead on a string structure that constitutes the 
chromatin fiber of ~10 nm in diameter. The linker DNA assists further compaction of 
chromatin structure into higher-order chromatin structure, which is essential for 
packaging of remarkable lengths of DNA into the cell nucleus. Furthermore, this compact 
chromatin structure limits accessibility of DNA to DNA-mediated processes like 
transcription, DNA replication, and DNA repair (Kouzarides, 2007). Evidence 
accumulated during the past 15 years reveals that three interrelated epigenetic 
mechanisms alter the highly compacted chromatin structure and facilitate accessibility of 
DNA for gene transcription. The interrelated epigenetic mechanisms that include DNA 
methylation, histone modification and ncRNA expression contribute to the epigenome 
making the epigenome dynamic rather than static like genome and thus, being 
predisposed to and influenced by environmental factors and extracellular stimuli. 
Deregulation of epigenetic mechanisms is observed in many different cancers and other 
human diseases. Thus, understanding of how epigenetic mechanisms contribute to gene 
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3.3 Histone modifications 
Histones are highly conserved basic proteins that undergo an amazing number and types of 
posttranslational modifications, which contributes to the active or inactive chromatin 
(Ekstrom, 2009; Kouzarides, 2007; Pons et al., 2009; Ranganna et al., 2006; Turunen, 2009). 
Each of the four core histones are composed of a conserved globular domain that forms the 
nucleosome core, and a highly dynamic amino-terminal tail of 20-35 residues rich in basic 
amino acids. Additionally, H2A histone has an extended tail of about 35 residues at the 
carboxy-terminal end. Both amino- and carboxy-terminal tails protrude from nucleosome 
into the nucleoplasm. Histones tails are the targets of an array of site-specific 
posttranslational modifications including lysine acetylation/deacetylation, lysine and 
arginine methylation, serine and threonine phosphorylation, lysine ubiquitylation and 
sumoylation, and glutamic acid ADPribosylation (Fischle et al., 2003; Ito, 2007; Jenuwein & 
Allis, 2001; Turner, 2003).  
Histone modifications are dynamic and reversible, and their ‘off’ and ‘on” modification 
states are influenced by different physiological and environmental factors like 
developmental state, stress condition and environmental cues. Many of histone 
modifications are associated with transcriptionally active euchromatin regions, while 
other histone modifications are localized to transcriptionally inactive heterochromatin 
regions. Even though issues such as how the process of modification is regulated, and 
how many modifications are required for their biological effect are still elusive, 
recognition of specific histone modifications by various effector proteins is suggested to 
mediate specific biological processes like gene activation or gene suppression by altering 
the chromatin structure and gene accessibility. Generally, conformationally relaxed and 
decondensed chromatin structure that is associated with histone acetylation and DNA 
hypomethylation is the feature of transcriptionally active chromatin. On the other hand, 
compact and condensed chromatin structure that is associated with deacetylation of 
histones and hypermethylation of DNA is transcriptionally silent. Condensed chromatin 
structure is essential during cell cycle, mitosis and meiosis, whereas decondensed 
chromatin structure is required for gene expression, replication, repair and 
recombination. The combinatorial pattern of the histone modifications indicates the state 
of the chromatin structure, and thus, regulates the accessibility of the DNA to the 
transcription-regulatory complexes, through it controls gene expression. The collection 
of various covalent histone modifications serve as epigenetic marks for the recruitment 
of different proteins or protein complexes to regulate disparate chromatin functions such 
as gene expression, gene suppression, mitosis, repair, replication and chromosome 
segregation (Taverna et al., 2007). Furthermore, there is also crosstalk between different 
histone modifications like acetylation, methylation and phosphorylation at independent 
sites forming a “histone code” that is translated to a specific biological event through the 
mediation of various effector proteins. For example, phosphorylation of serine 10 of 
histone H3 facilitates acetylation of lysine 14 and methylation of lysine 4, which create an 
open or relaxed chromatin conformation associated with an active gene. Serine 10-
phosphorylation also facilitates the acetylation of lysine 9, thus preventing the  
repressive lysine 9-methylation associated with an inactive gene (Jenuwein & Allis., 
2001; Lund & van Lohuizen, 2004; Mathew et al., 2010; Schreiber & Bernstein, 2002; 
Turner, 2003).  
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3.4 Chromatin modifying enzymes 
Consistent with the variety of posttranslational modifications of histones, a disparate family 
of enzymes, which are referred as histone modification writers, catalyzes addition of specific 
functional groups to histones. These modifications of histones alter the chromatin structure 
and function by two distinct manner: First, by directly altering the charges of histone 
proteins, certain posttranslational modifications cause localized relaxation of chromatin 
structure and second, by serving as recognition and binding sites for various classes of 
effector proteins that participate in chromatin remodeling, certain histone modifications 
indirectly alter the chromatin structure. However, most histone modification are reversible 
and diverse families of proteins, which include histone acetyltransferases (HATs) /histone 
deacetylases (HDACs), histone methyltransferases (HMTs)/demethylases, histone 
kinases/phosphatases, and ubiquitin ligases, catalyze addition and removal of the 
modifications from histones. One of the highlights of epigenetics is that it offers new 
therapeutic targets for diseases including cardiovascular diseases. The epigenetic regulators, 
HATs/HDACs and HMTs/demethylases, which exhibit counterbalancing activities are 
essential for the regulation of gene expression, which are required for the basic cellular 
processes such as cell proliferation and differentiation. This essential role of epigenetic 
regulators in basic cellular processes identifies potential therapeutic targets for diseases 
including cardiovascular diseases. Moreover, identification of those HATs and HDACs that 
plays a role in the transcriptional regulation of genes, products of which contributes to the 
processes of neointima formation like inflammation, VSMC proliferation, and matrix 
formation is also important in designing potential epigenetic therapy to target vascular 
proliferative diseases. Thus, pharmacological inhibition of enzyme activities involved in 
epigenetic DNA and histone modifications designed to induce or silence the transcription of 
disease-relevant genes offers an amenable therapeutic intervention for atherosclerosis and 
restenosis. In addition to modifying the effects of diseased genes, it is possible to change the 
effects of environmental risk factors by targeting epigenetic mechanisms. Here we will focus 
on HATs/HDACs, the principal epigenetic regulators that control histone acetylation, a 
major epigenetic modification for transcriptional control of gene expression. Because 
HATs/HDACs are essential for the regulation of gene expression, in all probability, they 
play crucial role in the development of multigene and multifactorial diseases such as 
atherosclerosis and restenosis.  
4. Histone acetyltransferases (HATs) and histone deacetylases (HDACs)  
One of the best- and most-studied posttranslational histone modifications is lysine 
acetylation catalyzed by HATs, the modification that is generally associated with gene 
activation (Ekstrom, 2009; Kouzarides, 2007; Pons et al., 2009; Ranganna et al., 2006; 
Turunen, 2009). Hyperacetylation of histones causes decondensation of chromatin allowing 
a more relaxed or open and active chromatin structure, which allows accessibility of DNA to 
basal transcription initiation machinery (Kouzarides, 2007; Roth, 2001). In contrast, gene 
repression is mediated by HDACs, and other co-repressors, which cause deacetylation of 
hyperacetylated histones and offset the activity of HATs resulting in a closed conformation 
of chromatin structure. Thus, the acetylation status of the chromatin associated with 
particular genes is dictated by the balance between the activities of HATs and HDACs. 
These enzymes are shown to regulate expression of genes associated with various cellular 
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al., 2009; Sahar et al., 2007; Vinh et al., 2008; Waltregny et al., 2005; Xu et al., 2007; Yan et al., 
2009). HATs and HDACs are also recruited to gene promoters by multiprotein 
transcriptional complexes, where they regulate transcription through chromatin 
modification without directly binding the DNA. 
A number of different HATs are identified and organized as families based on the presence 
of highly conserved structural motifs, which include PCAF/Gcn5, p300/CBP, MYST, SRC, 
and TAFII250 families. While they all differ in their HAT domains and substrate specificity, 
they all require the assembly of multiprotein complexes for acetylation of nucleosomes 
(Marmorstein, 2001). Likewise a number of HDACs are identified and are classified into 
three different classes based on cellular localization, substrates and binding site features 
(Lindemann et al., 2004; Santini et al., 2007). Class I and class II include zinc-dependent 
HDACs, and class III includes NAD-dependent HDACs, which are also called as sirtuins. 
Class I HDACs are widely expressed and include HDACs 1-3 and 8 that are exclusively 
localized to nucleus. They are known to modulate cell proliferation and survival. Class II 
HDACs are HDACs 4-7, 9, and 10, which shuttle between the nucleus and cytoplasm in 
response to certain cellular signals. They may be involved in cell differentiation (Pons et al., 
2009; Santini et al., 2007). Class II HDACs are further divided into Class IIa and Class IIb , 
which include HDACs 4, 5 ,7, and 9, and, HDACs 6 and 10, respectively. While Class IIa 
members have an extended N-terminal regulatory domain, Class IIb exhibit an extra 
catalytic domain (Lindemann et al., 2004; Pons et al., 2009; Santini et al., 2007). Class III 
HDACs are sirtuins (SIRT), which include NAD+-dependent enzymes (SIRT 1-7) potentially 
involved in apoptosis (Pons et al., 2009).  
HATs and HDACs are also recruited to gene promoters by multiprotein transcriptional 
complexes. There they regulate transcription through chromatin modification without 
directly binding the DNA (Johnstone & Licht, 2003; Pons et al., 2009). Moreover, HATs and 
HDACs are also involved in the acetylation status of lysine residues of transcription factors 
such as p53, E2F1, GATA1, RelA, YY1 and hormone receptors. Acetylation status of these 
transcription factors affects their DNA binding and transcriptional activity (Glozak et al., 
2005; Johnstone & Licht., 2003; Marks, 2001; Pons et al., 2009). Besides histones and 
transcription factors, several other non-histone proteins like α-tubulin, nuclear import 
protein importin-α7, and signal transduction protein β-catenin are also modified by HATs 
and HDACs, but their effects on gene expression is not dependent on chromatin remodeling 
(Johnstone & Licht., 2003; Marks, 2001). 
4.1 Epigenetic therapy targeting VSMC proliferation 
Because HATs/HDACs are involved in dynamic reversible epigenetic processes that 
contribute to modulation of gene expression profiles specific to cellular processes like cell 
proliferation, they probably play important role in cardiovascular pathologies such as 
atherosclerosis and restenosis. Moreover, epigenetic deregulation affects several aspects of 
cell biology, including cell growth, cell cycle control, differentiation, DNA repair, and cell 
death. This elevates the strong possibility that reversing deregulated epigenetic mechanisms 
may be an effective treatment strategy for proliferative diseases. Incidentally, the property 
of HDACs, suppression of gene expression by epigenetic mechanism, has been exploited in 
the field of cancer to reactivate transcriptionally silent tumor suppressor gene to arrest 
proliferation of cancer cells and growth (Pons et al., 2009; Ranganna, et al., 2005, 2007; 
Sharma et al., 2010). Moreover, HDAC inhibitors (HDACi) are emerging as a new class of 
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anticancer agents that are under clinical trials for different cancer treatment. Some of the 
early clinical studies have demonstrated that certain HDACi exhibit promising activity 
against several neoplasms (Bhalla, 2005). Naturally, it has stimulated great interest to 
determine how HATs/HDACs regulate transcriptome of different processes that are linked 
to the development of atherosclerosis and restenosis like inflammation, VSMC proliferation 
and matrix modification and to assess therapeutic potential of HDACi in these vascular 
proliferative diseases (Ekstrom, 2009; Pons et al., 2009; Ranganna et al., 2006; Turunen, 
2009). The following sections will focus on the role of HATs and HDACs in the 
transcriptional regulation of genes in the context of their contribution to VSMC proliferation 
and its disorders as well as on the potential applicability of HDACi in vascular disease 
management.  
4.1.1 Histone deacetylase inhibitors (HDACi) 
In the past few years, great effort has been focused on seeking and designing most effective 
HDACi because of their potential roles in reversing the silenced genes in tumor cells by 
modulating transcriptional processes. The balance between the acetylated/deacetylated 
states of histones, which is mediated by the counterbalancing activities of HATs and 
HDACs, contributes to the transcriptional states of chromatin structure. The structural 
modification of histones by acetylation/deacetylation of their N-terminal tails is crucial in 
modulating gene expression, because it affects the accessibility of DNA for the transcription-
regulatory protein complexes. HATs preferentially acetylate specific lysine residues of 
histones, which relaxes the DNA conformation, thus allowing its access to transcription 
machinery to turn on gene expression. On the contrary, HDACs restore the positive charge 
on lysine residues by removing acetyl groups, which promotes condensed chromatin 
structure. This promotes silencing of gene expression by blocking the access of transcription 
machinery to DNA. Inappropriate silencing of critical genes such as tumor suppressor genes 
can result in cancer based on the recent understanding of the cancer cell cycle (Kristeleit et 
al., 2004). This provides a rationale for using inhibition of HDAC activity to release 
transcriptional repression. As result, a flurry of HDACi has been recognized for their ability 
to inhibit HDACs activity. 
 
 
Fig. 1. Structural class of histone deacetylase inhibitors 
Structurally diverse classes of naturally occurring and synthetic compounds have been 
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anticancer agents that are under clinical trials for different cancer treatment. Some of the 
early clinical studies have demonstrated that certain HDACi exhibit promising activity 
against several neoplasms (Bhalla, 2005). Naturally, it has stimulated great interest to 
determine how HATs/HDACs regulate transcriptome of different processes that are linked 
to the development of atherosclerosis and restenosis like inflammation, VSMC proliferation 
and matrix modification and to assess therapeutic potential of HDACi in these vascular 
proliferative diseases (Ekstrom, 2009; Pons et al., 2009; Ranganna et al., 2006; Turunen, 
2009). The following sections will focus on the role of HATs and HDACs in the 
transcriptional regulation of genes in the context of their contribution to VSMC proliferation 
and its disorders as well as on the potential applicability of HDACi in vascular disease 
management.  
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In the past few years, great effort has been focused on seeking and designing most effective 
HDACi because of their potential roles in reversing the silenced genes in tumor cells by 
modulating transcriptional processes. The balance between the acetylated/deacetylated 
states of histones, which is mediated by the counterbalancing activities of HATs and 
HDACs, contributes to the transcriptional states of chromatin structure. The structural 
modification of histones by acetylation/deacetylation of their N-terminal tails is crucial in 
modulating gene expression, because it affects the accessibility of DNA for the transcription-
regulatory protein complexes. HATs preferentially acetylate specific lysine residues of 
histones, which relaxes the DNA conformation, thus allowing its access to transcription 
machinery to turn on gene expression. On the contrary, HDACs restore the positive charge 
on lysine residues by removing acetyl groups, which promotes condensed chromatin 
structure. This promotes silencing of gene expression by blocking the access of transcription 
machinery to DNA. Inappropriate silencing of critical genes such as tumor suppressor genes 
can result in cancer based on the recent understanding of the cancer cell cycle (Kristeleit et 
al., 2004). This provides a rationale for using inhibition of HDAC activity to release 
transcriptional repression. As result, a flurry of HDACi has been recognized for their ability 
to inhibit HDACs activity. 
 
 
Fig. 1. Structural class of histone deacetylase inhibitors 
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at its base, thereby inhibiting HDAC activity (Marks et al., 2000). A wide range of structures 
inhibits activity of class I/II HDAC enzymes with a few exceptions [Figure 1]. The HDACi 
are classified into structural classes including 1) short-chain fatty acids (carboxylates), 2) 
hydroxamic acids, 3) benzamides, and 4) cyclic and non-cyclic peptides. The various HDACi 
studied so far have been shown to inhibit class I (HDACs 1, 2, 3, and 8) and II (HDACs 4, 5, 
6, 9, and 10) HDACs. Their activities have been tested in cell lines and preclinical murine 
models, and appropriate drugs that are selected for clinical trials, demonstrated good 
tolerance and clinical activity against different human neoplasms (Santini et al., 2007). 
However, Class III HDACs (SIRT 1, 2, 3, 4, 5, 6, and 7), also known as sirtuins, require NAD 
rather than zinc as a co-factor for their activity, and are not inhibited by the HDACi. Instead, 
they are inhibited by Nicotinamide (Luo et al., 2001).  
4.1.2 HDACi effects on cellular processes  
HDACi exhibit multiple cellular effects, which are linked to chromatin-mediated altered 
transcriptional activity. In general, most HDACi exhibit inhibition of cell proliferation, 
stimulation of cell differentiation and/or induction of cell death by selectively modulating 
gene expression (Bhalla, 2005; Mathew et al., 2010; Ranganna, 2005). HDACi arrest cells at 
the G1 or G2/M, and promote cell differentiation mainly by stimulating cyclin-dependent 
kinase inhibitor (cdkI) p21Cip1 expression (Bhalla, 2005; Mathew et al., 2010; Ranganna et 
al., 2005). HDACi also cause cell cycle blockade through the modulation of mechanisms that 
involve repression of cyclin D and cyclin A and upregulation of other cdkI like p27Kip1, 
p16INK4A and p15INK4B, which blocks pRb/E2F pathway, thus preventing the cell cycle 
progression (Mathew et al., 2010; Bhalla, 2005) [Figure 2]. Now with the array technologies, 
it is recognized that HDACi selectively modulate about 2% to 10% of all genes, with as 
many genes upregulated as are downregulated genes in different cell types (Bhalla, 2005; 
Ranganna et al., 2003). One of the genes that are universally upregulated is the cdkI 
p21Cip1, in a p53-independent manner, which is necessary for HDACi-induced G1 arrest. 
Induction of GADD45α and β and upregulation of transforming growth factor beta, which 
inhibits c-myc expression may also contribute to the cell cycle arrest in G1 or G2 (Bhalla, 
2005.). HDACi treatment is also shown to transcriptionally downregulate the expression of 
CTP synthetase and thymidylate synthetase, which are required for DNA synthesis, thus, 
causing inhibition of S phase progression [Figure 3]. 
HDACi also stimulate differentiation of several cancer cells by inhibiting cell proliferation 
(Bhalla, 2005). Again, upregulation of p21Cip1 appears to be essential for differentiation 
because cells lacking p21Cip1 fail to respond to HDACi treatment (Bhalla, 2005). 
Furthermore, acute promyelocytic leukemic cells and primary leukemia blasts, expressed 
differentiated phenotype in response to a combination of ATRA, a retinoid-based 
chemotherapeutic drug and HDACi (Bhalla, 2005). HDACi stimulated gelsolin, an actin-
binding protein required for morphological and cytostructural changes associated with 
differentiation (Bhalla, 2005). 
It is interesting that HDACi induce growth arrest and cell differentiation in some cell, and in 
others, they cause apoptosis (Bhalla, 2005; Johnstone & Licht, 2003). HDACi-induced 
apoptosis triggers both the intrinsic and extrinsic pathways of apoptosis. Several types of 
HDACi, particularly hydroxamic acid analogs are shown to induce mitochondrial 
permeability transition, which releases prodeath molecules such as cytochrome c, Smac and 
Omi into cytosol (Bhalla, 2005). This triggers activation of Apaf-1, which leads to the 
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processing and activation of caspases-9 and-3 (Bhalla, 2005). HDACi appear to promote 
apoptotic cell death not only by upregulating several proteins that participate in apoptotic 
cell death including Bak, Bax, Bim, DR4, DR5, and TRAIL, but also by attenuating the levels 
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Besides affecting cell proliferation, differentiation and apoptosis, HDACi also alter the 
function of some of the non-histone transcription factors like p53, RelA, GATA1 and 
FoxO3A because HDACi enhance their acetylation, which may affect their DNA binding 
and transcriptional activity (Marks et al, 2001; Lindemann et al., 2004). Similarly, stimulating 
acetylation status of other non-histone protein such as nuclear import protein importin-α7, 
signaling protein β-catenin, DNA repair enzyme Ku70, and the cytoskeletal protein β-
tubulin, HDACi alter their activity (Bhalla, 2005). Taken together, by inducing acetylation of 
histones and non-histones, HDACi alter the levels of proteins that control cell cycle 
progression, differentiation and apoptosis appropriately by transcriptional and post-
transcriptional mechanisms, which implicate their potential use in disease treatment.  
4.2 VSMC proliferation and histone acetylation  
Although the common mechanism of pathogenesis shared by the atherosclerosis and cancer 
are linked to abnormal cell proliferation, very limited information is available with reference 
to anti-atherogenic potential of HDACi. Because HDACi not only alter gene expressions, but 
also cause inhibition of cell proliferation and induction of differentiation and/or apoptosis, 
a number of studies are initiated in the past few years to test the effects of HDACi as 
potential antiatherogenic agents. Even though both in vitro and in vivo studies have been 
done with the intention of targeting VSMC proliferation for the intervention and 
management of vascular proliferative diseases, most of the information that is available 
currently is from in vitro cell culture studies. There is limited in vivo data supporting the 
protective role of HDACi but needs further evaluation in models of VSMC injury.  
4.2.1 VSMC proliferation 
In general, HDACi exhibit almost same effects in VSMC as they do in cancer cells. They 
arrest cell proliferation, induce differentiation and/or apoptosis, and modulate expression 
of cell cycle regulators. Several studies have shown that trichostatin A (TSA), a well-known 
HDACi, arrests VSMC proliferation via upregulation of p21Cip1 and subsequent reduction 
of the phosphorylation of Rb protein at the G1-S phase (Okamoto et al., 2006; Pons et al., 
2009), the effects consistently observed in cancer cell (Bhalla, 2005). In contrast, in one of the 
studies TSA unexpectedly exhibited paradoxical pro-atherogenic effect on VSMCs via the 
reduction of thioredoxin 1 instead of antiatherogenic properties (Song et al., 2010).  
Besides TSA, butyrate, a well-known dietary HDACi, which has been used in different 
human cancer and other disease treatments, appears to exhibit potential antiatherogenic 
effect by arresting VSMC proliferation and appropriately altering both negative and positive 
cell cycle regulators (Davie, 2003; Mathew et al., 2010; Ranganna et al, 2005). Butyrate 
belongs to the class of short-chain fatty acids and is a derived from the intestinal microbial 
fermentation of dietary fiber. A number of epidemiological, animal and interventional 
studies suggest an inverse relationship between dietary fiber and chronic diseases such as 
bowel disorders and colorectal cancer, cancer of other tissues, cardiovascular disease, 
diabetes, obesity and hypertension (Anderson, 2003; Dashwood et al., 2006; Kim, 2000; 
Ranganna et al., 2005, 2006). Some of the studies suggest that the protective effect of dietary 
fibers in chronic diseases is linked to bioactivity of butyrate (Anderson, 2003; Dashwood et 
al., 2006; Kim, 2000; Ranganna et al., 2005, 2006). Butyrate elicits many cytoprotective, 
chemopreventive and chemotherapeutic activities mainly through inhibition of cell 
proliferation, stimulation of cell differentiation and/or induction of cell death by selectively 
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modulating certain gene expressions, but the mechanistic basis for these actions are far from 
clear. Butyrate has been known to alter chromatin structure and organization via 
hyperacetylation of histone amino-terminal tails, modulate gene expression and play a 
protective role in the prevention of cancer and inflammatory diseases of colon for a long 
time (Ranganna et al., 2005, 2006). However, its importance in the prevention of cancer of 
other tissues and different diseases has been recognized during the past ten years 
(Anderson, 2003; Dashwood et al., 2006; Kim, 2000; Ranganna et al., 2005, 2006). On the 
other hand, no similar studies are performed to indicate the protective role of butyrate in 
cardiovascular diseases due to atherosclerosis and restenosis.  
During last few years, significant interest is focused on potential utility of butyrate and its 
stable derivatives in the intervention of vascular proliferative diseases, besides their 
therapeutic applications in other diseases including cancers. Butyrate and its more stable in 
vivo analogue tributyrin, arrested proliferation and inhibited DNA synthesis of smooth 
muscle cells in a cAMP-independent manner. Butyrate also abolished serum-induced c-fos, 
c-myc, and Ki-Ras expression that are important for early G1 events initiated by serum 
growth factors, but stimulated the expression of PS4 and thromospondin (Feng et al., 1996). 
Moreover, studies performed in our own lab further supports the efficacy of butyrate and its 
stable derivatives in vascular proliferative diseases. Treatment of VSMC with butyrate 
inhibited serum and PDGF-induced proliferation and abolished expression of proliferation 
markers such as c-myc and proliferating cell nuclear antigen [PCNA] (Ranganna et al., 1995, 
2000). Furthermore, our analysis of profiles of VSMC transcriptome by array technology 
disclosed that butyrate-arrested VSMC proliferation is a multigene and multipathway-
mediated process. Our array data identified differential expression of several genes in 
butyrate arrested VSMC proliferation, which are mainly belonging to four different 
functional classes: cell proliferation and differentiation; stress response; vascular function; 
and genes normally present in neuronal cells (Ranganna, et al., 2003). Extension of this study 
reveals that an upper level regulatory mechanism mediated through epigenetic modification 
of chromatin structure controls the expression of both positive and negative cell cycle 
regulatory genes linked to VSMC proliferation arrest by butyrate (Mathew et al., 2010). To 
establish the mechanistic link between chromatin remodeling and antiproliferation action of 
butyrate, influence of butyrate on posttranslational modifications of histone H3 and its 
consequence on G1-specific cell cycle regulators were investigated [Figure 2]. Outcomes of 
the study indicate interplay between different site-specific posttranslational modifications of 
histone H3 in butyrate treated VSMCs that seem to alter chromatin structure and 
organization that supports downregulation of cdk2, cdk4/6, and PCNA, and upregulation 
of cdkI, p21Cip1 and p15INK4B. This causes inhibition of Rb phosphorylation resulting in 
arrest of VSMC proliferation [Figure 2 and Figure 3]. The effects of HDACi on cell cycle-
related gene expressions appear to be highly selective, leading to transcriptional activation 
of certain genes such as the cdkIs but repression of others like cdks to efficiently block cell 
proliferation. 
4.2.2 Histone acetylation 
Hypernuclear acetylation (HNA) also plays a role in proliferation (Kawahara et al., 2003). 
Presence of increased histone acetylation is observed in VSMC of atherosclerotic lesions 
unlike in normal arteries. Thrombin, a humoral factor that is known to activate and 
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pathway and CBP are implicated in thrombin-induced HNA suggesting that coactivators 
cooperating with signaling-dependent transcription activators play a role in atherosclerosis 
through HNA (Kawahara et al., 1999). 
5. Conclusions and perspectives 
Over the past few years, it has become abundantly evident that several interdependent 
epigenetic changes collaborate with genetic changes in the development of human diseases 
including cardiovascular diseases such as atherosclerosis and restenosis. Since the genetic 
foundations of diseases are generally immutable, but their epigenetic and chromatin changes 
are reversible, they are suitable for epigenetic therapy with epigenetic and chromatin 
modifiers. Therefore, thorough understanding on the roles of epigenetic processes in the 
etiology of atherosclerosis and restenosis is essential to launch an epigenetic therapy designed 
to target the epigenetic processes. Although a number of different therapeutic approaches 
have been investigated in the treatment of atherosclerosis and restenosis such as 
brachytherapy, pharmacotherapy, gene therapy, and immunotherapy, the therapeutic efficacy 
of these treatment modalities for atherosclerosis and restenosis is not adequate for a number of 
patients. Possible reasons are multiple factors, genes, pathways are involved in the disease 
pathogenesis, and targeting one or two genes or pathways are not sufficient to treat complex 
vascular pathologies. In these scenarios, epigenetic therapy, which is reversible, appears to be 
appropriate because HDACi exhibit multiple cellular effects that play major roles in vascular 
pathogenesis. HDACi exhibit antiproliferative, antioxidant and antiinflammatory effects and 
cause inhibition of cell proliferation and stimulation of differentiation or apoptosis by 
modulating expression of multiple genes (Natarajan, 2011; Ranganna, et al.,2005; 2006; 2007). 
For example, HDACi inhibit cell proliferation by appropriately altering both positive and 
negative regulators of cell cycle. While cell cycle inhibitors such as p21Cip1, p27kip1, 
p16INK4a and p15INK4b are upregulated, expressions of cyclin D, cyclin A, cdk2, cdk4/6, 
PCNA and pRb that promote cell cycle progression are downregulated (Figure 2 and Figure 3). 
With one single HDACi, multiple genes are altered that control cell cycle progression unlike 
gene therapy, where a cocktail of genes is required to bring about inhibition of cell 
proliferation. Furthermore, stents are ideal platform for the localized delivery of HDACi to the 
vascular wall because of their widespread use and safety in the treatment of restenosis. It is 
recognized that many of the processes that play critical role in atherosclerosis and restenosis 
such as VSMC proliferation, migration, inflammation, cellular redox state and matrix protein 
synthesis (Natarajan, 2011) are regulated by epigenetic mechanisms. As such, they present an 
exciting opportunity for therapeutic intervention, particularly to refractory or recurrent 
vascular pathologies such as restenosis and in-stent restenosis and vein graft failure. A number 
of natural and synthetic HDACi are already in the pipeline for the treatment of cancer either 
stand alone, or in combination with other anticancer drugs and several clinical trials are in 
progress. Exploring these particulars will speed the necessary epigenetic treatment strategies 
for the management of atherosclerosis and restenosis.  
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pathway and CBP are implicated in thrombin-induced HNA suggesting that coactivators 
cooperating with signaling-dependent transcription activators play a role in atherosclerosis 
through HNA (Kawahara et al., 1999). 
5. Conclusions and perspectives 
Over the past few years, it has become abundantly evident that several interdependent 
epigenetic changes collaborate with genetic changes in the development of human diseases 
including cardiovascular diseases such as atherosclerosis and restenosis. Since the genetic 
foundations of diseases are generally immutable, but their epigenetic and chromatin changes 
are reversible, they are suitable for epigenetic therapy with epigenetic and chromatin 
modifiers. Therefore, thorough understanding on the roles of epigenetic processes in the 
etiology of atherosclerosis and restenosis is essential to launch an epigenetic therapy designed 
to target the epigenetic processes. Although a number of different therapeutic approaches 
have been investigated in the treatment of atherosclerosis and restenosis such as 
brachytherapy, pharmacotherapy, gene therapy, and immunotherapy, the therapeutic efficacy 
of these treatment modalities for atherosclerosis and restenosis is not adequate for a number of 
patients. Possible reasons are multiple factors, genes, pathways are involved in the disease 
pathogenesis, and targeting one or two genes or pathways are not sufficient to treat complex 
vascular pathologies. In these scenarios, epigenetic therapy, which is reversible, appears to be 
appropriate because HDACi exhibit multiple cellular effects that play major roles in vascular 
pathogenesis. HDACi exhibit antiproliferative, antioxidant and antiinflammatory effects and 
cause inhibition of cell proliferation and stimulation of differentiation or apoptosis by 
modulating expression of multiple genes (Natarajan, 2011; Ranganna, et al.,2005; 2006; 2007). 
For example, HDACi inhibit cell proliferation by appropriately altering both positive and 
negative regulators of cell cycle. While cell cycle inhibitors such as p21Cip1, p27kip1, 
p16INK4a and p15INK4b are upregulated, expressions of cyclin D, cyclin A, cdk2, cdk4/6, 
PCNA and pRb that promote cell cycle progression are downregulated (Figure 2 and Figure 3). 
With one single HDACi, multiple genes are altered that control cell cycle progression unlike 
gene therapy, where a cocktail of genes is required to bring about inhibition of cell 
proliferation. Furthermore, stents are ideal platform for the localized delivery of HDACi to the 
vascular wall because of their widespread use and safety in the treatment of restenosis. It is 
recognized that many of the processes that play critical role in atherosclerosis and restenosis 
such as VSMC proliferation, migration, inflammation, cellular redox state and matrix protein 
synthesis (Natarajan, 2011) are regulated by epigenetic mechanisms. As such, they present an 
exciting opportunity for therapeutic intervention, particularly to refractory or recurrent 
vascular pathologies such as restenosis and in-stent restenosis and vein graft failure. A number 
of natural and synthetic HDACi are already in the pipeline for the treatment of cancer either 
stand alone, or in combination with other anticancer drugs and several clinical trials are in 
progress. Exploring these particulars will speed the necessary epigenetic treatment strategies 
for the management of atherosclerosis and restenosis.  
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1. Introduction 
Cardiovascular disease (CvDs) such as coronary artery disease, hypertension, congestive 
heart failure and stroke are the leading causes of death and disability in the Western 
World (Madamanchi et al., 2005;  Thom, 1989). The majority of CvDs results from 
complication of atherosclerosis. Prevention of cardiovascular events is therefore urgently 
needed and is one of the major recent challenges of  medicine. New molecular imaging 
approaches featuring the assessment of inflammatory processes in the vascular wall (on 
top of existing anatomic and functional vessel imaging procedures) could emerge as 
decisive tools for the understanding and prevention of cardiovascular events (Schafers et 
al., 2010). 
2. Atherosclerosis 
Atherosclerosis is a progressive disease, affecting medium and large-sized arteries, 
characterized by patchy intramural thickening of the subintimal that encroaches on the 
arterial lumen (Bonomini et al., 2008). The atherosclerosis plaque is characterized by an 
accumulation of lipid in the artery wall, together with infiltration of macrophages, T cells 
and mast cells, and the formation by vascular smooth muscle cells (VSMCs) of a fibrous 
cap composed mostly of collagen. Early lesions called “fatty streaks” consist of sub-
endothelial deposition of lipid, macrophage foam cells loaded with cholesterol and T cells. 
Over time, a more complex lesion develops, with apoptotic as well as necrotic cells, cell 
debris and cholesterol crystals forming a necrotic core in the lesion. This structure is 
covered by a fibrous cap of variable thickness, and its “shoulder” regions are infiltrated 
by activated T cells, macrophages and mast cells, which produce proinflammatory 
mediators and enzymes (Hansson et al., 2006). Plaque growth can cause stenosis 
(narrowing of the lumen) that can contribute to ischemia in the surrounding tissue 
(Hansson & Hermansson, 2011).  
Although the pathophysiological mechanisms underlying atherosclerosis are not 
completely  understood, it is widely recognized that both inflammation and oxidative 
stress play important roles in all of the phases of atherosclerosis evolution (Cipollone et 
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Fig. 1. Steps involved in atherosclerosis progression from endothelial dysfunction to 
cardiovascular complication. 
2.1 Atherosclerosis and oxidative stress  
Oxidative stress can be defined  as an “imbalance between oxidants and antioxidants in 
favor of the oxidants, potentially leading to damage” (Sies, 1991). Age, gender, obesity, 
cigarette smoking, hypertension, diabetes mellitus and dyslipidemia are known atherogenic 
risk factors that promote the impairment of endothelial function, smooth muscle function 
and vessel wall metabolism. These risk factors are associated with an increased production 
of reactive oxygen species (ROS) (Antoniades et al., 2003). ROS play a physiological role in 
the vessel wall and participate as second messengers in  endothelium-dependent function, 
in smooth muscle cells and endothelial cells (ECs) growth and survival, and in remodelling 
of the vessel wall. Each of these responses, when uncontrolled, contributes to  vascular 
diseases (Fortuño et al., 2005; Griendling & Harrison, 1999; Irani, 2000; Taniyama & 
Griendling, 2003).  
In the vasculature wall, ROS are produced by all the layers, including tunica intima, media 
and adventitia. ROS include superoxide anion radical (O2-), hydrogen peroxide (H2O2), 
hydroxyl radical (OH), nitric oxide (NO), and peroxynitrite (ONOO-) (Lakshmi et al., 2009). 
The major vascular ROS is O2−, which inactivates NO, the main  vascular relaxing factor, 
thus impairing relaxation (Cai & Harrison, 2000; Kojda & Harrison, 1999).  Dismutation of 
O2− by superoxide dismutase (SOD) produces H2O2, a more  stable ROS, which, in turn, is 
converted to water by catalase and glutathione peroxidase. H2O2 and other peroxides 
appear to be important in the regulation of growth-related signalling in VSMCs and 
inflammatory responses in vascular lesions (Irani, 2000; Li, P.F. et al., 1997). High levels of 
O2−, the consequent accumulation of H2O2 and diminished NO  bioavailability play a critical 
role in the modulation of vascular remodelling. Finally, ONOO-, resulting from the reaction 
between O2− and NO, constitutes a strong oxidant molecule, which is able  to oxidize 
proteins, lipids and nucleic acids and then causes cell damage (Beckman & Koppenol, 1996; 
Fortuño et al., 2005).  
There are several potential sources of ROS production. In cardiovascular disease the sources 
include xanthine oxidase, cyclooxygenase, lipooxygenase, mitochondrial respiration, 
cytochrome P450, uncoupled nitric oxide synthase (NOS) and NAD(P)H oxidase. They have 
been identified as sources of ROS generation in all type of vasculature. These sources may 
contribute to ROS formation, depending on cell type, cellular activation site and disease 
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context. Numerous studies have shown that various physiological stimuli that contribute to 
pathogenesis of vascular disease can induce the formation of ROS (Lakshmi et al., 2009). 
ROS have detrimental effects on vascular function through several mechanisms. First, ROS, 
especially hydroxyl radicals, directly injure cell membranes and nuclei. Second, by 
interacting with endogenous vasoactive mediators formed in ECs, ROS modulate 
vasomotion and the atherogenic process. Third, ROS peroxidize lipid components, leading 
to the formation of oxidized lipoproteins (LDL), one of the key mediators of atherosclerosis 
(Bonomini et al., 2008).  
 
 
Fig. 2. Potential sources of ROS production in atherosclerosis progression.  
Cholesterol  is transported in the blood by LDL. These particles contain esterified cholesterol 
and triglycerides surrounded by a shell of phospholipids, free cholesterol and 
apolipoprotein B100 (ApoB100).  Circulating LDL particles can accumulate in the intimal, 
the innermost layer of the artery. Here ApoB100 binds to proteoglycans of the extracellular 
matrix (ECM) through ionic interactions (Tabas et al., 2007). This is an important initiating 
factor in early atherogenesis (Skålen et al., 2002; Steinberg, 2009; Witztum & Steinberg, 
2001). As a consequence of this subendothelial retention,  LDL particles are trapped in the 
tunica intima, where they are prone to oxidative modifications caused by enzymatic attack 
of myeloperoxidase (Heinecke, 2007) and lipoxygenases, or by ROS such as hypoclorous 
acid (HOCl), phenoxyl radical intermediates or ONOO- generated in the intimal during 
inflammation  and atherosclerosis (Hansson & Hermansson, 2011).  
Oxidized LDL (Ox-LDL) has several biological effects (Madamanchi et al., 2005); it is pro-
inflammatory; it causes inhibition of endothelial NOS (eNOS); it promotes vasoconstriction 
and adhesion; it stimulates cytokines such as interleukins (ILs) and increases platelet 
aggregation. Ox-LDL-derived products are cytotoxic and induce apoptosis. Ox-LDL can 
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inhibitor-1 (PAI-1) synthesis. Another atherogenic property of Ox-LDL is its 
immunogenicity and its ability to promote retention of macrophages in the arterial wall by 
inhibiting macrophage motility (Singh & Jialal, 2006). In addiction, Ox-LDL stimulates 
VSMCs proliferation (Stocker & Keaney, 2004). Thus, intimal thickening further reduces the 
lumen of blood vessels, leading to further potentation of hypertension and atherosclerosis 
(Singh & Jialal, 2006). With ongoing oxidation, the physicochemical properties gradually 
change, including  alterations in charge, particle size, lipid content and other features. The 
precise nature of each of  these alterations obviously depends on the oxidizing agent. For all 
these reasons, Ox-LDL is  not a defined molecular species but is instead a spectrum of LDL 
particles that have undergone a  variety of physicochemical changes (Hansson & 
Hermansson, 2011).  
2.2 Atherosclerosis and inflammation 
Inflammation participates in atherosclerosis from its inception onwards. Fatty  streaks do 
not cause symptoms, and may either progress to more complex lesions or involute. Fatty  
streaks have focal increases in the content of lipoproteins within regions of the intimal, 
where they  associate with components of the ECM such as proteoglycans, slowing their 
egress.  This retention sequesters lipoproteins within the intimal, isolating them from 
plasma antioxidants, thus favoring their oxidative modification (Kruth, 2002; Packard & 
Libby, 2008; Skålen et al., 2002). Oxidatively modified LDL particles comprise an  
incompletely defined mixture, because both the lipid and protein moieties can undergo 
oxidative modification. Constituents of such modified lipoprotein particles can induce a 
local inflammatory response (Miller et al., 2003; Packard & Libby, 2008).  
Vascular ECs function to prevent clotting of blood and adhesion of blood cells to the 
endothelial  cells, in addition to playing the role of a barrier, as a cell monolayer, to prevent 
blood constituents from invading the vascular wall. When ECs are injured or activated by 
various coronary risk factors, infections or physical stimuli, adhesion molecules become 
expressed in ECs, and peripheral monocytes adhere to the endothelial cell surface. Adhesion 
molecules are broadly divided into three  molecular families: integrin family, 
immunoglobulin family, and selectin family (L-selectin, Eselectin, P-selectin) (Yamada, 
2001).  
Chemoattractant factors, which include monocyte chemoattractant protein-1 (MCP-1) 
produced by vascular wall cells in response to modified lipoproteins,  direct the migration 
and diapedesis of adherent monocytes (Boring et al., 1998; Packard & Libby, 2008). 
Monocytic cells, directly interacting with human ECs, increase several fold monocyte matrix 
metalloproteinase (MMP) 9 production, allowing for the subsequent infiltration of 
leukocytes through the endothelial layer and its associated basement membrane (Amorino 
& Hoover, 1998; Packard & Libby, 2008) Within the intima, monocytes mature into 
macrophages under the influence of macrophage  colony stimulating factor (M-CSF), which 
is overexpressed in the inflamed intima. M-CSF stimulation also increases macrophage 
expression of scavenger receptors, members of the pattern-recognition receptor superfamily, 
which engulf modified lipoproteins through receptor-mediated endocytosis. Accumulation 
of cholesteryl  esters in the cytoplasm converts macrophages into foam cells, i.e., lipid-laden 
macrophages characteristic of early-stage  atherosclerosis. In parallel, macrophages 
proliferate and amplify the inflammatory response through the secretion of  numerous 
growth factors and cytokines, including tumor necrosis factor α (TNFα) and IL-1β. Recent 
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evidence supports selective recruitment of a proinflammatory subset of monocytes to 
nascent atheroma in mice (Packard & Libby, 2008).  
A number of proinflammatory cytokines have been shown to participate in  atherosclerotic 
plaque development, growth and rupture (Dabek, 2010; Libby et al., 2002). Nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB) seems to be a crucial transcription 
factor in the cross-talk among cytokines, adhesion molecules and growth factors. On one 
hand, NF-kB is a major transcription factor leading to cytokine synthesis, and on the other 
hand, the above mentioned factors keep NF-kB persistently activated in acute coronary 
syndromes (Dabek, 2010). In atherogenesis, NF-kB before regulates the expression of 
cyclooxygenases, lipooxygenases, cytokines, chemokines (i.e., MCP-1) and adhesion 
molecules (Dabek, 2010; Kutuk & Basaga, 2003). Later in the  progression of the 
atherosclerotic lesion, NF-kB regulates gene expression of M-CSF, a factor stimulating 
infiltrating monocyte differentiation and transformation into “foamy cells”, and other genes 
participating in the transformation (Brach et al., 1991; Dabek, 2010). As stated, 
atherosclerosis is an inflammatory reaction  of the arterial wall. The factors IL-1β, TNF-α, IL-
6, IL-12 and interferon γ (IFNγ) are involved in this reaction and their expression is 
coregulated by NF-kB.  
Intracellular matrix degradation is an important process in both plaque development and 
rupture. The vital factors involved include MMPs, particularly those that are able to break 
down the vascular base  membrane. It has been shown that NF-kB is an essential regulator 
of MMP gene expression, especially MMP-2 and MMP-9, which are critical in plaque 
rupture (Bond et al., 1998; Dabek, 2010). Thus, NF-kB regulates the expression of a wide 
spectrum of atherosclerosis mediating factors. On the other hand, most of these factors also 
up-regulate NF-kB activity. Increased NF-kB activity was found in unstable regions of 
atherosclerotic plaques (Brand et al., 1997; Dabek, 2010). The significance of NF-kB activity 
has been confirmed in  some clinical studies as well. Li and colleagues reported significantly 
increased NF-kB activity in white blood cells from unstable angina patients vs. stable angina 
patients and vs. control patients (the lowest activity in the latter) (Li, J.J. et al., 2004).  
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3. Endothelial cells dysfunction in atherosclerosis 
The endothelium is responsible for the regulation of vascular tone, the exchange of plasma and 
cell biomolecules, inflammation, lipid metabolism and modulation of fibrinolysis and 
coagulation (Andrews et al., 2010). Aging affects many pathways involved in cardiovascular 
functions and particularly of ECs (Barton, 2010; Virdis et al., 2010). In fact, endothelial-aging is 
associated with anatomical disruption, morphological abnormalities in ECs size and shape 
(Haudenschild et al., 1981), susceptibility to apoptosis and abnormal release of EC-derived 
factors (Barton, 2010). These factors, which are synthetized not only by ECs, but also by VSMCs, 
are now known to contribute to pathogenetic mechanisms of CVDs (Higashi et al., 2009).  
 
 
Fig. 4. Central role of ROS in inducing endothelial dysfunction in vascular diseases. 
ECs dysfunction, inflammation, oxidative stress and dyslipidaemia are known to play 
prominent and vital roles not only in the development of atherosclerotic lesions, but also in 
their progression. (Andrews et al., 2010; Bai et al., 2010; Higashi et al., 2009 ; Virdis et al., 
2010). Number of factors and modalities are available to interfere with age related changes 
in EC function (Barton, 2010; Jensen-Urstad et al., 1999). When endothelial damage 
compromises the normal vascular function, the intracellular dynamic balance probably leans 
on an athero-prone phenotype.  
Growing evidence indicates that chronic and acute overproduction of ROS activates ECs as 
pivotal early event in atherogenesis. Oxidative stress induces cell proliferation, hypertrophy, 
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apoptosis and inflammation through activation of various signaling cascades, redox-
sensitive transcriptional factors and expression of pro-inflammatory phenotype (Higashi et 
al., 2009). ECs dysfunction has been shown to be associated with an increase of ROS in 
atherosclerotic animal models and in human subjects with atherosclerosis (Dai, D.Z. & Dai, 
Y., 2010; Davies et al., 2010; Higashi et al., 2009). Moreover, in APOE-deficient mice, a 
widely used animal model of atherosclerosis (Xu, 2009; Zhang, S.H. et al., 1992), studies 
have demonstrated that aged-ECs are more sensitive to apoptosis than younger ones. ECs in 
the areas of the artery resistant to atherosclerosis have a life span of about 12 months, 
whereas cells at lesion-prone sites live for few weeks and even shorter in aged animals  (Xu, 
2009). 
3.1 Endothelial cell-factors 
The vascular endothelium is nowadays considered to be a paracrine organ responsible for 
the secretion of several substances exerting atherogenic effects. The reduced bioavailability 
of NO as an indirect result of the effects of those factors, leads to atherosclerosis and its 
clinical manifestations (Muller & Morawietz, 2009; Tousoulis et al., 2010). Under normal 
conditions, ECs constantly produce a number of vasoactive and trophic substances that 
control inflammation, VSMC growth, vasomotion, platelet function and plasmatic 
coagulation (Barton & Haudenschild, 2001; Traupe et al., 2003).  
Normal vascular activity is essential for maintaining normal function of organs, dependent 
on a balance of vasoconstrictive and vasodilative substances derived from the endothelium, 
which mainly include NO to dilate and endothelin-1 (ET-1) to constrict the cells of tunica 
media. Furthermore, ECs activated by ROS can regulate vascular function via the release of 
inflammatory mediators, such as intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule (VCAM-1), MCP-1, ILs, angiotensin-II (A-II), TNFα, NF-kB and E- and P-
selectin, or the release of haemostatic regulators, such as von Willebrand factor, tissue factor 
inhibitor and plasminogen activator, fibrinogen and NO (Sima et al., 2009; Vanhoutte, 2009).  
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The purpose of the following paragraphs will be to provide a brief description and 
characterization of the main EC-factors that are synthesize and secrete after ROS stimulus 
during endothelial athero-susceptibility. 
3.1.1 Angiotensin-II 
A-II, a causal factor to the dysfunction of vascular endothelium, adversely stimulates the 
activity of the cardiovascular system (Dai, D.Z. & Dai, Y., 2010). A-II increases blood 
pressure by vasoconstriction and sodium and fluid retention and produces overt oxidative 
stress resultant from the activation of NADPH oxidase, a source of ROS in blood vessels, 
that promotes endothelial dysfunction, inducing cytokines, chemokines and adhesion 
molecules secretion and contributes to vascular remodeling (Dai, D.Z. & Dai, Y., 2010; 
Ferrario, 2009; Partigulova & Naumov, 2010). The A-II effects on gene expression are 
mediated, at least in part, through the cytoplasmic NF-kB transcription factor. Through 
these actions, A-II augments vascular inflammation, induces EC dysfunctions and, in so 
doing, enhances the atherogenic process (Sprague & Khalil, 2009). 
3.1.2 Endothelial nitric oxide synthase  
Endothelium-derived NO, formed by eNOS, (isoform 3 of NO shynthase) is known as a 
potent vasodilator (Barton, 2010). eNOS is also the master gene regulator used by ECs to 
orchestrate their own phenotype, function and survival. eNOS is modulated by shear stress 
(Rodella et al., 2010, a) and agonists acting on cell surface receptors; its activity is dependent 
on many mechanisms, including substrate availability, phosphorylation, Ca2+ flux and 
protein–protein interactions (Andrews et al., 2010).  
With age, a number of changes occur in the cardiovascular system that can be considered 
pro-atherogenic (Barton, 2010). It is widely accepted that the most important mechanism 
leading to endothelial dysfunction is the reduced bioavailability of NO; so the decreased 
bioavailability of NO is consequently regarded a critical precursor to the development of 
atherosclerotic plaque and has been considered as one of the factors contributing to the 
higher incidence of atherosclerosis, arterial hypertension and renal disease in aged 
individuals (Barton, 2005). Together with its role as a vasodilator, NO impedes processes 
that are vital for atherosclerotic progression, including vasoconstriction, VSMCs 
proliferation and monocyte adhesion (Napoli et al., 2006). Furthermore, with atherosclerotic 
conditions, eNOS can become dysfunctional as it uncouples from its dimeric state to a 
monomeric state, in which it is able to produce superoxide anions rather than NO (Andrews 
et al., 2010; Vàsquez-Vivar et al., 1998). 
3.1.3 Endothelin-1 
Endothelins are EC-derived vasoactive peptides. Since its discovery, ET-1 has been 
demonstrated as one of the most potent known vasoconstrictors (Barton, 2010). ET-1 is 
synthesized in bulk by ECs and VSMCs (Rodella et al., 2010,a) as well as by macrophages, 
cardiomiocytes, neurons, renal medulla and Kupffer cells (Piechota et al., 2010). Factors that 
stimulate the release of ET-1 include endotoxins, TNFα, IL-1, adrenaline, insulin, thrombin 
and A-II. ROS are involved in the modulation and activation of ET-1 that induced various 
signaling pathways; in fact, during the inflammation process, atherosclerosis and 
hypertension there are elevated levels of ET-1 (Piechota et al., 2010; Skalska et al., 2009; 
Teplyakov, 2004). 
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3.1.4 Tumor necrosis factor α 
TNFα is crucially involved in the pathogenesis and progression of atherosclerosis, 
myocardial ischemia/reperfusion injury and heart failure. The TNFα-mediated vascular 
dysfunction involves alterations in EC metabolism and function, platelet aggregation, EC-
blood cell interaction, VSMC function and proliferation (McKellar et al., 2009). It increases 
the expression of many pro-inflammatory, pro-coagulant, proliferative and pro-apoptotic 
genes involved in initiation and progression of atherosclerosis (Bergh et al., 2009). TNFα 
induces the rapid expression of cellular adhesion molecules (CAMs), such as VCAM-1 and 
ICAM-1, and E-selectin at the endothelial surface (Chandrasekharan et al., 2007; 
Kleinbongard et al., 2010). Endothelial dysfunction associated with TNFα during 
atherogenesis is linked to an excess in production of ROS and a decrease in NO 
bioavailability. The production of ROS can stimulate a cytokine cascade through NF-κB-
induced transcriptional events, which then induce the expression of TNFα (Zhang, H. et al., 
2009). 
3.1.5 Cellular adhesion molecules (ICAM-1 and VCAM-1) 
When ECs undergo inflammatory activation, an increase in the expression of CAMs 
promotes the adherence of inflammatory cells (monocytes, neutrophils, lymphocytes and 
macrophages) and the recruitment of additional cytokines, growth factors and MMPs 
into the vascular wall (Sprague & Khalil, 2009). ICAM-1 and VCAM1 are 
immunoglobulin-like CAMs expressed by several cell types including ECs and 
leukocytes. They are present in atherosclerotic lesions during their progression, because 
they are involved in the transendothelial migration of leukocytes, lymphocytes and 
antigen presenting cells to sites of inflammation (Blankenberg et al., 2001; Ho et al., 2008; 
Lawson & Wolf, 2009; Rodella et al., 2010,b). Nevertheless their pathological role remain 
still uncertain. An important stimulus for CAMs expression is the fluid shear stress, 
which exerts both pro-inflammatory and protective effects, depending on the type of 
shear.  
3.2 Shear stress 
As the regulator of vascular tone, ECs are highly sensitive to different types of shear stress 
caused by the complex structure of artery geometry. It is clearly observed that 
atherogenesis generally occurs at curved or branching points with disturbed flow. 
Endothelium in the regions of flow disturbances near arterial branches, bifurcations and 
curvatures shows an athero-prone phenotype, while laminar flow regions exhibit an 
athero-protective phenotype (Bai et al., 2010; Traub & Berk, 1998). When endothelial 
monolayer is stimulated by laminar flow, rapidly cellular responses occur, included 
opening of ion channels, release of vasoactive NO and activation of transcription factors 
and cell cycle regulators (Foteinos et al., 2008). In particular, laminar flow induces NO 
production through both the transcriptional up-regulation of eNOS gene expression and 
the posttranslational modification of eNOS protein (Jin et al., 2003; Xu, 2009). Compared 
with ECs under laminar flow, cells at disturbed flow show an atherogenic phenotype as 
alterated alignment, deformation of luminal ECs surface, accelerated proliferation and 
apoptosis (Bai et al., 2010; Zeng et al., 2009), higher permeability, immunoinflammation 
responses and more athero-prone gene expression which are proportional to risk factor 
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production in an NADPH-oxidase-dependent manner, resulting in NF-kB-mediated 
monocyte adhesion.  
NF-kB is an inducible transcription factor present at increased levels in the thickened 
intima-media of atherosclerotic lesions, whereas little or no activated NF-kB has been 
detected in healthy vessels (Andrews et al., 2010; Rodella et al., 2010,b). The NF-kB 
pathway have been implicated in athero-susceptibility for more than a decade. NF-kB is 
normally held inactive in the cytosol as a complex with IkB, a family of inhibitors of NF-
kB. Oxidative stress by ROS production induces IkB degradation, releases of NFkB for 
translocation to the nucleus where it regulates pro-inflammatory genes (Davies et al., 
2010). Several pro-inflammatory cytokines and growth factors found in atherosclerotic 
lesions, such as TNFα, ILs, MCP-1 and tissue factors, activate NF-kB signaling pathway in 
cultured ECs (Pennathur & Heinecke, 2007). NF-κB plays a central role in the 
development of inflammation through further regulation of genes encoding pro-
inflammatory cytokines, CAMs, chemokines, growth factors and inducible enzymes 
(Andrews et al., 2010; Sprague & Khalil, 2009). 
3.3 EC-foam cells 
The formation of foam cells as a result of the lipid loading in ECs is a late event in 
atherosclerosis. Since the atherogenesis process is gradual, it is known that plasma 
hypercholesterolemia is associated with increased transcytosis of lipoproteins (Lps), leading 
to their accumulation within the ECs. At this location, Lps interact with proteoglycans and 
other matrix proteins and carry on their conversion to oxidatively modified and 
reassembled Lps (MLps). MLps have been identified in early intimal thickenings of human 
aorta and in the late atheroma (Sima et al., 2009; Tirziu et al., 1995). 
It is known that, in the initial stage of atherogenesis, upon the accumulation and retention of 
MLp within intima, the EC lining the plaque take up MLp, which are either degraded within 
the cell or exocytosed into the lumen; in time, the non-regulated uptake of MLp by the EC-
scavenger receptor is overwhelmed, leading to the accumulation of numerous large lipid 
droplets within the ECs. Concurrently, the EC shifts to a secretory phenotype, characterized 
by an increased number of biosynthetic organelles that correlates with the appearance of a 
multilayer, hyperplastic basal lamina in meshes of which MLp in accumulate large numbers. 
These insults lead to a dysfunctional endothelium and inflammatory process in which the 
EC-derived foam cells express more of new CAM and synthesize EC-factors that attract and 
induce migration of plasma inflammatory cells, such as monocytes and T lymphocytes to 
the subendothelium (Simionescu & Antohe, 2006); however, ECs maintain some of their 
specific attributes, such as Weibel-Palade bodies, intercellular junctions and caveolae (Sima 
et al., 2009). Infiltration of atherogenic Lps, monocytes and T lymphocytes within the 
subendothelium start the atherogenetic process both in animal models and in humans 
(Lawson & Wolf, 2009; Simionescu & Antohe, 2006; Williams & Tabas, 2005). In late stages of 
atherosclerosis, all cellular components of the plaque, ECs, VSMCs and macrophages, 
accumulate considerable number of lipid droplets and exhibit the foam cell characteristics 
(Sima et al., 2009).  In the subendothelium, the monocytes become macrophage-derived 
foam cells, which release cytokines and factors that, within the oxidative stress process, 
change the cross-talk between ECs and the neighbouring VSMCs and induce migration of 
VSMCs from media to the developing neointima (Lawson & Wolf, 2009; Simionescu & 
Antohe, 2006). 
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4. The role of vascular smooth muscle cells in atherosclerosis 
VSMCs are important actors in the pathogenesis of atherosclerosis. The classical “response to 
injury” hypothesis of atherosclerosis suggests that one of the major events in the 
development of this pathology is the intimal thickening caused by hyperplasia and 
migration of VSMC in the tunica intima (Ross & Glomset, 1973): the combined action of 
growth factors, proteolytic agents, and ECM proteins, produced by a dysfunctional 
endothelium and/or inflammatory cells, induces proliferation and migration of VSMCs 
from the tunica media into the intima (Clowes et al., 1983; Hao et al., 2003). Finally, 
progression of atherosclerotic lesions in the intima is characterized by the accumulation of 
alternating layers of dedifferentiated VSMCs and lipid-laden macrophages (Sobue et al., 
1999). This model focuses on the central role of activated and proliferating VSMCs that are 
histologically observed in the early and late stages of atherosclerosis, thus being a key event 
in atherosclerosis (Dzau et al., 2002; Owens, 1995). Because of their involvement in 
atherosclerosis, intimal VSMCs, their origin and the mechanisms that regulate their 
phenotype have been the subject of numerous studies and much debate over recent years.  
4.1 Origin of intimal VSMCs in atherosclerosis 
4.1.1 Phenotypic modulation of VSMCs  
The long-standing dogma in the field has been that the majority of intimal VSMCs are 
derived from preexisting mature medial VSMCs that undergo phenotypic modulation on 
moving from the media to the intima (Owens et al., 2004). This hypothesis, proposed for the 
first time by Chamley-Campbell and colleagues (Chamley-Campbell et al., 1979) arose from 
a limited number of studies showing that in primary human cell cultures derived from 
different sources (e.g. medial cells or cells derived from atherosclerotic plaques) stable 
differences in phenotype could be identified. This dogma implies the potential for marked 
plasticity of the VSMC phenotype, with the ultimate phenotype being determined by a 
variety of extracellular stimuli (Bochaton-Piallat et al., 1996): numerous studies of cells 
cultured from different species have demonstrated that cytokines, matrix components, and 
mechanical stimuli can influence VSMC phenotype and behavior  (Shanahan et al., 1993; 
Topouzis & Majesky, 1996).   
VSMCs are the predominant cellular elements of the medial layer of the vascular wall, 
essential for good performance of the vasculature. VSMCs perform many different functions 
in maintaining vessel’s health (Rensen et al., 2007).  The VSMC is the only cell populating 
the normal vascular media, wherein it is uniquely responsible for maintaining vascular tone 
and hemodynamic stability: it is a highly specialized cell whose principal function is 
vasoconstriction and dilation in response to normal or pharmacologic stimuli to regulate 
blood vessel tone, blood pressure, and blood flow (Rzucidlo et al., 2007). Moreover, except 
in unusual circumstances when the adventitia may be involved, the VSMC is also the only 
vascular cell capable of repairing the injured vessel wall by migrating, proliferating, and 
elaborating an appropriate ECM. It is therefore equally essential that, when it is necessary, 
the VSMC can also adopt a phenotype capable of these synthetic functions (Shanahan & 
Weissberg, 1998). So, it is important that VSMCs retain remarkable plasticity and can 
undergo rather intense and reversible changes in phenotype in response to changes in local 
environmental cues, particularly under the influence of growth factors (Li, S. et al., 1999; 
Owens, 1995). In the pathogenesis of atherosclerotic lesions it is now accepted that VSMC 
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Owens, 1995). In the pathogenesis of atherosclerotic lesions it is now accepted that VSMC 





second typical of the cells invading the intima (Shanahan & Weissberg, 1999). These 
phenotypes are also seen in vitro: an elongated spindle-shaped phenotype, with the classic 
‘‘hill-and-valley’’ growth pattern typical of cultured contractile normal medial VSMCs and 
an epithelioid or rhomboid phenotype, with cells growing in a monolayer with a 
cobblestone morphology at confluence typical of the cells from neointima (Hao et al., 2003). 
In the medial layer of a mature blood vessel, VSMCs exhibit a low rate of proliferation, low 
synthetic activity and ECM proteins secretion, and express a unique repertoire of contractile 
proteins (e.g. intracellular myofilaments bundles are abundant), ion channels, and signalling 
molecules required for the cell’s contractile function that is clearly unique compared with 
any other cell type (Rzucidlo et al., 2007). The dense body, the dense membrane and 
myofibrils (composed of thin filaments and myosin thick filaments) are well developed in 
differentiated VSMCs, whereas organelles (e.g. rough endoplasmic reticulum (RER), Golgi 
and free ribosomes) are few in number (Owens, 1995). This “contractile” state (referred also 
as “differentiated phenotype”), is required for the VSMC to perform its primary function. 
The gene expression pattern in end-differentiated VSMCs is well characterized and 
comprised a number of proteins involved in contraction, membrane-skeletal markers 
specific to smooth muscle and cell adhesion molecules and their receptors (integrins), which 
are important either as a structural component of the contractile apparatus or as a regulator 
of contraction (Owens, 1995; Rensen et al., 2007). Their expressions are regulated at the gene 
levels, such as at transcription and splicing: caldesmon, smooth muscle myosin heavy chain 
(SMM-HC), α-smooth muscle actin (α-SMA), h-caldesmon, calponin, SM22, α- and β-
tropomyosins and α1 integrin genes are transcriptionally regulated; transcription of these 
genes (except for the α-smooth muscle actin gene) is upregulated in differentiated VSMCs, 
but is downregulated in dedifferentiated VSMCs (Stintzing et al., 2009). It’s important to 
note that, although α-SMA is permanently expressed in VSMCs, it is more abundant in 
contractile VSMCs than in synthetic VSMCs (Lemire et al., 1994). Isoform changes of 
caldesmon, α-tropomyosin, vinculin/metavinculin, and SMM-HC are instead regulated by 
alternative splicing in a VSMC phenotype-dependent manner (Sobue et al., 1999). At 
present, the two marker proteins that provide the best definition of a mature contractile 
VSMC phenotype are SM-MHC and smoothelin. SM-MHC expression has never been 
detected in non-VSMCs in vivo, and is the only marker protein that is also VSMCs-specific 
during embryogenesis (Miano et al., 1994). Smoothelin complements SM-MHC as a 
contractile VSMC marker in that it appears to be more sensitive.  
On the contrary, intimal VSMCs associated with vascular disease (as well as VSMCs 
involved in blood vessel formation) are phenotypically distinct from their medial 
counterparts (Campbell, G.R. & Campbell, J.H., 1985; Mosse et al., 1985): they resemble 
immature and show a typical “synthetic” state (referred also as “dedifferentiated 
phenotype”), characterized by an increased rate of proliferation, migration and ECM protein 
synthesis. Several studies by Aikawa and coworkers (Aikawa et al., 1997, 1998) 
demonstrated that intimal VSMCs show a synthetic phenotype including: 1) increased DNA 
synthesis and expression of proliferation markers and cyclins (Gordon et al., 1990); 2) 
decreased expression of smooth muscle-specific contractile markers (Layne et al., 2002); 3) 
alterations in calcium handling and contractility (Hill et al., 2001); 4) alterations in cell 
ultrastructure, including a general loss of myofilaments, which is replaced largely by 
synthetic organelles such as RER and large Golgi complex (Sobue et al., 1999),  supporting 
its function in production and secretion of ECM components that, leading to intimal 
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thickening and fibrosis of the vascular wall, may contribute to lesion development and/or 
stability (Schwartz et al., 1986, 1995). The preceding studies have been extended by Geary 
and colleagues (Geary et al., 2002), who completed microarray-based profiling of gene 
expression patterns of SMCs in the neointima. A total of 147 genes were differentially 
expressed in neointimal VSMCs versus normal aorta VSMCs, most genes underscoring the 
importance of matrix production during neointimal formation. Therefore, these VSMCs 
assume the proliferative activity in response to mitogens, while lose contractile ability. 
Markers that are upregulated in the synthetic phenotype are rare. SMemb/non-muscle 
myosin heavy chain isoform B (MHC-B) represents a suitable synthetic VSMCs marker, 
since this protein is quickly and markedly upregulated in proliferating VSMCs (Neuville et 
al., 1997). At last, an interesting correlation has been demonstrated, albeit occasionally, 
between dedifferentiated VSMC phenotype and increased LDL uptake (Thyberg, 2002) or 
decreased HDL binding sites (Dusserre et al., 1994). Nevertheless, the role of LDL and HDL 
processes in atheromatous plaque formation with respect to VSMC heterogeneity should be 
further investigated.  
 
 
Fig. 6. Factors involved in VSMCs development, differentiation and phenotypic modulation 
However, it is now recognized that a simple two-state model, based on “contractile” and 
“synthetic” states only, is inadequate to explain the diverse range of phenotypes that can 
be exhibited by the VSMCs under different physiological and pathological circumstances 
(Owens et al., 2004). In particular, the environmental cues that exist within atherosclerotic 
lesions are without doubts very different from those that exist within a normal healthy 
blood vessel and these change at different stages of lesion development and progression 
and thereby are likely to contribute to continued phenotypic switching of VSMC within 
the lesion. So, an heterogeneity of VSMC phenotype, ranging from contractile to synthetic, 
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nowadays considered. Not surprisingly, as the repertoire of VSMC markers has 
expanded, the picture that has emerged is that there is likely a wide spectrum of possible 
VSMC phenotypes that might exist such that it may be very artificial to assign cells to 
distinct subcategories. So the distinction between  “contractile” and “synthetic” state of 
the VSMC become very difficult. The complexity of different phenotypes that may be 
manifested by VSMC is clearly evident not only between VSMCs of different vessels or 
among VSMCs within the same vessel, but there is very clear evidence that the properties 
of the VSMCs vary also at different stages of atherosclerosis, within different lesion types, 
and between VSMCs located in different regions within a given lesion (Owens et al., 
2004).  
4.1.2 Monoclonality of atheromatous lesion and heterogeneity of proliferating VSMCs 
Alternative to the predominant hypothesis that all VSMCs of the media can undergo 
phenotypic modulation, is the concept that a predisposed VSMCs subpopulation is 
responsible for the production of intimal thickening. This possibility has been raised on the 
basis of original work by Benditt and Benditt (Benditt, E.P. & Benditt, J.M., 1973) who 
reported that VSMC accumulation in the atheromatous plaques is monoclonal or, at least, 
oligoclonal (Chung et al., 1998), implying that only a small number of “immature” cells in 
the vessels media and/or adventitia undergo proliferation (Holifield et al., 1996). More 
recent studies have questioned the origin of VSMCs comprising atherosclerosis and 
neointima formation. Intimal VSMCs have been proposed to originate from diverse sources, 
including fibroblasts of the adventitia (Zalewski et al., 2002), ECs (Gittenberger-de Groot et 
al., 1999) and/or circulating bone marrow–derived cells (Hillebrands et al., 2003). Whereas 
the gene expression pattern of differentiated VSMC is pretty well characterized (Shanahan & 
Weissberg, 1999), many in vivo and in vitro studies dealing with proliferating VSMC showed 
heterogeneous cell marker expressions of multilineage differentiation (Tintut et al., 2003). A 
possible explanation of the heterogeneity of VSMCs in adult vessels can be found in 
embryologic vascular development (Gittenberger-de Groot et al., 1999): interestingly, similar 
to atherosclerosis, processes of multilineage differentiation with transition states could be 
observed during vascular development (Slomp et al., 1997). During vasculogenesis, VSMCs 
originate from different sources via transdifferentiation (Liu et al., 2004) (a highly conserved 
phenomenon of transdifferentiation is proved by a stable cytokeratins expression in 
atherosclerotic lesions as well as it happens during development (Neureiter et al., 2005)) 
depending on the vessel type, including mesoderm, neurectoderm, epicardium (for 
coronary arteries) and, more rarely, endothelium (Orlandi & Bennett, 2010). It is thus 
possible that the various VSMC phenotypes can arise from distinct lineages. Another 
possibility is that local VSMC of the contractile phenotype re-obtain the embryonic potential 
of proliferation and migration (Bar et al., 2002) via transdifferentiation and dedifferentiation 
processes as a response to injury. Looking at atherosclerosis and VSMC, there is a lot of 
evidence that VSMC progenitor cells are essentially involved in the progression of 
atherosclerosis (Roberts et al., 2005).  
The origin of such VSMC progenitor cells is under debate. VSMC progenitor cells have been 
identified in the bone marrow (multipotent vascular stem cell progenitors and mesenchymal 
stem cells), in the circulation (circulating VSMC progenitor cells), in the vessel wall (resident 
VSMC progenitor cells and mesangioblasts) and various extravascular sites (extravascular, 
non-bone marrow progenitor cells) (Orlandi & Bennett, 2010).  
 




Fig. 7. Different origins of VSMCs progenitor cells. 
4.1.2.1 Bone marrow-derived VSMCs 
Several studies have suggested that circulating bone marrow-derived cells contribute to 
neointima formation: one possibility is that circulating smooth muscle precursor cells of 
myeloid or hematopoietic lineage relocate from the blood into the neointima following 
vascular injury (Metharom et al., 2008) and start to proliferate giving rise to cells that 
express at least some properties of VSMCs (Simper et al., 2002).  
Other studies, on the other hand, report no evidence for a contribution of bone marrow 
derived VSMCs in the neointimal layer (Hu et al., 2002; Li, J. et al., 2001). Alternatively, these 
circulating cells may fuse with resident VSMCs and thus show co-localization of VSMC 
markers and bone marrow lineage markers, although to date, no direct evidence for cell 
fusion in the vasculature has been shown (Owens et al., 2004).  
4.1.2.2 Resident VSMC progenitor cells and mesangioblasts 
Inside normal vessel walls the existence of resident progenitor cells (expressing stem cell 
antigens) capable of contributing to neointima formation has been recently shown (Orlandi 
et al., 2008; Torsney et al., 2007): the number of these resident VSMCs progenitors has been 
shown to increase in atherosclerotic lesions (Torsney et al., 2007). These progenitor cells are 
different from marrow-derived smooth muscle progenitor cells, since they lack the ability to 
differentiate into erythroid, lymphoid, or myeloid tissue (Jackson et al., 1999). Subsequent 
studies examining telomere loss indicate that fibrous cap VSMCs have undergone  more 
population doublings than cells in the normal media (Matthews et al., 2006), suggesting the 
existence of a resident arterial subpopulation predisposed to clonally contribute to arterial 
healing in response to injury (Hirschi & Majesky, 2004), so that plaques arise by selective 
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Unfortunately, against this theory, there is very limited evidence for the presence of vessel 
wall stem cells in human vessels. A population of CD34+/CD31- cells has been identified in 
the space between the media and adventitia of large and medium-sized human arteries and 
veins (Pasquinelli et al., 2007), but the capacity of these cells to give rise to VSMCs was low 
(Zengin et al., 2006). Few other studies showed that the adventitial layer potentially 
harbours a population of stem cells that can also contribute to vascular remodelling. In 
particular, Hu and colleagues demonstrated that abundant progenitor cells in the adventitia 
can differentiate in VSMCs (Hu et al., 2004).  
Moreover, satellite-like cells named ‘mesoangioblasts’ express both myogenic and EC 
markers (Drake et al., 1997), which can give rise to both hematopoietic and endothelial 
progenies (Cossu & Bianco, 2003). Gene expression profiles reveal that mesoangioblasts 
express genes belonging to developmental signaling pathways (such as β-catenin/Wnt 
signaling pathway) and are able to differentiate very efficiently into VSMCs (Tagliafico et 
al., 2004).  
In summary, there is evidence for several distinct resident progenitor cells in different layers 
of the normal adult arterial wall capable of proliferating and differentiating into VSMCs. 
What has not yet been established is how many of these cells contribute to formation of 
vascular lesions and whether clonality reflects selective proliferation of one or more of these 
populations. 
4.2 VSMCs: Friend or foe in atherosclerosis? 
It is important to note that the exact role of VSMCs, in the progression of atherosclerosis is 
not clear. The functional role of VSMCs likewise is likely to vary depending on the stage of 
the disease. For example, at the early onset of atherosclerosis, these cells presumably plays a 
maladaptive role, because of their involvement in neointima formation (Rodella et al., 2011): 
mobilisation of these cells would therefore be predicted to promote, as a “foe”, vascular 
disease (van Oostrom et al., 2009). On the other hand, over recent years, there has been an 
increasing recognition of the role played by intimal VSMCs in the formation and 
maintaining of a protective fibrous cap over the atherosclerotic plaque, desirable for plaque 
stability in the advanced atherosclerotic process (Weissberg et al., 1996). In particular, IFN-γ 
released by activated macrophages induces collagen synthesis by VSMCs, which is 
important for the stabilization of the fibrous cap (Shah et al., 1995). Moreover, injection of 
smooth muscle progenitor cells in a mouse model of advanced atherosclerosis reduced the 
progression of early atherosclerotic plaques (Zoll et al., 2008), confirming the potential 
benefit of VSMCs at advanced stages of atherosclerosis. Therefore, VSMCs could be 
beneficial in atherogenesis as a factor promoting plaque stability and can thus be considered 
a “friend” in vascular disease (van Oostrom et al., 2009).   
Since the VSMC is the only cell capable of synthesizing the fibrous cap, failure of this 
vascular repair response leads to weakening of the cap and plaque rupture, with potentially 
fatal consequences (Weissberg et al., 1996). In diseased tissue many factors are present that 
substantially alter the normal balance of proliferation and apoptosis, and the apoptosis may 
predominate (Bennett, 2002). In particular, in plaque VSMCs an elevated level of 
spontaneous apoptosis and enhanced susceptibility to apoptosis induced by ROS (Li, W.G. 
et al., 2000) has been recently described both in vivo and in vitro (Ross, 1999). Apoptosis of 
VSMCs, bringing a plaque with reduced number of VSMCs, could participate in the rupture 
of the stability of the plaque (Rudijanto, 2007). Rupture of atherosclerotic plaques is 
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associated with a thinning of VSMC-rich fibrous cap overlying the core (atrophic fibrous cap 
lesion), due to rapid replicative senescence and apoptosis of VSMCs (Schwartz et al., 2000). 
Rupture occurs particularly at the plaque shoulders, which exhibits lack of VSMCs and the 
presence of inflammatory cells (Newby et al., 1999). So, VSMCs may later contribute to 
plaque destabilization through apoptosis and/or activation of various protease cascades 
(Galis & Khatri, 2002).  
 
 
Fig. 8. Involvement of VSMCs apoptosis in fibrous plaque rupture. 
However, detailed studies demonstrating whether VSMC progenitors either protect or 
promote vessel disease are needed before cell-based or pharmacological approaches aimed 
at regulating progenitor cell trafficking can be recommended. 
4.3 VSMCs can auto-regulate their replication/migration 
The contemporary paradigm explaining smooth muscle replication in the vessel wall is that 
dysfunctional endothelium and/or inflammatory cells produce growth factors and ECM 
proteins that can induce replication and migration of VSMCs from the media to the intima 
(van Oostrom et al., 2009). In his “response-to injury” hypothesis, Ross proposed that VSMCs 
in the wall normally exist in a quiescent state, but, when the endothelium is injured, 
platelets release factors that stimulate VSMCs movement into and replication within the 
arterial intima (Ross, 1981-1982).  
Growth factors have been known to influence the differentiated state of VSMCs (Willis et al., 
2004). An interesting possibility is that smooth muscle replication may be controlled by 
factors intrinsic to the vessel wall. One possibility comes from evidence that normal 
endothelium contains inhibitors of smooth muscle proliferation (Haudenschild & Schwartz, 
1979). The principal factor involved in VSMCs replication is the platelet derived growth 
factor (PDGF), which is a potent VSMC mitogen linked to vascular homeostasis and 
atherogenesis (Majesky et al., 1992). This peptide not only is mitogenic for VSMCs, but is 
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maladaptive role, because of their involvement in neointima formation (Rodella et al., 2011): 
mobilisation of these cells would therefore be predicted to promote, as a “foe”, vascular 
disease (van Oostrom et al., 2009). On the other hand, over recent years, there has been an 
increasing recognition of the role played by intimal VSMCs in the formation and 
maintaining of a protective fibrous cap over the atherosclerotic plaque, desirable for plaque 
stability in the advanced atherosclerotic process (Weissberg et al., 1996). In particular, IFN-γ 
released by activated macrophages induces collagen synthesis by VSMCs, which is 
important for the stabilization of the fibrous cap (Shah et al., 1995). Moreover, injection of 
smooth muscle progenitor cells in a mouse model of advanced atherosclerosis reduced the 
progression of early atherosclerotic plaques (Zoll et al., 2008), confirming the potential 
benefit of VSMCs at advanced stages of atherosclerosis. Therefore, VSMCs could be 
beneficial in atherogenesis as a factor promoting plaque stability and can thus be considered 
a “friend” in vascular disease (van Oostrom et al., 2009).   
Since the VSMC is the only cell capable of synthesizing the fibrous cap, failure of this 
vascular repair response leads to weakening of the cap and plaque rupture, with potentially 
fatal consequences (Weissberg et al., 1996). In diseased tissue many factors are present that 
substantially alter the normal balance of proliferation and apoptosis, and the apoptosis may 
predominate (Bennett, 2002). In particular, in plaque VSMCs an elevated level of 
spontaneous apoptosis and enhanced susceptibility to apoptosis induced by ROS (Li, W.G. 
et al., 2000) has been recently described both in vivo and in vitro (Ross, 1999). Apoptosis of 
VSMCs, bringing a plaque with reduced number of VSMCs, could participate in the rupture 
of the stability of the plaque (Rudijanto, 2007). Rupture of atherosclerotic plaques is 
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associated with a thinning of VSMC-rich fibrous cap overlying the core (atrophic fibrous cap 
lesion), due to rapid replicative senescence and apoptosis of VSMCs (Schwartz et al., 2000). 
Rupture occurs particularly at the plaque shoulders, which exhibits lack of VSMCs and the 
presence of inflammatory cells (Newby et al., 1999). So, VSMCs may later contribute to 
plaque destabilization through apoptosis and/or activation of various protease cascades 
(Galis & Khatri, 2002).  
 
 
Fig. 8. Involvement of VSMCs apoptosis in fibrous plaque rupture. 
However, detailed studies demonstrating whether VSMC progenitors either protect or 
promote vessel disease are needed before cell-based or pharmacological approaches aimed 
at regulating progenitor cell trafficking can be recommended. 
4.3 VSMCs can auto-regulate their replication/migration 
The contemporary paradigm explaining smooth muscle replication in the vessel wall is that 
dysfunctional endothelium and/or inflammatory cells produce growth factors and ECM 
proteins that can induce replication and migration of VSMCs from the media to the intima 
(van Oostrom et al., 2009). In his “response-to injury” hypothesis, Ross proposed that VSMCs 
in the wall normally exist in a quiescent state, but, when the endothelium is injured, 
platelets release factors that stimulate VSMCs movement into and replication within the 
arterial intima (Ross, 1981-1982).  
Growth factors have been known to influence the differentiated state of VSMCs (Willis et al., 
2004). An interesting possibility is that smooth muscle replication may be controlled by 
factors intrinsic to the vessel wall. One possibility comes from evidence that normal 
endothelium contains inhibitors of smooth muscle proliferation (Haudenschild & Schwartz, 
1979). The principal factor involved in VSMCs replication is the platelet derived growth 
factor (PDGF), which is a potent VSMC mitogen linked to vascular homeostasis and 
atherogenesis (Majesky et al., 1992). This peptide not only is mitogenic for VSMCs, but is 





suggest, infact, a role in migration/localization of primordial VSMCs to the endothelium. 
This growth factor consists of two chain types, A and B, giving rise to three different PDGF 
subtypes (AA, AB, BB): PDGF-BB and -AB are known VMSCs chemoattractans, whereas 
PDGF-AA is associated with inhibition of chemotaxis (Zachary et al., 1999).  PDGF binds to 
specific dimeric receptors (α and β) found on smooth muscle cells (Bowen-Pope & Ross, 
1982) where initiates a series of events leading to DNA synthesis: receptor α can bind all 
PDGF subtypes, while receptor β binds only subtypes -AB and -BB. VSMCs have been 
determined to upregulate expression of receptor β in response to vascular injury, inducing 
their chemotaxis; at the same time, these cells are able to increase the PDGF-AA, acting as a 
paracrine or autocrine regulator of their chemotaxis. This represents the first described 
autoregulation pathway of VSMCs on their own proliferation/migration (Willis et al., 2004).   
The second known requirement for cell cycle progression is availability of insulin-like 
growth factor (IGF-1), a co-factor that VSMCs require for completion of the cell cycle 
following stimulation with PDGF (Clemmons, 1984). Perhaps more surprising is that, as 
reported above, VSMCs may be able to stimulate their own growth by synthesis of both 
PDGF and IGF-1 (PDGF is able to stimulate smooth muscle cells to produce IGF-1). 
Moreover, those VSMCs that, once migrated into the intima, retained the ability to produce 
mitogen, due to their dedifferentiated state (Schwartz et al., 1986), are able to sustain 
proliferation also after the initial stimulation of platelet and PDGF release during vascular 
injury. Selection of such a proliferogenic subpopulation could account for both the 
monoclonal phenotype of chronic human atherosclerotic lesions (Gown & Benditt, E.P., 
1982) and the suggestion that monoclonality arises gradually as the human lesion evolves 
(Lee et al., 1985). In summary, the emerging picture of growth control in arterial smooth 
muscle is a complex balance of forces. In addition to exogenous stimuli to cell growth, the 
vessel wall is capable of synthesis of endogenous growth inhibitors (including heparin 
sulfates, nitric oxide (NO), and transforming growth factor (TGF)-β) and growth stimulants 
(such as PDGF, IGF-1, ET-1, thrombin, FGF, IFNγ, and IL-1) (Berk, 2001). 
5. Conclusions 
Atherosclerosis and its associated complications remain the primary cause of death of the 21st 
century in humans. Recently it has been suggested that atherosclerosis is a multifactorial, 
multistep disease. Clinical and histopathological studies of atherosclerotic patient groups have 
identified inflammatory and oxidative stress-linked mechanisms as being pathogenetically 
important in atherosclerosis at every step from initiation to progression. Endothelial damage is 
also crucial for the progress of atherosclerosis and risk factors for atherosclerosis represent 
crucial factors associated with endothelial dysfunction. Studies have shown that patients with 
cardiovascular disease are characterized by impaired endothelial function, being vascular 
endothelium responsible for the secretion of several substances exerting proved anti-
atherogenic effects. Finally, VSMCs are an important component of atherosclerotic plaques, 
responsible for promoting plaque stability in advanced lesions. In contrast, VSMC apoptosis 
has been implicated in a number of deleterious consequences of atherosclerosis, including 
plaque rupture, vessel remodelling, coagulation, inflammation and calcification. A better 
understanding of the pathogenesis of atherosclerosis will aid in for reducing mortality. An in-
depth knowledge of the various pathogenic mechanisms involved in atherosclerosis can help 
in formulating preventive and therapeutic strategies and devising pharmaceutical and lifestyle 
modifications for reducing mortality. 
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1. Introduction 
Epidemiological studies over the past 50 years have revealed numerous risk factors for 
atherosclerosis. They can be grouped into factors with an important genetic component and 
environmental factors, particularly diet, which is one of the major, constant environmental 
factors to which our genes are expose through life. When a gene is activated, or expressed, 
functionally distinct proteins are produced which can initiate a host of cellular metabolic 
effects. Gene expression patterns produce a phenotype, which represents the physical 
characteristics of an organism (e.g., hair color), or the presence or absence of a disease. 
Nutrition scientists realize more and more that phenotypic treats (health status) are not 
necessarily produce by genes alone but also by the interaction of bioactive food components 
on the levels of DNA, RNA, protein and metabolites (Müller & Kersten, 2003). Nutritional 
genomics came into being at the beginning of the 1990s. There is some confusion about the 
delimitation of the concept, as often the terms of nutritional genomics, nutrigenetics, and 
nutrigenomics, are used as synonyms. Nutritional genomics refers to the joint study of 
nutrition and the genome including all the other omics derived from genomics: 
transcriptomics (mRNA), proteomics (proteins), and metabolomics (metabolites) (Fig. 1). The 
terms nutritional genomics would be equivalent to the wide-ranging term of gene-diet 
interaction. Within the wide framework of the concept of nutritional genomics, we can 
distinguish 2 subconcepts: nutrigenetics and nutrigenomics. Currently, there is a wide 
consensus on considering nutrigenetics as the discipline that studies the different 
phenotypic response to diet depending on the genotype of each individual. The term 
nutrigenomics is subject to a greater variability in its delimitation, but it seems that there is a 
certain consensus in considering nutrigenomics as the discipline which studies the 
molecular mechanisms explaining the different phenotypic responses to diet depending on 
the genotype, studying how the nutrients regulate gene expression, and how these changes 
are interrelated with proteomics and metabolomics (Corella & Ordovas, 2009). This 
interpretation of the nutrigenomics concept is the one that we shall use in this Chapter.  
Atherosclerosis is a complex, multifactorial disease associated with accumulation of lipids in 
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1. Introduction 
Epidemiological studies over the past 50 years have revealed numerous risk factors for 
atherosclerosis. They can be grouped into factors with an important genetic component and 
environmental factors, particularly diet, which is one of the major, constant environmental 
factors to which our genes are expose through life. When a gene is activated, or expressed, 
functionally distinct proteins are produced which can initiate a host of cellular metabolic 
effects. Gene expression patterns produce a phenotype, which represents the physical 
characteristics of an organism (e.g., hair color), or the presence or absence of a disease. 
Nutrition scientists realize more and more that phenotypic treats (health status) are not 
necessarily produce by genes alone but also by the interaction of bioactive food components 
on the levels of DNA, RNA, protein and metabolites (Müller & Kersten, 2003). Nutritional 
genomics came into being at the beginning of the 1990s. There is some confusion about the 
delimitation of the concept, as often the terms of nutritional genomics, nutrigenetics, and 
nutrigenomics, are used as synonyms. Nutritional genomics refers to the joint study of 
nutrition and the genome including all the other omics derived from genomics: 
transcriptomics (mRNA), proteomics (proteins), and metabolomics (metabolites) (Fig. 1). The 
terms nutritional genomics would be equivalent to the wide-ranging term of gene-diet 
interaction. Within the wide framework of the concept of nutritional genomics, we can 
distinguish 2 subconcepts: nutrigenetics and nutrigenomics. Currently, there is a wide 
consensus on considering nutrigenetics as the discipline that studies the different 
phenotypic response to diet depending on the genotype of each individual. The term 
nutrigenomics is subject to a greater variability in its delimitation, but it seems that there is a 
certain consensus in considering nutrigenomics as the discipline which studies the 
molecular mechanisms explaining the different phenotypic responses to diet depending on 
the genotype, studying how the nutrients regulate gene expression, and how these changes 
are interrelated with proteomics and metabolomics (Corella & Ordovas, 2009). This 
interpretation of the nutrigenomics concept is the one that we shall use in this Chapter.  
Atherosclerosis is a complex, multifactorial disease associated with accumulation of lipids in 





inflammatory components playing major roles in its cause. Environmental factors with 
particular emphasis on nutrition as well as genetic factors appear to be responsible for these 
aberrant oxidative and inflammatory components and the lipid abnormalities associated with 
the disease. Diet may contribute to the atherosclerotic process by affecting lipoprotein 
concentration, their composition and degree of oxidation. Although certain key risk factors 
affecting atherosclerosis have been identified, the full molecular characterization will remain a 
challenge in the next century to come. As a complex biological process, the cellular and 
molecular details of the growth, progression and regression of the vascular lesions of 
atherosclerosis call for application of the newly developing omics techniques of analysis. 
Profiling gene expression using microarrays has proven useful in identifying new genes that 
may contribute to features of the atherosclerosis lesion (transcriptomics). One of the interesting 
challenges of modern biology is to define the diet that best fits the needs of the human species. 
Understanding the details of gene-nutrient interactions and of how changes in a gene or in the 
amount or form of a nutrient influence atherosclerosis is essential to developing insight into 
how to support optimal health from a nutritional perspective. There has been much interest 
regarding the components that contribute to the beneficial health effects of the Mediterranean 
diet. Recent findings suggest that bioactive components found in extra-virgin olive oil (EVOO) 
(oleic acid and polyphenol compounds) are endowed with several biologic activities that may 
contribute to the lower incidence of atherosclerosis in the Mediterranean area. This review 
summarizes more recent studies, including omics technologies that have lead to the 
development of new hypothesis concerning the cellular response to virgin olive oil (VOO) 
ingestion and to identify the major cellular pathways responsive to them. 
 
 
Fig. 1. Health effects of bioactive food components are related to specific interactions on a 
molecular level. (Adapted from Van Ommen, 2004; Müller & Kersten, 2003). SNP, single 
nucleotide polymorphism. 
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2. Olive oil and atherosclerosis 
2.1 Olive oil classification according to International Olive Council 
Olive oil is the main source of fat in the Mediterranean diet, and different categories of olive 
oils may be distinguished according to the International Olive Oil Council. Olive oil is 
obtained solely from the fruit of the olive tree (Olea europaea; family Oleaceae), and is not 
mixed with any other kind of oil. Olive oil extraction is the process of extracting the oil 
present in the olive drupes for food use. The oil is produced in the mesocarp cells, and is 
stored in a particular type of vacuole called a lipovacuole; every cell within an olive contains 
a tiny olive oil droplet. Olive oil extraction is defined as the process of separating the oil 
from the other fruit contents (vegetative extract liquid and solid material) and extracting the 
oil present in the drupes for food use. This separation is attained only by physical 
procedures under thermal conditions that do not alter the oil. 
Several different types of oil can be oil extracted from the olive fruit and are classified as 
follows:  
Virgin indicates that the oil was extracted by physical procedures only with no chemical 
treatment, and is in essence crude oil.  
Refined indicates that the oil has been chemically treated to neutralise strong tastes (which 
are characterized as defects) and neutralise the acid content (free fatty acids). Refined oil is 
commonly regarded as a lower quality than virgin oil. 
Pomace olive oil indicates oil that has been extracted from the pomace (ground flesh and 
pits left after pressing olives) using chemical solvents (typically hexane) and by heat.  
Oil can be classified into different grades as follow: 
Extra-virgin olive oil is the highest quality of olive oils and is produced by cold extraction 
of the olives; the oil has a free acidity of no more than 0.8 grams of oleic acid per 100 grams 
(0.8% acidity), and is often thought to have a superior taste. There can be no refined oil in 
extra-virgin olive oil. 
Virgin olive oil has an acidity of less than 2%, and is often thought to have a good taste. 
There can be no refined oil in virgin olive oil. 
Olive oil. Oils labelled as Olive oil are usually a blend of refined olive oil and one of the 
above two categories of virgin olive oil; typically, these blends contain less than or equal to 
1.5% acidity. This grade of oil commonly lacks a strong flavour. Different blends are 
produced by adding more or less virgin oil to achieve different tastes. 
Olive-pomace oil is a blend of refined pomace olive oil and possibly some virgin oil. This oil 
is safe to consume, but it may not be called olive oil.  
Lampante oil is olive oil that is not used for consumption; lampante comes from olives that 
have strong physico-chemical and organoleptic defects and contain greater than 3,3% of 
acidity.  
2.2 Olive oil composition 
VOO is composed mainly of TGs (98-99 % of the total oil weight) and contains small 
quantities of free fatty acids (FFAs), and more than 230 chemical compounds such as 
aliphatic and triterpenic alcohols, sterols, hydrocarbons, volatile compounds and 
antioxidants. TGs are the major energy reserve for plants and animals. Chemically speaking, 
these are molecules derived from the natural esterification of three fatty acid molecules with 
a glycerol molecule. The glycerol molecule can simplistically be seen as an "E-shaped" 
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the case of olive oil) from about 14 to 24 carbon atoms in length (Fig. 2). The fatty acid 
composition of olive oil varies widely depending on the cultivar, maturity of the fruit, 
altitude, climate, and several other factors. A fatty acid has the general 
formula: CH3(CH2)nCOOH where n is typically an even number between 12 and 22. If no 
double bonds are present the molecules are called saturated fatty acids (SFAs). If a chain 
contains double bonds, it is called an unsaturated fatty acid. A single double bond makes 
monounsaturated fatty acids (MUFAs). More than one double bond makes polyunsaturated 
fatty acids (PUFAs). The major fatty acids in olive oil triglycerides are: oleic acid (C18:1), a 
monounsaturated omega-9 fatty acid. It makes up 55 to 83% of olive oil. Linoleic acid 
(C18:2), a polyunsaturated omega-6 fatty acid that makes up about 3.5 to 21% of olive oil. 
Palmitic acid (C16:0), a SFA that makes up 7.5 to 20% of olive oil. Stearic acid (C18:0), a SFA 
that makes up 0.5 to 5% of olive oil (Fig. 2). Linolenic acid (C18:3) (specifically alpha-
Linolenic acid), a polyunsaturated omega-3 fatty acid that makes up 0 to 1.5% of olive oil. In 
the triglycerides the main fatty acids are represented by monounsaturates (oleic acid), with a 
slight amount of saturates (palmitic and stearic acids) and an adequate presence of 
polyunsaturates (linoleic and α-linolenic acid) (Bermudez et al., 2011). Most prevalent in 
olive oil is the oleic-oleic-oleic (OOO) triglyceride, followed, in order of incidence, by 




Fig. 2. Structure of triglycerides and main fatty acids in olive oil triglycerides. 
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The minor components of VOO are α-tocopherol, phenol compounds, carotenoids (β-
carotene and lutein), squalene, pytosterols, and chlorophyll (in addition to a great number 
of aromatic substances). The factor that can influence the composition of VOO, especially in 
regard to its minor components, are the type of cultivar, the characteristics of the olive tree 
growing soil, climatic factors, fruit ripening stage, time of harvesting and degree of 
technology used in its production. The main antioxidants of VOO are phenols represented 
by lipophilic and hydrophilic phenols. Carotenes, on the contrary are contained in small 
concentrations. The lipophilic phenols, such as tocopherols and tocotrienols, can be found in 
other vegetable oils. In VOO more than 90% of total concentration of tocopherols is 
constituted by α-tocopherol. The VOO hydrophilic phenols constitute a group of secondary 
plant metabolites showing peculiar organoleptic and healthy properties. They are not 
generally present in other oils and fats (Servili et al., 2009). VOO contains four major classes 
of phenolic compounds: flavonoids, lignans, simple phenolics and secoiridois (Table 1). 
Although some cultivars contain flavonoids, the content in olive oil is low compared to 
other fruits and vegetables. Lignans are present at more significant 
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 amounts. The levels of secoiridoids and simple phenolics, many of which are exclusive to 
VOO, are the major phenolics found in olive oil. The simple phenolics present in VOO are 
predominantly hydroxytyrosol (HT) (3,4-dihydroxyphenylethanol) and tyrosol (TYR) (4-
hydroxyphenylethanol) whilst the secoiridoids are derived from the glusosides of 
oleuropein and ligstroside forms, they contain in their chemical structure an HT 
(oleuropein derivatives) or TYR (ligstroside derivatives) moiety linked to elenolic acid 
(Corona et al., 2009). After ingestion, olive oil polyphenols can be partially modified in the 
acidic environment of the stomach, aglycone secoiridoids are subject to hydrolysis leading 
to approximate 5-fold increase in the amount of free HT and 3-fold increase in free TYR. If 
the ingested secoiridoid is glucosylated it appears not to be subject to gastric hydrolysis, 
meaning that phenolics such as glucosides of oleuropein enter the small intestine 
unmodified, along with high amount of free HT and TYR and remaining secoiridoid 
aglycones. The major site for the absorption of olive oil polyphenols is the small intestine, 
HT and TYR are dose-dependently absorbed and they are metabolized primarily to O-
glucuronidated conjugates.  HT also undergoes O-methylation by the action of catechol-
O-methyl-transferase, and both homovanillic acid and homovanillyl alcohol have been 
detected in human and animal plasma and urine after the oral administration of either 
VOO or pure HT and TYR. Studies have also demonstrated that secoiridoids, which 
appear not to be absorbed in the small intestine, undergo bacterial catabolism in the large 
intestine with oleuropein undergoing rapid degradation by the colonic microflora 
producing HT as the major end product (Corona, et al., 2006). The intense interest in VOO 
polyphenols and their metabolites can be attributed to the association of such substances 
with several biological activities; these include antioxidant activity as well as other 
important healthy properties that will be discussed later. For this reason, olive 
polyphenols are recognized as potential nutraceutical targets for food and pharmaceutical 
industries. 
2.3 Atherosclerosis and virgin olive oil  
Atherosclerosis underlies the leading cause of death in industrialised societies (Lloyd-Jones 
et al., 2010). The key-initiating step of early stages of atherosclerosis is the subendothelial 
accumulation of apolipoprotein B-containing lipoproteins. These lipoproteins are produced 
by the liver and the intestinal cells and consist of a core of neutral lipids, mainly cholesteryl 
esters and triglycerides (TGs), surrounded by a monolayer of phospholipids and proteins. 
Hepatic apoB-lipoproteins are secreted as very-low density lipoproteins (VLDL), and they 
are converted to atherogenic low-density lipoproteins (LDL) during the circulation; in 
contrast, the intestinal apoB-lipoproteins are secreted as chylomicrons. The VLDL and 
chylomicrons can be converted into atherogenic remnant lipoproteins by lipolysis.  The 
VLDL, chylomicrons and their remnants, which are known as triglyceride-rich lipoproteins 
(TRLs), appear in the blood after a high-fat meal (postprandial state) and are considered to 
be highly atherogenic (Havel, 1994; Zilversmith, 1979). In fact, chylomicronemia causes 
atherosclerosis in mice (Weinstein et al., 2010) and decreasing the TRLs level reduces the 
progression of coronary artery disease to the same degree as decreasing the LDL-cholesterol 
level (Hodis et al., 1999).  TRLs comprise a large variety of nascent and metabolically 
modified lipoprotein particles that vary in size and density, as well as lipid and 
apolipoprotein composition. Studies have indicated that the size and the specific structural 
arrangement of lipids and apolipoproteins are associated with atherogenicity. Morover, 
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studies have consistently shown that there is an inverse relationship between the lipoprotein 
particle size and the ability to enter the arterial wall. Small TRLs and their remnants can 
enter the arterial wall and are independently associated with the presence, severity, and 
progression of atherosclerosis (Hodis, 1999). Short-term intake of the Mediterranean diet 
and the acute intake of an olive oil meal could favour the lower cardiovascular risk in 
Mediterranean countries by secreting a reduced number and higher-size TRLs particles 
compared with other fat sources (Perez-Martinez et al., 2011). Recent studies suggest that 
lipoproteins may also contribute to atherogenesis by affecting the mechanisms of the control 
of gene expression. Many lipoproteins-gene interactions have only been investigated under 
fasting conditions, Lopez et al., 2009 nicely reviews the emerging importance of gene-
nutrient interactions at the postprandial state, which impacts ultimately on atherosclerosis 
risk.  
A large body of knowledge exists from epidemiological, clinical, experimental animal 
models and in vitro studies that have indicated that olive oil can be regarded as functional 
food for its anti-atherogenic properties. Diets enriched with olive oil prevent the 
development and progression of atherosclerosis (Aguilera et al., 2002; Kanrantonis et al., 
2006) and may also play an important role in atherosclerosis regression (Mangiapane et al., 
1999; Tsalina et al., 2007, 2010). These and recent reports have suggested that the beneficial 
effects of olive oil on atherosclerosis may be influenced by the high oleic acid content and 
the minor fraction of the oil; potential benefitial microconstituents include tocopherols, 
phenolic compounds, phytosterols, triterpenoids and unusual glycolipids that exert an 
antagonistic effect on PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine). There are 
several mechanisms by which olive oil affects the development of atherosclerosis. Theses 
mechanisms have been nicely reviewed by Carluccio et al., 2007, and include the following: 
1) regulation of cholesterol levels as olive oil decreases LDL-cholesterol and increases HDL-
cholesterol; 2) decreased  susceptibility of human LDL to oxidation, because of the lower 
susceptibility of its MUFAs content and to the ability of its polyphenol fraction to scavenge 
free radicals and reduce oxidative stress; 3) both, oleic acid and olive oil antioxidant 
polyphenols inhibit endothelial activation and monocyte recruitment during early 
atherogenesis; 4) decreased macrophage production of inflammatory cytokines, eicosanoid 
inflammatory mediators derived from arachidonic acids and increased nitric oxide (NO) 
production, which improves vascular stability; 5) decreased macrophages matrix-
metalloproteinases (MMPs) production, which improves plaque stability; 6) oleic acid and 
olive oil polyphenols are associated with a reduced risk of hypertension;  7) oleic acid and 
olive oil polyphenols also affect blood coagulation and fibrinolytic factors, thereby reducing 
the risk of acute thrombotic cardiovascular events; and 8) a decreased rate of oxidation of 
DNA (Machowetz et al., 2007); human atherosclerosis is associated with DNA damage in 
both circulating cells and cells that comprise the vessel wall.  
EVOO is therefore becoming more important due to its beneficial effects on human health. 
EVOO has proven effective in controlling atherosclerotic lesions, mainly within the 
framework of a Mediterranean-type diet (low cholesterol). An animal model that reproduces 
the processes taking place in the development of human atherosclerosis has been crucial to 
obtaining these conclusions, and this has been provided by the apoE-deficient mouse. Using 
this model, it has been proved that EVOO possesses beneficial antiatherogenic effects, and 
its enrichment with polyphenols (Rosenblat et al., 2008) and with long chain n-3 PUFAs 
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studies have consistently shown that there is an inverse relationship between the lipoprotein 
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of gene expression. Many lipoproteins-gene interactions have only been investigated under 
fasting conditions, Lopez et al., 2009 nicely reviews the emerging importance of gene-
nutrient interactions at the postprandial state, which impacts ultimately on atherosclerosis 
risk.  
A large body of knowledge exists from epidemiological, clinical, experimental animal 
models and in vitro studies that have indicated that olive oil can be regarded as functional 
food for its anti-atherogenic properties. Diets enriched with olive oil prevent the 
development and progression of atherosclerosis (Aguilera et al., 2002; Kanrantonis et al., 
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polyphenols inhibit endothelial activation and monocyte recruitment during early 
atherogenesis; 4) decreased macrophage production of inflammatory cytokines, eicosanoid 
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production, which improves vascular stability; 5) decreased macrophages matrix-
metalloproteinases (MMPs) production, which improves plaque stability; 6) oleic acid and 
olive oil polyphenols are associated with a reduced risk of hypertension;  7) oleic acid and 
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EVOO is therefore becoming more important due to its beneficial effects on human health. 
EVOO has proven effective in controlling atherosclerotic lesions, mainly within the 
framework of a Mediterranean-type diet (low cholesterol). An animal model that reproduces 
the processes taking place in the development of human atherosclerosis has been crucial to 
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atherosclerosis development. Feeding these mice with various olive oils rich in different 
minor components or with these components in isolation has made it possible to assess the 
contribution of those molecules to the beneficial effect of this food, these effects have been 
review by Guillen et al., 2009 and include the following: 1) increase of small, dense HDL 
enriched with apo A-IV tightly bound to paraoxonase; these apolipoprotein A-IV-enriched 
particles were very effective in inactivating the peroxides present in the low-density 
lipoproteins (LDL) which are thought to initiate atherosclerosis;  2) minor components 
decrease plasma triglycerides and LDL-colesterol and very low density lipoprotein 
cholesterol (VLDL-colesterol), as well as 3) parameters of oxidative stress, such as 
isoprostane (8-iso-prostaglandin F2a); 4) EVOO acts against oxidative stress, which occurs 
primarily through a direct antioxidant effect as well as through an indirect mechanism that 
involves greater expression and activity of certain enzymes with antioxidant activities such 
as catalase and glutathione peroxidase-1 (Oliveras-Lopez et al., 2008). Among the 
antioxidants from EVOO, phenolic compounds have received the most attention. 
Oleuropein derivatives, especially HT, have been shown to have protective effects against 
markers associated with the atherogenic process (González-Santiago et al., 2006; Zrelli et al., 
2011), some studies (Acin et al., 2006), however, have shown opposite results with HT 
administration in the atherosclerotic process. Given the anti-atherogenic properties of EVOO 
evident in animal models fed a Western diet, clinical trials are needed to establish whether 
these oils are a safe and effective means of treating atherosclerosis. 
3. Nutrigenomics of olive oil 
3.1 Gene-diet interactions after acute ingestion of olive oil  
In addition to the mechanisms described above, olive oil components can exert an anti-
atherogenic affect by acting at the genomic level.  Nearly all evidence for the impact of olive oil 
on gene expression is derived from research using animal or human cells in culture. Carefully 
designed human clinical studies to establish a cause-and-effect relationship between olive oil 
affecting gene expression and the atherosclerotic process are scare and will be review here. 
Recent in vivo studies have shown that sustained consumption of VOO influence peripheral 
blood mononuclear cells (PBMNCs) gene expression (nutritional transcriptomics) (Table 2). 
PBMNCs are often used to asses changes in gene expression in vivo because the leucocytes 
recruitment from the circulation to the vessel wall for subsequent migration into the sub-
endothelial layer is a critical step in atherosclerotic plaque formation; additionally, PBMNCs 
can be easily obtained from volunteers through simple blood draws. Previous studies have 
shown that in healthy individuals, a 3-week consumption of VOO as a principal fat source in a 
diet low in natural antioxidants (Khymenets et al., 2009) up-regulated the expression of genes 
associated with DNA repair proteins such as, the excision repair cross complementation group 
(ERCC-5) and the X-ray repair complementing defective repair Chinese hamster cells 5 
(XRCC-5). VOO consumption also up-regulated aldehyde dehydrogenase 1 family, member 
A1 (ALDH1A1) and LIAS (lipoic acid synthetase) gene expression.  ALDH1A1 is a gene 
encoding protein which protect cells from the oxidative stress induced by lipid peroxidation; 
the LIAS protein plays an important role in α-(+)-lipolitic acid (LA) synthesis. LA is an 
important antioxidant that has been shown to inhibit atherosclerosis in mouse models of 
human atherosclerosis due to its anti-inflammatory, antihyperglyceridemic and weight-
reducing effects. Morover, apoptosis-related genes such as, BIRC-1 (baculoviral IAP repeat-
containing protein 1) and TNSF-10 (tumor necrosis factor (ligand) superfamily, member 10), 
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were also upregulated. BIRC-1 inhibits apoptosis while TNSF-10 promotes macrophages and 
lymphocytes apoptosis. VOO ingestion also modified OGT gene expression (O-linked N-
acetylglucosamine (GlcNAc) transferase). Nuclear and cytoplasmic protein glycosylation is a 
widespread and reversible posttranslational modification in eukaryotic cells; intracellular 
glycosylation via the addition of N-acetylglucosamine to serine and threonine is catalysed by 
OGT. Thus, OGT plays a significant role in modulating protein stability, protein-proteins 
interactions, transactivation processes, and the enzyme activity of target proteins; moreover 
OGT plays a critical role in regulating cell function and survival in the cardiovascular system. 
VOO consumption also profoundly impacted the expression of the USP-48 (ubiquitin specific 
peptidase-48) gene. USP-48 is a member of the ubiquitin proteasome system that removes 
damaged, oxidized and /or misfolded proteins; it also plays a role in inflammation, 
proliferation and apoptosis. PPARBP (peroxisome proliferator-activated receptor-binding 
protein), which is an essential transcriptional mediator of adipogenesis, lipid metabolism, 
insulin sensitivity and glucose homeostasis via peroxisome proliferator-activated receptor-γ 
(PPAR-γ) regulation, and ADAM-17 (a disintegrin and metalloproteinase domain 17), a 
membrane –anchored metalloprotease, were also upregulated. ADAM-17 is a candidate gene 
of atherosclerosis susceptibility in mice models of atherosclerosis (Holdt et al., 2008), it 
mediates the release of several cell-signaling and cell adhesion molecules such as vascular 
endothelial (VE)-cadherin, vascular cell adhesion molecule-1   (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) or L-selectin affecting endothelial permeability and leukocyte 
transmigration. According with this study, Reiss et al. 2011, have recently show that 
unsaturated FFA increase ADAM-mediated substrate cleavage, with corresponding functional 
consequences on cell proliferation, cell migration, and endothelial permeability, events of high 
significance in atherogenesis. 
LLorent-Cortes et al. 2010, have also concluded that a Mediterranean-type diet in a high-risk 
cardiovascular population impacts the expression of genes involved in inflammation, vascular 
foam cell formation and vascular remodelling in human monocytes. Inflammation plays a role 
in the onset and development of atherosclerosis. In this study, VOO ingestion prevented an 
increase in cyclo-oxygenase-2 (COX-2) expression and decreased monocyte chemotactic 
protein-1 (MCP-1) gene expression compared with a traditional Mediterranean diet (TMD) 
with nuts or a low fat diet. COX-2 is a pro-inflammatory enzyme that increases prostanoid 
levels (thromboxane A2; TXA2 and prostaglandine E2; PGE2); bioactive molecules present in 
VOO such as 1-hydroxityrosol and phenyl-6,7-dihydroxi-isochroman which is an ortho-
diphenol present in EVOO,  down-regulate COX-2 synthesis by preventing nuclear factor-
kappaB (NF-kB) activation in macrophages and monocytes (Maiuri et al., 2005; Trefiletti et al., 
2011). MCP-1 is a potent regulator of leucocyte trafficking, and animal studies have shown that 
a VOO diet can reduce neutrophil accumulation and decreases the MCP-1 blood levels (Leite 
et al., 2005); again, these data support the hypothesis that VOO is anti-inflammatory. Morover,  
the dietary intervention with VOO specifically prevented low density lipoprotein receptor-
related protein-1 (LRP-1) overexpression in the high cardiovascular risk population. LRP-1 
plays a major role in macrophage-foam cell formation and migration; additionally, LRP-1 is 
also a key receptor for the prothrombotic transformation of the vascular wall.  Morover, VOO 
dietary intervention prevented an increase in the expression of genes involved in intracellular 
lipid accumulation in macrophages and monocytes (e.g., CD36 antigen; CD36) and in the 
process of thrombosis (e.g., tissue factor pathway inhibitory, FFPI) compared to a TMD 
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Table 2. Changes in gene expression  of atherosclerotic-related genes after acute ingestion of 
virgin olive oil in human studies. 
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The last two nutritional interventions, suggest that the benefits associated with a TMD and 
VOO consumption can reduce cardiovascular risk via nutrigenomic effects; however, these 
studies could not distinguish between the effects elicited by minor components of VOO and 
those promoted by the fat content of the oil. A recent study by Konstantinidou et al, 2010 
indicated that olive oil polyphenols play a significant role in the down-regulation of pro-
atherogenic genes in human PBMNCs after 3 months of a dietary intervention with a 
TMD+VOO and TMD+WOO (washed virgin olive oil which has the same characteristics as 
VOO except for a lower polyphenol content). The dietary intervention decreased the 
expression of genes related to inflammation (e.g., interferon-γ, IFN-γ; Rho GTPase activating 
protein-15, ARHGAP-15; and Interleukin 7 receptor, IL7R) oxidative stress (e.g., adrenergic 
β-2 receptor surface, ADRB2) and DNA damage (e.g., polymerase DNA directed k, POLK). 
Changes in the expression of all of these genes, except POLK, were particularly observed 
when VOO, rich in polyphenols, was present in the TMD. The decrease in gene expression 
associated with inflammatory that was observed in this study agrees with previous studies 
that have reported a decrease in systemic inflammatory markers and oxidative stress due to 
the ingestion of polyphenols from olive oil and olive leaf extract (Poudyal et al., 2010; Puel et 
al., 2008). IFN-γ is considered to be a key inflammatory mediator and the release of this 
cytokine is regulated by polyphenols from red wine and dietary tea polyphenols (Deng et 
al., 2010; Magrone et al., 2008). ARHGAP-15 encodes for a Rho GTPase-activating protein 
that regulates the activity of GTPases. To date, little is known about the physiological role of 
ARHGAP-15, however, recent studies by Costa et al., 2011 have shown that this protein is 
associated with the selective regulation of multiple neutrophil functions. The protein 
encoded by the IL7R gene is a receptor for IL-7, which is associated with inflammation; 
interestingly, olive oil consumption has been shown to reduce the IL-7 serum concentration 
in patients with the metabolic syndrome (Esposito et al., 2004). POLK is a DNA repair gene 
that copies undamaged DNA templates. Previous studies have indicated that down-
regulation of POLK is not associated with polyphenol content of VOO. Thus, the protective 
effect of VOO associated with DNA repair is related to the fat content (MUFA) and other 
minor oil components. ADRB2 has previously been associated with body composition (Bea 
et al., 2010), overexpression of the receptor that enhances reactive oxygen species (ROS) 
signalling (Di Lisa et al., 2011), and ADRB2 inhibition, which reduces macrophage cytokine 
production. Down-regulation of the ADRB2 gene, particularly in the TDM+VOO 
intervention group, along with an improvement in the oxidative status of the volunteers, 
may indicate that olive oil polyphenols protect against oxidative stress. Collectively, these 
studies support the hypothesis that olive oil polyphenol consumption in the context of a 
TMD may protect against cardiovascular disease by modulating the expression of 
atherosclerosis-related genes.  
3.2 Influence of olive oil on gene-diet interaction at the postprandial state  
Humans that reside in industrialised societies spend most of the daytime in a non-fasting 
state that is influence by meal consumption patterns and the amounts of food ingested. 
Postprandial lipaemia is characterised by an increase in TGs, specifically in the form of TRLs. 
Over 25 years ago, Zilversmit, 1979 proposed that atherogenesis was a postprandial 
phenomenon because high concentrations of lipoproteins and their remnants following food 
ingestion could deposit on the arterial wall and accumulate in atheromatous plaques. In 
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composition according to the nutrient to be tested. In these studies, both, the amount and 
the type of fat ingested influence postprandial lipaemia. Although, controversial results 
have been obtained for comparing an olive oil fat meal with other dietary fats, some studies 
have shown that VOO intake decreases the postprandial TGs concentration and results in a 
faster TRLs clearance from the blood in normolipidemic subjetcs (Abia et al., 2001). The 
amount of fat ingested influences the results as small doses of olive oil (25 ml) did not 
promote postprandial lipaemia, whereas larger doses (40 and 50 ml) of any type of olive oil 
promoted lipaemia (Fitó et al., 2002; Covas et al., 2006). Olive oil is considered to be an 
optimal fat for the modulation of extrinsic cardiovascular risk factors in the postprandial 
state. The influence of olive oil on postprandial insulin release and action, endothelial 
function, blood pressure, inflammatory processes and hemostasis has been recently review 
by Bearmudez et al., 2011.  
3.2.1 Postprandial effect of olive oil in PBMNCs 
Early in vivo postprandial human studies have shown that VOO activates PBMCs 
immediately after ingestion and may induce changes in gene expression (Bellido et al., 2004). 
Postprandial studies have shown that high-fat meals can induce β cell dysfunction and 
insulin resistance in healthy individuals, as well as in subjects with type 2 diabetes or the 
metabolic syndrome.  However, postprandial olive oil (MUFAs) can buffer β cell 
hyperactivity and insulin intolerance compared to butter (SFAs) in subjects with high 
fasting triglyceride concentrations (Lopez et al., 2011). Moreover, changes in expression of 
insulin sensitivity related genes occur in human PBMNCs after an oral fat load of VOO 
(Konstantinidou et al., 2009) (Table 3).  In this study, the expression of genes such as OGT, 
arachidonate 5-lipoxygenase-activating protein (ALOX5AP), LIAS, PPARBP, ADBR2 and 
ADAM-17 were up-regulated at 6 h after VOO ingestion. LIAS and PPARBP regulate insulin 
sensitivity by activating and co-activating PPARγ, respectively. PPARγ is a nuclear hormone 
receptor that plays a crucial role in adipogenesis and insulin sensitisation. The authors 
hypothesised that the up-regulation of both of these genes may be one feed back mechanism 
that counteracts the postprandial oxidative stress that plays a role in the development of 
insulin resistance. The ADRB2 gene encodes for a major lipolytic receptor in human fat cells 
that modulates insulin secretion and protects against oxidative stress. Because insulin 
signaling activates the OGT gene, the authors attributed the increase in OGT expression 
with the several feedback mechanisms that serve to attenuate sustained insulin signalling. 
CD36 is an integral membrane glycoprotein expressed on the surface of cells active in fatty 
acid metabolism (adipocytes, muscle cells, platelets, monocytes, heart and intestine cells). 
This protein plays diverse functions, including uptake of long-chain fatty acids and oxidized 
low-density lipoproteins. CD36 deficiency underlies insulin resistance, defective fatty acid 
metabolism and hypertriglyceridemia in spontaneously hypertensive rats (SHRs), 
furthermore, lipid-induced insulin resistant has been associated with atherogenesis through 
mechanisms mediated by the expression of scavenger receptor CD36 (Kashyap et al., 2009).  
CD36 gene expression was modulated during the postprandial period after VOO ingestion 
(Konstantinidou et al., 2009), however the authors did not find a relationship between in 
CD36 gene expression and insulin levels in the subjects. Rather, they found an association 
with a postprandial increase in plasma fatty acids and the satiety response after VOO 
ingestion. ADAM-17 is considered to be an attractive target for controlling insulin resistance. 
It also regulates tumor necrosis factor (TNF-α), major negative regulator of the 
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ingestion. ADAM-17 is considered to be an attractive target for controlling insulin resistance. 
It also regulates tumor necrosis factor (TNF-α), major negative regulator of the 
Nutrigenomics and Atherosclerosis:  




Table 3. Changes in gene expression of atherosclerotic-related genes after the ingestion of 





insulin receptor pathway, at posttranscriptional level. PPARBP may also increase insulin 
sensitivity by down-regulating the expression of TNF-α.  The consumption of an olive oil-
enriched breakfast decreases postprandial expression of TNF-α mRNA compared with a 
breakfast rich in butter and walnuts (Jimenez-Gomez et al., 2009). Correspondingly, acute 
consumption of EVOO decreased the circulating levels of soluble TNF-α in young healthy 
individuals (Papageorgiou et al., 2011). TNF-α activates a cytokine production cascade and 
thereby has a crucial role in the inflammatory process that is associated with atherogenesis; 
thus, dietary modification of TNF-α may prevent atherosclerosis.  
In human interventional studies, an acute intake of olive oil increased the HDL cholesterol 
level, decreased inflammation, decreased lipid oxidation and decreased DNA oxidative 
damage. Studies by Konstantinidow et al. 2009, showed that there was a postprandial 
increase in the expression of PBMNCs genes related to DNA-repair (DNA-cross-link repair 
1C, DCLRE1C and POLK) and inflammation (interleukin-10, IL-10; IFN-γ) 6h after ingestion 
of 50 mL of VOO.  IL-10 is an anti-inflammatory cytokine that inhibits the production of 
interleukin-6 (IL-6), which is considered to be the most important inflammatory mediator.  
Il-6 release from rat adipocytes is regulated by the dietary fatty acid composition, and lower 
values of IL-6 are released with an olive oil diet (Garcia-Escobar et al., 2010); however, the 
postprandial change in plasma IL-6 concentrations does not seem to be altered by VOO 
ingestion (Teng et al., 2011; Manning et al., 2008). Postprandial VOO down-regulated IFN-γ 
gene expression. IFN-γ is a key pro-atherogenic cytokine that induces expression of 
adhesion molecules in endothelium and recruit leucocytes (Zhang et al., 2011), induces the 
expression of genes that have been implicated in atherosclerosis, promotes uptake of 
modified LDL (N. Li et al., 2010), and regulates macrophage foam cell formation and plaque 
stability, which are essential steps that mediate the pathogenesis of atherosclerosis. ATP-
binding cassette, subfamily A, member 7 (ABCA7) is a protein that mediates the biogenesis 
of HDL with cellular lipids and helical apolipoproteins. In agreement with this, an increase 
in ABCA7 gene expression was observed in the postprandial studies after VOO ingestion.  
The authors also observed up-regulation of several oxidative stress related genes and genes 
that may regulate NF-kB activation such as USP48 and a-kinase anchor protein-13 (AKAP-
13). NF-kB regulates numerous processes in the cardiovascular system, including 
inflammation, cell survival, differentiation, proliferation and apoptosis. In vascular cells, 
NF-kB activation is mediated by diverse extracellular signals including Ang II, oxLDL, 
TRLs, advanced glycation end-products, and inflammatory cytokines. NF-kB activation by 
circulating cytokines has been linked to atherosclerosis and thrombosis and a number of 
NF-kB-regulated pro-inflammatory proteins are relevant for the initiation and progression 
of atherosclerosis. The induction of NF-κB signalling, results in transcriptional regulation of 
pro-inflammatory genes, including cytokines, chemokines, adhesion molecules, 
antioxidants, transcription factors, growth factors, and apoptosis and angiogenesis 
regulators (van der Heiden et al., 2010). The data showed so far, suggest that olive oil 
ingestion may protective during the postprandial by altering gene expression changes. 
However, the authors could not distinguish whether the protective effect was caused by the 
minor components of olive oil or to the fat content. 
To adress this problem, Camargo et al., 2010 performed postprandial studies with two VOO 
based breakfast, with a high and low phenolic compounds content, administered to patients 
suffering form metabolic syndrome. The phenol fraction of VOO repressed the expression of 
several PBMNCs genes that are involved in inflammation processes mediated by cytokine-
cytokine receptor interactions, arachidonic acid metabolism, mitogen-activated protein 
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 kinases (MAPKs) and transcription factor NF-kB/AP-1, such as the SGK1 
(serum/glucocorticoid-regulated kinase-1) and the NFKBIA (nuclear factor of kappa light 
chain gene enhancer in B cells inhibitor, alpha) genes. SGK1 encodes a 
serum/glucocorticoid-regulated kinase that enhances nuclear NF-kB activity by 
phosphorylating the inhibitory kinase IKKα. The NFKBIA gene, encodes the IkBα 
protein,which is a member of an inhibitory IkB protein family that sequesters NF-kB into the 
cytoplasm. As NF-kB binds to the IKBα promoter to activate its transcription, a decrease in 
NFKBIA expression should be associated with a decrease in NF-kB activation. The 
hypothesis that olive oil polyphenols decreases NF-kB activation is supported by in vivo 
studies, which showed that VOO ingestion reduces inflammatory response of PMBSCs 
mediated by transcription factor NF-kB when compared to, butter and walnut-enriched 
diets during the postprandial state (Bellido et al., 2004). The study also showed the VOO 
consumption decreased the expression of PTGS2 (prostagladin-endoperoxide synthase-2), 
interleukin 1- β (IL-1β) and IL-6. The PTGS2 gene encodes for COX-2, which is an inducible 
isozyme that mediates prostaglandin biosynthesis from the substrate arachidonic acid. Pro-
inflammatory cytokines, prostaglandins and NO, which are produced by monocytes and 
activated macrophages, play critical roles in inflammatory diseases such as atherosclerosis. 
VOO and hydrolysed olive vegetation water (Bitler et al., 2005) exhibit anti-inflammatory 
activities in the human monocytic leukemia cell line (THP-1).  Previous studies have shown 
that, HT down-regulates iNOS and COX-2 gene expression in THP-1 cells (Zhang et al., 
2009) and in murine macrophages by preventing NF-kB, STAT-1alpha (signal transducer 
and activator of transcription-1) and IRF-1 (interferon regulatory factor-1) activation (Maiuri 
et al., 2005). In vitro studies by Graham et al., 2011 have recently shown that TRLs, isolated 
from healthy volunteers after ingestion of VOO and pomace olive oil, enriched in minor 
components, produces a decrease in IL-6 and IL-1B secretion along with a down-regulation 
of COX-2 mRNA in macrophages. IL-6 is a pro-inflammatory cytokines that may contribute 
to the development of atherosclerosis by promoting insulin resistance, dyslipidaemia and 
endothelial dysfunction (Wilson, 2008). IL-6 synthesis is stimulated by IL-1β, which is 
another pro-inflammatory cytokine that regulates endothelial cell proliferation and the 
expression of adhesion molecules on the arterial wall (Andreotti et al., 2002). Studies, with a 
high-fat diet induced insulin-resistant animal model, showed that the ingestion of green tea 
polyphenols decreased IL-1β and IL-6β mRNA expression in cardiac muscle (Qin et al., 
2010).  
Circulating monocytes are components of innate immunity, and many pro-inflammatory 
cytokines and adhesion molecules facilitate monocyte adhesion and migration to the 
vascular endothelial wall. Monocyte migration is a key event in the pathogenesis of 
atherosclerosis. Therefore, modulating PMBCs activity and creating a less deleterious 
inflammatory profile may decrease leucocytes recruitment from the circulation to the vessel 
wall, important process in the initiation of atherosclerosis.  According to this, Camargo et 
al., 2010 observed a decreased expression of chemokine, cc motif, ligand-3 (CCL3), 
chemokine, cxc motif, ligan-1 (CXCL1), chemokine, cxc motif, ligan-2 (CXCL2), chemokine, 
cxc motif, ligan-3 (CXCL3) and chemokine, cxc motif, receptor-4 (CXCR4) after acute-intake 
of phenol-rich olive oil. The CCL3 gene, which encodes for macrophage inflammatory 
protein-1 (MIP-1) has been implicated in inducing leucocyte-endothelial cell interactions 
and leucocyte recruitment in vivo (Gregory et al., 2006). CXCL1, CXCL2 and CXCL3, 
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stem cells migration through the endothelium in response to ox-LDL (M. Li et al., 2010). 
Dual-specificity phosphatase-1 (DUSP-1), dual-specificity phosphatase-2 (DUSP-2) and 
tribbes homology-1 (TRIB-1), gene expression were decreased by phenol-rich olive oil. 
DUSP-1 is actively involved in atherosclerosis and a chronic deficiency of DUSP-1 in ApoE(-
/-) mice leads to decreased atherosclerosis via mechanisms involving impaired macrophage 
migration and defective extracellular signal-regulated kinase signalling (Shen et al., 2010). 
TRBIR1 is also involved in MAPK signalling and is up-regulated in vascular smooth muscle 
cells (SMCs) of human atherosclerotic plaques; TRBIR1 expression levels are key for 
modulating the extent of vascular SMCs proliferation and chemotaxis (Sung et al., 2007). 
Extracellular matrix degradation occurs in several pathological conditions such as 
atherosclerosis. Among the circulating cells, activated monocytes may directly contribute to 
atherosclerosis by expressing MMPs. In particular, monocytes express matrix 
metalloproteinase-9 (MMP-9), which is a member of the MMPs family that acts on the 
extracellular matrix, facilitates the migration of recruited monocytes to the sub-endothelial 
layer and acts on precursors of inflammatory cytokines, thereby amplifying the 
inflammatory response. In vitro studies showed that oleuropein aglycone, which a typical 
olive oil polyphenol, prevented an increase in MMP-9 expression and secretion in THP-1 
cells (Dell´Agli et al., 2010); these data provide further evidence regarding the mechanisms 
by which olive oil reduces inflammation during atherosclerosis.  
3.2.2 Postprandial effect of olive oil on the endothelium 
Low-grade inflammation is often associated with endothelial dysfunction, which is 
associated with the development of atherosclerosis. Moreover, remnant like-lipoproteins 
have been associated with endothelial dysfunction and coronary artery disease in subjects 
with metabolic syndrome (Nakamura et al., 2005). A large number of genes are regulated 
after endothelial cells are exposed to TRLs with the net effect reflecting receptor and non-
receptor mediated pathways that are activated or inhibited depending on the fatty acid type, 
lipid and apolipoprotein composition of TRLs and the presence or absence of lipoprotein 
lipase (Williams et al., 2004). TRLs have been shown to induce pro- and anti-inflammatory 
responses in the endothelium, and TRL composition plays a key role in determining these 
responses. TRLs that were isolated after a meal enriched in SFAs induced E-selectin, VCAM-
1 and lectin-like oxidised-LDL receptor-1 (LOX-1) gene expression to a higher extent 
compared to TRLs that were isolated after a meal enriched in MUFAs and PUFAs (Williams 
et al., 2004); similarly, chylomicrons separated after ingestion of safflower oil, which is rich 
in polyunsaturated linoleic acid, induced a higher expression level of adhesion molecules 
compared with chylomicrons that were separated after ingestion of olive oil, rich in 
monounsaturated oleic acid (Jagla & Schrezenmeir, 2001). The effects of lipoproteins on 
vasoactive substances may also play a role in endothelial dysfunction. The endothelium-
derived relaxing factor NO has gained wide attention because the current data suggests that 
it may protect against hypertension and atherosclerosis. In general, high-fat meals have 
often been associated with a loss of postprandial vascular reactivity compared to low fat 
meals. However several studies have shown that differences in food composition and the 
fatty acid content of meals may contribute to the observed effects on vascular reactivity via 
postprandial lipoproteins modifications. Thus, meals that contain MUFAs and 
eicosapentaenoic/docosahexaenoic acids (EPA/DHA) can attenuate the endothelial 
function impairment likely by reducing the most atherogenic postprandial lipoprotein 
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subclass containing apolipoproteins B and C (Hilpert et al., 2007). Olive oil polyphenols can 
also inhibit endothelial adhesion molecule expression through NF-kB inhibition (Carluccio 
et al., 2003). In endothelial cell models, oleic acid (Carluccio et al., 1999) and phenolic 
extracts from EVOO, strongly reduced the gene expression of the vascular wall cell adhesion 
molecules (ICAM-1, VCAM-1), being HT, oleuropein and oleuropein aglycone the main 
polyphenols responsible for these effects (Dell´Agli et al., 2006; Carluccio et al., 2003)  
3.2.3 Postprandial effect of olive oil in smooth muscle cells 
SMCs are essential for proper vasculature function. SMCs contract and relax to alter the 
luminal diameter, which enables the blood vessels to maintain an appropriate blood 
pressure. However, vascular SMCs can also proliferate and migrate and synthesise large 
amounts of extracellular matrix (ECM) components. Thus, SMCs plays an important role in 
atherogenesis. TRLs induce the SMCs proliferation and migration via MAPKs activation, G 
protein–coupled receptor (GPCR)–dependent or independent protein kinase C (PKC) 
activation, epidermal growth factor receptor (EGF) transactivation and heparing-binding 
EGF-like growth factor shedding. TRLs can exert their effects on SMCs by acting at the 
genomic level (Lopez et al., 1999). TRL up-regulates the expression of genes involved in 
proliferation (e.g., cycin D1, CCND1; cyclin E, CCNE1; proliferating cell nuclear antigen, 
PCNA), inflammation (e.g., interleukin-8, IL-8; IL-1B; COX-2; suppressor of cytokine 
signaling 5, SOCS-5), signal transduction (e.g., mitogen-activated protein kinase 1, MAP3K-
1; mitogen-activated protein kinase phosphatase-3, MKP-3; dual-specificity tyrosine 
phosphorylation-regulated kinase 1A,  DYRK1A), oxidative stress (e.g., stress-activated 
protein kinase-3, SAPK-3 and stress-activated protein kinase-2A, SAPK-2A)  and 
cytoskeleton function and motility (e.g., vimentin, VIM; keratin 19, KRT-19; fibrillin, FBN; 
tubulin beta, TUBB) (Bermudez et al., 2008). Furthermore, increasing evidence has shown 
that the pathophysiological contribution of TRLs to atherosclerosis development of plaque 
stability depends on the fatty acid composition of TRLs. The same study showed that TRLs 
obtained after the ingestion of olive oil produced a less deleterious pro-atherogenic profile 
compared to TRLs obtained after ingestion of butter (SFAs) or a mix of vegetable and fish 
oils (PUFAs). Since the olive oil contained no minor components, the effects were mainly 
attributed to oleic acid. However, oleic acid is not the sole component of olive oil that 
confers health benefits. In that sense, oleanolic acid, which is a natural triterpenoid that is 
present in pommace olive oil, induces prostaglandine I2 (PGI2) production through a 
mechanism that involves COX-2 mRNA upregulation via MAPKs signalling pathways ( 
Martinez-Gonzalez et al., 2008). 
4. Conclusions 
Nutrigenomic analyses directly asseses the influence of bioactive food compounds on gene 
expression. An increasing amount of data indicate that the fatty acids and polyphenols 
present in EVOO modulate the expression of key atherosclerotic-related genes, in vascular 
(macrophages, endothelial and smooth muscle cells) and peripheral blood mononuclear 
cells, towards a less-atherogenic gene profile. These compounds exert an effect after acute 
ingestion of the oil and during the postprandial state, and may provide protection during 
several stages of atherosclerosis. These data presented here, suggest that the traditional 
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4. Conclusions 
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several stages of atherosclerosis. These data presented here, suggest that the traditional 
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1. Introduction 
Cardiovascular disease (CVD) is the main cause of death or invalidism in high-income 
countries today. Moreover, worldwide demographic changes are aiding CVD’s rapid 
progression towards the number one killer in middle- and low-income countries. The World 
Health Organisation estimates that if current trends are allowed to continue, about 20 
million people will die from CVD by 2015. This group of disorders, which affect the heart 
and blood vessels, includes coronary heart disease, cerebrovascular disease and peripherial 
arterial disease, deep vein thrombosis and pulmonary embolism. 
The main cause of these acute life-threatening conditions is atherosclerosis. Atherosclerotic 
plaques and restenosis can result in severe occlusions of peripheral and coronary arteries. 
Current treatments include drug therapy and bypass surgery, and depend on the severity of 
the disease. All treatments require molecular understanding of the processes that govern 
atherosclerosis. This is especially important when introducing artificial graft materials in 
vivo. 
Generally, the first choice for vascular replacement graft material is the patient’s own 
vessels, i.e., autologous vessels. If these are in shortage supply or do not exhibit sufficient 
quality due to, e.g., other diseases or previous surgery, artificial alternatives become 
necessary. Today, clinics use biomaterials such as expanded polytetrafluorethylene (ePTFE) 
and polyethylene terephtalate fibre (Dacron®) as prosthetic grafts for reconstructive 
vascular surgery. However, their performance is dismal in small diameter vessels (>6 mm) 
like coronary arteries and peripheral arteries below the knee, resulting in early thrombosis 
and intimal hyperplasia. Therefore, about 10% of patients with CVD are left untreated due 
to the lack of replacement material for small vessels. 
Considering the large number of patients who need replacement vessels, the substantial 
demand for alternative small-caliber grafts is urgent, driving scientists to search for and 
develop new materials. Recently, this has even led to the use of completely biological 
vessels. However, the growth of such requires months, rendering them unsuitable for acute 
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2. What is the ideal vascular graft? 
Several issues demand consideration when constructing a vascular graft: the mechanical 
properties of the graft must resemble those of a native blood vessel, and the graft must be 
biocompatible with its host. One important factor is compliance, i.e., how well the vessel 
withstands pressure from the bloodstream and whether it can maintain systemic pressure in 
the vascular system. Vascular grafts should also be “invisible” to the immune system and 
possess non-thrombogenic properties.  
One interesting option is bacterial cellulose (BC), whose unique properties (strength, good 
integration into host tissue and flexibility that allows production in various shapes and 
sizes) make it an exciting candidate for vascular graft material. The most abundant 
biopolymer on earth, cellulose is insoluble in water and degradable by microbial enzymes. 
Several organisms such as plants, algae and bacteria can produce BC. Some members of the 
bacterial genus Acetobacter, especially Gluconacetobacter xylinum, synthesize and secrete 
cellulose extracellularly. The network structure of cellulose fibrils resembles that of collagen 
in the extracellular matrix (ECM). 
This chapter describes how BC interacts with human endothelial cells (EC) and blood. 
Specifically, we will evaluate whether surface modifications could promote adhesion of EC 
and also whether BC’s thrombogenic properties compare favorably with conventional graft 
materials. These properties are critical because materials intended as vascular grafts must 
satisfy many important features, including blood compatibility, cell interactions and 
mechanical properties. 
3. Tissue engineering of blood vessels 
Tissue engineering is a relatively new scientific discipline that combines cells, engineering 
and materials to improve or replace biological functions. Langer and Vacanti, two pioneers 
in the field, describe tissue engineering as an interdisciplinary area that applies the 
principles of engineering and life sciences to the development of biological substitutes that 
restore, maintain or improve tissue formation (Langer & Vacanti, 1993). 
The basic concept of tissue engineering includes a physical support (3D-scaffold) composed 
of synthetic polymers or natural materials (collagen, elastin or fibrin). This support mimicks 
ECM and initially serves as a scaffold or template on which cells can organize and mature in 
vitro prior to implantation at the appropriate location. 
Initial research in the mid-20th century focused on developing bioinert materials, eliciting a 
minimal host response characterized by passive blood transport and minimal interactions 
with blood and tissues. Although widely available, these industrial materials, including 
Teflon and silicone, were not developed specifically for medical applications. Later, the 
production of completely non-reactive substances became unrealistic. 
Today, other biomaterials are being developed to stimulate reactions between proteins and 
cells at the molecular level in a highly precise and controllable manner. The key concept 
underpinning development of such biomaterials is that the scaffold should contain chemical 
or structural information that mimicks cell-cell communication and controls tissue 
formation, such as growth factors, the adhesion peptide Arg–Gly–Asp (RGD) and other 
molecules that mimic ECM components. RGD is the minimal sequence in basement 
membrane proteins such as fibronectin, fibrinogen and von Willebrand Factor, all required 
for cell adhesion (Pierschbacher & Ruoslahti, 1984). 
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A successful tissue engineered blood vessel must: be biocompatible, i.e., noninflammatory, 
nontoxic, nonimmunogenic and noncarcinogenic; infection-resistant and  nonthrombogenic. 
It also must have appropriate mechanical properties, e.g., tensile strength, burst strength, 
good suture retention and compliance, and possess appropriate vasoactive physiological 
properties, including contraction or relaxation in response to neural or chemical stimuli and 
more. 
The feasibility of constructing and using tissue engineered blood vessels was first 
demonstrated in landmark studies by L’Heureux (L'Heureux et al., 1998) and Niklason 
(Niklason et al., 1999). The vessels, which were produced using different in vitro techniques, 
had very good mechanical properties and functioned well in experimental animals. 
Although in vitro and experimental techniques have been developed since then, no clinical 
implantations have been made until now. 
3.1 Biomaterials/biomaterial scaffolds 
Williams defines biomaterial as any natural or man-made material that comprises the whole 
or part of a living structure or biomedical device that performs, augments, or replaces a 
natural function (Williams, 1999). 
Many different materials have been investigated for biomaterial applications. They can be 
divided into natural materials, i.e., collagen (Weinberg & Bell, 1986; L'Heureux et al., 1998); 
fibrin (Cummings et al., 2004; Kumar & Krishnan, 2002); hyaluronic acid (Remuzzi et al., 
2004; Turner et al., 2004); silk fibroin (Zhang et al., 2009) and BC (Backdahl et al., 2006; 
Klemm et al., 2001; Bodin et al., 2007; Fink et al., 2010)) and synthetic polymers, i.e., 
polyglycolic acid (PGA) (Niklason et al., 1999; McKee et al., 2003), polyethylene 
terephthalate (PET) (Sharefkin et al., 1983; Herring et al., 1984) and ePTFE (Zilla et al., 1987; 
Meinhart et al., 2005). The required properties for biomaterials vary with cell type, 
implantation site and strategy for tissue formation. Common demands for all biomaterials 
include biocompatibility, e.g., avoiding foreign body reactions, capsule formation and 
chronic inflammatory reactions. Additionally, materials intended to be in contact with blood 
require evaluation for thrombogenicity. Mechanical properties are important and depend on 
the target tissue. Since biomaterials used as vascular grafts must withstand blood pressure, 
they must be investigated for burst pressure, compliance, suture strength and fatigue before 
using them as implants. 
A recent and popular approach involves electrospinning different materials to create 
nanofibre constructs. Both electrospun synthetic polymers and native ECM proteins have 
been used for cell seeding to construct vascular grafts (Hashi et al., 2007; Huang et al., 2001; 
Boland et al., 2004; Kenawy el et al., 2003). 
3.2 Materials for vascular grafts 
Jaboulay and Briau performed the first arterial transplantation in 1896, but imperfect 
anastomoses resulted in thrombosis (Jaboulay & Briau, 1896). Since then, more sophisticated 
techniques have been developed. The search for arterial vascular grafts began in 1952, when 
Voorhees discovered Vinyon N (nylon), the first fabric graft (Voorhees et al., 1952). A few 
years later, DeBakey discovered Dacron® in 1958 (Nose, 2008). Today, arterial and even 
especially venous autografts are used routinely in surgery, creating bypasses for patients 
with peripheral or coronary occlusive vascular diseases. However, autograft availability is 





2. What is the ideal vascular graft? 
Several issues demand consideration when constructing a vascular graft: the mechanical 
properties of the graft must resemble those of a native blood vessel, and the graft must be 
biocompatible with its host. One important factor is compliance, i.e., how well the vessel 
withstands pressure from the bloodstream and whether it can maintain systemic pressure in 
the vascular system. Vascular grafts should also be “invisible” to the immune system and 
possess non-thrombogenic properties.  
One interesting option is bacterial cellulose (BC), whose unique properties (strength, good 
integration into host tissue and flexibility that allows production in various shapes and 
sizes) make it an exciting candidate for vascular graft material. The most abundant 
biopolymer on earth, cellulose is insoluble in water and degradable by microbial enzymes. 
Several organisms such as plants, algae and bacteria can produce BC. Some members of the 
bacterial genus Acetobacter, especially Gluconacetobacter xylinum, synthesize and secrete 
cellulose extracellularly. The network structure of cellulose fibrils resembles that of collagen 
in the extracellular matrix (ECM). 
This chapter describes how BC interacts with human endothelial cells (EC) and blood. 
Specifically, we will evaluate whether surface modifications could promote adhesion of EC 
and also whether BC’s thrombogenic properties compare favorably with conventional graft 
materials. These properties are critical because materials intended as vascular grafts must 
satisfy many important features, including blood compatibility, cell interactions and 
mechanical properties. 
3. Tissue engineering of blood vessels 
Tissue engineering is a relatively new scientific discipline that combines cells, engineering 
and materials to improve or replace biological functions. Langer and Vacanti, two pioneers 
in the field, describe tissue engineering as an interdisciplinary area that applies the 
principles of engineering and life sciences to the development of biological substitutes that 
restore, maintain or improve tissue formation (Langer & Vacanti, 1993). 
The basic concept of tissue engineering includes a physical support (3D-scaffold) composed 
of synthetic polymers or natural materials (collagen, elastin or fibrin). This support mimicks 
ECM and initially serves as a scaffold or template on which cells can organize and mature in 
vitro prior to implantation at the appropriate location. 
Initial research in the mid-20th century focused on developing bioinert materials, eliciting a 
minimal host response characterized by passive blood transport and minimal interactions 
with blood and tissues. Although widely available, these industrial materials, including 
Teflon and silicone, were not developed specifically for medical applications. Later, the 
production of completely non-reactive substances became unrealistic. 
Today, other biomaterials are being developed to stimulate reactions between proteins and 
cells at the molecular level in a highly precise and controllable manner. The key concept 
underpinning development of such biomaterials is that the scaffold should contain chemical 
or structural information that mimicks cell-cell communication and controls tissue 
formation, such as growth factors, the adhesion peptide Arg–Gly–Asp (RGD) and other 
molecules that mimic ECM components. RGD is the minimal sequence in basement 
membrane proteins such as fibronectin, fibrinogen and von Willebrand Factor, all required 
for cell adhesion (Pierschbacher & Ruoslahti, 1984). 
Molecular Understanding of Endothelial Cell and Blood  
Interactions with Bacterial Cellulose: Novel Opportunities for Artificial Blood Vessels  
 
163 
A successful tissue engineered blood vessel must: be biocompatible, i.e., noninflammatory, 
nontoxic, nonimmunogenic and noncarcinogenic; infection-resistant and  nonthrombogenic. 
It also must have appropriate mechanical properties, e.g., tensile strength, burst strength, 
good suture retention and compliance, and possess appropriate vasoactive physiological 
properties, including contraction or relaxation in response to neural or chemical stimuli and 
more. 
The feasibility of constructing and using tissue engineered blood vessels was first 
demonstrated in landmark studies by L’Heureux (L'Heureux et al., 1998) and Niklason 
(Niklason et al., 1999). The vessels, which were produced using different in vitro techniques, 
had very good mechanical properties and functioned well in experimental animals. 
Although in vitro and experimental techniques have been developed since then, no clinical 
implantations have been made until now. 
3.1 Biomaterials/biomaterial scaffolds 
Williams defines biomaterial as any natural or man-made material that comprises the whole 
or part of a living structure or biomedical device that performs, augments, or replaces a 
natural function (Williams, 1999). 
Many different materials have been investigated for biomaterial applications. They can be 
divided into natural materials, i.e., collagen (Weinberg & Bell, 1986; L'Heureux et al., 1998); 
fibrin (Cummings et al., 2004; Kumar & Krishnan, 2002); hyaluronic acid (Remuzzi et al., 
2004; Turner et al., 2004); silk fibroin (Zhang et al., 2009) and BC (Backdahl et al., 2006; 
Klemm et al., 2001; Bodin et al., 2007; Fink et al., 2010)) and synthetic polymers, i.e., 
polyglycolic acid (PGA) (Niklason et al., 1999; McKee et al., 2003), polyethylene 
terephthalate (PET) (Sharefkin et al., 1983; Herring et al., 1984) and ePTFE (Zilla et al., 1987; 
Meinhart et al., 2005). The required properties for biomaterials vary with cell type, 
implantation site and strategy for tissue formation. Common demands for all biomaterials 
include biocompatibility, e.g., avoiding foreign body reactions, capsule formation and 
chronic inflammatory reactions. Additionally, materials intended to be in contact with blood 
require evaluation for thrombogenicity. Mechanical properties are important and depend on 
the target tissue. Since biomaterials used as vascular grafts must withstand blood pressure, 
they must be investigated for burst pressure, compliance, suture strength and fatigue before 
using them as implants. 
A recent and popular approach involves electrospinning different materials to create 
nanofibre constructs. Both electrospun synthetic polymers and native ECM proteins have 
been used for cell seeding to construct vascular grafts (Hashi et al., 2007; Huang et al., 2001; 
Boland et al., 2004; Kenawy el et al., 2003). 
3.2 Materials for vascular grafts 
Jaboulay and Briau performed the first arterial transplantation in 1896, but imperfect 
anastomoses resulted in thrombosis (Jaboulay & Briau, 1896). Since then, more sophisticated 
techniques have been developed. The search for arterial vascular grafts began in 1952, when 
Voorhees discovered Vinyon N (nylon), the first fabric graft (Voorhees et al., 1952). A few 
years later, DeBakey discovered Dacron® in 1958 (Nose, 2008). Today, arterial and even 
especially venous autografts are used routinely in surgery, creating bypasses for patients 
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Dacron® and ePTFE are still widely used as arterial replacements. Despite their success in 
replacing large diameter (>6 mm) high-flow vessels, these materials show thrombogenicity 
and compliance mismatch in low-flow or small-diameter vessels. Sophisticated techniques 
have been evaluated to enhance patency, including chemical modifications, coatings and 
seeding of the surface with different cells. In contrast to natural materials, synthetics often 
lack adhesion sites. Although passive materials can reproduce sufficient physiological 
mechanical strength, proper metabolic function and cellular signalling requires intact 
cellular machinery. 
BC is an attractive material for biomaterial applications. Its structure resembles that of 
collagen, the component in arteries and veins that gives the blood vessel its strength. BC’s 
manufacturing process allows versatility in shape and size, including tubes. Studies have 
shown successful growth of cardiac rat-derived myocytes and fibroblasts (Entcheva et al., 
2004), rat-derived hepatocytes (Kino et al., 1998; Yang et al., 1994) and osteoprogenitor cells 
(Takata et al., 2001) from mice on cellulose-based materials. However, these matrices are 
based not on natural cellulose but rather on derivatives such as cellulose acetate and 
regenerative cellulose. 
Although BC is biocompatible, it generally does not promote cell growth (Watanabe et al., 
1993a). Thus, BC must be modified to support EC adherence. Modification of wet state BC is 
challenging because fibre structure and strength must be maintained. This is especially 
important for vascular grafts, which must withstand blood pressure. 
4. Different approaches to engineered blood vessels  
4.1 Collagen-based blood vessel model  
Weinberg and colleagues developed a collagen-based blood vessel model (Weinberg et al., 
1986). Improvement of the construct’s mechanical properties is ongoing due to poor 
mechanical integrity. 
4.2 Cell self-assembly model  
The cell self-assembly model is made using intact layers of human vascular cells grown to 
overconfluence to form visible sheets of cells and ECM (L’Heureux et al., 1993, 1998).  
A sheet of smooth muscle cells (SMCs) is rolled around a mandrel to form the medial layer. 
Similarly, a sheet of fibroblasts is rolled over the SMC sheet media, forming an adventitial 
layer. Finally, ECs seeded onto the lumen of the matured vessel form a confluent monolayer. 
These constructs withstood more than 2000 mmHg pressure before bursting. 
4.3 Cell-seeded polymeric scaffold–hybrid graft  
This graft was developed by Niklason (Niklason et al., 1999). Vascular cells were seeded into a 
biodegradable scaffold (PGA) and cultured for 8 weeks under pulsatile radial stress (165 beats 
per minute and 5% radial strain). ECs seeded onto the lumen of the construct formed a 
confluent monolayer. Cultured under pulsatile conditions, the histological structure of the 
constructs resembled that of native arteries. Due to high collagen content, the constructs had a 
burst pressure greater than 2000 mmHg and they could contract. In vivo studies of tissue 
engineered blood vessels in Yucatan miniature pigs were promising. 
With degradable material such as PGA, it is critical to ensure adequate strength of ECM 
(collagen, elastin) produced by the vascular cells. Degradation products may be toxic to the 
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cells. Non-degradable scaffolds offer durable support, but tissue acceptance is mandatory. 
Ideally, the scaffold should be compliant, similar to native vessels.  
4.4 Acellularized construct  
A rolled small intestinal submucosa (SIS) has been used as a small diameter vascular graft. 
A cell-free, 100-µm-thick collagen layer derived from small intestine, SIS is compliant, 
making it an interesting candidate for vascular implantation and requiring investigation 
(Roeder et al., 1999, Huynh et al., 1999).  
4.5 Artificial artery generated in the peritoneal cavity 
In the peritoneal cavity, artificial arteries are generated on silastic tubes. The arteries are 
lined by nonthrombogenic, mesothelial (endothelial-like) cells. The feasibility of this 
approach in humans is a matter of debate. 
5. Bacterial synthesized cellulose as biomaterial 
Cellulose, the most abundant biopolymer on earth, is insoluble in water and degradable by 
microbial enzymes. Several organisms, e.g., plants, algae and bacteria can produce cellulose, 
and the bacteria Gluconacetobacter xylinum can synthesize and secret cellulose extracellularly 
(Brown et al., 1976). BC is composed of linear nanosized fibrils of D-glucose molecules (Ross 
et al., 1991). The network structure of cellulose fibrils resembles that of collagen in the ECM 
of native connective tissue (Fig. 1) (Backdahl et al., 2006). 
 
  
Fig. 1. SEM images of (A) collagen and (B) BC reprinted with permission from Backdahl et 
al., 2006. Copyright Elsevier 2006. 
Although BC is not a hydrogel in the true sense of the meaning, it is often referred to as 
such because of its high water content, insolubility in water and highly hydrophilic 
nature. Since BC consists of a highly entangled network of fibrils, it also provides strong 
mechanical properties that ensure the ability of tissue engineered blood vessels to 
withstand mechanical forces and prevent rupture. BC can be designed and shaped into 
three dimensional structures such as tubes or sheets (Backdahl et al., 2006). A major 
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engineered blood vessels in Yucatan miniature pigs were promising. 
With degradable material such as PGA, it is critical to ensure adequate strength of ECM 
(collagen, elastin) produced by the vascular cells. Degradation products may be toxic to the 
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completely free of biogenic compounds such as lignin, pectin and arabinan found in, e.g., 
plant cellulose. During the production process, it is also possible to modify several other 
properties including pore size, surface properties and layering of the material (Backdahl 
et al., 2008). 
BC is used in various areas including food matrix (nata de coco), dietary fibres, acoustic or 
filter membranes and ultra-strength paper. In addition, BC has been suggested as a potential 
material for tissue engineering in several areas, e.g., as scaffold for tissue engineering of 
cartilage, blood vessels (BASYC) and successful treatment of second and third degree 
burns, stomach ulcers and other situations that require a temporary skin substitute (Biofill, 
Gengiflex, XCell) or to recover periodontal tissue (Gengiflex) (Czaja et al., 2006; Svensson 
et al., 2005; Fontana et al., 1990). 
5.1 Structure and morphology 
Beginning with the water-soluble monosaccharide D-glucose, cellulose synthesis is 
produced extracellularly as pellicles at the air/liquid interface. Glucan chains of BC are 
extruded from several enzyme complexes and aggregated by van der Waals forces to form 
sub-fibrils, approximately 1.5 nm wide. BC sub-fibrils crystallise into microfibrils and then 
into bundles, which form a dense reticulated structure stabilized by hydrogen bonding. In 
culture medium, the bundles assemble into ribbons, forming a network of cellulose. This 
network of cellulose nanofibrils provides BC with high mechanical strength and a water 
retention capacity of about 99% (Iguchi et al., 2000). 
The macroscopic morphology of BC varies with different culture conditions. In static 
conditions, BC accumulates on the surface of nutrient-rich culture medium, at the oxygen-
rich air-liquid interface. Statically cultured BC has lower crystallinity than BC fermented 
during agitation. 
Our molecular studies on EC-blood interactions with BC used BC synthesized by 
Gluconacetobacter xylinum (ATCC 1700178, American Type Culture Collection). Cellulose 
tubes were grown in corn steep liquid media at 30C for 7 days. The cellulose was then 
purified by boiling, first in 0.1 M NaOH at 60C for 4h and then in Millipore water. 
Finally, the cellulose was sterilised by autoclaving for 20 minutes. Due to the production 
process, BC consists of two distinctly different layers: one side has a compact network of 
fibrils with few if any pores, and the other side has a porous network structure. A density 
gradient arises between the sides. 
5.2 Mechanical properties 
The optimal scaffold is a biocompatible biomaterial that provides proper mechanical and 
physical properties, thus promoting cell adhesion and tissue formation. Prior to 
implantation into animals, BC tubes undergo extensive mechanical testing (burst strength, 
compliance and tensile strength). Films or sheets of BC show remarkable mechanical 
strength, due to high crystallinity, high planar orientation of the ribbons, ultrafine structure 
and a complex network (Iguchi et al., 2000). The mechanical properties of BC tubes are 
similar to those of pig carotid arteries (Backdahl et al., 2006). BC’s compliance curve 
resembles that of a native artery more than any other synthetic material on the market, 
which is advantageous. Material density can be altered by varying the culture conditions or 
by post-culture modifications. 
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Integration of a material with the host tissue is essential for the success of tissue engineered 
blood vessels. According to Williams, the biocompatibility of a material is defined as “the 
ability of a material to perform with an appropriate host response in a specific application” 
(Williams, 1999). Therefore, an appropriate host response would involve a biomaterial that 
induces a very low inflammatory and foreign body response in the host tissue. 
A study by Helenius et al. showed that BC is well integrated into the host tissue and does 
not induce inflammatory or foreign body responses (Helenius et al., 2006). They implanted 
BC pieces subcutaneously in rats and explanted them after 1, 4 and 12 weeks. Incorporation 
of the implant in the host tissue made it difficult to distinguish a clear interface between the 
implant and the host tissue (Helenius et al., 2006). These results are supported by another in 
vivo study, where BC tubes were implanted into the carotid arteries in pigs (Wippermann et 
al., 2009). Therefore, BC clearly has good biocompatibility and shows promising potential as 
scaffold material. 
5.4 Surface modification  
One challenge in the field of vascular grafts involves promoting EC attachment and 
spreading, since many biomaterials similar to BC exhibit limited support for cellular 
adhesion (Watanabe et al., 1993b). Over the years, many strategies have been developed to 
modify material surfaces.  
To optimize cell-biomaterial interactions, manufacturers coat synthetic scaffolds with cell 
adhesive proteins such as collagen, fibronectin or laminin (Seeger & Klingman, 1988; 
Kaehler et al., 1989). However, varying protein composition results in a biofilm with passive 
protein adsorption, and that composition can modify over time (Vroman, 1987). 
Additionally, protein adsorption to BC is very low.  
Much attention has focused on cell adhesion peptide RGD and its derivatives as possible 
alternative for stimulating reproducible and predictable cell adhesion (D'Souza et al., 1991; 
Hersel et al., 2003; Walluscheck et al., 1996; Gabriel et al., 2006). Most RGD modifications occur 
via covalent binding to the material (Massia & Hubbell, 1990). Although cellulose contains 
reactive hydroxyl groups that can be chemically modified, these very same hydroxyl groups 
participate in hydrogen bonding, which holds the cellulose fibre network together. Disruption 
of these bonds associates with loss of fibre ultrastructure (Sassi & Chanzy, 1995; Sassi et al., 
2000). Dry films of BC have been modified with carboxymethyl and acetyl groups (Kim et al., 
2002). However, surface modifications to wet state BC remain incompletely understood. Thus, 
modification of a BC hydrogel is especially challenging, since solvent exchange and cellulose 
modification typically destroy the hydrogel morphology. 
Modification of a BC hydrogel is especially challenging because solvent exchange and 
cellulose modification typically destroy hydrogel morphology. Thus far, most modifications 
have been performed on dried BC. Consequently, a new method is needed to increase cell 
attachment without altering the structure of the BC network. 
5.4.1 Xyloglucan 
Xyloglucan (XG), the most abundant hemicellulose, is present in the primary wall of many 
plants. In contrast to cellulose, XG is water-soluble and interacts strongly with cellulose fibres 
(Hanus & Mazeau, 2006). We have taken advantage of these properties, which provide an 
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BC and cotton linters, as reference material, were modified with XG and XG bearing a GRGDS 
pentapeptide (Bodin et al., 2007). Compared with organic solvents, modification in the water 
phase was clearly advantageous for preserving the morphology, as observed with SEM (Fig. 2). 
XG adsorption increased the wettability only to a minor extent, possibly explaining the 
decreased or undetectable adsorption of adhesive proteins shown by QCM-D. QCM-D studies 
further revealed that fibrinogen antibodies do not bind to BC, leading to the conclusion that 
cell enhancement would result from the presence of RGD epitopes, not from unspecific protein 
adsorption, e.g., fibronectin, from the cell culture medium. XG also enhances hepatocyte 
adhesion (Seo et al., 2004), and modification of BC with XG does not adversely affect ECs. 
5.4.1.1 Increased cell spreading and adhesion on XGD-modified BC 
XG-RGD-modification increased cell adhesion by 20%, and also increased the metabolism of 
seeded ECs as compared with unmodified BC. In contrast, the proliferation rate was less 
affected, presumably due to biological variation between cell donors. Our results (Fink et al., 
2011a) concur with studies on RGD-grafted regenerated cellulose, which showed that an 
adhesion peptide enhances adhesion by approximately 20% (Bartouilh de Taillac et al., 
2004). Another study showed that cellulose binding proteins bound to different adhesion 
peptides improve adhesion and spreading of human microvascular cells to cellulose 
(Andrade et al., 2010). In our study, the absence of serum negatively influenced cell 
adhesion on unmodified BC but did not act similarly in modified BC, further indicating that 
increased adhesion is peptide specific. 
 
 
Fig. 2. SEM micrograph of BC morphology of (A) cotton linter, (B) unmodified BC, (C) XG-
RGD modified BC and (D) acetone treated BC. Reprinted with permission from Bodin et al., 
2007. Copyright American Chemical Society 2007. 
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Initial cell attachment is crucial to subsequent behaviour such as spreading, proliferation 
and cell differentiation on substrates. The extent of cell spreading is an important parameter 
for the biocompatibility of materials. EC adhesion to the ECM proteins is normally followed 
by cell spreading, a process in which cells reorganize the f-actin cytoskeleton, resulting in 
flattening and spreading of the cell. These polymerised actin filaments attach the cells to the 
substrate via focal adhesions. Cells grown on RGD-modified BC spread out, displaying a 
well-organized actin cytoskeleton with prominent f-actin fibres. They also grow in clusters, 
which we believe is a step towards achieving a confluent monolayer.  
6. Endothelial cells as cellular source for graft lining 
The endothelium is composed of a monolayer of squamous epithelial cells that line the 
inside of blood vessels in a confluent layer, with a total area of 350-1000 m2 and a weight of 
0.5-1.5 kg (Pries et al., 2000; Jaffe, 1987). The morphology of these cells is flat, resembling a 
cobblestone pattern. This morphology is essential to maintaining good blood flow without 
turbulence. ECs function not only as a physiological barrier, separating the blood from 
surrounding tissues, but also as a dynamic layer of cells that displays antithrombotic 
properties in its resting state. This is achieved by physically preventing elements in the 
blood from contacting prothrombotic elements in the subendothelium and by active 
synthesis of various mediators. Endothelial functions help maintain blood vessel function. 
The endothelium upholds delicate balances in the vasculature, i.e., 
vasoconstriction/vasodilatation, anticoagulant/procoagulant properties, blood cell 
adherence/nonadherence and growth promotion/inhibition. It regulates vascular tone, 
maintains hemostasis, controls vascular structure and mediates inflammatory and 
immunological responses. 
The endothelium responds to inflammatory conditions by regulating its own permeability 
and releasing a variety of substances. It mediates inflammation with pro-inflammatory 
mediators including cytokines such as the interleukins (IL) (e.g., IL-1, IL-6, IL-8), platelet-
activating factor (PAF) and also by expressing endothelial cell leukocyte adhesion molecule-
1 (ELAM-1) and intercellular adhesion molecule 1 (ICAM-1), inflammatory mediators that 
control the interaction between EC and circulating blood cells and leukocytes, leading to 
extravasation of leukocytes. 
During an inflammatory response, adhesion molecule P-selectin is expressed on ECs after 
exposure to leukotrine B4 or histamine, which are produced by mast cells. Tumor necrosis 
factor alpha (TNF-) and lipopolysaccharides (LPS) induce P-selectin expression and the 
synthesis of E-selectin, another selectin that appears a few hours after the inflammatory 
process begins. Because the interactions between these selectins and their corresponding 
glycoprotein ligands (sialyl-Lewisx moiety) on leukocytes are relatively weak and reversible, 
leukocytes are unable to attach firmly to the endothelium. Instead, they “roll” along the 
surface of the vessel wall. The interactions are enhanced as other integrins are induced on 
the endothelium.  
Leukocyte integrins LFA-1 and Mac-1 normally adhere only weakly to leukocytes. On the 
other hand, IL-8 and other chemokines bound to the endothelial surface trigger a 
conformational change in LFA-1 and Mac-1 on the rolling leukocytes, increasing 
adhesiveness and consequently firmly anchoring the leukocytes to the endothelium. Rolling 
is arrested and the leukocytes squeeze between the ECs into the subendothelial tissue, a 
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6.1 Angiogenesis and vessel remodeling 
ECs regulate vessel structure by producing both growth promoting and growth inhibiting 
factors. SMC growth is stimulated by platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), transforming growth factor alpha (TGF-), endothelin and angiotensin 
II. Growth is inhibited by nitric oxide (NO), prostacylin (PGI2), some FGFs, insulin-like 
growth factor 1 (IGF-1) and thrombospondin.  
Angiogenesis is regulated by a variety of growth factors. Hypoxia and inflammatory 
cytokines such as FGF increase vascular endothelial growth factor-A (VEGF-A) levels 
through autocrine and paracrine mechanisms. VEGF-A, an endothelial-specific growth 
factor that consists of a heparin-binding homodimer, is a major regulator of EC function 
and angiogenesis. VEGF-A activates several EC functions, e.g., proliferation, migration 
and NO-release, processes that participate importantly in new blood vessel formation. 
VEGF-A also increases vessel wall permeability. Both VEGF and FGF induce EC 
production of proteases such as matrix metalloproteinases (MMPs) and plasminogen 
activator (PA). At least twenty MMPs participate in angiogenesis (Kroll & Waltenberger, 
2000; Lamalice et al., 2007). 
Proteases digest the basement membrane, allowing ECs to invade surrounding tissue, where 
they proliferate and migrate to form a sprout. The sprout elongates and the ECs differentiate 
to form a lumen. ECs in the newly formed vessel produce PDGF-BB, which attracts mural 
cells (pericytes to capillaries/SMC to larger arteries and veins) and stabilises the vessel. 
Expressed on ECs, heparin sulphate proteoglycans and their glycosaminoglycans (GAG) 
side-chains play an important role in angiogenesis because they bind circulating growth 
factors like VEGF (Kroll & Waltenberger, 2000). 
6.2 Regulation of vascular tone 
ECs regulate vessel tone and, consequently, local blood flow by managing the 
communication between the blood and the underlying SMCs, and by releasing substances 
that influence SMCs to relax or contract. In addition, ECs synthesise both vasodilating and 
vasoconstricting agents. 
Vasodilatation is mediated through PGI2 and (NO/endothelium-derived relaxing factor 
(EDRF) and endothelium-derived hyperpolarizing factor (EDHF), where NO plays a central 
role. Vasoconstricting agents released by ECs include endothelin, angiotensin II and 
thromboxane A2 (TXA2). 
Shear stress, bradykinin, thrombin, serotonin and various drugs stimulate ECs to release 
prostacyklin, thus stimulating adenylate cyclase, which increases cyclic adenosine 
monophosphate (cAMP) in SMCs. NO is synthesized from L-arginine by NO synthase and 
diffuses to SMCs, where it activates guanylate cyclase to produce cyclic guanosine 
monophosphate (cGMP). This leads to decreased intracellular calcium and muscle 
relaxation. Sensing mechanical changes in the environment, f-actin mediates mechanical 
induction of NO, leading to signal transduction into the cell.  
The eNOS gene contains a shear stress regulatory element (SSRE) that increases or decreases 
eNOS activity (Balligand et al., 2009). Acetylcholine stimulation of M1 muscarinic receptors 
releases endothelium-derived hyperpolarizing factor (EDHF), changing membrane potential 
(Pagliaro et al., 2000). Endothelin consists of three isoforms, ET-1, ET-2 and ET-3. ECs 
produce endothelin-1, the most potent mediator of vasoconstriction. Two endothelin 
receptors are found in the vasculature: ETA on SMCs and ETB on ECs. Binding of endothelin-
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1 to the ETA-receptor results in signal transduction and smooth muscle relaxation. On the 
other hand, activation of ETB on ECs stimulates NO and PGI2 production. In contrast, 
angotensin II is a much weaker vasoconstrictor. Renin cleaves angiotensinogen to 
angiotensin I, which is then converted to angiotensin by endothelial angiotensin-converting 
enzyme (ACE) (Nordt & Bode, 2000). 
7. Blood compatibility of biomaterials is a challenge 
A nonthrombogenic surface is the key to a successful vascular graft. Non-thrombogenicity 
can be achieved by various surface modifications. Since ECs could provide a 
nonthrombogenic surface, intense investigation has focussed on endothelialisation in this 
context. In our studies, we used ECs passage 4 from non-diseased human saphenous veins, 
by-products of coronary bypass surgery.  
The thrombogenicity of a biomaterial is an essential factor for any material that will be in 
contact with blood. Although the thrombogenic property of cellulose has been extensively 
researched as it has been used for haemodialysis membranes (Fushimi et al., 1998; Mao et 
al., 2004), the thrombogenicity of BC remains undetermined because it is a relatively new 
material for vessel grafts. Therefore, one of our studies focussed on delineating the blood 
compatibility of BC in comparison with ePTFE and PET vascular grafts, which are both used 
clinically as graft material (Fink et al., 2011b). 
The endothelium’s most important function in relation to biomaterials is hemostatic control. 
Under normal physiological conditions, ECs express thrombo-resistant molecules, but they 
must be able to switch to a procoagulant state upon injury to initiate coagulation and clot 
formation. Since blood is transported under high pressure, minimization of blood loss 
requires a rapid response. Some molecules are continuously secreted by ECs while others 
are only produced upon stimulation. Molecules can be expressed on the surface or secreted 
into the blood stream. The different endothelial anti- and procoagulant factors are discussed 
below in their biological context. 
7.1 Primary hemostasis – Platelet adhesion, activation and aggregation 
Prostacylin I2 (PGI2), nitric oxide (NO) and adenosine diphosphatase (ADPase) suppress 
platelet activation, aggregation and platelet-wall-interaction. Both NO and PGI2 are 
secreted and act in a paracrine manner, whereas ADPase is expressed on the EC surface. 
Platelet inhibition by PGI2 is mediated through a guanosine nucleotide binding receptor. 
This receptor-mediated signal transduction increases cAMP levels and inhibits platelet 
activation and the release of proaggregatory compounds such as TXA2 (Moncada, 1982). 
PGI2 production is stimulated by diverse agonists such as thrombin, histamine and 
bradykinin, and synthesised via arachidonic acid (AA) and prostaglandin (PGG2) (Wu, 
1995).  
ECs produce EDRFs, which are responsible for acetylcholine-induced vasorelaxation. The 
most important EDRF is NO, which synthesises nitric oxide synthase (NOS) by converting 
L-arginine. NO is a small molecule, so it diffuses easily. When NO enters platelets, it inhibits 
their adhesion and activation via guanylyl cyclise (Radomski et al., 1987c). PGI2 and NO 
have synergistic effects on inhibition of platelet adhesion, activation and aggregation and 
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7.2 Secondary hemostasis – Coagulation 
The endothelium physically separates coagulation factor VIIa from tissue factor (TF) and 
prevents platelet exposure to collagen and von Willebrandt factor (vWF) (Fig. 3). 
Thrombomodulin (TM) is expressed on the surface of ECs. Thrombin binds to TM, thereby 
undergoing a conformational change that results in enhanced affinity for protein C. 
Thrombin is the only enzyme capable of activating protein C. Activated protein C cleaves 
and inactivates clotting factors Va and VIIIa (Esmon, 1993). The thrombin-TM complex, 
effectively removes thrombin from the blood and internalises it, leading to its degradation. 
The TM molecule can also bind FXa, thus inhibiting prothrombin activation (Thompson & 
Salem, 1986). Protein S, also synthesised by ECs, binds to the endothelial surface and protein 
Ca to form a complex, thus enhancing FVa and FVIIIa inhibition (Fig.  3).  
The endothelium expresses heparin sulphate proteoglycans with anticoagulant activity on 
its surface. Heparin is a cofactor for antithrombin III, a plasma protein present that can 
inhibit thrombin, IXa, FXa and XIIa. The complex binding of thrombin to antithrombin III 
occurs slowly. This process is accelerated by the interaction with heparin, which has many 
binding sites for antithrombin, and serves to localise and increase its activity more than a 
thousand-fold. The β-isoform of antithrombin is more highly effective than the -isoform. 
Moreover, the -isoformis effectively inhibits thrombin-induced SMC proliferation 
(Swedenborg, 1998). Synthesised in the liver and also by ECs, tissue factor pathway inhibitor 




Fig. 3. Schematic illustration of the regulation of coagulation by ECs. 
7.2.1 Procoagulation factor 
The endothelium also participates importantly in the initiation of coagulation, which arrests 
bleeding. It expresses a variety of procoagulant factors, including vWF, coagulation factors 
V and VII, TF and high molecular weight kininogen (HMWK). 
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ECs synthesise vWF, a platelet adhesion molecule that secretes following stimulation by 
thrombin, and stores it in vesicles (Weibel-Palade bodies). vWF possesses binding sites for 
coagulation factor VIII, collagen (exposed after injury) and platelets (GPIb- XI-V), and acts 
as a bridging molecule in platelet aggregation and activation (Ruggeri, 1994). Importantly, 
the absence of vWF leads to severe bleeding disorders. 
ECs also secrete TF, which is found mainly in the subendothelium at sites not normally 
exposed to the bloodstream. The basal production of TF is low in comparison with the 
underlying SMCs and fibroblasts, but it can increase 10- to 40-fold upon stimulation. In 
addition, ECs have binding sites for factor VII, IX, IXa, X and Xa. Binding to factor IXa 
inhibits EC decay in the presence of factors VIII and X, which provide an additional 
feedback mechanism for cell-bound procoagulant activity (Jaffe, 1987; Vane et al., 1990). 
7.2.2 Fibrinolysis 
The endothelium also helps regulated fibrinolysis (Fig. 3). The degradation of fibrin requires 
plasmin. Plasminogen binds to the cell surface and facilitates plasmin conversion by two 
PAs, tissue type plasminogen activator (tPA) and urokinase (uPA) (van Hinsbergh). 
Physiologically, the most important PA in vascular fibrinolysis is tPA. Indeed, tPA enhances 
the conversion of plasminogen 100-fold when it binds to fibrin. The release of tPA is either 
constitutively or pathway-mediated. Thrombin, FVa, bradykinin, PAF and shear stress all 
induce the synthesis and release of tPA from ECs (Emeis, 1992; Giles et al., 1990; Brown et 
al., 1999). When tPA binds to the EC surface, it is protected from degradation by the two PA 
inhibitors (PAI), PAI-1 and PAI-2, which are also released by ECs. PAI-1 requires 
vitronectin, present in ECM, to maintain its activity; it is the main inhibitor to tPA. 
Recombinant t-PA (rt-PA) is the most frequently used substance for inducing thrombolysis 
by pharmacological means (Noble et al., 1995; Bennett et al., 1991). 
7.2.3 Biomaterial-induced coagulation 
Evaluation of coagulation induced by biomaterials is mostly studied in terms of platelet 
adhesion, partial thromboplastin time (PTT), protein adsorption by QCM-D or ellipsometry 
(Liu et al., 2009; Mao et al., 2004;van Oeveren et al., 2002; Keuren et al., 2003). The QCM-D 
method is surface-sensitive, but the distance from the surface to where measurement is 
possible is limited. Currently, it is not possible to attach BC to quartz crystals. Therefore, 
cellulose other than BC must be used. However, this material could be used for QCM-D 
measurements as a model surface, complementing other studies. Because ellipsometry is an 
optical method, it is not possible to use native BC for this assay either. Automated calibrated 
thrombin generation is very sensitive and has become a widespread method for quantitative 
analysis of coagulation kinetics in blood plasma (van Oeveren et al., 2002; Gerotziafas et al., 
2005; Hemker et al., 2003). Thrombin generation is also considered the most sensitive 
method to assay thrombogenicity. 
Since BC is used in a wet state, finding appropriate analysis techniques has been challenging. 
To our knowledge, ours is the first study to investigate the thrombogenic properties of BC 
compared with other graft materials (Fink et al., 2011b). We also developed a modified 
automated calibrated thrombin generation assay (Fink et al., 2010). This makes it possible to 
follow thrombin generation, in the presence of a material, in real time rather than using an 
endpoint assay. Our assay has led to new insights into the kinetics of thrombin generation 
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Most methods that study the coagulation process measure coagulation in the bulk without 
regards to where it began or the kinetics describing the propagation from the initiation 
point. Our method (Fink et al., 2011b) makes it possible to visualize the exact initiation point 
of coagulation and determine how coagulation propagates (Kantlehner et al., 2000). The 
captured images are used to calculate the coagulation time of the plasma at the surface 
(surface coagulation time) and into the bulk (propagation). Such factors are highly relevant 
to the study of material interactions with blood. 
 
 
Fig. 4. Thrombogram generated from thrombin generation assay displaying lagtime, time to 
peak (ttPeak), peak and endogenous thrombin potential (ETP). 
We measured the levels of thrombin and factor XIIa using calibrated automated 
thrombography, which displays the concentration of thrombin and factor XIIa, respectively, 
in clotting plasma with or without platelets (platelet-rich plasma/platelet-free plasma, 
PRP/PFP). The splitting of a fluorogenic substrate is monitored for either thrombin or factor 
XIIa and compared with a known thrombin or factor XIIa activity, respectively, in a parallel 
non-clotting sample. To evaluate thrombin and factor XIIa generation exclusively induced 
by the biomaterial surfaces, we fixed material samples with heparinised O-rings and 
analysed them by calculating the average rate of fluorescence increase over a period of 60 
min. 
7.2.3.1 Biomaterial induced coagulation of biological cellulose 
We compared biomaterial-induced coagulation of BC with clinically used graft materials, 
i.e., ePTFE and PET. In addition, we visualised coagulation propagation at the material 
surfaces and into the plasma bulk.  
Thrombin generation experiments revealed dramatic differences between the tested 
materials (Fink et al., 2010). Both ePTFE and BC generate longer lagtimes and time to Peak 
(ttPeak) values than PET (Fig. 4). Furthermore, BC generates the lowest ‘Peak’, indicating a 
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slower coagulation process at the surface. These results are also supported by the 
measurements of factor XIIa generation and analysis of surface coagulation times, where BC 
had the lowest FIIa generation and slowest propagation of coagulation into the bulk (Fig. 5). 
Compared with PET, thrombin generation in the whole blood Chandler-Loop system 
depicted the same response, yielding decreased accumulation of thrombin-antithrombin III 
complex (TAT) on both BC and ePTFE. Since the measurements are performed after one 
hour and not continuously, the difference in coagulation speed cannot be observed. On the 
other hand, this assay is performed in whole blood during flow conditions that more closely 
resemble an in vivo situation compared to measurements in platelet-free plasma during 
static conditions. It is interesting and promising that these two systems show similar results.  
 
 
Fig. 5. Representative time-lapse images from a comparative experiment in the imaging of 
coagulation setup. Graft material samples are attached along the left wall in the images. The 
colour represents the density of the formed fibrin network (Courtesy of Lars Faxälv, PhD). 
Hypothetically, the slower coagulation process on BC (Fig. 5) could be an advantage when 
blood contacts biomaterial applications, because it would provide time for the blood flow to 
divert and dilute activated coagulation products. The whole blood model also shows that 4 
mm BC tubes perform well regarding anti-thrombogenic properties and perform better 
compared with ePTFE than 6 mm tubes. Measurements of thrombin generation correlate 
very well with the XIIa generation assay and visualisation of propagation. Together these 
methods potentially could provide fast screening methods for evaluating the 
thrombogenicity of biomaterials.  
The amount of TAT generated depends on blood velocity (e.g., shear rate) in the loop 
system. Higher velocities associate with increased TAT generation. Shear rates are higher in 
the 4 mm loop system compared with the 6 mm system, and the narrower material also 
exhibits greater coagulation activation. Interestingly, however, platelet consumption does 
not increase, suggesting platelet activation. The amount of TAT generated on ePTFE 
increased 18-fold on 4 mm tubes as compared with 6 mm tubes, but we detected only a 3-
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compared with ePTFE than 6 mm tubes. Measurements of thrombin generation correlate 
very well with the XIIa generation assay and visualisation of propagation. Together these 
methods potentially could provide fast screening methods for evaluating the 
thrombogenicity of biomaterials.  
The amount of TAT generated depends on blood velocity (e.g., shear rate) in the loop 
system. Higher velocities associate with increased TAT generation. Shear rates are higher in 
the 4 mm loop system compared with the 6 mm system, and the narrower material also 
exhibits greater coagulation activation. Interestingly, however, platelet consumption does 
not increase, suggesting platelet activation. The amount of TAT generated on ePTFE 
increased 18-fold on 4 mm tubes as compared with 6 mm tubes, but we detected only a 3-





consumption of BC is remarkably low, especially compared with heparinised polyvinyl 
chloride (PVC), which is known to have low thrombogenic properties (Johnell et al., 2005). 
In addition, cellulose showed no visible sign of clotting following one hour of incubation 
with whole blood containing only small amounts of soluble heparin. 
7.3 Complement system  
The immune complement system (CS) is part of the innate immune system. Its main task is 
to protect the body from pathogenic agents like bacteria, viruses and fungi. On contact with 
a foreign surface, e.g., a bacterial surface, the CS activates in a cascade that either destroys 
the bacterial surface or releases bioactive degradation products, or both, causing 
inflammatory reactions in the surrounding tissue.  
Consisting of more than 30 different cell-bound and soluble proteins that circulate as 
inactive zymogens under nonpathological conditions, the immune CS is present in blood 
and serum. Its most important factor is complement factor 3 (C3). Cleavage of C3 by C3 
convertase creates C3a and C3b, causing a cascade of further cleavage and activation events. 
Three different pathways lead to the creation of C3 convertase: the classical pathway, the 
alternative pathway and the mannose-binding lectin pathway. The classical complement 
pathway typically requires antibodies for activation, whereas the alternative and lectin 
pathways can be activated by C3 hydrolysis or antigens without the presence of antibody. 
7.3.1 Classical pathway 
Classical convertase is initiated when antibodies bind to a surface such as a bacterium. 
When factor C1 binds to an antibody, it cleaves is cleaved and binds to additional factors  
forming the classical convertase (C4b2a) (Kinoshita, 1991). 
7.3.2 Alternative pathway 
The alternative pathway is triggered by either spontaneous C3 hydrolysis, which forms C3a 
and C3b, or covalent binding of C3b from the classical and lectin pathways to a surface. The 
C3b molecule is capable of covalently binding to a pathogenic membrane surface in its 
vicinity. If there is no pathogen in the blood, the C3a and C3b protein fragments will 
deactivate when they rejoin with each other. Upon binding with a cellular membrane, C3b is 
binds to factor Ba and P, forming the alternative pathway C3-convertase (C3bBbP). A 
characteristic feature of the alternative pathway is a feedback mechanism that leads to 
accelerated C3 activation. Such mechanisms are not present in the classical pathway 
(Medicus et al., 1976; Rother et al., 1998). 
7.3.3 Mannose-binding lectin pathway 
A variant of the classical pathway, the Mannose-binding lectin pathway does not require 
antibodies. Activation of this pathway occurs when mannose-binding lectin (MBL) binds to 
mannose residues on the pathogen surface. Subsequently, the MBL complex can split C4 
and C2, generating  C3-convertase, as in the classical pathway (Petersen et al., 2001). This 
pathway will not be discussed further in this chapter. 
The convertases from both the classical and alternative pathways cleave C5 into C5a and 
C5b. The C5b molecule associates with C6, C7, C8, and C9, forming the C5b-9 membrane 
attack complex (MAC), which is inserted into the cell membrane and initiates cell lysis. The 
C5b-9, also called the terminal complement complex (TCC), may exist as a soluble active 
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form denoted sC5b-9. This soluble form can be measured to assess complement activation .  
The C5a and C3a fragments are anaphylatoxins that participate in the recruitment of 
inflammatory cells and trigger mast cell degranulation. Therefore, these anaphylatoxins 
participate in many forms of acute and chronic inflammation including sepsis (Guo et al., 
2004; Ward, 2008). 
7.3.4 Complement activation 
Extracorporal treatments such as haemodialysis and cardiopulmonary bypass activate the 
CS. Contact between blood and biomaterials may generate degradation fragments of 
complement C3a and C5a and soluble C5b-9. These fragments result in chemotaxis of 
leukocytes, cytokine release and generation of prostaglandins, resulting in a life-threatening 
condition termed “whole body” inflammation. Biomaterial induced CS is activated by both 
the classical and alternative pathways (Nilsson et al., 2007).  
The Chandler-Loop system was also used to assess CS activation. The complement 
activation parameters (C3a and C5b-9) were much higher for BC compared with the other 
materials, for both 4 and 6 mm tubes. Cellulose is known to induce complement activation 
in hemodialysis membranes (Frank et al., 2001). The mechanisms underlying these results 
for BC are still unclear and require further investigation. Bacterial fragments could still be 
present in the material. However, endotoxin values are well within the limit for 
cardiovascular devices. It is also possible that exposed hydroxyl groups induce 
complement activation through the alternative pathway (Arima et al., 2009; Toda et al., 
2008). The physiological significance in vivo of this complement activation remains 
undetermined. Interestingly, platelet activation is low even when complement activation 
is high. According to the literature, platelet consumption and complement activation are 
closely related (Fushimi et al., 1998; Hamad et al., 2008; Peerschke et al., 2006; 
Gyongyossy-Issa et al., 1994). 
8. What are the future therapeutic possibilities? 
This chapter has presented possible approaches to modifying BC that enhance EC growth in 
vitro. The XG method, an easy one-step procedure carried out in water, is an elegant 
technique for modifying BC to promote EC. Its advantage is the preservation of the fibre 
structure, thus maintaining its strength. The modification of BC with the XG technique is far 
from limited to the RGD peptide. Different peptide sequences or other active groups and 
growth factors could be attached to the XG molecule. Platelets could potentially adhere to 
exposed RGD peptides. Therefore, other peptides, more specific to ECs, or different 
combinations of peptides should be explored. 
Measurements of thrombin generation correlated well with the XIIa generation assay and 
visualisation of the propagation of coagulation. Together, these methods could offer 
potential fast screening methods for evaluating the thrombogenicity of biomaterials and 
future surface modifications. 
BC could be used for vascular grafts in two different approaches: (i) implantation as a 
tube without cells or (ii) seeding prior to implantation. The ideal BC modification would 
provide an initial nonthrombogenic surface and promote long-term endothelialisation. 
Future modifications of BC could include heparinisation or combinations of surface 
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chloride (PVC), which is known to have low thrombogenic properties (Johnell et al., 2005). 
In addition, cellulose showed no visible sign of clotting following one hour of incubation 
with whole blood containing only small amounts of soluble heparin. 
7.3 Complement system  
The immune complement system (CS) is part of the innate immune system. Its main task is 
to protect the body from pathogenic agents like bacteria, viruses and fungi. On contact with 
a foreign surface, e.g., a bacterial surface, the CS activates in a cascade that either destroys 
the bacterial surface or releases bioactive degradation products, or both, causing 
inflammatory reactions in the surrounding tissue.  
Consisting of more than 30 different cell-bound and soluble proteins that circulate as 
inactive zymogens under nonpathological conditions, the immune CS is present in blood 
and serum. Its most important factor is complement factor 3 (C3). Cleavage of C3 by C3 
convertase creates C3a and C3b, causing a cascade of further cleavage and activation events. 
Three different pathways lead to the creation of C3 convertase: the classical pathway, the 
alternative pathway and the mannose-binding lectin pathway. The classical complement 
pathway typically requires antibodies for activation, whereas the alternative and lectin 
pathways can be activated by C3 hydrolysis or antigens without the presence of antibody. 
7.3.1 Classical pathway 
Classical convertase is initiated when antibodies bind to a surface such as a bacterium. 
When factor C1 binds to an antibody, it cleaves is cleaved and binds to additional factors  
forming the classical convertase (C4b2a) (Kinoshita, 1991). 
7.3.2 Alternative pathway 
The alternative pathway is triggered by either spontaneous C3 hydrolysis, which forms C3a 
and C3b, or covalent binding of C3b from the classical and lectin pathways to a surface. The 
C3b molecule is capable of covalently binding to a pathogenic membrane surface in its 
vicinity. If there is no pathogen in the blood, the C3a and C3b protein fragments will 
deactivate when they rejoin with each other. Upon binding with a cellular membrane, C3b is 
binds to factor Ba and P, forming the alternative pathway C3-convertase (C3bBbP). A 
characteristic feature of the alternative pathway is a feedback mechanism that leads to 
accelerated C3 activation. Such mechanisms are not present in the classical pathway 
(Medicus et al., 1976; Rother et al., 1998). 
7.3.3 Mannose-binding lectin pathway 
A variant of the classical pathway, the Mannose-binding lectin pathway does not require 
antibodies. Activation of this pathway occurs when mannose-binding lectin (MBL) binds to 
mannose residues on the pathogen surface. Subsequently, the MBL complex can split C4 
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activation parameters (C3a and C5b-9) were much higher for BC compared with the other 
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for BC are still unclear and require further investigation. Bacterial fragments could still be 
present in the material. However, endotoxin values are well within the limit for 
cardiovascular devices. It is also possible that exposed hydroxyl groups induce 
complement activation through the alternative pathway (Arima et al., 2009; Toda et al., 
2008). The physiological significance in vivo of this complement activation remains 
undetermined. Interestingly, platelet activation is low even when complement activation 
is high. According to the literature, platelet consumption and complement activation are 
closely related (Fushimi et al., 1998; Hamad et al., 2008; Peerschke et al., 2006; 
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8. What are the future therapeutic possibilities? 
This chapter has presented possible approaches to modifying BC that enhance EC growth in 
vitro. The XG method, an easy one-step procedure carried out in water, is an elegant 
technique for modifying BC to promote EC. Its advantage is the preservation of the fibre 
structure, thus maintaining its strength. The modification of BC with the XG technique is far 
from limited to the RGD peptide. Different peptide sequences or other active groups and 
growth factors could be attached to the XG molecule. Platelets could potentially adhere to 
exposed RGD peptides. Therefore, other peptides, more specific to ECs, or different 
combinations of peptides should be explored. 
Measurements of thrombin generation correlated well with the XIIa generation assay and 
visualisation of the propagation of coagulation. Together, these methods could offer 
potential fast screening methods for evaluating the thrombogenicity of biomaterials and 
future surface modifications. 
BC could be used for vascular grafts in two different approaches: (i) implantation as a 
tube without cells or (ii) seeding prior to implantation. The ideal BC modification would 
provide an initial nonthrombogenic surface and promote long-term endothelialisation. 
Future modifications of BC could include heparinisation or combinations of surface 





agent that functions by binding antithrombin. In recent years, heparinised ePTFE grafts 
(Propaten®) have been developed (Losel-Sadee & Alefelder, 2009). Although encouraging 
outcomes for below-knee bypass are reported, the compliance mismatch of ePTFE grafts 
still remains. However, this is an exciting modification and preliminary studies on 
heparinised BC tubes show considerably lower amounts of thrombin on the hep-BC 
surface. 
Our studies show that modification of BC with the adhesion-promoting peptide RGD results 
in increased EC adhesion, metabolism and spreading. Furthermore, BC induces slower 
coagulation than clinically available materials such as Gore-Tex® and Dacron® and induces 
the least contact activation as evaluated by Factor XIIa generation. In addition, BC consumes 
low quantities of platelets and generates low thrombin values as compared with Dacron® 
and Gore-Tex®.  
9. Conclusion 
Our work demonstrates that it is possible to introduce an adhesion peptide to BC that 
enhances EC adhesion without altering the fibre network or mechanical properties. The anti-
thrombogenic properties of BC, especially 4 mm tubes, are promising as compared with 
conventional graft materials. Therefore, BC emerges as a promising, novel vascular graft 
material for small-caliber grafts. Molecular studies confirm that BC exhibits low 
thrombogenicity and extensive EC adhesion, which are beneficial when introducing 
artificial materials in vivo during by-pass surgery. Together with the modification methods 
presented in this chapter, BC has the potential to become a material for artificial vessels, 
thus underlining the importance of increasing molecular understanding of EC and BC 
interactions to create novel opportunities for artificial blood vessels.  
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1. Introduction 
In the 16th century, Leonardo Da Vinci had described “the narrowing of the passage of blood 
vessels, thickening of the coats of these vessels and hardening of arteries” in his work (Boon, 
2009). This is the first known documentation of atherosclerosis (AS). Today, our 
understanding of atherogenesis as a process of a chronic inflammatory disease has been 
greatly promoted by many theories, such as, the cellular cycle of cholesterol and 
hypercholesterolemia, dysfunction of endothelial cells, oxidized lipoproteins, discovery of 
scavenger receptors and response to injury theory, among others. The factors leading to the 
elucidation of atherogenesis are still not all known, since AS can persist silently 
(subclinically) without showing any serious symptoms for a longer period. That, together 
with the fact that AS is not limited to warm-blooded vertebrates and the occurrence of 
intimal thickening of coronary arteries in rabbitfish (Duran et al., 2010), as well as evidence 
of coronary AS in salmonids (Farrell, 2002), brings proof that AS is still a largely elusive, 
complicated and multi-component disease.  
AS is not a modern world disease as determined by recent images obtained from coronary 
arteries and the aorta of ancient mummies. Atheromatous lesions, as well as aortic AS were 
identified in an Aleutian mummy from Alaska originating from 400 AD (Zimmerman, 
1998). In 2009, images generated by computer tomography of vascular calcifications in 
examined Egyptian mummies found that 16 out of the 22 examined mummies had 
identifiable cardiovascular tissue, with definite AS present in 5 and AS found in additional 4 
mummies (together 56% of total) (Allam et al., 2009). This study was recently expanded to 
52 ancient Egyptian mummies from the Middle Kingdom to the Greco-Roman period and 
identified cardiovascular structures in 44 mummies, with 20 of these showing either definite 
AS (n=12, as defined by calcification within the wall of an identifiable artery) or probable AS 
(n=8, as defined by calcifications along the expected course of an artery) (Allam et al., 2011). 
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The calcifications were located in the aorta, as well as coronary, carotid, iliac, femoral and 
peripheral arteries. The 20 mummies with definite and probable AS were significantly older 
at time of death (mean age 45.1 ± 9.2 years) as compared to mummies that had 
cardiovascular tissue identified without AS (mean age 34.5 ± 11.8 years). Since social status 
(mummies were usually of higher status, than others in the population), diet (mainly 
wildlife and grains) and tobacco (not yet known) were not risk factors in the life of ancient 
Egyptians, they could not contribute to the development of AS in this population. Age, 
however has been re-affirmed with these studies, as one of the most important independent 
systemic risk factors for AS. 
2. Brief clinical characterization of the disease 
AS is a chronic, multifocal immunoinflammatory, fibroproliferative disease and is the most 
common form of arteriosclerosis. AS is a disease of the arterial wall, which often starts in 
young people. In middle-aged individuals, AS can start to appear in clinically recognizable 
forms, such as coronary artery disease (CAD), cerebral vascular or peripheral artery disease. 
It can affect all large and medium-sized arteries including the coronary, carotid, cerebral 
arteries, the aorta, its branches and main arteries of the extremities. Areas of non-laminar 
blood flow are highly susceptible to plaque formation.  
The clinical endpoints of AS may result as a consequence of several mechanisms, such as:  
1. artery-to-artery embolism of thrombus formed on an atherosclerotic plaque, 
2. atheroembolism of cholesterol crystals or other atheromatous debris, 
3. acute thrombotic occlusion resulting from plaque rupture, 
4. structural disintegration of the arterial wall resulting from dissection or subintimal 
hematoma, and 
5. reduced perfusion resulting from critical stenosis or occlusion caused by progressive 
plaque growth 
Ultrasound is one of the most commonly used noninvasive examinations for assessment of 
early and advanced atherosclerotic vascular changes, also of the carotid intima media 
thickness. However, ultrasound has limited diagnostic and prognostic value, and for pre-
operative procedures, arteriographies and other methods of the involved vessels are 
necessary. 
AS is considered to be the leading cause of death and loss of disability adjusted life-years 
worldwide, particularly in the developed countries, according to United States Statistical 
Update from 2011 (Roger et al., 2011). CAD accounted for  1 of every 6 deaths and stroke  
1 of 18 deaths in 2007. Recently, peripheral artery disease was reported to be present in 12% 
of United States citizens (Beers et al., 2006). 
3. Inflammation and the involvement of cells/molecules in atherosclerosis 
Inflammation contributes to the formation and progression of AS (Libby, 2002; Moubayed et 
al., 2007). Since AS represents a chronic inflammatory state, levels of C-reactive protein 
(CRP) are important, and were found to be an independent predictor of cardiovascular 
disease (CVD) (Fruchart et al., 2004), although other studies have not been able to confirm 
this (Kullo & Ballantyne, 2005). Serum amyloid A (SAA) has been reported to also play a 
role in atherosclerosis (King et al., 2011) which has been supported by animal models (Chait 
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endothelial cells, SAA was reported to induce the release of interleukin-6 (IL-6), IL-8 and 
stimulate the expression and release of soluble intercellular adhesion molecule (sICAM) and 
soluble vascular adhesion molecule (sVCAM), as well as E-selectin synthesis. The data 
indicated greater susceptibility of coronary artery endothelial cells (in comparison to human 
umbilical vein endothelial cells) to SAA (Lakota et al., 2007) which indicated the potential 
role of SAA in CAD. Studies for fibrinogen consistently link this factor, which is involved in 
both inflammation and thrombosis, with AS burden and risk of coronary heart disease 
(CHD) (Kullo & Ballantyne, 2005). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a 
novel biomarker of vascular-specific inflammation providing information about 
atherosclerotic plaque inflammation and stability. Elevated levels of serum Lp-PLA2 are 
indicative of rupture-prone plaques and a strong independent predictor of cardiovascular 
risk (Colley et al., 2011). Most recently, Herder et al. reported on biomarkers associated with 
prediction of incident coronary events (Herder, Karakas, et al., 2011). The group mentioned 
the following markers: IL-6, IL-8, IL-18, macrophage migration inhibitory factor (MIF), 
monocyte chemotactic protein-1, interferon-γ inducible protein-10, transforming growth 
factor-β1 (TGF-β1), sE-selectin and sICAM (Herder, Baumert, et al., 2011). The data showed 
that the combination of blood biomarkers could improve the prediction of cardiovascular 
outcome above the traditional ones used. 
Some infectious diseases represent an independent initiator of vascular inflammation which 
can contribute to atherogenesis and progression of AS. Bacteria and viruses can upregulate 
cytokines, chemokines and acute phase reactants, such as CRP and SAA, which lead to 
endothelial dysfunction. Overall, expression of Toll-like receptors in the atheroma, mouse 
model experiments and the role of genetic polymorphisms, all currently suggest microbe 
activation of inflammation in plaques and AS progression (Vallejo, 2011). Infection is also 
known to convert a lipidogenic profile into a pro-atherogenic one (Khovidhunkit et al., 
2000).  
Infections important in association with AS were shown in many studies and include the 
following infectious agents Herpes virus, C. pneumonie, P. gingivitis, H. pylori, among others 
(Kowalski et al., 2006; Ludewig et al., 2004; Ross, 1999). There was also presence of bacterial 
antigens reported in atheroma (Ott et al., 2006). The latter finding raises the question of single 
antigen importance versus total infectious burden in accelerating AS (Gabrielli et al., 2002).  
Presence of antibodies against infectious agents represent a risk factor for CVD. In terms of 
specific antigen involvement in AS, the following (among others) have been reported: H.pylori 
heat shock protein (HSP)-60 elicited antibodies can crossreact with endogenous molecules, 
stress-related endothelial HSP-60 and the presence of HSP-60-specific T lymphocytes in the 
circulation, may increase the risk of AS (Ayada et al., 2007). Occurrence of antiphospholipid 
antibodies after certain infections is also common and can lead to initial endothelial 
dysfunction (Altman, 2003). Latency and intracellular infection importance stays an open 
ended question (especially in C.pneumonie, Cytomegalovirus). Long term effects of infections on 
AS progression are unclear, however statistics show undoubtedly more cases of stroke and 
myocardial infarction in the first 3 days following an acute urinary/respiratory infection with 
declining numbers in following weeks (Graham et al., 2007).  
A unifying view of the pathophysiology of AS proposes that inflammation has a key role by 
transducing the effects of many known risk factors of the disease. Although the combined 
experimental and clinical evidence may convince some, the chicken and egg problem about 
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3.1 Initial injury 
Endothelial cells provide a physical barrier layer between the circulatory system and the 
intima, however the cells also actively synthesize molecules responsible for the maintenance 
of circulatory homeostasis and participate in plaque development. 
The initial process in the development of AS is isolated endothelium injury and subsequent 
endothelial activation followed by expression of different pro-inflammatory cytokines, 
chemokines and adhesive molecules resulting in monocyte attraction, the rolling mechanism 
and their migration into the tunica intima (Jan et al., 2010; Ross, 1999). Monocytes transform 
into macrophages, the activation of which leads to the hallmark of plaque development or 
foam cell formation. An important molecule in this process is oxidized low density 
lipoproteins (oxLDL), which originates from retained LDLs in the tunica intima. Molecules 
of oxLDL and their binding to scavanger receptors on macrophages stimulates the 
accumulation of lipids in the cells and the formation of foam cells (Hansson, 2005).  
When inflammatory cells (such as leukocytes, monocytes and macrophages) migrating into the 
intima, start to accumulate subendothelial lipid, particularly oxidized lipid, this exacerbates 
the initial, local inflammatory reaction and maintains activation of the overlying endothelium. 
This results in continued expression of adhesion molecules and pro-inflammatory cytokines 
and chemokines perpetuating cell activation. Normally, the endothelium shows anti-adhesive, 
anti-thrombotic and vasoregulatory properties. Thus, stress conditions, mechanical damage or 
patho-physiological stimulation can cause modified endothelial cell characteristics (Stoltz et 
al., 2007). Endothelial injury can be different based on the different original vascular beds the 
cells arise from. Their physiological roles in coagulation, hemodynamics and susceptibility to 
patho-physiological stimuli can also differ depending on the vascular bed origin and the 
influence of the microenviroment (Aird, 2007; Cines et al., 1998; Lacorre et al., 2004; Luu et al., 
2010; Yano et al., 2007). For example, differences in endothelial cell responses were described 
for activation with tumour necrosis factor  (TNF-) (Lehle et al., 2007; Methe et al., 2007; 
Viemann et al., 2006), SAA and IL-1β (Lakota et al., 2007; Lakota et al., 2009) and oxLDL (Deng 
et al., 2006). Recently, endothelial damage has been reported as being able to be repaired with 
endothelial progenitor cells (Bai et al., 2010).  
Endothelial cells seem to be involved prevalently in the earlier stages of atherogenesis, 
leading to initial vascular injury, as well as in later stages, when they detach in response to 
injury and enter the circulation. Circulating endothelial cells can be used as a marker of 
vascular injury. Their number increase is associated with CVD, as well as they can serve as 
an accurate predictor of major adverse events following myocardial infarction. They also 
inversely correlate with flow-mediated dilatation and positively correlate with markers of 
endothelial injury (such as von Willebrand factor, tissue plasminogen activator inhibitor, E-
selectin) and prothombotic state (tissue factor). They are rarely found in healthy individuals, 
but are increased and correlate with disease activity in different vasculitides, in systemic 
lupus erythematosus (SLE) and systemic sclerosis (SSc) (Boos et al., 2006). Interestingly, 
Mutin et al. showed increased circulating endothelial cells in acute myocardial infarction 
and unstable angina without increased levels of markers of activation (ICAM, VCAM, E- 
selectin) and no apoptosis (Mutin et al., 1999).  
3.2 Progression of atherosclerotic plaques 
Early atherosclerotic lesions called fatty streaks involve a growing extracellular lipid core 
within the atherosclerotic plaques. The next stage of atherosclerotic plaque formation 
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involves the proliferation and migration of smooth muscle cells into the tunica intima, 
accumulation of collagen and fibrous cap formation (Hansson, 2005; Libby, 2002). T 
lymphocytes with a prevailing Th1 response, together with smooth muscle cell proliferation 
and deposition of collagenous fibers contribute to the fibrous cap formation. Fibrosis and 
collagen accumulation have a patho-physiological parallel in other chronic inflammatory 
diseases such as rheumatoid arthritis (RA), cirrhosis and pulmonary fibrosis, among others, 
where monocytes and lymphocytes are also the active players. In later stages of AS plaque 
development, expression of proteases increases (i.e. matrix metalloproteinases (MMPs)) 
leading to degradation of collagen.  
During the development of AS plaques, monocyte-derived macrophages and T-
lymphocytes that invade evolving atherosclerotic lesions produce soluble inflammatory 
mediators (cytokines and chemokines) which are very important in the perpetuation of 
the disease. Certain cytokines and chemokines (i.e. IL-1, IL-12, IL-18, TNF- α, MIF, 
interferon-γ (IFN-γ) , and granulocyte macrophage colony stimulating factor (GM-CSF) 
have explicit pro-atherogenic characteristics, others (i.e. IL-10 and probably IL-5) have 
anti-atherogenic properties, while IL-4, IL-6, and GM-CSF can have both pro- or anti-
atherogenic properties. Several of the pro-atherogenic cytokines affect plasma cholesterol 
levels, indicating that inflammation and lipid metabolism are interlinked processes in AS 
(Kleemann et al., 2008).  
Fatty streaks do not necessarily progress into advanced lesions. Certainly the progression of 
plaques is not linear (Figure 1) and depends largely on the microenvironment. Plaques can 
be clinically silent for years. Almost all adolescent children may already show some 



























Fig. 1. Simplified putative scheme of progression/regression of atherosclerosis at the 
cellular and molecular levels. MI, myocardial infarction; CVI, cerebrovascular insult 
Clinical prognosis is determined by the biological nature of the atherosclerotic plaque. 
Atheroma with active inflammatory processes are most prone to ruptures (Libby, 2002; 
Ross, 1999) and inflammation largely accounts for progression of stable to unstable angina 
(J.T. Wu & L.L. Wu, 2005). Rupture prone/unstable plaques are the ones with a large lipid 
core, many inflammatory cells and a thin fibrous cap (Gziut & Gil, 2008; Krone & Muller-
Wieland, 1999). 
There are three typical types of cellular/molecular influences of plaque rupture, among 
others:  
a. desquamation of the endothelium (due to proinflammatory mediators, MMPs, T cells 
which attack the basal membrane of the endothelium) which uncovers the collagen and 
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accounts for ¼ of fatal coronary thromboses (Libby, 2002). Mast cells contribute to 
endothelial erosions by releasing proteases that degrade cadherin and fibronectin 
(Mayranpaa et al., 2006) 
b. disruption of neo-angiogenic blood vessels, growing in the atheroma full of growth 
factors. This leads to thrombin activation, collagen expression and smooth muscle cell 
proliferation (Libby, 2002) 
c. fibrous cap rupture is the most common of plaque rupture and is due to inflammation 
in the lipid core, MMPs and tissue factor release from plaques. TGF-β and vascular 
endothelial growth factor released for the purpose of wound healing of the ruptures 
causes additional fibroses which narrow further the lumen of the vessel and can cause 
ischemia. 
Major clinical complications and subclinical events are presented in Figure 2. 
 
 
Fig. 2. Some clinical and subclinical atherosclerosis complications  
3.3 Regression of atherosclerotic plaques 
Previously, AS was thought to be reversible in early stages with changes of lifestyle and 
dietary modifications, as shown on animal models (J.J. Badimon et al., 1990; Malinow, 1983) 
and was believed to be reversible only to the stages before fatty streak formation. Currently, 
however, it is accepted that later stages can also be reversible as well. Some important 
regressions of even necrotic lesions and foam cell disappearance were achieved with 
injections of cholesterol-free phosphocholine liposomes which lower total cholesterol and 
mobilize cholesterol from plaques in animals (Williams et al., 2008). In regression of AS, 
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endothelium-dependent relaxation improves, as well as hypersensitivity of blood vessels, 
however maximal vasodilator activity/capacity does not improve (presumably due to 
fibrosis of arteries) (Heistad et al., 1990).  
There are some problems occurring with evaluating the extent of AS, as well as in 
extrapolating animal studies to humans (Vilahur et al., 2011). The evaluation of AS 
regression presents a problem especially because the probability of cardiovascular events is 
stochastic and not only dependent on size of the plaque. Due to this, interpreting clinical 
studies in a manner of regression can also be difficult.  
4. Autoimmunity and atherogenesis  
Our understanding of AS has been crucially changed from a simply degenerative disorder 
to one that is a complex, inflammatory and autoimmune disease, in which all branches of 
immune system are involved. The role of autoimmunity has been shown in clinical and 
experimental models. Active immunization with HSP-60 or β2-GPI induces autoantibodies 
and accelerates AS. The transfer of lymphocytes from β2-GPI-immunized mice to other mice 
resulted in advanced AS (Sherer & Shoenfeld, 2006).  
The AS process may be magnified and accelerated in patients with autoimmune diseases. 
Autoimmunity-related risk factors according to Bijl et al. include the presence of anti-
cardiolipid antibodies (aCL), antibodies against oxLDL, antibodies against endothelial cells, 
antibodies against neutrophil cytoplasm antigens, antibodies against ribonuclear proteins 
and antibodies against lipoprotein lipase (Bijl, 2003). Additional risk factors recorded by 
Ronda and Meroni included anti-HSP-60/70 antibodies and anti-β2-glycoprotein (β2-GPI) 
antibodies (Ronda & Meroni, 2008). It must be pointed out however, that HSP-70 antigen 
itself is protective for AS (Frostegard, 2005).  
The acceleration of AS in patients with autoimmune disease is due to the underlying 
immune system dysfunction, the presence of systemic inflammation and endothelial 
activation with the effects of chronic therapies (Ronda & Meroni, 2008). Accelerated and 
premature AS is associated specifically with autoimmune rheumatic diseases of 
inflammatory nature, most markedly with SLE (Roman et al., 2003; Salmon & Roman, 2008) 
and antiphospholipid syndrome (APS) (Jara et al., 2007), but also with RA (Salmon & 
Roman, 2008) and SSc (Shoenfeld et al., 2005), certain forms of vasculitis (Shoenfeld et al., 
2005) and Sjogren’s Syndrome (Gerli et al., 2010; Vaudo et al., 2005). For SSc however, the 
data are still inconsistent (Zinger et al., 2009).  
Many components of the immune system are involved in AS and all arms of the immune 
system are engaged in atherogenesis with different cells (such as monocytes, 
macrophages, T lymphocytes) and different molecules involving both the cellular and 
humoral, innate and adaptive immunity. Certain important mechanisms for AS in 
autoimmune diseases are proposed below. One of them postulates that pre-existing 
adaptive and innate immunity involving HSP-60 exposed on the arterial endothelial cells 
could lead to the development of an initial inflammatory stage of atherogenesis. The 
progress of AS depends on the expression and accessibility of atherogenic HSP-60 
epitopes on endothelial cells. Since low level of autoimmunity to HSP-60 is evolutionary 
present in all individuals, the development of AS depends mainly or even exclusively, on 
the condition of the endothelial cells (Wick & et al., 2006). β2-GPI is another autoantigen 
expressed within subendothelial regions and intimal-medial border of human 
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and antiphospholipid syndrome (APS) (Jara et al., 2007), but also with RA (Salmon & 
Roman, 2008) and SSc (Shoenfeld et al., 2005), certain forms of vasculitis (Shoenfeld et al., 
2005) and Sjogren’s Syndrome (Gerli et al., 2010; Vaudo et al., 2005). For SSc however, the 
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the condition of the endothelial cells (Wick & et al., 2006). β2-GPI is another autoantigen 
expressed within subendothelial regions and intimal-medial border of human 





β2-GPI antibodies, which results in increased amounts of colocalized CD4+ lymphocytes 
in the endothelia (Ronda & Meroni, 2008; Shoenfeld et al., 2001). These antibodies can also 
induce a pro-inflammatory and procoagulant phenotype (Harats & George, 2001).  β2-GPI 
can also form complexes with oxLDL, which stimulate the immune system to produce 
autoantibodies to these oxLDL/β2-GPI complexes. Such immune complexes are uptaken 
by macrophages. Complexes, together with autoantibodies, have been described in 
patients with SLE and/or APS, indicating another mechanism of accelerated AS in 
patients with underlaying autoimmune disease (Matsuura et al., 2009). Further data is 
emerging that IgG anti-oxLDL/β2-GPI antibodies have been associated with pro-
atherogenic functions, whereas IgM anti-oxLDL/β2-GPI have been considered to be anti-
atherogenic (Narshi et al., 2011). In our recent study of 70 RA female patients, which were 
followed for 5.5 years, neither antibodies against β2-GPI, nor rheumatoid factor or CRP 
contributed to AS progression, as measured by carotid intima media thickness and 
number of plaques (Holc et al., 2011). 
The increased risk of AS in patients with autoimmune rheumatic diseases is explained only 
in part by traditional AS risk factors, such as those from the Framingham study (Lloyd-Jones 
et al., 2004; Tegos et al., 2001), for example autoimmune patients commonly have 
dislipidemias. The process of inflammation (as a nontraditional risk factor) can aggravate 
atherosclerosis via different mechanisms secondary to autoimmunity and infectious 
diseases. Increased levels or presence of inflammatory markers: CRP, SAA, fibrinogen, IL-6, 
cluster differentiation markers CD40/CD40L and adhesion molecules have been reported 
(Shoenfeld et al., 2005).  
Peroxidation of LDLs is low in the blood, but is extensive in the intima. Oxygen radicals and 
oxidizing enzymes modify proteins and lipids of the LDL, which activate endothelial cells to 
express vascular cell adhesion molecules (L. Badimon et al., 2011). OxLDL is a target of the 
immune system resulting in the production of autoantibodies (R. Wu & Lefvert, 1995), 
which could be, on one hand, an enhancer of oxLDL uptake by macrophages, inflammation 
and atherogenesis (Ronda & Meroni, 2008) or, on the other hand, may contribute to oxLDL 
clearance in healthy persons (Cerne et al., 2002). Antibodies against HDL have also been 
implicated in AS. Cross-reactivity is thought to exist between aCL, anti-HDL and anti-
ApoA-I IgG antibodies in patients with SLE and primary APS and can lead to the 
diminishing HDL’s protective role (Delgado Alves et al., 2003; Shoenfeld et al., 2005; Tincani 
et al., 2006). 
A representative compilation of autoimmune diseases with accelerated AS is provided 
below (Figure 3). 
Possible risk factors for AS in autoimmune diseases also represent frequently 
accompanying renal involvement. Questions were raised if plaques are more prone to 
rupture due to the fact that they are also qualitatively different in autoimmune diseases. 
Since systemic autoimmune disease patients are on drug therapy for life, there is a need to 
stress the influence of some common drugs. For instance, corticosteroids increase 
triglyceride levels, while methotrexate increases the levels of serum homocysteine 
(Frostegard, 2005). 
Vaccination represents an attractive approach to induce long–term protective immunity. 
Atherosclerosis was reduced by vaccination with oxLDL or HSP-60 in animal 
experiments (Hansson, 2005) that could be due to the induction of protective antibodies 
or T cells. 
 




Fig. 3. Representative compilation of autoimmune diseases with accelerated AS with the 
processes and autoantibodies indicated. aCL, antibodies against cardiolipin; AECA, anti-
endothelial cell antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; Anti-2-GPI, 
antibodies against 2-glycoprotein I; Anti-dsDNA, antibodies against double stranded 
DNA; Anti-HSP, antibodies against heat-shock protein antibodies; Anti-oxLDL, antibodies 
against oxidized LDL; Anti-oxLDL/2-GPI, antibodies against oxidized LDL/2-
glycoprotein I complexes; RF, rheumatoid factor; APS, antiphospholipid syndrome; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjogren’s syndrome; SSc, 
systemic sclerosis 
5. Antiinflammatory atheroprotective effects and therapies in atherosclerosis  
A growing body of evidence indicates that inflammation not only provides the baseline for 
future atherosclerotic events, but is a necessity for coronary plaque formation. The unique 
responsiveness of human coronary artery endothelial cells could account for the greater 
susceptibility of coronary arteries to inflammation and atherogenesis leading to 
cardiovascular pathology. Both black tea extract and resveratrol have been shown to 
significantly inhibit IL-1β-induced IL-6 and tissue factor expression and activity responses in 
human coronary artery endothelial cells (Lakota et al.., 2009).  
The downregulation of TNF-alpha induced by skeletal muscle derived IL-6 may also 
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Powerful anti-inflammatory agents could represent treatments for acute coronary syndrome 
(Hansson, 2005; Libby, 2002; Nilsson et al., 2005). Eicosanoid-modulating anti-inflammatory 
compounds, such as the cyclooxygenase-2 inhibitor rofecoxib are inappropriate in patients 
with CVD, since enzymes inhibited by them, are important in both the production of pro- 
and anti-thrombotic eicosanoids, depending on the cells effected. Lipid-lowering statins also 
have anti-inflammatory properties, likely stemming from the ability of statins to inhibit the 
formation of mevalonic acid, effecting cholesterol, as well as several isoprenoid 
intermediates used by lipids to attach to different intracellular signaling molecules. In 
certain studies, the reduction of inflammation (reflected by CRP levels) through statin 
therapy improved the clinical outcome of CAD, independently of the reduction in serum 
cholesterol levels (Hansson, 2005). 
When macrophages are appropriately activated they can secrete anti-inflammatory 
cytokines and synthesize matrix repair proteins that stabilize vulnerable plaques (Wilson, 
2010). There are also many results from mice studies which show that modulating the 
activity of selected cytokines (either systemically or locally) can prevent or retard the 
development of atherosclerotic lesions and could significantly contribute to early detection 
and treatment of AS or in combination with established hypolipidaemic and 
antihypertensive treatment. The activity of the cytokines of interest can be modulated by 
different techniques such as genetic deletion, overexpression, immunoneutralization, or in 
vivo administration of the cytokines or their receptors or inhibitors (Kleemann et al., 2008). 
Chlamydia pneumoniae (Cp) infection has been associated with AS, and beneficial effects of 
antibiotic therapy on future cardiovascular events have been described. For example, a 
dramatic reduction in endpoints (cardiovascular death, hospital admission with unstable 
angina or acute myocardial infarction or need for revascularization) in a small number of 
high risk patients with CAD suggested the potential of azithromycin therapy in preventing 
future acute cardiac events (Mehta et al., 1998). The reduced intima media thickness 
progression after roxithromycin therapy in Cp seropositivity may be explained by several 
beneficial effects of antibiotic treatment on atherosclerotic plaque formation, such as those 
attributable to a reduced smooth muscle cell proliferation or a decreased smooth muscle cell 
migration from the media and adventitia into the intima, a reduced lipid accumulation, an 
improvement of endothelial function, and diminished inflammatory activity (Sander et al., 
2002). The group reported a significant reduction of CRP in the Cp-positive group of 
patients with ischemic stroke treated with roxithromycin in a two year follow-up study. In 
contrast, there was no significant change of CRP in the placebo-treated Cp-positive group. 
Reductions in CRP and other inflammatory markers were also observed in previous 
antibiotic trials (Gurfinkel et al., 1999; Muhlestein et al., 2000). 
6. Conclusion 
Taken together, AS is a complex, multi-component, inflammatory, as well as autoimmune 
disease. Balancing pro- and anti-inflammatory mediators, destructive and protective 
antibodies can be one approach to maintaining homeostasis. Serum markers of 
inflammation have emerged as an important component of cardiovascular risk factor 
burden. On the other hand, some current reports indicate that detection of novel 
inflammatory marker levels (i.e. using microchips or multi-marker panels) are adding only 
minimally to the ability of traditional risk factors to predict cardiovascular outcome. 
However, discovering novel detection methods for different types of markers may be a way 
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to help clinicians in identifying/clarifying which patients are at borderline risk and require 
drug therapy earlier. Fine-tuning the stage of disease progression using appropriate 
medication can lead to AS regression. Clinicians need more information to support their 
optimal judgment in this crucial decision-making process. Further directions suggest more 
predictive and personalized multi-marker medicine and appropriate earlier risk 
intervention. In addition, more preventive care and participatory feedback are necessary. 
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1. Introduction  
Atherosclerosis continues to be the leading cause of cardiovascular disease. Atherosclerotic 
lesion progression depends on chronic inflammation in the aorta and the immune response 
is involved in this process (Galkina & Ley, 2009; Hansson & Hermansson, 2011). While it is 
now generally accepted that chronic inflammation of the arterial wall, precipitated by an 
immune response targeting modified low density lipoproteins, heat shock protein 60, β2-
glycoprotein I, and other self-antigens, underlies the pathophysiology of atherosclerosis, this 
notion was met with scepticism historically. 
The term atherosclerosis was first introduced by the French surgeon and pathologist Jean 
Lobstein in 1829. Within a few years the associated cellular immune alterations in the 
arteries of atherosclerotic cadavers were described by two schools of pathology yielding two 
theories on the pathology atherosclerosis. Carl von Rokitansky proposed that initial injury 
of the aorta preceded the cellular inflammatory changes, suggesting a secondary role for 
aortic leukocytes. In contrast, Rudolf Virchow postulated an initiating role for aortic cellular 
conglomerates (Methe & Weis, 2007; Mayerl et al., 2006). However, despite these 
observations, the response-to- injury model of atherosclerosis prevailed in the literature 
until the early 1980s. In 1979, the presence of monocytes adhering to the endothelial layer of 
porcine and human atheroma was demonstarted (Gerrity & Naito, 1980). In 1980, expression 
of HLA-DR by vascular endothelial cells was reported (Hirschberg et al., 1980). It was also 
found that interferon-γ (IFN-γ) potently induced MHC-II expression on cultured endothelial 
cells, suggesting that T cell-derived cytokines may play an important role in the vasculature 
(Pober et al., 1983). In 1985 and 1986, the presence of HLA-DR+ cells, CD4+ and CD8+ T cells 
in carotid entarterectomy specimens was reported, further implicating that a cellular 
immune response occurs in atherosclerosis (Jonasson et al., 1985; Jonasson et al., 1986). Since 
these initial findings a plethora of recent papers have further highlighted the presence of 
multiple subsets of leukocytes in aortas, and demonstrated the importance of the immune 
system during atherogenesis. The occurrence of inflammatory cells in the aorta depends on 
the dynamics of their recruitment and possibly egress, as well as the balance between 
proliferation, survival, and apoptosis within the aorta. To date, several adhesion molecules 
and chemokines, which support subset-specific leukocyte homing into the aorta, have been 
identified, but questions concerning the role of the adventitial vasa vasorum in leukocyte 
homing, kinetics and the specific mechanisms of migration of different cell subsets including 
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2. Multiple steps of the adhesion cascade 
Peripheral blood leukocytes are programmed to constitutively home to secondary lymphoid 
organs in search of possible antigens, in order to mount an appropriate immune response 
against infections. It has also been recognized that a small subset of leukocytes home into non-
lymphoid tissues as a part of constitutive homing in order to sample antigens in local tissues. 
In line with this notion, leukocytes are found within normal/non-inflamed aortas and recent 
studies have demonstrated that these cells constitutively migrate into the aorta. The migration 
of leukocytes into non-lymphoid sites where injury, infection or inflammation has occurred is 
also highly specific. To date, there are several examples of immune-mediated chronic diseases 
such as rheumatoid arthritis, Type 1 diabetes mellitus, psoriasis, and multiple sclerosis that 
have marked adhesion molecule-mediated homing of leukocytes into the site of inflammation. 
It is now appreciated that atherosclerosis-prone conditions activate aortic vascular cells, 
upregulate adhesion molecules, and chemokines; thereby supporting leukocyte homing into 
the aorta (Galkina & Ley, 2007a) – a key step in the pathology of atherosclerosis.  
2.1 Steps of the adhesion cascade 
2.1.1 Selectins and rolling 
The adhesion cascade is defined as series of overlapping and synergistic interactions among 
adhesion molecules and chemokines. There are several major steps of the leukocyte 
adhesion cascade including selectin–dependent tethering and rolling, selectin or arrest 
chemokine-dependent activation, integrin-dependent arrest, firm adhesion and diapedesis, 
which are closely interconnected and regulate cell-specific migration. The first steps of the 
adhesion cascade consist of tethering, capture, and rolling, which are initiated via selectin-
carbohydrate ligand interactions along the endothelium (McEver, 2002). L-selectin is 
expressed by all leukocytes, mediates leukocyte rolling and can also participate in secondary 
capture, defined as leukocyte capture by adherent leukocytes (reviewed in (Ley et al., 2007)). 
P- and E-selectin are expressed by the activated endothelium and serve as rolling molecules 
for most leukocytes (McEver, 2002). Activated platelets also express P-selectin. P-selecin 
binds PSGL-1 expressing neutrophils, monocytes, and lymphocytes (Ley & Kansas, 2004). E-
selectin binds PSGL-1, CD44, E-selectin ligand-1(ESL-1) on myeloid cells and CD43 on T-
helper 1 lymphocytes (reviewed in (Ley et al., 2007)). Selectins tightly control leukocyte 
rolling velocity via regulation of the rapid formation and dissociation of bonds between 
selectins and their ligands (Alon et al., 1997). L- and P-selectin support rolling at relatively 
fast velocities, while E-selectin supports leukocyte rolling at very slow velocities (Kunkel & 
Ley, 1996). Evidence suggests that selectin ligation by endothelial ligands can induce 
activation of integrins, and provide a link between rolling and the subsequent integrin-
mediated firm adhesion (Zarbock et al., 2007). 
2.1.2 Integrins, arrest chemokines, and firm adhesion 
Following the steps of tethering and rolling, leukocyte integrins initiate slowing rolling, and 
induce further firm adhesion. The integrin family consists of  and  subunits that form 
heterodimers yielding a total of 24 integrins (Hynes, 2002). All leukocytes express leukocyte 
function-associated molecule (LFA-1, CD11a/CD18, or α-Lβ2), while myeloid cells 
predominately express Mac-1. Endothelial ligands for LFA-1 and Mac-1 include intercellular 
adhesion molecule 1 (ICAM-1) and ICAM-2. The 41 (VLA-4) integrin is a member of the 4 
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subfamily and is mostly expressed on extralymphoid monocytes and on lymphocytes 
(Luster et al., 2005). Vascular cell adhesion molecule-1 (VCAM-1) (Kinashi, 2007) and the 
CS-1 peptide of fibronectin (Guan & Hynes, 1990) serve as ligands for VLA-4. VCAM-1 is 
not constitutively expressed in most tissues, but is upregulated after stimulation with TNF- 
and IL-1. Chemokines support migration via the formation of chemotactic gradients from 
emigrated leukocytes and resident tissue cells. Endothelial cells synthesize and present 
chemokines on the luminal surface. Most chemokines can be also immobilized by 
extracellular matrix components, including heparan sulfate and glycosaminoglycans, and 
presented to leukocytes (Ley et al., 2007). Several members of a specialized group of arrest 
chemokines play an essential role in integrin activation and firm adhesion.  
2.1.3 JAMs, PECAM-1, VE-Cadherin and transmigration 
Increased time of firm leukocyte adhesion reduces rolling velocities, and initiates cell 
crawling or locomotion in order to find an appropriate site for transmigration/diapedesis. 
There are two principal mechanisms of transmigration: via intercellular junctions or 
through the endothelial cell body (Carman & Springer, 2004; Shaw et al., 2004). To date, it 
is unclear which parameters preferentially affect the pathways of transmigration. CD99-
related antigen (CD99L2), endothelial cell-selective adhesion molecule (ESAM) and 
junctional adhesion molecules (JAMs) are important regulators of diapedesis. JAMs 
belong to the members of immunoglobulin superfamily, which are localized to 
intercellular junctions of polarized endothelial and epithelial cells, but are also expressed 
on circulating leukocytes and platelets (Mandell & Parkos, 2005). JAMs participate in 
homophilic and heterophilic cell interactions, and thus, support the extravasation of 
leukocytes into tissues. JAM-A binds to LFA-1, JAM-B to VLA-4, and JAM-C to Mac-1 
(Vestweber, 2007). VE-cadherin is expressed between endothelial cells and serves as a 
barrier for extravasating leukocytes in vivo (Lampugnani et al., 1992). ICAM-1 and ICAM-
2 can also participate in leukocyte transmigration through the development of the specific 
structures that surround leukocytes during transmigration (Carman & Springer, 2004), 
and/or form ring-like clusters of LFA-1 at the interface between the transmigrating 
leukocyte and endothelial junctions (Shaw et al., 2004). Platelet endothelial cell adhesion 
molecule-1 (PECAM-1) is a member of the immunoglobulin superfamily that is expressed 
on leukocytes, platelets, and interendothelial junctions. PECAM-1 promotes leukocyte 
transmigration as an adhesion molecule (Newman, 1997), but can also serve as a signaling 
receptor (Vestweber, 2007).  
3. Regulators of adhesion molecule expression in atherogenesis 
Many inflammatory factors such as multiple cytokines, 5-lipoxygenase, 12/15-lipoxygenase, 
heme oxygenase-1, paraoxonases, C-reactive protein, reactive oxygen species, advanced 
glycation end products (AGE), oxidized-LDL, and blood flow conditions (reviewed by 
(Tedgui & Mallat, 2006; Galkina & Ley, 2009), play crucial roles during atherogenesis. One 
of the many essential functions of these factors is the induction and the regulation of the 
expression of adhesion molecules and chemokines. As these factors have been reviewed in 
depth elsewhere (Galkina & 2009; Tedgui & Mallat, 2006), we will focus briefly only on 
some inflammatory molecules and conditions that have been demonstrated to affect the 
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some inflammatory molecules and conditions that have been demonstrated to affect the 





3.1 Effects of cytokines on the expression of aortic adhesion molecules and 
chemokines 
3.1.1 TNFα and the TNFα superfamily 
The pro-inflammatory effects of TNF-α in atherogenesis are well established. TNF-α 
upregulates a variety of adhesion proteins, including LFA-1, VCAM-1, and ICAM-1 on human 
endothelial cells in vitro (Sprague & Khalil, 2009). Cleavage, but not the membrane bound form 
of TNF-α, is required for TNFα’s pro-atherogenic properties. Mast-cell-, M-, and neutrophil-
derived TNF-α and IL-6 similarly promote the expression of several adhesion molecules, 
including VCAM-1, ICAM-1, P- and E-selectin, in endothelial cells and further support the 
adherence of neutrophils under physiological shear stress conditions (Zhang et al., 2011). 
Another member of the TNF superfamily, Lymphotoxin-β (LTβ), can similarly promote 
CXCL13 and CCL21 induction in medial smooth muscle cells (Grabner et al., 2009). In 
addition, further investigation into the mechanisms behind LTβ-receptor mediated production 
of CXCL13 and CCL21 by smooth muscle cells revealed a synergistic interaction between TNF-
α and LTβ-β mediated activation of the NF-κB pathway that led in elevated expression of 
multiple chemokines in smooth muscle cells (Lötzer, et al. 2010). 
3.1.2 The interleukin-17 family 
Recently, several studies have demonstrated the presence of Th17 and other IL-17A+ cells 
within murine and human atherosclerotic tissues (Ait-Oufella et al., 2011). Th17 and other 
IL-17A+ T cells play critical roles in the defence against extracellular bacteria and fungi, but 
also promote inflammation in multiple autoimmune disorders through the production of 
several chemokines by IL-17 receptor expressing resident epithelial, endothelial cells, and 
fibroblasts. IL-17A may similarly be involved in atherogenesis through the production of 
multiple chemokines and adhesion molecules; however, the exact role of this cytokine is 
currently contested. 
3.2 The effect of other inflammatory factors and flow conditions on the expression of 
adhesion molecules and chemokines 
3.2.1 Modified LDL 
In addition to oxLDL’s antigenic properties and its ability to induce foam cell formation 
and endothelial cell dysfunction, several studies have demonstrated that modified LDL 
may also directly affect the expression of adhesion molecules, and thereby affect the 
recruitment of leukocytes to the aorta. OxLDL can be trapped beneath the subendothelial 
matrix via heparin sulphate-dependent binding in vivo (Pillarisetti et al., 1997) and thus, 
locally affect vascular cells. OxLDL promotes P-selectin expression in activated human 
aortic endothelial cells (Gebuhrer et al., 1995), and monocyte transmigration through 
human umbilical vein endothelial cell layers (Hashimoto et al., 2007). Similarly, modified 
(Keiper et al., 2005; Parhami et al., 1993) or enzymatically degraded LDL (Klouche et al., 
1999) induces CCL2, CXCL1, ICAM-1, PECAM-1, JAM-C, P- and E-selectin in endothelial 
cells in vitro. Several studies have demonstrated that lysophosphatidylcholine 
(LysoPTdCho), a component of oxidized LDL, functions as a chemotactic factor for 
monocytes (Quinn et al. 1988), and neutrophils (Murugesan et al. 2003), both directly 
(Quinn et al. 1987), and via regulation of endothelial VCAM-1, ICAM-1 (Kume et al. 1992), 
CCL2, and IL-8 (Murugesan et al. 2003). 
 




Fig. 1. Regulators of adhesion molecule expression. 
Several factors that may affect the expression of adhesion molecules during atherogenesis 
are shown. Multiple cytokines upregulate adhesion molecule expression in endothelial and 
smooth muscle cells. In addition, other pro-inflammatory conditions such as low shear 
stress, oscillatory blood flow (arrows, right), modified LDL, ROS and AGE (not shown) 
regulate endothelial and smooth muscle cell adhesion molecules. “Dec.” denotes adhesion 
molecules that have been demonstrated to be down regulated. 
3.2.2 Flow conditions 
Flow conditions at branching points of the vasculature may also affect the expression of 
adhesion molecules and account for anatomical variations in the sites of atherogenesis 
(VanderLaan et al., 2004).  Shear stress, the force that acts on the endothelium as a result of 
blood flow, plays a critical role in the development of endothelial dysfunction and 
atherosclerosis. Areas of coronary arties that exhibit low shear stress or areas where shear 
stress is oscillatory frequently contain atherosclerotic plaques (Davies et al., 2002; Pedersen 
et al., 1999). There are multiple lines of evidence indicating that the areas of low shear stress 
or oscillatory flow conditions display changes in the expression of adhesion molecules. 
Indeed, human aortic endothelial cell culture with oscillatory flow conditions in vitro 
upregulate VCAM-1 and ICAM-1 (Brooks et al., 2002). Similarly, in an in vivo model of 
oscillatory flow using a common carotid artery cast in Apoe-/- mice, several chemokines were 
upregulated in areas of low shear stress (CCL2, CXCL1, CXCL10, and CX3CL1) and 
oscillatory shear stress (CCL2, and CXCL1) (Cheng et al., 2007). Furthermore, in a study 
examining the response of endothelial cells to changes in shear stress, HAECs pre-
stimulated with TNF-α and simultaneously exposed to a linear gradient of shear stress (0-16 
dyne/cm2) resulted in the upregulation of VCAM-1, E-Selectin under lower shear stress 
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3.3 Soluble adhesion molecules and atherosclerosis 
Multiple studies have demonstrated that soluble adhesion molecules, including sE-Selectin, 
sP-Selectin, sL-Selectin, sVCAM-1, sICAM-1, sCD40, and sCD40L, are elevated within the 
plasma of coronary artery disease patients and are associated with the severity of stenosis, as 
well as, several atherosclerotic disease risk factors including smoking, obesity, diabetes, 
hypertension, etc (reviewed in Roldan, et al. 2003). However, the functional relevance of these 
soluble adhesion molecules is currently unclear. Increased levels of soluble adhesion 
molecules may arise from cytokine-stimulated shedding, enzymatic cleavage, loss of 
membrane integrity, necrosis, and/or apoptosis (Pigot et al., 1992; Leeuwenbern, et al. 1992; 
Newman, et al., 1993), and may play a role in antagonizing leukocyte recruitment (Tu, et al. 
2001) or promote leukocyte recruitment through the formation of cellular aggregates. 
Ultimately, additional mechanistic studies will be required in order to pinpoint the functions 
of these soluble forms in vivo. 
4. Leukocyte migration into aortas 
4.1 Monocytes 
4.1.1 Monocyte homing to the aortic wall 
Monocytes play a key role in atherosclerosis (reviewed in (Galkina & Ley, 2009; Hansson & 
Hermansson, 2011)). Monocytes migrate into the sub-endothelial space of the aortic intima, 
where they differentiate into M (Gerrity and Naito, 1980; Jonasson et al., 1986), and 
dendritic cells (Bobryshev and Lord, 1998). Although it has not been shown directly, some 
data suggest that environmental signals within the blood and aortas determine the 
differentiation programs that give rise to M or dendritic cells in the aorta. Monocyte 
accumulation is progressive and proportional to the extent of atherosclerosis (Swirski et al., 
2006). Monocyte-derived cells are found in both the aortic adventitia and in atherosclerotic 
lesions. Similar frequencies of adoptively transferred allelic CD45 isoform monocytes and 
recipient monocytes were found within the carotid lesions, but not the adventitia of 
recipients; suggesting that M-derived foam cells arise mainly from blood-derived 
monocytes rather than resident M (Lessner et al., 2002). Whether or not adventitial M 
include a self-renewing pool remains unclear. The spleen can also serve as a reservoir of 
monocytes (Swirski et al., 2009). The role of splenic monocytes in atherosclerosis remains to 
be determined.  
P-selectin was one of the first adhesion molecules that clearly showed its involvement in 
monocyte recruitment into the aorta. Blockade of P-selectin resulted in reduced monocyte 
rolling and attachment to the carotid endothelium (Ramos et al., 1999). Further experiments  
demonstrated that P-selectin deficiency caused a decrease in fatty streaks and reduction in 
M numbers within the plaques (Table I). E-selectin expression is elevated within 
atherosclerotic aortas, and E-selectin deficiency causes slightly reduced plaque burden 
(Collins et al., 2000). There is a functional overlap between E-selectin and P-selectin as 
combined deficiency in E- and P-selectin decreases atherosclerosis by 80% (Dong et al., 
1998). Recently, a potential role for 2 and 3 integrins and an intracellular protein- 
thrombopspondin (TSP)-4 in monocyte migration was proposed. Deficiency in TSP-4 lead to 
reduced number of lesional M, and decreased 2 and 3 integrin-dependent M adhesion 
and migration in vitro (Frolova et al., 2010). 
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VCAM-1 is a central adhesion molecule that supports slow rolling and tight adhesion of 
monocytes to the atherosclerotic endothelium. Blockade of VCAM-1 or 4 integrins 
resulted in increased rolling velocity and attenuated adhesion of monocytes in ex vivo 
models of isolated perfused carotid arteries (Huo et al., 2000; Ramos et al., 1999). Blockade 
of 4 integrin using blocking Abs showed reduced influx of M into plaques (Patel et al., 
1998). Since VCAM-1-deficient mice are not viable, mice in which the fourth Ig domain of 
VCAM-1 was disrupted (Vcam-1D4D/D4D) were generated (Cybulsky et al., 2001). Reduced 
levels of VCAM-1 resulted in the reduction of atherogenesis in Vcam1D4D/D4DLdlr-/- mice 
(Cybulsky et al., 2001). VCAM-1 levels affect plaque formation, since Vcam-1D4D/+Apoe-/- 
mice showed a gene-dosage dependent influx of monocytes and plaque burden (Dansky 
et al., 2001).  
Evidence suggests that several arrest chemokines expressed on the endothelium initiate 
integrin activation and firm leukocyte adhesion. CXCL1 (Huo et al., 2001) and CCL5 (Huo et 
al., 2003) either alone or as a heterodimer with CXCL4 (von Hundelshausen et al., 2005) 
have been discovered as aortic arrest chemokines for monocyte adhesion. CXCL1 and CCL5 
and their receptors CXCR2 and CCR5 promote monocyte arrest on the atherosclerotic 
endothelium in the flow chamber system (Huo et al., 2001; Huo et al., 2003; Weber et al., 
1999). CXCL7 also efficiently triggers monocyte arrest to the inflamed endothelium under 
flow conditions (Baltus et al., 2005). Migration inhibitory factor (MIF) regulates monocyte 
arrest via the interaction of the CXCR2/CD74 complex expressed on monocytes with MIF-
expressing atherosclerotic endothelium (Bernhagen et al., 2007). Additionally, MIF 
deficiency or the blockade of MIF with anti-MIF Abs resulted in reduced lipid deposition, 
intimal thickening and M infiltration in the aorta (Pan et al., 2004; Burger-Kentischer et al., 
2006). 
CCL2 is one of the key chemokines in monocyte biology. Classical CCR2+ monocytes exit 
the bone marrow in a CCL-2-dependent manner,  and both CCL2 and CCL7 maintain 
monocyte homeostasis in the circulation (Serbina & Pamer, 2006; Tsou et al., 2007). Several 
studies suggest that the CCL2/CCR2 axis participates in atherogenesis by the modulation 
of monocyte recruitment into the aorta  (Boring et al., 1998; Dawson et al., 1999; Gosling et 
al., 1999; Gu et al., 1998). Interestingly, since CCL2 has no effects on monocyte arrest on 
the early atherosclerotic endothelium (Huo et al., 2001), CCL2 may function as a regulator 
of monocytes egress from bone marrow or chemokine that regulates monocyte 
transmigration. 
Deficiency of JAM-A reduces monocyte arrest and transmigration on activated JAM-A-
deficient endothelial cells under flow conditions in vitro, and attenuates neointimal 
formation (Zernecke et al., 2006). In line with this notion, JAM-A is involved in monocyte 
adhesion to isolated perfused Apoe-/- carotid arteries (Ostermann et al., 2005). JAM-C 
blockade decreases neointimal M content and reduces neointimal hyperplasia 
indicating a potential role of JAM-C in the regulation of monocyte transmigration 
(Shagdarsuren et al., 2009). Inactivation of ESAM-1 leads to diminished transmigration 
of THP-1 cells in in vitro assays, and ESAM-deficient Apoe-/- mice display attenuated 
atherosclerosis (Inoue et al., 2010). It is interesting that not only the adhesion molecules, 
but also one of the scavenger receptors – CD36 regulates M migration. CD36 signaling 
in response to oxLDL alters cytoskeletal dynamics and inhibits the migration of Ms. 
This may be one of the mechanisms of M accumulation in aortic lipid-rich areas (Park 
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Table 1. Adhesion molecules and chemokine receptors that are involved in the recruitment 
of leukocytes into the aortic wall. (Adapted from (Galkina & Ley, 2007)) 
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Two subsets of human monocytes representing CD14high and CD14+CD16+ cells have been 
described (Passlick et al., 1989), and a new additional subset of CD14dim human monocytes 
that patrols blood vessels has been added (Cros et al., 2010). Similarly, there are two distinct 
subsets of blood circulating murine monocytes: Ly6Chigh/CCR2+/CX3CR1low inflammatory 
monocytes and Ly6Clow/CCR2-/CX3CR1high monocytes (Geissmann et al., 2003). Both 
circulate through lymphoid and non-lymphoid organs under homeostatic conditions 
(Geissmann et al., 2003; Tacke et al., 2007). Hypercholesterolemia induces monocytosis in 
Apoe-/- mice with a predominant increase in the numbers of Ly6Chigh monocytes (Swirski et 
al., 2007; Tacke et al., 2007). As different repertoires of chemokine receptors and adhesion 
molecules are expressed by each monocyte subset, these cells use different mechanisms to 
traffic into the aorta. Ly6Clow monocytes enter the atherosclerotic wall in a CCR5-dependent 
manner, but do not require CX3CR1 or CCR2 (Tacke et al., 2007). Surprisingly, 
Ly6Chigh/CCR2+ monocytes require not only CCR2, but also CX3CR1 and CCR5 for their 
recruitment into the aorta (Tacke et al., 2007). Monocyte subsets also differently express 
several adhesion molecules, which can affect their homing capacity. L-selectin is expressed 
by Ly6Chigh monocytes and likely provides primary and secondary capture of monocytes to 
the endothelium. Ly6Clow monocytes express low levels of L-selectin and CD54, but elevated 
levels of CD43 (Sunderkotter et al., 2004). Endothelial E-selectin may provide initial rolling 
of Ly6Clow monocytes on endothelium. Further understanding of the pathways that govern 
the recruitment of monocyte subsets into atherosclerotic aorta is crucial to advance our 
efforts to reduce the frequency of aortic pro-inflammatory monocytes/macrophages and 
thus, further aortic chronic inflammation. 
4.1.2 Egress of macrophages and dendritic cells from atherosclerotic aortas 
Elevated levels of monocyte-derived cells in atherosclerotic plaques could be the result of 
several processes including: 1) hyperlipidemia-induced monocytosis and increased 
monocyte recruitment, 2) increased proliferation, 3) altered balance of 
survival/apoptosis/clearance, 4) attenuated egress from the aorta. Evidence suggests that 
reduced numbers of plaque MFs orchestrate the regression of atherosclerosis repression; 
however, the cellular and molecular mechanisms underlying this process are not well 
understood. One of the first studies that focused on the potential mechanisms of M and 
dendritic cell egress from atherosclerotic plaques were performed using a surgical model 
of plaque regression. In this model, plaque-bearing aortas from Apoe-/- donor mice were 
transplanted into C57BL/6 mice with low levels of circulating cholesterol, such that the 
surgically transferred segment became a functional segment of the recipient's aorta 
(Llodra et al., 2004). Significant migration of CD68+ cells out of the plaque was detected in 
C57BL/6 recipients, whereas little emigration was detected from progressive plaques in 
Apoe-/- recipients (Llodra et al., 2004). Further experiments determined a role of the 
chemokine receptor CCR7 (Trogan et al., 2006). Liver X receptor α (LXR) and LXR— are 
nuclear hormone receptors that play key roles in maintaining cholesterol homeostasis in 
M, primarily by regulating multiple components of the reverse cholesterol transport 
pathway (Bradley & Tontonoz, 2005). Interestingly, emigrated CD68+ cells expressed LXRα 
mRNA in foam cells in the regression environment (Trogan et al., 2006). LXR increases 
expression of CCR7 on CD68+ cells, and thus supports CCR7-dependent regression of 
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Two subsets of human monocytes representing CD14high and CD14+CD16+ cells have been 
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of Ly6Clow monocytes on endothelium. Further understanding of the pathways that govern 
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mRNA in foam cells in the regression environment (Trogan et al., 2006). LXR increases 
expression of CCR7 on CD68+ cells, and thus supports CCR7-dependent regression of 





HDL on aortic Mφ egress were observed in a model of atherosclerosis regression. 
Transplantation of advanced atherosclerotic segments from Apoe-/- donors to recipient 
mice bearing different levels of HDL cholesterol levels revealed that normalization of 
HDL decreases plaque burden and emigration of CD68+ cells from aortas. Thus, these 
data establish that HDL can serve as a regulator of in vivo egress of CD68+ cells from the 
plaque (Feig et al., 2011). It is likely that the balance of “In and Out” processes regulates 
M and dendritic cells cellularity in the plaque. New data also suggest that normalization 
of cholesterol can correct monocyte recruitment into the aorta and additionally, lead to 
decreased M content in atherosclerotic aortas. Treatment of Apoe-/- with apoE-encoding 
adenoviral vectors induced plaque regression, and attenuated CCR7-independent aortic 
M content (Potteaux et al., 2011). Thus, interfering with monocyte recruitment into and 
possible egress from atherosclerotic plaques may be therapeutically beneficial, in parallel 
with aggressive lipid lowering therapies, to maintain and reinforce the reduction in 
monocyte recruitment to the aorta. 
 
 
Fig. 2. Mechanisms of leukocyte recruitment in atherosclerosis 
Different steps of the adhesion cascade and adhesion molecules control the recruitment of 
leukocytes to atherosclerotic plaques. The aortic adventitia, elastic laminia, smooth muscle, 
endothelial layers, as well as tertiary lymphoid aggregates and vasa vasorum are shown. The 
adhesion proteins and chemokines involved in the rolling and tethering (1), arrest and firm 
adhesion (2), and transmigration (3) of leukocytes to the endothelium are shown. Factors that 
play a role in the recruitment of leukocyte subsets in atherogenesis are denoted by question 
marks. While neutrophils and monocytes are known to be recruited from the lumen, it is not 
clear if NK, NKT, and mast cells are recruited from the lumen as well.  
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4.2 T cell recruitment 
4.2.1 Naive and effector T cell homing 
Initially T cells were found within human atherosclerotic plaques, predominantly in the 
regions of fibrous cap (Jonasson et al., 1986). Interestingly, CD8+ T cells were almost as 
frequent as CD4+ T cells in the plaques; this differs from the CD4/CD8 ratio normally seen 
in the blood or other peripheral lymphoid tissue (Jonasson et al., 1986). Even at the earlier 
stages of atherogenesis, activated T cells have been discovered within the intimal fatty 
streaks of the human aortic wall (Munro et al., 1987). Importantly, T cells were also 
detected in non-diseased young aortas (Wick et al., 1997). Leukocytes are distributed at 
the site-specific areas around the ostia of intercostal arteries of grossly normal aorta 
(Kishikawa et al., 1993). T cells also reside in the aortic adventitia of C57BL/6 (Galkina et 
al., 2006) and Apoe-/- mice (Galkina et al., 2006; Moos et al., 2005). Adoptive transfer of T 
cells into C57BL/6 mice revealed that T cells preferentially migrate into the aortic 
adventitia and to a lesser extent into the aortic layers of normal aortas. Indirect evidence 
suggests that T cell migration occurs likely through the vasa vasorum (Galkina et al., 
2006). T cells also preferentially migrate into the adventitia of Apoe-/- mice, indicating that 
T cells use similar routes of homing to the atherosclerotic and healthy aorta (Galkina et al., 
2006).  
There are many examples of tissue-specific sets of adhesion molecules that provide selective 
recruitment (reviewed in (Ley et al., 2007)). Little is known about lymphocyte recruitment 
into the aorta, and it is unclear whether a specific set of adhesion molecules and chemokines 
are responsible for the influx of the different types of leukocytes into healthy and 
atherosclerosis-prone aortas. At least one of the selectins, L-selectin, supports the migration 
of T cells into the aorta (Galkina et al., 2006). L-selectin might not only directly interact with 
aortic endothelium, but rather provide secondary capture through L-selectin/PSGL-1 
interactions (Eriksson et al., 2001; Kunkel et al., 1998). In support of this notion, L-selectin-
dependent secondary capture was observed by intravital microscopy in the femoral artery 
and abdominal aorta (Eriksson et al., 2001).  
Evidence demonstrates that different subsets of T cells, including naïve, Tregs, Th1 and 
Th17 cells are present within the atherosclerotic aortas. Although we are still far from 
understanding how these different populations accumulate in aortas, some mechanistic 
details have been already shown. CCL5 is expressed on the luminal surface of carotid 
arteries, and platelet-dependent CCL5 deposition has been reported (Huo et al., 2003; 
von Hundelshausen et al., 2001). Deficiency in CCR5 reduced aortic CD4+ cells in parallel 
with attenuated atherosclerosis in Ccr5-/-Apoe-/- mice (Braunersreuther et al., 2007), 
indicating the importance of the CCL5/CCR5 axis for T cell migration into aortas. Naïve 
T cells express CCR7, which plays important functions in T cell recruitment into 
secondary lymphoid tissues and sites of inflammation. Importantly, CCR7 deficiency 
attenuates atherosclerosis via the regulation of T cell egress (Luchtefeld et al., 2010). The 
ligand for CCR7, CCL19 is expressed by SMCs and M in the plaques (Reape et al., 
1999). CXCL9, CXCL11 (Mach et al., 1999; Ranjbaran et al., 2006), and  CXCL12 (Bi-
Younes et al., 2000), are also detected in the lesions. CXCL10 and CXCL9 mediate the 
CXCR3-dependent rapid shear-resistant arrest of T cells on stimulated EC (Piali et al., 
1998). It was also shown that CXCL10 participates in T cell homing into atherosclerotic 
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aortic endothelium, but rather provide secondary capture through L-selectin/PSGL-1 
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Evidence demonstrates that different subsets of T cells, including naïve, Tregs, Th1 and 
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Younes et al., 2000), are also detected in the lesions. CXCL10 and CXCL9 mediate the 
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CXCL16 is detected in human and mouse atherosclerosis-prone tissues and serves in the 
membrane-bound form as a scavenger receptor and in the soluble form as a chemokine. 
CXCL16 protects against atherosclerosis, likely through a benefit of CXCL16 as a scavenger 
receptor (Aslanian and Charo, 2006). Subsets of TEFF cell express CXCR6, a chemokine 
receptor for CXCL16 (Matloubian et al., 2000). The absence of CXCR6 in Cxcr6-/-Apoe-/- mice 
leads to reduced homing of CXCR6+ T cells into atherosclerotic aortas (Galkina et al., 2007). 
CXCR2 and CXCR4 were recently identified as functional receptors for macrophage 
migration inhibition factor (MIF) (Bernhagen et al., 2007b). Blockade of MIF resulted in a 
diminished number of monocytes/M and T cells within the aortas.  
Tregs play an important role in the maintenance of the immunological tolerance (review in 
(Sakaguchi et al., 2008)). Induction of a regulatory T cell type 1 (Treg type 1) responses and 
adoptive transfer of naturally arising CD4+CD25/+ T regs reduce atherosclerosis in Apoe-/- 
mice (Mallat et al., 2003; Ait-Oufella et al., 2006). Foxp3+ cells in human atherosclerotic 
lesions colocalize with the Treg-associated chemokine receptor CCR4 and its ligand, CCL17 
(Heller et al., 2006). The molecular mechanisms that regulate homing of Treg cells into 
aortas are not well understood. 
Th17 cells are a new lineage of CD4+ T cells that play important roles in acute inflammation and 
autoimmune diseases (Bettelli et al., 2007). Expression of CCR6 and CCR4 characterizes a 
unique subset of IL-17+ human peripheral blood T cells (Costa-Rodriguez et al., 2007). Th17 cells 
also express homeostatic CCR7 and CXCR5 and share some chemokine receptors with other T 
cell lineages. Although IL-17A+ cells are less abundant than Th1 cells, IL-17A+ T cells are present 
in both atherosclerotic human and mouse arteries. While the mechanisms of Th17 cell homing 
into aortas are unclear, some ligands such as CCL2, CCL20, and CCL21 are expressed within 
the plaques and could be used by Th17 and other IL-17+ cells to home to aortas.  
4.3 B cell influx 
In 1981, B cells were discovered within the adventitia (Parums & Mitchinson, 1981), and 
immunoglobulin-positive cells were detected within the subendothelial intima of 
atherosclerotic and non-atherosclerotic rabbits (Hansson et al., 1980). CD22+ B cells were 
also detected in atherosclerotic plaques of Apoe-/- mice (Zhou & Hansson, 1999). B cells 
reside in the adventitia of C57BL/6 aortas as a consequence of constitutive L-selectin-
dependent homing to the aorta (Galkina et al., 2006). The phenotype of B cells within the 
aorta and surrounding adventitia is unclear, and further studies are needed to 
characterize adhesion molecule and chemokine receptor repertoire of aortic B cells. 
Recently, a role for smooth muscle cells (SMCs) in the regulation of lymphocyte homing 
was suggested. SMCs induce the production of CCL7, CCL9, CXCL13, CCL19, CXCL16, 
VCAM-1, and ICAM-1 (Lotzer et al., 2010). Supernatants of TNF receptor superfamily 
member 1A (TNFR-1) and LT-receptor-activated SMC markedly supported migration of 
B cells in vitro (Lotzer et al., 2010). It remains unclear whether elevated levels of 
endothelial homeostatic chemokines lead to accelerated recruitment of B cells into 
atherosclerosis–prone vessels.  
4.4 Neutrophil recruitment in atherosclerosis 
Despite a clear association between neutrophilia, neutrophil activation, and coronary artery 
disease (Baetta & Corsini, 2010; Mazzone et al., 1993), neutrophils are relatively low in 
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abundance within human atherosclerotic plaques (Baetta & Corsini, 2010). While 
neutrophils in atherosclerosis have been understudied to date, several lines of evidence 
suggest that neutrophil recruitment occurs during atherogenesis. CXCR4 and its ligand 
CXCL12 are involved in the efflux of neutrophils from bone marrow and in the regulation of 
neutrophil recruitment to atherosclerotic plaques (Zernecke et al., 2008). In addition, 
neutrophils were shown to adhere to the endothelium on the shoulder regions of 
atherosclerotic plaques (Rotzius et al., 2010). CXCR4 blockade-induced neutrophilia resulted 
in elevated plaque neutrophil content. In addition, as neutrophil chemotaxis to 
atherosclerotic plaques was impaired in CCR1, CCR2, CCR5, and CXCR2 deficient Apoe-/- 
mice, CCL2 and platelet-derived CCL5 supported neutrophil recruitment to carotid arteries. 
Based on several studies, neutrophils might migrate to developing plaques in a CCR1- and 
CCR5-dependent manner where they participate in promoting atherogenesis by supporting 
monocyte recruitment (Soehnlein et al., 2009) and inflammation (Nicholls & Hazen, 2009).  
4.5 Mast cells in atherogenesis 
While vascular mast cells are rare, they are nonetheless present within the adventitia and 
shoulder regions of atherosclerotic plaques (Lindstedt et al., 2007). Mast cell deficient KitW-
sh/W-sh mice display alterations in ApoE and ApoAII-dependent cholesterol efflux (Lee et al., 
2002). Interestingly KitW-sh/W-sh mice on the Ldlr-/- background demonstrated increased 
collagen content, fibrous cap development and reduced plaque T cell and M  cellularity 
(Sun et al., 2007). Mast cell activation correlated with M and endothelial cell apoptosis, 
vascular leakage, CXCR2 and VLA-4-mediated recruitment of leukocytes to atheroma (Bot, 
et al., 2007). Mast cells play a pro-inflammatory role in atherogenesis; however, little is 
known about the recruitment of mast cells during atherosclerosis. Lesional mast cells 
express CCR3, suggesting that mast cells may utilize eotaxin, which is expressed by vascular 
smooth muscle cells, to migrate toward atherosclerotic plaques (Haley et al., 2000).  
4.6 Natural killer (NK) cell recruitment in atherogenesis  
NK cells are found within the shoulder regions of early and advanced human 
atherosclerotic lesions. While there is currently no NK-deficient mouse model of 
atherosclerosis, there are several lines of evidence to suggest that NK cells play a role 
during atherosclerosis (reviewed in Galkina & Ley, 2007, 2009). However, little is known 
about NK cell recruitment during atherogenesis. NK cells express a variety of adhesion 
molecules, including L-selectin, PSGL-1, β2 and α4 integrins, and chemokine receptors, 
including CXCR3, CCR2, and CX3CR1 (Galkina & Ley, 2007). Further studies are 
necessary. Further studies are necessary to identify the players in the migration cascade of 
NK cells to atherosclerotic aortas.  
4.7 Natural killer T (NKT) cell recruitment in atherogenesis  
Several lines of evidence support the pro-atherogenic nature of NKT-cells during the 
development of atherosclerosis in both humans and mice (Galkina and Ley, 2009). As 
glycolipid antigens can be presented by CD1 to CD1-restricted T cells, NKT cells possibly 
play an important role in responding to lipid antigen presentation within the aortic wall. 
NKT cells express receptors for inflammation-related chemokines, including CCR2, CCR5, 
CXCR3, and CXCR6 and CCL2. Thus, NKT cells likely use CCL5, CXCL9-11 and CXCL16 
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5. Leukocyte recruitment during experimental atherosclerosis: Luminal 
“inside-out” migration vs extra-luminal “outside-in” recruitment 
Traditionally, leukocyte migration during atherosclerosis has been considered to occur in an 
“inside-out” manner, focusing on monocyte adhesion to the endothelium on the luminal 
side of the artery and transmigration through the endothelium to arrive at the developing 
atherosclerotic plaque. Several lines of evidence support this model. Rolling and firm 
adherence of monocytes to the endothelium was demonstrated to occur in ex vivo carotid 
artery adhesion models as well as in vivo models (reviewed in (Galkina & Ley, 2007b; 
Zernecke and Weber, 2010)). However at present, there is no direct intravital microscopic 
evidence to support direct lymphocyte recruitment from the arterial lumen. Adoptive 
transfers of lymphocytes into Apoe-/- mice demonstrated that lymphocytes accumulate 
within the associated arterial adventitia suggesting a possible route of migration via 
adventitial vasa vasorum. Interestingly, the inhibition of plaque neovascularisation reduces 
M accumulation and the progression of advanced atherosclerosis (Moreno et al., 2006). 
Recent studies have also revealed that the vasa vasorum can penetrate the media, enter 
atheroma, and come close to the arterial lumen (Moreno et al., 2006; Ritman & Lerman, 2007; 
Mulligan-Kehoe, 2010). Furthermore, administration of growth factors in acid gelatine 
hydrogel microspheres around the periaortic area in 10-11 week old male Apoe-/- mice 
strongly promoted vasa vasorum neovascularisation of the aorta and corresponded with 
larger atherosclerotic plaques (Tanaka et al., 2011). Recently three studies have further 
implicated adventitial inflammation in the pathogenesis of atherosclerosis. Several reports 
have demonstrated that T and B cell aggregates accumulate within the aortic adventitia in 
atherosclerotic aortas (Galkina et al., 2003; Moos et al., 2005; Zhao et al., 2004). LTβ was 
required for the formation of aortic tertiary lymphoid organs within the adventitia (Grabner, 
et. al. 2009). Interestingly, these tertiary lymphoid structures were characterized by distinct 
clusters of germinal centers, proliferating T cells, and elevated production of the 
lymphorganogenic chemokines CXCL13 and CCL21. Mechanistic experiments utilizing LTβ-
receptor deficient smooth muscle cells revealed that TNF-α and LTβ-dependent activation of 
the NF-κB pathway was sufficient to induce the expression of multiple chemokines, 
including CCL2, CCL5, CXCL1, CX3CL1, CCL7, CCL9, CXCL13, CCL19, and CXCL16 
(Lötzer, et al. 2010). Together, these studies suggest that the adventitia plays an important 
structural role as the site of antigen presentation. In addition, neovascularisation from the 
adventitia to the arterial medial layer may provide a route of access for adventitial 
leukocytes to migrate to the media. Further studies will be necessary to truly determine the 
spatio-temporal relationship between the vasa vasorum, aortic tertiary lymphoid structures, 
and atherogenesis; and how these activities relate to leukocyte recruitment. 
6. Conclusions 
Our understanding of the mechanisms of leukocyte recruitment during atherogenesis has 
progressed notably since the early 1980s. The mechanisms of monocyte subset migration 
have been thoroughly studied; however, there are still many fundamental questions that 
remain to be investigated. To date, it is unclear what mechanisms are responsible for the 
recruitment of neutrophils, B cells, mast cells, NKT and NK cells into the aorta. In addition, 
while the recruitment of monocytes and neutrophils has been demonstrated to occur in an 
arterial lumen-to-plaque fashion, the directions of lymphocyte and mast cell recruitment in 
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atherogenesis has yet to be defined. While several studies have highlighted the importance 
of the vasa vasorum and adventitial lymphoid structures, the effects of these anatomical 
structures on leukocyte recruitment have yet to be explored. With progress in tissue-specific 
drug targeting, one potential alternative approach to halting the progression of 
atherosclerosis would be to develop blocking agents against crucial adhesion molecules 
within the aorta that play critical roles in aoritc leukocyte recruitment at the different stage 
of atherosclerosis.  
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1. Introduction 
This chapter is intended to describe the interactions between cell death, phagocytosis and 
autophagic survival in atherosclerosis, and how these processes could be attractive 
therapeutic targets for atherosclerotic plaque stabilization.  
Atherosclerosis is a long-term, progressive inflammatory disease characterized by the 
formation of atherosclerotic plaques in the intima of medium- and large-sized arteries. 
Progression of the disease is accelerated by well-known risk factors including gender, age, 
hypercholesterolemia, diabetes mellitus, hypertension, smoking, obesity and a sedentary 
life-style (Kannel et al., 2004). In the advanced stage, plaques can partially or totally 
occlude the blood vessel, known as arterial stenosis. However, not only the degree of 
stenosis, but also the composition and stability of the plaque determines the clinical 
outcome of the disease (Hansson, 2005). Indeed, plaques may become extremely unstable 
and prone to rupture through the presence of many inflammatory cells and mediators, a 
large necrotic core consisting of uncleared cell debris and lipids, a high degree of cell 
death leading to a scarce amount of smooth muscle cells, and the formation of leaky 
neovessels inside the plaque. Occlusive thrombi, as a result of plaque rupture, in turn 
cause acute (and often fatal) clinical manifestations, such as myocardial infarction and 
stroke. Current clinical therapy is focused on chirurgical interventions (stents, 
endarterectomy, bypass) and plasma cholesterol lowering drugs (e.g. statins). In addition, 
changes in diet and exercise have made significant inroads in preventing acute 
atherothrombotic events (Getz & Reardon, 2006). Although these aforementioned 
approaches have provided significant improvements, they are far from sufficient. 
Analysis of the cell death and phagocytosis machinery as well as survival strategies of 
cells in plaques could provide additional insights for development of new plaque 
stabilizing strategies. 
2. Phagocytosis of apoptotic cells 
Billions of cells in the human body die each day by the process of apoptosis (Henson et 
al., 2001). A critical process, called phagocytosis, is coupled with each of these cell death 





Zernecke,A., Bot,I., Djalali-Talab,Y., Shagdarsuren,E., Bidzhekov,K., Meiler,S., Krohn,R., 
Schober,A., Sperandio,M., Soehnlein,O., Bornemann,J., Tacke,F., Biessen,E.A., & 
Weber,C. (2008). Protective role of CXC receptor 4/CXC ligand 12 unveils the 
importance of neutrophils in atherosclerosis. Circ. Res. 102, 209-217, ISSN 1524-
4571. 
Zernecke,A., Liehn,E.A., Fraemohs,L., von Hundelshausen, P., Koenen,R.R., Corada,M., 
Dejana,E., & Weber,C. (2006). Importance of junctional adhesion molecule-A for 
neointimal lesion formation and infiltration in atherosclerosis-prone mice. 
Arterioscler. Thromb. Vasc. Biol. 26, e10-e13, ISSN 1524-4636. 
Zernecke, A & Weber, C., (2010). Chemokines in the vascular inflammatory response of 
atherosclerosis. Cardiovasc. Research. 86, 192-201, ISSN 1755-3245. 
11 
(Auto)Phagocytosis in Atherosclerosis: 
Implications for Plaque Stability and 
Therapeutic Challenges 
Dorien M. Schrijvers, Guido R.Y. De Meyer and Wim Martinet 
University of Antwerp, Laboratory of Pharmacology 
Belgium  
1. Introduction 
This chapter is intended to describe the interactions between cell death, phagocytosis and 
autophagic survival in atherosclerosis, and how these processes could be attractive 
therapeutic targets for atherosclerotic plaque stabilization.  
Atherosclerosis is a long-term, progressive inflammatory disease characterized by the 
formation of atherosclerotic plaques in the intima of medium- and large-sized arteries. 
Progression of the disease is accelerated by well-known risk factors including gender, age, 
hypercholesterolemia, diabetes mellitus, hypertension, smoking, obesity and a sedentary 
life-style (Kannel et al., 2004). In the advanced stage, plaques can partially or totally 
occlude the blood vessel, known as arterial stenosis. However, not only the degree of 
stenosis, but also the composition and stability of the plaque determines the clinical 
outcome of the disease (Hansson, 2005). Indeed, plaques may become extremely unstable 
and prone to rupture through the presence of many inflammatory cells and mediators, a 
large necrotic core consisting of uncleared cell debris and lipids, a high degree of cell 
death leading to a scarce amount of smooth muscle cells, and the formation of leaky 
neovessels inside the plaque. Occlusive thrombi, as a result of plaque rupture, in turn 
cause acute (and often fatal) clinical manifestations, such as myocardial infarction and 
stroke. Current clinical therapy is focused on chirurgical interventions (stents, 
endarterectomy, bypass) and plasma cholesterol lowering drugs (e.g. statins). In addition, 
changes in diet and exercise have made significant inroads in preventing acute 
atherothrombotic events (Getz & Reardon, 2006). Although these aforementioned 
approaches have provided significant improvements, they are far from sufficient. 
Analysis of the cell death and phagocytosis machinery as well as survival strategies of 
cells in plaques could provide additional insights for development of new plaque 
stabilizing strategies. 
2. Phagocytosis of apoptotic cells 
Billions of cells in the human body die each day by the process of apoptosis (Henson et 
al., 2001). A critical process, called phagocytosis, is coupled with each of these cell death 





phagocytosis in a rapid and efficient manner. This results in at least five critical protective 
effects: (1) it actively suppresses the secretion of inflammatory cytokines from the 
phagocyte, via autocrine/paracrine secretion of transforming growth factor beta (TGF), 
prostaglandin E2 (PGE2), and platelet-activating factor (PAF) (Fadok et al., 1998), (2) it 
prevents leakage of proinflammatory intracellular material from the dying cell, before 
membrane damage occurs, (3) it triggers a potent survival pathway in the phagocyte, 
involving Akt, NF-B and cholesterol efflux (Reddy et al., 2002; Kiss et al., 2006), (4) it can 
promote cell growth and wound healing through the release of vascular endothelial 
growth factor (VEGF) and TGFβ, respectively (Golpon et al., 2004; Sindrilaru et al., 2009), 
and (5) it has a vital role in maintaining immunological tolerance against cell-associated 
antigens, as the TGFβ, produced by the dying cells or the engulfing cells induce the 
differentiation of inducible regulatory T cells, which inhibit immune responses (Green et 
al., 2009). The entire process of phagocytosis (recognition, tethering, binding, 
internalization) is tightly regulated and involves a wide array of molecules, including 
receptors on the phagocyte, ligands on the AC and soluble bridging molecules (Figure 1). 
The multiplicity of ways in which phagocytes recognize and engulf AC suggests that a 
hierarchy of engulfment mechanisms and back-up mechanisms exists. Indeed, upon 
blocking essential receptors phagocytosis of AC is decreased but this inhibition is never 
complete, suggesting cooperation between different mechanisms of phagocytosis 
(Pradhan et al., 1997).  
Changes in composition and molecular topology of the plasma membrane of the AC 
involve the loss of “don’t-eat-me” signals, also called self-associated molecular patterns 
(SAMPs), such as CD31 (Brown et al., 2002) and CD47 (Gardai et al., 2005) and the 
exposure of “eat-me” signals, also known as apoptotic cell-associated molecular patterns 
(ACAMPs). The most renowned ACAMP is the redistributed phosphatidylserine (PS) 
(Fadok et al., 1992;, 1999; Callahan et al., 2000; Hoffmann et al., 2001), which on viable 
cells is actively confined to the inner leaflet of the plasma membrane. Annexin-1 is a 
caspase-dependent engulfment ligand that is recruited from the cytosol and exported to 
the outer plasma membrane leaflet, colocalizes with PS, and is required for efficient 
clearance of ACs (Arur et al., 2003). Similar to PS, calreticulin acts as a facultative 
recognition ligand on AC (Martins et al., 2010). Phagocyte pattern recognition receptors 
such as CD14 (Devitt et al., 1998; Schlegel et al., 1999), scavenger receptors such as CD36, 
and integrins such as αvβ3 (Savill et al., 1992), together with PS receptors such as BAI-1 
(D. Park et al., 2007), TIM-4 (Miyanishi et al., 2007) and stabilin-2 (S.Y. Park et al., 2008), or 
PS bridging molecules such as MFG-E8 (lactadherin) and Gas-6—which bind to PS on the 
AC and to integrins or MerTK on the phagocyte, respectively (Qingxian et al., 2010)—are 
well known phagocytic receptors. Upon engagement, strong tethering is achieved, the 
phagocytic synapse is set, and engulfment response pathways are activated. Other 
phagocyte receptors include an unidentified PS receptor (PSR), transglutaminase 2 (TG2) 
(Szondy et al., 2003), low density lipoprotein receptor-related protein 1 (LRP1) (Lillis et 
al., 2008), ATP binding cassette 7 (ABCA7), purinergic receptor  P2Y2, CD91 (Martins et 
al., 2010) and fractalkine receptor 1 (CX3CR1).    
Recognition signals and receptors are crucial for efficient phagocytosis. However, these 
signals can only be effective when the phagocyte and the AC are in close proximity. Soluble 
“come-get-me” signals are secreted by AC to attract phagocytes to sites of AC death 
(Grimsley & Ravichandran, 2003) (Table 1).  
(Auto)Phagocytosis in Atherosclerosis:  




Fig. 1. Phagocyte recognition of apoptotic cells. Several receptors on the phagocyte 
membrane are involved and interact either directly with their ligands on the AC surface 
(“eat-me”) or via bridging molecules. AC can send out chemoattractant signals to attract 
macrophages to the site of cell death (“come-get-me”). To prevent phagocytosis of healthy 
cells, the latter express molecules to identify themselves (“don’t-eat-me”). ABCA7, ATP-
binding cassette-7; CD14, lipopolysaccharide receptor; LOX-1, lectin-like oxidized low 
density lipoprotein receptor-1; CD36, thrombospondin receptor; CD68, macrosialin; SRA, 
scavenger receptor class A; FcR, Fc fragment of immunoglobulin G receptor; LRP, LDL 
receptor-related protein; CD91, 2-macroglobulin; GAS-6, growth arrest-specific gene 6; 2-
GPI, beta 2-glycoprotein 2; TSP, thrombospondin; PS, phosphatidylserine; PSR, PS receptor; 
v3, vitronectin receptor; MFG-E8, milk-fat globule epidermal growth factor 8; ICAM-3, 
intracellular adhesion molecule-1; C1q, complement complex 1q; Anx1, annexin 1; BAI-1, 
brain angiogenesis inhibitor-1; TIM-4, T-cell immunoglobulin and mucin domain-containing 
protein 4; MerTK, c-mer proto-oncogene tyrosine kinase; LPC, lysophosphatidylcholine; 
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The first identified attraction signal of AC was the covalent dimer of ribosomal protein S19 
(dRP S19) (Horino et al., 1998). It is an essential monocyte chemoattractant in the synovium 
of patients with rheumatoid arthritis (Nishiura et al., 1996). By using neutralizing 
antibodies, G-protein coupled receptor CD88 was identified as a crucial receptor for dRP 
S19. The most characterized AC-derived attractant is lysophosphatidylcholine (LPC), which 
is secreted in a caspase-3 dependent manner (Lauber et al., 2003). LPC exerts its chemotactic 
effect on monocytes via the G-protein coupled receptor G2A (Peter et al., 2008). Knockout 
mice that are deficient in G2A develop a typical autoimmune phenotype resembling 
systemic lupus erythematosus, which was already known to be caused by deficiencies in AC 
recognition (Le et al., 2001). Another AC-derived attraction signal is the endothelial 
monocyte-activating polypeptide II (EMAP II) that is proteolytically cleaved during 
apoptosis but not during necrosis to mature and release the active p23 protein (Knies et al., 
1998). Processing of pro-EMAP II was observed to be a rather late event in the course of 
apoptosis, occurring several hours after poly (ADP-ribose) polymerase cleavage. Since AC 
are phagocytised at an early stage, it was suggested that mature EMAP II serves as a back-
up signal at sites of excessive cell death (Behrensdorf et al., 2000). Importantly, in vitro 
experiments showed that human pro-EMAP II is not cleaved by caspases and mature EMAP 
II could not be found in AC, as opposed to murine EMAP II. Thus, it is not entirely clear 
whether mature EMAP II or its precursor is the real cytokine (Martinet et al., 2010). The only 
receptor that has been reported in the context of EMAP II is CX3CR1, but it remains to be 
elucidated whether this is the crucial sensor for EMAP II p23 (Hou et al., 2006). C1q 
facilitates the ingestion of apoptotic cells by human macrophages via binding to calreticulin 
(Ogden et al., 2001). Thrombospondin-1 (TSP1) modulates a number of processes, including 
migration, proliferation and angiogenesis and was also found to be actively secreted during 
apoptosis (Savill et al., 1992). It serves as a bridging molecule to physically connect the 
phagocyte to the AC, though the phagocyte sensor involved remains obscure. Recently, 
nucleotides such as ATP and UTP, which can be recognized by purinergic receptor P2Y2, 
were found to be released from AC and incite migration of monocytes and macrophages 
(Elliott et al., 2009). Membrane-bound fractalkine (CX3CL1) can be released from AC by a so 
far unknown protease, to induce recruitment of macrophages (Truman et al., 2008). The 
CX3CR1-fractalkine system seems to be particularly important in germinal centers, and is 
limited to certain cell types, such as B cells and neurons. Two less characterized AC-derived 
chemokines are sphingosine-1-phosphate (S1P) and the N-terminal fragment of tyrosyl 
tRNA synthetases (mini TyrRS) (Gude et al., 2008; Wakasugi & Schimmel, 1999). Both were 
identified in in vitro settings and might contribute to the anti-inflammatory character of AC 
clearance. While it is clear that apoptosis can be executed in the absence of blebbing and that 
phagocytic engulfment is not restricted to ‘bite-sized’ apoptotic bodies, it has been 
suggested that fragmentation of the AC may be important for chemotactic signaling to 
mononuclear phagocytes (Segundo et al., 1999; Hugel et al., 2005; Simons & Raposo, 2009). 
Yet, the range of action and the phagocyte sensors remain to be resolved. 
Note that plasma membrane-damaged cells (i.e. late apoptotic and necrotic cells) can also 
release or expose endogenous and exogenous signals, known as alarmins or damage-
associated molecular patterns (DAMPs), to alert the organism to tissue injury (Patel et al., 
2006; Peter et al., 2010) (Table 1). One such protein is the high mobility group box 1 protein 
(HMGB-1), which is released from necrotic cells, but not during apoptosis, and actively 
stimulates the secretion of proinflammatory cytokines (Scaffidi et al., 2002; Andersson et al., 
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2000). Toll like receptors (TLR)-2 and 4 have been described to be engaged in HMGB-1 
signaling (Yu et al., 2006). Another necrotic cell-derived danger signal, that is closely related 
to HMGB-1 is the hepatoma-derived growth factor (HDGF) (Nakamura et al., 1994). It is 
mainly located in the nucleus and remains trapped there during apoptosis, but is passively 
released during necrosis. The family of the calgranulin proteins, also referred to as the S100 
proteins, are potent chemoattractant proteins and play a significant role in the propagation 
of inflammation (Donato, 2003; Foell et al., 2008). Specifically, the S100A8-S100A9 complex 
and S100A12 proved to be useful diagnostic markers of inflammatory diseases, like arthritis 
and COPD, where they are found in high concentrations in the blood, sputum, stool and 
synovial fluid (Foell et al., 2004). Future studies need to clarify whether these proteins also 
represent therapeutic targets. Heat shock proteins (HSP) 70, 90 and 98 are released during 
heat-induced necrosis, probably via exosomes (Basu et al., 2000). Yet, knowledge about the 
secretion and exact functions is confusing and needs clarification. For example, apart from 
their TLR-mediated pro-inflammatory signaling, HSP also display anti-inflammatory effects 
(Wieten et al., 2007; Tang et al., 2007). Finally, concentrations of uric acid are increased 
during cell injury. Uric acid has the ability to prime T cells in the generation of helper and 
cytotoxic T cells (Shi et al., 2002; Ghaemi-Oskouie & Shi, 2011).        
 
 
Table 1. Comprehensive list of signals that are presented and/or secreted by healthy cells 
(“don’t-eat-me”), apoptotic cells (cell surface “eat-me” signals and soluble “come-get-
me”signals) or necrotic cells (“alarmins”). Abbreviations: PS, phosphatidylserine; Anx1, 
annexin 1; LPC, lysophosphatidylcholine, EMAP-II (p23), endothelial monocyte-activating 
polypeptide II active protein; TSP1, thrombospondin 1; CX3CL1, fractalkine; C1q, 
complement complex 1q; dRP S19, dimer of ribosomal protein S19; mini TyrRS, N-terminal 
fraction tyrosyl tRNA synthetase; S1P, sphingosine-1-phosphate; HMGB-1, high mobility 
group box 1 protein; HDGF, hepatoma-derived growth factor; S100 proteins, calgranulin 
family of proteins; HSP, heat-shock protein. 
Recognition of necrotic cells by phagocytes is less well understood than recognition of ACs, 
but an increasing number of recent studies are highlighting its importance. (Krysko et al., 
2006). C1q, mannose-binding lectin (MBL) and pentraxin-3 (PTX3) were demonstrated 
exclusively on late ACs and necrotic cells (Gaipl et al., 2001; Nauta et al., 2003; Rovere et al., 
2000). C-reactive protein (CRP), an acute phase protein binds to secondary necrotic 
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same is true for TSP1. Future studies are needed to identify the differences and similarities 
between the macrophage interaction with AC and necrotic cells. A pitfall in this area is the 
lack of a good cell culture system to study this. Current cell culture models are still very 
variable, displaying a mixture of early and late ACs and necrosis. In addition, detailed 
information on mechanisms of binding and internalization of necrotic cells is sparse. 
Importantly, the trigger provoking necrotic death has an important impact on the kind of 
immunological response of phagocytes (Hirt & Leist, 2003). Phagocytic uptake of late 
apoptotic/necrotic cells by antigen-presenting cells, such as DCs, can lead to the 
presentation of autoantigens to autoreactive T cells in a proinflammatory context, thus 
facilitating the onset of an autoimmune response (Poon et al., 2010). However, there are 
several studies reporting non-inflammatory responses of phagocytes, including modulation 
of anti-tumor immunity and tissue repair via VEGF induction (M. Li et al., 2001).  
For more comprehensive details of the molecular complexity of the clearance phases and 
engulfment signaling pathways, the reader is referred to recent reviews (Elliott & 
Ravichandran, 2010; Kinchen 2010; Poon et al., 2010; Devitt & Marshall, 2011). 
2.1 Phagocytosis of apoptotic cells in atherosclerosis  
In early human atherosclerotic plaques, phagocytic clearance of AC by macrophages is very 
efficient (Tabas, 2005) (Figure 2). Conversely, phagocytosis in advanced human 
atherosclerotic plaques is defective, resulting in secondary necrosis, expansion of the 
necrotic core and increased plaque vulnerability (Schrijvers et al., 2005; Thorp & Tabas, 2009; 
Thorp, 2010). Similar results have been found in mouse models of advanced atherosclerosis. 
The impact of defective clearance of AC on the plaque further exacerbated when essential 
effector molecules in phagocytosis were targeted. Examples of these effector molecules are 
MerTK (Thorp et al., 2008; Ait-Oufella et al., 2008), MFG-E8 (Ait-Oufella et al., 2007), C1q 
(Bhatia et al., 2007), LRP-1 (Yancey et al., 2010), TSP1 (Moura et al., 2008), TG2 (Boisvert et 
al., 2006) and ABCA7 (Jehle et al., 2006). 
The mechanisms of defective phagocytosis in advanced atherosclerotic plaques are not 
entirely clear, although in vitro experiments have put forward several plausible explanations 
(Schrijvers et al., 2005). It is unlikely that overwhelming apoptosis is a major factor, since 
phagocytosis is very efficient in early plaques, where phagocytosis is not defective, when 
excessive apoptosis is induced through genetic manipulation (Tabas, 2010). In addition, AC 
in plaques are found in the vicinity of macrophages, which rules out a possible geographic 
problem. Moreover, atherosclerotic plaques are highly inflamed tissue and contain large 
areas of macrophage infiltration. Therefore, it is not the quantity of the phagocytes that is 
important for phagocytosis, but their functionality. Most likely, phagocytosis itself becomes 
ineffective in advanced plaques. 
One of the first discovered mechanisms that contribute to defective clearance of AC in 
atherosclerosis is the competition of oxidized low density lipoproteins (oxLDL), but not 
acetylated LDL, with AC and oxidatively damaged cells for macrophage binding (Sambrano 
& Steinberg, 1995). AC, oxLDL as well as oxidized red blood cells share oxidatively 
modified moieties on their surfaces that serve as ligands for macrophage recognition, 
thereby profoundly inhibiting the phagocytosis of AC. Furthermore, secretion of MFG-E8 
(lactadherin), a macrophage-derived molecule that facilitates phagocytosis of AC, is down-
regulated upon free cholesterol-loading in macrophages (Su et al., 2005). Electron 
microscopy images from macrophage-derived foam cells in atherosclerotic plaques show 
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that these cells are often crammed with large lipid droplets. It is therefore tempting to 
speculate that these macrophages are no longer able to engulf AC (“full is full”). Uptake of 
AC in macrophages treated in vitro with an excess of platelets or aggregated LDL is not 
inhibited, most likely because foam cells in culture rarely reach the same degree of foam cell 
formation as seen in human plaques, but phagocytosis of beads results in a nearly complete 
inhibition of phagocytosis of AC (Schrijvers et al., 2005). These findings confirm a study by 
Moller et al. (2002) showing that uptake of indigestible, rigid particles by macrophages 
induces cellular ‘stiffening’ so that changes in cellular shape, which are needed to form 
pseudopodia for phagocytosis, are inhibited. In addition to foam cell formation, increased 
oxidative stress is a hallmark of advanced atherosclerotic plaques. Although several reactive 
oxygen species (ROS) can be found in human plaques, peroxynitrite (ONOO-) plays a 
central role in the pathophysiology of atherosclerosis as it induces protein nitrosylation and 
oxidative DNA damage. The peroxynitrite donor SIN1A concentration-dependently 
decreases phagocytosis of AC in vitro (Schrijvers et al., 2005), suggesting that PS or other 
factors present on macrophages or dying cells required for phagocytosis may be sensitive to 
oxidative conditions. Proteolytic cleavage of macrophage receptors exacerbates disease in 
cystic fibrosis and bronchiectasis (Vandivier et al., 2002). Potent proteases, such as matrix 
metalloproteinases and ADAM proteins (a disintegrin and metalloproteinase) are 
upregulated in advanced plaques. In vitro cleavage of MerTK leads to generation of soluble 
Mer, that binds to AC and prevents their uptake by macrophages (Sather et al., 2007). 
Interestingly, gene polymorphisms in CD31 (“don’t eat me”) and increasing levels of its 
soluble form have been associated with ischemic stroke, suggesting that extracellular CD31 
could affect phagocyte interactions with AC (Wei et al., 2009). These, and other ideas, will 
require careful assessment in advanced atherosclerotic plaques.  
The accumulation of AC has a number of consequences that promote plaque progression 
and destabilization (Figure 2). Firstly, impaired phagocytosis of AC results in enhanced 
secretion of proinflammatory cytokines including TNFα and IL-6 by the phagocyte, and a 
reduced release of anti-inflammatory proteins such as TGFβ and IL-10 (Fadok et al., 1998; 
Erwig & Henson, 2007). Deregulated expression of these cytokines may result in 
inflammatory autoimmune responses, as seen in systemic lupus erythematosus and 
rheumatoid arthritis, two non-atherosclerotic inflammatory disorders with a similar defect 
in phagocytosis of dying cells by macrophages. Secondly, tissue factor (TF) expression co-
localizes with AC, especially around the lipid core of human atherosclerotic plaques, 
suggesting that uncleared AC are an important source of this molecule (Tedgui & Mallat, 
2001). TF is a key element in the initiation of the coagulation cascade and mediates 
thrombus formation after rupture of an unstable plaque, when free AC are exposed to the 
blood stream. Thirdly, macrophages that have ingested cholesterol-loaded AC show a 
remarkable set of survival responses, some of which are not present during the loading of 
macrophages with lipoprotein-derived cholesterol (Cui et al., 2007). These responses include 
cholesterol esterification and massive cholesterol efflux, as well as the triggering of cell 
survival signal transduction pathways involving PI3-kinase/Akt and NF- κB. Consequently, 
impaired phagocytosis of AC renders the phagocyte more susceptible to cholesterol-induced 
death (Yvan-Charvet et al., 2010). Finally, expansion of the necrotic core is stimulated due to 
secondary necrosis of free AC. The interaction of macrophages with necrotic cells or 
compounds released from necrotic cells (alarmins) often results in an additional 
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degrading proteases. In this way, post-apoptotic necrosis may contribute to plaque 
instability through enlargement of the necrotic core, matrix breakdown and stimulation of 
inflammation and neovascularization (Figure 2). 
 
 
Fig. 2. Consequences of defective phagocytosis of apoptotic cells in atherosclerotic plaques. 
In early plaques, AC numbers are low and phagocytosis is very efficient, which stimulates 
active suppression of inflammatory pathways, prevents release of intracellular contents 
from the dying cells and promotes macrophage survival. In advanced plaques however, 
phagocytosis of ACs is severely impaired, leading to plaque progression and destabilization 
through various mechanisms. Unstable plaques are at risk for rupture, which results in the 
formation of an occlusive thrombus and subsequent, possible fatale, ischemic events. In 
addition, ACs expose phosphatidylserine (PS) and are a source of tissue factor (TF), both 
highly thrombogenic.  
2.2 Therapeutic possibilities  
Defective AC clearance can alter immune responses in ways that exacerbate human 
diseases, e.g. acceleration of SLE, COPD, cystic fibrosis and atherosclerosis. Therefore, a 
promising approach to stabilize atherosclerotic plaques would be to therapeutically enhance 
the phagocytic capacity of macrophages. Importantly, non-specific enhancement of 
phagocytosis is not desirable, because of the adverse effects associated with phagocytosis of 
lipoproteins, platelets or erythrocytes (Schrijvers et al., 2007).  
Statins are an important class of drugs in the treatment of atherosclerosis. They were 
discovered as drugs that reduce cholesterol levels by inhibiting the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA), but they also have an anti-inflammatory action by 
virtue of their ability to block prenylation of signaling molecules, i.e. Rho GTPases. 
Interestingly, it has been shown that lovastatin increases phagocytosis of ACs by 
(Auto)Phagocytosis in Atherosclerosis:  
Implications for Plaque Stability and Therapeutic Challenges 
 
237 
macrophages from COPD patients in an HMG-CoA reductase-dependent manner 
(Morimoto et al., 2006). In contrast, simvastatin impairs Fc-receptor mediated phagocytosis 
of bacteria (phagocytosis followed by oxidative burst and bacterial killing) and at the same 
time enhances the production of proinflammatory mediators (Benati et al., 2010). These data 
should be assessed to prevent potential side-effects in patients undergoing long-term 
treatment with this statin, who become exposed to an opportunistic pathogen such as S. 
aureus, that is commonly found on the skin and in the upper airways. 
Because oxLDL or oxLDL antibodies interfere with phagocytosis of AC, it is tempting to 
speculate that antioxidants can improve clearance of dying cells. However, clinical trials in 
humans with antioxidants showed only limited success in preventing coronary artery 
disease. Possibly the antioxidants lose activity too quickly or do not penetrate the plaque 
deep enough to reach the phagocytes. This idea is supported by the fact that antioxidants do 
not prevent the oxidation of phagocytized lipoproteins in the lysosome of macrophages 
(Wen & Leake, 2007). It is possible that more encouraging results will be obtained in the 
future through the use of drugs that are targeted to specific oxidation reactions in 
atherosclerosis. It should also be noted that certain antioxidants may not promote but inhibit 
recognition of AC by phagocytes by inhibiting oxidation of externalized PS (Tyurina et al., 
2004). 
In obesity and type 2 diabetes, the defect in efferocytosis of macrophages seems to be related 
to increased concentrations of saturated fatty acids (FA) and/or decreased concentrations of 
the ω-3 FA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (S. Li et al., 2009). 
This change in membrane lipid composition may lead to defective PI3K activation and 
failure to generate PIP3 in the macrophage phagocytic membrane. Interestingly, feeding 
ob/ob mice a fish oil diet increases ω-3 FA without appreciable changes in the content of 
saturated FA and leads to a reversal of the defect in efferocytosis and a reduction in plaque 
size (S. Li et al., 2009). These findings suggest that the level of ω-3 FA in the macrophage 
membrane is an important factor contributing to efficient efferocytosis.  
Examples of other drugs that promote phagocytic clearance of AC are chemerin, an 
endogenous chemoattractant (Cash et al., 2010), the macrolide antibiotic azithromycin 
(Hodge et al., 2006), members of the lipoxin family (Godson et al., 2000), inflammation 
resolution mediators such as resolvins (Serhan et al., 2008), inhibitors of MerTK cleavage 
(Sather et al., 2007), PPAR activators (Mukundan et al., 2009), LXR activators which 
increase expression of MerTK, as well as compounds that induce secretion of the 
efferocytosis effector apolipoprotein E and ABCA1/G1-mediated efflux of toxic sterols (A-
Gonzalez et al., 2009; Yancey et al., 2010; Yvan-Charvet et al., 2010).  
Phagocyte populations in atherosclerosis are heterogeneous (Waldo et al., 2008; Shimada, 
2009) and express different  express markers and phagocytic receptors, depending on their 
spatial location in the plaque and surrounding milieu. In vitro, alternatively activated 
macrophages (M2 phenotype) preferentially clear AC and secrete anti-inflammatory 
cytokines, including IL-10 and TGFW. Xu et al., 2006). On the other hand, classically 
activated (M1) macrophages secrete proinflammatory cytokines, such as TNF and IL-6, 
that can negatively affect phagocytosis. It would be interesting to elucidate whether 
communication between these subsets affects phagocytosis efficiency. Plaque phagocytes 
can polarize towards a spectrum of activation states, resulting in altered phagocytic 
capacities (Peng et al., 2009). Taking advantage of the fact that some subpopulations are 





degrading proteases. In this way, post-apoptotic necrosis may contribute to plaque 
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inflammation and neovascularization (Figure 2). 
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AC clearance in atherosclerotic plaques. For example, activation of PPAR stimulates 
macrophage polarization to the anti-inflammatory M2 phenotype (Bouhlel et al., 2007). 
Whether or not these aforementioned approaches will be effective at stabilizing 
atherosclerotic plaques through the amelioration of phagocytic clearance remains to be 
elucidated. 
3. Autophagy 
3.1 General principles 
While phagocytosis reflects clearance of non-self particles, autophagy represents a process 
for cells to dispose of their own unwanted or damaged proteins and organelles (Klionsky, 
2007). Autophagy or "self eating" refers to a conserved cellular process for the turnover of 
organelles and proteins that occurs in all eukaryotic cells (Yoshimori, 2004). It is activated as 
an adaptive response to environmental stress (e.g. nutrient deprivation, hypoxia, oxidative 
stress, exposure to xenobiotics) to promote cell survival through the recycling of precursors 
(amino acids, free fatty acids, nucleotides) derived from the degradation of endogenous 
cellular components. Typical of autophagy is the formation of double-membrane structures, 
called phagophores, that engulf intracellular material such as protein aggregates, lipid 
droplets and complete organelles for degradation (Figure 3). The phagophore expands and, 
on completion, forms an autophagosome, which then fuses with lysosomes, thereby 
generating an autophagolysosome (Shintani & Klionsky, 2004). Incorporation of the outer 
autophagosomal membrane in the lysosomal membrane allows the degradation of the 
remaining inner single membrane and the cytoplasmic content of the autophagosome by 
lysosomal hydrolases.  
Autophagy generally acts as a housekeeping mechanism, and is crucially involved in the 
maintenance of normal cellular homeostasis. Hereby, turnover of damaged or dysfunctional 
organelles, such as mitochondria, peroxisomes and endoplasmic reticulum, is facilitated to 
maintain a healthy population of these organelles. When stimulated by cellular stress 
conditions, autophagy functions as a self-cannibalization pathway that promotes cell 
survival in an unfavorable environment. This pro-survival function of autophagy has been 
demonstrated at the cellular and tissue level in different contexts, such as nutrient and 
growth factor deprivation, endoplasmic reticulum stress, development, microbial infection, 
and diseases characterized by the accumulation of protein aggregates. Preclinical studies 
have demonstrated that autophagy is associated with cancer, neurodegenerative disorders 
(e.g. Alzheimer’s, Parkinson’s and Huntington’s disease), embryogenesis, aging and 
immunity, but also with cardiovascular disease including ischemia-reperfusion injury of the 
heart, cardiomyopathy and atherosclerosis (Mathew et al., 2007; Levine & Kroemer, 2008; 
Mizushima et al., 2008; Martinet & De Meyer, 2008,2009a). Despite tremendous recent 
advances in this field, the functional significance of autophagy in human disease remains 
incompletely understood, and potentially involves both adaptive and maladaptive 
outcomes.  
There are three main types of autophagy, namely macroautophagy, microautophagy or 
chaperone-mediated autophagy (Klionsky et al., 2007). Macroautophagy is the most 
extensively analysed and quantitatively more important type of autophagy in which entire 
portions of the cytosol are sequestered by a de novo-formed phagophore that seals into an 
autophagosome (Figure 3). In addition to this ‘in bulk’ degradation, selective sequestration 
of cellular structures into autophagosomes is a common mechanism for removal of 
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organelles or particulate protein complexes (aggregates). This is then referred to as selective 
macroautophagy. The process of microautophagy is poorly characterized, at least in 
mammalian cells. Like in macroautophagy, entire cytosolic regions constitute the 
microautophagy cargo, but it is the lysosomal membrane itself that invaginates or protrudes 
to seclude the cytosolic components. Selective autophagy of soluble cytosolic proteins can 
occur via chaperone-mediated autophagy, the only type of autophagy that requires 
unfolding of the protein cargo before internalization into lysosomes (Dice, 2007). Selectivity 
is determined via the recognition of a pentapeptide in the amino acid sequence of the 
substrate proteins that are delivered to the surface of the lysosomes by a cytosolic chaperone 
(Hsc70). To reach the lysosomal lumen, these proteins interact with the lysosome-associated 
protein type 2A (LAMP-2A) receptor, and a complex of lysosomal chaperones at both sides 
of the lysosomal membrane.  
 
 
Fig. 3. Schematic depiction of the autophagy process. A phagophore is formed at the 
initiation of autophagy, in response to environmental stress (e.g. nutrient deprivation) to 
sequester cytoplasmic components for degradation. Upon completion, the phagophore 
forms a double-membraned vesicle called  an autophagosome. After fusion with a lysosome, 
the content is degraded by lysosomal hydrolases (LH). Following breakdown, the resulting 
macromolecules (e.g. nucleic acids, amino acids, free fatty acids) are released back into the 
cytosol for reuse by the cell. 
3.2 Molecular mechanisms of autophagy 
The molecular machinery and signaling cascades that regulate autophagy are very complex 
(Ravikumar et al., 2010; Yang & Klionsky, 2010). Briefly, the key regulator of autophagy in 
human and murine cells is the mammalian target of rapamycin (mTOR) kinase, which 
suppresses autophagy in conditions of sufficient nutrients and growth factors, via class I 
phoshatidylinositol-3-kinases (PI3Ks) and Akt. Activation of the mTOR complex 1 
(mTORC1) - and consequent repression of autophagy - can also be mediated by mitogen-
activated protein kinases (MAPKs), by activation of the p90 ribosomal S6 kinase, as well as 
by the Wnt signaling pathway. Other prominent regulators of autophagy include (but are 
not limited to): AMP-activated protein kinase (AMPK), which inhibits mTOR in response to 
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nutrient deprivation; c-Jun N-terminal kinase (JNK), which is involved in multiple signaling 
cascades activated by stressful conditions; members of the Bcl-2 protein family that contain a 
single Bcl-2 homology (BH) domain, the so-called BH3-only proteins, which displace (and 
hence derepress) the essential autophagy modulator Beclin 1 from inhibitory complexes 
with Bcl-2 or Bcl-XL; Sirtuin 1, which responds to high NAD+ levels, de facto acting as a 
sensor of nutrient availability; the oncosuppressor protein p53, which inhibits autophagy 
when present in the cytoplasm; the IκB kinase (IKK) complex, which is also essential for the 
activation of NF-κB by stress; the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) at the 
level of the ER and transglutaminase 2. Finally, autophagy is positively regulated by the 
transcription factor activity of E2F1, FoxO3a, NF-κB and p53 among others. 
3.3 Autophagy in atherosclerosis 
Autophagy in atherosclerotic plaques has not yet been analysed in full detail due to 
technical limitations, in particular the lack of adequate marker proteins. As a consequence, 
the role of autophagy in atherosclerosis is unclear and currently under intense investigation. 
However, transmission electron microscopy of smooth muscle cells (SMCs) in the fibrous 
cap of advanced plaques revealed ultrastructural features of autophagy such as 
vacuolization and formation of myelin figures (Martinet & De Meyer, 2009b). The latter 
structures, composed of phospholipids and membrane fragments, refer to autophagic 
degradation of membranous cellular components. Moreover, Western blot analysis of 
human carotid plaques showed processing of microtubule-associated protein 1 light chain 3 
(LC3) into the autophagosome-specific isoform LC3-II, indicating activation of autophagy. 
Importantly, these kind of data have to be interpreted with great caution. Autophagy is a 
dynamic process: formation of autophagosomes, followed by their degradation after 
lysosomal fusion (Figure 3). Many groups, including our own, have measured increased 
autophagosome formation or LC3 processing, and labelled this as increased autophagic 
activity. However, these parameters can also reflect impaired degradation. Therefore, it is 
essential to measure autophagic flux (Gottlieb & Mentzer, 2010). In tissue, this can be very 
challenging. A very elegant method now widely accepted to measure flux is using a tandem 
fusion protein of LC3 with the red acid-insensitive mCherry (or RFP) and the green acid-
sensitive GFP proteins to measure formation of autolysosomes and their degradation 
(Kimura et al., 2007). GFP fluorescence is quenched in the acidic environment of the 
lysosome, while mCherry (or RFP) fluorescence is stable at low pH. As a consequence, 
detection of yellow fluorescence (overlap of GFP and mCherry) reflects impaired flux, and 
the presence of red fluorescence reflects quenching of GFP and thus ongoing degradation in 
the lysosome (Mizushima et al., 2010). Besides LC3, levels of other autophagy substrates can 
be used for measuring autophagic flux, of which the best studied is p62, an adaptor protein 
that links ubiquitinated proteins to LC3. Accumulation of p62 reflects impaired degradation 
in the autophagolysosome, whereas low p62 levels indicate active degradation. 
Unfortunately, no data is available on p62 levels during atherosclerotic plaque formation 
and destabilization. 
In vitro studies identified several potential triggers for autophagy that are present in 
atherosclerotic plaques, such as inflammation (Heymann, 2006; Jia et al., 2006), ROS 
production (Scherz-Shouval & Elazar, 2011), accumulation of  oxidized lipoproteins (Muller 
et al., 2011; Nowicki et al., 2007) and endoplasmic reticulum stress (Qin et al., 2010). Also 
hypoxia is a common feature of advanced human atherosclerotic plaques (Sluimer et al., 
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2008), caused by inadequate vascularization, nutrient and growth factor deprivation, a well-
known condition leading to induction of autophagy (Azad et al., 2008).  
3.3.1 Dual role of autophagy in atherosclerosis  
Autophagy can protect plaque cells against oxidative stress by degrading damaged 
intracellular material, in particular polarized mitochondria (Kiffin et al., 2006). In this way, 
successful autophagy of the damaged components promotes cell survival by limiting the 
release of pro-apoptotic proteins such as cytochrome c into the cytosol (Gozuacik & Kimchi, 
2004). The protective role of autophagy in atherosclerosis was illustrated by in vitro findings 
showing that death of smooth muscle cells (SMC) induced by low concentrations of statins 
is attenuated by the autophagy inducer 7-ketocholesterol (Martinet et al., 2008). Also excess 
free cholesterol or exposure of SMCs to lipid peroxidation products such as 4-
hydroxynonenal activates autophagy, thereby prolonging SMC survival (K. Xu et al., 2010). 
Also, autophagy safeguards efficient phagocytosis of AC (Qu et al., 2007), which is beneficial 
for plaque stability (Figure 2). Altogether, induction of autophagy represents a vital 
component of a general stress response in vascular cells and could therefore be an important 
determinant of the stability of atherosclerotic plaques (Figure 4). 
In contrast, excessive autophagy in SMCs or endothelial cells may cause autophagic cell 
death (Levine & Yuan, 2005). SMC death in turn results in plaque destabilization owing to 
the reduced synthesis of collagen and thinning of the fibrous cap. Also endothelial cell death 
may be detrimental for the structure of the plaque as endothelial injury and/or death 
represents a primary mechanism for acute clinical events by promoting lesional thrombosis. 
In view of plaque stability and regression, these observations might advise against excessive 
autophagy induction in plaques. Conversely, autophagic death of macrophages is 
considered a promising approach to stabilize advanced plaques (Martinet et al., 2007). 
 
 
Fig. 4. Consequences of autophagy in atherosclerosis. While autophagy contributes  
beneficially to plaque stability by protecting cells from oxidative stress and ensuring 
efficient clearance of dead cells, it can also exert functions that are unfavorable in terms of 
plaque stability. Autophagy has a very potent inflammatory component and is very tightly 
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However, recent evidence indicates that phagocytosis of cells dying through autophagy 
results in an inflammatory response through inflammasome activation, IL-1release and 
subsequent IL-6 and TNFinduction in neighboring phagocytes (Petrovski et al., 2007) 
(Figure 4). Moreover, autophagy proteins themselves can exert proapoptotic functions. For 
example, Beclin-1 (Atg6), a key protein involved in autophagy, can interact with the anti-
apoptotic proteins Bcl-2 or Bcl-xL. This interaction is pro-apoptotic and antiautophagic, at 
least under non-autophagic stimuli. However, during autophagic conditions, Beclin-1 
binding to Bcl-xL is antiapoptotic (Pattingre et al., 2005; Wang, 2008). In addition, Atg5 
(when cleaved by activated calpain) can bind to Bcl-xL and induce apoptosis (Yousefi et al., 
2006; Yousefi & Simon, 2007). On the other hand, inactivation of autophagy genes (e.g. Atg5) 
also causes cell death (Komatsu et al., 2006), making matters even more complicated. These 
data demonstrate that the crosstalk between autophagy and apoptosis should not be 
neglected when designing interventions aimed at stabilizing atherosclerotic plaques via 
autophagy.  
3.3.2 Is autophagy an interesting drug target for plaque stabilization? 
Pharmacological modulation of autophagy can be achieved by targeting key players in the 
autophagy machinery (Rubinzstein et al., 2007). For example, rapamycin or its derivatives 
(e.g. everolimus) inhibit mTOR, thereby activating autophagy. Another way to modulate 
autophagy is to target the mTOR-independent route, mainly regulated by inositol-1,4,5-
triphosphate (IP3) levels. This can be achieved with drugs such as lithium, sodium valproate 
and carbamezapine. The first line of evidence that demonstrates the beneficial effects of 
autophagy induction in atherosclerosis was obtained after stent-based delivery of the 
rapamycin derivative everolimus in plaques of cholesterol-fed rabbits (Verheye et al., 2007). 
This treatment resulted in a marked reduction of macrophages via autophagic cell death 
without affecting the SMCs. However, recent in vitro work in our laboratory has 
demonstrated that pharmacological induction of autophagy in macrophages triggers 
secretion of proinflammatory cytokines such as IL-6, MCP1 and TNF(Martinet, De Meyer, 
unpublished data)suggesting that the autophagic process is not immunologically silent. 
This cocktail of cytokines has the potential to induce SMC death and exacerbate the 
inflammatory infiltration of leukocytes in the plaque. Combined treatment with anti-
inflammatory agents such as glucocorticosteroids may help to prevent the adverse effects of 
drug-induced autophagy. On the other hand, induction of autophagy in free cholesterol-
loaded SMCs by rapamycin inhibited AC death (K. Xu et al., 2010), possibly through the 
degradation of dysfunctional organelles such as mitochondria and endoplasmic reticulum. 
These findings provide a rationale for the use of rapamycin or analogs such as everolimus to 
stabilize advanced atherosclerotic plaques. 
Several studies have shed light on the potential detrimental consequences of autophagy 
inhibition with regard to plaque stability. Firstly, autophagy is essential for efficient 
phagocytosis of dying cells (Qu et al., 2007). ACs derived from cells lacking essential 
autophagy genes (Atg5 or beclin-1) fail to present the “eat-me” signal PS and secrete lower 
levels of the “come-get-me” signal lysophosphatidylcholine (Qu et al., 2007). This will result 
in a marked decrease in the engulfment of apoptotic corpses, enhanced plaque necrosis and 
recruitment of inflammatory cells (Gautier et al., 2009). Thus, inhibition of autophagy may 
further destabilize advanced plaques, where phagocytosis of ACs is already compromised 
(Schrijvers et al., 2005). Additionally, inhibition of autophagy using 3-methyladenine in free 
(Auto)Phagocytosis in Atherosclerosis:  
Implications for Plaque Stability and Therapeutic Challenges 
 
243 
cholesterol-treated SMCs enhances apoptosis and necrosis (K. Xu et al., 2010), indicating that 
a strong interaction exists between autophagy and other forms of cell death (Maiuri et al., 
2007). Of note, altering autophagy using pharmacological agents can be problematic, as they 
can interfere with general processes, such as glucose metabolism (e.g. metformin, 
deoxyglucose) or mitochondrial respiration (e.g. oligomycin). Broad-spectrum PI3 kinase 
inhibitors wortmannin and 3-methyladenine, widely used in autophagy research, inhibit 
Akt activation. Thus, results using these agents must always be interpreted carefully. 
4. Concluding remarks 
(Auto)phagocytosis plays a key role in maintaining atherosclerotic plaque stability (Figure 
5). Efficient phagocytosis of AC is required to prevent accumulation of dead cells, expansion 
of the necrotic core in plaques and inflammatory responses resulting from secondary 
necrosis of residual AC. These factors will undoubtedly promote plaque inflammation, 
destabilization and rupture, leading to possible fatal ischemic events (e.g. myocardial 
infarction and stroke). Autophagy may be viewed as a “cry for survival,” and such survival 
is the result of an adaptive response to fight against cellular stress. If this stress—such as 
oxidative damage in atherosclerotic plaques—is mild, autophagy is activated in order to 
 
 
Fig. 5. Implications of dysfunctional phagocytosis and autophagy on the stability of 
atherosclerotic plaques. In stable plaques, AC numbers are low and phagocytosis is very 
efficient. Basal autophagy contributes to maintain efficient phagocytosis and promote cell 
survival. In unstable plaques, however, phagocytosis of AC is severely impaired, leading to 
accumulation of AC, expansion of the necrotic core, thereby increasing the risk for plaque 
rupture, which results in the formation of an occlusive thrombus. Decreased autophagy 
probably worsens phagocytosis efficiency, which is already compromised in advanced 
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survive. On the other hand, if cellular stress is overwhelming or continuous, the adaptive 
response fails and cells undergo an autophagic type of death. Crossbreeding of mouse 
models for atherosclerosis (e.g. ApoE or LDL receptor knockout animals) with autophagy-
deficient mice (e.g. conditional Atg5 or Atg7 knockout animals) will undoubtedly shed more 
light on the potential role of autophagy in atherosclerosis. Based on the literature and 
promising experiments in our lab and that of others, it is definite that cells need autophagy 
to be able to survive under stressful circumstances. Therefore, controlled (moderate) 
induction of autophagy, but not excessive induction or inhibition of autophagy, seems to be 
a promising strategy for stabilization of atherosclerotic plaques. The challenge for the future 
in the stabilization of atherosclerotic plaques will be to turn on the protective pro-survival 
effects of autophagy in a selective manner, without activating unwanted death pathways or 
proinflammatory signaling cascades. With progress being made in tissue-specific drug 
targeting using nanoparticles, one potential future approach to stabilize atherosclerotic 
plaques would be to develop macrophage-specific phagocytosis and/or autophagy inducers 
combined with anti-inflammatory drugs. However, stimulation of autophagy can only be 
beneficial if autophagic flux is not impaired, since this condition could lead to lysosomal 
leakage or ejection of autophagosomes as well as the induction of cell death. Altogether, 
(auto)phagocytosis is a crucial process involved in atherogenesis that significantly affects 
the stability of the atherosclerotic plaque. 
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1. Introduction 
The inflammatory response is an important process, aiming to restore tissue homeostasis 
following tissue injury or infection. Acute inflammation is a tightly controlled process. If an 
inflammatory stimulus persists or if normal immune function is perturbed, inflammation 
may become chronic. Atherosclerosis is a chronic inflammatory disorder involving 
components of both the innate and adaptive immune systems (Ross, 1999). The innate 
immune system provides the first line of defence against invading pathogens. Innate 
immune detection of pathogens relies on a set of pattern recognition receptors (PRRs) that 
recognise and respond to conserved pathogen-associated molecular patterns (PAMPs). 
Growing evidence supports roles for PRRs in the initiation and progression of 
atherosclerosis. In this chapter, the agonists, signalling pathways, expression and functions 
of PRRs, in particular in reference to atherosclerosis, will be discussed. The potential 
therapeutic benefit of targeting PRRs for treatment of atherosclerosis will also be explored. 
2. Pattern recognition receptors 
PAMPs are recognised by an expanding number of PRRs, which currently includes at least 
50 members. PRRs can be categorised into one of three families: Toll-like receptors (TLRs), 
Retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), and Nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs). Both extracellular and intracellular 
compartments are patrolled by PRRs with each family of receptors specialising in surveying 
a given location. TLRs are transmembrane PRRs either located in the cellular membrane 
(interacting with the extracellular space) or within intracellular vesicles such as endosomes 
or lysosomes. Cytosolic PRRs include RLRs and NLRs that detect intracellular PAMPs. 
While cytosolic PRRs are universally expressed in the majority of cells in the body (Takeuchi 
&  Akira, 2010), TLR expression is more restricted. TLR, NLR and RLR ligation by an agonist 
stimulates downstream signalling cascades activating 2 major types of transcription factor: 
the nuclear factor kB (NFκB), and interferon response factors (IRFs). 
2.1 Toll-like receptors (TLRs) 
The TLR family contains at least 13 different members in mammals. Following ligand 
binding, TLRs dimerise, with most receptors (with the exception of TLR2 and TLR4) 
forming homodimers. Components of the bacterial cell wall including bacterial lipoproteins, 
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binding, TLRs dimerise, with most receptors (with the exception of TLR2 and TLR4) 
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and TLR9 are not located on the cell surface and are instead located on the membranes of 
endoplasmic reticulum (ER), endosomes and lysosomes, where they detect nucleic acids 
derived from bacteria or viruses. The TLR family share their cytoplasmic Toll/Interleukin-1 
Receptor (TIR) domain – essential for signal transduction - with their larger parent family 
which includes interleukin-1-receptor (IL-1Rs). The extracellular regions of TLRs contain 
tandemly arranged leucine rich repeats (LRR) creating a horseshoe-shaped solenoid 
structure (Liu et al., 2008a). TLRs are connected to their downstream signalling cascades via 
five TLR adaptor molecules that are recruited to and homophilically interact with the TIR 
domain: myeloid differentiation protein 88 (MyD88), Toll–interleukin-1 receptor domain-
containing adaptor inducing interferon-β (TRIF), TIR domain-containing adaptor protein 
(TIRAP)/MyD88-adaptor-like (MAL), TRIF related adaptor molecule (TRAM) and sterile 
alpha and HEAT/Armadillo motif (SARM).  
2.2 RIG-I-like receptors (RLRs) 
Double stranded RNA (dsRNA) in the cytoplasm can be sensed in both immune and non-
immune cells via RLRs. The RLR family includes retinoic acid inducible gene I (RIG-I), 
melanoma differentiation associated gene 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2). RLRs possess a central RNA helicase domain with the ATPase 
binding motif DExD/H. The C-terminal regulatory domain is responsible for binding to 
dsRNAs. RIG-I and MDA5 have two N-terminal caspase activation and recruitment 
domains (CARDs), which allows homophilic interactions between activated RIG-I or 
MDA5 and the adaptor protein mitochondrial antiviral signaling (MAVS, also known as 
IPS-1, VISA, and Cardif), which is found in the outer mitochondrial membrane (Takeuchi 
&  Akira, 2010).  
2.3 NOD-like receptors (NLRs) 
NLRs belong to a large family of soluble proteins that are present in the cytoplasm and 
detect intracellular ligands. There are 23 NLR genes in humans and 34 in mice. Three 
distinct subfamilies of NLRs exist: NODs, NLRPs (or NALPs) and IL-1β-converting enzyme 
(ICE)-protease activating factor (IPAF). NLRs are composed of the following domains: a C-
terminal ligand-sensing leucine-rich repeat (LRR) domain, a central nucleotide-binding and 
oligomerization (NACHT) domain (responsible for oligomerization), and an N-terminal 
effector pyrin domain (PYD), caspase recruitment domain family (CARD) or baculoviral 
IAP repeat (BIR) mediating homophilic interactions in downstream signalling. The 
physiological function of most NLRs is still not understood. 
3. PRR agonists in atherosclerosis 
A vast and diverse array of ligands including viruses, lipids and extracellular matrix 
components are collectively recognised by PRRs (Lundberg &  Hansson, 2010). Each 
individual PRR exhibits specificity in the repertoire of ligands that it recognises and 
responds to. In a process known as ‘sterile inflammation’, activation of PRRs can occur in 
the absence of exogenous stimuli (Rifkin et al., 2005). The PRR agonists in this context are 
generated as a result of tissue damage and inflammation and are known as ‘damage-
associated molecular patterns’ (DAMPs). Thus, PRR ligands encompass both exogenous 
PAMPs and endogenous DAMPs. Increasing evidence suggests that different co-receptors 
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and accessory molecules and thus different mechanisms of action are used by TLRs in 
response to ligation by PAMPs and DAMPs (reviewed in (Piccinini &  Midwood, 2010)). 
Exogenous PRR ligands, such as viruses and bacteria, and endogenous PRR ligands, 
including extracellular matrix components, modified lipids and heat shock proteins are PRR 
ligands that may be relevant in the context of atherosclerosis. 
3.1 Exogenous PRR agonists  
Exogenous agonists are the best defined PRR ligands and include components of bacteria 
and viruses. TLR2 recognises a diverse array of PAMPs using heterodimerisation with 
TLR1 or TLR6. TLR2 is key in the recognition of Gram-positive bacteria (Underhill et al., 
1999a; Underhill et al., 1999b). Lipoteichoic acid, is a ligand of TLR2/TLR6 heterodimers 
as are peptidoglycan and zymosan (Gantner et al., 2003; Ozinsky et al., 2000; Schroder et 
al., 2003). Using CD36 as a co-receptor, TLR2/TLR6 heterodimers also recognise 
mycoplasma diacylated lipoproteins peptide (Brightbill et al., 1999; Hoebe et al., 2005; 
Takeuchi et al., 2001). Triacylated lipoproteins are ligands for TLR1/TLR2 heterodimers 
(Jin et al., 2007; Takeuchi et al., 2002). Endotoxin (lipopolysaccharide), a component of the 
outer membrane of Gram-negative bacteria, is an agonist for the TLR4 signalling complex 
(Shimazu et al., 1999; Wright et al., 1990). Compared to TLR2 and TLR4, other TLRs have 
a relatively limited repertoire of TLR ligands. TLR3 senses viral double-stranded RNA 
and some small interfering RNAs. A synthetic dsRNA analogue Poly(I:C) is commonly 
used as a TLR3 activator (Takeuchi &  Akira, 2010). Bacterial flagellin is recognised by 
TLR5 and TLR9 detects unmethylated CpG DNA, typically of bacterial origin (O'Neill &  
Bowie, 2007). TLR7 is the main sensor of ssRNA derived from RNA viruses including 
human immunodeficiency virus and influenza A. More recently, TLR7 on myeloid 
dendritic cells has also been shown to be capable of sensing bacterial RNA (Mancuso et 
al., 2009). 
Genomic RNA of dsRNA viruses and dsRNA generated as the replication intermediate of 
ssRNA viruses in the cytosol are ligands for RLRs. Short dsRNAs with 5’ triphosphate ends 
are sensed by RIG-I whereas MDA5 recognises longer dsRNAs (Kato et al., 2006). NOD1 
and NOD2 sense peptidoglycan. NOD1 recognises a peptidoglycan motif: dipeptide γ-d-
glutamyl-meso-dia-minopimelic acid (iE-DAP) and NOD2 recognises muramyl dipeptide 
(Chamaillard et al., 2003; Girardin et al., 2003a; Girardin et al., 2003b; Inohara et al., 2003). 
Whole pathogens including bacteria with pore-forming toxins and viruses including 
influenza virus are activators of the NLRP3 inflammasome (reviewed in (Schroder &  
Tschopp, 2010)). 
Numerous exogenous PAMPS may be ligands for PRRs in atherosclerosis. Chlamydia 
pneumonia, porphyromonas gingivalis and cytomegalovirus are exogenous PRR ligands found 
in atherosclerotic plaques (Chiu et al., 1997; Kuo et al., 1993). These bacterial and viral 
infectious agents have been associated with an increased risk of atherosclerosis 
development (Kalayoglu et al., 2002; Kiechl et al., 2001; Scannapieco et al., 2003) and are 
recognised by TLR2 and TLR4 (Burns et al., 2006; Compton et al., 2003; Naiki et al., 2008). 
The failure to detect active viral replication within atherosclerotic plaques (Kol et al., 1995; 
Zhou et al., 1999) suggests PRR activation by infectious agents and not viral replication itself 
is the link between infectious disease and cardiovascular risk. Exogenous heat shock 
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and some small interfering RNAs. A synthetic dsRNA analogue Poly(I:C) is commonly 
used as a TLR3 activator (Takeuchi &  Akira, 2010). Bacterial flagellin is recognised by 
TLR5 and TLR9 detects unmethylated CpG DNA, typically of bacterial origin (O'Neill &  
Bowie, 2007). TLR7 is the main sensor of ssRNA derived from RNA viruses including 
human immunodeficiency virus and influenza A. More recently, TLR7 on myeloid 
dendritic cells has also been shown to be capable of sensing bacterial RNA (Mancuso et 
al., 2009). 
Genomic RNA of dsRNA viruses and dsRNA generated as the replication intermediate of 
ssRNA viruses in the cytosol are ligands for RLRs. Short dsRNAs with 5’ triphosphate ends 
are sensed by RIG-I whereas MDA5 recognises longer dsRNAs (Kato et al., 2006). NOD1 
and NOD2 sense peptidoglycan. NOD1 recognises a peptidoglycan motif: dipeptide γ-d-
glutamyl-meso-dia-minopimelic acid (iE-DAP) and NOD2 recognises muramyl dipeptide 
(Chamaillard et al., 2003; Girardin et al., 2003a; Girardin et al., 2003b; Inohara et al., 2003). 
Whole pathogens including bacteria with pore-forming toxins and viruses including 
influenza virus are activators of the NLRP3 inflammasome (reviewed in (Schroder &  
Tschopp, 2010)). 
Numerous exogenous PAMPS may be ligands for PRRs in atherosclerosis. Chlamydia 
pneumonia, porphyromonas gingivalis and cytomegalovirus are exogenous PRR ligands found 
in atherosclerotic plaques (Chiu et al., 1997; Kuo et al., 1993). These bacterial and viral 
infectious agents have been associated with an increased risk of atherosclerosis 
development (Kalayoglu et al., 2002; Kiechl et al., 2001; Scannapieco et al., 2003) and are 
recognised by TLR2 and TLR4 (Burns et al., 2006; Compton et al., 2003; Naiki et al., 2008). 
The failure to detect active viral replication within atherosclerotic plaques (Kol et al., 1995; 
Zhou et al., 1999) suggests PRR activation by infectious agents and not viral replication itself 
is the link between infectious disease and cardiovascular risk. Exogenous heat shock 





(Laman et al., 2002) are also present in atherosclerotic lesions and thus may activate PRRs in 
atherogenesis.   
3.2 Endogenous PRR agonists 
Many endogenous PRR ligands are present in atherosclerotic lesions and thus PRR 
activation in atherosclerosis could result from a combination of exogenous and 
endogenous ligand sensing. Indeed, work by Curtiss and colleagues supports a role for 
endogenous TLR ligands in atherogenesis (Mullick et al., 2005).  Extracellular matrix 
(ECM) is degraded during tissue injury and remodelling leading to the generation of ECM 
components, which can function as PRR ligands. Fibrinogen can activate TLR4 signalling 
as can the fibronectin alternatively spliced exon encoding type III extra domain A (EDA) 
and tenascin C (Midwood &  Orend, 2009; Okamura et al., 2001; Smiley et al., 2001). 
Hyaluronan, a large glycosaminoglycan component of the ECM, and biglycan activate 
TLR2 and TLR4 signalling (Schaefer et al., 2005; Scheibner et al., 2006; Taylor et al., 2004). 
Hyaluronan can induce IL-1 release by macrophages in a NLRP3-dependent manner 
(Yamasaki et al., 2009)  while biglycan also activates the NLRP3 inflammasome (Babelova 
et al., 2009). The large ECM proteoglycan versican is a TLR2/6 ligand associated with 
cytokine production in tumor-infiltrating macrophages (Kim et al., 2009). These ECM 
components may be generated during injury and remodeling of the vessel wall and thus 
may activate PRRs in atherosclerosis. 
Lipids, key components of atherosclerotic plaques, are TLR ligands. Minimally modified 
low-density lipoproteins induce cytokine and reactive oxygen species generation via TLR4 
signalling complexes (Miller et al., 2003). In association with CD36, TLR4/TLR6 hetero-
dimers sense oxidized LDL leading to increased chemokine expression (Stewart et al., 2010). 
Saturated fatty acids elicit TLR4 activation whereas polyunsaturated fatty acids inhibit TLR4 
activation (Lee et al., 2003). However, the ability of saturated fatty acids to directly induce 
TLR signaling has been questioned (Erridge &  Samani, 2009). TLR2 can also sense ApoCIII, 
a component of very-low-density lipoprotein (VLDL) (Kawakami et al., 2008). 
HSPs are present in murine atherosclerotic lesions and are ligands for TLR2 and TLR4 
(Asea et al., 2002; Kanwar et al., 2001). However, some studies using low-endotoxin 
preparations have disputed the role of HSPs as ligands for TLRs (Bausinger et al., 2002). 
The nuclear protein high-mobility group box-1 (HMGB-1) is expressed in human 
atherosclerotic smooth muscle cells (Porto et al., 2006). HMGB1 binds DNA and is a 
ligand for TLR2, TLR4, TLR9 and other nucleic acid sensors (Park et al., 2004; Yanai et al., 
2009). mRNA from necrotic cells, which may be present in atherosclerotic plaques, is a 
TLR3 agonist (Kariko et al., 2004).   
The NLRP3 inflammasome can be activated by many factors including extracellular ATP, 
potassium efflux and reactive oxygen species. In addition, intracellular crystals such as 
monosodium urate crystals and cholesterol crystals can activate the NLRP3 inflammasome 
(Duewell et al., 2010; Martinon et al., 2006).  
4. Signalling of pattern recognition receptors 
4.1 Toll-like receptor signalling 
TLR signalling is composed of two distinct signalling pathways depending on whether the 
adaptor molecule MyD88 is used following ligation and activation (Figure 1). 
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Fig. 1. Toll-like receptor & RIG-I-like receptor signalling. MyD88-dependent signalling: 
All TLRs, except TLR3, recruit the adaptor protein MyD88. MyD88 recruits IRAK1 and 
IRAK4 to its death domain, which then recruit TRAF6. IRAK1 with TRAF6 subsequently 
activate a complex consisting of TAK1, which activates the canonical IκB kinase (IKK) 
complex and the mitogen-activated protein kinase pathway (not shown). NFκB (p50/p65) is 
then activated to transcribe multiple proinflammatory cytokine genes. The production of 
type I IFNs by TLR7 and TLR9 depends on MyD88 in plasmacytoid dendritic cells (pDCs). 
TRIF-dependent signalling: TLR3 and endosomal TLR4 (via TRAM), utilise TRIF to interact 
with the non-canonical IKKs, TBK-1 and IKKε via TRAF3, which phosphorylate IRF3 to 
induce expression of IFNs. RIG-I-like receptor signalling: RIG-I and MDA5 interact with 
IPS-1 to activate TBK1 enabling the phosphorylation of IRF3 and IRF7. These transcription 
factors then homo- or heterodimerize, translocate into the nucleus and activate the 
transcription of type I IFN genes.  
4.1.1 MyD88-dependent signalling pathway 
All TLRs with the exception of TLR3 use MyD88 to initiate downstream signalling. TLR2 
and TLR4 require TIRAP/MAL as a bridge between the TLR and MyD88 (Kagan &  
Medzhitov, 2006; Yamamoto et al., 2002). Following PAMP recognition by TLRs, MyD88 
recruits members of the IL-1 receptor-associated kinase (IRAK) family, including IRAK4, 
IRAK1, IRAK2 and IRAKM. IRAK4 is activated first, followed by IRAK1 and IRAK2, with 
all being essential for robust activation of NFκB and MAPK (Kawagoe et al., 2008). The 
IRAKs then dissociate from MyD88 and associate with TRAF6, an E3 ubiquitin ligase, 
leading to the activation of a complex consisting of transforming growth factor-β-activated 
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Fig. 1. Toll-like receptor & RIG-I-like receptor signalling. MyD88-dependent signalling: 
All TLRs, except TLR3, recruit the adaptor protein MyD88. MyD88 recruits IRAK1 and 
IRAK4 to its death domain, which then recruit TRAF6. IRAK1 with TRAF6 subsequently 
activate a complex consisting of TAK1, which activates the canonical IκB kinase (IKK) 
complex and the mitogen-activated protein kinase pathway (not shown). NFκB (p50/p65) is 
then activated to transcribe multiple proinflammatory cytokine genes. The production of 
type I IFNs by TLR7 and TLR9 depends on MyD88 in plasmacytoid dendritic cells (pDCs). 
TRIF-dependent signalling: TLR3 and endosomal TLR4 (via TRAM), utilise TRIF to interact 
with the non-canonical IKKs, TBK-1 and IKKε via TRAF3, which phosphorylate IRF3 to 
induce expression of IFNs. RIG-I-like receptor signalling: RIG-I and MDA5 interact with 
IPS-1 to activate TBK1 enabling the phosphorylation of IRF3 and IRF7. These transcription 
factors then homo- or heterodimerize, translocate into the nucleus and activate the 
transcription of type I IFN genes.  
4.1.1 MyD88-dependent signalling pathway 
All TLRs with the exception of TLR3 use MyD88 to initiate downstream signalling. TLR2 
and TLR4 require TIRAP/MAL as a bridge between the TLR and MyD88 (Kagan &  
Medzhitov, 2006; Yamamoto et al., 2002). Following PAMP recognition by TLRs, MyD88 
recruits members of the IL-1 receptor-associated kinase (IRAK) family, including IRAK4, 
IRAK1, IRAK2 and IRAKM. IRAK4 is activated first, followed by IRAK1 and IRAK2, with 
all being essential for robust activation of NFκB and MAPK (Kawagoe et al., 2008). The 
IRAKs then dissociate from MyD88 and associate with TRAF6, an E3 ubiquitin ligase, 
leading to the activation of a complex consisting of transforming growth factor-β-activated 





into the cytosol where TAK1 phosphorylates IKKβ. Subsequently, the IKK complex, 
consisting of IKKα, IKKβ and NFκB essential modulator (NEMO), phosphorylates IκBα, an 
NFκB inhibitory protein. Phosphorylated IκBα is degraded by the ubiquitin proteosome 
system, freeing NFκB to translocate to the nucleus and mediate transcription of 
inflammatory genes. TAK1 also phosphorylates MAPK6 activating the MAP kinases Erk1, 
Erk2, p38 and Jnk. Activation of the MAPK pathway triggers the formation of activated 
protein (AP)-1, a transcription factor complex controlling genes encoding many cytokines 
(Johnson &  Lapadat, 2002).  
TLR7 and TLR9 induce the production of type 1 IFNs and NFκB-dependent cytokines via 
the MyD88 dependent pathway. Plasmacytoid dendritic cells (pDCs) constitutively express 
Interferon Regulatory Factor (IRF)7 which binds to MyD88 forming a complex with IRAK1, 
IRAK4, TRAF3, TRAF6 and IKKα (Kawai &  Akira, 2008). Phosphorylated IRF7 then 
translocates to the nucleus and facilitates the production of type 1 IFNs (Kawai &  Akira, 
2010). In contrast, conventional dendritic cells (cDCs) mediate the activation of IRF1 
resulting in IFN-β gene expression (Negishi et al., 2006; Schmitz et al., 2007).  
MyD88 is critical for the downstream inflammatory effects following ligation of many TLRs. 
MyD88 knockout (MyD88-/-) mice do not respond to peptidoglycan and lipoprotein 
stimulation of TLR2 (Takeuchi et al., 2002; Takeuchi et al., 2000), Imidazoquinoline 
stimulation of TLR7 (Hemmi et al., 2002) or stimulation of TLR9 by CpG DNA motifs 
(Häcker et al., 2000; Schnare et al., 2000). Similarly, MyD88-/- mice have an abolished 
response to TLR4 stimulation by LPS (Kawai et al., 1999) or TLR5 stimulation by bacterial 
flagellin (Hayashi et al., 2001).   
4.1.2 TRIF-dependent signalling pathway 
TLR3 utilises signalling via TRIF to elicit responses (Alexopoulou et al., 2001). TRIF 
associates with TRAF3 and TRAF6 via its N-terminal TRAF binding-motifs (Takeuchi &  
Akira, 2010). TRAF3 activates 2 noncanonical IKK-related kinases, TBK1 and IKKε which 
phosphorylate IRF3 enabling its nuclear translocation (Häcker &  Karin, 2006; Oganesyan et 
al., 2006). IRF3 mediates the production of proinflammatory cytokines, type 1 IFNs and 
increased expression of IFN-induced genes including Adar1, Ifit3 and IRF7 (Tenoever et al., 
2007).  TRIF also interacts with RIP1 and RIP3 (Takeuchi &  Akira, 2010). The TNFR-
associated death domain protein (TRADD) is involved in TRIF dependent signalling 
(Ermolaeva et al., 2008). A complex is formed consisting of TRADD, FADD and RIP1. 
TRADD triggers the ubiquitination of RIP1 activating NF-κB. Following stimulation by 
Poly(I:C), a synthetic dsRNA analogue, FADD activates caspase-8 and caspase-10 
(Takahashi et al., 2006). These cleaved caspases activate NFκB (Takahashi et al., 2006). In 
addition, TRIF associates with TRAF6 to activate TAK1. This is thought to occur in an 
ubiquitination-dependent mechanism similar to the MyD88-dependent pathway resulting in 
phosphorylation of the inhibitory molecule IκBα by IKKα and IKKβ (Alexopoulou et al., 
2001). SARM is a an inhibitor of TRIF-mediated signalling in humans (Carty et al., 2006). 
TLR4 is unique in that it can utilise both the MyD88 and TRIF dependent pathways with the 
sequential activation of 4 adaptor molecules. It appears that the receptor’s cellular 
localisation determines which pathway is triggered (Kagan et al., 2008; Tanimura et al., 
2008). Upon ligand binding, membrane bound TLR4 recruits MyD88 which binds to MAL to 
activate NFκB and MAPK (Kagan &  Medzhitov, 2006). Secondly, TLR4 translocates to the 
endosome via dynamin-dependent endocytosis. There TLR4 associates with TRAM to 
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trigger the TRIF-dependent pathway resulting in IRF3 activation and late phase activation of 
NFκB and MAPK (Kagan et al., 2008; Rowe et al., 2006; Tanimura et al., 2008). 
4.2 RIG-I-like receptor (RLR) signalling 
RLR signalling activates NFκB, MAPK, and IRFs to induce type I IFNs. LGP2 may regulate 
the functions of RIG-I and MDA5 as LGP2-deficient mice have elevated levels of type I IFNs. 
Overexpression of IPS-1 (also called MAVS) activates the promoters of NFκB and type I 
IFNs inhibiting viral replication. The induction of IFNβ by IPS-1 requires TBK1 and IKKi 
(Kawai et al., 2005). IPS-1 has a C-terminal transmembrane domain required for 
mitochondrial targeting (Seth et al., 2005), and deleting this region of IPS-1 prevents IRF3 
and NF-κB activation. TRAF3 directly binds both IPS-1 and TBK1/IKKi enabling type I IFN 
induction in response to ssRNA viral infection. TBK1 is broadly expressed in many tissues 
while IKKi expression is stimulated upon pro-inflammatory signals such as TNF-α and IFN-
γ. It has been suggested that TBK1 aids the initiation of signalling following viral infection 
while IKKi regulates the immune response in the later stages of viral infection (Kawai &  
Akira, 2007). IKKi can phosphorylate STAT1 and IRF3 to regulate antiviral gene expression. 
IPS-1 also interacts with RIP-1 and FADD (Kawai et al., 2005) forming a complex with 
caspase-10 and caspase-8. The detection of poly I:C triggers the cleavage of these caspases 
(Takahashi et al., 2006) activating their death effector domain to activate NF-κB.  
4.3 NOD-like receptor (NLR) signalling 
NODs activate MAPKs and NFκB via the serine–threonine kinase RICK and consequently 
activate TAK1 kinase. NLRs activate the release of the IL-1 family of inflammatory cytokines 
through the formation of large cytoplasmic complexes known as ‘inflammasomes’, which 
include caspase-1. Inflammasomes are characterised into three main complexes —the 
NLRP3/NALP3 inflammasome, the NLRP1/NALP1 inflammasome and the IPAF/NLRC4 
inflammasome. The NLRP3 inflammasome is currently the most studied and consists of the 
NLRP3 scaffold, the apoptosis-associated speck-like protein-containing CARD (ASC) 
adaptor, and caspase-1. ASC links the NLR and caspase; normally caspase 1 and 11 (Wang 
et al., 1998). Upon activation, caspase-1 cleaves the precursor cytokines into their bioactive 
form, most notably activating IL-1β and IL-18.  
4.4 Integration of pattern recognition signalling 
The pattern recognition system involves numerous interactions between components of 
different pathways. NOD stimulation, TLR activation and proinflammatory cytokine 
stimulation can act as priming signals leading to NFκB activation, pro-IL1β synthesis, and 
the activation of inflammasomal components such as caspase-11 and NLRP3 (Mariathasan 
&  Monack, 2007). A second signal then activates caspase-1 in the inflammasome complex. 
Such second signals include activation by ATP of the P2X7 purinergic receptor with 
potassium efflux, PAMPs and DAMPs such as oxidative stress, large particles and 
ultraviolet light (Wang et al., 1998). 
The interaction of IPS-1 with NLR proteins can modulate the activation of NFκB and IRF3 
signalling. NLRX1/NOD5 may interact with IPS-1 and inhibit its binding to RIG-I and the 
production of type I IFNs and pro-inflammatory cytokines. RIG-I can also directly activate the 
inflammasome. Finally, NOD2 can translocate into mitochondria, and signal via IPS-1, inducing 
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5. Expression of PRRs in health and atherosclerotic disease 
TLRs are expressed by both leukocyte subsets and resident tissue cells (reviewed in (Cole et 
al., 2010)). In contrast to veins, which are relatively atherosclerosis-resistant, the arterial 
system is more predisposed to atherosclerotic lesion formation. This is mirrored by the 
sensitivity of venous and arterial cells to TLR agonists with arterial cells responding to a 
broader range of TLR agonists than venous cells (Erridge et al., 2008). Different arterial beds 
exhibit heterogeneity in their TLR mRNA expression. Carotid arteries and the aorta share a 
similar pattern of TLR expression with high expression of TLRs 1 through 6 and minimal to 
no expression of TLRs 7, 8 and 9. Iliac arteries display the broadest expression of TLRs 
expressing all but TLR3 whereas mesenteric and subclavian arteries express a narrower 
range of TLRs. TLR2 and TLR4 are the only TLR described to be ubiquitously expressed in 
normal human arteries (Pryshchep et al., 2008). During human atherogenesis, TLR 
expression (in particular expression of TLR1, TLR2 and TLR4) is increased in diseased 
vessels compared to healthy vessels (Edfeldt et al., 2002). Increased expression of TLR2 and 
TLR4 are found both in macrophages and in resident cells including adventitial fibroblasts, 
endothelial cells and smooth muscle cells from human atherosclerotic vessels (Edfeldt et al., 
2002; Otsui et al., 2007; Vink et al., 2002; Xu et al., 2001). Similar to human atherosclerotic 
tissue, expression of TLR2 and TLR4 is increased in murine models of the disease (Mullick et 
al., 2008; Xu et al., 2001).     
In early atherosclerotic lesions, endothelial cells are the first cells to display TLR expression. 
In LDLR-/- mice endothelial cells at atherosclerosis-prone regions of the vasculature, such 
as the inner curve of the aortic arch, display increased TLR2 expression, which is also 
associated with areas of monocyte recruitment (Mullick et al., 2008). Whether endothelial 
TLR2 expression is a cause or effect of monocyte recruitment is unknown. Smooth muscle 
cells (SMC) also respond to PAMPs and express TLRs. TLR-1, -3, -4 and -6 are constitutively 
expressed at the mRNA level by cultured human vascular smooth muscle cells and TLR2, 
TLR3 and TLR4 stimulation induces SMC production of cytokines and chemokines such as 
IL6 and MCP1 (Stoll et al., 2004; Yang et al., 2005a; Yang et al., 2005b; Yang et al., 2006). 
Recently, atheroma-derived SMC have been shown to exhibit a specific increase in TLR3 
expression and TLR3-dependent functional responses compared to control aortic SMC (Cole 
et al., 2011).  
Although all leukocyte populations express TLRs, TLR expression on monocytes/ 
macrophages and dendritic cells is the best characterised. Monocytes, which constitute 5-
10% of circulating blood leukocytes in both mouse and man, are key players at all stages of 
atherogenesis. Constant recruitment of monocytes into atherosclerotic plaques occurs and 
their recruitment is proportional to plaque size (Swirski et al., 2006). Human blood 
monocytes highly express TLR2 and TLR4 mRNA and respond to stimulation with their 
respective TLR ligands by secreting pro-inflammatory cytokines including TNFα and IL6 
(Kadowaki et al., 2001; Visintin et al., 2001). TLR4 expression on peripheral blood monocytes 
appears to correlate with disease activity with monocytes from patients with acute coronary 
syndromes expressing more TLR4 than monocytes from patients with stable angina (Methe 
et al., 2005; Shiraki et al., 2006). Similarly, TLR2 expression is also increased on circulating 
blood monocytes from patients with atherosclerotic disease (Kuwahata et al., 2009; 
Mizoguchi et al., 2007). Circulating monocytes in ApoE-/- mice with advanced 
atherosclerosis also exhibit increased expression of TLR2 and TLR4 (Schoneveld et al., 2008). 
Subsets of monocytes and macrophages with differing characteristics have been described. 
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The balance of these subsets in disease may determine the outcome for the patient. In both 
humans and mice, two major subsets of monocytes; ‘inflammatory’ and ‘resident’, have 
been described (Gordon &  Taylor, 2005), which can be distinguished on the basis of size, 
granularity and expression pattern of adhesion molecules and chemokine receptors. 
Macrophages can also be divided into subsets and can be broadly defined as M1 ‘classically 
activated’ or M2 ‘alternatively activated’ (Gordon &  Taylor, 2005). In terms of TLR 
responses, differing levels of LPS responsiveness has been described in two subsets of 
CD14+ peripheral blood monocytes (Moreno-Altamirano et al., 2007), type I interferon 
production following TLR2 stimulation has been shown to occur specifically in murine 
inflammatory monocytes from bone marrow and spleen (Barbalat et al., 2009) and M2 
macrophages have been shown to exhibit 12-fold higher expression of TLR5 than M1 
macrophages (Martinez et al., 2006). Despite these few studies, as yet, the differential 
expression of TLRs on monocyte and macrophage subsets has not been examined in detail.  
The role of dendritic cells (DC) in atherosclerosis is unknown however in normal arteries 
dendritic cells form networks in the intima, which is described as being part of a ‘vascular-
associated lymphoid tissue’ (Bobryshev &  Lord, 1995; Millonig et al., 2001; Wick et al., 
1997). Their location in the healthy vessel wall, particularly in regions prone to 
atherosclerotic lesion development such as branch-points, suggests a role in atherosclerosis 
development (Lord &  Bobryshev, 1999; Millonig et al., 2001). DCs can be broadly classified 
as either myeloid (mDC) or plasmacytoid (pDC) with both subsets being present in 
atherosclerotic plaques (Erbel et al., 2007; Niessner et al., 2006). mDCs express TLRs 2-8 at 
the mRNA level and secrete cytokines and upregulate costimulatory molecule expression in 
response to TLR-2, -3 and -4 activation (Jarrossay et al., 2001; Matsumoto et al., 2003). On the 
other hand, pDCs strongly express TLR7 and TLR9 mRNA and are activated, mature and 
secrete cytokines following exposure to the TLR9 ligand CpG (Hornung et al., 2002; 
Jarrossay et al., 2001; Kadowaki et al., 2001; Matsumoto et al., 2003). Both mDCs and pDCs 
express and respond to TLR7 ligation with R848 albeit with different functional outcomes: 
mDCs express IL12 while pDCs express IFNα (Ito et al., 2002). 
Although less is known regarding the expression of RLR and NLRs in atherosclerosis, 
increasing evidence supports a similar trend to that seen for TLRs. Intimal macrophages in 
aortic atherosclerotic lesions highly express RIG-I (Imaizumi et al., 2007). In healthy human 
coronary artery ring cultures, IFNγ treatment augmented the expression of the RNA sensors 
TLR3, MDA5 and RIG-I (Ahmad et al., 2010).  
6. Functional consequences of PRR activation in atherosclerosis 
6.1 The role of the IL1/TLR superfamily in atherosclerotic lesion development 
The use of mice deficient in IL1/TLR superfamily molecules has revealed key roles for these 
signalling pathways in atherosclerotic lesion development. Deletion of MyD88 in ApoE-/- 
mice inhibits atherosclerotic lesion formation by 60% and also results in a 75% reduction in 
macrophage recruitment (Bjorkbacka et al., 2004; Michelsen et al., 2004). In addition, 
following carotid ligation, an 89% reduction in lesion formation is observed in ApoE-/- mice 
bred with an IRAK4 kinase-inactive knock-in mouse (Rekhter et al., 2008). MyD88 and 
IRAK4 are part of both the TLR and interleukin receptor (IL1R and IL18R) signalling 
pathways. ApoE-/-IL18-/- double knockout mice exhibit smaller lesions with a more stable 
phenotype compared to ApoE-/- (Elhage et al., 2003). Similarly, IL1β deficiency in ApoE-/- 
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such as VCAM-1 and MCP-1 (Kirii et al., 2003). Overexpression of the endogenous IL1 
inhibitor, IL1 receptor antagonist (IL1RA), attenuates lesion production (Merhi-Soussi et al., 
2005) whereas IL1RA deletion in ApoE-/- augments lesion development at early timepoints 
(Isoda et al., 2004).  
TLR2 and TLR4 have been the most extensively studied in animal models of atherosclerosis. 
A missense mutation in the TLR4 gene causing resistance to endotoxin has been identified in 
C3H/HeJ mice (Poltorak et al., 1998; Qureshi et al., 1999). These mice are resistant to diet-
induced atherosclerosis (Nishina et al., 1993). However, no effect on lesion development was 
observed when bone marrow from C3H/HeJ mice was transplanted into ApoE-/- mice (Shi 
et al., 2000) suggesting resident vascular cell TLR4 signalling may be more important than 
TLR4 on hematopoietic cells. Interestingly, a similar observation has been made for TLR2, 
with TLR2-/- bone marrow transfer into LDLR-/- mice having no effect on lesion 
development. However, a role for hematopoietic cells in recognition of exogenous TLR2 
ligands was revealed when LDLR-/- mice were transplanted with TLR2-/- bone marrow 
prior to stimulation with a synthetic TLR2 ligand as this led to reduced lesion development 
(Mullick et al., 2005). In vascular injury models, deficiency of TLR2 or TLR4 leads to reduced 
neointima formation and activation of TLR2 and TLR4 with agonists augments neointima 
formation (Schoneveld et al., 2005; Vink et al., 2002).  Furthermore, genetic deletion of either 
TLR2 or TLR4 in atherosclerosis-prone mice confers marked protection from atherosclerotic 
lesion development attenuating plaque formation by 30-69% (TLR2-deletion) and 55% 
(TLR4-deletion) (Liu et al., 2008b; Michelsen et al., 2004; Mullick et al., 2005). Lesional 
macrophage content is also significantly reduced in these TLR deficient animals (Liu et al., 
2008b; Michelsen et al., 2004). Administration of a TLR2 agonist to LDLR-/- mice promotes 
lesion development (Mullick et al., 2005). A rabbit hypercholesterolemia model has revealed 
that the expression of TLR2 and TLR4 may have a synergistic effect on lesion development 
(Shinohara et al., 2007). 
A protective role for TLR3 in arterial injury and early atherosclerosis has been described, 
challenging the prevailing view that TLRs are purely detrimental in atherogenesis. TLR3 
activation using the synthetic ligand Poly(I:C) led to attenuated neointima formation in 
C57BL/6 but not TLR3-/- mice following carotid injury (Cole et al., 2011). Furthermore, TLR3 
was shown to mediate protection against medial damage even in the absence of exogenous 
TLR3 stimulation suggesting that following injury an endogenous TLR3 ligand is released 
which maintains the integrity of the vessel wall. In addition, ApoE-/-TLR3-/- mice exhibited 
increased lesion formation compared to ApoE-/- at an early but not later timepoint (Cole et al., 
2011). The mechanisms of the protective effects of TLR3 remain to be explored as does the 
identification of endogenous TLR3 ligands in atherosclerosis. mRNA from necrotic cells and 
stathmin, a microtubule regulatory protein have both been identified as potential endogenous 
TLR3 ligands (Bsibsi et al., 2010; Kariko et al., 2004). A recent study showed that intravenous 
administration of poly(I:C) induces endothelial dysfunction and increased atherosclerotic 
lesion development (Zimmer et al., 2011). Together the studies of Cole et al., and Zimmer and 
colleagues suggest a complex role for dsRNA sensing in atherosclerosis. 
Evidence from human polymorphism and atheroma-cell culture studies also support roles for 
TLRs in atherosclerosis. Asp299Gly and Thr399Ile are two single-nucleotide TLR4 
polymorphisms that are associated with reduced responses to inhaled LPS (Arbour et al., 
2000). Despite individuals who carry these polymorphisms having lower circulating levels of 
proinflammatory cytokines and adhesion molecules (Cook et al., 2004), no definitive effect of 
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these polymorphisms on cardiovascular disease has been identified (reviewed in (Frantz et al., 
2007)). The TLR2 polymorphism Arg753Gln has been found, in a relatively small study, to be 
associated with restenosis and an increased risk of developing mycobacterial disease (Hamann 
et al., 2005). In human atherosclerosis, TLR2 and MyD88 have been shown to play a 
predominant role in NFκB activation, the production of proinflammatory cytokines including 
MCP-1 and IL6 and the generation of the matrix degrading enzymes MMP-1, -2, -3 and -9 
(Monaco et al., 2009). This finding suggests that TLR2 signalling may promote plaque 
vulnerability and rupture. The same study found that TLR4 and its adaptor protein TRAM 
were not rate-limiting for cytokine production in human atherosclerosis but may have a role in 
MMP-1 and -3 production (Monaco et al., 2009).  
6.2 Involvement of TLRs in lipid-associated signalling 
Foam cells are a hallmark feature of atherosclerotic lesions. TLR2, TLR4 and TLR9 ligation on 
macrophages promotes lipid uptake and foam cell formation (Funk et al., 1993; Kim et al., 
2009; Lee et al., 2008; Oiknine &  Aviram, 1992). Whilst TLR4-dependent fluid phase uptake 
(macropinocytosis) of lipids occurs in differentiated macrophages (Choi et al., 2009), TLRs also 
promote macrophage lipid uptake indirectly. In response to TLR3, TLR4 and TLR9 activation, 
macrophage expression of the scavenger receptors SRA, macrophage receptor with 
collagenous structure (MARCO) and lectin-like oxidised low-density lipoprotein receptor-1 
(LOX-1) is increased (Doyle et al., 2004; Lee et al., 2008). Similarly TLR2, TLR3 and TLR4 
ligation induces expression of fatty acid binding proteins such as aP2 and Mal1 in murine but 
not human macrophages (Feingold et al., 2010; Kazemi et al., 2005).  Lipid-X receptors (LXRs) 
regulate expression of genes including ATP-binding cassette transporter A1 (ABCA1) and G1 
(ABCG1), which are involved in cholesterol efflux. Activation of TLR3 and TLR4, via 
signalling pathways involving IRF3, leads to attenuated expression of ABCA1 and ABCG1 
through inhibition of LXR transcriptional activity (Castrillo et al., 2003). Furthermore, in a 
recent study, low-grade endotoxemia in vivo inhibited reverse cholesterol transport in mice 
and also impaired cholesterol efflux in ex vivo cultured human macrophages (McGillicuddy et 
al., 2009). Thus TLR signalling can both promote lipid uptake and disrupt cholesterol efflux 
therefore promoting foam cell formation and atherosclerotic lesion development. 
6.3 The role of NLR and RIG-I in atherosclerosis 
The role of NLR in the development of atherosclerosis is emerging. The NLRP3 
inflammasome, is the best characterised NLR thus far in atherosclerosis. Neointima 
formation is reduced in ASC-/- mice compared to control mice following wire-injury of the 
femoral artery (Yajima et al., 2008). In addition, neointima in ASC-/- mice exhibited 
attenuated IL1β and IL18 expression. BMT experiments revealed hematopoietic cell ASC 
expression is important for neointima formation in this model (Yajima et al., 2008). 
Cholesterol crystals, previously thought to be present only in advanced atherosclerotic 
lesions have been shown to be present in lesions of ApoE-/- mice as soon as 2 weeks after 
the initiation of high-fat feeding (Duewell et al., 2010). Cholesterol crystals can activate the 
NLRP3 inflammasome in human and murine macrophages leading to caspase-1 cleavage 
and IL1β release suggesting that these crystals may be endogenous danger signals in 
atherosclerosis (Duewell et al., 2010; Rajamaki et al., 2010). Bone marrow transfer of 
hematopoietic cells from mice lacking NLRP3, ASC or IL1α/β into LDLR-/- mice leads to 
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bone marrow cells from wild-type mice (Duewell et al., 2010). However more recently, 
Menu et al have crossed ApoE-/- mice with NLRP3-/-, ASC-/- and caspase1-/- mice to 
create double knockout mice (Menu et al., 2011). Suprisingly, deletion of these 3 key 
components of the NLRP3 inflammasome in ApoE-/- mice did not greatly affect 
atherosclerotic lesion development, macrophage recruitment nor lesion stability suggesting 
that these molecules do not affect atherosclerosis (Menu et al., 2011). The use of different 
murine models may explain the differences between these findings and those of Duewell 
and colleagues. The role of other NLRs and RIG-I in atherosclerosis remains to be examined. 
7. The therapeutic potential of PRRs in treating atherosclerosis 
Atherosclerosis, the leading cause of coronary artery and cerebrovascular disease, which 
together comprise the leading causes of death worldwide (Lopez et al., 2006), are a 
significant social and economic burden. Thus, there is a pressing need to identify new 
molecular targets and develop novel therapeutics for the treatment of atherosclerosis. Since 
PRRs are key players at all stages of atherosclerotic lesion development, targeting PRRs is an 
exciting prospect for the treatment of cardiovascular disease.  
TLR2 and TLR4 are the best-characterised PRRs in atherosclerosis. Both receptors have been 
ascribed pro-atherogenic roles and thus inhibition of these receptors is currently the most 
appealing prospect for generation of PRR therapeutics. Reduction of protein expression of 
TLR2 and TLR4 in murine and human cells has been achieved using angiotensin II blockade, 
statin and insulin treatment (Ahn et al., 2007; Foldes et al., 2008; Ghanim et al., 2008). 
Whether such reductions translate to inhibition of functional responses and whether this 
inhibition is achievable in patients with cardiovascular disease remains to be determined. 
TLR2 blockade can inhibit cytokine, chemokine and MMP production in human 
atherosclerosis, while disruption of TLR4 signalling had little effect on the same outcomes 
(Monaco et al., 2009). Blockade of TLR2 is also beneficial in a murine model of myocardial 
ischemia/reperfusion injury (Arslan et al., 2010). TLR4 antagonists such as Eritoran are in 
development for immune disorders (reviewed in (Hennessy et al., 2010)) and may be 
beneficial in the treatment of cardiovascular disease. However, caution is needed when 
extrapolating murine data into human targets and therapeutics. Deletion of IL-1, TLR-2 and 
TLR-4 is equally effective in murine models of atherosclerosis, however only TLR-2 has a 
predominant role in human disease (Monaco et al., 2009). In addition to developing 
antagonists of pro-atherogenic PRRs, it is important to consider generating PRR agonists to 
target athero-protective PRRs such as TLR3.  
Before the most effective PRR therapeutics can be generated, it will be important to discern 
the precise pattern of PRR expression and the consequence of PRR signalling on all cell 
types in the vessel wall in both health and disease. As lesions develop, the composition of 
atherosclerotic plaques change and thus different PRRs and cell types may need to be 
targeted at different time-points during disease progression.  
8. Concluding remarks 
Evidence supporting a key role for PRRs in the initiation and development of atherosclerosis 
is growing and yet the full contribution of PRR activation and signalling to atherogenesis is 
only just emerging. Prominent pro-atherogenic roles have been assigned to TLR2 and TLR4 
as these receptors have been shown to promote foam cell formation, macrophage 
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recruitment and cytokine/MMP production – all key components of atherosclerotic plaque 
development. However, recent data has shown TLR3 to be atheroprotective. Furthermore, 
the roles and functions of the other PRRs including NODs and RIG-I remain to be explored. 
Given the complex consequences of TLR activation, further studies are required to fully 
elucidate the expression patterns, ligands (both endogenous and exogenous), signalling 
pathways and functions of PRRs in both health and at all stages of disease development. 
With increased knowledge, it may then be possible to design novel therapeutics targeting 
PRRs for the treatment of cardiovascular disease. 
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1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) encompasses a variety of diseases ranging from 
simple steatosis or fatty liver through non-alcoholic steatohepatisis (NASH) to fibrosis that 
can eventually lead to irreversible cirrhosis. NASH was first described by Ludwig et al. 
(Ludwig et al., 1980) in a number of patients who reported no “significant” alcohol intake 
but whose liver histology resembled that of alcoholic liver disease. Today the term NAFLD 
is used either when referring to a full spectrum of liver disease or when the aetiology of the 
disease is unknown, excluding secondary causative factors such as excessive alcohol intake, 
hepatotoxic drugs, metabolic/genetic and other liver diseases (for instance autoimmune or 
viral hepatitis) (Treeprasertsuk et al., 2011). 
The occurrence of NAFLD has been persistently increasing in parallel with the concerning 
worldwide epidemic of obesity and diabetes and is expected to rise in the future (Portincasa 
et al., 2005). In the Western countries NAFLD is already becoming the most common cause 
of liver disease with the estimates of prevalence being between 17 and 33 % in the general 
population (McCullough, 2005) and rising as high as 90 % in morbidly obese individuals 
(Machado et al., 2006). NASH, the most severe and clinically significant form of NAFLD, is 
less common and is expected to be present between 5.7 and 17 % of the population 
(McCullough, 2005), again the numbers increase in the morbidly obese (up to 37 %) 
(Machado et al., 2006). Although NAFLD can occur in lean patients, the majority of the 
patients are overweight or obese (McCullough, 2005). Of particular concern, especially in the 
view of the future disease burden, is the presence of NAFLD in children and adolescents. 
For instance, the prevalence of obesity among US children has tripled in just one decade, 
rising from 5 % in 1980 to 15 % in 1990 and is currently around 17 %(Centers for Disease 
Control and Prevention CDC, 2011). The estimates of NAFLD prevalence in childhood have 
risen accordingly and are already between 2.6 and 9.6 % among the general pediatric 
population (Pacifico et al., 2010), reaching 68 % in obese children (Fu et al., 2011). Most cases 
of NAFLD arise in the detrimental environment of various metabolic disorders commonly 
known as the metabolic syndrome. The disease is strongly associated with insulin 
resistance, hypertension, glucose intolerance, central obesity and dyslipidemia and is thus 
recognized as the hepatic manifestation of the metabolic syndrome (Marchesini et al., 2005). 
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proportion of steatotic patients will develop steatohepatitis, which is characterized by 
hepatocyte injury and inflammation with 20–25 % possibility of progression to advanced 
fibrosis and cirrhosis (Farrell et al., 2005). In patients with cirrhosis liver failure is the most 
common cause of death warranting a liver transplantation (Grattagliano et al., 2011). 
NAFLD is also significantly associated with cardiovascular disease (CVD) independently of 
metabolic syndrome components and the classical risk factors (Nakao & Yoneda, 2009; 
Targher & Arcaro, 2007). In fact, one of the leading causes of death in NAFLD patients is 
coronary artery disease (Adams et al., 2005; Matteoni et al., 1999). Recent evidence thus 
suggests that NAFLD might play an important role in the development of atherosclerosis 
(see Chapter 4). NASH has also been found to be associated with increased risk of 
hepatocellular carcinoma (Marrero et al., 2002). 
NAFLD is clinically silent. The symptoms usually described by the patients, such as fatigue 
and vague discomfort over the liver, are quite non-specific (Farrell et al., 2005). The presence 
of the disease is often suspected upon abnormal results of routinely performed liver tests in 
the presence of metabolic syndrome risk factors and exclusion of secondary causes. It should 
be noted, however, that elevated liver enzymes have poor sensitivity since serum 
transaminases can be normal in up to 80 % of patients with steatosis (Browning et al., 2004). 
Hepatic imaging, which can be ordered as a part of investigations into abdominal pain or 
elevated liver enzymes, usually provides the first clues of the presence of steatosis. Hepatic 
ultrasound, where steatosis is seen as increased echogenicity or “bright liver”, has a quite 
high sensitivity, especially when more than 33 % of hepatocytes are fatty. The same 
sensitivity has been found with the use of computerized tomography and magnetic 
resonance imaging, but unfortunately all three methods are unable to detect features of 
fibrosis and cirrhosis, which present the greatest risk of liver failure (Saadeh et al., 2002). 
Today liver biopsy is the gold standard for diagnosing NASH, since only histological 
evaluation of the liver tissue is able to discern simple steatosis from steatosis with 
inflammation, which represents the hallmark of NASH. It is of vital clinical importance to 
distinguish advanced liver disease from the more benign states because of its poor outcome. 
Guidelines on when to perform the liver biopsy are still a matter of discussion since the 
procedure is costly, invasive, prone to complications such as pain or even death (0.01 % 
procedural mortality) and inclined to sampling variability (Guha et al., 2006; Poynard et al., 
2006). Indication for liver biopsy is currently based upon risk assessment for fibrosis, which 
takes into consideration obesity, diabetes, age over 45 and aspartate transaminase (AST) to 
alanine transaminase (ALT) ratio over 1 (Angulo & Lindor, 2002). 
Despite an ever increasing knowledge about the mechanisms of NAFLD pathogenesis (see 
Chapter 3), an efficient therapy remains elusive. Several key pieces of information for 
targeted treatment are still missing, such as why only a certain proportion of patients with 
simple steatosis progress to steatohepatitis and a better understanding of causal 
relationships of NAFLD and metabolic syndrome components. In fact, the use of term 
NAFLD itself suggests an unknown aetiology of the disease. Because of this and because of 
strong association of NAFLD to metabolic syndrome, the therapy is primarily directed 
towards lifestyle modifications. Patients are encouraged to lose weight through physical 
exercise improving body mass index (BMI), insulin resistance and diabetic control (Musso et 
al., 2010). It was shown that the benefits of relatively consistent weight loss are removal of 
fat from hepatocytes, which can even lead to improved necroinflammation and decreased 
fibrosis (Hickman et al., 2002; Palmer & Schaffner, 1990; Ueno et al., 1997). It is estimated 
that a change in nutritional habits in which we would reduce caloric intake by as little as 100 
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kilocalories per day would prevent epidemic of both obesity and NAFLD (Hill et al., 2003). 
Pharmacological interventions are indicated for patients with a risk of developing advanced 
liver disease. Because insulin resistance is the single most prevalent predisposing factor for 
NAFLD (Bugianesi et al., 2005b), treatment is mainly aimed to improve insulin sensitivity. 
Insulin sensitizers metformin and thiazolidinediones are gaining acknowledgement as 
drugs with beneficial effects on NAFLD (Ahmed & Byrne, 2009). Other therapy strategies 
are directed towards improving dyslipidemia and oxidative stress, which are commonly 
associated with NAFLD, and drugs such as statins, polyunsaturated fatty acids, vitamins C 
and E and ursodeoxycholic acid are currently being evaluated in clinical trials (Musso et al., 
2010). 
At present, NAFLD can best be described as a multi-factorial disorder with no specific 
diagnostic tests and no approved treatment regimen. Increasing interest in the research of 
this complex disease is implicating more and more factors that contribute to the 
pathogenesis of NAFLD. In this chapter we will first describe pathology and pathogenesis of 
NALFD and move on to establish a link between NAFLD and atherosclerosis. Subsequently 
we will depict the interplay of cholesterol metabolism and inflammation and their relation 
to atherosclerosis through NAFLD. 
2. Pathology of NAFLD 
NAFLD covers a wide range of pathological states and it is often difficult to draw the line 
where one condition ends and the other begins. First efforts were put into defining 
histopathological criteria for the diagnosis of NASH. In order to avoid the early confusions, 
it was proposed that liver biopsies of NASH should closely resemble those of alcoholic 
steatohepatitis (Lee, 1995). However, many of the more subtle forms of steatosis with 
inflammation were thus unjustifiably excluded from being designated as NASH. To 
overcome the diagnostic inconsistencies, Matteoni et al. (Matteoni et al., 1999) divided 
NAFLD into four categories (Table 1). 
 
Category of 
NAFLD Pathology Clinical correlation 
Type 1 Simple fatty liver (steatosis) Not progressive with a good prognosis 
Type 2 Steatosis and lobular inflammation (steatohepatitis) 
Probably benign, does not resemble 
alcoholic steatohepatitis, not 
diagnosed as NASH 
Type 3 
Steatosis, lobular inflammation 
and ballooning degeneration 
(steatonecrosis) 
NASH without fibrosis – may 
progress to cirrhosis 
Type 4 
Steatosis, ballooning 
degeneration and Mallory 
bodies, and/or fibrosis 
NASH with fibrosis – may progress 
to cirrhosis and liver failure 
Table 1. Categories of non-alcoholic fatty liver disease (NAFLD) and their clinical correlation 
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Steatosis (or fatty liver) is the hallmark of NAFLD and is characterized by the accumulation 
of fat droplets in hepatocytes. To diagnose steatosis at least 5 % of fatty hepatocytes need to 
be present (Kleiner et al., 2005), while less liver fat accumulation can be physiological and is 
transient in nature. At the histological level, fat is seen as a single macrovesicular droplet 
that displaces the nucleus to the periphery of the cell although a smaller amount of fat 
accumulation can be microvesicular (smaller vacuoles around the rim of the cell) (Hall & 
Kirsch, 2005). Steatosis, which is entirely microvesicular, is prompting other aetiology such 
as excessive alcohol intake or drugs (Hall & Kirsch, 2005). Other types of lipid accumulation 
that can be present in steatosis are lipogranulomas and fat cysts (Brunt, 2011). 
Steatosis with lobular inflammation is considered a type 2 NAFLD. The inflammation 
infiltrate comprises of neutrophils, lymphocytes, plasma cells and macrophages. It is usually 
present as scattered clusters of cells across the lobule, but it can also be seen in portal tracts 
(Yerian, 2011). It is rather difficult to delineate simple steatosis from steatosis with lobular 
inflammation, because truly simple steatosis is very uncommon. One large study that 
evaluated 933 adult and pediatric liver biopsies found out that only four were completely 
void of inflammatory infiltration (Brunt et al., 2009). On the other hand, just one or two focal 
collections of mononuclear cells in the parenchyma are not enough to diagnose a type 2 
NAFLD. Minimum criteria to define any type of hepatitis in fatty liver are yet to be defined 
(Hall & Kirsch, 2005). 
The third prerequisite to diagnose NASH, besides the fatty hepatocytes and inflammatory 
infiltrate, is the hepatocyte injury present either as reversible hepatic ballooning 
degeneration or irreversible hepatic necrosis or apoptosis. Ballooned hepatocytes are large 
in size and have a pale, “cobweb-like” cytoplasm that is a consequence of fluid retention 
(Yerian, 2011). They are quite difficult to distinguish from fatty hepatocytes with small fat 
droplets that resemble mildly hidropic cells. It is possible to discern fat from fluid with 
certain histochemical stainings of liver tissue but these are not routinely performed (Brunt & 
Tiniakos, 2010). Mallory bodies are often seen in ballooned hepatocytes and they appear as 
irregularly shaped eosinophilic masses in the cytoplasm. They are composed of cytokeratin 
polypeptides and can be stained with antibody to ubiquitin (French, 2000). Mallory bodies 
are not required for the diagnosis of NASH. Apoptotic hepatocytes are observed as deeply 
eosinophilic cytoplasmic aggregates that may or may not be surrounded by Kupffer cells 
(liver macrophages), however, apoptosis of hepatocytes in NAFLD is never so prominent as 
in viral hepatitis (Hall & Kirsch, 2005). 
In the progressive forms of liver disease fibrosis and cirrhosis may occur. The former is 
characterized as aberrant deposition of extracellular matrix (collagen) by activated hepatic 
stellate cells as part of the injury healing process. Fibrosis is characteristically pericellular in 
distribution and is first observed in the centrilobular region of the liver. With progression it 
extends towards portal areas (Brunt, 2011). Cirrhosis or liver scarring is defined as a 
complete loss of the normal lobular architecture and replacement of liver tissue by fibrosis, 
scar tissue and regenerative nodules of hepatocytes (Grattagliano et al., 2011). It eventually 
leads to the loss of liver function. 
3. Pathogenesis of NAFLD 
3.1 Insulin resistance as a predominant factor for NAFLD 
NAFLD is strongly associated with components of the metabolic syndrome and the majority 
of cases of NAFLD occur in patients with obesity (60–95 %), type 2 diabetes mellitus (28–55 
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%) and hyperlipidemia (27–92 %) (Marchesini & Bugianesi, 2005). Insulin resistance (IR), 
being the cardinal feature of the metabolic syndrome, is almost uniformly found in patients 
with NAFLD (Bugianesi et al., 2005a; Comert et al., 2001; Marchesini et al., 1999; Sanyal et 
al., 2001). The causes of IR are as of yet unknown and are being researched extensively. IR 
can be classified as either peripheral IR in which we have reduced insulin-mediated uptake 
of glucose by skeletal muscle and adypocites or hepatic IR where insulin is unable to 
suppress glucose production in the liver. There is mounting evidence that the main 
pathological event leading to peripheral IR is ectopic accumulation of fat (fatty acid 
metabolites) in skeletal muscle, which causes a defect either in glucose transport or 
phosphorylation of insulin receptors (Samuel & Shulman, 2005). The same mechanism is 
believed to cause hepatic IR (Kim et al., 2001). In the presence of peripheral IR, insulin is 
unable to efficiently exert its antilipolytic effects on adipose tissue resulting in increased free 
fatty acid (FFA) flux into the bloodstream. Hyperlipidemia thus arising exacerbates IR in the 
muscle and adipose tissue and causes fat deposition in the liver affecting its function and 
inducing hepatic IR. It was found out that not only in obese, but also in lean NAFLD 
patients with normal glucose tolerance and lipid levels lipolysis and lipid oxidation at the 
basal level were increased and inefficiently inhibited after insulin administration 
(Marchesini & Bugianesi, 2005). The source of increased FFA flux in NAFLD patients is not 
clear but it seems that visceral adiposity may play an important role since it is more insulin 
resistant than subcutaneous adipose tissue (Lefebvre et al., 1998). This notion is supported 
by the fact that the aforementioned lean NAFLD patients had enlarged waist girth, which is 
in good correlation with central (visceral) adiposity. 
NAFLD could thus possibly stem from a defect in insulin sensitivity causing derangements 
in glucose metabolism (which explains its link with other metabolic disorders) and in lipid 
metabolism that predisposes to hepatic steatosis, which is the first step in the pathogenesis 
of advanced liver disease. 
3.2 The two-hit hypothesis and beyond 
According to the initial “two-hit” hypothesis NASH develops in two subsequent steps (Day 
& James, 1998). The “first hit” leads to hepatic accumulation of triglycerides (steatosis) that 
makes liver susceptible to hepatocyte injury mediated by “second hits” such as 
inflammatory cytokines, oxidative stress and mitochondrial dysfunction, which in turn 
promote inflammatory infiltration and fibrosis. 
3.2.1 Steatosis 
Lipids that accumulate in the liver are mainly triglycerides formed from esterification of 
glycerol and FFA within the hepatocyte (Figure 1). Three distinct sources of FFA are: 
lipolysis in the adipose tissue, de novo lipogenesis in the liver and dietary sources. 
Mechanisms for FFA utilization in the liver are: use as energy source in the process of β-
oxidation, storage in the form of triglyceride droplets or export in the form of very low-
density lipoproteins (VLDL). Hepatic fat accumulation can therefore be a consequence of a 
malfunction of any of these three mechanisms of FFA utilization or because of an increased 
fat delivery. In the case of NAFLD the increased influx of FFA from adipose tissue as a 
consequence of IR and obesity plays the dominant role since 60 % of liver triglycerides 
derive from FFA overflow from adipose tissue, 25 % from de novo lipogenesis and 15 %  
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%) and hyperlipidemia (27–92 %) (Marchesini & Bugianesi, 2005). Insulin resistance (IR), 
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Hyperinsulinemia, which accompanies IR, inhibits β-oxidation of FFA (Postic & Girard, 
2008) and at the same time increases expression of lipogenic genes through up-regulation of 
transcription factor, sterol regulatory element binding protein-1c (SREBP-1c) (Kohjima et al., 
2008). As a consequence, synthesis of lipids is intensified, which further promotes hepatic 
steatosis. As an answer to the increased synthesis of triglycerides, the production of VLDL is 




Fig. 1. Pathogenesis of NAFLD. Prominent feature of liver steatosis is the accumulation of 
excess FFA from the adipose tissue in the form of triglycerides. Gradual increase of FFA β-
oxidation due to increased hepatic insulin resistance generates ROS, which activate 
inflammatory pathways and initiate lipid peroxidation. As a result, apoptosis and necrosis 
of hepatocytes, which are further aggravated by FFA lipotoxicity, activate Kupffer cells, 
which in turn stimulate hepatic stellate cells to produce excess amounts of collagen. 
CYP2E1: cytochrome P450 2E1; ER: endoplasmic reticulum; FFA: free fatty acids; HPC: 
hepatic progenitor cells; IKKβ/NF-κB: inhibitor kappa kinase beta/nuclear factor kappa B; 
IL-6: interleukin-6; TG: triglycerides; ROS: reactive oxygen species; TNF-α: tumor necrosis 
factor α; VLDL: very low-density lipoproteins. 
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3.2.2 Steatohepatitis and fibrosis 
As was already stated, steatosis is tightly associated with hepatic inflammation. Again, 
visceral adipose tissue (insulin resistant) plays an important role in the transition from 
simple steatotic to inflamed liver, since it is not solely a site of energy storage, but also 
actively secreting endocrine organ. Most adipocyte-derived adipokines, such as tumor 
necrosis factor-α (TNF-α), resistin and angiotensin II, induce both IR and low-grade 
inflammation through activation of c-Jun NH2-terminal kinase-1 (JNK-1) and inhibitor 
kappa kinase beta (IKKβ)/nuclear factor kappa B (NF-κB) pathway in the liver. Induction of 
the latter pathway leads to feed forward loop of increased expression of pro-inflammatory 
cytokines like interleukin-6 (IL-6), interleukin 1-beta (IL-1β), TNF-α and activation of 
Kupffer cells (Cai et al., 2005; Wieckowska et al., 2008). Patients with NAFLD have elevated 
serum and hepatic levels of TNF-α (Haukeland et al., 2006; Hui et al., 2004) as well as IL-6 
(Wieckowska et al., 2008). Concentrations of both correlate well with histological severity of 
NAFLD (Crespo et al., 2001; van der Poorten et al., 2008). Two additional well studied 
adipokines that have been implicated in NAFLD development are leptin and adiponectin. 
Leptin has an important role in the regulation of energy intake (Mantzoros, 1999) but also in 
the immune system (Lord, 2002) and in the promotion of fibrogenesis (Saxena et al., 2002). 
Together with TNF-α and IL-6 it activates hepatic stellate cells to deposit excessive amounts 
of collagen either directly (with binding to the receptors) or through stimulating secretion of 
transforming growth factor-β (TGF- β) by Kuppfer cells (Nieto, 2006; Shoelson et al., 2007). 
The obese and patients with NAFLD have higher levels of leptin and are considered to be 
leptin resistant (Uygun et al., 2000). In contrast to other adipokines, adiponectin protects the 
liver from inflammation and fibrogenesis. It antagonizes actions of TNF-α, inhibits 
lipogenesis (it down-regulates SREBP-1c) and increases insulin sensitivity (Polyzos et al., 
2010; Whitehead et al., 2006). Circulatory levels of adiponection were found to be reduced in 
NAFLD patients (Bugianesi et al., 2005c) and it was shown that administration of 
recombinant adiponectin can substantially improve NASH in ob/ob mice, one of the animal 
models of NAFLD (Musso et al., 2010). 
Oxidative stress and mitochondrial dysfunction are closely related and are both contributing 
to the liver injury. Mitochondria are the major site of free radical formation in the 
hepatocytes. Reactive oxygen species (ROS) are physiological by-products of energy 
production from glucose breakdown and FFA β-oxidation and are more or less successfully 
controlled by endogenous radical scavenging system. However, in the IR (NAFLD) state 
there is an increase of FFA delivery to the hepatocytes and gradual loss of suppression of 
fatty acid oxidation by insulin, generating levels of ROS that are beyond control of 
endogenous antioxidants (Sanyal et al., 2001). Mitochondria are the first to be exposed to the 
effects of ROS, which cause uncoupling of oxidation and phosphorylation process of 
forming adenosine triphosphate, and positive feedback loop of ROS production is thus 
created. ROS then activate inflammatory pathways through stimulated production of TNF-α 
and initiate lipid peroxidation, which is detrimental to mitochondria and which causes cell 
death either by signaling apoptosis or promoting necrosis (Mylonas & Kouretas, 1999; Tang 
et al., 2002). Hepatocyte apoptosis caused by peroxidation of excess triglycerides seems to be 
the critical step in progression from simple steatosis to NASH and cirrhosis (Syn et al., 2009). 
Apoptotic hepatocytes are phagocytized by adjacent Kupffer cells, leading to hepatic stellate 
cell activation and fibrogenesis. The role of apoptosis in the progression of liver injury was 
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significantly improved upon inhibition of caspase signaling (Witek et al., 2009). Another 
potent source of ROS in NAFLD patients is overexpression of cytochrome P450 2E1 
(CYP2E1), a microsomal fatty acid oxidizing enzyme (Weltman et al., 1998). 
3.2.3 FFA lipotoxicity 
Recently, new evidence has come into light that urge the “two-hit” hypothesis to be revised 
and modified. There is an increasing appreciation about a more direct role of FFA in 
promoting liver injury. It has been shown that accumulation of triglycerides in hepatocytes 
can actually be beneficial in preventing development of NAFLD. Inhibition of triglyceride 
synthesis in obese mice with NASH has improved steatosis, but worsened liver injury, 
inflammation and fibrosis (Yamaguchi et al., 2007). In the same mouse model the pathology 
of NAFLD has worsened in parallel with the FFA burden. It seems that hepatic triglyceride 
accumulation acts as a buffering system disabling FFA to exert their toxic effects on the 
liver. FFA directly induces lipotoxicity in the liver in the following manners: 
1. Detergent effects at high concentrations, inhibition of ion pumps, ion channels and 
calcium ionophor activity (Bass & Merriman, 2005; Nguyen et al., 2000; Schonfeld et al., 
2000). 
2. Mediation of hepatocyte apoptosis through JNK-1 pathway. Saturated fatty acids seem 
to be more toxic than unsaturated fatty acids in this respect (Malhi et al., 2006). 
3. Saturated fatty acids promote endoplasmic reticulum stress that is initially aimed at 
compensating for cell damage but can trigger hepatocyte apoptosis when dysregulated 
or activated for longer time like in the case of NAFLD (Wang et al., 2006). Endoplasmic 
reticulum stress can also be triggered by other biological stresses such as 
hyperinsulinemia and hyperlipidemia (Ron, 2002).  
4. Adipokine-independent hepatocyte IKKβ/NF-κB pathway activation that leads to 
increased expression of pro-inflammatory cytokines (Boden, 2005). 
3.2.4 The third hit 
Recently, a “third-hit” was proposed to be involved in pathogenesis of NAFLD (Dowman et 
al., 2010; Syn et al., 2009). In the healthy liver, ability of mature hepatocytes to replicate in 
order to replace dead tissue is a core feature of liver’s remarkable capability to regenerate 
itself after various injuries. Oxidative stress, especially excessive and prolonged production 
of H2O2 by mitochondria, results in impaired replication of mature hepatocytes, which in 
turn leads to expansion of the hepatic progenitor cells (HPCs). These cells reside in the 
Canal of Hering near the portal veins (periportal area) of the liver and upon activation first 
proliferate to intermediate hepatocyte-like cells that finally evolve into either cholangiocytes 
(epithelial cells of the bile duct) or mature hepatocytes, both contributing to liver repair. It 
seems that this type of response is an important factor in the development of late stage liver 
disease since numbers of HPCs and intermediate hepatocytes strongly correlate with the 
fibrosis stage (Roskams et al., 2003). Possible mechanisms for stimulating a progressive 
periportal fibrosis that is seen in advanced types of NAFLD include secretion of 
profibrogenic cytokines (IL-6, IL-8, TGF-β) by HPCs and intermediate hepatocytes 
(Svegliati-Baroni et al., 2008), as well as a possible transition of cholangiocytes to 
myofibroblasts (Xia et al., 2006). On the other hand, evidence exists that fibrosis preceds 
expansion of HPCs, suggesting a more complex interaction between both phenomena (Van 
Hul et al., 2009). 
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Why only a small portion of patients with simple steatosis progress to NASH and end-stage 
liver disease is still poorly explained. There is a rationale that genetic factors in concert with 
environmental factors might represent the missing link. A number of genes involved in 
oxidative stress, lipid metabolism and fibrosis are differentially up- or down-regulated in 
patients with NASH compared to patients with simple steatosis (Younossi et al., 2005). 
Several candidate genes are currently being investigated for their roles in the development 
of NAFLD (Day & Daly, 2005). 
In respect to the overwhelming new knowledge about pathogenesis of NAFLD, it is perhaps 
reasonable to gradually abandon the notion of “two hits” acting one after the other in favor 
of multiple interactive pathogenic networks that centrally converge towards factors 
promoting liver fat accumulation in a fashion capable of causing liver injury. The 
underlying origin of these changes is probably a combination of genetic and environmental 
factors (Farrell & Larter, 2006). 
4. NAFLD and atherogenesis  
4.1 Associations of NAFLD and atherogenesis 
A link between cardiovascular disease (CVD) and metabolic syndrome components has 
already been established (Dekker et al., 2005). Given the recent recognition of NAFLD as 
being a hepatic manifestation of the metabolic syndrome, patients with NAFLD would be 
expected to have an increased risk of CVD development and events. Moreover, NAFLD has 
actually been established as an independent risk factor of CVD regardless of other 
confounding metabolic disorders. Last but not least, a possibility exists that NAFLD is not 
solely a risk marker, but an early mediator of CVD development as well (Targher & Arcaro, 
2007). 
NAFLD has been shown to be associated with circulatory endothelial dysfunction, one of 
the early atherosclerosis markers. NAFLD patients in comparison with non-steatotic 
controls had a significant decrease in the brachial artery flow-mediated vasodilation that 
was related to the histological severity of NAFLD. In addition, these patients had an 
increased 10-year probability of CVD events (Villanova et al., 2005). Another reliable marker 
of subclinical atherosclerosis is an increase in the carotid artery intima-media thickness 
(IMT) (O'Leary & Polak, 2002). Again, NAFLD histology predicted the carotid IMT 
independently of age, sex, BMI and other traditional risk factors such as IR and features of 
the metabolic syndrome (Targher et al., 2006a). IMT has also been found to strongly 
correlate with elevated liver enzymes alanine aminotransferase and gamma-glutamyl 
transpeptidase, surrogate markers of NAFLD (Sookoian & Pirola, 2008). 
Notably, there have been numerous reports about associations of NAFLD and increased 
CVD prevalence. In a study with a large sample of middle-aged male workers they found 
that people with NAFLD were more likely to have CVD than those without it, even more, 
the association was independent of obesity and other prognostic factors (Lin et al., 2005). 
Another study showed that the occurrence of NAFLD was significantly higher in subjects 
with acute myocardial infarction and also, that the severity of coronary artery disease was 
greater in these individuals independent of age, sex and BMI (Kessler et al., 2005). 
Mortality rate among NAFLD patients is increased in comparison to the general population 
(Adams & Angulo, 2005). In one study, 132 patients with NAFLD were followed for 
approximately 18 years and it was reported that CVD was the second most common cause 
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that people with NAFLD were more likely to have CVD than those without it, even more, 
the association was independent of obesity and other prognostic factors (Lin et al., 2005). 
Another study showed that the occurrence of NAFLD was significantly higher in subjects 
with acute myocardial infarction and also, that the severity of coronary artery disease was 
greater in these individuals independent of age, sex and BMI (Kessler et al., 2005). 
Mortality rate among NAFLD patients is increased in comparison to the general population 
(Adams & Angulo, 2005). In one study, 132 patients with NAFLD were followed for 
approximately 18 years and it was reported that CVD was the second most common cause 





al., 1999). Another study with greater number of patients (420), but with mean follow-up of 
only 7.6 years, also found CVD and malignancy to have the highest rates of mortality that 
was overall higher in comparison to the people without NAFLD (Adams et al., 2005). It is 
questionable whether findings of these studies are applicable to the broader population 
since the number of patients was relatively low and the data originated from non-NAFLD 
oriented institutions (Targher & Arcaro, 2007). However, as in the case of subclinical 
atherosclerosis, elevated liver enzymes have been found to have a strong correlation not just 
with CVD risk, but also with increased CVD-related deaths in studies with a much higher 
number of participants (Lee et al., 2007; Schindhelm et al., 2007; Wannamethee et al., 1995). 
Practically in all of these studies NAFLD has been shown to be a risk factor of CVD 
independently of traditional risk factors or components of metabolic syndrome. 
It has recently been suggested that childhood NAFLD could be an early contributing factor 
for development of atherosclerosis (Schwimmer et al., 2005). The authors of the study 
proposed that the process of atherosclerosis could already start in childhood and progress to 
symptomatic CVD in adulthood. Namely, in a sample of 817 children, atherosclerosis was 
twice as prevalent in children with fatty liver as in those without fatty liver. It is therefore 
reasonable to assume that steatosis is a potential early mediator of atherosclerosis, and this 
notion predicts an even greater epidemic of CVD in the future in parallel with increasing 
prevalence of NAFLD in pediatric population. 
It seems that NAFLD brings with it an increased risk of developing atherosclerosis 
independently of other predictive factors. Whether this is true will need to be confirmed in 
subsequent studies with a larger number of patients and well defined and uniform 
diagnostic criteria for NAFLD. Nevertheless, a body of evidence clearly points in the 
direction that NAFLD is not just an innocent by-stander, but a pathological state that is 
actively contributing to atherosclerosis. From the clinician point of view these findings 
suggest that when NAFLD is detected either by ultrasound imaging or routinely performed 
liver enzyme tests, attention should be directed towards establishing whether other 
underlying CVD risk factors are also present. Similar if not greater efforts than for the 
treatment of NAFLD should then be considered to prevent development of atherosclerosis, 
since many NAFLD patients will die because of a major CVD event before the end-stage 
liver disease actually develops (Targher, 2007). 
4.2 Mechanisms linking NAFLD and atherogenesis 
Many studies clearly established a strong association of NAFLD and CVD, however, the 
mechanistic links between both diseases are still inadequately understood. One of the main 
problems in inferring causal relationships between NAFLD and accelerated atherosclerosis 
is their almost uniform coexistence with IR and other components of the metabolic 
syndrome. In this respect we will need to harness the aid of different NAFLD animal models 
that provide unique and to a certain extent controllable (patho)physiological conditions, 
which enable us to study these intertwined mechanisms separately from one another or in 
various combinations (Larter & Yeh, 2008). What are the possible routes of interaction 
between fatty liver disease and atherosclerosis? 
4.2.1 Inflammation 
One of the principal features of NAFLD, especially NASH, is increased oxidative stress and 
chronic, subclinical inflammation. The key pro-inflammatory cytokine that plays a vital role 
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in mediating inflammation is believed to be TNF-α (Figure 2). Expanded and insulin 
resistant abdominal adipose tissue is secreting increased amounts of TNF-α into the 
bloodstream that activates hepatic production of TNF-α through activation of IKKβ/NF-κB 
pathway. Activation of Kupffer cells by cytokines or hepatocyte damage further increases 
expression of TNF-α and IL-6 elevating both liver and systemic levels of pro-inflammatory 
cytokines. These enhance the inflammation and IR of the adipose tissue as well as the liver, 
and the vicious circle is closed. Another reinforcing route for inflammation starts with the 
inability of the insulin to suppress lipolysis in the adipose tissue that causes excess FFA flux 
to the liver where FFA are subjected to increased hepatic β-oxidation. Elevated levels of ROS 
cause oxidative damage that further intensifies the activation of inflammatory pathways in 
the liver (see Chapter 3). TNF-α promotes expression of IL-6 and IL-6 is the main hepatic 
stimulus for the production of C-reactive protein (CRP) (Heinrich et al., 1990). It has been 
known for a long time that inflammatory processes mediate the initiation and development 
of atherosclerotic lesions (Ross, 1999). Levels of TNF-α and IL-6 have been commonly 
associated with increased risk of coronary events (Ridker et al., 2000; Ridker et al., 2000). 
Until recently, CRP was thought to be an inactive downstream marker of the inflammation 
process. However, it has been shown that it can actively contribute to the development of 
atherosclerosis. CRP causes expression of cell adhesion molecules, activation of complement 
as well as mediating low-density lipoprotein (LDL) uptake by macrophages (Blake & 
Ridker, 2002). In NAFLD patients the levels of CRP were expectedly found to be increased 
compared to controls (Brea et al., 2005). 
On the other side of the inflammation spectrum adiponectin acts as an anti-inflammatory 
mediator, mainly by antagonizing effects of TNF-α (Whitehead et al., 2006). Adiponectin has 
also been found to have antithrombotic effects, inhibiting thrombus formation and platelet 
aggregation (Kato et al., 2006). In NAFLD patients adiponectin levels are decreased (Hui et 
al., 2004; Targher et al., 2006b), thus lacking its protective effects against vascular diseases 
(Dekker et al., 2008). 
In addition to direct predisposition of cytokines to atherosclerosis, the reinforcing 
inflammatory response through liver-adipose tissue axis exerts its effect indirectly as well. It 
has been shown that TNF-α interferes with intracellular insulin signaling cascade in the 
liver, adding to both hepatic and peripheral IR (Pandey et al., 2009). One of the dominant 
features of IR is atherogenic dyslipidemia, which will be discussed in the next subchapter. In 
corroboration of the effects of inflammatory cytokines on lipid status it has been shown that 
administration of recombinant TNF-α to treat cancer patients resulted in increased 
concentrations of VLDL and triglycerides and decreased high-density lipoprotein (HDL) 
particles (Sherman et al., 1988). 
4.2.2 Dyslipidemia and aberrant cholesterol metabolism 
Patients with metabolic syndrome usually have a state of dyslipidemia characterized by 
high triglycerides, low HDL-cholesterol, increased small dense LDL particles and increased 
apolipoprotein B100 concentration (Targher et al., 2008), which have all been recognized as 
atherogenic with strong associations to increased CVD risk (Heine & Dekker, 2002). In 
healthy people insulin suppresses hepatic production of VLDL in order to maintain normal 
hepatic lipid homeostasis (Sparks & Sparks, 1990). However, in the state of hepatic IR that 
has been further aggravated by steatosis, the secretion of VLDL is increased in conjunction 
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triglycerides are gradually removed by the action of lipoprotein lipase resulting in small, 
dense LDL (the most atherogenic subclass of LDL) (Fon Tacer & Rozman, 2011). 
Concentrations of triglycerides, VLDL and small dense LDL particles have been increased in 
patients with fatty liver (Adiels et al., 2006; Cali et al., 2007; Sugino et al., 2011). 
Additionally, it has been shown that hepatic steatosis is a better predictor of the composition 
and severity of dyslipidemia than hyperglycemia or IR in type-2 diabetic patients (Toledo et 
al., 2006). In patients with NAFLD, HDL or “the good cholesterol” has been found to be 
decreased as a secondary abnormality due to increased VLDL and LDL (Cali et al., 2007). 
Contrary to the simple fatty liver, VLDL synthesis and secretion are impaired in the state of 
steatohepatitis, contributing further to the accumulation of triglycerides in the liver and thus 
promoting lipid oxidative damage (Fujita et al., 2009). 
 
 
Fig. 2. Mechanisms linking NAFLD and atherosclerosis. Two principal atherogenic features 
of NAFLD are dyslipidemia and chronic subclinical inflammation. Increased cholesterol and 
triglyceride synthesis are the driving forces of increased secretion of VLDL and 
consequentially increased concentrations of LDL and TG. As a secondary abnormality HDL 
is decreased. Inflammed liver are producing excessive amounts of TNF-α, IL-6, CRP, PA-1, 
angiotensin II and cholesterol, which all stimulate the process of atherosclerosis. CRP: C-
reactive protein; HDL: high-density lipoprotein FFA: free fatty acids; IKKβ/NF-κB: inhibitor 
kappa kinase beta/nuclear factor kappa B; IL-6: interleukin-6; LDL: low-density lipoprotein; 
PAI-1: plasminogen activator inhibitor -1; TG: triglycerides; TNF-α: tumor necrosis factor α; 
VLDL: very low-density lipoproteins. 
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Alongside aberrant lipoprotein metabolism driven mainly by IR, disturbances of cholesterol 
metabolism have also been found in patients with NAFLD. Detrimental effects of 
hypercholesterolemia on the progression of atherosclerosis have long been established. 
Cholesterol is capable of accumulating within the vascular wall, causing alterations in 
vascular structure and interfering with endothelial function leading to lesions, plaques, 
occlusions and emboli. Excess cholesterol concentration has also been associated with 
endothelial cell dysfunction, elevated oxidative stress and strong pro-inflammatory state in 
microcirculation (Stapleton et al., 2010).  In humans cholesterol originates either from de novo 
synthesis or from the diet and is excreted mainly in the form of bile acids. Elevated 
concentrations of cholesterol have been found in the fatty liver of obese hyperlipidemic 
individuals compared to those without fatty liver (Reunanen et al., 1969). Obesity, metabolic 
syndrome, type 2-diabetes and IR have all been associated with increased cholesterol 
synthesis and lowered absorption of dietary cholesterol (Gylling et al., 2007; Miettinen & 
Gylling, 2000; Pihlajamaki et al., 2004; Simonen et al., 2002). Recent study has shown that the 
same happens in NAFLD patients (Simonen et al., 2011), where an increase in expression of 
cholesterogenic genes has been observed (Nakamuta et al., 2009). It seems that excess 
cholesterol synthesis, along with increased synthesis of triglycerides, presents one of the 
driving factors for increased production of VLDL particles in hepatic steatosis (Fon Tacer & 
Rozman, 2011). 
Emerging evidence has started to place cholesterol in the “second hit” group that mediates 
the transition from simple steatosis to steatohepatitis. It has been shown that mitochondrial 
loading of free cholesterol, rather than FFA or triglycerides, sensitizes the liver to TNF-α 
induced steatohepatitis (Mari et al., 2006). In hyperlipidemic mouse models of NASH, 
dietary cholesterol, and not steatosis, predisposed to hepatic inflammation (Wouters et al., 
2008). TNF-α also has a direct influence on lipid homeostasis since it activates cholesterol 
synthesis and inhibits formation of bile acids, thus increasing LDL-cholesterol and 
decreasing HDL-cholesterol (Fon Tacer et al., 2007; Fon Tacer et al., 2010). In contrast to its 
role in atherosclerosis, cholesterols implication in NAFLD has been poorly investigated. 
Nevertheless, limited research in this area is indicating an important role of cholesterol in 
pathogenesis of NAFLD as well as a novel link between disrupted cholesterol metabolism in 
NAFLD and atherosclerosis. 
4.2.3 Other factors connecting fatty liver and the process of atherosclerosis 
Apart from many positive feedback loops between fatty liver and IR, visceral adipose tissue, 
hyperglycemia and dyslipidemia, several other factors are mediating a cross-talk between 
atherosclerosis and NAFLD. Many coagulation factors are synthesized by hepatocytes. In 
NAFLD patients several are overproduced, and of particular concern is plasminogen 
activator inhibitor-1, which has direct atherogenic effects (Bansilal et al., 2007). Hepatocytes 
also produce angiotensinogen, a precursor of angiotensin II, and hepatic stellate cells are 
even capable of synthesizing and secreting mature form of angiotensin II upon activation by 
hepatocyte damage (Bataller et al., 2003). Angiotensin II is a pro-atherogenic 
vasoconstrictive peptide that predisposes to elevated blood pressure (Bataller et al., 2003; 
Massiera et al., 2001) and possibly also to CVD (Silventoinen et al., 2008).  
Many other factors that contribute to both NAFLD and increased risk of atherosclerosis, like 
disturbances in endocrine system, hypoxia and ectopic fat deposition, are reviewed 
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5. Conclusion – The intertwined roles of cholesterol and inflammation in 
NAFLD and atherogenesis 
In affluent economies NAFLD is already the most common cause of liver-related diseases 
and a major cause of morbidity and mortality. Sedentary life style and increased caloric 
intake, a hallmark of modern societies, are of particular concern in this respect, since 
NAFLD is found exclusively in obese individuals with insulin resistance. One of the 
emerging problems is also the increasing prevalence of fatty liver in children and 
adolescents, forecasting an even bigger social and economic impact of the disease in the 
future. Even though simple steatosis is benign, if not averted, it could predispose to more 
severe forms of liver disease with poor outcome. Despite the fact that the first description of 
NAFLD was made as many as 30 years ago, the decisive factor tipping the scales towards 
NASH is largely unknown. Genetic factors might play an important role here. Because of 
poorly understood mechanisms linking different stages of NAFLD, therapy is directed 
mainly towards improving the metabolic disorders without liver-specific drugs yet 
available. Surprisingly, cardiovascular events are among the leading causes of death in 
NAFLD patients, and recent research has enthroned NAFLD as an independent risk factor 
for CVD. Many direct as well as indirect links between fatty liver and atherosclerotic vessels 
have been established in the recent years. Inflammation and dyslipidemia are the most 
important factors contributing to both diseases with disrupted cholesterol metabolism 
gaining recognition, especially in the pathogenesis of NAFLD. Unfortunately, information 
about the role of cholesterol in NAFLD is limited, and hopefully new and emerging animal 
models (Horvat et al., 2011; Keber et al., 2011) of disturbed cholesterol metabolism will 
provide the missing insights. Better understanding of these mechanisms is important since 
inhibition of cholesterol synthesis by statins has proven beneficial in NAFLD patients 
(Ekstedt et al., 2007). However, the use of statins presents a risk of developing adverse drug 
reactions such as elevation of liver enzymes or hepatotoxicity due to drug interactions 
(Rozman & Monostory, 2010). 
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5. Conclusion – The intertwined roles of cholesterol and inflammation in 
NAFLD and atherogenesis 
In affluent economies NAFLD is already the most common cause of liver-related diseases 
and a major cause of morbidity and mortality. Sedentary life style and increased caloric 
intake, a hallmark of modern societies, are of particular concern in this respect, since 
NAFLD is found exclusively in obese individuals with insulin resistance. One of the 
emerging problems is also the increasing prevalence of fatty liver in children and 
adolescents, forecasting an even bigger social and economic impact of the disease in the 
future. Even though simple steatosis is benign, if not averted, it could predispose to more 
severe forms of liver disease with poor outcome. Despite the fact that the first description of 
NAFLD was made as many as 30 years ago, the decisive factor tipping the scales towards 
NASH is largely unknown. Genetic factors might play an important role here. Because of 
poorly understood mechanisms linking different stages of NAFLD, therapy is directed 
mainly towards improving the metabolic disorders without liver-specific drugs yet 
available. Surprisingly, cardiovascular events are among the leading causes of death in 
NAFLD patients, and recent research has enthroned NAFLD as an independent risk factor 
for CVD. Many direct as well as indirect links between fatty liver and atherosclerotic vessels 
have been established in the recent years. Inflammation and dyslipidemia are the most 
important factors contributing to both diseases with disrupted cholesterol metabolism 
gaining recognition, especially in the pathogenesis of NAFLD. Unfortunately, information 
about the role of cholesterol in NAFLD is limited, and hopefully new and emerging animal 
models (Horvat et al., 2011; Keber et al., 2011) of disturbed cholesterol metabolism will 
provide the missing insights. Better understanding of these mechanisms is important since 
inhibition of cholesterol synthesis by statins has proven beneficial in NAFLD patients 
(Ekstedt et al., 2007). However, the use of statins presents a risk of developing adverse drug 
reactions such as elevation of liver enzymes or hepatotoxicity due to drug interactions 
(Rozman & Monostory, 2010). 
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1. Introduction  
Coronary artery disease (CAD) is the leading cause of death in United States and contributes 
to significant mortality around the world. According to the Heart Disease and Stroke 2011 
update, released by the American Heart Association, 82,600,000 American adults (>1 in 3) 
have 1 or more type of cardiovascular disease and >2200 Americans die of CAD every day 
which is an average of 1 in every 39 seconds. These are alarming statistics and underscore 
the importance of continued understanding of the processes involved in the development of 
CAD. Atherosclerosis, characterized by increased lipid accumulation in the artery wall, is 
the major underlying cause of CAD.  
Atherosclerosis is a chronic disease that often starts during early teens and progresses 
silently without any overt clinical symptoms till about age 40 when it manifests as heart 
attack or even stroke. While it is well established that accumulation of lipid-laden 
macrophage foam cells in the artery wall is the hall mark of atherosclerosis, two different 
theories are proposed to describe the events leading to infiltration of macrophages and 
subsequent development of foam cells within the artery wall. According to “response to 
injury” hypothesis, the initiating event is injury to the endothelial lining of the artery wall 
leading to the subsequent migration of monocytes and circulating lipoproteins mainly the 
low density lipoprotein (LDL) into the intimal space. This is followed by the unregulated 
uptake of modified LDL (mLDL) by monocyte derived macrophages leading to the 
formation of foam cells (Ross et al, 1977, Ross, 1993). “Response to retention” hypothesis, on 
the other hand, proposes that LDL migrates into the intimal space and is retained by 
association with the proteoglycans and is modified. Subsequent uptake by infiltrating 
macrophages results in development of foam cells (Williams and Tabas, 1995). Regardless of 
the sequence of events, the end result is accumulation of foam cells in the intimal space of 
the artery wall. This initiates the formation of fatty streaks which develops into an 
atherosclerotic plaque with continued accretion of foam cells. Figure 1 below summarizes 
these major events that lead to the formation of atherosclerotic plaque. 
Continuous accumulation of lipid laden foam cells in an atherosclerotic plaque not only 
contributes to its volume but also enhances plaque associated inflammation and thus 
determines its vulnerability to rupture (Davies and Thomas, 1985). Therefore, reduction in 
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well as enhance plaque stability. However, no therapies are currently available to reduce the 
lipid burden of atherosclerotic plaque. The presently used therapies for CAD include 
cholesterol lowering drugs such as statins that reduce plasma cholesterol by inhibiting the 
endogenous cholesterol synthesis. As a consequence, there is reduction in plasma LDL 
cholesterol levels which limits further foam cell formation and progression of atherosclerotic 
plaque. Nonetheless, these cholesterol lowering drugs do not increase removal of lipid from 
existing plaques and, therefore, cannot achieve plaque regression. Cleveland Clinic study by 
Nissen et al (Nissen et al, 2003) provided the first direct evidence of the clinical benefit of 
enhancing removal of cholesterol from macrophage foam cells. A detailed understanding of 
the cellular mechanisms that regulate lipid accumulation within macrophage foam cells and 
processes that are critical for mobilization of stored lipid is central to future development of 
targeted strategies to reduce atherosclerotic plaque burden with the aim to reduce CAD. 
 
 
CE: Cholesteryl esters; M: macrophage; mLDL: modified LDL 
Fig. 1. Schematic showing the events in the artery wall that lead to the formation of 
atherosclerotic plaque 
2. Macrophage cholesterol homeostasis 
Cholesterol homeostasis in macrophages and other peripheral cells is maintained by a 
balance between the influx and efflux processes. Cholesterol influx occurs by receptor and 
non-receptor mediated uptake of both normal and modified lipoproteins. The uptake of 
native LDL via the LDL receptor is regulated by the feedback inhibition of LDL receptor 
expression by cellular cholesterol levels and most peripheral cells limit their cholesterol 
uptake by this mechanism. Excess LDL returns to the liver where it is, once again, taken up 
via LDL receptor. Under conditions of increased dietary intake or increased endogenous 
synthesis of cholesterol, circulating LDL that cannot be taken by peripheral tissues or liver 
due to the inhibition of the expression of LDL receptor, becomes modified and is no longer 
a ligand for LDL receptor. Macrophages play a critical role in the removal of this modified 
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LDL. Macrophages express scavenger receptors, namely, scavenger receptor A (SR-A) and 
CD-36, that facilitate the uptake of modified LDL. Scavenger-receptor mediated uptake of 
modified LDL is largely unregulated and should be regarded as a mechanism that evolved 
to effectively clear modified lipoproteins from circulation and thus preventing the 
associated toxicity. Non-receptor mediated uptake pathways have recently been identified 
such as phagocytosis of aggregated LDL and macropinocytosis of native LDL that can also 
potentially contribute to lipid accumulation in macrophage foam cells. Cholesteryl esters 
(CE) associated with LDL are hydrolyzed in late endosomes/ lysosomes to free cholesterol 
(FC) which then traffics to and integrates into the plasma membrane. Excess membrane 
cholesterol and also a fraction of LDL-derived FC is transported to endoplasmic reticulum 
where it is re-esterified by acyl CoA:cholesterol acyltransferase-1 (ACAT1) and stored in 
cytoplasmic lipid droplets. While this re-esterification of cholesterol is initially beneficial to 
the cells in preventing the FC-associated cell toxicity, under conditions of unregulated or 
increased uptake of modified LDL, it leads to excessive accumulation of CE present as 
cytoplasmic lipid droplets giving the cells their characteristic “foamy” appearance. Cellular 
CE undergo constant cycle of hydrolysis and re-esterification (cholesteryl ester cycle) with 
a half life of 24h. Brown et al demonstrated for the first time that hydrolysis of stored CE is 
extra lysosomal and defined the “need” for a neutral cholesteryl ester hydrolase (CEH) 
(Brown et al, 1980) that can release FC from the lipid droplet associated CE which can 
either be re-esterified again by ACAT-1 or removed from the cells by extracellular 
acceptor-mediated cholesterol efflux. This acceptor mediated FC efflux is the major 
mechanism for the removal of cellular cholesterol. Efflux of FC occurs either by aqueous 
diffusion or via several transporters namely ATP binding cassette transporter A1 (ABCA1) 
and ABCG1. Bidirectional flux of FC also occurs through scavenger receptor BI (SR-BI). 
Since FC is extremely hydrophobic, its efflux from the cells is coupled to its association 
with specific extracellular acceptors. Macrophages secrete apolipoprotein E (ApoE) and it 
is believed that ApoE serves as the extracellular acceptor for FC that is effluxed via 
aqueous diffusion pathway. Serum albumin, present in the interstitial fluid, also serves as 
an important acceptor for FC effluxed via non-transporter mediated pathways. 
Apolipoprotein A1 that is synthesized in the liver and secreted as minimally lipidated 
particle containing small amount of phospholipids is the acceptor for FC effluxed via 
ABCA1. After acquiring some amount of FC, ApoA1 can no longer accept FC from ABCA1. 
Bulk of FC efflux occurs via ABCG1 and ApoA1 with some FC or high density lipoprotein 
(HDL) serve as the extracellular acceptor for this process. A small amount of FC is also 
converted into 27-hydroxycholesterol which can readily diffuse out of the cell and 
contribution of this pathway towards total FC removal from macrophages remains 
undefined. Figure 2 summarizes the various influx and efflux pathways involved in 
macrophage cholesterol homeostasis. Under normal physiological conditions a balance 
between these influx and efflux pathways maintains the levels of cellular cholesterol in 
macrophages and prevents foam cell formation. However, an imbalance between influx 
and efflux, occurring by either increased influx (under conditions with high levels of 
circulating LDL such as hypercholesterolemia) or decreased efflux (under conditions of 
aberrant cellular processes reducing FC availability for efflux or decreased levels of 
extracellular FC acceptors), cellular accumulation of CE containing lipid droplets increases 
resulting in the formation of foam cells and initiating atherogenesis. Improved 
understanding of these processes is, therefore, critical to developing new strategies to not 
only prevent foam cell formation but also to reduce CE burden of existing foam cells that 
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ABC: ATP binding cassette transporter; ACAT: Acyl-CoA cholesterol acyltransferase; ACEH: Acid 
cholesteryl ester hydrolase; ApoE: Apolipoprtoein E; CE: Cholesteryl ester; CEH: Cholesteryl ester 
hydrolase; FC: Free cholesterol; LDLR: LDL receptor; mLDL: Modified LDL; PL: Phospholipids; SR-A: 
Scavenger receptor type A; SR-BI: Scavenger receptor class B type I. 
Fig. 2. Macrophage Cholesterol Homeostasis: Influx and Efflux Pathways 
2.1 Cholesteryl ester accumulation  
Cellular CEs exist in dynamic equilibrium with FC in a futile cholesteryl ester cycle with a half 
life of 24h. The two enzymes involved in this cycle are Acyl-CoA cholesterol acyltransferase 
(ACAT) and cholesteryl ester hydrolase (CEH). Two distinct genes have been identified for 
ACAT; ACAT1 is ubiquitously expressed in all cell types including macrophages and ACAT2 
expression is restricted to liver and intestine. Since foam cells are characterized by 
accumulation of CE and ACAT1 is responsible for formation of CE, pharmacological inhibition 
of ACAT was initially pursued as a means to prevent or attenuate foam cell formation 
(Matsuda, 1994, Matsuo et al, 1995, Nicolosi et al, 1998, Sliskovic and White, 1991). However, 
increased plaque formation by preferential pharmacological inhibition of ACAT-1 was noted 
in mouse and rabbit models of atherosclerosis (Perrey et al, 2001). Ablation of ACAT1 gene 
resulted in marked systemic abnormalities in lipid homeostasis in hyper-cholesterolemic Apo-
E deficient and LDL-receptor deficient mice, leading to extensive deposition of free cholesterol 
in skin and brain (Accad et al, 2000, Yagu et al, 2000). Further, ACAT1-deficient mice also 
displayed an increase in lesion area and the systemic lipid abnormalities. Inhibition or 
deficiency of ACAT1 also results in increased intracellular FC since it cannot be esterified to 
CE which is its inert and storage form. A rise in FC above its physiological concentration is 
associated with cellular toxicity (Glass and Witztum, 2001). Enrichment of the endoplasmic 
reticulum (ER) with FC induces ER stress leading to apoptosis. Therefore, although intuitively 
a logical strategy to limit cellular CE accumulation, inhibition or deficiency of ACAT1 has 
detrimental effects.  
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Alternatively, reduction in CEs stored in macrophage foam cells can also be achieved by 
enhancing mobilization. The first and the rate limiting step in cellular CE mobilization is CEH-
mediated hydrolysis. Consistently, macrophages with high neutral CEH activity accumulate 
less cholesterol esters in the presence of atherogenic -migrating very low-density lipoproteins 
(-VLDL) in comparison to macrophages with low CEH activity (Ishii et al, 1992). Further, 
animal models of atherosclerosis, such as the hypercholesterolemic rabbit and the white 
Carneau pigeon, appear to possess macrophages in which stored cholesterol esters are 
resistant to hydrolysis and subsequent mobilization (Mathur et al, 1985, Yancey and St. Clair, 
1994). While increased hydrolysis of CE will also lead to increase in FC but there is a 
fundamental difference between CEH activation and ACAT1 inhibition. Under conditions of 
ACAT1 inhibition, cellular FC has only one fate, namely, efflux to extracellular acceptors. 
However, FC generated as a result of CEH activation can either be re-esterified by ACAT1 or 
be effluxed to extracellular acceptor (two fates). Thus, CEH activation or over-expression does 
not result in an increase in cellular FC and is not associated with toxicity seen with ACAT1 
inhibition indicating that CEH-mediated increase in cellular CE mobilization is a valid 
approach to target attenuation of foam cell formation (Ghosh et al, 2009). 
2.2 Cholesteryl ester hydrolysis and cellular CE mobilization 
Unregulated uptake of modified lipoproteins by macrophages can be regarded as a defence 
mechanism by which removal of these potentially toxic particles is facilitated. As discussed 
above, efflux of FC from macrophage foam cells is the major mechanism by which this CE 
accumulation can be reversed underscoring the importance of intracellular CE hydrolysis. 
Since the first description for the “need” of an extra lysosomal neutral CEH, several 
candidate enzymes have been identified as potential CE hydrolases in macrophages. Based 
on the observations that cAMP enhances FC efflux from macrophages and hormone 
sensitive lipase (HSL), an enzyme initially characterized from adipose tissue, requires 
protein kinase A and cAMP dependent activation, HSL was thought to be the likely 
candidate for macrophage CE hydrolysis (Goldberg and Khoo, 1990, Small et al, 1989). HSL 
is expressed in murine macrophages (Khoo et al, 1993) but its expression in human 
macrophages remains controversial (Johnson et al, 2000, Li and Hui, 1997, Reue et al 1997). 
Over-expression of HSL by transient transfection in murine macrophages led to increased 
mobilization of CE in the presence of an ACAT inhibitor (Escary et al 1998) but macrophage-
specific transgenic expression of HSL led to a paradoxical increase in atherosclerosis and 
macrophages isolated from these mice stored 2-3 fold higher CE when incubated with 
AcLDL in vitro (Escary et al 1999). In addition, macrophages from HSL deficient mice did 
not have reduced CE mobilization suggestive of a limited, if any, role of HSL in macrophage 
CE mobilization. Since the effects of HSL deficiency on atherosclerosis have not been 
studied, it remains to be seen whether HSL plays a role in atherogenesis. 
The second candidate enzyme speculated to play a role in macrophage CE mobilization was 
carboxyl ester lipase or CEL. CEL was first characterized from pancreas as a bile salt 
dependent cholesteryl esterase (Gallo, 1981, Kissel et al, 1989) that was also present in other 
tissues and was secreted in milk to facilitate digestion of CE in infants and newborns (Hui and 
Kissel, 1990). Li and Hui demonstrated the presence of CEL in human monocyte/macrophage 
cell line THP1 as well as primary blood derived monocyte macrophages and reported the 
absence of HSL in these cells (Li and Hui, 1997). However, since CEL is a secretory enzyme 
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Alternatively, reduction in CEs stored in macrophage foam cells can also be achieved by 
enhancing mobilization. The first and the rate limiting step in cellular CE mobilization is CEH-
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dependent cholesteryl esterase (Gallo, 1981, Kissel et al, 1989) that was also present in other 
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absence of HSL in these cells (Li and Hui, 1997). However, since CEL is a secretory enzyme 





Pursuing the characterization of neutral CEH, we purified and cloned rat liver neutral 
cytosolic CEH which belonged to the carboxylesterase family and was distinctly different 
from HSL and CEL although it shared the same catalytic triad (Ghosh and Grogan, 1991, 
Ghosh et al, 1995). Using the strategy of homology cloning, we subsequently identified 
human macrophage CEH (Official gene symbol CES1, Accession number NG_012057) and 
demonstrated its expression in the THP1 human monocyte/macrophage cell line, as well as 
in human peripheral blood monocyte/macrophages (Ghosh, 2000). This enzyme associated 
with the surface of lipid droplets in lipid-laden cells (its physiological substrate) and 
hydrolyzed CE present in lipid droplets (Zhao et al, 2005). Over-expression of this enzyme 
resulted in mobilization of cellular CE (Ghosh et al, 2003) demonstrating its role in 
regulating cellular CE accumulation. Stable over-expression of this CEH in human 
monocyte/macrophage cell line, THP1, resulted in significantly higher FC efflux to ApoAI, 
HDL and serum demonstrating that FC released by CEH-mediated hydrolysis of 
intracellular CE is available for efflux by all known pathways (Zhao et al, 2007). Taken 
together, these data support the role of this enzyme in regulating macrophage CE content 
and FC efflux. 
Stating the inability to measure CE hydrolytic activity associated with human CEH and its 
murine orthologue triglyceride lipase (TGL), Okazaki et al used a proteomics approach to 
identify another enzyme containing lipase consensus motifs and /-hydrolase folds and 
reported the characterization of murine orthologue of AADACL1 (a deacetylase) also 
known as KIAA1363 (Okazaki et al, 2008). While its deficiency significantly reduced the 
deacetylase activity it did not affect CE hydrolase activity (Buchebner et al, 2010). These 
authors also found no difference in lipid droplet formation and cellular CE and FC content 
of HSL-deficient macrophages. Based on the data obtained with HSL and AADACL1 or 
KIAA1363 deficient macrophages, it can be concluded that macrophage CE hydrolysis is 
likely a multi-enzyme process. Considering the importance of CE hydrolysis in cellular CE 
mobilization, natural redundancy in enzymes capable of catalyzing this reaction is probably 
a protective mechanism evolved to prevent pathological consequences of lipid 
accumulation. 
2.3 CEH and atherogenesis 
Despite the apparent uncertainty surrounding the identity of macrophage CE hydrolase, 
the importance of this step in mobilization of CE and thereby attenuating atherosclerosis 
cannot be over-emphasized. The hypothesis that enhancing CE hydrolysis will reduce 
foam cell formation and consequently attenuate atherogenesis, was initially tested by 
development of HSL transgenic mice (Escary et al, 1999). Paradoxically, these mice had 
increased atherosclerosis and it was thought to be due to limiting levels of extra cellular 
acceptors. Subsequently, Choy et al developed ApoA IV and HSL double transgenics in 
C57BL/6 background and demonstrated a decrease in diet-induced atherosclerosis 
compared to HSL transgenics (Choy et al, 2003). HSL deficiency, however, did not have 
any effect on macrophage CE hydrolytic activity (Osuga et al, 2000) precluding its role in 
macrophage cholesterol homeostasis (Contreras, 2002) and no studies have been 
performed to date to directly assess the development of atherosclerosis in HSL deficient 
mice. 
Since CEL expression was demonstrated in human macrophages, Kodvawala et al 
developed macrophage-specific CEL transgenic mice to evaluate the role of this CE 
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hydrolase in the development of atherosclerosis (Kodvawala et al, 2005). In athero-
susceptible ApoE-/- background, CEL transgenic mice displayed an approximate 4-fold 
higher atherosclerotic lesion area than ApoE(-/-) mice without the CEL transgene. It was 
speculated that perhaps its extracellular location or its hydrolysis of ceramide and 
lysophosphatidylcholine leads to increased cholesterol esterification and decreased 
cholesterol efflux resulting in increased atherosclerosis. Regardless of the underlying 
mechanisms, these studies demonstrate a minimal role for CEL in macrophage CE 
mobilization and thereby in atherogenesis. 
To evaluate the role of CEH in foam cell formation and atherogenesis, we developed 
macrophage-specific CEH transgenic mice and crossed them into an atherosusceptible 
LDLR-/- background. High-fat high-cholesterol diet induced atherosclerosis was 
evaluated and we reported almost a 50% reduction in lesion area in LDLR-/-CEH 
transgenic mice compared to LDLR-/- mice (Zhao et al, 2007). In addition, CEH-mediated 
increase in CE mobilization also reduced total cholesterol and CE content of the lesions 
resulting in significantly reduced lesion necrosis. Consistent with our in vitro studies, 
macrophages from CEH transgenic mice showed higher FC efflux and decreased cellular 
CE levels upon loading with modified LDL. Over-expression of CEH in macrophages 
alone increased the process of reverse cholesterol transport and there was increased 
elimination of cholesterol in the feces of CEH transgenic mice (Zhao et al, 2007). The 
success in attenuating atherosclerosis and lesion necrosis by transgenic expression of CEH 
underscores the importance of the role of CE hydrolysis in atherogenesis. Transgenic mice 
over-expressing the newly identified CE hydrolase (AADACL1 or KIAA1363) have not 
yet been developed and the role of this enzyme in affecting atherogenesis remains to be 
evaluated.  
2.4 CEH and elimination of cholesterol from the body 
While hydrolysis of CE stored in macrophage represents the first step towards removal of 
FC from lesion associated foam cells, final removal of FC occurs from the liver either via 
direct secretion into bile or by conversion into bile acids, both of which are excreted in the 
feces. Figure 3 below summarizes the different steps involved in the movement of FC from 
macrophages to liver for final elimination, a process called Reverse Cholesterol Transport. 
FC effluxed from macrophages becomes associated with extracellular cholesterol acceptors 
and apolipoprotein A1 (ApoA1) is the major acceptor. Lipid free ApoA1 accepts FC 
transported via ABCA1 and this partially lipidated ApoA1 or nascent HDL (High density 
lipoprotein) then becomes the acceptor of FC transported via ABCG1. Bulk of FC efflux to 
HDL occurs via ABCG1 although bidirectional flux of FC also occurs through SR-BI. In the 
plasma compartment, FC in HDL particle is esterified by plasma Lecithin cholesterol 
acyltransferase (LCAT) and CE constitutes greater than 80% of total cholesterol carried by 
the HDL particle. In the liver, HDL binds to its receptor SR-BI and delivers its lipid “cargo”, 
and lipid poor HDL is presumed to return into circulation to further serve as the 
extracellular cholesterol acceptor and facilitate removal of cholesterol from peripheral 
tissues including artery wall associated macrophage foam cells. This function of HDL is 
responsible for its alias “Good cholesterol” in contrast to LDL or “Bad cholesterol” that 
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hydrolase in the development of atherosclerosis (Kodvawala et al, 2005). In athero-
susceptible ApoE-/- background, CEL transgenic mice displayed an approximate 4-fold 
higher atherosclerotic lesion area than ApoE(-/-) mice without the CEL transgene. It was 
speculated that perhaps its extracellular location or its hydrolysis of ceramide and 
lysophosphatidylcholine leads to increased cholesterol esterification and decreased 
cholesterol efflux resulting in increased atherosclerosis. Regardless of the underlying 
mechanisms, these studies demonstrate a minimal role for CEL in macrophage CE 
mobilization and thereby in atherogenesis. 
To evaluate the role of CEH in foam cell formation and atherogenesis, we developed 
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LDLR-/- background. High-fat high-cholesterol diet induced atherosclerosis was 
evaluated and we reported almost a 50% reduction in lesion area in LDLR-/-CEH 
transgenic mice compared to LDLR-/- mice (Zhao et al, 2007). In addition, CEH-mediated 
increase in CE mobilization also reduced total cholesterol and CE content of the lesions 
resulting in significantly reduced lesion necrosis. Consistent with our in vitro studies, 
macrophages from CEH transgenic mice showed higher FC efflux and decreased cellular 
CE levels upon loading with modified LDL. Over-expression of CEH in macrophages 
alone increased the process of reverse cholesterol transport and there was increased 
elimination of cholesterol in the feces of CEH transgenic mice (Zhao et al, 2007). The 
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yet been developed and the role of this enzyme in affecting atherogenesis remains to be 
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FC from lesion associated foam cells, final removal of FC occurs from the liver either via 
direct secretion into bile or by conversion into bile acids, both of which are excreted in the 
feces. Figure 3 below summarizes the different steps involved in the movement of FC from 
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Fig. 3. Reverse Cholesterol Transport 
FC delivered to the liver via SR-BI is believed to be directly secreted into bile (Kozarsky et 
al, 1997). On the other hand, for generation of FC, the HDL-delivered CE, once again, needs 
to be hydrolyzed underscoring the importance of CEH in hepatic CE metabolism. FC enters 
the hepatic metabolic pool where it is either re-esterified by ACAT2 (distinct from ACAT1 
present in macrophages) or secreted into bile or converted into bile acids where the rate-
limiting step is catalyzed by cholesterol 7 hydroxylase (C7H). It should be emphasized 
that although humans and other mammals can synthesize cholesterol starting from acetate, 
they lack the enzymes required to degrade the steroid nucleus. Extremely hydrophobic 
cholesterol requires several modifications to increase its water solubility and to facilitate its 
excretion. Conversion of cholesterol to water soluble bile acids is one such mechanism 
which along with direct secretion of cholesterol in bile represents the major route of 
cholesterol elimination from the body.  
2.4.1 Hepatic CE hydrolysis 
Based on immunological cross reactivity and observed variations in CE hydrolytic activities 
in rat liver, Harrison speculated that hepatic CE hydrolytic activity is due to the uptake of 
pancreatic cholesterol esterase and that liver does not synthesize a similar enzyme 
(Harrison, 1988). This concept gained further support by the observed similarity between 
pancreatic and liver enzymes (Camulli, 1989, Chen 1997). However, we purified and 
characterized a rat hepatic CEH that was immunologically distinct from pancreatic CEH 
(Ghosh 1991). Molecular cloning of this rat liver CEH identified it as a member of the 
carboxylesterase family of enzymes (Ghosh et al., 1995). Biochemical, physiological and 
developmental characterization of this enzyme confirmed its role in regulating hepatic 
cholesterol homeostasis (Natarajan et al, 1996, 1998, Ghosh et al 1998). Homology cloning, 
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based on this rat liver CEH, was used to identify the human macrophage CEH described 
above (Ghosh 2000). We also cloned CEH from human liver and demonstrated that, unlike 
ACAT, hepatic and macrophage CEH are products of the same gene Ces1 (Zhao et al., 2005).  
To evaluate the role of hepatic CEH in regulating hepatic cholesterol metabolism, we over 
expressed CEH in mouse liver using adenovirus. Our data demonstrated a significant 
increase in bile acid secretion following adenovirus-mediated over-expression suggesting 
that CEH plays an important role in regulating this last step of RCT and enhances the 
elimination of cholesterol from the body (Zhao et al, 2008). To address the question whether 
enhancing CEH mediated CE hydrolysis in liver can increase in vivo RCT, we utilized 
“macrophage-to-feces” in vivo RCT model described by Zhang et al (Zhang et al, 2003). 
Adenovirus mediated over-expression of CEH led to a significant increase in the flux of 
cholesterol from macrophages to feces, predominantly in fecal bile acids (Zhao et al, 2008). 
These data demonstrate that increase in hepatic CEH alone can increase the flux of 
cholesterol from peripheral tissues such as macrophages to liver and ultimate elimination 
from the body into feces. Such enhanced elimination of cholesterol from the body should be 
potentially anti-atherogenic and to test the hypothesis that increase in hepatic CEH alone 
can reduce atherosclerosis, we have developed liver-specific CEH transgenic mice and 
studies are in progress to evaluate the effects on diet-induced atherosclerosis in these 
transgenic mice in an LDLR-/- background.  
Initially HSL was thought be not expressed in liver (Holm et al, 1987), but re-evaluation of 
HSL-/- mice has provided some evidence that suggests that HSL might be expressed in liver 
and may contribute to CE hydrolysis in hepatocytes (Sekiya et al 2008, Fernandez et al 2008). 
However, to date, there are no reports of direct evaluation of HSL in regulating bile acid 
synthesis precluding the determination of its role in RCT and cholesterol elimination from 
the body. Expression of AADLAC1 or KIAA1363 is negligible in human and mouse liver 
and it is unlikely to play a significant role in either hepatic cholesterol homeostasis or in 
regulating the terminal step of RCT, namely hydrolysis of HDL-delivered CE.  
2.5 Metabolic consequence of CE accumulation in macrophages 
Intracellular accumulation of CE or cholesterol is considered to enhance the expression of 
pro-inflammatory mediators. Fazio and Linton proposed a feedback loop linking 
macrophage cholesterol balance and inflammatory mediators and suggested that a 
primary defect in cellular cholesterol balance may induce changes in the inflammatory 
status of the macrophage (Fazio and Linton 2001). Close relationship between 
macrophage cholesterol efflux and inflammation is also exemplified by attenuation of in 
vitro efflux and in vivo RCT by endotoxins (McGillicuddy et al 2009). In addition, pro-
inflammatory cytokines such as IL-1 and TNF enhance lipid accumulation and foam 
cell formation by reducing lipid catabolism (Persson et al 2008). Consistently, under 
conditions of enhanced cholesterol accumulation, for example by deficiency of cholesterol 
transporter ABCA1, there was a marked increase in TNF- secretion from macrophages 
(Koseki et al 2007) and increased inflammation with resulting loss in pancreatic beta cell 
function (Tang and Oram, 2009). It is also noteworthy that macrophages from ldlr-/-
Abca1-/- mice with 80-fold increase in cellular CE content display an exaggerated 
inflammatory response (Francone et al, 2005). Thus, accumulation of CE in macrophages 
is likely to be central to the development of multiple metabolic disorders including 
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based on this rat liver CEH, was used to identify the human macrophage CEH described 
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Fig. 4. Role of macrophage foam cell in regulating multiple metabolic disorders 
2.5.1 CEH-mediated CE mobilization and inflammation 
In contrast to CE accumulation, over-expression of ApoA1 that enhances CE removal and 
decreases cellular cholesterol levels results in attenuated response to pro-inflammatory 
insult by LPS (Levine et al 1993). Further, a recent clinical study demonstrated beneficial 
effects of re-constituted HDL infusions that enhance cholesterol efflux from cells on 
suppression of inflammation (Patel et al 2009) underscoring the importance of cholesterol 
removal in modulating inflammatory processes.  
The observed decrease in lesion necrosis in CEH transgenic mice (Zhao et al 2007) was the 
first indication that CEH-mediated increase in macrophage CE mobilization is likely to be 
anti-inflammatory. We, therefore, directly examined the effects of CEH mediated hydrolysis 
of intracellular CE on reducing inflammation and inflammation-linked pathologies. 
Macrophage-specific transgenic expression of CEH significantly improved glucose tolerance 
and insulin sensitivity in LDLR-/- mice (Bie et al, 2010) demonstrating a critical role for CE 
mobilization in the development of insulin resistance and Type-2 diabetes mellitus (T2DM). 
Chronic low grade inflammation is increasingly being recognized as a key step in the 
pathogenesis of obesity-induced insulin resistance and T2DM and expanding adipose tissue 
was initially recognized as the site of production of pro-inflammatory mediators (Trayhurn 
and Wood 2004, Weiss 2004) responsible for this low grade inflammation. However, recent 
studies have demonstrated that majority of adipose tissue derived cytokines (TNF, IL-6 
and IL-1) actually originate in non-fat cells and among them, infiltrated macrophages play 
the most prominent role. This low-grade inflammation is mediated by the activation and 
recruitment of macrophages into the expanding adipose tissue (Bouloumié et al 2005). The 
level of macrophages within a tissue represents a balance between recruitment, 
survival/expansion and emigration which is facilitated by several chemokines and growth 
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factors produced by adipocytes as well as infiltrated resident macrophages. These include 
monocyte chemoattracttant protein 1 (MCP-1) (Kanda et al, 2006), macrophage colony 
stimulating factor (M-CSF) and granulocyte-macrophage colony stimulating factor (GM-
CSF) (Kim et al, 2008) that recruit and assist in expansion or colonization of macrophages, 
respectively. Whether accumulation of cholesterol in macrophages can affect macrophage 
recruitment into the adipose tissue due to increased production of these pro-inflammatory 
mediators has not been explored. Subramanian et al have recently reported that addition of 
relatively small amount (0.15%) of dietary cholesterol resulted in marked increase in 
accumulation of macrophages in adipose tissue (Subramanian et al, 2008). Although this 
study provides the first evidence that cholesterol plays an important role in macrophage 
infiltration into the adipose tissue, the role of macrophage cholesterol balance in regulating 
this process remains undefined. We demonstrated that CEH-mediated increase in CE 
mobilization in macrophages decreased activation of pro-inflammatory transcription factor 
NF-B resulting in decreased expression of pro-inflammatory chemokines (e.g., MCP-1) and 
cytokines (e.g., IL-1 and IL-6) resulting in significant reduction in circulating cytokines. 
Macrophage infiltration into expanding adipose tissue was also significantly reduced in 
CEH transgenic mice. Further, insulin signaling in adipocytes was not dramatically 
perturbed by CEH over-expressing macrophages (Bie et al, 2010). Collectively, these data led 
us to propose the following model (Figure 5) whereby CEH-mediated reduction in 
macrophage CE levels regulate infiltration of macrophages into the expanding adipose 
tissue. Reduction in the number of macrophages limits the deleterious effects of 
macrophage-adipocyte interactions that are central to the development of insulin resistance. 
 
 







Fig. 4. Role of macrophage foam cell in regulating multiple metabolic disorders 
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factors produced by adipocytes as well as infiltrated resident macrophages. These include 
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Besides hypercholesterolemia, chronic low grade inflammation, obesity and T2DM are 
additional risk factors for development of atherosclerosis and CAD. Our data showing CEH-
mediated attenuation of insulin resistance and systemic as well as adipose tissue 
inflammation establishes macrophage CE mobilization as an important therapeutic target 
that can simultaneously affect multiple and linked metabolic disease processes. 
2.5.2 CEH-mediated CE mobilization and hepatic steatosis 
In addition to the development of obesity and insulin resistance, both of which are risk 
factors for atherosclerosis, excessive intake of high calorie or high fat food also leads to the 
ectopic deposition of excess fat in tissues other than the physiological fat depots such as 
adipose tissue. Increased accumulation of lipids in liver results in hepatic steatosis that is 
central to the development of non-alcoholic fatty liver disease and which progresses into 
non-alcoholic steatohepatitis. The etiology of this disease is distinct from a similar liver 
pathology seen with alcoholism and hence the name.  
Upon excessive lipid storage liver overproduces multiple cardiovascular risk factors such as 
glucose, very low density lipoproteins, plasminogen activator inhibitor-1 (PAI-1) 
coagulation factors and C-reactive protein (CRP). In addition, liver fat content is closely 
related to fasting insulin concentrations and direct measures of hepatic insulin sensitivity 
and increase in hepatic lipid contents predicts T2DM (Yki-Jarvinen, 2005). The mechanism(s) 
responsible for increased intra-hepatic triglyceride accumulation are not completely 
understood. It has been suggested that dysfunctional adipose tissue, characterized by 
adipocyte hypertrophy, macrophage infiltration, impaired insulin signaling, and insulin 
resistance, releases a host of inflammatory adipokines and excessive amounts of free fatty 
acids (FFA) that promote ectopic fat deposition in liver (Cusi, 2010). Alterations in FFA 
uptake regulated at the level of fatty acid transporter, CD36 expression is thought to be 
involved in increased triglyceride accumulation and hepatic CD36 expression is directly 
correlated with liver fat in human subjects (Greco et al, 2008).  
Kupffer cells are resident macrophages present in the liver and, therefore, changes in 
macrophage metabolism and/or phenotype will also affect kupffer cells. However, the role 
of hepatocyte microenvironment namely the effect of Kupffer cells in regulating triglyceride 
accumulation in hepatocytes is not completely defined. Pro-inflammatory cytokines 
(namely, IL-1β, IL-6 or TNFα) secreted by Kupffer cells activate hepatocytes (Scott et al, 
2005), affect gluconeogenesis (Yerkovich et al, 2004), increase the expression of acute phase 
proteins (Knolle et al, 1995) and enzymes involved in xenobiotic metabolism (Milosevic et al, 
1999). On the other hand, anti-inflammatory cytokine IL-10 secreted by Kupffer cells is 
essential for hepatocyte homeostasis and its loss under conditions of Kupffer cell depletion 
is associated with increased STAT3-dependent signalling and steatosis leading to decreased 
insulin signalling (Clementi et al, 2009). These studies underscore the importance of 
understanding the mechanisms involved in regulating the inflammatory status of Kupffer 
cells. To directly evaluate the role of kupffer cells, we examined hepatocyte triglyceride (TG) 
accumulation in livers of leptin-deficient obese (ob/ob) mice that were crossed with 
macrophage-specific CEH transgenic mice. Leptin deficiency in these ob/ob mice leads to 
increased obesity resulting in significant ectopic lipid accumulation in the liver and, thus, 
providing an ideal model to test the effects of decreased CE accumulation in kupffer cells as 
a result of transgenic expression of CEH on hepatocyte TG metabolism. Accumulated lipids 
are stored as cytoplsamic lipid droplets that continue to occupy greater cellular area and 
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total area occupied by lipid was used as a measure of total lipid accumulation and percent 
area occupied by lipid was significantly reduced by transgenic expression of CEH (Table 1). 
These data were confirmed by direct quantification of TG in total hepatic lipids where a 
significant decrease in hepatic TG content was observed in ob/ob-CEH transgenic mice. It is 
important to note that expression of CEH transgene in this model is macrophages-specific 
and, therefore, the observed effects are due to the changes in kupffer cell CE metabolism. 
 
Gentotype Percent area occupied by lipid Total TG (g/mg tissue) 
ob/ob 45.4 ± 5.3 32.3 ± 4.3 
ob/ob-CEH 
Transgenic 39.5 ± 3.1** 23.1 ± 4.2** 
Table 1. Macrophage-specific transgenic expression of significantly decreases hepatic lipid 
accumulation **P<0.05 
Consistent with a reduction in hepatic lipid content, ob/ob-CEH transgenic mice showed 
improved glucose tolerance and insulin sensitivity.  
Macrophage polarization plays a pivotal role in the development of insulin resistance and 
it is promoted by a transition from an alternative M2 activation state maintained by 
STAT6 and PPARs to a classical M1 activation state driven by NF-B, AP1, and other 
signal-dependent transcription factors that play crucial roles in innate immunity (Olefsky 
and Glass, 2010). While IL-1β, IL-6 and TNFα are the predominant cytokines secreted by 
M1 macrophages, M2 macrophages secrete anti-inflammatory cytokines IL-10 and IL-13. 
M1 activation by LPS via Toll-like receptor 4 (TLR4) or by free fatty acids as identified 
recently, triggers inflammatory responses (Bilan et al, 2009). Intracellular lipid content, 
specifically the cholesterol content, is increasingly being recognized as another major 
factor that contributes to macrophage activation. While cholesterol loading of 
macrophages activated TLR4 (Sun et al, 2009), HDL or ApoA1-mimetic stimulated 
removal of cellular cholesterol abolished LPS-induced mRNA expression of pro-
inflammatory mediators such as MCP-1, MIP-1, RANTES, IL-6, and TNF-alpha but 
significantly up-regulated LPS-induced anti-inflammatory IL-10 expression (Smythies et 
al, 2010). Interaction of ApoA1 with cholesterol transporter ABCA1, suppressed the ability 
of LPS to induce pro-inflammatory cytokine expression suggesting that cholesterol 
removal from macrophages is an anti-inflammatory event (Tang et al, 2009). CEH-
mediated increase in CE mobilization and subsequent decrease in cellular cholesterol 
content is, therefore, likely to polarize the macrophages to an M2 or anti-inflammatory 
phenotype. This is consistent with our earlier data demonstrating a decrease in expression 
of pro-inflammatory cytokines via reduced activation of NF-B and AP-1 in CEH 
transgenic macrophages (Bie et al, 2010) that leads to a decrease in the levels of pro-
inflammatory cytokines (e.g., IL-6) in circulation and reduction in systemic inflammation. 
Based on these data, we propose the following model (Figure 6) to integrate the cellular 
events and interactions that lead to the increased accumulation of TG in the liver and how 
CEH-mediated reduction in cellular CE content resulting in M2 polarization of Kupffer 
cells as well as decrease in circulating cytokines such as IL-6 can attenuate this process. 
The studies described above and the recent developments linking cellular CE content to 
macrophage phenotype and inflammation underscore the importance of macrophage 
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Fig. 6. Proposed model by which CEH-mediated macrophage CE mobilization attenuates 
hepatic TG accumulation and improves insulin sensitivity. 
2.5.3 CEH-mediated CE mobilization and atherosclerotic plaque stability 
In recent years, there has been a shift in the paradigm of arterial re-modelling during 
progression of atherosclerosis and improved understanding of the mechanism underlying 
acute coronary syndromes or sudden heart attacks. The earlier notion of gradual narrowing 
of the arterial lumen that eventually occludes the coronary artery resulting in heart attacks is 
being replaced by the concept of a developing plaque in the arterial wall (that may or may 
not affect the lumen) that becomes unstable and prone to rupture. Thrombotic events 
resulting from the sudden release of lipid contents of the plaque into circulation is now 
considered as the primary cause of acute coronary events. Large necrotic cores as well as 
increased inflammation associated with plaques are the two main factors that determine 
plaque stability. 
Macrophage content of plaque is variable during the development of plaques (from fatty 
streaks to complex plaques) and is determined by processes involved in macrophage 
recruitment, apoptosis and egress. A balance between these processes limits plaque 
progression and is also likely to maintain favourable plaque characteristics. With increased 
lipid accumulation, plaque-associated foam cells undergo apoptosis and functional 
macrophages are required for efficient clearance of apoptotic cells (or efferocytosis). Inability 
to effectively clear the apoptotic cells results in accumulation of released lipids and other 
inflammatory mediators that lead to secondary necrosis. Growth of acellular necrotic core 
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not only destabilizes the plaque by altering its physical characteristics, but it also limits 
smooth muscle cell proliferation required to maintain the integrity of the fibrous cap of the 
plaque. Our earlier studies have demonstrated a decrease in lesion necrosis in macrophage-
specific CEH transgenic mice. These lesions also contained increased number of 
macrophages and significantly less number of apoptotic cells (Zhao et al, 2007). Collectively, 
these characteristics are suggestive of a more stable plaque. 
Khallou-Laschet et al evaluated the phenotype of macrophages associated with progression 
of atherosclerosis in mice and demonstrated that early lesions were infiltrated with 
alternatively activated and anti-inflammatory M2 macrophages which favoured smooth cell 
proliferation and deposition of extra-cellular matrix (tissue repair phenotype). However, a 
phenotypic switch of existing macrophages within the plaques from M2 to M1 (classically 
activated macrophages with pro-inflammatory properties) occurred during plaque 
progression resulting in increased inflammation (Khallou-Laschet et al, 2010). M1 
macrophages, identified by high expression of Ly6C surface antigen (Ly6CHi), increase with 
hypercholesterolemia, actively adhere to endothelium, become lesional macrophages and 
represent a newly recognized component of the inflammatory response in atherosclerosis 
(Swirski et al, 2007). We examined the phenotype of diet-induced lesion associated 
macrophages isolated from LDLR-/- and LDLR-/-CEH transgenic mice. Consistent with our 
earlier results described above, increased polarization towards M2 phenotype was noted in 
lesional macrophages from CEH transgenic mice. Studies are in progress to determine the 
effects of CEH-mediated shift in macrophage polarization on lesion-associated 
inflammation. 
Increase in inflammation with increasing cellular cholesterol content has been known for a 
long time. Recent studies have also shown that deficiency of cholesterol transporter ABCA1 
in LDLR-/- mice that results in massive CE accumulation, leads to an exacerbated response 
to lipopolysaccharide and increased inflammation (Francone et al, 2005). Increased 
inflammatory gene expression was also noted in macrophages from ABCG1 deficient 
macrophages (Balden et al, 2008). However, cellular mechanisms that directly link changes 
in cellular cholesterol homeostasis to inflammatory pathways remain undefined. In cells 
with increased CE accumulation, we demonstrated that CEH-mediated CE mobilization 
directly attenuated NF-B and AP1-driven gene expression suggesting that pro-
inflammatory transcription factor-driven gene expression is directly affected by cellular CE 
content (Bie et al 2010). However, the intracellular processes that are involved in “sensing” 
and “linking” of cellular CE content to inflammatory gene expression still remain to be 
elucidated.  
3. Conclusions 
Maintaining macrophage cholesterol homeostasis is central to atherogenesis. While 
unregulated uptake of modified LDL results in increased cellular CE content and foam cell 
formation, CEH-mediated mobilization of CE represent an important mechanism by which 
macrophages reduce the lipid burden. Given the importance of this step, intracellular CE 
hydrolysis is a multi-enzyme process and several enzymes catalyze this reaction. It is 
extremely important that the future focus is maintained on intracellular CE hydrolysis and 
not on establishing the “major” CE hydrolase in either human or mouse macrophages. 
Current strategies of single gene ablation are likely to be inconclusive not only due to the 
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inflammatory gene expression was also noted in macrophages from ABCG1 deficient 
macrophages (Balden et al, 2008). However, cellular mechanisms that directly link changes 
in cellular cholesterol homeostasis to inflammatory pathways remain undefined. In cells 
with increased CE accumulation, we demonstrated that CEH-mediated CE mobilization 
directly attenuated NF-B and AP1-driven gene expression suggesting that pro-
inflammatory transcription factor-driven gene expression is directly affected by cellular CE 
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and “linking” of cellular CE content to inflammatory gene expression still remain to be 
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unregulated uptake of modified LDL results in increased cellular CE content and foam cell 
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macrophages reduce the lipid burden. Given the importance of this step, intracellular CE 
hydrolysis is a multi-enzyme process and several enzymes catalyze this reaction. It is 
extremely important that the future focus is maintained on intracellular CE hydrolysis and 
not on establishing the “major” CE hydrolase in either human or mouse macrophages. 
Current strategies of single gene ablation are likely to be inconclusive not only due to the 





mechanisms that may become operative under conditions of single gene deficiency leading 
to erroneous dismissal of the candidate CE hydrolase as unimportant . 
Removal of cholesterol from arterial wall associated macrophage foam cells represents the 
first step in prevention of atherosclerotic plaque formation or regression of existing plaques. 
Our results with CEH over-expression conclusively demonstrate the anti-atherogenic role of 
this enzyme in mobilizing stored CE from macrophages and attenuating atherogenesis. 
Cholesterol removed from the periphery including artery wall associated macrophages is 
returned to the liver via HDL and liver is the only organ that facilitates final elimination of 
cholesterol from the body. Since 80% of the total cholesterol delivered by HDL is CE, hepatic 
hydrolysis of CE is crucial to further metabolism of cholesterol. Consistently, increase in 
hepatic CE hydrolysis enhances elimination of cholesterol as bile acids in faeces. More 
importantly, increasing CE hydrolysis in liver alone stimulates movement of cholesterol 
from macrophages to faeces. Thus, hydrolysis of CE is an extremely important step in 
removal of cholesterol from the body and intracellular CE hydrolysis represents an 
important anti-atherogenic step that should be targeted for therapeutic benefit.  
Although macrophage cholesterol homeostasis is intuitively linked to atherogenesis as the 
primary disease process, continuing characterization of macrophage-specific CEH 
transgenic mice has revealed novel roles of CEH in regulating several disease processes and 
has established the central role of macrophage cholesterol homeostasis. By modulating 
infiltration of macrophages into adipose tissue and thus affecting adipose tissue as well as 
systemic inflammation, mobilization of CE from macrophages improves glucose tolerance 
and insulin sensitivity. Similarly, by altering the polarization towards a more anti-
inflammatory phenotype, increased CE mobilization from kupffer cells attenuates hepatic 
steatosis. Altered polarization towards M2 phenotype in atherosclerotic lesions also leads to 
decreased lesion necrosis and increased macrophage survival. Collectively, these studies 
clearly establish CEH as an important therapeutic target with a potential to simultaneously 
affect multiple disease processes. Ongoing studies will establish the direct link(s) between 
cellular CE content and inflammatory pathways and identify the intracellular pathways 
involved. 
From a clinical and translational perspective, future studies are necessary to delineate 
endogenous mechanisms that regulate these CE hydrolases such that these can be 
specifically targeted (e.g., by pharmacological means) to increase the activity in vivo.  
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mechanisms that may become operative under conditions of single gene deficiency leading 
to erroneous dismissal of the candidate CE hydrolase as unimportant . 
Removal of cholesterol from arterial wall associated macrophage foam cells represents the 
first step in prevention of atherosclerotic plaque formation or regression of existing plaques. 
Our results with CEH over-expression conclusively demonstrate the anti-atherogenic role of 
this enzyme in mobilizing stored CE from macrophages and attenuating atherogenesis. 
Cholesterol removed from the periphery including artery wall associated macrophages is 
returned to the liver via HDL and liver is the only organ that facilitates final elimination of 
cholesterol from the body. Since 80% of the total cholesterol delivered by HDL is CE, hepatic 
hydrolysis of CE is crucial to further metabolism of cholesterol. Consistently, increase in 
hepatic CE hydrolysis enhances elimination of cholesterol as bile acids in faeces. More 
importantly, increasing CE hydrolysis in liver alone stimulates movement of cholesterol 
from macrophages to faeces. Thus, hydrolysis of CE is an extremely important step in 
removal of cholesterol from the body and intracellular CE hydrolysis represents an 
important anti-atherogenic step that should be targeted for therapeutic benefit.  
Although macrophage cholesterol homeostasis is intuitively linked to atherogenesis as the 
primary disease process, continuing characterization of macrophage-specific CEH 
transgenic mice has revealed novel roles of CEH in regulating several disease processes and 
has established the central role of macrophage cholesterol homeostasis. By modulating 
infiltration of macrophages into adipose tissue and thus affecting adipose tissue as well as 
systemic inflammation, mobilization of CE from macrophages improves glucose tolerance 
and insulin sensitivity. Similarly, by altering the polarization towards a more anti-
inflammatory phenotype, increased CE mobilization from kupffer cells attenuates hepatic 
steatosis. Altered polarization towards M2 phenotype in atherosclerotic lesions also leads to 
decreased lesion necrosis and increased macrophage survival. Collectively, these studies 
clearly establish CEH as an important therapeutic target with a potential to simultaneously 
affect multiple disease processes. Ongoing studies will establish the direct link(s) between 
cellular CE content and inflammatory pathways and identify the intracellular pathways 
involved. 
From a clinical and translational perspective, future studies are necessary to delineate 
endogenous mechanisms that regulate these CE hydrolases such that these can be 
specifically targeted (e.g., by pharmacological means) to increase the activity in vivo.  
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1. Introduction 
Researchers discovered a new cytokine with the capability to transform fibroblasts in 1983 
while studying epidermal and platelet derived growth factors in rat fibroblasts. Originally 
called sarcoma growth factor, TGFβ was first isolated from neoplastic mouse tissue by 
Moloney sarcoma virus (Assoian et al., 1983). After more than three decades TGF-β family 
comprise several members including – nodals, activins, bone morphogenic proteins 
(BMPs), myostatin, anti-Muellerian hormone (AMH) and others – control cell division, 
differentiation, migration, adhesion, organization and programmed cell death (Massague, 
1998). There are three TGF-β isoforms currently described in humans, including TGF-β1, 
TGF-β2, and TGF-β3.  Alignment of the amino acid sequences of the three mammalian 
TGF-β isoforms reveals that the different isoforms share a high level of similarity between 
the active domains; TGF- β3 is 86% similar to that of TGF- β1 while it shares 91% similarity 
with that of TGF-β2. However, despite TGF- β2 and - β3 sharing the highest level of 
sequence similarity of the three isoforms, TGF- β2 binds to the TGF-β receptor II (TβRII) in 
a different way from TGF β1 and - β3. Furthermore, while TGF-β1 and -β3 are both capable 
of binding directly to the type II receptor, presentation of TGF-β2 to the receptor requires 
the presence of a co-receptor (beta glycan or endoglin), which may explain the differences 
in activities of TGF-β2 and -β1 (Laverty et al., 2009).  The importance of TGF-β isoforms in 
mammalian biology is highlighted by the lack of viability in TGF-β−/− mice. Targeted 
disruption of the TGF-β1 genes leads to hematopoietic and vasculogenic defects that result 
in death of about half of null embryos by 10 days gestation. Moreover, embryos that 
survive die within 3 weeks due to widespread inflammatory disease (Shull et al., 1992). 
TGF-β2 null mice die in the perinatal period due to cyanotic heart disease, pulmonary 
insufficiency, and another abnormalities in urogenital, visual, auditory, neural and skeletal 
systems (Sanford et al., 1997). Additionally, mice lacking TGF-β3 exhibit cleft palate with 
100% penetration and die immediately after birth due to an inability to suckle effectively 
(Proetzel et al., 1995). In addition, other organs are not affected when compared with mice 
lacking TGF-β1 and TGF-β2.  
Several other papers showed differences in postnatal effects of different TGF-β isoforms, 
including different role in neovascularization (Wu et al., 1997), collagen production and 
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mammalian biology is highlighted by the lack of viability in TGF-β−/− mice. Targeted 
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in death of about half of null embryos by 10 days gestation. Moreover, embryos that 
survive die within 3 weeks due to widespread inflammatory disease (Shull et al., 1992). 
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insufficiency, and another abnormalities in urogenital, visual, auditory, neural and skeletal 
systems (Sanford et al., 1997). Additionally, mice lacking TGF-β3 exhibit cleft palate with 
100% penetration and die immediately after birth due to an inability to suckle effectively 
(Proetzel et al., 1995). In addition, other organs are not affected when compared with mice 
lacking TGF-β1 and TGF-β2.  
Several other papers showed differences in postnatal effects of different TGF-β isoforms, 
including different role in neovascularization (Wu et al., 1997), collagen production and 





and detected in wound fluid, especially during inflammation and tissue repair. Although all 
three TGF-β isoforms participate in wound healing TGF-β1 plays a dominant role in the 
wound repair process while TGF-β2 and TGF-β3 have been shown to play a key role in 
embryonic development and scarless wound healing (Tandon et al., 2010).   
TGF-β1 (the first member of the family to be discovered and the best-studied member to 
date) is present at high levels in the healthy blood vessel wall, whereas TGF-β2 and TGF-β3 
isoforms are either absent (β2) or present only at low levels (β3) (Lebrin et al., 2005).  
Moreover, TGF-β1 is a potent regulator of vascular development and vessel remodeling and 
plays key roles in atherosclerosis and restenosis, regulating endothelial, smooth muscle cell 
(SMC), macrophage, T-cell and probably vascular calcifying cell responses (Bobik, 2006). 
Thus, in this review, we will focus on TGF-β1 cytokine and its receptors and transducers 
related mostly to in vivo atherogenesis, both in animals and humans. 
2. TGF-β1 and atherogenesis 
There are a number of studies which demonstrate the role of TGF-β1 cytokine in 
atherosclerosis. TGF-β1 is produced by both inflammatory and vascular cells and is 
expressed in human and mouse atherosclerotic plaques (Mallat et al., 2001). 
There is some controversial information regarding the role of TGF-β1 in atherogenesis. One 
group of papers show anti-atherogenic role of TGF-β1 cytokine. Inhibition of TGF-β1 
activity by various approaches results in pro-atherogenic changes in the vessel wall in 
animal models of atherosclerosis (Singh and Ramji, 2006). Deletion of a single allele of the 
TGF-β1 gene, which reduces the amount of TGF-β1 protein in the vessel media by ~ 50%, 
results in reduced SMC differentiation, and increased susceptibility to endothelial cell 
activation and vascular lipid lesion formation in response to pro-atherogenic stimuli such as 
a lipid-rich diet (Grainger et al., 2000). Moreover treatment with neutralizing anti-TGF-β1 
antibodies led to increased vascular inflammation, accelerated lipid lesion formation and a 
shift in plaque morphology towards an unstable phenotype (Mallat et al., 2001). Inhibition 
of TGF-β1 with a recombinant soluble TGF-β receptor fusion protein was associated not 
only with increased inflammation but also with intraplaque hemorrhage (Lutgens et al., 
2002). Additionally, TGF-β1 has been shown to increase bovine aortic endothelial cell 
(BAEC) and human umbilical vein endothelial cell (HUVEC) steady-state eNOS mRNA 
expression (Inoue et al., 1995), suggesting the protective role of this cytokine in the vessel 
endothelium. Moreover, smooth muscle cells in stable lesions express greater amounts of 
TGF-β1 than unstable lesions (Cipollone et al., 2004). Furthermore, disruption of TGF-β1 
signaling specifically in T-cells also results in increased lesion size and development of an 
unstable phenotype (Li et al., 2006; Robertson et al., 2003). Additionally, TGF-β1 attenuates 
macrophage foam cell formation, increases cholesterol efflux (Panousis et al., 2001) and 
inhibits lipoprotein lipase expression (Irvine et al., 2005). Furthermore, TGF-β1 reduces 
cytokine-stimulated inducible nitric oxide synthase (iNOS) expression (Werner et al., 2000), 
promotes iNOS protein degradation (Mitani et al., 2005), and inhibits expression of cell 
adhesion molecules (DiChiara et al., 2000). 
On the other hand, there have been some reports discussing a possible atherogenic activity 
of this cytokine. Elevated TGF-β1 levels have been found in vessel wall lesions (Majesky et 
al., 1991; Nikol et al., 1992). Moreover, TGF-β is a potent stimulator of proteoglycan 
biosynthesis in human SMCs (Chen et al., 1987), its presence in fatty lesions is likely to 
contribute to the synthesis of lipoprotein-trapping proteoglycans, which can contribute to 
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accumulation of lipoproteins in the vessel wall (O'Brien et al., 1998) and their subsequent 
chemical modification (Grainger et al., 1995). Moreover TGF-β1 stimulates leukocyte 
chemotaxis (Ashcroft, 1999), suggesting that TGF-β contributes to early macrophage 
migration and lipid accumulation. When infused into rats with preexisting vascular lesions, 
TGF-β1 caused an 80% increase in lesion size due to extracellular matrix accumulation 
(Majesky et al., 1991). Localization of TGF-β1 correlated with areas of neointimal formation, 
where increase in expression of fibronectin and collagen types I and III was observed 
(Bahadori et al., 1995; Majesky et al., 1991). Antibodies against TGF-β1 suppressed intimal 
hyperplasia in a rat model (Wolf et al., 1994). Similarly, Schulick et al. demonstrated that 
overexpression of active TGF-β1 in uninjured rat arteries results in the development of a 
matrix-rich neointima (Schulick et al., 1998). All these data generally suggest a strong 
participation of TGF-β1 in the development of atherosclerosis. 
In summary, TGF-β1 seems to participate in the development of atherosclerosis, but maybe 
more interestingly promote a stable lesion phenotype, suggesting its role in the protection of 
acute ischemic situations like myocardial infarction. 
TGF-β1 is secreted in a latent form, where it is associated in a complex with latency-
associated protein (LAP) and latent TGF-β1 binding protein-1 (LTBP). Latent TGF-β1 can be 
activated by a number of physical processes, including heat, acid, reactive oxygen species, 
and biological processes such as proteolysis or integrin - mediated activation. A number of 
proteases, including plasmin, thrombin, elastase, MMP-2 (matrix metalloproteinase-2) and 
MMP-9, have been shown to be capable of directly activating latent TGF-β1 in vitro (Jenkins, 
2008). TGF-β1 can bind a heteromeric complex of type I and type II transmembrane 
serine/threonine kinase receptors. This complex is usually formed by ligand, one TGF-β 
type II receptor (TβR-II) and two TGF-β type I receptors called activin receptor-like kinase 
(ALK) (ten Dijke and Hill, 2004). This process can be affected by type III receptor known as 
endoglin (CD105) (Grainger, 2007). In the ligand-bound complex, the type II receptor 
phosphorylates serine and threonine residues in the GS region of the type I receptor. After 
that, conformational changes in the type I receptor appear and subsequently, 
phosphorylation of signaling molecules named Smads propagate the signal to the nucleus, 
where they finally regulate transcription of several genes, including those with importance 
in atherogenesis (Lebrin et al., 2005). Human genome encodes seven type I receptors (ALKs 
1–7) and five type II receptors (ActR-IIA, ActR-IIB, BMPRII, AMHR-II and TβR-II) that are 
paired in different combinations as receptor complexes for various members of TGF-β 
family (Massague and Gomis, 2006). Moreover, there are also three distinct types of Smad 
proteins (Feinberg and Jain, 2005). 
In the following part of this review we will discuss the role of TGF-β receptors in 
atherogenesis. 
2.1 TGF-β receptors I and their role in atherogenesis 
As mentioned above there are seven type I receptors, designated activin receptor-like 
kinases (ALK-1 to ALK-7) (de Caestecker, 2004; Miyazono et al., 2000). The decision which 
type I receptor is activated is determined by receptor expression and/or ligand 
concentration (Goumans et al., 2002). The most important and the most studied type I 
receptors with respect to atherogenesis are ALK-1 and ALK-5. 
Many previously published in vitro studies demonstrated a large interplay and mostly 
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II receptor can activate endothelial cell-restricted ALK-1 and/or broadly expressed ALK-5, 
which have opposite effects on endothelial cell behavior (Lebrin et al., 2005). Both ALK-1 
and ALK-5 can activate various Smad proteins, which will be discussed later. ALK-5 was 
found to be important for recruitment of ALK-1 into a TGF-β receptor complex, and 
additionally, the kinase activity of ALK-5 is essential for efficient ALK-1 activation 
(Massague and Gomis, 2006). 
Both ALK-1 and ALK-5 are important for endothelial cell regulation. The TGF-β/ALK-1 
pathway stimulates endothelial cell proliferation and migration, whereas the TGF-β/ALK-5 
pathway inhibits these processes. ALK-1 stimulates the expression of Id-1, an inhibitor of basic 
helix-loop-helix proteins, and promotes endothelial cell proliferation, migration and tube 
formation (Valdimarsdottir et al., 2002), whereas ALK-5 induces expression of fibronectin, an 
extracellular matrix protein (Lebrin et al., 2005), and plasminogen activator inhibitor-1, a 
negative regulator of endothelial cell migration and angiogenesis (Watabe et al., 2003). 
Very little is known about changes in expression patterns of type I receptors during 
atherogenesis. 
The study of Yao et al. showed that ALK-1 is minimally expressed in atherosclerosis-free 
segments of human coronary arteries. On the other hand, ALK-1 expression was strongly 
upregulated in atherosclerotic lesions. The expression was detected in neointima, coronary 
endothelium and in areas of the shoulder region that appeared to be a site of 
neoangiogenesis. In addition, the expression was detected in the core of the lesions and in 
areas that appeared to undergo cellular organization (Yao et al., 2007). Authors also 
suggested that ALK-1 signaling in the endothelium may be important in the initiation of the 
atherosclerotic lesion. Moreover, ALK-1 expression in atherosclerotic lesions may contribute 
to regulation of proliferation and promotion of SMC differentiation, both during 
development and progression of atherosclerosis (Yao et al., 2007). Another study showed 
that ALK-1 may stimulate expression of vascular endothelial growth factor (VEGF) in 
endothelial cells (Yao et al., 2008), which might represent a protective effect on vessel 
endothelium with respect to the development of endothelial dysfunction (Walshe et al., 
2009). In line with these results, ALK-1 expression was related to decreased plaque size after 
both atorvastatin treatment (Rathouska et al., 2011) and reduction of cholesterol in 
apoE/LDLr-deficient mice (Strasky et al., 2011). 
In many studies, ALK-5, usually named simply TGF-β receptors I, is weakly expressed in 
intimal cells in human non-atherosclerotic aortas. On the other hand, strong ALK-5 
expression was detected in fatty streaks/fibrofatty lesions. Additionally, its expression was 
strongly decreased in fibrous plaques (Bobik et al., 1999), suggesting that ALK-5 might 
support TGF-β1 activity in the promotion of lipoprotein retention, activation of proteolytic 
systems of macrophages, and also limitation of SMC proliferation in fatty lesions (Bobik et 
al., 1999). On the other hand, ALK-5-mediated signaling plays an important role in keeping 
the endothelium quiescent by inhibiting EC proliferation, tube formation and migration, 
thus angiogenesis (Goumans et al., 2002). Additionally, most of the effects of TGF-β on SMC 
function appear to be mediated via ALK-5 (Bobik, 2006). All effects of ALK-5 are mediated 
by Smad2/3 proteins which will be discussed later. 
2.2 TGF-β receptor II and its role in atherogenesis 
As mentioned above, TβR-II interacts with various TβR-I, including ALK-1 and ALK-5. 
However, there are some studies focusing on the role TβR-II in atherosclerosis alone. 
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In general, it was shown that TβR-II expression is strong in non-atherosclerotic human 
vessels in the majority of cells in media and intima and also in fatty streaks, predominantly 
in smooth muscle cells and macrophages. On the other hand, the expression of TβR-II was 
reduced in fibrous plaque and associated media (Bobik et al., 1999). These data assume 
strong activity of TGF-β1/TβR-II system in fatty streaks/fibrofatty lesions. Moreover, Piao 
and Tokunaga observed in human aortic atherosclerotic lesions increased levels of TβR-II, 
mainly in intima, SMCs, and macrophages, as well as in endothelial cells, when compared 
with non-atherosclerotic vessels, proposing its participation in atherosclerosis (Piao and 
Tokunaga, 2006).  On the other hand, papers showed that there are some differences in TGF-
β receptor expression patterns in vascular SMCs derived from normal versus diseased 
arteries. It was demonstrated that the type II receptor is decreased in SMCs derived from 
atherosclerotic lesions, with little change in the type I or III receptors. Subsequent analysis of 
human lesion versus normal tissues confirmed that the type I receptor is consistently 
present in the lesion, while the type II receptor was much more variable and commonly 
absent in both coronary artery and carotid artery lesions (McCaffrey, 2000). Additionally, 
others suggested an important role of TβR-II expression with respect to plaque stability. In 
mouse, suppression of TGF-β signaling through expression of a dominant negative type II 
TGF-β receptor, either systemically (Lutgens et al., 2002) or selectively in T-cells (Gojova et 
al., 2003); (Robertson et al., 2003), results in accelerated lipid lesion formation, increased 
vascular inflammation and a shift to an unstable lesion phenotype, thus more macrophage 
and lymphocyte and less collagen content. In addition, Lutgens et al. showed that inhibition 
of TGF-β activity following systemic administration of a recombinant soluble TGF-β type II 
receptor leads to change of plaque morphology into inflammatory phenotype that is low in 
fibrosis (Lutgens et al., 2002). 
In summary, these data suggest a protective role of TβR-II expression in atherosclerosis. 
3. Endoglin, the accessory type III receptor 
Endoglin (or CD105) is a homodimeric transmembrane glycoprotein, that interacts with TGF-
β1 and TGF-β3, but only when it is associated with TβRII (Lastres et al., 1996). Endoglin is not 
the true receptor but it strongly modulates activities of TGF-βRII (Guerrero-Esteo et al., 2002), 
ALK-1 (Guerrero-Esteo et al., 2002; Lebrin et al., 2004) and ALK-5 (Guerrero-Esteo et al., 2002). 
Endoglin physically interacts with TGF-βRI and TGF-βRII, and this interaction is not modified 
by the presence of exogenous ligand or by the activation state of the signaling kinases (Wrana 
et al., 1994). Additionally, endoglin inhibits phosphorylation levels of TGF-βRII in vivo and in 
vitro. On the other hand, endoglin was found to affect not only the phosphorylation status of 
TGF-βRII but also that of TGF-βRI. The presence of endoglin also appears to affect signaling 
downstream of TGF-βRI-TGF-βRII complex (Lopez-Novoa and Bernabeu, 2010). In general, 
endoglin is highly expressed by vascular endothelial cells (Li et al., 2000), SMCs (Adam et al., 
1998), macrophages (Lastres et al., 1992) and T-cells (Bobik, 2006), which are cells strongly 
participating in the atherogenesis. 
There are some studies showing the expression of endoglin in atherosclerotic lesions, both in 
humans and experimental animals. Low levels of endoglin expression in endothelial cells, 
medial smooth muscle cells and adventitial fibroblasts were detected in normal porcine 
coronary arteries. However, balloon injury in these vessels significantly increased its 
expression in both endothelial cells and smooth muscle cells (Ma et al., 2000). Moreover, in 
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humans and experimental animals. Low levels of endoglin expression in endothelial cells, 
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smooth muscle alpha-actin (SM a-actin) positive cells of atherosclerotic plaques, but it was 
not expressed in normal vascular smooth muscle, suggesting that endoglin may play a role 
in the response of the vessel wall to injury, including the development of atherosclerosis 
(Conley et al., 2000). Also other studies showed higher expression of endoglin in 
atherosclerotic vessels when compared with non–diseased vessels, suggesting that endoglin 
participates in atherogenesis (Piao and Tokunaga, 2006; Tashiro et al., 2002). Additionally, 
endoglin expression was linked to neo-angiogenesis within atherosclerotic aortic and carotid 
plaques, supporting its role in this process (Krupinski et al., 2008). Moreover, endoglin 
serum levels were found to be elevated in patients with atherosclerosis and correlated with 
total cholesterol levels (Blann et al., 1996). 
On the other hand, several papers suggested an important role of endoglin in regulation of 
expression and activity of endothelial NO synthase (eNOS). The levels of eNOS are strongly 
related to the amount of endoglin, both in vivo and in vitro (Jerkic et al., 2004; Toporsian et 
al., 2005). Toporsian et al. found that partial or total loss of endoglin in murine endothelial 
cells is associated with a 50% decrease in eNOS levels (Toporsian et al., 2005). In addition, 
eNOS - derived NO seems to play a major role in endoglin-dependent angiogenesis (Jerkic 
et al., 2006). Santibanez et al. demonstrated that endoglin-dependent induction of eNOS 
occurs at the transcriptional level and moreover that endoglin is able to regulate eNOS 
expression independently of TGF-β (Santibanez et al., 2007). Endoglin colocalization with 
eNOS in aortic endothelial cells in mice atherosclerosis was also demonstrated (Nachtigal et 
al., 2009b). More recently, it was demonstrated that endoglin serum levels are decreased by 
extracorporeal LDL-cholesterol elimination in patients with familial hypercholesterolemia, 
suggesting that endoglin can serve as a marker for evaluation of the treatment efficacy of 
these procedure (Blaha et al., 2008). 
In the light of above mentioned data, it is suggested that endoglin plays a role in 
atherogenesis, however its role with respect to atherogenic and/or atheroprotective effects 
remains to be elucidated. 
4. Smad proteins in atherogenesis 
As mentioned above, TGF-β1 and its receptors activate intracellular signal transducers 
called Smad proteins (Derynck et al., 1996). Eight Smad proteins are encoded in the 
human and mouse genomes but only five of them are substrates for TGF-β receptors, 
which are commonly referred to as receptor-regulated Smads, or RSmads ( Smad1, 
Smad2, Smad3, Smad5, and Smad8) (Massague, 1998). Smad4, named Co-Smad, serves as 
a common partner for all RSmads. Moreover, there are inhibitory Smad6 and Smad7 
(Miyazono et al., 2000). 
In general, no expression of Smad2 and Smad3 was detected in healthy human non-
atherosclerotic aorta. On the other hand, strong Smad2 and Smad3 expression was 
detected in macrophages after differentiation from monocytes in fatty streaks/fibrofatty 
lesions (Kalinina et al., 2004). Smads were not detected in smooth muscle cells in these 
lesions. On the contrary, strong SMAD2 and SMAD3 expression was detected in SMC in 
aortic fibrous plaques, suggesting their participation in collagen production in these 
lesions, which seems to be important for lesion stability (Kalinina et al., 2004).  Several 
other, mostly in vitro, studies revealed the effects of various Smads on the cellular 
components of atherosclerotic lesions. Smad3 was shown to be important for 
suppressing the inflammatory response in macrophages, including inhibition of 
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inducible nitric oxide synthase (iNOS), monocyte chemoattractant protein-1 (MCP-1), 
and MMP-9 (Feinberg et al., 2004a; Werner et al., 2000). These inhibitory effects of Smad3 
were attributed to inhibition of transcription factors, including AP-1, and to competition 
with NF-κB for limiting quantities of the co-activator p300/CBP (Feinberg and Jain, 
2005). 
Moreover, Smad3 seems to be important also in the modification of T-cell activity related 
to atherosclerosis. CD4+ and CD8+ T-cells from Smad3-deficient mice had increased IL-2 
production (McKarns and Schwartz, 2005). Moreover, it was demonstrated that Smad3 
stimulates production of Th2 cytokine shown to have anti-inflammatory effects in various 
experimental atherosclerotic models (Blokzijl et al., 2002). Smad3 potentiated by Smad4 is 
also able to reduce expression of SMC activation markers IL-6 and iNOS (Feinberg et al., 
2004b), which are also linked to the progression of atherosclerosis.  
Smad2 was shown to be important in endothelial cells. Saura et al demonstrated that the 
overexpression of Smad2 induces expression of eNOS, a critical regulator of vascular 
function and response to inflammation (Saura et al., 2002). Potential role of Smad2 in 
regulation of vascular inflammation can be related to its inhibition of NF-κB via competition 
with NF-κB for limiting amounts of p300/CBP (DiChiara et al., 2000). 
These data nicely demonstrate anti-inflammatory and endothelial-protective effects of 
Smad2 and Smad3 in atherogenesis. 
Smad1 effects on atherogenesis are not well documented so far. In general, Smad1 can be 
activated by BMP ligands, as well as by TGF-β1/ALK-1 activation mostly in endothelial 
cells (Goumans et al., 2002). This activation is related to activation of cell proliferation and 
angiogenesis (Oh et al., 2000). Since the specific role of angiogenesis in atherosclerosis with 
respect to pro- or anti-atherogenic effects is still not clear, the role of Smad1 in 
atherosclerosis remains to be elucidated in the future (Khurana et al., 2005). 
Smad4 can form a complex with other Smads, including Smad2 and/or Smad3, and 
participates in augmenting of several effects of these Smads in a variety of cell types 
important in vascular inflammation (Feinberg and Jain, 2005). Smad4 was expressed 
together with Smad2 and Smad3 in fibrous plaques participating in collagen production, 
suggesting its effects on stable plaque phenotype (Kalinina et al., 2004). 
Smad6 and Smad7 are inhibitors of both Smad2 and Smad3 phosphorylation (Shi and 
Massague, 2003). However, their effects in different tissues are not the same. For example, 
Smad7 blocked the TGF-β1-induced growth inhibition in VSMCs, Smad6 did not possess 
this ability (Ikedo et al., 2003). NF-κB and IFN-γ signaling rapidly induce Smad7 expression. 
This results in an increased expression of pro-inflammatory cytokines (IL-1β or TNF-α) in 
macrophages and vascular SMCs, suggesting that Smad7 blocks anti-inflammatory effects of 
TGF-β1 at least in vitro (Kato et al., 2001). 
Recently, a splice variant of Smad6 (Smad6s) expressed in endothelial cells has been shown 
to affect TGF-β signaling. Both isoforms were detected in both normal vessels and 
atherosclerotic lesions localized in endothelial cells of the intima and in vasa vasorum as 
well as in smooth muscle cells of media (Krishnan et al., 2001). However, functional roles of 
these two isoforms in the context of atherogenesis have not been determined. 
It can be concluded that Smad proteins are expressed in atherosclerotic lesions, where 
Smad2 and Smad3 play potential anti-atherogenic roles. The role of other Smads in relation 
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5. TGF-β1 related signaling pathways and atherogenesis 
In previous chapters, we described studies that focused on the role of one or two members 
of TGF-β pathway. In this part, we are going to focus on studies, in which at least 3 
members were part of the study. 
As mentioned previously, TGF-β1 activates TGF-β receptor II which is followed by 
activation of different TGF-β receptor I, e.g. ALK-1 and ALK-5, with subsequent 
phosphorylation of various Smad proteins (Goumans et al., 2009). All these pathways can be 
modified by accessory TGF-β III receptors, mainly by endoglin (Lopez-Novoa and 
Bernabeu, 2010). 
In general, TGF-β/ALK-5 signaling induces Smad2/3 phosphorylation and blocks 
angiogenesis by inhibiting EC proliferation, tube formation and migration. TGF-β/ALK-
5/Smad2/3 signaling plays an important role in keeping the endothelium quiescent 
(Goumans et al., 2009; Goumans et al., 2002). 
In contrast to TGF-β/ALK-5, TGF-β/ALK-1 signaling induces Smad1/5 activation and has 
been shown to stimulate EC migration, proliferation and tube formation (Goumans et al., 
2003). Strong interplay between both cascades has been demonstrated in vitro. ALK-5-
deficient ECs are not only defective in TGF-β/ALK-5 signaling but also exhibit impaired 
TGF-β/ALK-1 responses. Furthermore, ALK-1 can directly antagonize ALK-5/Smad2/3 
signaling at the level of Smads (Goumans et al., 2002; Oh et al., 2000). 
Piao et al studied the expression of TGF-1, endoglin and TGF-β receptor II in human aortic 
atherosclerotic lesions and non-atherosclerotic aortas. Immunohistochemical analysis 
revealed a weak expression of all studied markers in the vessel wall. On the other hand, 
they described simultaneous expression of TGF-1, endoglin and TβR-II in most 
atherosclerotic aortas in endothelium, macrophages and smooth muscle cells, suggesting the 
participation of these proteins in atherosclerosis (Piao and Tokunaga, 2006). 
In another in vitro study Santibanez et al revealed a mechanism in which endoglin regulates 
the expression of eNOS. They showed that endoglin strongly supports TGF-β/Smad2 
signaling by increasing the levels of Smad2 protein as a consequence of enhancing Smad2 
stability. Secondary to the increase in Smad2 protein levels, they observed increased 
association of Smad2 with the receptor complex, higher levels of Smad2 phosphorylation, 
and an increase in Smad2/Smad4 heteromeric complex formation which was followed by 
increased expression of eNOS (Santibanez et al., 2007). These data suggest an important role 
of TGF-β1/endoglin/Smad2/eNOS pathway in the function of endothelium and 
atherosclerosis. 
Moreover, Chen et al also demonstrated an important role of TGF-β receptors and Smad2 
with respect to cholesterol levels. They demonstrated that cholesterol inhibits TGF-β1/TβR-
II/TβR-I/Smad2 signaling by lowering of TβR-II/TβR-I binding ratio in plasma membrane 
and decrease in Smad2 phosphorylation, which was related to progression of atherosclerosis 
(Chen et al., 2008; Chen et al., 2007). These data were supported recently by Strasky et al, 
who demonstrated that hypercholesterolemia decreases endoglin, phosphorylated Smad2 
and endothelial protective VEGF expression simultaneously with increased atherosclerosis 
in mice aorta (Strasky et al., 2011). In addition, Bot et al, described endoglin/TGF-
β1/Smad2/3 expression and signaling in human atherosclerotic lesions. These authors 
demonstrated that endoglin/TGF-β1/Smad2/3 expression and activity correlates with a 
fibrous plaque phenotype, increased collagen levels, less matrix degradation, more SMC 
proliferation, reduction in inflammatory cell number and decreased amount of intraplaque 
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thrombi. This suggests that these markers are associated with more stable plaque phenotype 
in human atherosclerosis (Bot et al., 2009).  
In summary, activation of TGF-β1 signaling pathway, which includes endoglin and Smad2, 
seems to play a protective role in atherogenesis via protection of vascular endothelium and 
atherosclerotic plaque stabilization.  
 
 
Fig. 1. TGF-β1 signaling pathway. TGF-β1 activates TβR-II, and the complex TGF-
β1/TGF-RII is presented to TGF-R-I, which can represent several subtypes called activin-
like kinases or ALKs. In atherogenesis, the activation of ALK-1 or ALK-5 under the 
control of endoglin is the most common. Activation of TGF-β1/TβR-II/endoglin/ALK-
5/Smad2/3 signaling is related to several anti-atherogenic effects, including increased 
eNOS expression, increased collagen production (plaque stabilization), inhibition of 
inflammatory activities of macrophages, T-cells and inhibition of NF-κB signaling. On the 
other hand activation of TGF-β1/TβR-II/endoglin/ALK-1/Smad1 was related to 
increased VEGF production which was demonstrated to be important in angiogenesis 
and/or vascular endothelium protection. 
5.1 TGF-β1 related pathways and statins 
In this part we would like to discuss TGF-β1 pathway and possible effects of the most 
used hypolipidemic drugs in clinical practice. 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG CoA-reductase) inhibitors, commonly known as statins, inhibit the rate-
limiting step of the cholesterol biosynthesis pathway. This hypolipidemic effect is very 
important, regarding the benefit of statin treatment in humans. However, statins also 
have non-lipid effects that were demonstrated in both humans and experimental models 
of atherosclerosis (Zhou and Liao, 2010). Statins regulate many of cellular responses, via 
the blockade of isoprenoid production and inhibition of intracellular signaling  
systems, including transcription factors, such as NF-κB, and kinases, like mitogen-
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Baccante et al showed that pravastatin induces TGF-β1 expression and down-regulates 
the expression of type A scavenger receptor in THP-1 cells (human macrophage cell line) 
by a TGF-β1-dependent mechanism, suggesting the protection against formation of foam 
cells (Baccante et al., 2004). Additionally, pravastatin treatment up-regulated TGF-β1 
serum levels in hypercholesterolemic patients, and also TGF-β1 production in vitro in 
human monocytes (Porreca et al., 2002). Chen et al. showed that fluvastatin and lovastatin 
increase accumulation of TβR-II in non-lipid raft microdomains, and attenuate 
degradation of TβR-II which results in enhanced TGF-β1 signaling (Chen et al., 2008; 
Chen et al., 2007) in endothelial cells. Moreover, simvastatin and atorvastatin significantly 
increased TGF-β1 secretion, TβR-II expression and induced Smad2 and Smad3 
phosphorylation in a dose-dependent manner in vascular smooth muscle cells 
(Rodriguez-Vita et al., 2008). Additionally, atorvastatin increased phosphorylation of 
Smad3 and expression of TβR-II in atherosclerotic lesions in apoE-deficient mice 
(Rodriguez-Vita et al., 2008). This increase was related to decreased plaque size and 
increased production of collagen in vascular smooth muscle cells. Further studies also 
confirmed atheroprotective effects of statin administration via TGF-β1 dependent 
pathway. Atorvastatin treatment significantly induced expression of endoglin, SMAD2, 
phosphorylated SMAD2/3 and eNOS in mice aortic atherosclerotic lesions (Nachtigal et 
al., 2009a). Moreover, in another study atorvastatin treatment increased expression of 
endoglin/ALK-1/p-Smad1/VEGF pathway simultaneously with decreased 
atherosclerosis in aorta of ApoE/LDLR double knockout mice (Rathouska et al., 2011). In 
addition, colocalization of all these proteins was demonstrated in endothelial cells, 
suggesting that activation of these pathways might contribute to TGF-β related protection 
of endothelial cells (Nachtigal et al., 2009b). 
In summary, statin treatment activates TGF-β1 signaling cascades involving TβR-II, 
endoglin, Smad2/3 which results in reduced plaque size, increased collagen content and 
increased production of NO in endothelium. 
6. Conclusion 
In conclusion, the data presented in this chapter show the importance of TGF-β1 signaling 
in atherosclerosis in both animals and humans. Despite a few papers showing 
participation of TGF-β1 in early atherosclerosis, most of the papers demonstrate 
atheroprotective effects of TGF-β1 signaling. Activation of TGF-β1 signaling pathway 
results in anti-inflammatory effects, including decreased expression of cell adhesion 
molecules (with participation of Smad2 and endoglin), inhibition of inflammation in 
macrophages, T-cells (with participation of Smad3), increased expression of nitric oxide 
synthase (with participation of endoglin and Smad2), smooth muscle cells production of 
collagen and plaques stabilization (with participation of endoglin and Smad2/3). 
Moreover, reduction of cholesterol levels and/or statin treatment significantly enhances 
atheroprotective effects of TGF-β1 signaling. 
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atheroprotective effects of TGF-β1 signaling. Activation of TGF-β1 signaling pathway 
results in anti-inflammatory effects, including decreased expression of cell adhesion 
molecules (with participation of Smad2 and endoglin), inhibition of inflammation in 
macrophages, T-cells (with participation of Smad3), increased expression of nitric oxide 
synthase (with participation of endoglin and Smad2), smooth muscle cells production of 
collagen and plaques stabilization (with participation of endoglin and Smad2/3). 
Moreover, reduction of cholesterol levels and/or statin treatment significantly enhances 
atheroprotective effects of TGF-β1 signaling. 
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1. Introduction 
Atherosclerosis and its consequences (i.e. myocardial infarction and cardiac death) remain 
the major cause of morbidity and mortality in Western countries (Roger et al. 2011). Despite 
clinical advances that have substantially improved outcomes in patients suffering from 
coronary artery disease, including pharmacological interventions (e.g. novel anti platelet 
therapies, statins, etc.) as well as interventional and surgical therapies (e.g. drug-eluting 
stents), there is still a huge demand for improved diagnostic tools to identify patients at risk 
for adverse events as well as therapeutic means to prevent adverse events in these patients. 
Biomarkers such as high sensitivity CRP (Ridker 2007) or high sensitivity troponin T (Kurz 
et al. 2011) have brought some improvement in identifying patients requiring more intense 
treatment; however, the clinical need for better tools remains. 
An important concept that may help to improve clinical care for patients with coronary 
artery disease is the inducement of plaque stability. Atherosclerotic lesions can show 
features of plaque stability or plaque instability (Naghavi et al. 2003a, Naghavi et al. 2003b). 
Stable plaques are characterized by a thick fibrous cap and a small necrotic core. By contrast, 
unstable plaques display a thin fibrous cap and a large necrotic core consisting of apoptotic 
macrophages, foam cells, and smooth muscle cells. Unstable plaques are more likely to 
rupture, and plaque rupture may subsequently result in thrombosis and occlusion of the 
vessel leading to a myocardial infarction or stroke. 
A promising approach to identify potential markers of plaque instability may be the study 
of atherogenesis on a cellular and molecular level. During the development of 
atherosclerotic lesions, blood monocytes adhere to the activated endothelium, transmigrate 
into the subendothelial space, and differentiate towards macrophages, dendritic cells, or 
foam cells (Galkina & Ley 2009). Among the various leukocyte types involved in 
atherogenesis, monocytes and monocyte-derived macrophages represent the major fraction. 
The monocyte-macrophage differentiation process is affected by the extracellular matrix as 
well as by the combination of chemokines and cytokines representing the micromilieu of the 
plaque (Shashkin et al. 2005). In addition, cell-cell interactions may also affect the fate of 
monocytes within the atherosclerotic plaque. Monocyte-derived cells secrete chemokines, 
cytokines, and other mediators, leading to attraction of other immune cells and thereby 
promoting plaque progression and plaque instability (Shashkin et al. 2005). While it was 
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of cells, substantial heterogeneity of human plaque macrophages has been recognized for 
almost two decades (Poston & Hussain 1993). However, only recently has the 
pathophysiological importance of macrophage heterogeneity aroused further scientific 
interest (Bouhlel et al. 2007, Boyle et al. 2009, Gleissner et al. 2010a, Waldo et al. 2008). 
Platelets and platelet-derived mediators represent important players potentially promoting 
macrophage heterogeneity in atherosclerosis. It has been long known that platelets play an 
important role in inflammatory processes reaching far beyond their function in hemostasis 
(Ross 1999). Especially in the context of atherosclerosis, platelets and platelet-derived 
molecules are heavily involved. Thus, platelet-derived chemokines may interact with the 
endothelium as well as with various leukocyte types (Gleissner et al. 2008). Accordingly, 
activated platelets promote atherogenesis as shown in Apoe-/- mice (Huo et al. 2003). This 
effect may in part be chemokine-mediated by promotion of monocyte adherence to the 
endothelium (von Hundelshausen et al. 2001, von Hundelshausen et al. 2005), but it may 
also be a consequence of chemokine-induced monocyte-macrophage differentiation 
(Gleissner et al. 2010a, Gleissner et al. 2010b, Scheuerer et al. 2000). 
The current review will discuss novel insights into the effects of CXCL4, one of the most 
abundant platelet chemokines, on macrophage differentiation in the context of 
atherogenesis. It attempts to summarize what is known about CXCL4-induced 
macrophages, put it into context with knowledge of macrophage heterogeneity in human 
atherosclerosis, and try to answer the question of whether specifically targeting these 
CXCL4-induced macrophages may be a promising approach to prevent or treat 
atherosclerosis in humans. 
2. Macrophages and atherogenesis 
2.1 Studying macrophages in human and murine models 
Studying myeloid cells and especially monocyte-derived macrophages in humans is a 
difficult task. While monocytes can easily be isolated from human peripheral blood and 
differentiated towards macrophages in order to perform in vitro studies, the possibility of 
studying human macrophages within atherosclerotic lesions is restricted to the analysis of 
post mortem tissues or explanted tissues, e.g. of carotid endatherectomy specimens or 
explanted hearts after heart allograft transplantation. Even though these materials will allow 
studying macrophages within their pathophysiological environments, the systems may still 
be biased by post mortem processes or effects due to prolonged ischemic time resulting in 
changes that do not allow correctly assessing the in vivo situation. 
On the other hand, using mouse models to study monocytes and monocyte-derived 
macrophages offers great potential by using differently-labeled or genetically modified 
monocyte subsets (e.g. using the CXC3CR1 FITC mice) that allow the generation impressive 
in vivo tracking models that have helped to identify differential roles of specific monocyte 
subsets (Auffray et al. 2007, Geissmann et al. 2003). However, these systems have one 
notable problem: it is extremely difficult to transfer the information gained from these 
mouse models to the human system. Thus, some of the markers used to identify murine 
monocyte subsets (e.g. Gr-1. Ly6C, etc.) do not exist in the human system or do not have a 
human marker that clearly corresponds to them. Furthermore, in many aspects, murine 
monocyte-derived macrophages behave differently from human macrophages. Thus, 
treating murine macrophages with lipopolysaccharide (LPS) leads to increased uptake of 
modified LDL (Fitzgerald et al. 2000). Conversely, treating human macrophages with LPS 
 
CXCL4-Induced Macrophages: A Novel Therapeutic Target in Human Atherosclerosis? 
 
347 
prevents uptake of modified LDL (own unpublished observation). Considering that uptake 
of modified LDL represents a crucial step during macrophage foam cell formation with 
great impact on atherogenesis, it becomes questionable as to how relevant results from 
murine experiments may be for the human situation.  
A recent extremely valuable study has compared the transcriptomes of human and murine 
monocyte subsets (Ingersoll et al. 2010). In this study, the authors used CCR2 and CXC3CR1 
to identify the two murine monocyte subsets, whereas CD14 and CD16 were used to 
differentiate between the human monocyte subsets. About 270 genes in humans and 550 
genes in mice were differentially-expressed between the monocyte subsets. Interestingly, 
only about 130 were conserved between species and a substantial number of genes were 
found to be differentially-expressed in a cross-species comparison. Among those, the 
authors identified genes extremely important in atherogenesis, including the scavenger 
receptors CD36 or macrophage scavenger receptor-A, as well as other functionally 
important molecules such as receptors for apoptotic cells. Again, this supports the notion 
that there are considerable differences between the human and murine system, and that 
results from murine experiments should be taken with care when drawing conclusions for 
human atherosclerosis. 
Based on these considerations, the current article will specifically focus on data derived 
from studies on human macrophages wherever possible. Murine data will only be referred 
to when no data on human cells are available. 
2.2 Macrophage heterogeneity 
2.2.1 General concept of macrophage plasticity and polarization 
A central feature of macrophages is their plasticity. Macrophage plasticity is defined as the 
capacity of the cell to readily change its phenotypic and functional capacities depending on 
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differ substantially depending on the external conditions. By contrast, the term macrophage 
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probably determined primarily by the micromilieu. In fact, the presence of differentially-
polarized macrophages has been postulated early on (Poston & Hussain 1993) and has been 
confirmed within human atherosclerotic lesions by various groups including ourselves 
(Bouhlel et al. 2007, Boyle et al. 2009, Gleissner et al. 2010a, Waldo et al. 2008). These 
findings make clear that macrophages within one atherosclerotic plaque can not be 
considered to be a uniform cell population but may have different functions depending on 
their specific polarization type. 
2.2.2 Accepted models of macrophage polarization 
There is currently a well defined scheme of macrophage polarization in vitro and in vivo. The 
first to describe an “alternative” macrophage activation were Gordon et al., who demonstrated 
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Fig. 1. The established paradigm of macrophage polarization. While M1 macrophages are 
thought to be involved in type I inflammation (bacterial killing or tumor resistance), M2 
macrophages are associated with type II inflammation (allergy, parasital killing).  For each 
polarization type, typical cytokines, chemokines, chemokine receptors, other receptors, 
surface molecules involved in antigen presentation, and intracellular enzymes are indicated. 
According to this paradigm, M1 macrophages can be induced by a combination of 
interferon- and LPS or by tumor necrosis factor- and are characterized by expression of 
pro-inflammatory cytokines like interleukin-1, interleukin-6, tumor necrosis factor-, or 
interferon-. Furthermore, M1 macrophages express chemokines like CLL2 or CCL5, surface 
receptors like TLR2 or TLR4, and enzymes like iNOS. It is thought that M1 macrophage 
polarization mirrors the Th1 response of T cells, i.e. they represent a rather pro-
inflammatory type of macrophage.  
By contrast, M2 macrophages can be induced by Th2 cytokines like IL-4. They can express Th2 
cytokines like IL-10 and are specifically characterized by the expression of surface receptors 
like CD163, CD206 (mannose receptor), or scavenger receptor-A and CD36. Since the first 
description of alternative macrophage activation has been published, several additional types 
of M2 macrophages have been identified, now defined as M2a (induced by IL-4 or Il-13), M2b 
(induced by immune complexes and TLR ligands), and M2c (induced by Il-10). Overall, M2 
macrophages reflect the Th2 response and can be considered rather anti-inflammatory. 
M1 and M2 macrophage polarization have been extensively studied including a 
comprehensive transcriptomic analysis of both macrophage polarization types (Martinez et 
al. 2006). In this gene array analysis, Martinez et al. confirmed the basic M1-M2 paradigm. 
Interestingly, monocyte-macrophage differentiation induced by MCSF alone leads to 
expression of many M2 genes, suggesting that basal conditions favour a default shift toward 
M2. Beyond this novel finding, the authors identified specific gene clusters involved in lipid 
metabolism, specific clusters of G protein-coupled receptors, and specific chemokines 
clusters in both M1 and M2 macrophages (Martinez et al. 2006). Both M1 and M2 
macrophage polarization have been excellently reviewed by Gordon et al. as well as by 
Mantovani (Gordon 2003, Mantovani et al. 2009). 
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3. Platelet factor-4 (CXCL4), macrophages, and atherogenesis 
3.1 CXCL4 – A platelet-derived chemokine in atherogenesis 
Platelets and platelet-derived chemokines are important factors during atherogenesis 
(Gleissner et al. 2008, von Hundelshausen et al. 2007, Weber 2005, Weber 2008, Zernecke et 
al. 2008). In 2003, Ley et al. were able to demonstrate that activated platelets are able to 
promote atherogenesis (Huo et al. 2003). Upon activation, platelets release various 
chemokines from their alpha granules. Furthermore, activated platelets present or deposit 
chemokines and thereby induce recruitment of other cells to the arterial wall.  
Among the plethora of chemokines released from activated platelets, CXCL4 (formerly 
known as platelet factor-4) is one of the most abundant. Accordingly, CXCL4 is released in 
human blood in micromolar concentrations upon platelet activation (Brandt et al. 2000). 
CXCL4 has been considered an “enigmatic” chemokine as it lacks the ELR domain typically 
seen in CXCL chemokines (Gear & Camerini 2003) and has been demonstrated to have 
effects on various cell types including endothelial cells, lymphocytes, neutrophils, and 
monocytes (Gleissner et al. 2008). However, the mechanisms by which CXCL4 exerts its 
effects, including receptors and signal transduction, have not fully been elucidated. Notably, 
CXCL4 has been demonstrated to induce monocyte adhesion to endothelial cells in 
conjunction with CCL5 (RANTES) (von Hundelshausen et al. 2005) and to promote 
macrophage differentiation from human peripheral blood monocytes (Scheuerer et al. 2000). 
Both mechanisms may be relevant during atherogenesis. 
3.2 CXCL4 and macrophage differentiation 
A role for CXCL4 for monoycte-macrophage differentiation has been suggested by Scheuerer 
et al. in 2000 (Scheuerer et al. 2000). Their data demonstrate that CXCL4 not only acts in an 
anti-apoptotic manner on human peripheral blood monocytes, but also promotes their 
differentiation towards macrophages in a dose-dependent manner as demonstrated by 
increased myeloperoxidase expression. The fact that these CXCL4-induced macrophages do 
not express any detectable CD86 levels on their cell surface suggested that they may be 
different from those induced by the typically used growth factor macrophage colony-
stimulation factor MCSF (Scheuerer et al. 2000).  
Interestingly, these first data had been abandoned for almost a decade. One reason for this 
may be the fact that up to now, nobody has been able to identify the CXCL4 receptor on 
human monocytes and macrophages. While on T cells and microvascular endothelial cells 
CXCR3 or splice variants thereof like CXCR3B (Lasagni et al. 2003) have been clearly 
identified, it is still not clear by which receptor and signal transduction CXCL4 acts on 
human myeloid cells. Accordingly, it was not until 2010 that our own group did a 
comprehensive gene expression screen on these cells revealing novel insights into the 
potential role of CXCL4-induced macrophages (Gleissner et al. 2010b). 
3.3 Potential role of CXCL4-induced macrophages in human atherosclerosis 
3.3.1 General considerations 
Monocyte-derived macrophages are present in atherosclerotic lesions at very early stages of 
the disease (Galkina & Ley 2009). Activated platelets have been demonstrated to promote 
atherogenesis, an effect mediated by chemokines released from their alpha granules (Huo et 
al. 2003). CXCL4 is one of these platelet chemokines and is released from platelets upon 






Fig. 1. The established paradigm of macrophage polarization. While M1 macrophages are 
thought to be involved in type I inflammation (bacterial killing or tumor resistance), M2 
macrophages are associated with type II inflammation (allergy, parasital killing).  For each 
polarization type, typical cytokines, chemokines, chemokine receptors, other receptors, 
surface molecules involved in antigen presentation, and intracellular enzymes are indicated. 
According to this paradigm, M1 macrophages can be induced by a combination of 
interferon- and LPS or by tumor necrosis factor- and are characterized by expression of 
pro-inflammatory cytokines like interleukin-1, interleukin-6, tumor necrosis factor-, or 
interferon-. Furthermore, M1 macrophages express chemokines like CLL2 or CCL5, surface 
receptors like TLR2 or TLR4, and enzymes like iNOS. It is thought that M1 macrophage 
polarization mirrors the Th1 response of T cells, i.e. they represent a rather pro-
inflammatory type of macrophage.  
By contrast, M2 macrophages can be induced by Th2 cytokines like IL-4. They can express Th2 
cytokines like IL-10 and are specifically characterized by the expression of surface receptors 
like CD163, CD206 (mannose receptor), or scavenger receptor-A and CD36. Since the first 
description of alternative macrophage activation has been published, several additional types 
of M2 macrophages have been identified, now defined as M2a (induced by IL-4 or Il-13), M2b 
(induced by immune complexes and TLR ligands), and M2c (induced by Il-10). Overall, M2 
macrophages reflect the Th2 response and can be considered rather anti-inflammatory. 
M1 and M2 macrophage polarization have been extensively studied including a 
comprehensive transcriptomic analysis of both macrophage polarization types (Martinez et 
al. 2006). In this gene array analysis, Martinez et al. confirmed the basic M1-M2 paradigm. 
Interestingly, monocyte-macrophage differentiation induced by MCSF alone leads to 
expression of many M2 genes, suggesting that basal conditions favour a default shift toward 
M2. Beyond this novel finding, the authors identified specific gene clusters involved in lipid 
metabolism, specific clusters of G protein-coupled receptors, and specific chemokines 
clusters in both M1 and M2 macrophages (Martinez et al. 2006). Both M1 and M2 
macrophage polarization have been excellently reviewed by Gordon et al. as well as by 
Mantovani (Gordon 2003, Mantovani et al. 2009). 
 
CXCL4-Induced Macrophages: A Novel Therapeutic Target in Human Atherosclerosis? 
 
349 
3. Platelet factor-4 (CXCL4), macrophages, and atherogenesis 
3.1 CXCL4 – A platelet-derived chemokine in atherogenesis 
Platelets and platelet-derived chemokines are important factors during atherogenesis 
(Gleissner et al. 2008, von Hundelshausen et al. 2007, Weber 2005, Weber 2008, Zernecke et 
al. 2008). In 2003, Ley et al. were able to demonstrate that activated platelets are able to 
promote atherogenesis (Huo et al. 2003). Upon activation, platelets release various 
chemokines from their alpha granules. Furthermore, activated platelets present or deposit 
chemokines and thereby induce recruitment of other cells to the arterial wall.  
Among the plethora of chemokines released from activated platelets, CXCL4 (formerly 
known as platelet factor-4) is one of the most abundant. Accordingly, CXCL4 is released in 
human blood in micromolar concentrations upon platelet activation (Brandt et al. 2000). 
CXCL4 has been considered an “enigmatic” chemokine as it lacks the ELR domain typically 
seen in CXCL chemokines (Gear & Camerini 2003) and has been demonstrated to have 
effects on various cell types including endothelial cells, lymphocytes, neutrophils, and 
monocytes (Gleissner et al. 2008). However, the mechanisms by which CXCL4 exerts its 
effects, including receptors and signal transduction, have not fully been elucidated. Notably, 
CXCL4 has been demonstrated to induce monocyte adhesion to endothelial cells in 
conjunction with CCL5 (RANTES) (von Hundelshausen et al. 2005) and to promote 
macrophage differentiation from human peripheral blood monocytes (Scheuerer et al. 2000). 
Both mechanisms may be relevant during atherogenesis. 
3.2 CXCL4 and macrophage differentiation 
A role for CXCL4 for monoycte-macrophage differentiation has been suggested by Scheuerer 
et al. in 2000 (Scheuerer et al. 2000). Their data demonstrate that CXCL4 not only acts in an 
anti-apoptotic manner on human peripheral blood monocytes, but also promotes their 
differentiation towards macrophages in a dose-dependent manner as demonstrated by 
increased myeloperoxidase expression. The fact that these CXCL4-induced macrophages do 
not express any detectable CD86 levels on their cell surface suggested that they may be 
different from those induced by the typically used growth factor macrophage colony-
stimulation factor MCSF (Scheuerer et al. 2000).  
Interestingly, these first data had been abandoned for almost a decade. One reason for this 
may be the fact that up to now, nobody has been able to identify the CXCL4 receptor on 
human monocytes and macrophages. While on T cells and microvascular endothelial cells 
CXCR3 or splice variants thereof like CXCR3B (Lasagni et al. 2003) have been clearly 
identified, it is still not clear by which receptor and signal transduction CXCL4 acts on 
human myeloid cells. Accordingly, it was not until 2010 that our own group did a 
comprehensive gene expression screen on these cells revealing novel insights into the 
potential role of CXCL4-induced macrophages (Gleissner et al. 2010b). 
3.3 Potential role of CXCL4-induced macrophages in human atherosclerosis 
3.3.1 General considerations 
Monocyte-derived macrophages are present in atherosclerotic lesions at very early stages of 
the disease (Galkina & Ley 2009). Activated platelets have been demonstrated to promote 
atherogenesis, an effect mediated by chemokines released from their alpha granules (Huo et 
al. 2003). CXCL4 is one of these platelet chemokines and is released from platelets upon 





al. 2000) and to promote differentiation of a specific macrophage phenotype distinct from 
previously identified macrophage polarizations (Gleissner et al. 2010b). Taking into account 
that the genetic deletion of CXCL4 in Apoe-/- mice is accompanied by reduced atherogenesis 
(Sachais et al. 2007), and that in human atherosclerotic lesions the presence of CXCL4 has 
been associated with plaque progression and clinical symptoms (Pitsilos et al. 2003), it seems 
extremely reasonable to hypothesize that CXCL4-induced macrophages significantly 
contribute to atherogenesis and progression of atherosclerosis. An important mechanisms of 
this action may represent the induction of CXCL4-specific, pro-atherogenic macrophages. 
3.3.2 Features of CXCL4-induced macrophages – The M4 macrophage 
To identify potential mechanisms by which CXCL4-induced macrophages are induced to act 
in a pro-atherogenic manner, we studied their transcriptome and compared it to that of 
MCSF-induced macrophages from the same donors. In this analysis, we found that both 
MCSF- and CXCL4-induced macrophages have strong phenotypic similarities. Thus, they 
both express similar mRNA and surface levels of CD45, CD14 or intracellular levels of 
CD68. Their transcriptomes show a strong correlation clearly indicating that they both 
represent macrophages  (Gleissner et al. 2010b). 
Interestingly, while CXCL4-treated human monocytes display phenotypic and functional 
characteristics of macrophages after six days in culture, they also have characteristics that 
clearly distinguish them from MCSF-induced macrophages. We found 375 genes 
differentially-expressed between MCSF- and CXCL4-induced macrophages, 206 of them being 
over-expressed in CXCL4-induced macrophages. Interestingly, CXCL4-induced  macrophages 
displayed neither typical markers of M1 nor of M2 polarization (Gleissner et al. 2010b). 
Accordingly, using different statistical approaches including gene set enrichment analyses 
(Subramanian et al. 2005), modified principal components analysis (PCA), and hierarchical 
clustering (based on transcriptomic data from MCSF-treated, M1-polarized and M2-polarized 
macrophages (Martinez et al. 2006)), we were able to demonstrate that CXCL4 induces a 
transcriptome distinct from every macrophage polarization type described thus far (Gleissner 
et al. 2010b). In all statistical models, it turned out that in relation to their corresponding 
MCSF-control macrophages, M1 (induced by LPS and interferon-γ) and M2 macrophages 
(induced by IL-4) clustered together more closely than CXCL4-induced macrophages.  
These findings suggest that CXCL4 induces a macrophage phenotype with specific 
phenotypic and functional characteristics, which will be discussed in more detail below. 
Based on these results, we have suggested calling these macrophages M4 – a term that we 
believe reflects both the fact that these cells are distinct from M1 and M2 macrophages and 
that they can be induced by CXCL4. Accordingly, in the following paragraphs CXCL4-
induced macrophages will be referred to as M4 macrophages. Fig. 2 summarizes some of the 
findings described below in more detail. 
3.3.3 Gene expression of matrix metalloproteinases in M4 macrophages 
Considering that CXCL4 promotes atherogenesis in Apoe-/- mice, we hypothesized that M4 
macrophages would over-express genes that are involved in atherogenesis as compared to 
their MCSF-induced counterparts. Therefore, it was a surprise to discover that M4 
macrophages cannot generally be considered pro-atherogenic: some genes implicated in 
atherogenesis showed higher expression levels, others lower expression levels as compared 
to MCSF-induced macrophages.  
 




Fig. 2. Features of MCSF- and CXCL4-induced macrophage (M0 and M4 macrophages). For 
each polarization type, typical cytokines, chemokines, chemokine receptors, other receptors, 
surface molecules involved in antigen presentation, and intracellular enzymes are indicated. 
The figures at the bottom indicate functional differences regarding scavenger receptor 
expression, uptake of modified LDL and the differential potential to clear hemoglobin-
haptoglobin complexes resulting in heme oxygenase-1 upregulation. 
This ambiguous picture was also seen with matrix metalloproteinases (MMP), of which 
some showed higher expression in M4 macrophages (e.g. MMP7 or MMP12) while others 
were expressed more highly in MCSF-induced macrophages (e.g. MMP8). Of course, gene 
expression data do not necessarily reflect protein expression and in the case of MMPs, 
enzyme activities may be also differentially-regulated; the regulation of MMPs is 
furthermore affected by activation through cathepsins, which in part are also differentially-
regulated (cathepsin B and K significantly higher in M4 macrophages) (Newby 2008).  
Taken together, due to the lack of functional data at this stage, it is impossible to judge 
whether differential-expression of MMPs and potentially different MMP activity in M4 
macrophages represent a pro-atherogenic feature of M4 macrophages. 
3.3.4 Foam cell formation in M4 macrophages 
Based on previous data, that CXCL4 promotes atherogenesis in Apoe-/- mice, we 
hypothesized that CXCL4-induced macrophages would be more prone to foam cell 
formation induced by modified (i.e. acetylated or oxidized) low density lipoprotein (LDL). 
Interestingly, the opposite was the shown to be true. While cholesterol efflux transporter 
ABCA1 and ABCG1 were not differentially-expressed on the mRNA level, scavenger 
receptors involved in uptake of modified LDL showed significantly lower expression in 
CXCL4-induced macrophages. Specifically, CD36 and macrophage scavenger receptor-A 
(which both account for the vast majority of uptake of modified LDL during macrophage 
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measured by flow cytometry were only significant for CD36. Interestingly, both uptake of 
acetylated and oxidized LDL (acLDL and oxLDL) was significantly lower in M4 
macrophages, suggesting that CXCL4-induced macrophages have a lower tendency to 
differentiate towards foam cells. This was somewhat unexpected and supports the notion 
that the pro-atherosclerotic effects of CXCL4 as shown in Apoe-/- likely reflects a multitude of 
different effects, including those on cells other than macrophages (i.e. endothelial cells, T 
cells, and potentially smooth muscle cells). 
3.3.5 CD163 and heme oxygenase-1 in M4 macrophages 
When analyzing the transcriptome of M4 macrophages, we found CD163 mRNA coding for 
the hemoglobin-haptoglobin scavenger receptor to be significantly down-regulated as 
compared to MCSF-induced macrophages (Gleissner et al. 2010a). CD163 binds hemoglobin-
haptoglobin complexes (and hemoglobin with lower affinity). Binding of the ligand to 
CD163 results in upregulation of heme oxygenase-1 (Schaer et al. 2006). Heme oxygenase-1 
(and specifically heme oxygenase-1 expressed in bone marrow-derived cells like monocytes 
and monocyte-derived macrophages) is thought to be atheroprotective as demonstrated in 
several mouse models (Juan et al. 2001, Orozco et al. 2007, Yet et al. 2003). 
Further experiments studying gene and protein expression in freshly isolated blood 
monocytes and macrophage induced either by MCSF or CXCL4 confirmed the significant 
differences. Thus, while MCSF treatment resulted in further up-regulation of CD163 
expression, exposure to CXCL4 resulted in complete loss of the receptor within hours. This 
loss was not mediated by shedding of the receptor, which is one mechanism by which 
CD163 surface expression can be down-regulated (e.g. after treatment with LPS (Buechler et 
al. 2000)). Functionally, loss of CD163 resulted in loss of heme oxygenase-1 up-regulation 
upon exposure to hemoglobin-haptoglobin complexes confirming the functional relevance 
of our findings. 
To assess whether these in vitro findings play a role in vivo, we studied CD163 protein 
expression in human atherosclerotic lesions and found that it is differentially-expressed on 
CD68+ macrophages (Gleissner et al. 2010a). Furthermore, in a cohort of 18 consecutive 
patients undergoing carotid endatherectomy we found an inverse correlation between gene 
expression of PF4 (coding for CXCL4) and CD163. Considering that PF4 is exclusively 
expressed in megakaryocytes and platelets and CD163 expression is restricted to myeloid 
cells, we concluded that the presence of large amounts of CXCL4 is associated with low 
levels of CD163 supporting that this mechanism does play a role in vivo. 
3.4 M4 macrophages as therapeutic target in atherosclerosis? 
As described above, macrophages present in human atherosclerotic lesions do not represent 
a homogeneous entity, but are composed of different subsets that are characterized by 
differential-expression of cytokines, chemokines, surface receptors and their enzymatic 
repertoire. We believe that the platelet-derived chemokine CXCL4 may represent an 
important inducer of macrophage heterogeneity as it (I) is present in the atherosclerotic 
lesions, (II) is associated with disease progression, and (III) promotes monocyte 
differentiation towards a distinct macrophage polarization type.   
Based on these considerations, it was surprising to discover that CXCL4-induced M4 
macrophages do not display a clearly pro-atherogenic phenotype. In fact, some of their 
features seem clearly pro-atherogenic (e.g. loss of CD163), while others are ambiguous (e.g. 
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MMP expression) or may even be anti-atherogenic (e.g. reduced uptake of modified LDL). 
However, many of these functional data have been obtained in vitro on isolated 
macrophages. Thus, it is possible that in the context of an atherosclerotic lesion consisting of 
extracellular matrix as well as various other cells types, CXCL4-induced macrophages may 
have a more clearly pro-atherogenic phenotype. On the other hand, it is possible that the 
pro-atherogenic effects of CXCL4 represent the summary of various effects on various cell 
types. 
The possibility to specifically address the interaction between a chemokines and its partner 
(in this case CXCL4 and CCL5 (RANTES)) in the context of atherogenesis has been 
demonstrated in a very elegant study by Koenen et al., who have designed a small molecule 
that specifically inhibits the interaction between those two chemokines (Koenen et al. 2009). 
When treating Apoe-/- mice with this substance, lesion development was significantly 
reduced. Even though at this point it is unclear to what extent this effect was due to direct 
inhibition of CXCL4 effects on macrophages, it still demonstrates that tackling pro-
atherogenic chemokines represents a promising approach to prevent or even treat 
atherosclerosis. 
4. Macrophage heterogeneity and the novel M4 macrophage 
4.1 Unresolved questions on macrophage heterogeneity 
There are a number of unresolved questions regarding macrophage heterogeneity, which 
make it difficult to assess the specific role of M4 macrophages in this context. Firstly, in 
vitro models usually do not account for the diversity of peripheral blood monocytes. 
Thus, CD14+ cells are used to generate macrophages and it is unknown whether certain 
monocyte subsets (Geissmann et al. 2010, Ziegler-Heitbrock 1989) may be more likely to 
differentiate towards a specifically polarized macrophage type than others. Secondly, the 
concept of macrophage polarization is somewhat artificial as it considers the effects of 
isolated soluble factors (like TNF-alpha or IL-4), whereas in vivo the local micromilieu 
may be composed of a combination of various cytokine and chemokines. Thirdly, when 
studying macrophage polarization in vitro, dynamics over time are rarely being taken into 
account. Even though Mantovani et al. have studied the transcriptomes of monocytes, and 
monocyte-derived macrophages after three or six days’ treatment with MCSF (plus 
additional treatment with LPS/interferon- (M1) or IL-4 (M2)) (Martinez et al. 2006), more 
detailed information on time courses are lacking at this point. Finally, we do not know 
exactly which of the thus far defined macrophage polarization types represent final states 
of differentiation and which of them are temporary, i.e. whether induction of a specific 
polarization type is reversible or not.  
4.2 Macrophage polarization beyond M1 and M2 
The recent data on macrophage heterogeneity in human atherosclerosis is interesting and 
puzzling at the same time. Thus, while Bouhlel et al. were able to demonstrate gene 
expression of both M1 and M2 markers in different areas of human atherosclerotic plaques 
suggesting that both polarization types may exist in vivo (Bouhlel et al. 2007), other groups 
including ourselves have described macrophage phenotypes in vitro and in vivo that do not 
necessarily fit into the established scheme of macrophage polarizations (Boyle et al. 2009, 
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Waldo et al. compared MCSF- and GMCSF-induced macrophages (even though the latter 
are sometimes considered dendritic cells) and found significant differences in the expression 
of CD14, which was virtually absent in GMCSF-induced cells (Waldo et al. 2008). 
Furthermore, these cells were less likely to spontaneously accumulate modified LDL. The 
authors were able to confirm the existence and the functional characteristics of these 
macrophages in vitro as well as in human atherosclerotic lesions. 
Boyle et al. described a novel macrophage that is induced by haemoglobin-haptoglobin 
(Hb-Hp) complexes and is characterized by high levels of CD163 and low levels of HLA-
DR (Boyle et al. 2009). In vitro, these cells cleared Hb-Hp complexes more efficiently and 
showed reduced oxidative stress (Boyle et al. 2009). Mechanistic data show, that this 
phenotype is induced by autocrine effects of IL-10 suggesting a certain similarity to M2c 
macrophages.  
Our own group has studied the effects of oxidized LDL on human monocyte-derived 
macrophages and found that these cells express markers that have been associated with 
dendritic cells (Cho et al. 2007). Thus, these cells up-regulate genes coding for MHC-II, 
CD11c, and DC-STAMP, suggesting that there may be phenotypic and functional overlap 
between foam cells and dendritic cells within atherosclerotic lesions. 
Finally, as mentioned above, we have studied the phenotypic and functional characteristics 
of CXCL4-induced macrophages and found features that clearly distinguish these 
macrophages from any polarization type described thus far (Gleissner et al. 2010b).  
4.3 Suggestion for a novel nomenclature of macrophage polarization 
Based on this evidence, we feel the necessity to develop a novel classification of macrophage 
polarization that includes the novel macrophage types described in vitro and in vivo over the 
past years. Therefore, we here propose a novel framework that tries to systematically cover 
those macrophage types that have been unequivocally identified in human atherosclerotic 
plaques. Many of these polarization types have been extensively characterized, sometimes 
including transcriptomic analysis. Accordingly, we suggest assigning the “novel” 
macrophage polarization types names that consist of “M” (for macrophage) and a second 
number, or letter, or combination of both that is related to the inducers of this polarization 
type.  
Our proposed system has several advantages: Firstly, it allows keeping the established 
terms M1 and M2 and thereby not only respects the pioneering work by Gordon et al., but 
also avoids confusion associated with the introduction of new terms. Secondly, for 
“novel” macrophage polarization types the proposed names hint as to what inducers are 
involved. Finally, the system allows flexibility as based on the above-mentioned 
principles, so further addition of novel macrophage polarization types remains possible in 
the future.  
Notably, the proposed nomenclature is restricted to monocyte-derived cells that occur 
during pathology, i.e. it does not cover tissue macrophages like Kupffer cells in the liver or 
alveolar macrophages in the lung. By including dendritic cells (DC) in the system, we 
specifically address myeloid dendritic cells derived from monocyte precursors. 
Plasmacytoid DCs or DCs constitutively present in certain tissues like Langerhans cells of 
the skin are again not covered by the proposed system. Accordingly, our system may have 
some overlap with other classifications of DCs. Table 1a and b give an overview of the 
proposed system. 
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In summary, we have discussed the role of the platelet-derived chemokine CXCL4 for 
macrophage differentiation in the general context of macrophage heterogeneity in 
atherogenesis. There is good evidence that CXCL4 promotes atherogenesis, even though at 
this point, the relevance of CXCL4-induced macrophages for this process is not entirely 
understood. While CXCL4-induced macrophages display some potentially pro-atherogenic 
features, their pro-atherogenic nature is not as evident as expected. Thus, we believe that it 
will be necessary to study these cells in more detail to elucidate the mechanisms involved in 
CXCL4-induced macrophage differentiation, but also to study these cells in their 
pathohpysiological environment, i.e. within the human atheroclerotic plaque.  
As CXCL4 is not the only mediator of monocyte macrophage differentiation and as an 
increasing number of polarized macrophages clearly distinct from M1 and M2 macrophages 
with potential implication for atherogenesis have been identified in vitro and in vivo, we 
have proposed a novel macrophage classification schema, that both respects the established 
M1 and M2 paradigm and takes into account novel macrophage phenotypes and their 
inducers.  
Taken together, even though our knowledge on macrophage heterogeneity in general and 
the impact of CXCL4 on macrophage heterogeneity in atherogenesis is growing, we still 
need more insight into the mechanisms involved  in order to use this knowledge as the basis 
for novel, specific therapies for atherosclerosis. 
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1. Introduction 
Cardiovascular diseases, including coronary artery disease (CAD), ischemic gangrene, 
abdominal aortic aneurysms, and many cases of heart failure and stroke currently account 
for the most number of deaths in the Western world (Hansson et al., 2006). The root cause 
of these diseases is atherosclerosis, which is widely accepted these days to be a chronic 
inflammatory disease in addition to the more recognized disorder of lipid metabolism. 
Although it was established long ago that high levels of low-density lipoprotein (LDL) 
cholesterol is a major risk factor for atherosclerosis, more recently both innate and 
adaptive immune systems have been accepted as major participants in the initiation and 
progression of atherosclerosis. Besides monocytes/macrophages, T cells and dendritic 
cells (DCs) can be detected within atherosclerotic lesions and have been implicated in the 
pathogenesis of atherosclerosis (Hansson and Libby, 2006) (Weber et al., 2008). 
Atherosclerotic lesion progression has been shown to depend on ongoing, chronic 
inflammation in the artery wall. Following hyperlipidemia, a rapid influx of circulating 
monocytes into the atherosclerosis-prone areas of the arterial intima occurs. These 
recruited inflammatory monocytes differentiate into macrophages and take up modified 
atherogenic cholesteryl ester (CE)- rich lipoproteins in the intima of the vessel wall (Lusis, 
2000) (Ross, 1999) (Wang and Tall, 2003). The accumulation of cholesterol-loaded 
macrophages in the arterial wall called “foam cells” is a key feature of early 
atherosclerotic lesions (Brown and Goldstein, 1983).  
Upon lipid uptake within the artery wall, macrophage foam cells activate a compensatory 
pathway for cholesterol efflux, mediated by the ATP-binding cassette (ABC) transporters 
ABCA1 and ABCG1 (Wang et al., 2007). During systemic hypercholesterolemia, however, 
this homeostatic mechanism is overwhelmed, leading to the accumulation of foam cells and 
the initiation of fatty streak lesions. The importance of these transporters is illustrated by the 
fact that a combined deficiency of ABCA1 and ABCG1 accelerates foam cell accumulation 
and atherosclerotic development in mice (Yvan-Charvet et al., 2007). Cholesterol loading of 
macrophages also stimulates the production of inflammatory mediators, which recruit other 
cell types and contribute to the development of a complex lesion (Hansson et al., 2002). 
Thus, processes that interfere with the intracellular cholesterol balance would be expected to 
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cholesterol is a major risk factor for atherosclerosis, more recently both innate and 
adaptive immune systems have been accepted as major participants in the initiation and 
progression of atherosclerosis. Besides monocytes/macrophages, T cells and dendritic 
cells (DCs) can be detected within atherosclerotic lesions and have been implicated in the 
pathogenesis of atherosclerosis (Hansson and Libby, 2006) (Weber et al., 2008). 
Atherosclerotic lesion progression has been shown to depend on ongoing, chronic 
inflammation in the artery wall. Following hyperlipidemia, a rapid influx of circulating 
monocytes into the atherosclerosis-prone areas of the arterial intima occurs. These 
recruited inflammatory monocytes differentiate into macrophages and take up modified 
atherogenic cholesteryl ester (CE)- rich lipoproteins in the intima of the vessel wall (Lusis, 
2000) (Ross, 1999) (Wang and Tall, 2003). The accumulation of cholesterol-loaded 
macrophages in the arterial wall called “foam cells” is a key feature of early 
atherosclerotic lesions (Brown and Goldstein, 1983).  
Upon lipid uptake within the artery wall, macrophage foam cells activate a compensatory 
pathway for cholesterol efflux, mediated by the ATP-binding cassette (ABC) transporters 
ABCA1 and ABCG1 (Wang et al., 2007). During systemic hypercholesterolemia, however, 
this homeostatic mechanism is overwhelmed, leading to the accumulation of foam cells and 
the initiation of fatty streak lesions. The importance of these transporters is illustrated by the 
fact that a combined deficiency of ABCA1 and ABCG1 accelerates foam cell accumulation 
and atherosclerotic development in mice (Yvan-Charvet et al., 2007). Cholesterol loading of 
macrophages also stimulates the production of inflammatory mediators, which recruit other 
cell types and contribute to the development of a complex lesion (Hansson et al., 2002). 
Thus, processes that interfere with the intracellular cholesterol balance would be expected to 





Cholesterol is an essential structural component in the cell membrane and a precursor for 
steroid hormone and bile acid synthesis in metabolic pathways. Thus, cholesterol homeostasis 
needs to be strictly regulated. The intracellular cholesterol concentration is tightly controlled 
by feedback mechanisms that operate at both transcriptional and posttranscriptional levels 
(Brown and Goldstein, 1997). For example, the liver X receptor (LXR), belonging to the family 
of nuclear hormone receptors, contributes to cholesterol homeostasis by activating the 
transcription of genes involved in the response to cholesterol excess, including ABCA1 and 
ABCG1 (Beaven and Tontonoz, 2006). These transporters promote cellular cholesterol efflux to 
high-density lipoprotein (HDL) and its associated apolipoprotein (apo)-A1, a crucial step in 
the initiation of reverse cholesterol transport (RCT) to the liver for excretion (Tall et al., 2008). 
Other ways in which lipid-loaded and activated macrophage foam cells can significantly 
contribute to the maintenance and progression of atherogenesis is by producing nitric oxide, 
reactive oxygen species, inflammatory lipids, growth factors, and pro-inflammatory cytokines 
such as interleukin (IL) -1, IL-6, interferon (IFN)-γ and tumor necrosis factor (TNF)-α (Hansson, 
2001). Taken together, alterations in both lipid metabolism and the immune responses in 
macrophages play a significant role in promoting the development of atherosclerotic lesions. 
Knowledge of the mechanisms that regulate these responses could therefore be of considerable 
value with respect to the development of new approaches to prevention and treatment. 
As a prototypic anti-inflammatory cytokine, IL-10 is made primarily by the macrophages and 
T lymphocytes of the Th2 subtype. Its major functions include inhibition of macrophage 
activation as well as inhibition of MMP, pro-inflammatory cytokines and cyclooxygenase-2 
expression. IL-10 induces the proliferation of mast cells, B and T lymphocytes, and enhances T 
cell response to IL-2. Although it is clearly documented that IL-10 is expressed in the 
atherosclerotic plaque (de Vries, 1995) (de Waal Malefyt et al., 1991) (Gerard et al., 1993) it is 
not fully understood how IL-10 influences the atherogenic process. This chapter will highlight 
the current knowledge about the role of IL-10 in the initiation and progression of 
atherosclerosis. Inasmuch as macrophages play a critical role in the pathogenesis of 
atherosclerosis, the review will focus largely on how IL-10 stimulates and regulates the 
activities of macrophages that are important in the development of atherosclerosis. 
2. Anti-atherogenic properties of IL-10 
IL-10 exerts its atheroprotective effect on plaque progression, rupture, or thrombosis 
throughout the different stages of atherosclerosis by influencing the local inflammatory 
process within the atherosclerotic lesion. As an anti-inflammatory cytokine IL-10’s athero-
protective effects are exerted mainly by inhibiting various cell processes including the 
production of inflammatory mediators, matrix metalloproteinases (MMPs) and tissue factor 
(TF) production, and apoptosis. IL-10 is produced predominantly by macrophages within 
the local atherosclerotic lesion where it could play a significant role in the modulation of the 
local inflammatory response for both macrophages and T cells.  
2.1 Influence on macrophage function 
Macrophages play a central role during all stages of atherosclerosis (Moore and Tabas, 2011). 
Early in vivo studies using immunochemistry and PCR have indicated that macrophages in 
atherosclerotic lesion are the main source of IL-10 production in advanced atherosclerotic 
plaques (Mallat et al., 1999b). IL-10 plays an essential role in down-modulating adaptive and 
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innate immune responses, partly by inhibiting the activation of human monocytes and 
monocyte-derived dendritic cells (Woszczek et al., 2008). 
Atherogenesis is initiated with the recruitment of inflammatory cells to the intima. 
Following inflammatory activation, the recruited monocytes are differentiated into 
macrophages which take up modified LDL particles such as oxidized LDL (oxLDL), through 
scavenger receptors, thereby promoting cholesterol loading and foam cell formation in the 
plaque’s core. Lipid-laden macrophages produce multiple pro-inflammatory mediators, 
reactive oxygen species (ROS), and TF pro-coagulant that promote local inflammation and 
promote thrombotic complications. The paradigm that macrophages play a critical and 
definitive role in human atherosclerosis has been evidenced by a large number of 
publications from various studies of experimental atherosclerosis. The morphological 
observation that macrophages are abundantly distributed from early stage lesion in fatty 
streak to the late stage within fibrous plaques indicates; macrophage-derived foam cells are 
absolutely critical for development of atheromas (Libby et al., 2011) (Little et al., 2011). 
The mechanisms by which IL-10 may protect against atherogenesis can be categorized, 
albeit artificially, into 4 aspects of macrophage function: 1. anti-inflammatory properties 2. 
inhibition of MMPs and TF 3. anti-apoptotic feature 4. modulation of lipid metabolism.  
2.1.1 Anti-inflammatory properties of IL-10  
Atherosclerosis is a chronic inflammatory condition of the arterial wall characterized by 
progressive accumulation of lipids, cells (macrophages, T lymphocytes, and smooth muscle 
cells), and extracellular matrix (Ross, 1999) (Libby et al., 2011) (Charo and Taub, 2011) 
(Maskrey et al., 2011). During recent years, inflammation has emerged as a major driving 
force in atherosclerotic lesion development throughout the different stages of the disease 
(Libby et al., 2011) (Charo and Taub, 2011) (Moubayed et al., 2007) (Little et al., 2011), from 
early fatty streak to advanced fibro-fatty plaque formation. Of the cells participating in 
atherogenesis, monocyte-derived macrophages and T-lymphocytes are the most prominent 
cells that secrete various pro- or anti-atherogenic cytokines that can influence the disease 
development and affect plaque stability (Ferri et al., 2009) (Pasqui et al., 2006) (Kleemann et 
al., 2008) (Galkina and Ley, 2009) (Woollard and Geissmann, 2010) (Weber et al., 2008). 
Being the most abundant inflammatory cell type in the plaque, macrophages are the most 
important source of cytokine production in atherosclerotic lesions (Tedgui and Mallat, 2006) 
and can produce pro-inflammatory cytokines such as TNF-, IL-1, IL-6, IL-12, IL-15, IL-18, 
as well as the anti-inflammatory cytokines like IL-10 and transforming growth factor-β 
(TGF-β). It has been well documented that pro-inflammatory cytokines can promote 
development of atherosclerosis (Little et al., 2011) while anti-inflammatory cytokines like 
TGF- (Bobik et al., 1999) and IL-10 (Nishihira et al., 2006) can have an anti-atherogenic 
effect.  
One of the earlier studies showed that IL-10 mRNA was detected by RT-PCR in 4 of 5 
human atherosclerotic specimens but not in plaque-free aortic specimens (Uyemura et al., 
1996). When human monocytes isolated from PBMC were incubated with oxLDL, IL-10 
protein production was increased (Uyemura et al., 1996). The presence of IL-10 in advanced 
human atherosclerotic plaque was subsequently verified by another group (Mallat et al., 
1999b). They showed also by using RT-PCR, that IL-10 mRNA was present in 12 of 17 
atherosclerotic plaques, mainly in macrophages (Mallat et al., 1999b). These studies suggest 
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IL-10 is a potent anti-inflammatory cytokine. Increased IL-10 serum level is a beneficial 
prognostic determinant in patients with acute coronary syndromes (Heeschen et al., 2003). A 
line of publications has shown that IL-10 expression by plaque macrophages limits the 
inflammatory response and promotes plaque healing (de Vries, 1995) (de Waal Malefyt et al., 
1991) (Gerard et al., 1993) by inhibiting IL-12 (Uyemura et al., 1996) and inducible nitric oxide 
synthase (iNOS) production (Mallat et al., 1999b) (Ito and Ikeda, 2003). Attenuation of 
atherogenesis by IL-10 was attributed to its anti-inflammatory effects, most notably its ability 
to inhibit the release of several pro-inflammatory cytokines (including IL-1, TNF-, and IL-8) 
from monocytic cells, and to induce the production of IL-1 receptor antagonist (Terkeltaub, 
1999) (van der Poll et al., 1994) (Wang et al., 1995). IL-10 also suppresses the production of the 
chemokine KC/GRO- (Kishore et al., 1999) which is implicated in intimal macrophage 
accumulation and the progression of complex atherosclerotic lesions in advanced disease 
(Boisvert et al., 1998). MCP-1 is chemotactic for monocytes and highly expressed in 
macrophage-rich areas of the lesion. IL-10-induced inhibition of MCP-1 (Ajuebor et al., 1999) 
(Han et al., 2009) (Han et al., 2010) (Zimmerman et al., 2004), a key player in monocyte 
recruitment to early atherosclerotic lesions (Gosling et al., 1999), has been regarded as an 
important protective mechanism of atherogenesis by IL-10. 
2.1.2 Inhibition of matrix metalloproteinases and tissue factor 
Pathological studies have provided evidence that extracellular matrix content and its 
degradation are related to vulnerability and instability of plaques (Libby, 1995). It has been 
well documented that clinical instability of atherosclerosis is related to the activation of local 
inflammatory and immune cells with increased expression of MMPs (Libby, 1995) and TF 
(Ardissino et al., 1997) in the culprit plaque as well as increased systemic production of 
MMPs (Kai et al., 1998) and thrombin (Biasucci et al., 1996) (Caligiuri et al., 2003). 
Macrophages are important sources of MMPs within atherosclerostic lesions , including 
MMP-2, MMP-8, MMP-9, MMP-12, MMP-13, and MMP-14 (Gough et al., 2006) (Little et al., 
2011). MMPs affect lesion development and progression by degrading extracellular matrix 
proteins, leading eventually to the development of unstable, rupture-prone atherosclerotic 
lesions (Boyle, 2005) (Little et al., 2011). Tissue factor is a prothrombotic molecule expressed 
by various cell types within atherosclerotic plaques and has been thought to play an 
essential role in thrombus formation after atherosclerotic plaque rupture (Kamimura et al., 
2005). There is evidence that IL-10 may have protective effects against plaque rupture and 
thrombus formation (Waehre et al., 2002). IL-10 can inhibit the secretion of MMPs (Waehre 
et al., 2002) (Han et al., 2009) (Han et al., 2010) (Holven et al., 2006), the synthesis of TF 
(Kamimura et al., 2005) (Ramani et al., 1993), and the production of thrombin (Pajkrt et al., 
1997) from PBMC and macrophages. Decreased collagen synthesis and increased activity of 
macrophage-derived matrix degrading metalloproteinases are responsible for fibrous cap 
thinning and fragility. Therefore, low levels of IL-10 may lead to augmented MMP activity 
which may in turn promote plaque instability to cause acute cardiovascular events in certain 
individuals (Holven et al., 2006) (Mallat et al., 1999a). In addition, the balance between Th1 
(IFN-) and Th2 (IL-10) polarization in T helper cells may play an important role in 
atherogenesis. IFN- may destabilize plaques not only by inhibiting collagen production 
(Amento et al., 1991) in human vascular smooth muscle cells, but by stimulating MMP 
production in macrophages (Libby, 1995) (Saren et al., 1996) and modulating the fibrinolytic 
response of endothelial cells (Arnman et al., 1995) (Gallicchio et al., 1996).  
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2.1.3 Anti-apoptotic properties 
Both IL-10 transgenic animal models and mice deficient in either IL-10 or IL-10 receptor 
have highlighted the anti-apoptotic feature of IL-10. Both apoptosis and necrosis occur in the 
atherosclerotic plaque (Geng and Libby, 1995) (Isner et al., 1995) (Han et al., 1995) 
(Bjorkerud and Bjorkerud, 1996; Cai et al., 1997; Geng and Libby, 1995; Han et al., 1995; Isner 
et al., 1995). IL-10’s anti-apoptotic properties have been reported in cultured macrophages 
(Arai et al., 1995) (Han et al., 2009) (Han et al., 2010) and in T lymphocytes (Cohen et al., 
1997). Inflammatory nitric oxide has apoptotic effects (Geng et al., 1996) (Albina et al., 1993) 
and can induce cell death, at least in part through local peroxynitrite formation (Luoma et 
al., 1998) (Kockx et al., 1998). One mechanism by which IL-10 can protect from excessive cell 
damage and death in the plaque is by inhibition of iNOS production (Cattaruzza et al., 
2003). The production of ROS is increased in atherosclerotic arteries (Minor et al., 1990), 
leading to endothelial damage, oxidation of lipid components (Witztum and Steinberg, 
2001), and recruitment of inflammatory cells to the site of injury. IL-10 may down-regulate 
immune responses in atherosclerosis by inhibiting antigen presentation to T cells (de Waal 
Malefyt et al., 1991), and by inhibiting production of reactive oxygen intermediates which 
result in oxidation of LDL (Bogdan et al., 1991). In addition, IL-10 activates signal transducer 
and activator of transcription 3 (STAT3), which suppresses endoplasmic reticulum (ER) 
stress-induced apoptosis in macrophages by inducing the expression of cell-survival 
molecules (Li et al., 2008). The increased expression of the anti-apoptotic genes Bfl-1 and 
Mcl-1 in response to IL-10 contributes to the suppression of apoptosis by IL-10 in lipid-laden 
foam cells (Halvorsen et al., 2005). Furthermore, because excessive accumulation of free 
cholesterol can cause apoptosis in cells, one other way in which IL-10 may exert its anti-
apoptotic effects is by stimulating ABCA1/ABCG1 production which increases the 
cholesterol efflux from lipid laden foam cells (Rubic and Lorenz, 2006) (Han et al., 2009) 
(Han et al., 2010). 
2.1.4 Polarization of macrophage by IL-10  
In response to cytokines and microbial products, macrophages have the ability to be 
polarized into one of two subgroups: classically activated M1 and alternatively activated M2 
form (Benoit et al., 2008). The concept of macrophage polarization has been widely accepted 
in recent years (Mantovani et al., 2005) (Martinez et al., 2008). M1 macrophages are induced 
by IFN-, microbial stimuli (e.g. LPS) or cytokines such as TNF-α and GM-CSF. M2 
macrophages are induced by IL-4, IL-10, IL-13, immune complexes, glucocorticoid or 
secosteroid (vitamin D3) hormones (Mantovani et al., 2005; Martinez et al., 2008). One of the 
notable features of M1 macrophage is its low level of IL-10 expression and high levels of IL-
12 and IL-23 expression. As efficient producers of reactive oxygen and nitrogen 
intermediates and inflammatory cytokines, M1 macrophages are associated with protection 
during acute infectious diseases, and can induce and polarize Th1 response as well as 
mediate immune response against intracellular parasites and tumors (Benoit et al., 2008).  
By contrast, M2 macrophage phenotype is characterized by abundant expression of IL-10 
and low levels of IL-12 and IL-23 production. By expressing high levels of scavenger, 
mannose and galactose-type receptors, M2 macrophages participate in polarized Th2 
response and exert immunoregulatory functions (Martinez et al., 2008) (Mantovani et al., 
2005) by promoting killing and encapsulation of parasites (Noel et al., 2004). They are 
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infectious diseases are associated with macrophage reprogramming towards an M2 profile 
(Benoit et al., 2008).  
Both M1 and M2 macrophages are present in atherosclerotic lesions (Khallou-Laschet et al.). 
Exposure of macrophages to oxLDL renders M2 macrophages pro-inflammatory (van Tits et 
al., 2011). Compared with pro-inflammatory M1 macrophages, anti-inflammatory M2 
macrophages are more susceptible to foam cell formation (van Tits et al., 2011). 
Interestingly, however, a recent report indicates that M2 phenotype may exert an athero-
protective action in experimental atherosclerosis (Khallou-Laschet et al.). On the other hand, 
PPARγ activation plays an essential role in promoting polarization of circulating blood 
monocytes to become M2 macrophages (Bouhlel et al., 2007) (Charo, 2007) (Chinetti-
Gbaguidi and Staels). Convincing clinical evidence and animal experiments from PPARγ-
deficient mice and from the mice treated with PPARγ ligands have demonstrated the 
beneficial role of PPARγ activation in preventing atherosclerosis (Staels, 2005) (Ricote et al., 
1998). Because IL-10 increases ABCA1-mediated cholesterol efflux through PPARγ 
activation (Han et al., 2009) (Han et al., 2010), it is likely that PPARγ-driven M2 macrophage 
formation plays an important role in athero-protective action by IL-10. 
2.1.5 Modulation of lipid metabolism 
The loading of macrophages with lipoprotein-derived cholesterol alters macrophage 
functions during atherogenic processes. The fact that IL-10 production is increased in lipid 
laden macrophages suggests that IL-10 may be involved in lipid metabolism in these cells. 
In fact, oxLDL can promote immune activation by inducing pro-inflammatory cytokines  
IL-12 and TNF-, and anti-inflammatory cytokine IL-10 production by mononuclear 
leukocytes from human atherosclerotic plaque (Fei et al., 2003). During recent years, the 
involvement and importance of IL-10 in lipid metabolism, particularly in macrophages, has 
been increasingly recognized.  
With regard to lipid metabolism and foam cell formation, two steps are critical in 
maintaining lipid homeostasis in macrophages: 1. cholesterol uptake mediated by scavenger 
receptors and 2. cholesterol efflux mediated by ABCA1/ABCG1. Scavenger receptors such 
as scavenger receptor A and CD36 on macrophages mediate the uptake of modified 
lipoproteins from the vessel wall (Nagy et al., 1998). In addition, reverse cholesterol 
transport through ABCA1 and ABCG1 is an important mechanism to export cytotoxic 
cellular free cholesterol to lipid poor apoAI and lapidated HDL particles (Chinetti et al., 
2001; Kennedy et al., 2005) . It is well documented that cholesterol efflux via ABCA1 and 
ABCG1 is essential to slow the development of atherosclerosis by decreasing lipid loading 
(Yvan-Charvet et al., 2007) (Zhao et al., 2010) (Calkin and Tontonoz, 2010) (Fitzgerald et al., 
2010) (Ye et al., 2011). Although the role of scavenger receptors appears complicated because 
of conflicting results from gene knockout or transgenic mouse studies (Hansson and 
Hermansson, 2011) the general consensus among recent publications is that these receptors 
are protective against atherosclerosis due to their ability to remove modified LDL from the 
vessel wall (Marleau et al., 2005) (Moore et al., 2005) (Van Eck et al., 2000) (Whitman et al., 
2002) (Liao et al., 2000) (Teupser et al., 1999).  
Recent in vivo results show that the role of IL-10 in regulating lipid metabolism remains 
elusive. Plasma lipoprotein levels including LDL, HDL and triglyceride have been measured 
in these animal models but the results appear controversial and are dependent on several 
factors such as the animal model used, route of administration and stage of atherosclerosis 
 
The Role of IL-10 in Atherosclerosis 
 
367 
investigated. In C57BL/6J mice, total plasma cholesterol and HDL cholesterol levels were 
not affected by IL-10 deficiency (Mallat et al., 1999a) (Pinderski Oslund et al., 1999). Systemic 
IL-10 overexpression lowered plasma VLDL and LDL cholesterol levels in LDLR-/- mice 
(Von Der Thusen et al., 2001), but IL-10 overexpression in T cells did not alter circulating 
lipoprotein profiles (Pinderski et al., 2002). No changes in plasma (Namiki et al., 2004) or 
reduced cholesterol levels (Yoshioka et al., 2004) were observed in apoE-/- mice with 
intramuscular gene transfer of IL-10 cDNA. Interestingly, the lack of IL-10 led to increased 
LDL cholesterol whereas VLDL was reduced in apoE-/- mice with no significant changes 
observed in either total cholesterol or triglyceride levels (Caligiuri et al., 2003). However, 
systemic delivery of adeno-associated virus type 2-hIL-10 inhibited atherogenesis in LDLR 
knockout mice with no changes in plasma cholesterol levels (total cholesterol, LDL, HDL, 
and TG) compared with those with no treatment (Liu et al., 2006). In APOE*3-Leiden mice, 
IL-10 deficiency did not lead to significant changes in cholesterol levels but overexpression 
of IL-10 reduced cholesterol levels after feeding a high-fat, cholesterol-rich diet (Eefting et 
al., 2007). These confusing set of results suggest that IL-10-modulated lipid metabolism and 
plasma cholesterol levels vary widely and is dependent on the animal models utilized. The 
role of IL-10 in lipid metabolism needs to be rigorously elucidated, especially in relation to 
human atherosclerosis. 
Recent publications provide convincing evidence that IL-10 can modulate cellular lipid 
metabolism, including cholesterol uptake and cholesterol efflux (reverse cholesterol 
transport). In 2005, Halvorsen et al. reported that IL-10 enhances oxLDL-induced formation 
of macrophage foam cells (Halvorsen et al., 2005). The authors propose that IL-10 not only 
enhances foam cell formation but also has anti-apoptotic effects by increasing the expression 
of anti-apoptotic genes Bfl-1 and Mcl-1 (Halvorsen et al., 2005). In 2006, Rubic and Lorenz 
showed that IL-10 can stimulate ABCA1/ABCG1 which increases the cholesterol efflux from 
lipid-laden foam cells. In addition, they observed a down-regulation of CD36-mediated 
oxLDL uptake in macrophages. According to their results IL-10 is able to decrease oxLDL 
uptake and increase reverse cholesterol transport in macrophages, thereby preventing foam 
cell formation (Rubic and Lorenz, 2006). These results appear to contradict the report by 
Halvorsen et al. in which IL-10 increases foam cell formation. These confusing findings were 
partially clarified by a study by Han et al. in 2009 in which they reported that IL-10 
modulates lipid metabolism in macrophages by facilitating both cholesterol uptake and 
efflux (Han et al., 2009). This study clearly revealed that IL-10 not only can up-regulate 
ABCA1 in a PPAR--dependent mechanism but can increase the expression of scavenger 
receptors (scavenger receptor A and CD36). In support of this Montoya et al. reported that 
IL-10 stimulates the expression of scavenger receptors and enhances foam cell formation 
(Montoya et al., 2009). These data support the hypothesis that increased cholesterol uptake 
by IL-10 may be athero-protective by actively removing the highly atherogenic lipoproteins 
from the artery wall. On the other hand, the increase in ABCA1-dependent cholesterol efflux 
by IL-10 is a crucial factor in the efficient disposal of cytotoxic free cholesterol through 
reverse cholesterol transport. Interestingly, a recent report indicated that anti-inflammatory 
M2 macrophages but not pro-inflammatory M1 macrophages rapidly accumulate oxidized 
LDL (van Tits et al., 2011). As IL-10 is one of the effectors that promote M2 macrophage 
polarization as mentioned above (Martinez et al., 2009) (Tabas, 2010), it is likely that IL-10 is 
involved in the lipid accumulation predominantly in M2 macrophages. These results 
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traditional role of IL-10 in inhibiting inflammatory molecules (e.g. TNF-, iCAM-1, and 
MMP9) and reducing apoptosis (Han et al., 2009) (Han et al., 2010) . A cartoon depicting the 
multi-faceted anti-atherogenic role of IL-10 in macrophages is shown in the figure below. 
 
 
Fig. 1. Schematic overview of the protective role of IL-10 during atherosclerosis involving 
regulation of lipid metabolism in macrophages. Upon binding to its receptor, IL-10 up-
regulates scavenger receptors, SR-A (SR-I and SR-II) and CD36, which account for an 
increase in modified LDL uptake by macrophages. This promotes cholesteryl ester 
accumulation and foam cell formation. IL-10 also promotes ABCA1-mediated free 
cholesterol efflux to apoAI in a PPAR-dependent manner. In a more traditional role as an 
anti-inflammatory cytokine, IL-10 markedly suppresses the expression of pro-inflammatory 
molecules such as TNF-, MCP-1 and MMPs, presumably through the inhibition of NF-B 
activity as documented before (Wang et al., 1995), and diminishes apoptosis in the lipid-
laden foam cells (Han et al., 2009).  
2.2 Influence on T lymphocyte function 
Recent publications have shown that, although T cell numbers are far fewer than 
mononuclear phagocytes, they are also recruited to the intima and play an important role in 
the development of atherogenesis. Therefore, the protective action of IL-10 in atherogenesis 
is likely to involve T cell immune response. 
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2.2.1 Polarization and balance of T helper cells 
T lymphocytes are found in lesions in an activated state and coexist with lesion macrophages, 
particularly in early phases of atherosclerosis. The key role for Th1 cytokines, such as IL-12 
(Lee et al., 1999) or IFN- (Gupta et al., 1997) as well as the general role of lesion T lymphocytes 
in atherogenesis have been reviewed elsewhere (Daugherty and Rateri, 2002). As a prototypic 
anti-inflammatory cytokine, IL-10 down-regulates Th1 cytokines such as IL-12 and IL-18 
leading to inhibition of Th1-biased immune response (Moore et al., 2001), and polarization of 
the Th1:Th2 balances toward Th2 (Daugherty and Rateri, 2002). Induction of a regulatory T cell 
type 1 response attenuates the development of atherosclerosis in apoE-knockout mice by 
decreasing the Th1 response, decreasing the production of IFN- and increasing IL-10 
production (Mallat et al., 2003). Also, it may be that the reduction in atherosclerotic lesion 
formation in FcRIII (CD16) -/- mice crossed onto the LDLR-/- mice is associated with 
increased production of IL-10 by the expansion of CD4+ T cells (Kelly et al., 2010).  
The imbalance between pro- and anti-inflammatory forces influences plaque disruption and 
recurrent cardiovascular events (Trompet et al., 2007) with a shift towards the Th1 
dominance seen in atherosclerosis patients (Ait-Oufella et al., 2011). In support of this 
concept is the report that serum IL-18/IL-10 ratio is an independent predictor of in-hospital 
adverse events in patients with acute coronary syndrome (Chalikias et al., 2005). 
Furthermore, an anti-inflammatory marker such as IL-10 is a better prognostic marker than 
inflammatory markers such as CRP and IL-18 to predict cardiovascular events in ACS 
patients (Tziakas et al., 2007). Likewise, it has been demonstrated that CRP accentuates 
inflammation, which is pivotal in atherothrombosis, by lowering IL-10, thereby altering the 
anti-inflammatory/pro-inflammatory balance (Singh et al., 2006). There is an inverse 
correlation between pro-inflammatory CRP and anti-inflammatory IL-10 levels in patients 
with athersoclerosis (Seyrek et al., 2005). More recently, an inflammatory imbalance between 
the TNF- system and IL-10 has been characterized in children with familial 
hypercholesterolemia (Narverud et al., 2011).  
Th1 biased phenotype is responsible for clinical instability (Liuzzo et al., 2000) and 
atherogenesis (Jonsson et al., 2001) (Hurt-Camejo et al., 2001) (Laurat et al., 2001) (Zhou et 
al., 1998) (Caligiuri et al., 2003) (Mallat and Tedgui, 2004) (Mallat et al., 2005). Interestingly, 
in IL-10-/- ApoE-/- double KO mice, Th1-bias was accompanied by a higher susceptibility 
to atherosclerosis, but only at the early stage of the disease when macrophages dominate 
(which is when they are sensitive to Th1 and Th2 cytokines (Caligiuri et al., 2003)). 
2.2.2 Regulatory T cells and Th17 cells 
Recently, the role of regulatory T cells (Treg) and IL-17-producing T cells (Th17 cells) has 
been emphasized in atherosclerosis (Taleb et al., 2010) (Lahoute et al., 2011). Treg are 
important in protection against atherosclerosis at least in part through the production of IL-
10 (Mor et al., 2007) (Taleb et al., 2010) (George, 2008) (Feng et al., 2009). It is also believed 
that the pro-atherogenic response by Th1 cells can be controlled by Treg (Binder et al., 2004).  
IL-17-producing Th17 cells also play an important role in atherosclerosis (Hansson and 
Hermansson, 2011). Irradiated LDLR-/- mice transplanted with IL-17R deficient bone marrow 
exhibit reduced lesion size in aortic root, increased IL-10 production, and decreased IL-6 
production (van Es et al., 2009). This suggests that signaling via the IL-17 receptor in bone 
marrow derived cells enhances atherosclerosis. Similarly, blockade of IL-17 results in reduced 
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17 in atherogenesis is controversial in that increased level of IL-17 is associated with a stable 
human plaque phenotype while defective Th17 cell differentiation may be implicated in 
increased susceptibility to vascular inflammation (Taleb et al., 2009). In addition, Th17 
response is protective against vascular inflammation and the progression of atherosclerosis 
(Taleb et al., 2010). Similarly, a deficiency of SOCS3 in T cells leads to IL-17-dependent 
reduction in lesion development and vascular inflammation by increasing IL-17 and IL-10 
production, and by inducing an anti-inflammatory macrophage phenotype (Taleb et al., 2009)  
3. Human studies and in vivo animal models 
The role of IL-10 in atherosclerosis has been investigated using different animal models as 
listed on the table below. In 1996, Uyemura et al. (Uyemura et al., 1996) first described 
that IL-10 was produced in human atherosclerotic lesions and that ox-LDL induced IL-10 
release from monocytes in vitro. The down-regulation of IL-12 by IL-10 (Sieling et al., 
1994) (D'Andrea et al., 1993) (de Waal Malefyt et al., 1991) observed in this study and 
others suggest that the balance between IL-12 and IL-10 production contributes to the 
level of immune-mediated tissue injury in atherosclerosis. IL-12 and IL-10 are two 
important cytokines produced by activated monocytes that regulate the Th1 and Th2 
responses, respectively (D'Andrea et al., 1992) (Gately et al., 1991) (Germann et al., 1993) 
(Hsieh et al., 1993) (Seder et al., 1993) (Sieling et al., 1994) (de Waal Malefyt et al., 1991) 
(Barnes et al., 1992). IL-12 is a T cell growth factor (Gately et al., 1991) that is primarily 
produced by activated monocytes (D'Andrea et al., 1992) which selectively induces the 
Th1 cytokine pattern (Gately et al., 1991) (Germann et al., 1993) (Hsieh et al., 1993) (Seder 
et al., 1993) (Sieling et al., 1994). One important mechanism of IL-10 action is that it 
inhibits the local production of IL-12 which may potentiate the chronic inflammatory Th1 
cell and macrophage responses leading to tissue injury in atherosclerosis (Uyemura et al., 
1996). The complicated issue of athero-regulation by both IL-12 and IL-10 was further 
exhibited by an observation that IL-12 is expressed at an earlier stage of atherosclerosis 
than IL-10 in apoE-/- mice (Lee et al., 1999). This suggests that IL-12 and IL-10 may play 
an active role in regulating the immune response during the different phases of 
atherosclerosis.  
In 1999, Mallat et al. reported the expression and potential effects of IL-10 in advanced 
human atherosclerotic plaques (Mallat et al., 1999b). Immunohistochemical staining from 
this study indicated that macrophages in advanced human atherosclerotic plaques are the 
main source of IL-10. The local anti-inflammatory response of IL-10 and its effect on 
protection from excessive cell death in the plaque was supported by the data that high 
levels of IL-10 expression were associated with low levels of iNOS expression and cell 
death.  
Studies involving IL-10-deficient and IL-10-overexpressing mouse models on either apoE-/- 
or LDLR -/- background have greatly advanced our understanding of the mechanism of IL-
10 function in atherogenesis. In 1999, two labs independently reported that IL-10 is 
protective in atherosclerosis (Mallat et al., 1999a; Pinderski Oslund et al., 1999). Since then, 
more than ten groups utilized different animal models and various IL-10 delivery systems in 
an attempt to understand how IL-10 affects atherosclerosis. The first report using the IL-10-
deficient mice fed an atherogenic diet showed an increased lipid accumulation, higher T-cell 
infiltration, abundant IFN- expression, and decreased collagen content in the lesion 
compared with wild-type mice (Mallat et al., 1999a). Transfer of murine 
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Publication Approach Animal model Underlying mechanism 
Mallat et al. 1999, 
Circ Res (Mallat et 
al., 1999a)  
IL-10-encoding plasmid 
transferred to muscle cells using 
electrotransfer procedures 
C57BL/6 mice Inhibit inflammation, plaque collagen 
content and stability  
Pinderski Oslund et 
al. 1999, ATVB 
(Pinderski Oslund et 
al., 1999)  
Systemic overexpression of IL-
10  
C57BL/6J mice Block monocyte adhesion to human aortic 
endothelial cells 
Von der Thusen et 
al. 2001, FASEB J 
(Von Der Thusen et 
al., 2001)  
Systemic adenovirus-mediated 
transfer of IL-10 
LDLR-/- mice Monocyte deactivation by inhibition of 
TNF- and lowering of serum cholesterol 
levels 
Pinderski et al. 2002, 
Circ Res (Pinderski 
et al., 2002)  
Murine IL-10 transgene under 
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17 in atherogenesis is controversial in that increased level of IL-17 is associated with a stable 
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Publication Approach Animal model Underlying mechanism 
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IL-10 through in vivo intramuscular electrotransfers of pCor-IL-10 plasmid DNA achieved 
a 60% reduction in lesion size in IL-10-deficient mice. In agreement with these findings, 
Pinderski Oslund et al. observed that diet-induced atherosclerotic lesions were larger in 
IL-10 null mice than in control mice (Pinderski Oslund et al., 1999). In addition, they also 
observed that transgenic murine IL-10 expression which was selectively driven in T cells 
by human IL-2 promoter decreased atherosclerotic lesion formation (Pinderski Oslund et 
al., 1999).  
In 2001, von der Thusen and colleagues reported that increased plasma concentrations of 
IL-10 as a result of adenoviral gene transfer in LDLR-/- mice led to reduction in 
atherosclerotic lesion size by inhibiting the production of TNF- (Han et al., 2010; Von 
Der Thusen et al., 2001). The mechanism involves the inhibition of anti-inflammatory 
TNF- production by IL-10 (Han et al., 2010; Von Der Thusen et al., 2001). At the same 
time, Pinderski et al. demonstrated that overexpression of IL-10 by activated T 
lymphocytes attenuated lesion formation by driving the shift to a Th2 phenotype with 
decreased IFN- production (by peripheral blood lymphocytes, splenocytes, and 
circulating monocytes) (Pinderski et al., 2002). Alteration of macrophage function was 
exhibited by markedly decreased apoptosis in macrophage foam cells within the lesions of 
IL-10 transgenic mice (Pinderski et al., 2002).  
The athero-protective results obtained with IL-10-deficient mice on the C57BL/6J 
background (Mallat et al., 1999a; Pinderski Oslund et al., 1999) were confirmed in IL-10 and 
apoE double knockout mice as demonstrated by Caligiuri et al. (Caligiuri et al., 2003). 
Several significant findings were revealed by this study: (1) Th-1 response and lesion size 
were dramatically increased in double knockout mice compared with apoE-/- controls at 
the early phase of lesion development; (2) the proteolytic and procoagulant activity was 
elevated in advanced lesions as indicated by an increase in TF and MMP activities, 
suggesting that IL-10 may reduce atherogenesis and improve the stability of plaques; and (3) 
lipid metabolism regulated by IL-10 was implicated in this study as LDL cholesterol was 
increased but VLDL was decreased in the double KO mice without significant changes in 
total cholesterol or triglyceride levels (Caligiuri et al., 2003).  
In an attempt to utilize IL-10 as a therapeutic agent, several techniques have been used by 
different groups to deliver the IL-10 gene in vivo. One study showed that intramuscular 
gene transfer of IL-10 cDNA reduces atherosclerotic lesion formation in apoE-/- mice 
(Namiki et al., 2004). IL-10 gene transfer quelled the Th1 response by inhibiting IL-12 and 
IFN- expression in transgenic mice (Namiki et al., 2004). These results were confirmed in 
another study in which adeno-associated virus vector-mediated IL-10 gene transfer via 
intramuscular injection inhibited atherosclerosis in apoE-/- mice (Yoshioka et al., 2004) by 
lowering MCP-1 expression in both the vascular wall of the ascending aorta and serum. In 
agreement with these results, a systemic delivery of adeno-associated virus type 2-hIL-10 
inhibited atherogenesis in LDLR-/- mice by combating inflammation and oxidative stress 
(Liu et al., 2006). Similar effects of IL-10 deficiency and overexpression on neointima 
formation were seen in the hypercholesterolemic apoE*3-Leiden mice as well (Eefting et al., 
2007).  
Anti-atherosclerotic properties of IL-10 were further displayed in high fat diet-fed LDLR -/- 
mice in which IL-10 was overexpressed in macrophages by utilizing a macrophage-specific 
retroviral vector that allows long-term in vivo expression of IL-10 in macrophages through 
transplantation of retrovirally transduced bone marrow cells (BMCs) (Han et al., 2010). The 
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IL-10 expressed by macrophages in the plaques derived from transduced BMCs inhibited 
atherosclerosis in these mice, at least in part by reducing the inflammation and apoptosis in 
IL-10-overexpressing macrophages. These results are consistent with previous findings (Han 
et al., 2009) and provided evidence that IL-10 production in macrophages is protective 
against atherosclerosis. Their results also highlight a novel therapeutic technique against 
atherosclerosis using an effective stem cell transduction system that allows prolonged 
production of IL-10 from macrophages. 
It is worth emphasizing that most strategies mentioned above had systemic effects on 
multiple cells including T cells, monocytes and endothelium resulting from overexpression 
of IL-10 in circulation. For example, overexpression of IL-10 in activated T lymphocytes 
inhibited monocyte activation and led to a shift to either Th2 phenotype (Pinderski et al., 
2002) or Th1 phenotype (Zhou et al., 1998). As a cytokine with diverse effects on most 
hematopoietic cell types, IL-10 can inhibit the activation and effector function of T cells, 
monocytes, and macrophages (Moore et al., 2001). In addition, IL-10 can regulate the growth 
and/or differentiation of B cells, NK cells, cytotoxic and helper T cells, mast cells, 
granulocytes, dendritic cells, keratinocytes, and endothelial cells (Moore et al., 2001). 
Therefore, alterations in circulating IL-10 levels can influence the function of other immune 
cells which may in turn influence atherosclerosis. In the study by Han et al. there was no 
detectable IL-10 in circulating plasma at any time point during the atherogenic diet feeding 
whereas IL-10 was readily detected in IL-10-overexpressing macrophages in atherosclerotic 
lesions. This suggests that IL-10 was expressed in differentiated macrophages but not in 
circulating monocytes. Therefore, their technique of overexpressing IL-10 only in 
differentiated macrophages is useful to evaluate the unique role of locally-produced IL-10 in 
atherogenesis, and clearly shows that IL-10 acting in the vessel wall can decrease the 
development of atherosclerosis despite ongoing hyperlipidemia.  
However, a recent study using a rabbit model showed that prolonged and stable expression 
of IL-10 in rabbit carotid arteries achieved with a helper-dependent adenoviral vector had 
neither an atheroprotective effect nor any effect on adhesion molecules or any other 
atherogenic cytokines (Du et al., 2011). Possible explanation accounting for the discrepant 
results may be inadequate protein expression in vivo or lack of suitability of this rabbit 
model to detect IL-10’s therapeutic effects. This study suggests that gene therapy involving 
IL-10 delivery may bring about different results in different species.  
4. Therapeutic considerations 
In light of the findings that systemic and intralesional delivery of IL-10 can be anti-
atherogenic, it is tempting to speculate that IL-10 treatment may have the potential to be a 
novel therapeutic agent against atherosclerosis in the future. IL-10 expression after 
intramuscular DNA electrotransfer or other techniques leads to a persistent expression of 
this protective cytokine in circulation and in local lesion (Deleuze et al., 2002; Han et al., 
2010; Pinderski et al., 2002). It is likely that systemic delivery of IL-10 will result in 
suppression of immune response and increase the opportunity of infection, particularly 
involving intracellular pathogens such as Chlamydia and Listeria monocytogenes (Terkeltaub, 
1999). Compared with systemic delivery of IL-10, local expression of IL-10 in atherosclerotic 
lesions may have much less impact on the general immune response. On the other hand, a 
robust local expression driven by retrovirus or adenovirus makes it difficult to regulate IL-
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safety and effectiveness of exogenous IL-10 administration utilizing these techniques will 
need to be evaluated in the future before they are adopted in human patients for the 
treatment of atherosclerosis.  
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1. Introduction 
1.1 Inflammation in atherosclerosis 
Inflammation is a process integral to atherosclerosis, a concept that dates back from the studies 
by Ross (1999). Since then, circulating markers have been established as predictive to 
atherosclerosis and its clinical events (Hansson et al., 2005; Packard & Libby, 2008).  
Accumulated subendothelial lipid, particularly if oxidized, exacerbates the local inflammatory 
reaction and maintains activation of the overlying endothelium (Tiwari et al., 2008). Atheroma 
formation involves expression of selectins and adhesion molecules and also expression of 
chemokines, in particular monocyte chemoatractant proteins-1 (MCP-1). Chemokines are 
proinflammatory cytokines that function in leukocyte chemoattraction and activation. 
Atheroma prone mice lacking MCP-1 develop smaller atherosclerotic lesions than those 
expressing MCP-1. Once captured at the vascular wall, inflammatory cells migrate into the 
subendothelial space where, under the influence of local chemokines, they become activated. 
There the monocytes mature into macrophages and express the necessary scavenger receptors 
to ingest modified lipids and become macrophage foamy cells. The predominant role of the 
macrophages in atherosclerosis is to ingest and dispose of atherogenic lipids. However, 
activated macrophages and T cells also express a variety of proinflammatory cytokines and 
growth factors that may contribute to atherosclerotic plaque formation. The progression of an 
atherosclerotic plaque is best understood in terms of dynamic interaction between a 
subendothelial inflammatory stimulus and the local reactive “wound healing” response of 
surrounding vascular smooth muscle cells (VSMCs) (Clarke & Bennett, 2006).  
Inflammation produces reactive oxygen species (ROS) as a by-product, and antioxidant 
therapeutic  strategies may have proved disappointing possibly because oxidative events are a 
consequence, rather than a cause of atherosclerosis. In this scenario, ROS scavenging would 
have little impact on the disease process. This notion is consistent with the observation that the 
relationship between the risk factors of atherosclerosis and inflammation is tight, in that all of 
the established cardiovascular disease risk factors are predictive of circulating inflammation 
markers. Also, modification of atherosclerotic risk factors by lipid lowering therapies, 
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1. Introduction 
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by Ross (1999). Since then, circulating markers have been established as predictive to 
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formation involves expression of selectins and adhesion molecules and also expression of 
chemokines, in particular monocyte chemoatractant proteins-1 (MCP-1). Chemokines are 
proinflammatory cytokines that function in leukocyte chemoattraction and activation. 
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subendothelial inflammatory stimulus and the local reactive “wound healing” response of 
surrounding vascular smooth muscle cells (VSMCs) (Clarke & Bennett, 2006).  
Inflammation produces reactive oxygen species (ROS) as a by-product, and antioxidant 
therapeutic  strategies may have proved disappointing possibly because oxidative events are a 
consequence, rather than a cause of atherosclerosis. In this scenario, ROS scavenging would 
have little impact on the disease process. This notion is consistent with the observation that the 
relationship between the risk factors of atherosclerosis and inflammation is tight, in that all of 
the established cardiovascular disease risk factors are predictive of circulating inflammation 
markers. Also, modification of atherosclerotic risk factors by lipid lowering therapies, 





of inflammation. These and other findings suggest that inflammation is a primary process and 
oxidative stress is only secondary one in relation to atherosclerosis (Rodriguez-Moran et al., 
2003). Nevertheless, traditional anti-inflammatory therapies do not add to the recovery 
process, moreover, they may even slightly exacerbate atherosclerotic events (Libby et al., 2011).  
1.2 Therapeutic strategies in atherosclerosis 
The presence and biological consequences of DNA damage in atherosclerosis imply that 
both prevention and reversal of damage are therapeutic aims. In vitro, antioxidants can 
ameliorate ROS-induced DNA damage, even though antioxidant trials in humans have been 
disappointing so far. Whereas high dietary intake of vitamin E and C is associated with 
reduced risk of cardiovascular disease (CVD), well powered clinical trials in atherosclerosis-
related CVD have indicated that supplements with vitamin C or vitamin E alone do not 
provide sufficient benefit, in comparison to, for example, statins (Kunitomo et al., 2009). 
Specific antioxidants scavenge or metabolize some, but not all of the relevant oxidized 
species. For example, radical scavengers will limit lipid peroxidation, but will have no 
effects on protein modification by peroxinitrite (ONOO-), cell signalling by H2O2, or HOCl 
mediated oxidation reaction. Thus, whenever a physiological process goes unchecked in 
case of disease, strategies that rely simply on scavenging the offending species must be 
employed with extreme caution (Stocker and Keaney, 2005). 
In contrast, cholesterol lowering by diet is associated with a reduction in DNA damage, at 
least in animal models (Singh et al., 2009). Drugs that have been proven to alter plaque 
progression have also been shown to alter vascular oxidative stress. In particular, 3-
hydroxy-3-methylglutaryl coenzyme A (HMGCoA ) reductase inhibitors (Statins) reduce 
NAD(P)H oxidase activation and superoxide production in vitro, in part because of their 
capability to inhibit membrane translocation (and thus activity) of the small GTP-binding 
protein Rac-1, which is a regulatory component  of vascular NAD(P)H oxidase activation 
(Cosotpoulos et al., 2008). Another trial, which investigated the use of niacin combined with 
a prostaglandin D2 receptor antagonist, intended to reduce cutaneous flushing, and has 
shown durability of benefit (Insull, 2009; Libby et al., 2011). Namely, together with lipid 
lowering therapy acute clinical benefits were cumulative, but tolerability issues has limited 
its use. Understanding the non-lipid associated events in atherogenesis raises the prospect 
of developing drugs targeted at specific events in its pathogenesis which might act 
synergistically with lipid lowering drugs to enhance plaque stability (Singh et al., 2009).  
1.3 Translocator Protein 18 kDa (TSPO) as a potential participant in atherosclerosis 
It was shown previously that the 18 kDa translocator protein (TSPO) is present throughout 
the cardiovascular system and may be involved in cardiovascular disorders such as 
ischemia. At cellular levels TSPO is present in virtually all of the cells of the cardiovascular 
system, where they appear to take part in responses to various challenges that an organism 
and its cardiovascular system face (Veenman & Gavish, 2006), including atherosclerosis and 
accompanying symptoms (Onyimba et al., 2011; Bird et al., 2010; Dimitrova-Shumkovska et 
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Mitochondrial membranes form the primary location for TSPO (Anholt et al., 1985). The 
present name of the TSPO, translocator protein, was chosen because of the TSPO’s 
capability to transport molecules over the outer the mitochondrial membrane 
(Papadopoulos et al., 2006).  For example, TSPO is known to transport cholesterol over the 
outer the mitochondrial membrane. At the mitochondria, TSPO are closely associated 
with the 32 kDa voltage-dependent anion channel (VDAC) and the 30-kDa adenine 
nucleotide translocator (ANT) ( Mc Enery et al., 1992; Veenman et al., 2007; Figure 1). 
VDAC and ANT are considered to form the core components of the mitochondrial 
permeability transition pore (mPTP) (Galiegue et al., 2003).  The ratio of TSPO to VDAC 
and ANT appears to be tissue- and treatment-dependent (Golani et al., 2001; Veenman et 
al., 2002). The mitochondrial location of the TSPO is interesting in relation to 
cardiovascular diseases, as it is well known that mitochondria are a main source of 
cellular ROS (Lenaz, 1998).  Furthermore, several studies have shown that the TSPO 
appears to be a participant in ROS generation at mitochondrial levels (Veenman et al., 
2008,2010a; Zeno et al., 2009; Choi et al., 2011). As discussed above, ROS may play a role 
in cardiovascular diseases.   
Furthermore, by its interactions with the VDAC and the ANT, the TSPO is able to modulate 
the flow of electrolytes over the outer and inner mitochondrial membranes and participate 
in the collapse of the mitochondrial membrane potential (Kugler et al., 2008; Zeno et al., 
2009).  In this context, TSPO is a participant in the initiation of mitochondrial apoptosis 
cascade, including release of cytochrome c from the mitochondrial membrane potential 
(Levin et al., 2005; Kugler et al., 2008; Veenman et al., 2010).  It has been suggested that the 
role of TSPO in importing proteins and cholesterol into the mitochondria may partake in 
mitochondrial membrane biogenesis, required for cell growth and proliferation 
(Papadopoulos et al., 2006; Veenman et al., 2007).  Even though many functions were 
attributed to the TSPO, its primary roles are still discussed and the mechanisms whereby 
TSPO takes part in many of these functions still need further clarification (Veenman & 
Gavish, 2006; Veenman et al., 2010b).  Because TSPO appear to be involved in a large variety 
of physical diseases, mental disorders and responses to stress, clinical benefit may be 
attainable by increasing knowledge regarding the TSPO.  Including its  involvement in 
cardiovascular disorders. 
TSPO are found throughout the animal kingdom, including insects, mollusks, pisces, 
amphibians, aves and mammals (Peterson et al., 1988; Veenman et al., 2007), yet have not 
been found in reptiles as to date (Bolger et al., 1986).  Widely expressed throughout the 
body, TSPO exhibit different patterns of tissue specific expression (Golani et al., 2001; 
Veenman et al., 2002).  In vivo studies showed the rank order of TSPO binding density in rats 
to be adrenal >> kidney ~ heart ~ testis ~ ovary >> liver ~ brain (Awad & Gavish, 1987; 
Gavish et al., 1999).  In humans and dogs, the heart appears to be one of the organs with 
high TSPO density (Veenman & Gavish, 2006). 
The rat TSPO protein consists of 169 amino-acids, is highly hydrophobic, and is rich in 
tryptophan. TSPO appears to constitute a five α-helical transmembrane structure that 
stretches the outer mitochondrial membrane.  The human homologous TSPO also consists of 
169 amino-acids, including two cysteine residues that may allow for S-nitrosylation of the 
protein. (Gavish et al., 1999; Babbage, A. Direct Submission, GenBank: CAB55884.1, 2009).  
The TSPO gene is conserved from prokaryotes to plants and animals, including humans and 
appears to have the hallmarks of a typical housekeeping gene, suggesting that this gene’s 
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Fig. 1. TSPO structure, localization and functions.  TSPO molecules are often found in 
groups and in conjugation with VDAC and ANT.  As indicated in the figure, pk10, PRAX-1, 
and PAP7 face the cytosol.  Furthermore, molecules of the Bcl-2 family and creatine kinase 
and hexokinase can be attached to VDAC and ANT.  The TSPO is involved in various 
functions some of which are indicated towards the bottom of the figure.  The encircled 
functions may relate to an association of the TSPO with cardiovascular pathology.  
Abbreviations: ANT, adenine nucleotide transporter; ATP, adenosine triphosphate; DBI, 
diazepam binding inhibitor; PAP7, PBR associated protein 7; PBR, peripheral-type 
benzodiazepine receptor; pk10, protein of 10 kiloDalton; PLA2, phospholipase A2; PRAX-1, 
PBR associated protein 1; TSPO, translocator protein (18-kDa); TTN, triakontatetra-
neuropeptide; VDAC, voltage dependent anion channel  (Veenman et al., 2007). 
Recently, TSPO has been found to occur not only in the 18 kDa form, but also as 36-, 54-, and 
72 kDa TSPO polymers (Delavoie et al., 2003).  This topic has arisen from the electron 
microscopic observation that the 18 kDa TSPO protein was organized in clusters of 2-7 
molecules on Leydig cell mitochondrial membranes (Papadopoulos et al., 1997). It was also 
suggested that free TSPO (meaning not in complex with VDAC and ANT) may be present in 
mitochondrial membranes (Veenman et al., 2002; Liu et al., 2003).  This claim further takes into 
consideration that modulation of steroidogenesis only requires a mitochondrial channel that is 
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formed by the mitochondrial TSPO, without participation of VDAC and ANT (Papadopoulos 
et al., 2006). It should be noted that, apart from mitochondria, TSPO can be found in various 
other subcellular locations (Veenman & Gavish, 2006). Nuclear/perinuclear-located TSPO, for 
example, is considered to play a part in cell proliferation (Brown et al., 2000).  Other studies 
detected TSPO binding in plasma membrane and in mature human red blood cells, which lack 
mitochondria (Oke et al., 1992). It has been suggested that intracellular locations of the TSPO in 
human lymphocytes might be correlated with its capacity to bind to various endogenous 
TSPO ligands at these locations, and that this capability might be related to the ratio of TSPO 
to VDAC and ANT in such locations (Gavish et al., 1999). 
1.3.2 General TSPO functions  
TSPO have been implicated in various functions (Figure 1), including apoptosis, 
steroidogenesis, oxidative stress, mitochondrial respiration, modulation of voltage 
dependent calcium channels, effects on the immune and phagocyte host-defence response, 
microglial activation related to brain damage, ischemia, regulation of the mitochondrial 
membrane potential, inflammation, cell growth and differentiation, and cancer cell 
proliferation (For reviews, see: Gavish et al., 1999; Veenman & Gavish, 2006, 2011; Veenman 
et al., 2007, 2008, 2010b, 2011).  TSPO may potentially be involved in the regulation of 
several major stress systems, such as the Hypothalamic-Pituitary-Adrenal (HPA) axis, the 
sympathetic nervous system, the renin-angiotensin axis and the neuroendocrine-immune 
axis (Gavish et al., 1999; Veenman and Gavish, 2000, 2006). Thus, TSPO possibly plays a role 
in the mediation of organisms’ various adaptations to stress and anxiety disorders.  
In the endocrine system, TSPO is well known to participate in steroid production and may 
also play a role in the host-defence response (Papadopoulos et al., 2006).  The presence of 
TSPO in glia of the central nervous system (CNS) has suggested that they might also be 
involved in glial functions in the brain. In neurodegenerative disorders, including 
Alzheimer’s disease, TSPO ligand binding density is increased in the affected brain regions. 
Thus, it has been suggested that TSPO in glia may play a role in neurodegenerative 
processes and brain damage. In animal studies, both PK 11195 and Ro5-4864 presented 
neuroprotective effects against brain injury, which have been suggested to involve 
neurosteroid activation (Veenman et al., 2002; Veenman & Gavish, 2006, 2011; Soustiel et al., 
2008). Alternatively, it has been suggested that enhanced levels of TSPO in neural cells (due 
to damage, disease, etc.)  are inductive for apoptosis.  In particular, activation of the TSPO 
may lead to a decrease of the mitochondrial membrane potential, mitochondrial 
dysfunction, and subsequent release of mitochondrial cytochrome c, followed by the 
activation of a caspase cascade leading to apoptosis (Levin et al., 2005).   
Interestingly, as ROS generation accompanies in cardiovascular diseases, it has also been 
shown that oxidative stress modulates TSPO structure and function (Delavoie et al., 2003).  
Vice versa, TSPO appears to be an essential participant in ROS generation at mitochondrial 
levels induced by various agents (Veenman et al., 2008, 2010a; Zeno et al., 2009; Choi et al., 
2011).  In addition, Carayon et al. (1996) demonstrated that Jurkat cells transfected with 
human TSPO cDNA exhibited increased resistance to H2O2 toxicity, suggesting a function of 
these sites and their ligands in protecting cells against the toxicity of ROS produced during 
inflammatory processes.  In the liver, the TSPO was found in co-localization with a ROS 
scavenger, the mitochondrial manganese-dependent superoxide dismutase (SOD) (Fischer 
et al., 2001). At present, no conclusive model is available to incorporate the various 
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1.3.3 Cholesterol translocation and steroidogenesis in relation to TSPO 
TSPO has been reported to take part in the translocation of cholesterol from the outer to the 
inner mitochondrial membrane, which is the rate-limiting step in steroidogenesis 
(Papadopoulos et al., 1990).  The fact that TSPO is abundant in steroidogenic endocrine 
organs (Benavides et al., 1983; Gavish et al., 1999; Papadopoulos et al., 2006), such as the 
adrenal gland and male and female gonads in rats, has been the first suggestion that TSPO 
may play a role in steroidogenesis.  
The biosynthesis of steroids in all steroidogenic tissues begins with the enzymatic conversion 
of the precursor cholesterol to form pregnenolone.  This reaction is catalyzed by the enzyme 
cholesterol side-chain-cleavage (P-450scc), which is located on the matrix side of the inner 
mitochondrial membrane and is dependent on an electron transport system comprised of 
adrenodoxin and adrenodoxin reductase. Pregnenolone leaves the mitochondrion to undergo 
enzymatic transformation in the endoplasmic reticulum, giving rise to the final steroid 
products (Papadopoulos et al., 2006; Veenman et al., 2007).  The rate-limiting step in this 
process, is the transport of cholesterol from cellular stores across the aqueous intermembrane 
space of the mitochondria to the inner mitochondrial membrane and P-450.  
It has been suggested that TSPO and StAR (steroidogenic acute regulatory protein), the latter 
which is involved in the acute trophic hormone regulation of steroid synthesis, work together 
in the cholesterol transport into the mitochondria (Stocco & Clark, 1996).  Steroids have also 
been shown to be able to affect TSPO ligand-binding characteristics (Veenman et al., 2007), for 
example, as demonstrated by a 10-day estradiol treatment of rats that resulted in a marked 
reduction in TSPO binding in the rat testis, and up regulation of these sites in the kidney 
(Gavish & Weizman, 1997).  Other observations were provided by the removal of the testes, 
which caused a significant decrease in TSPO density in Cowper's glands and the adrenal 
gland, while administration of testosterone acetate prevented this castration induced TSPO 
depletion (Weizman et al., 1992).  Furthermore, removal of the pituitary gland, which resulted 
in the elimination of corticotrophin (ACTH) secretion, caused a significant reduction in the 
adrenal TSPO density (Anholt et al., 1985).  Recently, it has been shown that steroid treatment 
can regulate gene expression of the TSPO (Mazurika et al., 2009). 
Three-dimensional models of the channel formed by the five α-helices of the TSPO indicated 
that it would be able to accommodate a cholesterol molecule in the space delineated by the 
five helices. According to these models, the inner surface of the channel formed by the TSPO 
molecule would present a hydrophilic but uncharged pathway, allowing amphiphilic 
cholesterol molecules to cross the outer mitochondrial membrane (Papadopoulos et al., 2006; 
Veenman et al., 2007).  
TSPO ligands are reported to induce TSPO-mediated translocation of cholesterol from the 
outer mitochondrial membrane to the inner mitochondrial membrane (Papadopoulos et al., 
1997).  Moreover, PK 11195 and Ro5-4864 (the classical specific TSPO ligands) increased 
cholesterol transport into the mitochondria and subsequent steroid synthesis in gonadal, 
adrenal, brain, and liver cells (Delavoie et al., 2003).  Ro5-4864 directly stimulated the release 
of corticotrophin releasing hormone (CRH) in rats, whereas PK 11195 directly stimulated the 
secretion of ACTH.  In various models of induced stress in rats, the increase in CRH and 
ACTH was attenuated by treatment with diazepam. It was reported that the presence of the 
endogenous ligand DBI was vital for steroidogenesis and stimulated cholesterol transport.  
DBI regulated steroidogenesis activated by ACTH and luteinizing hormone via binding to 
TSPO, and thus controlled mitochondrial cholesterol transport (Papadopoulos et al., 1991; 
Brown et al., 1992).  
 




Fig. 2. Proposed model of cholesterol and ligand binding to TSPO.  TSPO is found either as a 
monomer or polymer in the outer mitochondrial membrane.  Binding of cholesterol and 
TSPO ligands to TSPO at this site may result in import of cholesterol or protein into the 
mitochondria.  This may support cellular functions such as membrane biogenesis, 
mitochondrial permeability, and mitochondrial respiration. The final effects may include 
steroidogenesis, apoptosis, and immune responses. Abbreviation:  OMM, outer 
mitochondrial membrane (Veenman et al., 2007).  
The actual participation of TSPO in mitochondrial cholesterol translocation was 
demonstrated by disruption  of the TSPO gene in Leydig cells, which resulted in the arrest 
of cholesterol transport into the mitochondria as well as steroid formation, while the 
reintroduction of TSPO by cDNA rescued steroidogenesis (Papadopoulos et al., 1997).  The 
suggestion of TSPO involvement in steroidogenesis modulated by TSPO ligands was further 
supported by TSPO antisense knockdowns in MA-10 Leydig cells, which reduced steroid 
production (Hauet et al., 2005). 
It has been proposed that TSPO polymerization modulates the function of this receptor in 
cholesterol transport, since polymer formation induced by ROS increased both TSPO ligand 
binding and cholesterol-binding capacities (Delavoie et al., 2003).  The monomer binds 
cholesterol with high affinity but not so with TSPO ligands.  The presence of cholesterol on 
the TSPO monomer prevents the ROS - induced polymer formation.  The polymer binds 
TSPO ligands with high affinity and ligand binding induces rapid cholesterol binding.  This 
process would allow a membrane that contains TSPO to import high levels of cholesterol in 
a time and ligand dependent manner. Apart from the significance of cholesterol transport by 
TSPO for steroidogenesis, it may also be relevant for membrane biogenesis and metabolic 
needs required for cell survival (Veenman et al., 2007).  TSPO’s interactions with cholesterol 
may be suggestive of a role of TSPO in atherosclerosis. 
1.3.4 TSPO and responses to cardiovascular damage 
In the cardiovascular lumen, TSPO are present in platelets, erythrocytes, lymphocytes, and 
mononuclear cells (Maeda et al., 1998).  In the walls of the cardiovascular system, TSPO can 
be found in the endothelium, the striated cardiac muscle, the vascular smooth muscles, and 
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Fig. 2. Proposed model of cholesterol and ligand binding to TSPO.  TSPO is found either as a 
monomer or polymer in the outer mitochondrial membrane.  Binding of cholesterol and 
TSPO ligands to TSPO at this site may result in import of cholesterol or protein into the 
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steroidogenesis, apoptosis, and immune responses. Abbreviation:  OMM, outer 
mitochondrial membrane (Veenman et al., 2007).  
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diseases, the TSPO has been found to be involved in ischemic processes, including oxidative 
stress and apoptosis (Kunduzova et al., 2004).  Furthermore, TSPO may be involved in aortic 
damage due to diet and toxins (Dimitrova-Shumkovska et al., 2010a,b,c).   
TSPO in the cardiovascular system appears to play roles in several aspects of the immune 
response, such as phagocytosis and the secretion of interleukin-2, interleukin-3, and 
immunoglobulin A (Veenman & Gavish, 2006).  Mast cells have been implicated in immune 
responses to pathogens, in the regulation of thrombosis and inflammation, and in 
cardiovascular disease processes such as atherosclerosis, as well as in neoplastic conditions 
(Wojta et al., 2003; Marshall, 2004).  Studies have shown that the benzodiazepines’ inhibition 
of serotonin release in mast cells could reduce the blood brain permeability and influence 
pain levels and decrease vascular smooth muscle contractions (Veenman et al., 2006).  
Benzodiazepines have been found to bind to specific receptors on macrophages and to 
modulate in vitro their metabolic oxidative responsiveness (Lenfant et al., 1985).  Since these 
tissues and cells possess TSPO, but not CBR, it is most likely that these benzodiazepines 
cause their effects via the TSPO present in these tissues and cells. 
Recently, we have established that the TSPO appears to be an active participant in the 
generation of ROS at mitochondrial levels and maintenance of the mitochondrial membrane 
potential, in relation to apoptosis (Kugler et al., 2008; Zeno et al.,  2009).  In turn, ROS levels 
also affect TSPO function (Delavoie et al., 2003).  As a result of this, we suggest that the 
TSPO may be involved in oxidative stress related to cardiovascular disorders. 
1.3.5 TSPO ligands 
A wide variety of endogenous molecules with affinity for the TSPO have been identified, 
including Diazepam Binding Inhibitor (DBI), which is an 11 kDa polypeptide of 86 amino 
acids.  As its name suggests, DBI was originally shown to inhibit the binding of [3H] 
diazepam to brain membranes and gamma aminobutyric acid (GABA) activated Cl - 
channel activation. DBI has the same low (µM) affinity for both the TSPO and the CBR.  
Other putative endogenous ligands  for TSPO include the porphyrins (protoporphyrin IX, 
mesoporphyrin IX, deuteroporphyrin IX and haemin), which are known to modulate 
enzymatic activity of several enzymes and are involved with several mitochondrial proteins 
(Gavish et al., 1999; Zeno et al., in press).  These compounds exhibit a very high (nM) 
affinity for TSPO, and hence are considered as putative endogenous TSPO ligands (Verma et 
al., 1987). Regarding synthetic ligands, the TSPO exhibits nanomolar affinity to the 
benzodiazepine Ro5-4864 (4’- chlorodiazepam, Figure 3), but low affinity to most other 
benzodiazepines species (Le Fur et al., 1983).  Furthermore, it has been reported that 
isoquinolines, such as 1-(2- chlorophenyl)-N-methyl-N-(1-methyl-prop 1)-3 isoquinoline-
carboxamide (PK 11195, Figure 3) interact specifically with TSPO (Le Fur et al., 1983; 
Gavish, 2006Veenman &) and that PK 11195 is currently the most widely used TSPO ligand, 
in part due to its high affinity for TSPO for all of the studied species (Le Fur et al., 1983; 
Veenman & Gavish, 2006).   
PK 11195 and Ro5-4864 compete with each other in binding experiments, suggesting 
overlapping but not necessarily identical binding sites.  It has been suggested that they 
interact with two different conformations or domains of the mitochondrial TSPO (Awad & 
Gavish, 1987).  Behavioral studies have demonstrated that Ro5-4864 possesses anxiogenic 
and convulsant properties, whereas PK 11195 has been found to be anxiolytic and 
anticonvulsant (Gavish et al., 1999).  Other studies have shown that Ro5-4864 and PK 11195 
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have identical effects, for example inhibition of apoptosis (Kugler et al., 2008).  These effects 
are similar to, albeit less strong than TSPO knockdown, implying that these TSPO ligands 
block the pro-apoptotic functions of the TSPO (Levin et al., 2005; Zeno et al., 2009).   
 
 
Fig. 3. Chemical structures of the two archetypical TSPO ligands: (A) the benzodiazepine, 
Ro5-4864; and (B) the isoquinoline carboxamide, PK 11195. 
In some cases, various effects of TSPO ligands have been observed in TSPO deficient and 
TSPO knockdown cells (Hans et al., 2005), raising the issue of the possible presence of 
TSPO-independent mechanisms of action of these ligands (Falchi et al., 2007). 
The effects induced by TSPO ligands have been widely investigated in steroidogenic cells 
(Gavish et al., 1999; Casellas et al., 2002).  In addition, effects of TSPO ligands have been 
studied in non-steroidogenic cells, including cardiovascular tissues:  1)  they were shown to 
modulate physiological mechanisms such as cellular respiration in heart, kidney, and liver 
(Moreno-Sanchez et al., 1991; Veenman & Gavish, 2006),  2)  generation of ROS in neurons and 
HL60 human leukaemia cells (Fennell et al., 2001; Jayakumar et al., 2002), 3) anion transport in 
kidney (Basile et al., 1998),  4) mitochondrial permeability transition in cardiomyocytes (Chelli 
et al., 2001),  5)  inhibition of cell proliferation in human fibroblasts (Kletsas et al., 2004), and  6)  
apoptosis in various cell lines (Decaudin et al., 2002; Chelli et al., 2004). 
Numerous findings have suggested that TSPO ligands might act as potential therapeutic 
agents that may be useful for the treatment of a large spectrum of diseases.  TSPO drug 
ligands are evaluated regarding their ability to regulate neurosteroid synthesis and brain 
function, to detect tumor cells in vivo, and to modulate apoptotic rates, with major potential 
therapeutic implications for cancer therapy (Galiegue et al., 2003). PK 11195 has been 
administrated safely to patients, and has been suggested to be included in clinical trials as a 
chemo sensitizing agent. In addition, alternative TSPO ligands with potential therapeutic 
effects are being developed in various laboratories. 
2. TSPO binding density decreases in aorta due to atherogenic challenges 
By its very nature, plaque rupture is difficult to study directly in humans. Therefore, animal 
models have been developed to study atherosclerosis, including plaque rupture and 
thrombus formation, and also how to take measures to prevent these from happening.  
However, all of the existing models (biological or mechanical triggering models, the 
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mouse model, and the LDL-receptor mouse model) suffer the drawback of lacking an end-
stage atherosclerosis that would show plaque rupture accompanied by platelet and fibrin-
rich occlusive thrombus at the rupture site (Singh et al., 2009). This is a very important 
limitation. There are additional disadvantages of the existing models, such as long 
preparatory activities, complicated manipulation, high cost of development, low yield of 
triggering, and high mortality, which hamper the execution of large-scale studies. Also, the 
study of human tissue in in vitro cell systems is limited by the obvious fact that these are not 
whole organisms, accompanied by the inherent problem of drifting phenotypes. 
For the present study, regarding the potential involvement of the TSPO in atherosclerosis, 
we used outbred rats (Wistar) to study dietary factors applied by us that contribute to 
cardiovascular damage.  We chose these outbred rats since they are atherosclerotic non - 
prone animals and under normal circumstances they typically do not show cardiovascular 
damage within the time-frame we applied. Although the use of rodents as a model may 
have some limitations to achieve complete understanding of the diet - disease relations in 
humans, it presents a unique opportunity to simultaneously explore several underlying 
mechanisms in vivo in the whole organism which is otherwise difficult to achieve with other  
approaches (Dorfman et al., 2003). 
Classes of risk factors for cardiovascular disorders (CVD), also named “cardiovascular toxins”, 
are presented by environmental pollutants with very well known carcinogenic effects (Iwano et 
al., 2006). Not only may pollutants exacerbate and accelerate CVD, risk factors associated with 
CVD could predispose and sensitize for pollutant toxicity. Chronic hypercholesterolemia, for 
instance, could significantly affect xenobiotic metabolism and disposition by either altering the 
expression of detoxification enzymes in liver and peripheral tissues, or by providing additional 
circulating nucleophylic binding sites, e.g., lysine residues of apolipoprotein and ethanolamine 
phospholipids (Miyata et al., 2001; Miller and Ramos, 2001).   Realizing the need to study 
cardiovascular toxicity as a significant consequence of exposure to environmental pollutants, 
one of the aims of our research was to highlight the effects and cell responses due to exposure to 
carcinogen and air pollutant  7, 12 dimethylbenz [α]anthracene (DMBA) on hyperlipidemic rats 
chronically exposed on high fat high cholesterol (HFHC) diet.  In previous studies we showed 
that HFHC diet as well as DMBA exposure caused oxidative stress in the aorta, in association 
with damage to this organ, as well as reduced TSPO binding density in this organ (Dimitrova-
Shumkovska et al., 2010a,b,c). To further illustrate these effects, we present here data from a 
recent study combining HFHC diet with DMBA exposure. 
To determine the effects of an HFHC diet in combination with DMBA exposure in our 
paradigm of cardiovascular damage, rats received a custom tailored HFHC diet (Dimitrova-
Shumkovska et al., 2010a).  Before application of the HFHC diet, the rats were randomized 
into 2 general groups: 1) control rats (C-rats) receiving commercial standard pellet feed for a 
period of 18 weeks (n = 18); 2) experimental rats (HFHC+DMBA) (n = 12) receiving HFHC 
diet for a period of 18 weeks, and then a single  administration of 10 mg DMBA / 1 mL 
sesame oil applied by gavage), followed by an additional  4 weeks with HFHC diet. After 22 
weeks in total, animals were sacrificed by exsanguination, and procedures related to TSPO 
binding characteristics, ROS parameters in aorta and histopathology were done, as 
described in detail previously (Dimitrova-Shumkovska et al., 2010 a,b,c).   Specimens of 
aorta and plasma were collected for lipid analysis and analysis of parameters of oxidative 
stress. The parameters of oxidative injury that we studied included lipid peroxidation 
(TBARs assay described by Okhawa et al., 1989, modified by Draper and Hadley, 1990); 
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protein carbonylation  (Levine et al., 1990, adopted by Reznick et al., 1994 and modified by 
Shacter, 2000), and advanced oxidized protein products (AOPP, Witko-Sarsat et al., 1996). 
Furthermore, anatomical observation and histopathology of aorta were performed. To 
determine TSPO binding characteristics in this paradigm we applied binding assays with 
[3H]PK 11195. The effects of HFHC diet and of DMBA application by themselves were 
analyzed previously (Dimitrova-Shumkovska et al., 2010 a,b,c).  Building on these previous 
studies, the present study seeks to determine whether the toxin DMBA may exacerbate the 
oxidative stress due to atherogenic diet. 
In the endothelium of the aorta wall of the HFHC+DMBA rats, we observed the appearance 
of foamy cells (20-25% of the lumen circumference, visible among 5 animals from 8 
analyzed). Early mild fibrosis, was observed in 2 of the 8 rats. All the control aortas 
remained negative for these changed, as described before (Dimitrova-Shumkovska et al., 
2010 a, b, c). These present results indicate that combining the HFHC diet with the DMBA 
exposure do not cause more damage to the aorta of rats than previously found with HFHC 
diet alone (Dimitrova-Shumkovska et al., 2010a,b,c).  These previous studies also did show 
that HFHC diet was more damaging to the aorta than DMBA exposure (Dimitrova-
Shumkovska et al., 2010a,b,c)   
Regarding protein oxidation and lipid peroxidation in the aorta (Table 1), in the HFHC + 
DMBA rats significant increases in TBARs, AOPP and PC levels could be observed, 
compared to vehicle control.  In detail, regarding lipid peroxidation, TBARs production was 
significantly increased more than 2 fold (+129%, p < 0.05) in comparison to control (Table 1). 
Regarding protein oxidation, AOPP levels showed a significant more than 3 fold increase 
compared to control (+216%, p < 0.001).  Protein carbonyls (PC) in the aorta showed an 
increase of 47% compared to control. The obtained results were similar to those of the 
HFHC diet only group (Dimitrova-Shumkovska et al., 2010a), but the observed effect of 
enhanced  oxidative stress was higher than in DMBA only treated rats (Dimitrova-
Shumkovska et al., 2010b).   In the control tissue (kidney) such effects differences between 
the HFHC-DMBA and vehicle groups not observed (data not shown).  
 
Variables / Aorta Control HFHC + DMBA 
 TBARs nmol/mg  1.22 ± 0.2 (n=8) 2.8 ± 1.4*    (n=7) 
AOPP   nmol/mg  12.5 ± 4.5 (n=8) 39.5 ± 13.0** (n=7) 
 PC        pmol/mg  63.5 ± 24.0 (n=8) 93.5 ± 24.1*  (n=7) 
Table 1. Effects of HFHC diet combined with a DMBA exposure  (HFHC + DMBA) on aorta 
oxidative stress parameters in rats. Mann Whitney non-parametric test, * p < 0.05, ** p < 0.01. 
Binding assays of the aorta with the TSPO specific ligand [3H]PK 11195 were done to 
determine potential effects on TSPO binding characteristics in HFHC + DMBA treated rats. 
For representative examples, see Figure 4. The kidney was used as a control tissue, where no 
changes were expected.  The Bmax and Kd values for TSPO in the aorta and kidney of control 
rats (Table 2) were in the range of previous described results (Gavish et al., 1999; Dimitrova-
Shumkovska et al., 2010a,b,c). In the present study TSPO binding characteristics of the aorta 
of untreated vehicle rats were as follows:  Bmax = 4100 ± 1400 fmol/mg and Kd = 1.2 ± 0.4 nM 
(Table 2). Regarding the effect of HFHC+DMBA, we observed significantly reduced TSPO 
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Binding assays of the aorta with the TSPO specific ligand [3H]PK 11195 were done to 
determine potential effects on TSPO binding characteristics in HFHC + DMBA treated rats. 
For representative examples, see Figure 4. The kidney was used as a control tissue, where no 
changes were expected.  The Bmax and Kd values for TSPO in the aorta and kidney of control 
rats (Table 2) were in the range of previous described results (Gavish et al., 1999; Dimitrova-
Shumkovska et al., 2010a,b,c). In the present study TSPO binding characteristics of the aorta 
of untreated vehicle rats were as follows:  Bmax = 4100 ± 1400 fmol/mg and Kd = 1.2 ± 0.4 nM 
(Table 2). Regarding the effect of HFHC+DMBA, we observed significantly reduced TSPO 





The TSPO Bmax in aorta of the HFHC+DMBA group (Bmax = 2092 ± 670 fmol/mg) was not 
significantly different from those subjected to HFHC diet alone as reported previously 
(Dimitrova-Shumkovska et al., 2010a,b) or DMBA exposure alone. No significant differences 
were observed between experimental and control groups regarding the Kd (Table 2).  
In contrast to aorta, a highly significant enhancement in the Bmax of TSPO (+ 41%) 
determined with [3H]PK 11195 binding was observed in testis tissue due to the HFHC + 
DMBA treatment, compared to control (data not shown). This was similar to the effects seen 
with HFHC diet alone and DMBA treatment alone (Dimitrova-Shumkovska et al., 
2010a,b,c).  [3H]PK 11195 binding levels in kidney appeared not to be significantly affected 
by the HFHC + DMBA treatment (Table 2).  For all tissues, both in the HFHC + DMBA 
group and control group, Kd values determined with [3H]PK 11195 binding were in the nM 
range (0.8 – 1.9 nM, which is in the range typically observed for [3H]PK 11195 binding 
(Awad & Gavish, 1987; Dimitrova-Shumkovska et al., 2010a,b).  This implies also that all of 




Fig. 4. Representative examples of Scatchard plots (B, D) and saturation  curves (A,C) of 
[3H]PK 11195 binding to membrane homogenates of  aorta, respectively of vehicle control  rats 
(A,B) and of rats exposed to HFHC  and DMBA (C,D).  Abbreviations:  C = vehicle control; 
The experimental group of HFHC+DMBA treatment (HFHC + DS 10 DMBA) is as described 
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  C - Control       HFHC+DMBA 
Tissue  n B max (fmol / mg)  Kd (nmol) n B max (fmol / mg)  Kd (nmol) 
Aorta  10 4100  ± 1400  1.2  ± 0.4  6 2092  ± 670 *  1.4  ± 0.8  
Kidney  7 4270  ± 900  1.9  ± 0.9  7 4543  ± 870  2.8  ± 0.8  
Table 2. Average Bmax values fmoles / mg protein and Kd values (nM) of [3H]PK 11195 
binding to TSPO of aorta and kidney of HFHC+DMBA exposed rats  versus vehicle control 
(C-Control).   Kruskal-Wallis non-parametric, one-way analysis of variance ANOVA was 
used, with Mann-Whitney as the post-hoc, non-parametric test, * p < 0.05. 
3. Discussion 
It is well known that the  TSPO is involved in tumorigenicity and also appears to be 
involved in atherosclerosis (Veenman & Gavish, 2006;  Veenman  et al., 2008; Dimitrova-
Shumkovska et al., 2010a,b,c). Research over the past 30 years has suggested striking 
similarities between the pathways leading to atherosclerosis and cancer (reviews: Ross et al., 
2001; Ramos and Partridge, 2005). Benditt and Benditt (1973) proposed that atherosclerotic 
plaque could be seen as neoplasm of smooth muscle cell origin, thereby paving the way for 
further research on the parallels between atherosclerosis and cancer. In accordance to this 
hypothesis, there is a body of evidence showing that established mutagenic and carcinogenic 
polycyclic aromatic hydrocarbons (PAHs), including methylcholantrene, benzopyrene, and 
DMBA, cause DNA-adducts in atherosclerotic lesions in humans or atherosclerotic prone 
animals (Izzoti et al., 2001; Iwano et al., 2005; Knaapen et al., 2007). Furthermore, smoking 
represents major risk factors for both cardiovascular disease and cancer (Knaapen et al., 2007; 
Catanzaro et al., 2007; Chiang et al., 2009). In addition, several animal studies have shown that 
components in tobacco smoke accelerate atherosclerosis in atherosclerotic prone animals, 
because of an increase in inflammatory cell content in atherosclerotic plaques (Izotti et al., 2001; 
Curfs et al., 2005).  
For this study a HFHC diet was used in order to determine relations between systemic 
hypercholesterolemia, atherogenic pathology and oxidative stress in the cardiovascular 
system, in correlation with modulations in TSPO binding characteristics in these organs 
(Dimitrova-Shumkovska, 2010a).  To observe the development of atherosclerosis in various 
animal models, atherogenic diets containing cholesterol, saturated fat, cocoa butter, and 
chocolate have been applied to vertebrates, including rodents (Faggiotto et al., 1984; 
Dimitrova, 2002; Kitade et al., 2006). Since the rat presents a resistant animal model for 
provoking atherosclerosis, relatively long time-courses are required to induce even 
moderate hypercholesterolemia and triglyceridemia (Nakamura et al., 1989; Lorkowska et 
al., 2006).  Previous studies applying 1 – 2% cholesterol diets did not affect the endothelium, 
even though increased density of lipid loading at the adventitial vasa vasorum could be 
observed (Pisulewski et al., 2006; Lorkowska et al., 2006). Generally, HDL cholesterol is the 
dominating form in rats. Interestingly, increased expression of inflammatory cytokines 
(TNF, IL-1, IL-8 and VCAM-1) and augmented foamy cell formation can be found during 
chronic infection induced by Chlamydia pneumonia in white rats (Aziz, 2006). Furthermore, 
rats show augmented thrombotic response under hypertensive and hyperlipidemic 
conditions (Singh et al., 2009).  These previous studies suggested that rats could present a 
useful model for studying hypercholesterolemia along with hypertension, but not a suitable 
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overcome at least in part the rats’ resistance to elevation of plasma cholesterol levels but also 
initiated moderate cardiovascular damage (Dimitrova-Shumkovska et al., 2010a).   
As a further indication of the validity of the HFHC diet (with 3% cholesterol) applied by us, 
the rats in our study showed obesity as well as hyperlipidemia and steatohepatitis (Dimitrova-
Shumkovska et al., 2010a).  Parameters for enhanced oxidative stress, as we detected in plasma 
of our HFHC rats may correlate with inflammatory processes, including atherogenic effects 
observed by us and others (Witko-Sarsat et al., 1998; Liu et al., 2006; Dimitrova-Shumkovska et 
al., 2010a).  In particular the high AOPP levels observed in the liver, plasma, and aorta, as 
induced by the HFHC diet, may present factors reflecting liver pathology and atherogenesis 
(Watanabe et al., 2004; Oettl et al., 2008; Dimitrova-Shumkovska et al., 2010a).).  In general, the 
involvement of oxidized proteins in atherosclerosis has been studied less than oxidized lipids. 
However, protein oxidation products have been found in the extracellular matrix of human 
and animal atherosclerotic plaques (Woods et al., 2003; Li et al., 2007). The study by Liu et al. 
(2006) was the first to our knowledge to provide in vivo evidence for a causal relationship 
between chronic AOPPs accumulation and atherosclerosis.  This research suggests that 
increases in plasma AOPP, particularly in a hypercholesterolemic environment, accelerate 
atherosclerosis. Interestingly, a study from Wong et al. (2008) showed that protein carbonyls 
are not merely damaging, but can also serve as a second messenger for signal transduction in 
vascular smooth muscle cells.  
Previous studies have shown that the TSPO is present throughout the cardiovascular system 
(Veenman & Gavish, 2006).  Furthermore, the TSPO has been reported to be involved in 
oxidative stress and inflammation. In more detail, the TSPO is involved in various 
mechanisms that also have been found to play a role in atherosclerosis, including oxidative 
stress, ROS generation, inflammation, immune responses, apoptosis, and mitochondrial 
cholesterol transport (Papadopoulos et al., 1997, 2006). Most recent experimental data 
suggest that TSPO plays regulatory roles in adhesion to the extracellular matrix, 
vascularization, heme metabolism, and processes affected by nitrosylation of various 
proteins (Veenman and Gavish, 2011; Zeno et al., 2011; Bode et al., submitted).  Thus, we 
assumed that the TSPO may be involved in cardiovascular disorders as induced in our 
paradigm. 
Oxidative damage mediated by DMBA exposure and HFHC diet presents two examples of 
the plethora of risk factors in provoking atherosclerosis. Different forms of oxidative stress 
may give rise to different oxidation products, several of which were elevated in the aorta of 
our model induced by DMBA exposure and HFHC applied to the rats of this research 
(Table 1). As we used outbred Wistar rats, genetic disposition apparently is not a 
precondition for cardiovascular damage induced by DMBA.  Histopathological analysis of 
the aorta showed that the HFHC + DMBA treatment induced foamy cells and fibrinoid 
connective tissue accumulation, as reported also for the separate treatments of HFHC and 
DMBA by themselves (Dimitrova-Shumkovska et al., 2010a,b,c). Furthermore, in the aorta 
the TSPO expression was inversely correlated with aggravated oxidative stress (Table 2).   
Previous in vitro studies of rat liver have shown as well that particular forms of oxidative 
stress can reduce TSPO binding density in this organ. For example, 0.001 mM Fe [2+] in 
combination with 1 mM ascorbate reduced TSPO binding density by half (Courtiere et al., 
1995).  Interestingly, it was also shown that in response to UV irradiation-induced ROS 
covalent TSPO polymers were formed in Leydig and breast cancer cells in vitro and in vivo, 
resulting in increased binding affinity of the TSPO (Delavoie et al., 2003).  Other evidence 
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for TSPO’s participation in oxidative processes has been indicated in a study by Carayon et 
al. (1996), where a correlation between the levels of TSPO expression and the resistance to 
H2O2 toxicity was demonstrated in hematopoietic cell lines.   It may be considered that the 
reduction in TSPO binding density determined in the present research and other studies 
may impair such protective, anti-oxidative functions of the TSPO (Dimitrova-Shumkovska 
et al., 2010a,b,c). Alternatively, the reduced levels of TSPO may be a compensatory response 
to the challenges posed by the HFHC diet and DMBA exposure, i.e. reduced ROS generation 
otherwise due to TSPO activation and protection against the triggering of cell death, as for 
example was also found in various studies applying knockdown of TSPO by genetic 
manipulation in vitro (Levin et al., 2005; Zeno et al., 2009).  Possibly, the enhanced levels of 
AOPP found in liver and aorta may be a contributing factor to the reduced binding density 
of TSPO in these organs (Dimitrova-Shumkovska et al., 2010a, b,c). As an alternative 
explanation, regulation of TSPO binding density can take place via modulations of gene 
expression (Giatzakis and Papadopoulos, 2004).  With various studies we have 
demonstrated that steroids and stress are able to regulate TSPO binding density (for 
example, Veenman & Gavish, 2006; Veenman et al., 2007, 2009; Mazurika et al., 2009). As 
mentioned, growth hormone may take part in the effects of obesity.  Similarly, testosterone 
levels may also be involved in the effects of atherogenic diet as discussed further below. 
Our previous studies indicated the HFHC diet alone had more profound effects than DMBA 
exposure with a single dose of 10 mg in regard to aortic damage, histopathological changes in 
the liver, and oxidative stress measured in blood plasma and liver of rats (Dimitrova-
Shumkovska et al., 2010a,b,c,).  In the present study, also regarding oxidative stress in aorta, 
effects of HFHC combined with DMBA were more pronounced than of DMBA alone with a 
dose of 10 mg, but not more pronounced than of HFHC alone. The combination of HFHC diet 
and DMBA exposure did not appear to present a major synergetic effect on TSPO binding 
characteristics in the aorta. Possibly TSPO responses in the aorta may be part of a protective 
mechanism against lipid overload.  Others have also suggested a role for TSPO in vascular 
inflammatory responses, for example in vascular permeability caused by carrageenin 
(Lazzarini et al., 2001). Presently, it is not known which components of the vascular wall, i.e. 
mast cells, smooth muscular, or dermal vascular endothelial cells, would be important for the 
potential correlation between TSPO expression and atherosclerosis (Morgan et al., 2004; 
Veenman & Gavish, 2006).  Also, the importance of TSPO in relation to other mechanisms 
potentially associated with cardiovascular damage needs further research.   
As TSPO may be modulated by ROS, and can modulate ROS generation itself (Courtiere et 
al., 1995; Papadopoulos et al., 1997, 2006; Delavoie et al., 2003; Veenman et al., 2007, 2008; 
Zeno et al., 2009), it can be postulated that the oxidative stress detected in aorta of our 
HFHC +DMBA rats may be associated directly with a reduction in TSPO binding density in 
these organs.  While we did not see synergetic effects of HFHC and DMBA in rat aorta, 
preliminary data by us suggest that the combined effect of HFHC and DMBA in rat liver 
may lead to enhanced reductions in TSPO binding densities in this organ, compared to each 
treatment alone (unpublished results).  At present it is not clear whether the TSPO levels 
modulate oxidative stress, or whether TSPO levels are only affected by oxidative stress.  
More studies are needed to resolve these questions.  
As our studies showed an increase in the Bmax of TSPO binding in the testes, it would be 
interesting to study by which mechanisms this may occur.  As discussed above, steroid 
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important positive correlations between high fat saturated supplementation and the levels 
of urinary excretion of testosterone (Hammoud et al., 2006). This is an important point to 
consider in evaluating levels of testosterone bioactivity in the body (Hill et al., 1980). 
Another approach to increase bioavailable testosterone would be to decrease the levels of 
sex-hormone binding globulin (SHBG). Reed et al. (1987) noted that normal men fed with a 
high fat diet showed increased SHBG levels, whereas a diet low in fat resulted in decreased 
in SHBG levels.  It has been reported that decreased SHBG levels result in elevated 
testosterone bioactivity (Longcope et al., 2000).  As with previous studies, showing 
increased TSPO binding density in the testes after DMBA and HFHC exposure (Dimitrova-
Shumkovska et al., 2010a,b,c), also the combination of DMBA and HFHC exposures 
increased TSPO binding density in the testes (unpublished results). Potentially, this may be 
due to changes in testosterone levels, as previous studies have shown that increased 
testosterone can increase TSPO binding levels (Weizman et al., 1992). 
Regarding future studies, it would be interesting indeed to find out whether modulation of 
TSPO responses by TSPO ligands would be able to counteract or enhance the effects of HFHC 
alone or with DMBA exposure.  Similarly, it would be interesting to study in this paradigm the 
effects of hormones, as they are known to affect TSPO expression.  For example, it is known 
that testosterone levels are reduced in humans as well as in rats as a consequence of a fattening 
diet and obesity (MacDonald et al., 2010).  Since reduced testosterone levels are correlated with 
reduced TSPO levels in various tissues (Weizman et al., 1992), this may very well present part 
of the mechanism whereby the HFHC diet and the obesity of the rats of this research may lead 
to reduced TSPO levels in the aorta and liver.  Alternatively, if enhanced oxidative stress in 
our paradigm contributes to changes in TSPO levels in various types of tissue, it will be 
interesting to study TSPO homomer polymerization, a phenomenon that has been reported by 
Delavoie et al. (2003).  The potential appearance of TSPO multimers would suggest whether 
changes in TSPO binding capacity in some of the tissues studied may be due to the oxidative 
stress caused by the HFHC diet.   
4. Conclusions 
Our studies have shown that HFHC diet as well as DMBA exposure of rats can lead to 
oxidative stress in the aorta, as well as a reduction of TSPO binding density.  The 
combination of HFHC diet plus an exposure to DMBA of rats did not affect the studied 
parameters regarding histopathological damage, oxidative stress and TSPO binding 
characteristics in aorta more than the maximal effects achieved by HFHC diet (Dimitrova-
Shumkovska et al., 2010a), although they were higher than with DMBA treatment alone 
(Dimitrova-Shumkovska et al., 2010b).  As addition of DMBA to HFHC treatment does 
not enhance levels of oxidative stress or changes in TSPO binding density in the aorta 
elicited by HFHC alone, this may indicate that HFHC treatment by itself already elicit 
maximal response from the TSPO / oxidative stress “system” in the aorta. Potentially, as 
the effects are not further enhanced, this may mean that the TSPO responses in the aorta 
indeed are a physiological response and do not simply represent damage to the TSPO 
protein (due to oxidative stress or otherwise).  
We consider that the TSPO responses in aorta may present compensatory functions to deal 
with the oxidative stress induced by HFHC diet and DMBA exposure. Alternatively, the 
TSPO response may either be part of the oxidative stress mechanisms, or result from it.  As 
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discussed, TSPO function is not restricted to oxidative stress, but also encompasses adhesion 
to the extracellular matrix, angiogenesis, heme metabolism, protein nitrosylation, apoptosis, 
and immune responses.   
Our research does show that exposure to irritants of the vascular endothelium (metabolical 
of chemical) decreases 18kDa TSPO binding capacity in the aorta. These decreases in TSPO 
binding capacity are potentially related to the oxidative stress in this organ. The data of this 
study suggest that TSPO may present a target for novel therapies designed to reduce the 
risk of atherosclerosis, including its component of oxidative stress.   
5. Summary 
The 18 kDa translocator protein (TSPO) is present throughout the cardiovascular system and 
may be involved in cardiovascular disorders. At cellular levels TSPO is present in virtually 
all of the cells of the cardiovascular system, where they appear to take part in the responses 
to various challenges that an organism and its cardiovascular system face, including 
atherosclerosis and accompanying symptoms.  Several studies have shown that the TSPO 
appears to be a participant in reactive oxygen species (ROS) generation at mitochondrial 
levels.  This may be part of oxidative stress challenges a cell may face.  This potentially may 
play a role in cardiovascular diseases. In this context, TSPO modulates the initiation of 
mitochondrial apoptosis cascade.  Furthermore, TSPO may be a participant in processes 
related to adhesion to the extracellular matrix, vascularisation, heme metabolism, and 
processes affected by nitrosylation of various proteins.  Oxidative damage mediated by 
DMBA exposure and HFHC diet presents two examples of the plethora of risk factors in 
provoking atherosclerosis. Our studies have shown that a high fat, high cholesterol (HFHC) 
diet as well as 7, 12 dimethylbenz[α]anthracene (DMBA) exposure of rats can lead to 
oxidative stress in the aorta, in association with damage to the aorta wall, as well as a 
reduction of TSPO binding density.   We consider that the TSPO responses in aorta may 
present compensatory functions to deal with the oxidative stress induced by HFHC diet and 
DMBA exposure.  Alternatively, the TSPO response may either be part of the oxidative 
stress mechanisms, or result from it.  The reviewed studies suggest that TSPO may present a 
target for novel therapies designed to reduce the risk of atherosclerosis, including its 
component of oxidative stress.   
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disease; DMBA, 7, 12 Dimethylbenz[a]anthracene; DS 10 - single dose of 10 mg  DMBA 
administered (10 mg/ 1ml of sesame oil); GABA, gamma-amino butyric acid; HDL, high-
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NADH, reduced nicotinamide adenine dinucleotide; PAHs, polycyclic aromatic 
hydrocarbons; PBR, peripheral-type benzodiazepine receptor; PC protein carbonyls; PK 
11195, 1-(2- chlorophenyl)-N-methyl-N-(1-methyl-prop 1)-3 isoquinolinecarboxamide; 
ONOO-, peroxinitrite ; Ro5-4864, (4’- chlorodiazepam); ROS , reactive oxygen species; SaβG, 
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thiobarbituric acid reactive substances; TNF, tumor necrosis factor; TSPO, 18 kDa 
translocator protein; VCAM, vascular cell adhesion molecule; VDAC, 32 kDa voltage-
dependent anion channel; VSMCs, vascular smooth muscle cells. 
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Israel 
1. Introduction 
Oxidative stress has long been associated with cardiovascular disease (CVD) (Abuja & 
Albertini, 2001; Halliwell & Gutteridge, 1990; Parthasarathy et al., 2001; Steinbrecher et al., 
1984). It was even assumed that the prevalence of CVD alone indicates the prevalence of 
oxidative stress (Witztum, 1994). Moreover, cross-sectional studies indicated that 
supplementation of low molecular weight antioxidants is associated with a relatively low 
incidence of CVD (Jha et al., 1995). By contrast, in most of the interventional studies the 
antioxidant supplementation did not prevent the progression of CVD nor did it improve 
any of the many clinical endpoints (Shekelle et al., 2004; Vivekananthan et al., 2003; Miller 
2005; Bjelakovic, 2007; Dotan, 2009a; Dotan, 2009b). Based on these findings, Witztum 
(Witztum, 1998) and Morrow (Morrow, 2003) hypothesized that only individuals under 
oxidative stress may benefit from antioxidant supplementation. This, of course, implies that 
only people under oxidative stress should be treated with antioxidants. This, in turn, means 
that a criterion must be established for the ill-defined, intuitively understood term 
“oxidative stress”. 
This issue is of special importance in light of our previous study that demonstrated that no 
single index can be used as a universal criterion, indicating that there are several types of 
oxidative stress (Dotan et al., 2004). Hence, the question remains which criterion (or criteria) 
can be used to identify who is likely to benefit from antioxidant supplementation. The 
answer to this question can, theoretically, be based either on a criterion for the relevant type 
of oxidative stress (e.g. lipid peroxidation, as assessed by the concentrations of MDA or 
isoprostanes) or/and on diagnosis of specific diseases for which there is sufficient evidence 
for benefit of antioxidant supplementation. 
In the current study, we present the results of a meta-analysis of case-control studies used to 
assess the association between CVD and oxidative stress, as evaluated on the basis of 
different criteria. Unlike previous meta-analyses, we analyzed the association between CVD 
and criteria for each of the types of OS. We hope that eventually this analysis will enable us 
to define threshold values of relevant indices of the relevant type of oxidative stress for 
treatment with antioxidants (Deeks, 2001; Deeks & Altman, 2004). 
2. Methods 
This work was performed according to the guidelines outlined by the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) group (Stroup et al., 2000). A detailed 
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description of the data retrieval process, the selection criteria and the analyses of the data is 
given in the following subsections. 
2.1 Retrieval and selection of studies to be included in the analysis 
First, we had to define criteria to be used in our search for clinical trials to be included in our 
meta-analysis (Fig. 1). The following criteria were defined for our search: 
i. Design: only case-control or nested case control studies were included.  
ii. Methods: for a clinical study to be included in our meta-analysis it had to use only 
generally accepted methods for the evaluation of oxidative stress (Dotan et al., 2004). 
iii. Size: to be included in our meta-analysis, the study had to involve at least 20 CVD 
patients and at least 20 “CVD-free” individuals, serving as a control group. 
The latter demand requires further definition of the two populations that can be regarded as 
being “CVD patients” and their respective controls. We included in the control group only 
“pathology-free” individuals. To be included in the group of “CVD patients”, a person had 
to be diagnosed with one of the following conditions: (i) either stable angina pectoris (STP) 
or unstable angina pectoris (UTP), diagnosed either by angiogram or by physical 
examination, (ii) patients suffering from any of the stages of coronary stenosis and (iii) a 
recorded history of CVD (e.g. myocardial infraction). 
With these criteria in mind, we searched through two major databases, namely, the Medline 
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed) 
and the Thomson Reuters ISI Web of Science. Reference mining was conducted to find an 
arbitrarily predefined number of studies (20) that fit all the above selection criteria. We 
defined a list of keywords to search and conducted a simple keyword search, similar to that 
described by Shekelle et al. (Shekelle et al., 2004). 
Data of case-control studies may be biased towards the prevailing paradigm and the 
findings of other recent trials (French et al., 2005; Moher & Tsertsvadze, 2006). Such bias 
must be considered when conducting a search for studies to be included in meta-analyses 
because it may cause a change in the significance of the pooled variables (French et al., 2005; 
Moher & Tsertsvadze, 2006). This is of special importance in the present meta-analysis 
because the prevailing paradigm changed from viewing “oxidative stress” as a cause of 
atherosclerosis (Witztum, 1994) to viewing it as being merely a result of questionable 
significance (Witztum & Steinberg, 2001). In addition, we had to assess the completeness of 
the retrieved data and its validity with respect to the complete body of published data 
(Bennett et al., 2004). Towards this end, we have devised an algorithm similar to the 
“capture-recapture technique” proposed by Spoor et al. (Spoor et al., 1996). Spoor et al. used 
different methods of data retrieval to assess their results. We used, for the same purpose, 
different time frames. Briefly, to achieve as random as possible subset of studies (Furukawa 
et al., 2002), we searched the Medline database to identify studies published between 
1.1.1990 and 1.8.2003 and used studies dating from 1.8.2003 until 1.2.2006 to reassert our 
findings, as proposed by Moher & Tsertsvadze (Moher & Tsertsvadze, 2006). By that, we 
have minimized the bias towards recent publications. 
2.2 Data analysis 
The difference between individuals with prevalent CVD and their controls, as observed in 
each of the selected studies, was expressed in terms of two factors: (i) the standard mean 
difference (SMD), which is a composite index, and (ii) the 95% confidence interval of the 
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SMD, which reflects both the mean difference and the standard deviation. Our study 
required the use of SMD for two reasons: (i) it allows pooling of results obtained from 
different studies and (ii) its use compensates, at least partially, for the use of different 
methods, different units of measurement and inter-lab differences (Deeks et al., 2001). We 
implemented SMD by using "Hedges' adjusted g" because it contains a correction for small 
sample bias (Bennett et al., 2004). 
 
 
Fig. 1. An outline of the flow of studies in the meta-analyses. We identified many 
publications that contained the required sets of keywords (e.g. [CVD or CHD] and oxidative 
stress). 
To pool our results, we have considered two possible models, namely the “fixed effect 
model”, which assumes that all the studies and trials are the repeating of the same 
experiment (Lau et al., 1998) or the “random effects model” of DerSimonian and Laird, 
which assumes that the clinical trials estimate a different, yet related, variables with a 
common distribution (Higgins et al., 2002; Lau et al., 1998). From these two models, we 
chose to use the random effects model, because we expected heterogeneous results from 
observational studies (Egger et al., 1998). In our view, the “fixed effect model” 
oversimplifies the problem and its accuracy has been questioned by others in the same 
context (Lau et al., 1998), particularly when there was a need to pool results of 
heterogeneous populations (Lau et al., 1998). 
In our analyses of the data, we relate not only to the mean value of the pooled variables. We 
also used the collected data to assess the credibility of the results as previously proposed by 
Smith et al. (Smith et al., 1997). Assessment of heterogeneity in a meta-analysis of 
observational studies is as important as the mean results (Egger et al., 1998; Egger et al., 
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difference (SMD), which is a composite index, and (ii) the 95% confidence interval of the 
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SMD, which reflects both the mean difference and the standard deviation. Our study 
required the use of SMD for two reasons: (i) it allows pooling of results obtained from 
different studies and (ii) its use compensates, at least partially, for the use of different 
methods, different units of measurement and inter-lab differences (Deeks et al., 2001). We 
implemented SMD by using "Hedges' adjusted g" because it contains a correction for small 
sample bias (Bennett et al., 2004). 
 
 
Fig. 1. An outline of the flow of studies in the meta-analyses. We identified many 
publications that contained the required sets of keywords (e.g. [CVD or CHD] and oxidative 
stress). 
To pool our results, we have considered two possible models, namely the “fixed effect 
model”, which assumes that all the studies and trials are the repeating of the same 
experiment (Lau et al., 1998) or the “random effects model” of DerSimonian and Laird, 
which assumes that the clinical trials estimate a different, yet related, variables with a 
common distribution (Higgins et al., 2002; Lau et al., 1998). From these two models, we 
chose to use the random effects model, because we expected heterogeneous results from 
observational studies (Egger et al., 1998). In our view, the “fixed effect model” 
oversimplifies the problem and its accuracy has been questioned by others in the same 
context (Lau et al., 1998), particularly when there was a need to pool results of 
heterogeneous populations (Lau et al., 1998). 
In our analyses of the data, we relate not only to the mean value of the pooled variables. We 
also used the collected data to assess the credibility of the results as previously proposed by 
Smith et al. (Smith et al., 1997). Assessment of heterogeneity in a meta-analysis of 
observational studies is as important as the mean results (Egger et al., 1998; Egger et al., 





(Song et al., 2001): (i) χ² (Deeks et al., 2001), (ii) i² (used by the RevMan 4.2.8 software) and 
(iii) log(χ²/DF+1), where DF is the number of degrees of freedom (Deeks et al., 2001), for 
comparing the degree of heterogeneity between heterogeneous results. 
To detect variables that affect our models, we used stratification, clustering of associated 
variables and meta-regression models (Smith et al., 1997; Song et al., 2001). Yet, unlike in the 
case of clinical trials, we analyzed either the complete trial or a specific subgroup within the 
trial (Lau et al., 1998). We also analyzed the correlations between indices of oxidative stress 
and various stages of CVD, to determine causality (Egger et al., 1998; Mulrow, 1994; Smith et 
al., 1997). To assess the effects of exposure variables on the outcome, we used stratification 
for common risk-related variables such as age (in subgroups), gender and history of 
smoking (Smith et al., 1997; Sterne, et al., 2001). We also used stratification for variables 
specific to the pathology (e.g. stable and unstable angina pectoris in CVD), as proposed by 
Smith et al (Smith et al., 1997). We used meta-regression (logistic and multiple linear) to 
model the increase in continuous and ordinal SMD, as well as the annual event rates (Lau et 
al., 1998). We used the observed SMD as our dependent variable and the covariates of 
interest (independent variables) to assess the sources of heterogeneity (Lau et al., 1998). A 
mixed stepwise regression was used to detect trends and factors affecting SMD of MDA 
concentration in CVD (Lau et al., 1998). 
To detect (and assess) the degree of bias in our meta-analyses, we have used both the "Trim 
and Fill method” (Duval & Tweedie , 2000) and a simple funnel plots (Sutton et al., 2000). A 
funnel plot is a regression of each trial's effect size against a measure of its size (e.g. 
1/standard error) (Sutton et al., 2000). An asymmetry in a forest plot is attributed to the high 
probability that smaller studies with less statistical power are not published. Asymmetric 
publications were "trimmed" and then the number of studies missing was calculated. We 
used a simulation to fill the missing studies as described by Duval & Tweedie (Duval & 
Tweedie, 2000), thus verifying our initial assumption. We used additional methods to assess 
the relations between study size and results, mainly because publication-bias is not the only 
reason for asymmetry in funnel plots, and because this method may be subjective and have 
a relatively high false-positive rate of detecting bias (Sterne et al., 2001). We compensated for 
the subjective nature of graphical assessment by using the rank correlation method 
(Thornton and Lee, 2000) and an adjustment of the “Egger’s method” (Egger et al., 1997b). 
Rank correlation is the statistical analogue of the funnel plot, namely a regression of the 
effect size (SMD) against both sizes of study and 1/SE (Thornton and Lee, 2000). We used an 
adjustment of the “Egger's method” to detect publication bias and its direction. We defined 
the standard normal deviate (SND) as the mean difference, divided by its standard error 
regressed against the estimate's precision (Bennett et al., 2004). We defined the threshold p-
value for the intercept at a value of 0.1 to detect possible bias (Bennett et al., 2004). 
3. Results 
As depicted in Fig. 1, we reviewed 172 studies, of which 20 were selected for analysis. These 
chosen 20 studies compared 1068 CVD patients to 2128 matched controls, using 15 common 
indices to assess oxidative stress. A summary of the results is given in Fig. 2 (Akkus et al., 
1996; Cavalca et al., 2001; Chiu et al., 1994; Cipollone et al., 2000; Clejan et al., 2002; Delanty 
et al., 1997; Durak et al., 2001; Ferns et al., 2000; Gackowski et al., 2001; Haidari et al., 2001; 
Halevy et al., 1997; Karmansky et al., 1996; Kesavulu et al., 2001; Kostner et al., 1997; 
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McMurray et al., 1992; Schisterman et al., 2002; Singh et al., 1995; Tamer et al., 2002; Turgan 
et al., 1999; Weinbrenner et al., 2003). 
 
 
Fig. 2. Indices of oxidative stress in cardiovascular disease. We present both graphically and 
numerically the pooled standardized mean difference (SMD) and the 95% confidence 
interval. Also given is the heterogeneity, as defined by χ²/df + 1, of the studies regarding 
each index. Note that MDA is the only accepted index of oxidative stress that shows a mean 
difference greater the 1SMD. 
Given the prevailing paradigm regarding the association between atherosclerosis and lipid 
peroxidation (Witztum & Steinberg, 2001), it is not surprising that MDA was the most 
frequently used index utilized to assess oxidative stress (13/20 studies). Furthermore, only 
MDA exhibited a strong effect size, given by a SMD of 1.60 (0.75 to 2.45). Using the “Trim 
and Fill” method (Duval & Tweedie, 2000) revealed that at least three studies were missing 
from the funnel plot. Adjusting for the latter finding resulted in a much lower SMD of 0.71 
(0.37 to 1.05). The "Egger method" (Egger et al., 1997b) identified an intercept that was 
significant and positive, supporting the conclusion that the previously observed differences 
were overestimated. 
We performed a mixed stepwise regression for MDA concentrations, factoring in age, 
gender, smoking habits, severity of CVD, prevalence of hypertension and diabetes mellitus 
as well as the use of NSAIDs. This analysis indicated that the inclusion of smokers in both 
CVD patients and control groups (estimate1 = -1.3, p =0.04), results in an underestimation of 
the association between CVD and oxidative stress. By contrast, the inclusion of patients with 
both acute (severe CVD) and chronic (mild CVD) coronary syndromes (estimate =3.1, 
p=0.01), results in an overestimation of the latter associations. 
We stratified the results from those studies that assessed MDA concentrations into three 
groups: (i) patients with unstable angina pectoris (UAP), (ii) patients with stable angina 
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pectoris (SAP) and (iii) healthy controls. As seen in Fig. 3, the MDA concentrations of 
patients with SAP are not different from matched controls, whereas UAP patients have 
significantly higher MDA concentrations than both healthy controls and patients with SAP. 
We also stratified the results from two types of studies, those that had acute coronary 
conditions (MI, UAP) and those CVD patients who had chronic coronary conditions (SAP 
and occlusions). As seen in Fig. 4, patients with acute coronary conditions had marked and 
significantly higher MDA concentrations (SMD = 2.30, 0.93 to 3.67) than matched controls. 
By contrast, patients with chronic coronary conditions had only slightly higher MDA 
concentrations (SMD = 0.60,  0.18 to 1.01) as compared with matched controls. 
The concentrations of beta-carotene, as evaluated by Singh et al. (Singh et al., 1995), were 
significantly lower in CVD patients than in matched controls. The difference between the 
concentrations all other low molecular weight antioxidants (LMWA) in patients with CVD and 
healthy controls were not statistically significant (Fig. 2). In six of the seven studies vitamin E 
concentration in CVD patients and controls was similar (SMD = 0.02, -0.17 to 0.21). 
Significantly lower concentrations were observed only by Singh et al. Furthermore, pooling 
the results from all the seven studies failed to achieve statistically significant differences 
(SMD = -0.19, -0.67 to 0.29), although the heterogeneity index substantially increased from 
1.35 to 11.51. The differences between the results of Singh et al. and all other studies cannot 
be attributed either to publication bias or to small-sample bias. A viable possibility is that 
the difference is due to selection bias, particularly by a biased selection of controls. Indeed, 
the major difference between the results obtained by Singh et al. and the results observed in 
all the other studies assessing LMWA was that Singh et al. selected their control group to 
exclude most, if not all of the CVD-related risk factors (smoking, DM and glucose 
intolerance), whereas the CVD patients were not devoid of these risk factors. 
 
 
Fig. 3. A forest plot of studies assessing the differences between patients with stable angina 
pectoris and patients with unstable angina pectoris (upper panel) and comparison of each of 
these groups with controls (two lower panels). 
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Unfortunately, those studies that used either DNA damage or total antioxidant capacity 
(TEAC) to assess oxidative stress in patients with CVD in comparison to healthy controls 
(Fig. 2) were too few and too small to enable any conclusions. 
4. Discussion 
Based on many lines of indirect evidence, oxidative stress has long been associated with CVD. 
The following findings have been considered to lend support to the oxidative theory of CVD: 
(i) oxidized LDL may cause formation of foam cell in-vitro (Chisolm & Steinberg, 2000), (ii) the 
development of atherosclerosis is preceded by an increase of the levels of many indicators of 
oxidative stress in lab animals (Chisolm & Steinberg, 2000) and (iii) the incidence of CVD in 
individuals with low concentrations of antioxidants is relatively high (Chisolm and Steinberg, 
2000). These (and other) findings and clinical trials led researchers to two assumptions: (i) 
oxidative stress plays a pivotal role in the formation of atherogenic plaque and (ii) individuals 
with prevalent CVD are likely to be under oxidative stress and therefore have high plasma 
concentrations of lipid peroxidation products and loss of LMWA. 
The first assumption has long been disputed and is currently under scrutiny (Williams & 
Fisher, 2005). The second assumption is weakened by the results of our current meta-
analysis, which shows that the prevalence of CVD is only slightly associated with OS, as 
defined on the basis MDA concentration. By contrast, no evidence is available for 
association between CVD and OS, as determined on the basis of all other indices of 
oxidative stress. Specifically, the concentrations of almost all the micronutrients in the 
plasma of CVD patients are within normal ranges (Fig. 2), the activities of relevant enzymes 
did not differ from those observed in matched controls (Fig. 2). The same results were 
observed for most of the indices of lipid peroxidation. The only index that is significantly 
different with the prevalence of CVD is the plasma concentration of MDA. Even if we 
choose to ignore the reservations regarding the use of MDA as an index of lipid 
peroxidation (Draper et al., 1993), the possibility of publication bias should not be ignored. 
Hence, we think that the existing evidence for association between oxidative stress and the 
prevalence of CVD is quite weak. In other words, it appears that the role of oxidative stress 
in atherogenesis has been overestimated. In accordance with this conclusion, is the 
viewpoint of the recent review, regarding association of several more OS indices (circulation 
levels of oxidized LDL and myeloperoxidase) with CVD (Strobel et al., 2011). The authors 
conclude that “results of studies using Ox-LDL have been equivocal” and that “the ability of 
oxidative stress biomarkers to predict CVD has yet to be established”. 
The latter considerations accord with the current trend in cardiovascular disease research, 
which views atherosclerosis as mostly an inflammatory disease (Ross, 1999) and implies 
that oxidative stress is a result and not the cause for atherosclerosis. This trend also 
accords with and therefore is strengthened by two of our findings: (i) we observed that 
patients with UAP, a condition commonly associated with acute inflammation, are under 
higher “oxidative stress”, as assessed by the serum concentration of MDA, than both 
patients with SAP and matched controls (Fig. 3) and (ii) we observed that studies 
including more acute conditions are under higher “oxidative stress” than matched 
controls (Fig. 4). 
In our opinion, these findings are of little relevance to the possibility that many individuals 
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Our ongoing research is aimed at developing such an assay (or assays) that can serve as a 
basis for selective antioxidant supplementation. Our working hypothesis is a two step 
approach of identifying those individuals that may benefit from antioxidant 
supplementation. The first step is an initial, short-term treatment with vitamin E. The 
second step should be to assess plasma concentrations of lipid peroxidation products and to 
continue treatment with vitamin E only to individuals, responding to treatment by reducing 
significantly plasma concentration of lipid peroxidation products. In conclusion, we have no 
evidence that justify indiscriminate supplementation of vitamin E, nor do we have sufficient 
evidence to ban it, as recommended by the authors of the Cache County Study (Hayden et 
al., 2007). At present we have no assay that can be used to identify patients that are likely to 
benefit from Vitamin E supplementation. 
 
 
Fig. 4. A forest plot comparing two strata of studies. The first stratum compares the 
differences between patients with either stable angina pectoris or mild occlusions of the 
coronary arteries and healthy controls. The second stratum compares the differences 
between patients with either unstable angina pectoris or MI and healthy controls. Notably, 
while the first stratum of patients with SAP varies slightly from healthy controls, the second 
stratum of patients with UAP shows a significant difference. The two strata differ 
significantly (p = 0.02). 
5. Conclusion 
Our meta-analysis shows that the commonly accepted paradigm regarding the role of OS in 
the pathogenesis of CVD appears to be overestimated. CVD is associated with OS only 
when the evaluation of OS is based on plasma concentrations of MDA. Notably, even this 
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association is questionable due to (i) poor reliability of the laboratory assay of MDA and (ii) 
publication bias. 
Most of the clinical trials that were designed to reduce OS by means of antioxidant 
supplementation yielded disappointing results. The latter results are consistent with the 
results of our meta-analysis. Hence, oxidative stress is only weakly associated with the 
prevalence of cardiovascular disease.  
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approach of identifying those individuals that may benefit from antioxidant 
supplementation. The first step is an initial, short-term treatment with vitamin E. The 
second step should be to assess plasma concentrations of lipid peroxidation products and to 
continue treatment with vitamin E only to individuals, responding to treatment by reducing 
significantly plasma concentration of lipid peroxidation products. In conclusion, we have no 
evidence that justify indiscriminate supplementation of vitamin E, nor do we have sufficient 
evidence to ban it, as recommended by the authors of the Cache County Study (Hayden et 
al., 2007). At present we have no assay that can be used to identify patients that are likely to 
benefit from Vitamin E supplementation. 
 
 
Fig. 4. A forest plot comparing two strata of studies. The first stratum compares the 
differences between patients with either stable angina pectoris or mild occlusions of the 
coronary arteries and healthy controls. The second stratum compares the differences 
between patients with either unstable angina pectoris or MI and healthy controls. Notably, 
while the first stratum of patients with SAP varies slightly from healthy controls, the second 
stratum of patients with UAP shows a significant difference. The two strata differ 
significantly (p = 0.02). 
5. Conclusion 
Our meta-analysis shows that the commonly accepted paradigm regarding the role of OS in 
the pathogenesis of CVD appears to be overestimated. CVD is associated with OS only 
when the evaluation of OS is based on plasma concentrations of MDA. Notably, even this 
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association is questionable due to (i) poor reliability of the laboratory assay of MDA and (ii) 
publication bias. 
Most of the clinical trials that were designed to reduce OS by means of antioxidant 
supplementation yielded disappointing results. The latter results are consistent with the 
results of our meta-analysis. Hence, oxidative stress is only weakly associated with the 
prevalence of cardiovascular disease.  
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1. Introduction 
Eukaryotic cells face constantly the formation of reactive oxygen species (ROS) as a result of 
their aerobic metabolism. ROS play an important role in the regulation of signal 
transduction pathways and gene expression but its over-production is acutely harmful to 
cells, particularly in cardiovascular diseases (CVD) by a mechanism that is not fully 
understood. Most CVD (the leading cause of mortality in developed countries) entail the 
focal development of atherosclerotic plaques in response to various deleterious insults that 
affect the artery wall’s cells (Simionescu, 2007). Atheroma may occlude partially or totally 
the arterial lumen and ultimately, rupture of the vulnerable plaques results in thrombus 
formation and obstruction of the vessels of vital organs like heart, brain, lung, and kidney. 
Atheroma formation is characterized by progressive lipid accumulation in the vessel’s 
intima, dysfunctions of endothelial cells (EC) and smooth muscle cells (SMC), and a strong 
inflammatory reaction with the participation of extravasated immune cells (Fearon & Faux, 
2009). Compelling evidence (including ours) revealed that oxidative stress and NADPH 
oxidase - derived ROS play the key role in all stages of atherosclerosis and that genetic 
ablation of various oxidase components protects the cells against the detrimental effects of 
oxidative stress (Simionescu et al., 2009). Therefore, understanding the molecular 
mechanisms of ROS formation and function is a prerequisite of an effective anti-oxidative 
stress therapy.  
2. Reactive oxygen species formation in the vasculature 
As the name indicates, ROS are a class of highly reactive molecules derived from chemical 
conversion of molecular oxygen (O2). ROS are formed in all the aerobic cells and organisms 
as by-products of metabolic and respiration processes, under the influence of ionizing 
radiation or produced deliberately by specialized enzyme systems. ROS formation is 
initiated by reduction of O2 with one electron leading to the formation of short-lived and 
highly reactive superoxide anion (O2•-). Successive reduction of O2•-, protonation or 
interaction with various converting enzymes gives rise to a large spectrum of molecules 
with diverse physicochemical characteristics such as H2O2 and HO•. The dismutation of 
O2•- to H2O2 can be either spontaneous or catalyzed by specialized enzymes namely, 
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1. Introduction 
Eukaryotic cells face constantly the formation of reactive oxygen species (ROS) as a result of 
their aerobic metabolism. ROS play an important role in the regulation of signal 
transduction pathways and gene expression but its over-production is acutely harmful to 
cells, particularly in cardiovascular diseases (CVD) by a mechanism that is not fully 
understood. Most CVD (the leading cause of mortality in developed countries) entail the 
focal development of atherosclerotic plaques in response to various deleterious insults that 
affect the artery wall’s cells (Simionescu, 2007). Atheroma may occlude partially or totally 
the arterial lumen and ultimately, rupture of the vulnerable plaques results in thrombus 
formation and obstruction of the vessels of vital organs like heart, brain, lung, and kidney. 
Atheroma formation is characterized by progressive lipid accumulation in the vessel’s 
intima, dysfunctions of endothelial cells (EC) and smooth muscle cells (SMC), and a strong 
inflammatory reaction with the participation of extravasated immune cells (Fearon & Faux, 
2009). Compelling evidence (including ours) revealed that oxidative stress and NADPH 
oxidase - derived ROS play the key role in all stages of atherosclerosis and that genetic 
ablation of various oxidase components protects the cells against the detrimental effects of 
oxidative stress (Simionescu et al., 2009). Therefore, understanding the molecular 
mechanisms of ROS formation and function is a prerequisite of an effective anti-oxidative 
stress therapy.  
2. Reactive oxygen species formation in the vasculature 
As the name indicates, ROS are a class of highly reactive molecules derived from chemical 
conversion of molecular oxygen (O2). ROS are formed in all the aerobic cells and organisms 
as by-products of metabolic and respiration processes, under the influence of ionizing 
radiation or produced deliberately by specialized enzyme systems. ROS formation is 
initiated by reduction of O2 with one electron leading to the formation of short-lived and 
highly reactive superoxide anion (O2•-). Successive reduction of O2•-, protonation or 
interaction with various converting enzymes gives rise to a large spectrum of molecules 
with diverse physicochemical characteristics such as H2O2 and HO•. The dismutation of 
O2•- to H2O2 can be either spontaneous or catalyzed by specialized enzymes namely, 





means of various peroxidases such as catalase and glutathione peroxidase or partially 
reduced to HO•, one of the most powerful oxidizing agent identified in biological systems. 
The generation of HO• is mediated by various free transition metal ions (e.g., Fe2+, Cu2+) via 
the Haber-Weiss reaction (Manea, 2010).  
Apart from the aforementioned chemical processing of O2, superoxide can react with other 
molecular species including nitrogen species such as nitric oxide (NO) or polyunsaturated 
fatty acids. The reaction between O2•-   and NO is tightly controlled by the rate of diffusion 
of both radicals, and result in the formation of ONOO- a potent oxidant. Alternative 
reactions may led to the generation of mixed reactive oxygen and nitrogen radicals such as 
nitrogen dioxide radical (•NO2) and nitryl chloride (NO2Cl) (Turrens, 2003).  
Lipid peroxidation products formation represents an important mechanism whereby ROS 
elicit physiological and pathophysiological function in the living cells. ROS (especially HO•, 
•NO2, and ONOO-) may react with polyunsaturated fatty acids present on biological 
membranes or circulating/infiltrated lipoproteins, a condition that facilitate the formation of 
fatty acid peroxyl radical (R-COO-) that can further attack adjacent fatty acid chains and 
trigger the production of other lipid radicals by a chain reaction mechanism (Negre-Salvayre 
et al., 2010; Riahi et al., 2010; Shao & Heinecke, 2009). 
Tyrosyl radicals produced by myeloperoxidase (MPO) have also been shown to be involved 
in the initiation of lipid peroxidation (Hazen et al., 1997). In vitro studies revealed that lipid 
peroxidation occurred only in the presence of free L-tyrosine suggesting that tyrosyl radicals 
formation by MPO are essential mediators for the initiation of lipid peroxidation and 
subsequent LDL oxidation by activated human neutrophils, which contain abundant MPO 
and H2O2 (Savenkova et al., 1994). Tyrosyl radicals have also been shown to play a role in 
LDL oxidation in vivo and in atherogenesis. Analysis of LDL isolated from human vascular 
tissue demonstrated that o,o’-dityrosine levels were 100 times greater than that observed in 
circulating LDL. Similarly, o,o’-dityrosine formation was found to be robust increased in 
atherosclerotic fatty streaks and in advanced atheromas compared to normal aortic tissue, 
indicating that tyrosyl radical formation was capable of protein damage in vivo 
(Leeuwenburgh et al., 1997). 
3. Molecular targets of ROS 
The biological function of ROS is highly regulated by their basic physicochemical properties, 
cellular compartmentalization and the formation rate. Since O2•- is a short-lived charged 
species, it cannot diffuse through biological membranes and acts closeness of the formation 
site. Nevertheless, an anion channel-dependent plasma membrane transport mechanisms 
has been demonstrated to play an important role in mediating cell-to-cell communication. 
Notably, O2•- is water-soluble and functions either as an oxidizing agent (e.g., one-electron 
reduction of O2•- yields H2O2) or as a reducing agent (e.g., ONOO- formation). HO• is 
extremely reactive and does not diffuse more that a few molecular diameters from its site of 
formation (Touyz, 2003). In contrast, H2O2 is highly stable under physiological conditions. 
Being an uncharged molecule, H2O2 is membrane-permeable and able of activating 
downstream signalling molecules relatively far from the site of formation. 
At low, physiological concentration, ROS modulate key signalling processes initiated by 
hormones, cytokines, vasoactive agents, blood coagulation factors, and hemodynamic shear 
stress. Reactive oxygen intermediates react at near-diffusion rate and influence the activity 
of numerous of signalling molecules including receptors, protein kinases/phosphatases, 
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transcription factors, peptides, ion channels and transporters, lipids, carbohydrates, and 
other oxygen-based species, a process that influence dramatically the cell behavior (Shao & 
Heinecke, 2009). The affinity of ROS for a specific substrate is dictated by both 
physicochemical features of the reactive oxygen intermediates and also of the targeted 
molecules. In addition, the occurrence and the abundance of specific functional groups, such 
as iron-sulfur centers, disulfide-bonds, amino and hydroxyl groups or fatty acids double-
bonds, greatly influence the chemical interactions between ROS and redox-sensitive 
biological molecules. As initially showed in microorganisms, eukaryotic cells respond to 
increased generation of O2•- and H2O2 by the up-regulation of various gene products, 
largely antioxidant enzymes and molecules implicated in the preservation of cellular 
homeostasis, self-renewal, and reparatory processes. In terms of selectivity, O2•- reacts 
preferentially with the transcription factors and electron transporters in respiratory chains 
containing iron-sulfur clusters. In contrast, H2O2 reacts mainly with the disulfide-bonds 
present on the protein kinases/phosphatases, transcription factors, and ion channels. 
Additional compelling evidence highlights that the redox-regulation of cell function 
represents an evolutionary conserved mechanism that alter directly or indirectly the 
activities of a large spectrum of signaling molecules (Liu et al., 2005).    
Protein tyrosine phosphatases (PTPs) are probably the best characterized signaling 
molecules targeted directly by ROS, especially of H2O2, owing to the existence of a highly 
conserved 230-amino-acid domain that contains reactive cysteine, which catalyzes the 
hydrolysis of protein phosphotyrosine residues. Consequently, a key mechanism whereby 
H2O2 controls various cellular processes is determined by the reversible oxidation of PTPs 
catalytic cysteines that blocks protein dephosphorylation causing transient inhibition of 
PTPs. 
Notably, several members of the protein tyrosine kinases (PTKs) family, including non-
receptor protein tyrosine kinases (i.e., Src, Jak, Pyk) have been shown to be activated in 
response to cellular redox variations (Tonks, 2006). Nevertheless, the precise molecular 
mechanisms of PTKs redox regulation are not entirely understood, and it is not clear if the 
PTK activities are directly correlated with the alterations induced by ROS action on enzyme 
structures Still, most of the available date suggests that the majority of the effects are 
attributable to PTP inhibition by ROS rather than PTK oxidation (Tabet et al., 2008). 
Another important class of molecules regulated by redox-dependent mechanisms is 
represented by the mitogen-activated protein kinase (MAPKs) family, that control key 
physiological processes such as mitosis, differentiation, proliferation, cell survival, and 
apoptosis. MAPKs are serine/threonine-specific protein kinases which activities are tightly 
regulated by complex phosphorylation pathways. Emerging evidence demonstrates that in 
the cardiovascular system, the functions of MAPKs are also influenced by extracellular and 
intracellular ROS by yet incompletely defined mechanisms (Wu et al., 2008). Apparently, the 
upstream regulators of MAPKs, namely MAPK kinases (MEKs), PTKs, and PTPs, might be 
the actual molecular targets of ROS and the genuine sensors of the intracellular redox state 
changes (Sedeek et al., 2009).  
Similar to PTPs, MAPK phosphatases (MKPs) display a highly conserved redox-sensitive 
cysteine in their catalytic core. Thus, the oxidative inhibition of MKPs may results in the 
persistent activation of MAPKs, as observed in various developmental or pathological 
states. Taken together, redox-dependent and as well as redox-independent activation of 
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hormones, growth factors, pro-inflammatory mediators, and vasoactive agents. Besides 
MAPKs, the activity of serine/threonine protein kinases Akt and Rho has been indicated to 
be redox-sensitive and to play a central role in cellular survival pathways (Lee & Griendling, 
2008). Apart from protein kinases/phosphatases and transcription factors, ROS are 
important regulators calcium homeostasis, by mechanisms that engages reversible thiol 
oxidation of the cysteine residues present on ion channels and transporters. In the vascular 
cells ROS, particularly O2•- and H2O2, also enhance intracellular Ca2+ concentrations by 
increasing the extracellular influx through the plasma membrane channels and mobilization 
from intracellular stores, and by the inhibition of Ca2+-ATPases located in the plasma 
membrane and endoplasmic reticulum. The plasma membrane K+ channels have been 
shown to be redox-sensitive, a process that mediates hyperpolarization-dependent vascular 
relaxation (Belia et al., 2009; Briones &Touyz, 2010). These data indicates that the redox 
status of ion channels and transporters plays an essential role in cell physiology and 
represents an important determinant of vascular pathology under conditions of the altered 
production of ROS. 
4. Antioxidant mechanisms in the cardiovascular cells  
ROS are physiologically produced at low concentration during metabolic processes in non-
phagocytic cells, by the mitochondrial respiratory chain, cyclooxygenases, lipoxygesases, 
cytochrome P450 reductase, xanthine oxidase. 
Almost three decades ago, the commonly accepted assumption was that the antioxidant 
system has developed to defend the cells against the damaging and unavoidable effects of 
ROS, which are capable to  produce irreversible, structural, and functional oxidative damage 
of DNA, proteins, lipids, and carbohydrates. This theory was supported by many 
experimental evidence regarding the strategic tissular distribution, 
expression/concentration levels, and localization of the antioxidants within cellular 
compartments. Nevertheless, soon after the discovery of enzyme systems that deliberately 
generates ROS (e.g., NADPH oxidases) under physiological and pathological states, it has 
become apparent that ROS are not just the by-products of aerobic metabolism, but also 
important signalling molecules (Forman et al., 2010; Go & Jones 2010). Therefore, the subtle 
relationship among oxidizing and reducing agents permits ROS to function as second 
messengers and to regulate various cellular functions. Thus, besides neutralization of ROS, 
the antioxidant system has emerged as a critical regulator of the redox-sensitive processes. 
The concentration of various oxygen-based reactive intermediates is maintained in 
physiological range by a very complex antioxidant system comprising both enzymatic ROS 
scavengers, namely superoxide dismutase, catalase, glutathione peroxidase, thioredoxin, 
glutaredoxin, peroxiredoxin, heme oxygenase, and paraoxonase, and non-enzymatic ROS 
quenchers, such as glutathione, vitamins, lipoate, urate, and ubiquinone (Zadák et al., 2009). 
Superoxide dismutases (SOD) represent a family of enzymes that catalyze the dismutation 
of O2•- into O2 and H2O2. Three SOD isoforms are expressed concomitantly in different 
cellular compartments, including the cytosol (SOD1; Cu/ZnSOD), mitochondria (SOD2; 
MnSOD), and the extracellular space (SOD3; ecSOD) (Valdivia et al., 2009). Catalase (CAT) 
is found in peroxisomes where it decomposes H2O2 to H2O and O2. Glutathione peroxidases 
(GPx) represent a family of isoenzymes encoded by separate genes that differ in cellular 
distribution pattern and substrate specificity. GPx1, the most abundant isoform, is expressed 
in the cytosol and has H2O2 as its main substrate. GPx2 is an extracellular space enzyme, 
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while GPx3 is particularly abundant in the plasma. GPx4 has as substrates lipid 
hydroperoxides and is present at a low level in nearly every cell type. Thioredoxins (TRx) 
and glutaredoxins (GRx) are proteins that function as antioxidants by enabling the reduction 
of other proteins by cysteine thioldisulfide exchange. Apart from being involved in 
antioxidant defense, different isoforms of the TRx and GRx families have been shown to 
play an important role in regulation of gene expression by redox-dependent processes. 
Peroxiredoxins (PRx) represent a ubiquitous family of antioxidant enzymes whose activities 
are tightly regulated by phosphorylation cascades and by changes in the redox and 
oligomerization states. PRx controls intracellular peroxide levels and mediate signal 
transduction in cardiovascular cells (Woo et al., 2010).  
5. Role of oxidative stress in atherogenesis 
Physiological production of ROS contribute to the preservation of vascular homeostasis by 
regulating important biological processes such as cell growth, proliferation, differentiation, 
apoptosis, cytoskeletal organization, and cell migration. Still, in the last few decades, it has 
become apparent that overproduction of ROS correlated with alterations of the antioxidant 
system, vascular inflammation and metabolic dysfunction are key pathological initiators of 
cardiovascular disorders. Generated in excess, ROS react randomly with all of biological 
molecules inducing the irreversible alterations of DNA, proteins, carbohydrates, and lipids 
components, thus altering cell functions (Martinet et al., 2001). As a result, extensive studies 
have concentrated on the role of oxidative stress-induced cellular dysfunction, redox control 
of vascular response to inflammatory and metabolic insults, the molecular mechanisms of 
ROS generation and the means that this class of molecules contributes to vascular damage. 
Oxidative stress represents a pathological condition characterized by the incapacity of 
antioxidant mechanisms to neutralize the deleterious effects of ROS and their metabolites. 
The means of oxidative stress onset and progression in vascular pathological states, include 
the overproduction of ROS, changes in the endogenous antioxidant system, and the 
production of various oxygen intermediates such as ONOO- and HO• that cannot be 
efficiently buffered by the naturally occurring antioxidant mechanisms. In addition, spatial 
and temporal co-expression and co-localization of various enzymatic and non-enzymatic 
ROS-producing sources at the site of vascular insults may potentially exacerbate predispose 
to vascular insults and dysfunction (Kondo et al., 2009; Lee et al., 2009).  
The importance of oxidative stress in onset and development of atherosclerosis is 
commonly accepted (Fearon & Faux, 2009). Still, numerous clinical trials failed to 
demonstrate that the antioxidant therapy improve the health of patients with 
cardiovascular diseases (Yusuf et al., 2000). Consequently, many questions arise relative 
to our current knowledge of the molecular processes implicated in ROS formation and 
action. Hitherto, different pharmacological approaches have been employed to counteract 
oxidative stress-induced injury in the cardiovascular system i.e. antioxidant supplements 
containing vitamins C and E, polyphenols or selective inhibitors of distinct sources of ROS 
(Olukman et al., 2010). Nevertheless, these pharmacological interventions have many 
disadvantages such as inadequate concentration of active compounds at the site of ROS 
formation, or vitamins themselves becoming radicals with pro-oxidant activity or not 
being effective scavengers for various reactive oxygen/nitrogen intermediates, namely 
hydrogen peroxide (H2O2), peroxynitrite anion (ONOO-), hydroxyl anion (HO•), and 
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Excessive ROS formation in atherogenesis triggers a chain of critical events such as EC 
dysfunction, oxidation of macromolecules especially LDL and extracellular matrix 
constituents, phenotypic alterations of SMC and macrophage/SMC-derived foam cell and 
modulate the function of signalling molecules in fibroblasts, which promotes inflammation 
of vascular adventitia (Sima et al., 2009). Vascular resident cells and transvasated immune 
cells are important sources of ROS within the atheroma (Heistad et al., 2009). These 
particularities show that atherosclerosis represents a multifactorial vascular disorder 
characterized by complex interactions and cross talk between the resident cells of the 
vascular wall, the cells of the immune system and the factors they produce. 
As shown in various animal models of atherosclerosis, oxidative stress is a primary 
occurrence and a key contributor to endothelial dysfunction portrayed by diminished 
endothelial NO bioavailability, enhanced endothelial transcytosis, up-regulation of pro-
inflammatory molecules, and the alteration of EC fibrinolytic activity (Dejana et al., 2009; 
Vendrov et al., 2007). In addition, oxidation of macromolecules especially of LDL (oxLDL) 
plays a key role in all stages of atherogenesis such as fatty streak formation, development of 
complex lesion, and plaque rupture. Of particular importance is that oxidative stress 
contributes, at least in part in the modulation of SMC phenotype switching and ultimately 
contributes to artery wall thickening. In atherosclerosis, SMCs undergo hypertrophy, 
produce excess extracellular matrix and inflammatory cytokines, proliferate and migrate 
from the media towards the vessel’s intima.  
Clinical evidence highlights that oxidative stress is a characteristic feature of many 
pathological conditions that predispose to atherosclerotic lesion formation such as 
hypercholesterolemia, hypertension, and diabetes. However, the precise pathological 
mechanisms accountable for the installation of oxidative stress are still an unsettled subject. 
In this context, although not completely validated in humans, oxidative stress may not be 
the sole causative effect of atherosclerosis and one has to consider the diversity of enzymatic 
and non-enzymatic sources of ROS, their vascular distribution pattern and subcellular 
compartmentalization, and complex regulation during various stages of the disease 
progression (Förstermann, 2008). 
6. Vascular sources of ROS: Role of NADPH oxidases 
Various pathways of ROS generation that can potentially contribute to oxidative stress have 
been described in the cardiovascular system including non-enzymatic decomposition of 
various compounds and metabolites (e.g., glucose autoxidation), production of ROS as 
byproducts of cellular respiration and metabolism (i.e., mitochondrial respiratory chain, 
lipo-/cyclooxygenases, dysfunctional nitric oxide (NO) synthases, cytochrome P450 
reductases, xanthine oxidase), lysosomal enzymes or generated in a highly regulated 
manner by specialized enzymes (e.g., NADPH oxidases) (Gu et al., 2001; Harrison et al., 
2003; Madamanchi et al., 2005; Martinez-Hervas et al., 2010; Zalba et al., 2007). 
NADPH oxidases (Nox) represent a family of multi-component enzymes, whose unique 
biological function is the production of ROS both in physiological and pathological states 
(Lambeth, 2004). Nox was originally identified and characterized as being a “burst” enzyme 
in professional phagocytes such as neutrophils and macrophages. In phagocytes, in 
cooperation with MPO, Nox plays a major role in host defense process against invading 
pathogens through the production of toxic hypochlorous acid (HOCl), a highly reactive 
oxidant. During phagocytosis, macrophages also generate significant amounts of NO. As a 
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result, the Nox-derived O2•- reacts with NO thus producing ONOO-, an extremely cytotoxic 
chemical species which directly affect and oxidize biological molecules in invading 
microorganisms, resulting in molecular alteration and microbial death (El-Benna et al., 
2007). The phagocyte-type Nox consists of five subunits: a membrane-associated cytochrome 
b558, comprising a heavily glycosylated 91-kDa protein (gp91phox; Nox2) and non-
glycosylated 22-kDa subunit (p22phox), and three cytosolic regulatory components, 
p40phox, p47phox, and p67phox. Besides “Phox” components, assembly of Nox in an active 
complex requires the contribution of a low-molecular-weight GTP-binding protein, Rac1/2 
or Rap 1A. In latent cells, the Nox complex is dissociated but is rapidly assembled and 
activated following the exposure to pathogens or inflammatory mediators. Serine 
phosphorylation of p47phox represents the limiting step of Nox activation and triggers 
complex formation of cytosolic subunits followed by translocation to the membrane and 
association with cytochrome b558 (Hoyal et al., 2003; Lassègue & Griendling 2002; Li & Shah 
2003;). Other than Nox2, macrophages also express Nox1 and Nox4 as inducible isoforms 
that, reportedly mediate LDL oxidation in the vascular wall (Lee et al., 2009; Maitra et al., 
2009). 
The expression of functionally active Nox subtypes has been reported in non-phagocytes, 
including cardiovascular cells. Thus far, the members of the Nox enzyme family consists of 
seven isoforms (Nox1-5, Duox1/2), each with a particular cell and tissue distribution. Nox 
enzymes are broadly divided into three major categories, as a function of the extra catalytic 
domains to the phagocyte-type subunit Nox2. The first group includes Nox1, Nox3, and 
Nox4 isoforms, which display a number of similarities with Nox2, for instance their 
structural organization and molecular weight. Besides Nox2-type catalytic core, Nox5, the 
second group of the Nox family, possess an extra amino-terminal calmodulin-like domain 
that contains four Ca2+-binding EF-hands structures (Lambeth, 2007). Thus far, four splice 
variants of Nox5, namely Nox5α, Nox5β, Nox5γ, and Nox5δ, have been identified in 
humans. In particular, the Nox5 gene is not present in the rodents’ genome. A third class of 
of Nox is represented by the Nox5-like dual oxidases (Duox) which possess, in addition to 
the Nox5-type structure, an extracellular peroxidase domain that uses the H2O2 generated 
by its Nox catalytic core. For their function, all the Nox1-4 subtypes necessitate the p22phox 
component, while Nox5 and Duox are activated directly by calcium. As shown in aortic 
SMCs, activation of Nox1 requires the participation of a ClC-3 anion transporter. The anion 
transporter co-expresses with Nox1 in early endosomes and is required for charge 
neutralization of the electron flow generated by Nox1 across the membrane of signalling 
vesicles (Miller et al., 2007). Nox4 is constitutively active and its activity is supported by the 
association with p22phox, required for the electron transfer, and polymerase delta 
interacting-protein 2 (Polidp2), that apparently may serve to stabilize the enzymatic 
complex (Lyle et al., 2009). The activities of Nox1, Nox2, and Nox3 isoforms are highly 
controlled by phosphorylation reactions involving regulatory subunits that initiate the 
assembly of Nox into an active enzymatic complex. Other than p40phox, p47phox, and 
p67phox cytosolic regulatory components, two different structurally related proteins have 
been discovered in non-phagocyte, specifically Nox organizer 1 (Noxo1), which is an analog 
of p47phox, and Nox activator 1 (Noxa1), which is an analog of p67phox. Despite the 
structural similarities, dissimilar functional aspects are involved in the regulation of enzyme 
activity. For instance, different to p47phox, which in the resting cells is located in the 
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2004). Different subtypes of the Nox enzyme family along with their regulatory proteins are 
expressed in the cardiovascular cells (i.e., ECs, SMCs, vascular and cardiac fibroblasts, 
cardiac myocytes, and pericytes), and in circulating immune cells interacting with the blood 
vessels (i.e., monocytes/macrophages, neutrophils, lymphocytes, platelets, dendritic cells) 
(Manea et al., 2005).  
Nox subtypes are differentially located within the cellular compartments, suggesting a 
specific correlation between Nox subtypes, subcellular distribution and their specific 
function to control precise ROS-mediated signal transduction cascades. For instance, Nox1 
and Nox2 were detected in caveolae, in the plasma membrane, and endosomes. Nox4 has 
been detected in focal adhesions, mitochondria endoplasmic reticulum, and the nucleus 
(Ago et al., 2010; Kuroda & Sadoshima, 2010). Nox5 is present in the perinuclear regions, 
endoplasmic reticulum, and in the plasma membrane (BelAiba et al., 2007; Fulton, 2009). 
7. Involvement of Nox enzymes in atherogenresis  
Studies in cell culture and transgenic/knockout mice provided most of the existing data 
concerning the role of Nox-dependent oxidative stress in atherosclerosis. Nox activity is up-
regulated by numerous factors linked to atherosclerotic lesion formation and progression 
namely, inflammatory cytokines (tumor necrosis factor α, interferon γ), vasoactive agents 
(angiotensin II, endothelin 1), metabolic factors (high glucose, modified 
proteins/lipoproteins/lipids, homocysteine), growth factors (platelet-derived growth 
factor), coagulation factors (thrombin), and pathological shear stress (Chung et al., 2010; 
Hwang et al., 2003). Apart from direct detrimental effects, compelling data exists that Nox-
derived ROS interact and stimulate other enzymatic sources of oxygen/nitrogen reactive 
intermediates, and generally amplify the initial response to insults (Cohena & Tong, 2010; 
Schrader & Fahimi, 2006).  
It is generally accepted that Nox-derived ROS cooperate, and act in concert with other 
pathological factors leading to vascular inflammation and injury, and that genetic ablation of 
various Nox subunits (i.e., p47phox, Nox1, Nox2) defends the vascular cells against the 
harmful effects of oxidative stress. ApoE-/- mice, which develop atherosclerotic lesions that 
cover the entire range of human lesions (i.e., fatty streaks, intermediate lesions, fibrous 
plaques, and vulnerable plaques exhibiting necrotic core and intra-plaque hemorrhage) have 
been extensively used to investigate the role of Nox enzymes in atherogenesis (Nakashima 
et al., 1994). Using this animal model, it has become evident that enhances in Nox activity 
and expression occur early in atherogenesis, and hyperactivity of Nox associated with the 
up-regulation of various isoforms marks all the stages of the plaque formation (Fenyo et al., 
2011).  
In contrast, ApoE/p47phox double-knockout mice display significantly less atherosclerotic 
lesions compared with ApoE-/- mice. In the same line, aortic O2•- levels have been shown to 
be are lower in p47phox-/- mice than in wild-type mice. In addition, aortic SMCs from 
p47phox-/- mice exhibit a decreased proliferative response to growth factors compared with 
that of the SMCs of wild-type mice (Vendrov et al., 2007). 
Accelerated atherosclerosis represents a major vascular complication of diabetes mellitus 
and is responsible for 70-80% of deaths in diabetic patients in developed and developing 
countries. Numerous reports revealed that the Nox expression and activity are significantly 
up-regulated in the vasculature of diabetic subjects, and are associated with the 
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development of atherosclerosis and microvascular diseases (retinopathy, neuropathy, and 
nephropathy). In addition, Nox1, Nox2, and Nox4 are activated and up-regulated in the 
blood vessels of diabetic animals (Ding et al., 2007; Xu et al., 2007).  
Hyperglycemia, the primary clinical manifestation of diabetes, contributes at least in part to 
diabetic complications by inducing Nox and the ensuing oxidative stress. Moreover, 
advanced glycation end-products (AGEs), a direct consequence of the high and persistent 
blood glucose level, are also important inducers of Nox-derived ROS in vascular cells in 
diabetes. Besides hyperglycemia, hyperinsulinemia contribute to aberrant ROS production 
and vascular wall dysfunction. Since Nox is one of the main triggers of oxidative stress, it 
has a prominent role in the pathology of diabetes-induced vasculopathy (Gao & Mann, 
2009). These data make Nox enzymes potential therapeutic targets to counteract the 
deleterious effects of ROS in diabetes. 
Hypertension represents a major risk factor for atherosclerosis and its complications and 
several reports highlight that oxidative stress is both cause and consequence of hypertension 
(Briones & Touyz, 2010). Nox1 deficiency in mice reduces angiotensin II (Ang II) -dependent 
blood pressure, media hypertrophy, and extracellular matrix deposition, but not cell 
proliferation (Gavazzi et al., 2007; Matsuno et al., 2005). In agreement with these data, 
AngII-treated mice overexpressing Nox1 in vascular smooth muscle cells exhibit an increase 
of blood pressure, a condition that is associated with medial hypertrophy and significant 
production of ROS (Dikalova et al., 2005). Furthermore, overexpression of Nox1 in vascular 
SMCs leads to enhanced responsiveness to Ang II causing up-regulation of ROS, eNOS 
uncoupling and the consequent decline in NO bioavailability, followed by impaired 
vascular relaxation (Dikalova et al., 2010).  
Consistent with these reports, compared with wild-type mice, Nox2 ablation (Nox2-/-) 
diminishes robustly ROS-mediated protein oxidation, neointimal formation, SMCs 
proliferation and leukocyte accumulation, indicating that Nox2-mediated signalling and 
oxidation has a requisite role in the cell response to injury (Chen et al., 2004). 
The role of Nox4 and Nox5 enzymes in atherogenesis is less investigated and consequently, 
not entirely elucidated, since there are few atherosclerosis-related studies conducted on 
Nox4 deficient mice, and the Nox5 gene is not present in the rodent’s genome. Thus, most of 
the current data are provided by studies performed in vitro on various cell-types and 
isolated tissues.  
Recently, a Nox4 deficient mouse model and a cardiomyocyte-targeted Nox4-transgenic 
model have been developed to investigate the role of Nox4 during cardiac stress. (Zhang 
et al., 2010). One of the main breakthroughs of this study is that in contrast to the effects 
of generated by activated Nox1 or Nox2, the up-regulation cardiomyocyte Nox4 results 
in protection against pressure overload-induced adverse cardiac remodeling. The 
authors conclude that Nox4 facilitates the maintenance of myocardial capillary density 
during pressure overload by regulating stress-induced cardiomyocyte hypoxia inducible 
factor-1 activation and release of vascular endothelial growth factor, resulting in 
increased paracrine angiogenic activity. In addition, unlike Nox1, Nox2 or Nox5, it seems 
that Nox4 produces directly H2O2 and thus is incapable of scavenging NO or producing 
ONOO-. 
The beneficial effects of Nox4-derived ROS were also reported by means of a newly 
developed transgenic mouse with endothelial-specific Nox4 overexpression (Ray et al., 
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a significant increase in H2O2 generation rather that O2•- and a significant augmentation of 
the pro-oxidative status. Despite of these aspects, the blood pressure of the animals was 
lower under basal conditions and after angiotensin II treatment. Interestingly, endothelium-
dependent relaxation was significantly improved compared with wild-type animals. 
Notably, these effects were sensitive to the ex vivo addition of catalase and in vivo 
administration of N-acetylcysteine, indicating that they were mediated by peroxide-type, 
namely H2O2, mechanisms. Mechanistically, it seems that an H2O2 action on potassium 
channels may be responsible for the elaboration of endothelium-derived hyperpolarizing 
factor (EDHF) type. Thus, one has to ponder that the type of ROS released in the vascular 
system determines their biological function. 
As mentioned above, less is know about the role of Nox5 in atherogenesis, and this is due 
mainly to the absence of Nox5 gene in the rodents’ genome and therefore to the lack of a 
reliable animal model., Still, it has been reported a significant correlation between Nox5 
expression and atherosclerotic lesion progression. Interestingly, a specific expression pattern 
was reported; with Nox5 being expressed mainly by the endothelium in the early stages of 
the disease while its expression is significantly increased in SMCs underlying fibro-lipid 
atherosclerotic lesions (Guzik et al., 2008).   
8. Mechanisms of Nox regulation 
8.1 Phosphorylation pathways and transcription factors 
Nox activity and expression is highly regulated at multiple levels by various physiologic 
and pathological factors which, by this means, dictate the enzyme complex function. The 
activities of both Nox1 and Nox2 isoforms are primarily regulated by complex 
networking of phosphorylation cascades involving regulatory components (i.e., p40phox, 
p47phox, p67phox, Noxo1, Noxa1) which induce the assembly of the enzyme complex. 
Nox4 is constitutively active and does not necessitate phosphorylation of regulatory 
proteins, whereas Nox5 has been demonstrated to be Ca2+-responsivenes. Yet, activation 
mechanisms involving protein kinase C and the proto-oncogenic tyrosine kinase c-Abl 
phosphorylation of Nox5 have been reported (El Jamali et al., 2008; Serrander et al., 
2007).   
The phosphorylation mechanisms responsible for Nox1 and Nox2 activation consist of a 
large spectrum of signalling molecules such as protein kinase C (PKC), phosphatidylinositol 
3-kinase (PI3K), GTP-binding proteins (Ras, Rac1/2), members of the mitogen-activated 
protein kinase (MAPK) family (p38MAPK, ERK1/2), phospholipases (PLCβ/γ, PLD), 
arachidonic acid metabolites, and non-receptor protein tyrosine kinases (Kilpatrick et al., 
2010; Yamamori et al., 2004). Besides the aforementioned kinases, chaperone proteins (e.g., 
protein disulfide isomerase) have been proved to be important regulators on Nox function 
(Janiszewski et al., 2005). 
In addition to the phosphorylation of cytosolic regulatory subunits, alterations of the Nox 
isoforms expression have been shown to be critical for their activity. Multiple transcription 
factors are coordinately implicated in the modulation of Nox expression and function. PU.1, 
Elf-1, IRF-1 (interferon regulatory factor-1), and ICSBP (interferon consensus sequence 
binding protein) are important transcriptional regulators of Nox2 in the myelomonocytic 
cell lineage (Kakar et al., 2005). In human colon epithelial Caco-2 cells, GATA-binding 
factors are critical for Nox1 transcriptional activity (Brewer et al., 2006), whereas in murine 
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stimulation is mediated at least in part, by pro-inflammatory transcription factors 
CCAAT/enhancer-binding protein (C/EBP)β and C/EBPδ (Maitra et al., 2009).  
In previous studies, we have shown that in human aortic SMCs exposed angiotensin II or 
tumor necrosis factor-α, the pro-inflammatory transcription factor AP-1 is an essential 
regulator of the genes coding for p22phox, Nox1, and Nox4 components (Manea et al., 2008; 
Raicu & Manea, 2010). Other than, activator protein -1 (AP-1), the vascular inflammation-
related and growth-promoting transcription factors signal transducer and activator of 
transcription (STAT1 and STAT3) proteins physically interact with the promoters of human 
Nox1 and Nox4 genes in SMCs exposed to interferon (IFN) γ and a Jauns kinase 
(Jak)/STAT-dependent mechanisms are implicated in the ensuing O2•- production. 
Moreover, the promoter activities of the genes coding for p22phox, p47phox, and p67phox, 
have been demonstrated to be considerably augmented in SMCs overexpressing 
STAT1/STAT3, a result that suggests the existence of functionally gamma activated 
sequence (GAS)/interferon-stimulated response element (ISRE) consensus sequences 
(Manea et al., 2010a). In human aortic SMCs, Ets1, a critical mediator of vascular 
inflammation and remodelling, regulates p47phox expression in response to AngII (Ni et al., 
2007). Similar observations were made in A7r5 cells and primary mouse aortic SMCs, in 
which the growth-promoting transcription factor E2F actually interacts and controls the 
Nox4 transcriptional program (Zhang et al., 2008).  
In atherosclerosis, and other major cardiovascular disorders, nuclear factor kB (NF-kB) 
signalling represents a critical regulating mechanism involved in disease onset and 
progression, including inflammation, cell proliferation, migration, differentiation and 
apoptosis. Several line of evidence indicate that NF-kB is a redox-sensitive transcription 
factor which is robustly activated by ROS possible generated by activated Nox. 
Interestingly, a positive feed-back loop of Nox activation by NF-kB has been proposed in 
several studies. Thus, a new integrative concept has emergedthe “vicious cycle”, to describe 
the interconnection between metabolic dysfunction, inflammation, and oxidative stress that 
converges to vascular disorders (Manea, 2010). In murine monocytes, the expression of the 
Nox2 is induced by NF-kB. Moreover, the up-regulation of p47phox and p22phox 
expression by LPS/IFNγ was blunted in IkBα-overexpressing cells suggesting the 
involvement of the NF-kB signaling in the regulation of the Nox components (Anrather et al. 
2006). Similar finding were reported in human monocytes/macrophages exposed to TNFα 
(Gauss et al., 2007). Moreover, in previous studies we have shown that, NF-kB is an 
important transcriptional regulator of the genes coding for p22phox, Nox1, and Nox4, and 
has a profound impact in the up-regulation of Nox activity in TNFα-treated human aortic 
SMCs (Manea et al., 2007; Manea et al., 2010b). 
The molecular mechanisms that facilitate hypoxia sensing and related signalling events 
are critical for the maintenance of vascular cell homeostasis. Compelling data depicts that 
hypoxic conditions up-regulate the expression and activity various Nox subtypes (Goyal 
et al., 2004). It has been demonstrated that persistent hypoxia induces Nox4 gene and 
protein expression levels in pulmonary artery SMCs and in pulmonary vessels in mice 
exposed to hypoxic conditions (Diebold et al., 2010). Mechanistically, the response is 
dependent on hypoxia inducible factor-1α (HIF-1α), which interacts with the 
corresponding elements in the Nox4 promoter. As a result, the HIF-1α dependent up-
regulation of Nox4 by may be an essential mechanism to preserve ROS level after hypoxia 
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activating transcription factor-1 (ATF-1), a transcription factor of the CREB (CRE-binding 
protein)/ATF family, proved to play a key role in the induction of Nox1 in rat vascular 
SMCs (Katsuyama et al., 2005).  
Nuclear factor (erythroid-derived 2)-like 2, also known as Nrf2 represents a master 
modulator of the antioxidant responses by inducing genes (e.g., Sod genes) with important 
function in combating oxidative stress. Interestingly, it has been demonstrated that Nrf2, 
also controls Nox4 expression in mouse lung and human lung endothelium in response to 
hyperoxia (Pendyala & Natarajan, 2010). 
8.2 Genetic and epigenetic mechanisms of Nox regulation 
Genetic studies highlight that several Nox-related polymorphisms are closely associated 
with an increased susceptibility for cardiovascular disorders. One of the most investigated 
genes from the Nox complex is CYBA which encodes the p22phox essential subunit. The 
p22phox is ubiquitously expressed in cardiovascular cells and forms stable and functional 
heterodimers with Nox1, Nox2 or Nox4, a critical structure for enzyme activity as shown 
by studies employing siRNA technology to knock-down p22phox expression (Kawahara 
et al., 2005). Moreover, it has been demonstrated that p22phox is more abundant in 
advanced atherosclerotic plaques than in nonatherosclerotic arteries, suggesting a 
correlation between p22phox expression, O2•- production, and the severity of 
atherosclerosis (Azumi et al., 1999).  
The occurrence of particular polymorphisms of the CYBA gene has been shown to 
predispose to oxidative stress and to be independently correlated with cardiovascular risk 
factors and disease occurrence namely hypertension, coronary artery disease, myocardial 
infarction, cerebrovascular disease, diabetic and non-diabetic nephropathy) (San José et al., 
2008). Various CYBA allelic variants were detected in both exonic sequences such as C242T, 
A640G, C549T (Dinauer et al., 1990; Guzik et al., 2000; Inoue et al., 1998), and promoter 
regions namely -930A/G, -675A/T, -852C/G, -536C/T (Lim et al., 2006; Moreno et al., 2007), 
which potentially affect the p22phox expression and consequently the Nox activity. Thus 
far, data indicating the existence of functional Nox1-5 polymorphisms with a relevant 
impact on vascular pathology are not available yet.     
Emerging evidence demonstrates that epigenetic events such as DNA methylation and 
modifications of histone tails are important processes of oxidative stress onset. DNA 
methylation mechanisms of the promoter CpG islands has been shown to be involved in the 
up-regulation of 15-lipoxygenase, a pro-oxidative enzyme with implications in plaque 
formation and vulnerability, and down-regulation of superoxide dismutase 3, endothelial 
NO synthase, and various anti-proliferative genes (estrogen receptor-α), a condition that 
leads to oxidative stress, impaired vascular relaxation, and aberrant SMC hyperplasia 
(Fernandez et al., 2010). Hitherto, data about the role of epigenetics in the regulation of Nox 
subtypes are missing. Nevertheless, using both in vitro (e,g., human aortic SMCs exposed to 
pro-inflammatory conditions) and in vivo (ApoE-/- mice fed a high fat, cholesterol rich diet) 
models, we have found recently that an aberrant methylation of the Nox1 promoter may be 
responsible for the up-regulated expression and activity of this enzyme (Manea et al., 
unpublished data).  
A schematic representation of the key molecular pathways implicated in the up-regulation 
of Nox enzymes as well as the potential pharmacological targets intended to counteract 
oxidative stress are presented in the figure below.   
 




Fig. 1.  Schematic depiction of the major mechanisms responsible for the up-regulation of 
Nox enzymes and installation of oxidative stress in atherosclerosis. In response to 
cardiovascular risk factors, vascular cells through their receptors activate a range of 
signalling pathways that up-regulate Nox expression, activity, and the ensuing ROS 
production. This triggers a chain of critical events that generally amplify the initial response 
to vascular insults (i.e., activation of other cellular sources of ROS and redox-sensitive 
signalling effectors). Persistent Nox activation leads to oxidative stress that is a major 
contributor to the initiation and the development of atherosclerotic lesions. The diagram 
highlights that genetic, epigenetic, as well as genetic/non-epigenetic-independent 
mechanisms linked to Nox up-regulation and hyperactivity in atherosclerosis may be used 
to target and control pharmacologically the Nox-derived oxidative stress (green text).  
9. Conclusion 
The Nox-derived ROS may have both beneficial and deleterious effects. Thus, we can safely 
assume that these effects are function of the expression pattern and regulation of various 
Nox isoforms, their subcellular compartmentalization, and the rate of ROS generation. 
Despite of the numerous existing data, the precise mechanisms of Nox regulation in 
atherosclerosis and the stream of signalling molecules (up-, or down-regulated) responsible 
for the increased oxidative stress that is associated with the onset and development of 
cardiovascular dysfunction, is poorly understood. Thus, a complex interplay of genetic, 
epigenetic and non-epigenetic factors, transcription factors, co-activators, and/or co-
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atherogenesis. Therefore, elucidation of the complex interactions among different 
mechanisms that control Nox subtypes expression/activity and subcellular 
compartmentalization of ROS production and its subsequent biological meaning, may lead 
to a more focused and effective antioxidant therapies. The expected impact of these 
pharmacological strategies goes well beyond the atherosclerosis field. Oxidative stress is a 
common occurrence in most pathologies i.e. diabetes, neurodegenerative diseases, cancer, 
etc. The knowledge gained will be applicable to all these pathologies since controlling 
oxidative stress ought to have a beneficial knock-on effect on these diseases. Identifying the 
basic molecular mechanism regulating the oxidative stress will be used to find ways to 
manage its occurrence and correct its adverse effects. 
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1. Introduction  
High blood concentration of low-density lipoprotein (LDL) cholesterol is a major risk factor 
for early development of atherosclerosis. Massive accumulation of cholesterol in the arterial 
wall and formation of lipid-laden cells (foam cells) typical of the atheromatous plaque occur 
after LDL entrapment in the subendothelial space. However, there is a general agreement 
that native non-modified LDL does not present any of the typical features of an atherogenic 
lipoprotein; native LDL does not promote foam cell formation and has no inflammatory, 
proliferative or apoptotic capacity. It is therefore assumed that when LDL is trapped in the 
arterial wall it is modified by several mechanisms such as lipoperoxidation, non-enzymatic 
glycosylation, enzymatic lipolysis and/or proteolysis. As a consequence, modified LDL 
particles acquire inflammatory and apoptotic capacity and are recognizable by scavenger 
receptors to promote foam cell formation. Although most studies on LDL modification have 
focused on mechanisms that could occur in the vessel wall, modified LDL particles have 
been reported in blood. The concentration of these particles is increased in subjects with 
high cardiovascular risk. The present chapter reviews the possible mechanisms leading to 
LDL modification. It then focuses on a subfraction of modified LDL particles detected in 
plasma, named electronegative LDL.  
2. Modification of LDL as a key event for atherosclerosis 
Pioneering studies by Goldstein and Brown demonstrated the involvement of LDL receptor 
(LDLr) in the plasma clearance of LDL and its major role in the development of 
atherosclerosis (Goldstein & Brown, 1985). However, these authors’ outstanding 
observations gave rise to what was called the “cholesterol paradox” (Brown & Goldstein, 
1983). Patients with homozygous familial hypercholesterolemia lack functional LDLr. 
Moreover, LDLr expression is negatively regulated by the intracellular cholesterol content, 
which results in a tight control of the concentration of esterified cholesterol in the cytoplasm 
(Brown & Goldstein, 1986). However, atherosclerosis is characterized by an abundance of 
foam cells loaded with esterified cholesterol droplets. Hence, there must be an alternative 
pathway leading to the massive accumulation of cholesterol in foam cells of the 
atherosclerotic lesion. This alternative pathway was discovered through the study of the 
scavenger receptors (SR) expressed by monocyte-derived macrophages (Krieger, 1992). 
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1. Introduction  
High blood concentration of low-density lipoprotein (LDL) cholesterol is a major risk factor 
for early development of atherosclerosis. Massive accumulation of cholesterol in the arterial 
wall and formation of lipid-laden cells (foam cells) typical of the atheromatous plaque occur 
after LDL entrapment in the subendothelial space. However, there is a general agreement 
that native non-modified LDL does not present any of the typical features of an atherogenic 
lipoprotein; native LDL does not promote foam cell formation and has no inflammatory, 
proliferative or apoptotic capacity. It is therefore assumed that when LDL is trapped in the 
arterial wall it is modified by several mechanisms such as lipoperoxidation, non-enzymatic 
glycosylation, enzymatic lipolysis and/or proteolysis. As a consequence, modified LDL 
particles acquire inflammatory and apoptotic capacity and are recognizable by scavenger 
receptors to promote foam cell formation. Although most studies on LDL modification have 
focused on mechanisms that could occur in the vessel wall, modified LDL particles have 
been reported in blood. The concentration of these particles is increased in subjects with 
high cardiovascular risk. The present chapter reviews the possible mechanisms leading to 
LDL modification. It then focuses on a subfraction of modified LDL particles detected in 
plasma, named electronegative LDL.  
2. Modification of LDL as a key event for atherosclerosis 
Pioneering studies by Goldstein and Brown demonstrated the involvement of LDL receptor 
(LDLr) in the plasma clearance of LDL and its major role in the development of 
atherosclerosis (Goldstein & Brown, 1985). However, these authors’ outstanding 
observations gave rise to what was called the “cholesterol paradox” (Brown & Goldstein, 
1983). Patients with homozygous familial hypercholesterolemia lack functional LDLr. 
Moreover, LDLr expression is negatively regulated by the intracellular cholesterol content, 
which results in a tight control of the concentration of esterified cholesterol in the cytoplasm 
(Brown & Goldstein, 1986). However, atherosclerosis is characterized by an abundance of 
foam cells loaded with esterified cholesterol droplets. Hence, there must be an alternative 
pathway leading to the massive accumulation of cholesterol in foam cells of the 
atherosclerotic lesion. This alternative pathway was discovered through the study of the 
scavenger receptors (SR) expressed by monocyte-derived macrophages (Krieger, 1992). 





characteristic of high electronegative charge. The first SR described was the type A SR (SRA) 
(Goldstein, 1979). SRA do not recognize native LDL but is able to bind modified forms of 
LDL; indeed, SRA expression is not regulated by the cytoplasm concentration of cholesterol. 
Early studies were performed using acetylated LDL (acLDL), a good ligand for SRA. 
However, acetylation does not occur spontaneously “in vivo”. Soon, researchers looked for 
further modifications of LDL that would increase its negative charge and were able to occur 
“in vivo”. The finding that oxidized LDL (oxLDL) could be internalized through SR and 
promote the formation of foam cells opened a vast field of research (Steinberg, 1989).  
2.1 Oxidative modification of LDL 
Oxidative modifications of lipid and proteins are frequent in many pathophysiological 
processes “in vivo” and it is now well-established that LDL undergoes oxidative 
modifications that confer to these modified particles a number of atherogenic properties 
(Witztum & Steinberg, 1991). In the early 80s several researchers independently observed 
that the incubation of LDL with endothelial cells in culture drastically altered these particles, 
transforming them into more electronegative LDL, after which they become a ligand for 
macrophages SR (Henriksen, 1981; Hessler, 1979). These studies concluded that the changes 
induced by endothelial cells on LDL were due to free radical modification. This was the 
origin of the oxidative modification hypothesis of atherogenesis (Steinberg, 1989). This 
hypothesis was gradually strengthened by subsequent findings regarding the properties of 
oxLDL obtained over the ensuing years. Table 1 summarizes the atherogenic properties 
observed in oxLDL and their contribution to atherosclerosis. 
 
Characteristic Consequence in atherosclerosis 
Impaired binding to the LDL receptor Decreased plasma clearance 
Recognition by SR  Foam cell formation 
Increase in the expression of cytokines, 
chemokines and vascular adhesion 
molecules 
Leukocyte recruitment, inflammation 
Increase in  the expression of growth factors Cell proliferation and collagen secretion 
Promotion of apoptosis and cytotoxicity Formation of necrotic core 
Immunogenicity Immunogenic component of atherosclerosis 
Inhibition of NO release and function Vasoconstriction 
Increase of tissue factor activity Thombosis 
Table 1. Atherogenic characteristics of oxLDL 
Oxidation of LDL primarily attacks the double bonds of unsaturated fatty acids in 
phospholipids and generates a plethora of lipid-derived compounds, including oxidized 
cholesterol (oxysterols), oxidized-fragmented phospholipids, lysophosphatidylcholine, 
hydroperoxids, aldehydes and ketones (Esterbauer, 1990). The protein moiety of LDL can 
be modified by reacting with lipid-oxidation products. Both aldehydes and ketones, for 
example, malondialdehyde (MDA) or 4-hydroxynonenal (HNE), have the ability to 
derivatize lysine and arginine residues in apoB (Fogelman, 1980). This reaction forms an 
adduct that eliminates the positive charge of these aminoacids and increases the negative 
charge of the particle, favouring its recognition by SRA (Goldstein, 1979). In addition to 
SRA, further SRs and other receptors which bind different forms of modified LDLs have 
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been described in the last two decades (SRBI, CD36, LOX-1, CD68, LRP1, TLR4) (Adachi & 
Tsujimoto, 2006; Llorente-Cortes & Badimon, 2005; Miller, 2003; Van Berkel, 2000). These 
receptors play a role in innate immunity, scavenging a number of ligands and 
extracellular debris. Some of these are also expressed in endothelial cells or in smooth 
muscle cells (Adachi & Tsujimoto, 2006).  The derivatization of lysines has an additional 
effect on LDL; since a lysine-rich cluster is the LDLr binding site of apoB (residues 3359-
3369), the loss of their positive charge abolishes the interaction between oxLDL and LDLr 
(Boren, 1998a). 
Besides lipid accumulation, other phenomena occur during the evolution of the disease. 
Atherosclerosis is a chronic inflammatory process that begins with leukocyte recruitment 
to the lesion area (Ross, 1999). A number of inflammation mediators, such as cytokines 
(IL6), chemokines (IL8, MCP1) or vascular adhesion molecules (VCAM, ICAM1, e-
selectin) are hyperexpressed in response to oxLDL by all cells involved in atherogenesis, 
including endothelial cells, monocytes/macrophages, lymphocytes and smooth muscle 
cells (Berliner, 1997; Tedgui & Mallat, 2006). Related to the inflammatory activity of 
oxLDL is its ability to promote the expression of growth factors and colony stimulating 
factors. This proliferative activity is mediated by oxidation-derived lipids, and in smooth 
muscle cells it induces the change of the normal contractile phenotype to a proliferative 
phenotype (Auge, 2002). The proliferative phenotype of smooth muscle cells is 
characterized by the high production of collagen that will contribute decisively to the 
thickening of the arterial wall (Negishi, 2004).  
Another hallmark of the atheromatous plaque in its advanced stages is the presence of a 
necrotic core formed by debris from dead cells (Stary, 2000). OxLDL also contributes to 
the formation of this necrotic core, because when the content of esterified cholesterol 
exceeds the storage capacity of foam cells apoptotic processes are induced (Hessler, 1983). 
Another mechanism of cytotoxicity is the high content of lysophosphatidylcholine in 
oxLDL that disrupts the integrity of cytoplasmatic membrane and promotes cell death 
(Naito, 1994).  
OxLDL is immunogenic, and autoantibodies against oxidation-specific epitopes are detected 
in normal and hyperlipemic subjects (Lopes-Virella & Virella, 2010). The role of these 
autoantibodies is not well defined and published results are divergent; positive or negative 
associations between autoantibodies and atherosclerosis have been reported. In general, 
antibodies of IgG class are presumed to be pro-atherogenic, whereas IgM antibodies would 
play a protective role (Frostegard, 2010). Further deleterious properties of oxLDL are its 
capacity to increase the tissue factor activity (Petit, 1999), favouring thrombosis, or the 
inhibition of the release of nitric oxide (Minuz, 1995), promoting vasoconstriction.  
The lipoperoxidative process is sequential and lipids degrade to produce new products 
which in turn form other molecules (Quehenberger, 1988). As a consequence, oxLDL 
comprises an extremely heterogeneous group of particles that have different atherogenic 
characteristics depending on the relative content of each molecule (Esterbauer, 1993). For 
instance, minimally oxidized LDL (mmLDL) has a high inflammatory activity due to its 
high content in oxidized phospholipids formed during the early phases of oxidation. 
However, mmLDL has normal affinity to the LDLr and is not recognized by SR. In contrast, 
extensively oxidized LDL has relatively low inflammatory activity but it is a major inductor 
of cytotoxicity due to its high content of oxysterols. Indeed, the more oxidized the LDL the 
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2.2 Further modifications of LDL occurring in the arterial wall 
Oxidative modification is not the only process affecting the native properties of lipoproteins 
in the arterial wall. Disappointing results from large-antioxidant trials have led to the 
concept that alternative mechanisms of modification could be involved (Steinberg, 2009). 
Current knowledge indicates that although oxidation is still relevant, other processes could 
contribute substantially to the development of atherosclerosis. A number of modifications 
have been studied over the past three decades.  
Enzymes that are hyperexpressed in the microenvironment of the lesion area, such as lipases 
(cholesterol esterase (CEase), sphingomyelinase (SMase) or secretary phospholipase A2 
(sPLA2)) or proteases (matrix metalloproteases or cathepsins) can modify LDL (Pentikainen, 
2000). In the case of diabetes, non-enzymatic glycosylation could have a major role in LDL 
modification (Witztum, 1997). The interaction of LDL with the proteoglycans (PG) could 
modify apoB conformation, destabilizing its conformation and promoting aggregation 
(Pentikainen, 1997). Other putative physiological processes that could modify LDL are 
carbamylation (Basnakian, 2010) or desialylation (Tertov, 1990). Table 2 summarizes several 
possible physiological mechanisms leading to LDL modification. 
 





Oxidation1 +++ +++ +++ 
Modification by CEase and 
protease -/+ ++ ++ 
Lipolysis by SMase + - -/+ 
Lipolysis by PLA2 -/+ ++ + 
Non-enzymatic glycosylation -/+ -/+ -/+ 
Binding to PG ++ - - 
Carbamylation ++ ++ ++ 
Desialylation ++ + ++ 
Table 2. Atherogenic properties of several modified LDLs. 1 The characteristics of oxLDL, 
and also those of the other modifications, depend on the extent of modification  
2.2.1 Enzymatically-modified LDL (E-LDL)  
In an attempt to find a modified LDL alternative to oxLDL, Bhakdi and coworkers 
performed a series of studies using LDL that was modified by means of one protease and 
CEase. They found that this “enzymatically-modified LDL” (E-LDL) acquired a number of 
atherogenic properties (Bhakdi, 1995). As a result of the enzymatic treatment, E-LDL 
presents mild apoB fragmentation, and it has high free cholesterol and non-esterified fatty 
acids (NEFA) content (Klouche, 1998). E-LDL induces inflammation, proliferation and 
apoptosis (Dersch, 2005; Klouche, 1999; Klouche, 2000). The high content of NEFA seems to 
be major factor responsible for these atherogenic properties (Suriyaphol, 2002). E-LDL adds 
further atherogenic characteristics because it binds to C-reactive protein and activates the 
classical complement pathway (Bhakdi, 2004). The activation of complement by E-LDL 
concurs with the emerging concept of the innate immune response as a potentially 
important factor in atherosclerosis (Hartvigsen, 2009). 
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2.2.2 Phospholipase A2-modified LDL (PLA2-LDL)  
Several studies have focused on the atherogenic effects of LDL modified with different  
types of secreted phospholipase A2 (sPLA2) (Divchev & Schieffer, 2008). Some sPLA2 have 
been detected in atherosclerotic lesions and their products, lysophosphatidylcholine (LPC) 
and NEFA, induce cytotoxicity at relatively high concentrations by disrupting membrane 
integrity (Dersch, 2005; Naito, 1994). Moreover, both molecules have inflammatory potential 
by stimulating the expression of cytokines and chemokines (Sonoki, 2003). In addition, 
extensively lipolyzed LDL with some (type X), but not all (type IIA or V), sPLA2 are able to 
induce foam cell formation (Curfs, 2008). An interesting approach was performed by 
Sparrow and coworkers, which combined sPLA2 and lipoxygenase to modify LDL 
(Sparrow, 1988). This combination of lipoperoxidation and phospholipolysis generated LDL 
particles with similar properties to those promoted by endothelial cell-induced oxidative 
modification. Another atherogenic characteristic of sPLA2-modified LDL is its increased 
affinity for PG binding due to the exposition of an alternative binding site in apoB that 
specifically recognizes PG (Boren, 1998b). As occurs with SMase-modified LDL, this would 
lead to increased subendothelial retention.  
PAF-acetylhydrolase (PAF-AH), another PLA2 with relevance in the metabolism of LDL, 
merits special mention. This enzyme is transported in plasma bound to lipoproteins 
(approximately 70% in LDL and 25% in HDL) but, in contrast to sPLA2, its substrate is  not 
native phospholipids but fragmented phospholipids that have been generated by oxidation 
(Tjoelker & Stafforini, 2000). Thus, LPC content is high in oxLDL due to the action of PAF-
AH. However, there is controversy regarding the pro- or anti-atherogenic role of PAF-AH 
(Tellis & Tselepis, 2009). On one hand, its function should be atheroprotective since it 
degrades highly-inflammatory fragmented phospholipids. On the other hand, however, the 
by-products formed are LPC and short-chain NEFA, which also have inflammatory 
potential, though to a lesser extent than oxidized phospholipids (MacPhee, 1999). 
2.2.3 Sphingomyelinase-modified LDL (SMase-LDL)  
The hyperexpression of acid and neutral SMases in atherosclerotic lesions has been  known 
for several years (Tabas, 1999). SMase hydrolyzes sphingomyelin (SM) yielding 
phosphorylcholine and ceramide. Ceramide directly exerts several biological effects, but its 
main action is to elicit the production of bioactive sphingolipids, such as sphingosine-1-
phosphate that plays a major role in apoptosis (van Blitterswijk, 2003). Another action of 
SMase is to promote extensive LDL aggregation (Oorni, 2000). Aggregation of LDL confers 
several atherogenic properties. First, aggregated LDL (agLDL) is able to induce foam cell 
formation, not through SR in this case but through the LDL-receptor related protein 1 
(LRP1), a receptor of aggregated lipoproteins highly expressed in smooth muscle cells 
(Llorente-Cortes & Badimon, 2005). Second, agLDL binds with higher affinity to PG (Oorni, 
1998). As discussed below, this binding promotes structural changes in apoB. The 
association of agLDL to PG precludes the exit of this lipoprotein from the subendothelial 
space, and consequently favours that agLDL could undergo further modifications. 
2.2.4 Glycated LDL (glLDL)  
Although non-enzymatic glycosylation of LDL occurs in all subjects, it has stronger 
consequences in people with diabetes mellitus. Glucose can interact with the free amino 
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Amadori product (Brownlee, 1992). This modification leads to a loss of electropositive charges 
in glycated LDL (glLDL), decreasing its affinity to the LDLr and consequently prolonging its  
mean lifetime in plasma (Witztum, 1982). The increase in lifetime can result in further 
modification of LDL forming advanced glycation end-products (AGE) and producing a form 
of LDL named AGE-LDL (Menzel, 1997). AGE-LDL can also be internalized by specific 
receptors (RAGE) (Bucala, 1996). AGE-LDL and glLDL increase chemotactic activity in 
monocytes, stimulate cell proliferation and enhance platelet aggregation, although the relative 
contribution that the coexistence of oxidation could have is not well established. The formation 
of AGE involves oxidative reactions and it has been demonstrated that lipoperoxidation and 
non-enzymatic glycosylation are mutually potentiated processes (Sobal, 2000). Thus, 
glycosylation of LDL is not only noxious per se but also because it promotes LDL oxidation. 
2.2.5 Proteoglycan-bound LDL (PG-LDL)  
PG are the main constituents of the arterial intima. It has been hypothesized that 
subendothelial retention of lipoproteins due to the binding of LDL to PG is the initial event 
in atherogenesis, even prior to endothelial dysfunction or inflammation (Williams & Tabas, 
2005). The retention itself increases the time of LDL in the subendothelial space and, 
therefore, the possibility that further modifications occur. Furthermore, the binding LDL-PG 
also has a direct effect on LDL modification because this binding promotes changes in the 
structure of apoB that facilitate processes such as oxidation or lipolysis mediated by SMase 
or sPLA2 (Hevonoja, 2000). On the other hand, LDL-PG complexes are taken up by cells 
through different types of SR, promoting foam cell formation. 
3. Modified LDL in human plasma 
For many years it was considered that LDL modification was a phenomenon occurring 
mainly in the intima layer of the arterial wall. Oxidative modification was the most studied 
process, and most researchers accepted that the abundance in plasma of soluble molecules 
with antioxidant capacity (albumin, uric acid, bilirubin, glutathione, ascorbic acid) would 
inhibit oxidation of lipoproteins. Moreover, the binding of oxLDL by SR expressed in 
circulating monocytes is known to promote a rapid clearance of extensively oxidized LDL. 
However, progress in enzyme immunoassay procedures has provided direct evidence of 
oxLDL in circulating plasma. Besides oxLDL, similar methods have been used to detect 
other forms of modified LDL in blood. These include glLDL, AGE-LDL, carbamylated LDL 
(ca-LDL), desialylated LDL and electronegative LDL (LDL(-)).  
3.1 Oxidized LDL in plasma  
Despite the abundance of antioxidant defences in blood, increased oxidative stress has been 
described in plasma from patients with atherosclerosis. Early studies reported that increased 
levels of oxidized lipids in plasma were associated with atherosclerosis development 
(Avogaro, 1986). In agreement with that, the existence of oxLDL in blood is increased in 
subjects with high cardiovascular risk (Holvoet, 1999; Holvoet, 1998) or in diseases, such as 
diabetes, obesity, metabolic syndrome and hyperlipemia (Ishigaki, 2009). Although it cannot 
be totally ruled out that a part of oxLDL could be formed in blood, it is generally accepted 
that oxLDL originates primarily in the arterial wall and that the molecules reach the blood 
from the subendothelial space. For this reason, oxLDL is considered not only a biomarker of 
 
Modified Forms of LDL in Plasma 
 
453 
atherosclerosis development but also a reflection of the presence of unstable and ruptured 
atherosclerotic plaques (Fraley & Tsimikas, 2006). The fact that oxLDL increases temporarily 
during the acute phase of myocardial infarction or stroke supports this notion (Fraley & 
Tsimikas, 2006; Nishi, 2002; Uno, 2003) and some studies have raised the possibility that 
plasma oxLDL could predict future cardiovascular events (Meisinger, 2005). The 
concentration of oxLDL in plasma is very low, and data reported by several authors are 
disperse, ranging from 0.01% to 0.5% of total LDL. The heterogeneous nature of oxLDL is 
one reason to explain variation in the reports of oxLDL concentration, but another could be 
the use of several antibodies that recognize different epitopes (Ishigaki, 2009). The fact that 
in vitro oxidation does not reproduce the same epitopes generated during in vivo 
modification makes it difficult to develop a golden standard. 
Several studies have shown that besides its utility as a biomarker, oxLDL in plasma acts as a 
pathogenic factor. It has been reported that oxLDL contributes to increase the systemic 
inflammatory status by stimulating the activity of the transcription factor NF-kB in 
peripheral blood mononuclear cells (Cominacini, 2005). More direct demonstration of the 
implication of oxLDL in blood has been obtained by increasing the expression of SR, such as 
SRA1 (Whitman, 2002), LOX-1 (Ishigaki, 2008), or the chimerical fusion protein SRA1-
growth hormone (Laukkanen, 2000), which favours oxLDL removal from blood. These 
studies showed an inhibition of atherosclerosis development. It was recently reported that 
repeated administration of the chimerical fusion protein Fc-CD68 decreases the extent of 
atherosclerosis in hyperlipemic mice (Zeibig, 2011). However, these studies have been tested 
to date in animal models only. Regarding humans, several trials have reported that lipid-
lowering therapy in atherosclerotic patients lowers oxLDL, although this decrease is parallel 
to that of LDL cholesterol (Ky, 2008). However, no trial with a therapy specifically focused 
on oxLDL is yet available. The development of novel therapies for lowering oxLDL itself is a 
promising strategy for atherosclerosis treatment. 
3.2 Glycated LDL in plasma  
The concentration of glLDL in plasma from patients with diabetes is increased, reflecting the 
hyperglycemia in these patients. This concentration varies depending on the method used 
for its quantification (ELISA, affinity chromatography), but it is generally higher than that of 
oxLDL (Cohen, 1993; Reaven, 1995). The proportion of glLDL in diabetics can reach up to 7-
8% of total LDL and approximately half in normoglycemic subjects. It is important to note 
that glLDL is present in all individuals, and even in normoglycemic subjects the 
concentration in plasma is higher than that of oxLDL. This suggests glLDL plays a role in 
the development of atherosclerosis even in absence of hyperglycemia. Interestingly, glLDL 
is more abundant in the subfractions of LDL that are smallest and have the highest density, 
probably because these small-dense LDL particles are prone to non-enzymatic glycosylation 
(Younis, 2009). These particles are also more susceptible to oxidation and have a relatively 
low affinity to the LDL receptor. These properties are related to  the strong association 
between small-dense LDL and high cardiovascular risk (Krauss, 1995). 
Alternative pathways can also result in LDL glycosylation without a direct involvement of 
glucose. Metabolites of glucose such as glyoxal, methylglyoxal or glycaldehyde have a 
higher reducing capacity as glycating agents (Rabbani & Thornalley, 2011). Minimal 
modification by methylglyoxal renders LDL particles with atherogenic properties, including 
binding to PG and susceptibility to aggregation (Rabbani, 2011). LDL particles with this low 
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A more advanced form of glLDL is AGE-LDL, in which AGE are formed due to auto-
oxidation of Amadori adducts yielding a number of products, such as carboxymethyl lysine 
or pentosyl lysine (Brownlee, 2000). AGE-LDL has atherogenic characteristics that are 
similar to oxLDL, probably because their oxidized lipid content is similar. Although it was 
generally considered that AGE-LDL was generated in the arterial wall this modified form of 
LDL has also been detected in blood (Lopes-Virella & Virella, 2010). AGE-LDL, like other 
AGE-containing proteins, is recognized in circulation by RAGE. RAGE activation stimulates 
cytokyne and growth factors release (Ramasamy, 2009). An excess of stimulation (i.e. an 
excess of AGE-LDL) plays an essential role in atherogenic alterations.  
3.3 Carbamylated LDL (ca-LDL)  
Carbamylation of proteins is a post-translational modification in which amine-containing 
residues react with cyanate, a compound that derives from urea or from thiocyanate. This 
modification is relatively frequent in patients with chronic uremia or in heavy smokers. Both 
situations are closely related to  increased cardiovascular risk and carbamylated LDL (ca-
LDL) is increased in the plasma in  both groups of subjects (Basnakian, 2010). Ca-LDL is 
recognized by SR, promotes monocyte adhesion to endothelium, stimulates cell proliferation 
and causes cell injury (Apostolov, 2007; Carracedo, 2011).   
3.4 Desialylated LDL (ds-LDL)  
Native LDL has high content of sialic acid in the carbohydrate chains attached to apoB. 
Tertov and colleagues isolated a fraction of desialylated LDL from plasma (Tertov, 1990). 
This fraction, which was increased in patients with advanced atherosclerosis, induced foam 
cell formation in cultured smooth muscle cells and presented inflammatory properties 
(Orekhov, 1991). They suggested that low sialic acid in LDL was a cardiovascular risk factor 
(Ruelland, 1993) but this idea was not supported by other authors (Cerne, 2002). Later 
studies revealed that desialylated LDL was oxidized and that the loss of sialic acid was a 
consequence of oxidative modification (Tertov, 1995).   
4. Electronegative LDL, a pool of modified LDL in blood 
A common characteristic of most of the previously described modifications is an increase of 
the negative electric charge. Taking advantage of this property, Avogaro and co-workers 
fractionated total LDL from human plasma  by anion-exchange chromatography, into two 
subfractions, a major subfraction of native LDL and an electronegatively-charged fraction of 
LDL (LDL(-)) (Avogaro, 1988). In this first report, LDL(-) accounted for 5-20% of total LDL 
in normolipemic subjects and presented a number of atherogenic characteristics, including 
impaired binding to LDLr, high aggregation level, capacity to induce cholesterol 
accumulation in macrophages and higher conjugated diene (a by-product of lipid 
peroxidation) content. Since then, a number of studies have tried to elucidate the physico-
chemical and biological characteristics of LDL(-) and its relationship with atherosclerosis. 
4.1 Origin of LDL(-) – Discrepancies regarding the oxidative origin  
Early studies focused on the physico-chemical characteristics LDL(-) concluded, in 
accordance with the high content of oxidized lipids, that LDL(-) was the in vivo 
counterpart of in vitro oxidized LDL (Cazzolato, 1991). However, as isolation procedures 
improved and measures to prevent modification increased, the proportion of LDL(-) and 
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the content in lipoperoxides decreased (De Castellarnau, 2000; Demuth, 1996; Sevanian, 
1997). Discrepancies regarding the increased content in oxidized lipids in LDL(-), 
continue; some authors do not find differences compared to native LDL (Benitez, 2007b; 
Demuth, 1996; Sanchez-Quesada, 2003), and others report increased amounts of oxidized 
lipids in LDL(-) (Asatryan, 2003; Sevanian, 1997; Ziouzenkova, 2002). But in any case, this 
level of lipoperoxidation is closer to minimally oxidized LDL than to extensively oxidized 




Fig. 1. Formation of LDL(-). The modification of native LDL by one or several mechanisms 
alters the composition of LDL surface. These alterations include the increase of 
inflammatory, proliferative and apoptotic lipids and non-apoB proteins in LDL(-), as well as 
structural abnormalities in apoB. 
4.1.1 Impaired catabolism of LDL 
LDL is a heterogeneous mixture of particles that differ in size (24-28 nm of diameter) and 
density (1.019-1.063 g/ml). Small-dense particles have fewer lipid molecules while large-
buoyant particles have more. It is known that LDL particles at both extremes of the 
density range have increased electronegative charge compared with mid-density particles 
(Lund-Katz, 1998). It has been proposed that the origin of LDL(-) could be related with the 
impairment of the catabolic cascade that transforms VLDL-to-IDL-to-LDL in blood 
(Sanchez-Quesada, 2004). Such impairment leads to the formation of small-dense or large-
buoyant LDL particles. In agreement with this, LDL(-) is most abundant (>80% of LDL(-)) 
in small-dense particles in normolipemic subjects. Interestingly, in hypercholesterolemic 
and hypertriglyceridemic patients, LDL(-) are also abundant large-buoyant particles 
(Sanchez-Quesada, 2002). Another consequence of impaired LDL catabolism is the 
presence of non-apoB proteins in LDL. Theoretically, the protein moiety of LDL consists 
of a single copy of a very large protein, apoB. However, it is known that some particles of 
LDL also contain other proteins. In native LDL, the content of non-apoB proteins is less 
than 1%. In contrast, LDL(-) contains up to 5% of non-apoB proteins (Bancells, 2010a; 
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4.1.2 Lipolysis  
Some characteristics of LDL(-), such as high LPC and NEFA content, suggest that a 
possible mechanism of formation could be mediated by phospholipases. It has been 
described that in vitro modification of LDL with sPLA2 renders modified particles that 
mimics some properties of LDL(-) (Asatryan, 2005; Benitez, 2004a; Benitez, 2004b). On the 
other hand, PAF-AH, which has a 5-10-fold higher activity in LDL(-) than in native LDL, 
could also play a role in increasing the content of LPC and NEFA and in the generation of 
LDL(-) (Gaubatz, 2007; Sanchez-Quesada, 2005). Some type of SMase activity could also 
be involved in LDL(-) generation since a minor subfraction of LDL(-) is aggregated 
(Bancells, 2010b). It has been reported that LDL(-) has an intrinsic phospholipase C-like 
(PLC-like) activity that degrades with high affinity both SM and LPC (Bancells, 2008). The 
origin of such activity is currently unknown, but it could be due to conformational 
changes in apoB. One or a combination of these phospholipolityc activities could be 
involved in the formation of LDL(-). 
4.1.3 Content of non-esterified fatty acids (NEFA)  
NEFA are transported in blood mainly associated to albumin. However, in some 
situations that increase NEFA or decrease albumin there is a partition of NEFA towards 
other proteins, including lipoproteins. In posprandial lipemia or when high energy is 
required (such as during heavy exercise) the increase of NEFA in blood increases LDL(-) 
proportion (Benitez, 2002). NEFA content in LDL(-) is three to four-fold higher than in 
native LDL (Benitez, 2004a; De Castellarnau, 2000; Demuth, 1996). In this context, it has 
been reported that the main determinant of the electronegativity of LDL(-) is NEFA 
(Gaubatz, 2007).  
4.1.4 Non-enzymatic glycosylation  
It would seem reasonable to consider that glLDL contributes in part to the pool of LDL(-), 
especially in diabetic patients. However, most glycated LDL particles isolable by affinity 
chromatography do not have a sufficient negative charge to be isolated with LDL(-) and  the 
content of glLDL in LDL(-) is similar to that in native LDL (Benitez, 2007b; Sanchez-
Quesada, 2005).  
4.1.5 Hemoglobin derivatization and carbamylation 
Patients with severe renal failure have a high proportion of LDL(-) (Asatryan, 2003). It was 
reported that LDL from these patients suffered a cross-linking with hemoglobin, rendering a 
particle with increased negative charge (Ziouzenkova, 2002). Recent studies on 
carbamylated LDL, however, suggest that carbamylation could underlie the high proportion 
of LDL(-) in patients with severe renal disease (Apostolov, 2010). 
4.2 Biological properties of LDL(-)  
Whatever the mechanism involved in its formation LDL(-), has several potentially 
atherogenic properties. These include abnormal binding to receptors, inflammatory and 
cytotoxic properties, high susceptibility to aggregation and increased affinity to PG  
(Fig. 2).  
 




Fig. 2. Atherogenic properties of LDL(-). Modified lipids in LDL(-) surface have 
inflammatory, proliferative and apoptotic capacity. Aggregation, which is induced by the 
formation of ceramide, favours the binding to PGs and increases subendothelial retention. 
The alteration of apoB conformation in LDL(-) induces a partial loss of affinity to the LDLr 
and impairs its plasma clearance.   
4.2.1 Binding to receptors  
LDL(-) presents a partial loss of affinity to the LDLr, a property that could lengthen its half-
life in blood (Benitez, 2004b). It was initially believed that this was due to the derivatization 
of lysines in apoB involved in receptor recognition, in a mechanism similar to oxLDL (MDA-
Lys) or glLDL (glucose-Lys). However, recent studies have shown that lysines in LDL(-) are 
not derivatized but have an altered ionization state due to differences in the conformation of 
apoB (Blanco, 2010). Regarding SR, LDL(-) binds differently to distinct types of SR. The 
increment of electronegativity in LDL(-) is not sufficient to allow its binding to SRA in 
macrophages (Benitez, 2004b). However, it has been reported that LDL(-) binds to another 
SR, LOX-1, in endothelial cells (Lu, 2009). This binding does not promote foam cell 
formation, but could mediate the signaling of endothelial apoptosis.   
4.2.2 Inflammatory activity  
LDL(-) has the ability to activate the transcription factors NF-kB, AP-1 and PPAR, inducing 
the expression of a number of inflammatory molecules in endothelial cells (Abe, 2007; 
Benitez, 2006; De Castellarnau, 2000; Ziouzenkova, 2003). These molecules include cytokines 
(IL6) chemokines (IL8, MCP-1, GRO), vascular adhesion molecules (VCAM) and growth 
factors (GM-CSF, PDGF). Interestingly, LDL(-) also induces the paradoxical expression of 
the anti-inflammatory cytokine IL10 in lymphocytes and monocytes (Benitez, 2007a). It has 
been suggested that IL10 production could be a mechanism to control an excessive 
inflammatory response limiting the extent of injury. LDL(-) could also play a role in 
angiogenesis modulation since it stimulates vascular endothelial growth factor (VEGF) 
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apoB (Blanco, 2010). Regarding SR, LDL(-) binds differently to distinct types of SR. The 
increment of electronegativity in LDL(-) is not sufficient to allow its binding to SRA in 
macrophages (Benitez, 2004b). However, it has been reported that LDL(-) binds to another 
SR, LOX-1, in endothelial cells (Lu, 2009). This binding does not promote foam cell 
formation, but could mediate the signaling of endothelial apoptosis.   
4.2.2 Inflammatory activity  
LDL(-) has the ability to activate the transcription factors NF-kB, AP-1 and PPAR, inducing 
the expression of a number of inflammatory molecules in endothelial cells (Abe, 2007; 
Benitez, 2006; De Castellarnau, 2000; Ziouzenkova, 2003). These molecules include cytokines 
(IL6) chemokines (IL8, MCP-1, GRO), vascular adhesion molecules (VCAM) and growth 
factors (GM-CSF, PDGF). Interestingly, LDL(-) also induces the paradoxical expression of 
the anti-inflammatory cytokine IL10 in lymphocytes and monocytes (Benitez, 2007a). It has 
been suggested that IL10 production could be a mechanism to control an excessive 
inflammatory response limiting the extent of injury. LDL(-) could also play a role in 
angiogenesis modulation since it stimulates vascular endothelial growth factor (VEGF) 





2008; Tai, 2006). The specific molecules that mediate these actions are not well defined; LPC 
and NEFA probably play a major role, but the action of oxidized lipids remains under 
discussion (Abe, 2007; Benitez, 2004a; Chen, 2004). If they are present in LDL(-) they could 
stimulate inflammatory responses, but it is also possible that high PAF-AH activity in LDL 
(-) degrades readily oxidized phospholipids (Benitez, 2003). Their degradation products, 
LPC and short-chain NEFA, would therefore be responsible for triggering inflammation. 
4.2.3 Cytotoxicity and apoptosis  
LDL(-) induces citotoxicity and apoptosis in endothelial cells and macrophages by different 
signaling pathways. The mechanisms involved are well defined, especially in endothelial 
cells, where LOX-1 signaling inhibits fibroblast growth factor 2 (FGF2) transcription and Akt 
phosphorilation (Chen, 2003; Chen, 2007; Lu, 2008; Tang, 2008; Yang, 2007). In contrast, 
macrophage apoptosis involves the Fas/FasL signaling pathway and the activation of the 
transcription factor Nrf2 (Pedrosa, 2010).  
4.2.4 Binding to proteoglycans  
LDL(-) and PG present a high affinity for binding (Bancells, 2009). This could favor the 
subendothelial retention of LDL(-) and trigger the inflammatory response. Some 
characteristics in LDL(-) are involved in this higher affinity. Aggregation of lipoproteins 
favors PG binding, and LDL(-) has a high tendency to aggregate (Bancells, 2010b). In fact, a 
subfraction of aggregated LDL(-) is responsible for the binding to PG (Bancells, 2009). This 
subfraction has an abnormal conformation that exposes an epitope in apoB, known as site 
Ib, that is an alternative binding site to PGs (Bancells, 2011). 
4.3 Physico-chemical characteristics of LDL(-)  
4.3.1 Structure  
The earliest physical abnormalities reported in LDL(-) were a great heterogeneity in size and 
density and a high susceptibility to aggregation (Avogaro, 1988). A subpopulation of 
aggregated LDL(-) has recently been isolated and characterized. This subpopulation, which 
accounts for only 0.1-0.5 of total LDL in blood, has high affinity to arterial PG (Bancells, 
2009). This increased binding seems to be mediated by abnormal conformation of the amino-
terminal extreme of apoB (Bancells, 2011). Further evidence of apoB misfolding, in this case 
affecting LDLr binding, has been obtained by two dimensional nuclear magnetic resonance 
analyses (Blanco, 2010). LDL(-) is reported to promote aggregation of non-aggregated LDL 
particles in a process that fits an amyloidogenic model (Parasassi, 2008). It has been reported 
that the capacity to induce aggregation could be mediated by the PLC-like activity (Bancells, 
2010b), although other authors have suggested that plasma sPLA2 could be involved in apoB 
misfolding (Greco, 2009). Regarding secondary structure of apoB, some authors have 
reported loss of secondary -helix structures whereas others did not find differences with 
native LDL (Asatryan, 2005; Bancells, 2009; Benitez, 2004b; Parasassi, 2001). 
4.3.2 Lipids  
Although there are contradictory data regarding differences in the lipid content between 
native LDL and LDL(-) most studies concur in a higher content of triglycerides, NEFA and 
LPC in LDL(-) (Cazzolato, 1991; De Castellarnau, 2000; Sanchez-Quesada, 2003; Sevanian, 
1997; Yang, 2003). The high content of triglycerides reflects impairment of the VLDL-to-IDL-
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to-LDL cascade. High NEFA could be a consequence of the increase in NEFA concentration 
in plasma (posprandial lipemia, intense exercise) (Benitez, 2002; Ursini, 1998), or it could 
come from lipolysis mediated by phospholipases (Benitez, 2004a). This latter possibility 
would be the same mechanism of increased LPC content in LDL(-).  
4.3.3 Proteins  
The most abundant proteins in LDL(-) are apoA-I (0.15 molecules/particle of LDL(-)), apoE 
(0.22), apoC-III (0.37) and apoA-II (0.14), with a content 3-5 fold higher in LDL(-) than in 
native LDL (Bancells, 2010a). The role of these proteins is unclear but their relevance is 
probably low. However, other proteins whose absolute content in LDL(-) is lower, such as 
apoF (0.06 molecules/particle), apoJ (0.01) or PAF-AH (0.004) (Bancells, 2010a; Yang, 2007), 
but their relative content compared with native LDL is 10, 20 and 100-fold higher, 
respectively, could have a much more relevant role. ApoF is the physiological inhibitor of 
cholesteryl ester transfer protein (Morton, 2008), a protein that regulates the catabolism of 
the VLDL-IDL-LDL cascade. It could therefore be one cause of impaired LDL(-) maturation. 
ApoJ (also known as clusterin) is an extracellular chaperone that binds to hydrophobic 
unfolded proteins, favoring their extracellular clearance (Oda, 1995). ApoJ binds mainly to 
aggregated LDL(-), supporting the presence of misfolded apoB in this subfraction. The role 
of PAF-AH in LDL(-) would be to deactivate oxidized phospholipids, but its undesirable 
effect would be the formation of LPC and short-chain NEFA. It has been suggested that the 
PLC-like activity present in LDL(-) could act in cooperation with PAF-AH degrading LPC 
(Bancells, 2010b). Therefore, this would be a mechanism to limit the deleterious effects 
exerted by minimal LDL oxidation on vascular cells. 
4.4 Association of LDL(-) with cardiovascular risk   
The proportion of LDL(-) is increased in a number of pathologic situations having a  
cardiovascular risk. Familial hypercholesterolemia and hypertriglyceridemia present a 
proportion of LDL(-) 3-5 fold higher than normolipemic healthy subjects (Sanchez-Quesada, 
2002; Sanchez-Quesada, 1999). These results were obtained using ultracentrifugation plus 
anion-exchange chromatography, both being laborious and time-consuming techniques. 
This limits their use for routine analysis of lipoprotein profiles. However, more reliable 
techniques for rapid analysis have recently been developed, including capillary 
electrophoresis and ELISA (Santo Faulin Tdo, 2008; Zhang, 2009; Zhang, 2008). These 
methods have confirmed previous data obtained by anion-exchange chromatography. Statin 
therapy decreases the proportion of LDL(-) but the process is not parallel to the lipid-
lowering effect. This is  because  total LDL cholesterol decreases very rapidly (in 2 weeks)  
whereas LDL(-) decreases more slowly (in up to six months)  (Sanchez-Quesada, 1999). This 
suggests that LDL(-) generation not only depends on lipid metabolism but also on other 
factors such as chronic inflammation.  
Both type 1 and type 2 diabetics have a high proportion of LDL(-) (Moro, 1998; Sanchez-
Quesada, 1996; Sanchez-Quesada, 2001; Zhang, 2005). This would suggest that non-
enzymatic glycosylation could be involved. However, insulin therapy decreases LDL(-) in 
type 1 diabetes but not in type 2 diabetes. The different response to insulin treatment has 
been attributed to differences in the systemic inflammation level, which is higher in type 2 
patients. This agrees with the finding that pre-diabetic insulin-resistant subjects with high 
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hyperglycemia would not promote the increase of LDL(-) directly but through an increase of 
systemic inflammation. Another group of subjects with a high proportion of LDL(-) are 
patients with severe renal disease (Ziouzenkova & Sevanian, 2000). It has been described 
that -tocopherol supplementation decreases LDL(-) in hemodialysis patients (Mafra, 2009).  
Regarding patients with established coronary disease, it has been shown that LDL(-) is 
increased in patients with angiographically documented coronary artery disease (Tomasik, 
2003). Moreover, acute coronary syndromes, such as unstable angina or acute myocardial 
infarction, have higher levels of LDL(-) than chronic coronary syndromes (Mello, 2011). 
These observations support the partial subendothelial origin of LDL(-) and open the 
possibility for  LDL(-) to be used as a biomarker of the progression of atherosclerotic lesions.  
5. Conclusion  
LDL is modified by several mechanisms that confer a number of atherogenic properties to 
these particles. Although it is believed that such modifications are more frequent in the 
subendothelial space of the artery wall than in blood, different types of modified LDL have 
been detected in plasma. LDL(-) is a mixture of modified LDL particles that represent the 
total pool of modified LDL in plasma. The biological and physico-chemical characteristics of 
LDL(-) and  its association with high cardiovascular risk indicate that this lipoprotein plays 
a direct role in the development of atherosclerosis. However, although statin and insulin 
treatment decrease the proportion of LDL(-) , the development of a specific therapy for  
LDL(-) would be of great interest. Another field of research would be the use of LDL(-) as a 
biomarker. This could be a promising strategy to evaluate the cardiovascular risk and to 
monitor the success of distinct therapeutic strategies. 
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1. Introduction 
Atherosclerosis is a complex, multifactorial disease, developed in the arterial wall in 
response to various forms of injurious stimuli, resulting in excessive inflammatory and 
fibro-proliferative reactions. The endothelial cells are involved in all stages of atherogenesis 
and their dysfunction is a key initial event in the atherosclerotic plaque formation 
(Simionescu, 2007). The vascular endothelium, with its broad spectrum of paracrine and 
autocrine functions, can be regarded as a multifunctional organ and “chief governor” of 
body homeostasis. Occupying a strategic location between the blood and tissues, the 
endothelial cells exist in a “high-risk position” and react progressively to aggressive factors, 
at first by modulation of the constitutive functions - permeability and biosynthesis 
(Simionescu & Antohe, 2006; Sima et al., 2009). Atherogenesis is an intricate process 
involving hyperlipidemia, oxidative stress and vascular inflammation. Among the diversity 
of mechanisms implicated in the pathogenesis of atherosclerotic vascular diseases two of 
them have been discovered in parallel and studied extensively: the oxidation of low-density 
lipoprotein (LDL) and the synthesis of endothelium-derived nitric oxide (NO). 
1.1 Relationship between oxidized LDL and NO as biomarkers of oxidative stress and 
endothelial dysfunction 
Oxidized LDL and NO are recognized to exert contradictory actions within the vascular 
endothelium microenvironment and to influence the key events in the development of 
atherosclerosis such as leukocyte adhesion, platelet aggregation and vascular smooth-
muscle cell proliferation and migration. While oxidized LDL (oxLDL) - a biomarker of 
lipoprotein-associated oxidative stress, is identified as a non-traditional pro-atherogenic 
emerging cardiovascular risk factor, NO is a free radical signal-transducing molecule that 
maintains the vasodilating tone, modulates in vitro lipid peroxidation reactions and alters 
proinflammatory gene expression (Figure 1). 
Endothelial dysfunction - known to precede the development of atherosclerosis, is a 
systemic pathological state of the endothelium defined as an imbalance between 
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vasodilating and vasoconstricting substances produced by (or acting on) the endothelium 
(Deanfield et al., 2007), leading to a reduced vasodilation, and even a proinflammatory and 
prothrombotic state (Cottone & Cerasola, 2008). 
The most important of the vasodilating substances is nitric oxide, characterized as a non-
eicosanoid component of endothelial-derived relaxation factor (EDRF), which is 
continuously synthesized by the endothelium under the action of different neurohumoral 
mediators such as acetylcholine, histamine, bradikinine, vasopressine, thrombine and 
serotonine (Rubbo et al., 1996).  
 
 
Fig. 1. Antiatherogenic effects and role of nitric oxide (NO) versus proatherogenic actions of 
oxidized LDL (oxLDL) exerted on vascular endothelium. 
NO is produced by a variety of mammalian cells including: vascular endothelial cells, 
neurons, smooth muscle cells, macrophages, neutrophils, platelets, cardiomyocytes and 
pulmonary epithelium. The family of three enzymes responsible for the synthesis of NO, 
nitric oxide synthases (NOSs): endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) 
require calmodulin binding for their activities. The inducible nitric oxide synthases are 
transcriptionally regulated by cytokines and redox-sensitive transcriptional factors. Bacterial 
and parasitic antigens, which potently induce the expression of cytokines, also lead to 
induction of iNOS gene expression (Rubbo et al., 1996; Lundberg & Weitzberg, 2005). 
In the endothelial microenvironment, concurrently, a variety of substances that adversely 
influence endothelial function have been recognized, including free fatty acids, cytokines 
such as TNF-, and prooxidant molecules - including oxidized low-density lipoprotein 
(oxLDL). There are strong evidences for the role of oxidative stress in all stages of 
atherogenesis. Among different molecular targets affected by oxidative stress associated 
with hyperlipidemia and hyperglycemia, LDL is one of the most significant because is the 
major cholesterol carrier in the blood and contains also a relevant amount of 
polyunsaturated fatty acids (PUFAs) - the major substrate for lipid peroxidation.  
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The initial event in atherogenesis is the increased transcytosis of low-density lipoprotein, 
and its subsequent deposition, retention and oxidative modification in the subendothelium. 
It is followed by the infiltration of activated inflammatory cells from the coronary 
circulation into the arterial wall (Hulsmans & Holvoet, 2010).  
The oxLDL is a byproduct of exposure to reactive oxygen species (ROS), and several 
potential mechanisms have been proposed for LDL oxidation: cell-mediated lipoxygenase 
and myeloperoxidase activities, non-enzymatic metal ion-mediated oxidation (iron, copper), 
superoxide generators (xanthine oxidase, NADPH-oxidase), thiol-dependent oxidation, 
peroxynitrite and other radical generation compounds (Parthasarathy et al., 2008). 
Oxidatively modified lipoproteins lead to progression of atherosclerosis through 
macrophages engulfing oxLDL at the level of scavenger receptors, intracellular depositing of 
cholesterol esters and at last macrophages transformation into foam cells. Also,  oxLDL can 
induce an immune response leading to anti-oxLDL autoantibodies production, which will 
determine formation of immune complexes (Steinberg et al., 1989; Tsimikas & Witztum, 
2001; Parthasarathy et al., 1999, 2008).  
Endothelium relaxant factor is a central molecule in vascular homeostasis as a modulator of 
endothelial tone and reactivity, exerting pleiotropic positive effects on the cardiovascular 
system. Important for the cardiovascular biology is the consumption of NO by reactive 
oxygen species. Oxidative modification of NO not only leads to reduced bioavailability but 
also produces the toxic oxidant peroxynitrite (ONOO-), which further aggravates the 
imbalance of protective and aggressive factors (Cai & Harrison, 2000; Schnabel & 
Blankenberg, 2007). Subsequently, LDL oxidative modifications are made possible through 
simultaneous NO and superoxide anion radical (O2.-) actions.  
A key determinant of the pro-oxidant versus oxidant-protective influences of NO is the 
underlying oxidative status of tissue. When NO is in excess of surrounding oxidants, lipid 
oxidation and monocyte margination into the vascular wall are attenuated, producing 
antiatherogenic effects. However, when endogenous tissue rates of oxidant production are 
accelerated or when tissue oxidant defenses become depleted, NO gives rise to secondary 
oxidizing species that can increase membrane and lipoprotein lipid oxidation as well as 
foam cell formation in the vasculature, thus promoting proatherogenic effects (Bloodsworth 
et al., 2000). 
Therefore, targeting particularly upstream targets – substrates for oxidation and 
inflammation, will be important to better understand interactions of hyperlipidemia, 
inflammation and oxidation.  
Current evidence suggests that endothelial function is an integrative marker of the net 
effects of damage from traditional and emerging risk factors on the arterial wall and its 
intrinsic capacity for repair. This endothelial-dependent vascular biology is critical, not only 
in the initiation and progression of atherosclerosis, but also in the transition from a stable to 
an unstable disease state with attendant risks. As a result, study of endothelial function has 
emerged as an important endpoint in clinical research (Deanfield et al., 2007). 
1.2 Oxidized LDL and NO endothelial synthesis as factors affecting the vascular 
ageing 
Diseases of the vascular system have long been considered to be age-related in terms of their 
onset and progression. Longevity is a vascular question. More than 50 years ago, a famous 
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old as his arteries”. Senescent cells undergo distinct changes in gene expression that may 
cause an impairment of cellular function. In endothelial cells these changes result in a 
phenotype that is pro-inflammatory, pro-atherosclerotic, and prothrombotic. Endothelial 
cell senescence can be induced by a number of factors implicated in vascular pathologies, 
particularly by sustained cell replication and oxidative stress (Erusalimski, 2009). 
Oxidative stress and inflammation are major determinants of arterial and biological ageing. 
Recent studies underscore the association between white blood cell (WBC) telomere length, 
as index of systemic aging, oxidized LDL, and human vascular aging, expressed by the 
distensibility of the carotid artery. Results showed that higher levels of oxidized LDL are 
associated with shorter WBC telomeres and increased stiffness of the carotid artery (Nawrot 
& Staessen, 2008; Nawrot et al., 2010). 
Ageing is characterized not only by a reduced arterial compliance and alteration of the 
contractile properties of the vascular wall, but also by endothelial dysfunction (Alvarez de 
Sotomayor, et al., 2005; Brandes et al., 2006). At present, there are several reasons to believe 
that in vivo NO synthesis from L-arginine could indeed be impaired in atherosclerosis, 
hypertension, dyslipidemia, diabetes, obesity, insulin resistance, metabolic syndrome, as 
well as in ageing (Lind, 2002; Laroia et al., 2003; Hsueh & Quinones, 2003; Holvoet et al., 
2003, 2008a; Vickers et al., 2009; Park et al., 2009; Njajou et al., 2009; Huang, 2009; Park et al., 
2011; Tabit et al., 2010).  
Recent studies support the fact that advancing age increases the LDL susceptibility to 
oxidation and decreases the nitric oxide availability and bioactivity (Heffernan et al., 2008). 
Not only LDL but also very low-density lipoprotein (VLDL), beta–VLDL and even HDL 
undergo oxidative modification that must be taken into consideration in the complex 
process of atherosclerosis (Parthasarathy et al., 2008). In elderly, higher oxLDL levels were 
associated with high coronary risk before any clinical manifestation of CHD (Holvoet et al., 
2003), and with higher arterial stiffness, independent of cardiovascular disease risk factors 
(Brinkley et al., 2009). The oxLDL/Apo-B100 ratio and to a lesser extent the oxLDL/LDL-C 
ratio were significantly negative associated with the flow-mediated-dilation (FMD) of the 
brachial artery (van der Zwan et al., 2009). 
1.3 Methods for measuring the circulating oxidized LDL and NO endothelial synthesis 
Oxidative biomarkers are now showing strong associations with progression of coronary 
artery disease (CAD) and predict cardiovascular events, suggesting that they may serve as 
surrogates and may complement diagnostic investigations. Both in vitro and in vivo, low-
density lipoprotein (LDL) particles are susceptible to oxidation and peroxidation by all of the 
causes of oxidative stress. Therefore, oxidized LDL are included among the “downstream 
markers” of oxidative stress.  During the last decade, several monoclonal antibodies have been 
generated, each recognizing at least a substantial subset of the whole spectrum of oxLDL 
particles, leading to a myriad of new reports on the relation between circulating ox-LDL and 
cardiovascular pathological processes (Itabe and Ueda, 2007; Tsimikas, 2006).  
Currently used assays for oxLDL detect minimally oxidized LDL particles. In addition, 
concentrations of oxLDL depend on the sensitivity of LDL to oxidation; small dense LDLs 
contain smaller amounts of antioxidants and are, therefore, more prone to oxidation. The 
widely applied sensitive immunoassay quantifying the circulating levels of oxLDL uses a 
monoclonal antibody – 4E6, directed against oxidized apolipoprotein B-100 moiety of LDL 
(Rietzschel et al., 2008; Holvoet et al., 2008b).  
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The NO activity is assessed representatively using a variety of clinical invasive and 
noninvasive methods among which, the use of acetylcholine that induces endothelium-
dependent dilation and smooth muscle–mediated constriction. The coronary artery diameter 
is compared by quantitative angiography before and after infusion of acetylcholine. The 
functional status of the coronary microvasculature can also be assessed using intracoronary 
Doppler ultrasound to measure blood flow in resistance vessels in response to substances 
that produce either endothelial-dependent or endothelial-independent vasodilation. Another 
noninvasive method of detecting endothelial dysfunction uses high-resolution ultrasound to 
measure the brachial artery diameter in response to reactive hyperemia, which stimulates 
NO release and FMD (Davignon & Ganz, 2004). 
NO present in the circulation is originating from endothelial, smooth muscle cells, 
thrombocytes, leukocytes and cardiomiocytes. NO activity is the net result of a balance 
between its production and its inactivation by oxygen free radicals. NO released “in vivo” 
by nitric oxide synthase (NOS) activity in endothelial cells and platelets, rapidly 
autooxidizes to yield nitrite (NO2-), which interacts with oxyhemoglobin yielding nitrate 
(NO3-). Because nitrite plus nitrate are relatively stable compounds in blood, their levels 
may be a biochemical index of systemic NO production. This is convenient because direct in 
vivo measurements of NO can be very difficult due to the extremely low levels and its short 
half life. When combined measurements of nitrate and nitrite are conducted, this is usually 
denoted by the term NOx (Lundberg & Weitzberg, 2005; Hirata et al., 2010).  
2. Study on correlations of oxLDL and NOx with the metabolic profile in 
elderly with hyperlipidemia 
The LDL oxidation and nitric oxide are the key mediators involved in all stages of 
atherosclerosis: initiation, progression and complications. Their role is antagonistic: oxLDL 
have pro-atherogenic and NO antiatherogenic functions on vascular endothelium (Figure 1). 
A reduction in NO production or activity has been proposed as major mechanisms of 
endothelial dysfunction and a contributor to atherosclerosis. The endothelial dysfunction is 
considered an early marker for atherosclerosis and can be detected before structural changes 
in the vascular wall. An impairment of NO bioactivity or synthesis will reduce its braking 
effect on processes involved in atherogenesis. 
2.1 Purpose 
In the present study we evaluated the levels of circulating oxidized LDL (oxLDL) and the 
basal plasma levels of the NO metabolic pathway products, NOx (NO2- + NO3-), and 
examined their relationships with the global metabolic profile in a group of elderly patients 
with hyperlipidemia. We explored the determinants of oxLDL and NOx, as well as the 
relation between oxLDL and NOx in order to investigate whether the oxLDL/NOx and 
oxLDL/HDL-cholesterol ratios are more informative than the individual variables. 
2.2 Materials and methods 
2.2.1 Study design  
The study population included 170 subjects (72 men and 98 women) aged 60 - 70 years, of 
the patients hospitalized at the Ana Aslan- National Institute of Gerontology and Geriatrics 
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The NO activity is assessed representatively using a variety of clinical invasive and 
noninvasive methods among which, the use of acetylcholine that induces endothelium-
dependent dilation and smooth muscle–mediated constriction. The coronary artery diameter 
is compared by quantitative angiography before and after infusion of acetylcholine. The 
functional status of the coronary microvasculature can also be assessed using intracoronary 
Doppler ultrasound to measure blood flow in resistance vessels in response to substances 
that produce either endothelial-dependent or endothelial-independent vasodilation. Another 
noninvasive method of detecting endothelial dysfunction uses high-resolution ultrasound to 
measure the brachial artery diameter in response to reactive hyperemia, which stimulates 
NO release and FMD (Davignon & Ganz, 2004). 
NO present in the circulation is originating from endothelial, smooth muscle cells, 
thrombocytes, leukocytes and cardiomiocytes. NO activity is the net result of a balance 
between its production and its inactivation by oxygen free radicals. NO released “in vivo” 
by nitric oxide synthase (NOS) activity in endothelial cells and platelets, rapidly 
autooxidizes to yield nitrite (NO2-), which interacts with oxyhemoglobin yielding nitrate 
(NO3-). Because nitrite plus nitrate are relatively stable compounds in blood, their levels 
may be a biochemical index of systemic NO production. This is convenient because direct in 
vivo measurements of NO can be very difficult due to the extremely low levels and its short 
half life. When combined measurements of nitrate and nitrite are conducted, this is usually 
denoted by the term NOx (Lundberg & Weitzberg, 2005; Hirata et al., 2010).  
2. Study on correlations of oxLDL and NOx with the metabolic profile in 
elderly with hyperlipidemia 
The LDL oxidation and nitric oxide are the key mediators involved in all stages of 
atherosclerosis: initiation, progression and complications. Their role is antagonistic: oxLDL 
have pro-atherogenic and NO antiatherogenic functions on vascular endothelium (Figure 1). 
A reduction in NO production or activity has been proposed as major mechanisms of 
endothelial dysfunction and a contributor to atherosclerosis. The endothelial dysfunction is 
considered an early marker for atherosclerosis and can be detected before structural changes 
in the vascular wall. An impairment of NO bioactivity or synthesis will reduce its braking 
effect on processes involved in atherogenesis. 
2.1 Purpose 
In the present study we evaluated the levels of circulating oxidized LDL (oxLDL) and the 
basal plasma levels of the NO metabolic pathway products, NOx (NO2- + NO3-), and 
examined their relationships with the global metabolic profile in a group of elderly patients 
with hyperlipidemia. We explored the determinants of oxLDL and NOx, as well as the 
relation between oxLDL and NOx in order to investigate whether the oxLDL/NOx and 
oxLDL/HDL-cholesterol ratios are more informative than the individual variables. 
2.2 Materials and methods 
2.2.1 Study design  
The study population included 170 subjects (72 men and 98 women) aged 60 - 70 years, of 
the patients hospitalized at the Ana Aslan- National Institute of Gerontology and Geriatrics 





criteria. The subjects did not have diabetes or any liver, kidney, hematological or oncological 
overt diseases. We selected in a first group 125 subjects with a high cardiovascular risk lipid 
profile characterized by hypercholesterolemia [serum total cholesterol (TC) > 200 mg/dL 
and LDL-cholesterol (LDL-C) > 130 mg/dL], associated or not with hypertriglyceridemia 
[serum triglycerides (TG) < or > 150 mg/dL]. Subjects were not previously diagnosed with 
cardiovascular disease and were not under treatment with any vasoactive or cardiovascular 
drugs. None of the patients used lipid-lowering therapy or antioxidants. The second group 
considered as the control group included 45 apparently healthy subjects with normal lipid 
profile (TC < 200 mg/dL, LDL-C < 130 mg/dL and TG < 150 mg/dL). Anthropometric and 
clinical characteristics were collected after a complete clinical examination. All the 
participants in this study gave their written informed consent, and the study protocol was 
approved by the Ana Aslan - NIGG ethics committee. All the procedures followed were in 
accordance with the institutional guidelines. Venous blood samples were drawn after an 
overnight fast and 24-hours refraining from smoking, caffeinated foods and beverages. 
2.2.2 Biochemical methods 
Total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides 
(TG) and glycemia (G) were determinated by standard enzymatic methods. Results were 
expressed in mg/dL.  
The circulating plasma oxLDL was evaluated by a competitive ELISA kit with the 
monoclonal antibody 4E6 (kit 10-1158-01, Mercodia, Sweden) directed against an epitope in 
the apolipoprotein B-100 moiety of oxLDL, formed from substitution of lysine residues of 
apoB-100 with aldehydes (Holvoet et al., 2008). Results were expressed in U/L plasma. 
The total amount of plasma stable metabolic pathway products of NO, [NOx, the sum of 
nitrites and nitrates (NO2- + NO3-)] was determined using the Griess reagent, following the 
quantitative conversion of nitrates (NO3-) to nitrites (NO2-), with nitrate reductase (kit  
23479, SIGMA). Results were expressed in µmols NOx/L plasma. All the biochemical and 
immunoenzymatic tests were performed on a ChemWell 2190 Analyser (Awareness 
Technology, USA). 
The plasma atherogenic index (Ai) was calculated by the logarithmically transformed ratio of 
triglycerides on HDL-cholesterol (TG/HDL-C) (1) (Dobiasova, 2006; Dobiasova et al., 2011). 
 Ai = log(TG/HDL-C)  (1) 
2.2.3 Statistical analysis 
Data are expressed as meansSD. The subjects clinical characteristics were compared using 
the Mann Whitney Wilcoxon non-parametric test. Differences in means of studied 
parameters between the groups (hyperlipidemic vs. control group) were assessed by 
Student’s paired t test. The Pearson’s correlation test was used to perform bivariate 
correlation analysis. Multiple regression analysis was performed to evaluate the 
independent relation between studied parameters using the Statistical Package for Social 
Sciences software (SPSS) version 15. Significance was defined at the 0.05 level of confidence. 
2.3 Results 
The study population included 170 subjects aged 60-70 years. In order to establish the link of 
the traditional markers for the evaluation of the cardiovascular risk (TC, TG and LDL-C) at 
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systemic level with the oxidative stress and endothelial function parameters, patients were 
divided into two groups: a group with normal lipid profile (TC<200 mg/dL, LDL<130 
mg/dL, TG<150 mg/dL; n=45), and a group with high cardiovascular risk lipid profile  
(TC>200 mg/dL, LDL>130 mg/dL, TG < or > 150 mg/dL; n = 125).  
We firstly collected anthropometric data (body weight, height), clinical parameters, 
including systolic blood pressure, body mass index (BMI), fasting plasma glucose and the 
lipid profile in the two groups of our interest.  
Both cardiovascular disease risk and healthy control subjects showed not significantly 
different values of weight and body mass index, but systolic blood pressure, fasting plasma 
glucose and triglycerides were significantly higher in hyperlipidemic patients. The HDL-
cholesterol concentrations of the two groups were comparable. The atherogenic index and 
the TC /HDL-cholesterol ratio were significantly higher in hyperlipidemic group versus 
control (Table 1).  
Also, the increased lipid profile group had a significantly higher circulating levels of oxLDL 
associated with a significant decrease of the plasma nitric oxide metabolic pathway products 
(NOx) compared to the normolipidemic group (Table 1).  
 
Variables Control Group 
(n = 45) 
Hyperlipidemic 
Group 
(n = 125) 
Age (years) 653 664 
Sex (males/females) 15/30 55/70 
Systolic blood pressure (mmHg) 115.616.0 129.021.5** 
Diastolic blood pressure (mmHg) 74.69.7 73.512.7 
Body mass index (kg/m2 ) 22.52.9 23.25.3 
Glucose (mg/dL) 9112 10012** 
Total cholesterol (mg/dL) 18222 28532** 
Triglycerides (mg/dL) 7722 10348** 
LDL-cholesterol (mg/dL) 10524 21435** 
HDL-cholesterol (mg/dL) 5611 549 
Total cholesterol/HDL-C ratio 3.400.83 5.341.11** 
Atherogenic index (Ai) 0.130.15 0.240.19** 
Uric acid(mg/dL) 5.872.07 6.091.94 
oxLDL (U/L) 71.5113.11 85.5020** 
NOx (µmol/L) 32.5210.63 23.528.66** 
oxLDL/HDL cholesterol ratio 1.350.46 1.620.58* 
oxLDL/NOx ratio 2.440.92 4.131.87** 
Values are expressed as meansstandard deviation LDL, low-density lipoprotein; HDL-C high-density 
lipoprotein cholesterol; oxLDL, oxidized low-density lipoprotein; NOx,  nitric oxide metabolic pathway 
products * p values derived from Student t test: significantly different vs. control group;  
* p < 0.01;  ** p < 0.001 
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To establish which variables other than LDL-C and NO were independent determinants of 
oxLDL and NO, we explored multiple linear regression models with oxLDL, NOx, 
oxLDL/HDL-C ratio and oxLDL/NOx ratio, as dependent variables, in control, 
hyperlipidemia, and whole study population. The results are presented in Table 2 and 3 and 
Figures 3-6. 
In multiple regression analysis for estimating the association between the degree of 
endothelial dysfunction and metabolic parameters, we found different statistically 
significant correlations within the two study groups. Tables 2 and 3 show the correlations of 
oxLDL and NOx with serum metabolic variables, atherogenic markers and indices in 
normal and hyperlipidemic subjects.  
In the control group (table 2) circulating oxLDL level positively correlated with glycemia 
and triglycerides, as well as the total cholesterol/HDL-cholesterol ratio.  
In subjects with high cardio-vascular risk (table 3) significant positive correlations between 
oxLDL and LDL-cholesterol were pointed out. In both study groups oxLDL was 
significantly negative correlated with HDL-cholesterol, and significantly positive with the 
atherogenic index (Ai).  
 
Variables oxLDL oxLDL/HDL-C ratio NOx 
oxLDL/NOx 
ratio 
Control Group (n = 45) 
Glucose (mg/dL) 0.351* 0.273 (NS) 0.164 (NS) - 0.004 (NS) 
Total cholesterol 
(mg/dL) 0.257 (NS) - 0.470** - 0.088 (NS) 0.097 (NS) 
Triglycerides (mg/dL) 0.358* 0.273 (NS) - 0.259 (NS) 0.414** 
LDL-cholesterol 
(mg/dL) 0.257 (NS) 0.396** - 0.024 (NS) 0.031 (NS) 
HDL-cholesterol 
(mg/dL) - 0.471** - 0.832** 0.081 (NS) - 0.291 (NS) 
Total cholesterol/HDL-
C 0.528** 0.537** - 0.075 (NS) 0.252 (NS) 
Atherogenic index (Ai)  0.502** 0.605** - 0.267 (NS) 0.234** 
Uric acid(mg/dL) 0.200 (NS) 0.063 (NS) 0.184 (NS) - 0.045 (NS) 
oxLDL (U/L)  0.850** 0.074 (NS) 0.404** 
oxLDL/HDL-C ratio 0.850**  0.045 (NS) 0.357* 
NOx (µmol/L) 0.074 (NS) 0.045 (NS)  - 0.826** 
oxLDL/NOx ratio 0.404** 0.357* - 0.826**  
LDL, low-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; oxLDL, oxidized low-
density lipoprotein; NOx,  nitric oxide metabolic pathway products  
* p < 0.05; ** p < 0.01; NS, non-significant 
Table 2. Interrelationships between studied markers of lipoxidative stress, endothelial 
function, and metabolic profile parameters, in control subjects, determined as Pearson’s 
correlation coefficients (r).  
As regards the nitric oxide metabolic pathway products, the statistical analysis of the data 
pointed out a significant negative correlation, between NOx and the total cholesterol/HDL-
cholesterol ratio, but only in the hyperlipidemic group (Table 2 and 3).  
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Variables oxLDL oxLDL/HDL-C ratio NOx 
oxLDL/NOx 
ratio 
Hyperlipidemic Group (n = 125) 
Glucose (mg/dL) 0.275** 0.329** - 0.096 (NS) 0.245** 
Total cholesterol (mg/dL) 0.390** 0.298** - 0.340** 0.437** 
Triglycerides (mg/dL) 0.320** 0.293** 0.037 (NS) 0.128 (NS) 
LDL-cholesterol (mg/dL) 0.377** 0.391** - 0.315** 0.411** 
HDL-cholesterol (mg/dL) - 0.445** - 0.762** 0.011 (NS) - 0.223* 
Total cholesterol/HDL-C 
ratio 0.578** 0.796** - 0.191* 0.416** 
Atherogenic index (Ai) 0.549** 0.637** 0.054 (NS) 0.220* 
Uric acid(mg/dL) 0.270** 0.201* 0.158 (NS) - 0.006 (NS) 
oxLDL(U/L)  0.895** - 0.143 (NS) 0.641** 
oxLDL/HDL-C ratio 0.895**  - 0.111 (NS) 0.546** 
NOx (µmol/L) - 0.143 (NS) - 0.111 (NS)  - 0.729** 
oxLDL/NOx ratio 0.641** 0.546** - 0.729**  
LDL, low-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; oxLDL, oxidized low-
density lipoprotein; NOx,  nitric oxide metabolic pathway products 
* p < 0.05; ** p < 0.01; NS, non-significant 
Table 3. Interrelationships between studied markers of lipoxidative stress, endothelial 
function, and metabolic profile parameters, in hyperlipidemic subjects, determined as 
Pearson’s correlation coefficients (r) 
To further estimate the extent of oxLDL involvement in endothelial dysfunction, the ratio of 
oxLDL to HDL-cholesterol and the newly introduced ratio of oxLDL to NOx, were 
calculated.  
Significant differences as regards oxLDL/HDL-cholesterol ratio as well as oxLDL/NOx 
ratio were found out between the study groups; both ratios were higher in the 
hyperlipidemic subjects (Table 1).  
Moreover, in the group of subjects with cardiovascular risk, oxLDL/NOx ratio correlated 
significantly with almost each of the traditional parameters of the metabolic profile, namely: 
glycemia, total cholesterol, LDL-cholesterol and HDL-cholesterol, as well as the Ai and 
cardiovascular risk markers (TC/HDL-C and oxLDL/HDL-C ratios) (Table 3). 
We explored the metabolic determinants of oxLDL and NOx by performing the statistical 
multiple correlation test in the whole study population (n=170). Regarding the oxLDL we 
identified significant (p < 0.01) positive correlations with each studied parameters of the 
metabolic profile, such as glycemia (r = 0.351), total cholesterol (r = 0.457), LDL-cholesterol 
(r = 0.456), triglycerides (r = 0.414) and uric acid (r = 0.253). A strong significant negative 
association between oxLDL and HDL-C (r= -0.425, p <0.01) was pointed out. 
In all 170 subjects we pointed out significantly negative correlations (p < 0.01) of NOx levels 
and lipid profile: total cholesterol (r = - 0.470), LDL-C (r = - 0.451), and the atherogenic risk 
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Fig. 2. Plasma nitric oxide metabolic pathway products (NOx) is inversely correlated with 
total cholesterol/HDL-cholesterol ratio in all the study subjects (n=170) 
Finally, it is important to underscore the most interesting significant, negative, 
correlation, identified between oxLDL and NOx (r = - 0.205, p < 0.01; n = 170) in all study 
population (Figure 3). In the hyperlipidemic group this association was negative but not 
significant. 
The newly introduced ratio oxLDL/NOx was significantly related to the ratio oxLDL/HDL 
(r = 0.547, p < 0.01, n=170), the atherogenic index (Ai) and also the total cholesterol/HDL-
ratio (r = 0.478, p < 0.01 and r = 0.537, p < 0.01) (Figure 4 - A, B, C).   
 
 
Fig. 3. Oxidized LDL (oxLDL) levels are inversely associated with plasma nitric oxide 
metabolic pathway products (NOx) in all the study subjects (n = 170). 
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Fig. 4. oxLDL/NOx ratio is directly correlated with total cholesterol/HDL-cholesterol ratio 
(A), with oxLDL/HDL-cholesterol ratio (B), and with the Atherogenic index (C)  in all the 
study subjects (n=170) 
2.4 Discussion 
The purpose of this work was to point to the interrelationships of oxLDL and NO as 
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negatively correlated with circulating oxLDL concentrations. Overall, this work pointed out 
the link between the vascular endothelium vasodilating/vasoconstricting imbalance and the 
metabolic profile in hyperlipidemic elderly patients. 
The evaluations of LDL-cholesterol, high-density lipoprotein-cholesterol, and triglycerides 
are the traditionally recommended lipid screening tests for coronary heart disease (CHD). 
Several studies do suggest that total cholesterol/HDL-cholesterol ratio, a major lipid index, 
is better than the individual total cholesterol, LDL-cholesterol, HDL-cholesterol, and 
triglycerides parameters (Lemieux et al., 2001). This ratio is easily obtained and one of the 
most powerful important risk factors for CHD. Both oxLDL and NOx significantly 
correlated with all markers and calculated atherogenic indices (TC/HDL-C, oxLDL/HDL-C 
and Ai). Hence, our data support the fact that measurements of the oxLDL and NOx levels 
at different times may help to monitor the state and severity of endothelial dysfunction. 
Based on the multiple correlations analysis in both study groups and all subjects we found 
that TC, TC/HDL-C, and oxLDL/HDL-C ratios are major determinants of oxLDL and NO. 
These associations are stronger for the newly introduced oxLDL/NOx ratio. As well, the 
oxLDL/NOx ratio is strongly correlated with the atherogenic index and more importantly, 
with the oxLDL/HDL-C ratio, the best lipid biomarker used for discriminating between 
coronary artery disease patients and healthy control subjects, and also the best blood 
biomarker that reflects atherosclerotic disease activity in the arterial wall (Huang et al., 2008; 
Lankin et al., 2011) 
Our results are in accordance with literature with regard to the damaging effects of 
hyperlipidemia, mediated or stimulated by oxidative stress. Numerous studies have 
supported the role of hyperlipidemia in atherosclerosis, endothelial dysfunction and 
progression of coronary heart diseases (Wallace et al., 2010; Deanfield et al., 2007; 
Highashino et al., 2010; Van den Oever et al., 2010). The hypothesised mechanisms for this 
effect are via hyperlipemia-induced oxidative stress, especially LDL oxidation and 
subsequent reduced NO bioavailibility. The strong significant association of oxidized LDL 
with plasma lipid profile (TC, LDL-C, TG), atherogenic risk markers (TC/HDL-c, 
oxLDL/HDL) and atherogenic index (Ai) found out in the hyperlipidemic group as well as 
the whole population studied, underscore the validity of the observation that hyperlipemia 
induces LDL oxidation and oxidative stress. The oxidative stress generates the superoxide 
radicals (O2.-), which are scavenged by nitric oxide to form peroxynitrite (ONOO-), a 
powerful oxidant. The overproduction of O2.- has direct and indirect effects on vascular NO 
bioavailability. Moreover, O2.- and  ONOO. can oxidize tetrahydrobiopterin (BH4), the 
cofactor necessary for NO production by eNOS enzyme, leading to eNOS uncoupling, and 
thus to more O2.- generation and reduced NO production. Also, the significant negative 
correlation found out in this study between oxLDL and NOx shows that the excess of LDL 
oxidation itself may contribute to reduce NO level. Taken toghether, hyperlipidemia, 
oxidative stress and LDL oxidation result in reduced NO bioavailability via combinatory 
effects of direct elimination and decreased production of NO. This NO reduced 
bioavailability compromises all the antiatherogenic functions of the endothelium. This 
hypothesised mechanism shown above could be a target for interventions to protect against 
hyperlipidemia-induced atherogenesis and cardiovascular disease. 
Based on the strong interrelationships pointed out in this clinical study and the numerous 
experimental and clinical research in the field of atherosclerosis we summarize in figure 5 
the important relationships among hyperlipidemia, oxidative stress, LDL oxidation, nitric 
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oxide and endothelial dysfunction. Hyperlipidemia, oxidative stress and LDL oxidation are 
harmful at multiple steps in atherogenesis, including direct contributions to endothelial 
functions. As shown in figure 5, hyperlipidemia induces enhanced oxidative stress, 
superoxide (O2.-) excessive generation and LDL oxidation. Increased O2.- generation as a 
result of excess mitochondrial lipid oxidation, LDL oxidation and other sources, is critically 
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Fig. 5. Simplified scheme of the interrelationships between oxidative stress, LDL oxidation 
and NO in the hyperlipidemic state leading to endothelial dysfunction. 
There is abundant experimental evidence indicating the role of NO oxidative inactivation as 
a mediator of endothelial dysfunction and a pre-pathogenic vascular phenotype (Harrison, 
1997; Bermudez et al., 2008). The NO is the kinetically preferred scavenger for O2.-, because 
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superoxide dismutase (SOD) (Beckman & Koppenol, 1996; Cai & Harrison, 2000). Both 
excess generation of reactive oxygen species (ROS) including O2.- and oxidized LDL, and 
decreased antioxidant defence mechanisms  contribute to enhanced degradation  of  NO. 
Many studies support the role of the O2.- as an essential element in the decrease of NO 
bioavailability in oxidative stress conditions. Thus, studies on rabbbits with aortic 
atherosclerosis, demonstrated a remarkable decrease in endothelium-related relaxation, 
which was corrected by SOD treatment (Dulak et al., 1997). 
Also, peroxynitrite is itself a powerful oxidant which contributes to enhance oxidative 
stress and turn the balance NO - ROS in the favour of ROS. Both radicals, O2.- and ONOO- 
can oxidize tetrahydrobiopterin (BH4) leads to eNOS uncoupling, which in turn will 
produce O2.- instead of NO, and activate this vicious cycle (Fostermann, 2006). 
Uncoupling eNOS directly leading to decreased NO production. Not only BH4 oxidation, 
but also decreases in BH4 concentrations may reduce the NO production. Thus, many 
studies have shown a significant decrease in BH4 activity in various pathological states, 
such as: hyperlipidemia, hypercholesterolemia, insulin resistance, probably through the 
oxLDL increase, as well as increased expression in some proinflammatory cytokine (TNF-
alpha, interleukin-1 beta) (Bowers et al., 2011; Wever et al., 1997; Stroes et al., 1997). 
Furthermore, clinical and experimental studies have confirmed these mechanisms, 
showing that acute administration of BH4 improve the endothelial dysfunctions related to 
hyperlipidemia, atherosclerosis and hypertension (Setoguchi et al., 2001). Also, a decrease 
in arginine and consequently a lack in eNOS substrate bioavailability leads to a failure in 
NO synthesis (Bermudez et al, 2005). 
Recent in vitro studies (Bowers et al., 2011) demonstrated that tetrahydrobiopterin (BH4) 
could reduce oxLDL-induced O2.- production by NADPH oxidase, increasing NO synthesis 
in endothelial cells. The superoxide anion production was increased by pretreatment of cells 
with an inhibitor of BH4 synthesis, and decreased following pretreatment with a BH4 
precursor. Thus, BH4 concentrations can modulate the NADPH oxidase-induced imbalance 
of endothelial NO and O2.- production. BH4 may be critical in combating oxidative stress, 
restoring proper redox state and reducing risk for cardiovascular disease including 
atherosclerosis. 
Other mechanisms are also involved in the interrelations of LDL oxidation, nitric oxide and 
endothelial dysfunction. The oxidized LDL may reduce eNOS levels by inhibiting eNOS 
gene expression (Dulak et al., 1997) and also can displace eNOS from caveolae by binding to 
endothelial cell CD36 receptors and by depleting caveolae cholesterol content and therefore 
disrupt eNOS activity (Barbato et al., 2004). These adverse effects of oxLDL are prevented by 
HDL via binding to scavenger receptor BI (SR-BI), colocalized with eNOS in endothelial 
caveolae. This occurs through the maintenance of caveolae cholesterol content by cholesterol 
ester uptake from HDL. Moreover, HDL binding to SR-BI may stimulate eNOS activity in 
endothelial cells, and enhance endothelium- and NO-dependent relaxation. Thus, 
lipoproteins have potent effects on eNOS function in caveolae via actions on both membrane 
cholesterol homeostasis and the level of activation of the enzyme, processes that may be 
critically involved in the earliest phases of atherogenesis (Rigotti et al., 1997; 
Uittenbogaraard et al., 2000; Yuhanna et al., 2001; Schaul, 2003). The significant negative 
correlations between HDL and oxLDL, oxLDL/HDL ratio, atherogenic index and more 
important oxLDL/NO ratio pointed out in hyperlipidemic group and all subjects, 
underscore the beneficial effect of HDL on the endothelium. 
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Recent studies demonstrated that oxLDL causes impairment of endothelium-dependent, 
nitric oxide-mediated vasodilation involving L-arginine deficiency. The oxLDL may reduce 
L-arginine availability to eNOS for NO production, by up-regulating arginase. The 
experimental studies indicated that oxLDL increased arginase expression in the vascular 
wall without altering eNOS expression (Wang et al., 2011). 
Experimental studies underscore the dual role of oxLDL on endothelial cells causing either 
proliferation or apoptosis, depending on its concentration and exposure time (Galle et al., 
2001). Thus, oxLDL induced proliferation at low (5 to 10 microg/mL) and apoptosis at 
higher concentrations (50 to 300 microg/mL). Both effects are mediated by O2.- formation via 
NADPH oxidase as it major source. Thus, oxLDL contributes importantly to vascular 
cellular turnover through the induction of oxidative stress. More recently, was 
demonstrated that oxLDL at low concentrations (5 microg/mL) promotes in vitro 
angiogenesis and activate nitric oxide synthase through Pl3K/Akt/eNOS pathway in 
human coronary artery endothelial cells (Yu et al., 2011). 
On the whole, the decline in nitric oxide bioavailability is caused by the cummulative effects 
of many factors and processes discussed above: the decreased expression of the endothelial 
NO synthase, a reduction of substrate or cofactors for eNOS, alterations of cellular signaling, 
eNOS inhibition by asymmetric demethyl arginine, reduced NO production and accelerated 
NO degradation by hyperlipidemia, oxidative stress and LDL oxidation.  
Taking into account overall the atherogenic properties of oxidized LDL, involved in all 
stages of atherosclerosis (Steinberg et al., 1989; Steinberg, 2009), and the vasoprotective and 
antioxidant functions of NO (Bermudez et al., 2008; Yasa & Turkseven, 2005), we introduced 
for the first time the ratio oxLDL to NOx for quantifying their possible cumulative effect on 
vascular endothelium. The strong positive associations of this ratio with the atherogenic 
index and the atherogenic risk markers: TC/HDL and oxLDL/HDL ratios, supported us to 
propose this newly introduced ratio (oxLDL/NOx) as a potential marker of endothelial 
dysfunction. The future in depth studies, will take into consideration the association with 
clinical parameters of vascular endothelial functions using acethylcholine to induce 
endothelium dependent dilation, quantitative angiography, and high resolution ultrasound 
to measure brachial artery diameter, to further support this new candidate marker. 
Wu et al., (2006) suggested in a prospective cohort study that circulating oxLDL as an 
individual parameter, measured with antibody 4E6, was not an independent overall 
predictor of coronary heart disease (CHD), after adjustment of lipid markers and less 
predictive in development of CHD than apoB and total cholesterol/HDL-cholesterol ratio 
(Wu et al., 2006). Therefore, based on the results obtained in our study it is important to 
examine in future research whether the ratio oxLDL to NOx correlates with endothelial 
function and predicts CHD independently of the lipid markers.  
Data of this study support the relevance of oxLDL and NOx as biomarkers reflecting, at 
systemic level, the progressive damage at cellular level under the action of prooxidant 
pathogenic factors. These biomarkers could be valuable in the complex evaluation of 
oxidative stress in the endothelium. 
Despite numerous evidences of oxidative processes involved in atherosclerosis and the 
multiple experimental research on their inhibition by traditional antioxidants, and the 
success in several animal trials, the human clinical trials using antioxidants have failed 
(Parthasarathy et al., 2008; da Luz et al., 2006). There were not taken into consideration all 
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lesions, their interrelations, and the most important the pro-oxidant properties and actions 
of antioxidants in different oxidative process steps and disease stages. 
These interrelatioships pointed out in our study could be very important in the management 
of new effective therapeutic strategies for atherosclerosis and cardiovascular disease. 
Because oxidative stress, LDL oxidation and endothelial dysfunction centrally contributes to 
cardiovascular disease, further sustained efforts must be undertaken to translate this 
knowledge into the characterization and identification of biomarkers that enable preventive 
or early detection of injuries and allow improved risk stratification by integration into 
cardiovascular risk stratification models.  
2.5 Limitations of our study 
The study population included only elderly and therefore the results may be different in 
other age-groups subjects, in order to have identified the early onset of hyperlipidemia-
induced vascular impairment. Another important limitation was that we did not evaluate 
the endothelial function using the flow-mediated dilation (FMD) and ultrasound 
examination of the right brachial artery.  
3. Conclusion 
The results of this correlations study pointed out that in hyperlipidemic elderly patients the 
endothelial NO synthesis could indeed be impaired and associated with a higher oxidative 
stress exerted on circulating LDL particles. Oxidized LDL has a large range of biological 
effects that contribute to atherogenesis, but NO also has many biological effects that prevent 
atherogenesis. In this context, the interrelations pointed out between hyperlipidemia, 
oxidative stress, LDL oxidation and nitric oxide leading to endothelial dysfunctions, 
emphasized their implications in molecular mechanisms of endothelial dysfunction.  
It is important to distinguish between the effect of oxidized LDL and the effect of a 
deficiency in the release of NO and to draw a link between these two biomarkers. According 
to the results obtained in this study, we propose the use of a new marker of endothelial 
dysfunction, the ratio of oxLDL to NOx, which could be a more accurate estimation of the in 
vivo cumulative implications of oxLDL and NO in atherogenesis. Future studies taking into 
account the association of this newly introduced marker with other markers of endothelial 
function will be undertaken to support the marker validity. 
The strong interrelations pointed out in our study underscore the molecular mechanisms 
implicated in endothelial dysfunctions and atherosclerosis presented in this chapter. Future 
research is needed to translate this knowledge into the identification, characterization and 
validation of new and known biomarkers of lipoxidative stress-induced endothelial 
dysfunctions and atherosclerosis, and their integration into cardiovascular risk 
stratifications models. 
These findings suggest the importance of understanding the senescent specific changes 
occurring in endothelium associated with age-related disease. Such an understanding may 
not only provide answers regarding mechanisms of disease development, but may also 
provide biomarkers of endothelium specific ageing.  
As perspectives, the nutritional and therapeutic strategies should attempt to correct the lipid 
profile and lipoxidative stress in order to prevent the amplification of redox and 
inflammatory phenomena that lead to increased cardiovascular risk. As well, therapeutic 
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approaches in the prevention and treatment of atherosclerosis based on improving NO 
bioactivity and reducing LDL oxidation may become a challenge for future studies. 
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lesions, their interrelations, and the most important the pro-oxidant properties and actions 
of antioxidants in different oxidative process steps and disease stages. 
These interrelatioships pointed out in our study could be very important in the management 
of new effective therapeutic strategies for atherosclerosis and cardiovascular disease. 
Because oxidative stress, LDL oxidation and endothelial dysfunction centrally contributes to 
cardiovascular disease, further sustained efforts must be undertaken to translate this 
knowledge into the characterization and identification of biomarkers that enable preventive 
or early detection of injuries and allow improved risk stratification by integration into 
cardiovascular risk stratification models.  
2.5 Limitations of our study 
The study population included only elderly and therefore the results may be different in 
other age-groups subjects, in order to have identified the early onset of hyperlipidemia-
induced vascular impairment. Another important limitation was that we did not evaluate 
the endothelial function using the flow-mediated dilation (FMD) and ultrasound 
examination of the right brachial artery.  
3. Conclusion 
The results of this correlations study pointed out that in hyperlipidemic elderly patients the 
endothelial NO synthesis could indeed be impaired and associated with a higher oxidative 
stress exerted on circulating LDL particles. Oxidized LDL has a large range of biological 
effects that contribute to atherogenesis, but NO also has many biological effects that prevent 
atherogenesis. In this context, the interrelations pointed out between hyperlipidemia, 
oxidative stress, LDL oxidation and nitric oxide leading to endothelial dysfunctions, 
emphasized their implications in molecular mechanisms of endothelial dysfunction.  
It is important to distinguish between the effect of oxidized LDL and the effect of a 
deficiency in the release of NO and to draw a link between these two biomarkers. According 
to the results obtained in this study, we propose the use of a new marker of endothelial 
dysfunction, the ratio of oxLDL to NOx, which could be a more accurate estimation of the in 
vivo cumulative implications of oxLDL and NO in atherogenesis. Future studies taking into 
account the association of this newly introduced marker with other markers of endothelial 
function will be undertaken to support the marker validity. 
The strong interrelations pointed out in our study underscore the molecular mechanisms 
implicated in endothelial dysfunctions and atherosclerosis presented in this chapter. Future 
research is needed to translate this knowledge into the identification, characterization and 
validation of new and known biomarkers of lipoxidative stress-induced endothelial 
dysfunctions and atherosclerosis, and their integration into cardiovascular risk 
stratifications models. 
These findings suggest the importance of understanding the senescent specific changes 
occurring in endothelium associated with age-related disease. Such an understanding may 
not only provide answers regarding mechanisms of disease development, but may also 
provide biomarkers of endothelium specific ageing.  
As perspectives, the nutritional and therapeutic strategies should attempt to correct the lipid 
profile and lipoxidative stress in order to prevent the amplification of redox and 
inflammatory phenomena that lead to increased cardiovascular risk. As well, therapeutic 
Oxidized LDL and NO Synthesis as  
Biomarkers of Atherogenesis  Correlations with Metabolic Profile in Elderly 
 
489 
approaches in the prevention and treatment of atherosclerosis based on improving NO 
bioactivity and reducing LDL oxidation may become a challenge for future studies. 
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1. Introduction 
Modest levels of stored iron, far less than conventional iron overload, may promote 
cardiovascular disease, i.e.  sustained iron depletion may be protective [1-6]. This so-called 
“iron hypothesis” was initially presented to explain for the sex difference in cardiovascular 
disease and the increase in disease following menopause. The idea, although continually 
debated for more than 25 years, has achieved standing as a plausible and testable hypothesis 
[7-18] [19]. 
The hypothesis has not yet been definitively tested. A first randomized clinical trial (FeAST) 
to  address aspects of the hypothesis was recently reported [7]. The FeAST trial [7] had 
significant limitations as a general test of the idea: 1) it was a trial of secondary prevention, 
and 2) the iron reduction protocol fell far short of achieving full iron depletion. Zacharski et 
al [7] reported that reducing iron stores significantly improves survival for patients with 
symptomatic but stable peripheral arterial disease (PAD), if iron reduction begins at a young 
age. The FeAST trial provides compelling support for a new trial designed to test the 
original hypothesis. 
Controversial results from multiple epidemiological studies investigating a variety of 
atherosclerotic events using all kinds of variable parameters of body iron load have 
presented a confusing picture of the iron hypothesis [20]. Confusion became complete when 
it appeared that patients with homozygous hemochromatosis who were afflicted with 
serious, life long iron overload had no increased atherosclerosis and might even be 
protected against atherosclerosis. In the debate on the hypothesis, the disease pattern in 
homozygous hemochromatosis has been intrepreted as perhaps the most persuasive 
evidence against the hypothesis [21]. This “hemochromatosis paradox” is seen as a anomaly 
that makes the hypothesis untenable for some investigators. How can normal stored iron 
levels be bad for the vascular system, when massive amounts of stored iron in genetic iron 
overload are not associated with increased atherosclerosis? 
2. Hemochromatosis and atherosclerosis: More to it than iron load alone 
An early corollary to the iron hypothesis was the proposal that heterozygous 
hemochromatosis might be a significant risk factor for premature myocardial infarction [22]. 
This was proposed despite the general impression at the time that homozygous 
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that makes the hypothesis untenable for some investigators. How can normal stored iron 
levels be bad for the vascular system, when massive amounts of stored iron in genetic iron 
overload are not associated with increased atherosclerosis? 
2. Hemochromatosis and atherosclerosis: More to it than iron load alone 
An early corollary to the iron hypothesis was the proposal that heterozygous 
hemochromatosis might be a significant risk factor for premature myocardial infarction [22]. 
This was proposed despite the general impression at the time that homozygous 





absence of definitive data, this was not seen as necessarily incompatible with the iron 
hypothesis [22-24]. An impact on cardiovascular event rates in hemochromatosis was not 
excluded based on available data. In addition, even without promotion of atherosclerosis by 
genetic iron overload, relevant issues that continue to be unresolved include roles of 
hemochromatosis mutation-associated iron overload in myocardial reperfusion injury [2;24-
26] and endothelial dysfunction [27;28]. Future investigations are needed, as long term 
exposure to non-transferrin bound iron (NTBI) in genetic iron overload may contribute to 
life-long progression of atherosclerosis as it promotes monocyte-endothelium interaction 
and inflammatory pathways. 
Mutational effects other than promotion of an increase in total body iron were not 
considered in the  1990 hypothesis relating heterozygosity to early onset of myocardial 
infarction [22]. The idea that total body iron load was the only factor that might influence 
cardiovascular disease expression in hemochromatosis was restated as recently as 2007 in a 
JAMA editorial on the status of the iron hypothesis by Hu [8]: 
“The 1996 discovery of HFE gene mutations responsible for most cases of hereditary hemochromatosis 
[[29]] has led to the use of genetic markers of iron stores (ie, heterozygosity for the C282Y mutation 
in the HFE gene as a marker of lifelong moderate iron overload) in epidemiologic studies. In contrast 
to biomarkers, genetic markers of iron overload can be measured exactly and are not influenced by 
such factors as inflammation, recent blood loss, diet, and use of medications (eg, aspirin).” 
The corollary hypothesis that heterozygosity might be associated with myocardial infarction 
[22] led to a number of investigations, especially after the identification of the disease-
causing mutation in most cases of hemochromatosis in 1996 [29]. Early findings appeared to 
support some increase in cardiovascular events among heterozygotes [23;30;31]. However, 
these studies taken together with  subsequent investigations [32-36] do not support an 
increase in myocardial infarction, stroke or atherosclerosis in patients who are heterozygous 
for hemochromatosis. In fact, the body of relevant work, including some older studies 
[37;38] does not exclude protection against atherosclerosis in hemochromatosis. In an 
autopsy series that examined coronary artery disease in heavily iron overloaded 
individuals, Miller and Hutchins [37] reported an odds ratio of coronary artery disease with 
iron overload of 0.18. This is suggestive of a significant protective effect in patients 
presumptively homozygous for hemochromatosis who comprised 80% of the autopsy cases 
reviewed by Miller and Hutchins [37]. Could some poorly understood feature of 
homozygous hemochromatosis confound the relationship between iron load and 
atherosclerosis?  
3. Hepcidin and a resolution of the hemochromatosis paradox 
An iron loading mutation is not just “a marker of lifelong moderate iron overload” as 
indicated by Hu [8]. Hemochromatosis mutations also radically alter the distribution of 
body iron [39]. Iron-poor Kupffer cells adjacent to iron-loaded hepatocytes are a classic 
finding in hereditary hemochromatosis [39]. Another classic finding in homozygotes is a 
relative scarcity of coronary artery iron deposition despite extensive iron deposits in 
myocardial tissue [39;40]. 
In 1998, Moura et al [41] reported that monocytes from hereditary hemochromatosis patients 
released twice as much iron in the low molecular weight form as normal human monocytes 
after erythrocyte phagocytosis. Thus, even before the discovery and understanding of the 
iron regulatory hormone, hepcidin [42-44], there was an understanding of  “a macrophage 
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defect in hemochromatosis leading to a constriction. of the macrophage/reticuloendothelial iron pool” 
[24]. This macrophage defect [41] in hereditary hemochromatosis was suggested as a factor that might 
“protect homozygotes from foam cell formation and thus, to a degree, gives some specific protection 
against atherosclerosis,” [24] with a partial protective effect in heterozygotes. 
The discovery of hepcidin [42-44] and the details of its influence on iron metabolism [45-49] 
illuminated patterns of macrophage iron retention and led to a conceptual volte-face on the 
possibility of diminished atherosclerosis in homozygotes [4;6].  
Hepcidin is the major regulator for the amount of iron retained within macrophages. 
Production of hepcidin is regulated by iron intake and a number of interrelated factors. 
Elevated levels, favoring macrophage iron retention, are seen with increased iron intake, 
infection and inflammation. Iron loading in secondary iron overload in wild type 
individuals is associated with increased hepcidin expression. Reduced hepcidin levels and 
iron-poor macrophages accompany iron deficiency, hypoxia, anemia and hereditary 
hemochromatosis. Hepcidin binds to the iron exporter protein ferroportin, leading to the 
internalization, and intracellular degradation of ferroportin. Loss of the iron exporter 
function of ferroportin from macrophages leads to intracellular retention of iron and to 
reduced serum iron levels. In intestinal epithelial cells, hepcidin-induced loss of ferroportin 
results in reduced iron internalization into the systemic circulation.   
Remarkably, the most extreme reductions in hepcidin level are associated with the opposite 
extremes of total body iron load, i.e. in iron deficiency anemia and in homozygous 
hemochromatosis [50]. Loss of hepcidin expression can be produced by mutations in 
hepcidin, hemojuvelin, TFR2, and HFE [51]. Mutations at these sites leads to hereditary iron 
overload. In this discussion, the term “hemochromatosis” indicates hereditary iron overload 
associated with one of the mutations causing lower hepcidin expression. The homozygous 
HFE C282Y mutation is the most common cause of hereditary iron overload and is 
associated with lower liver expression of hepcidin mRNA [51]. 
The very low hepcidin levels seen in homozygous hemochromatosis are associated with 
systemic iron loading because reduced hepcidin levels permit unregulated ferroportin-
mediated transfer of iron from intestinal epithelial cells into the systemic iron pool. The 
more extreme the degree of hepcidin deficiency, the more severe the level of parenchymal 
iron load, but also the more extreme the macrophage iron retention deficit. These patterns 
offer a potential resolution of the paradox of the proposed protection by iron depletion in 
wild type subjects against cardiovascular disease despite of the lack of increased 
atherosclerosis in genetic iron overload [4;6]. Hepcidin may act as an iron-dependent risk 
factor for atherosclerosis by causing iron loading of plaque macrophages with promotion of 
foam cell formation. According to this proposal, hepcidin amplifies the plaque iron loading 
effects of an increased iron load as iron itself upregulates hepcidin concentration. At the 
other end of the iron status spectrum, iron deficiency downregulates hepcidin and promotes 
removal of iron from plaque macrophages. In hemochromatosis, the associated hepcidin 
deficiency is hypothesized to reduce progressive iron accumulation within arterial walls and 
foam cell formation. Hemochromatosis patients may thus enjoy a specific protection against 
plaque progression in proportion to the severity of hepcidin deficiency. Hepcidin deficiency 
would not protect these patients from direct iron-mediated injury to heart muscle from 
parenchymal iron accumulation in myocardial tissue. The corollary hypothesis that 
identifies hepcidin as a risk factor for atherogenesis [4] may explain the conundrum of 
decreased atherosclerosis in the face of massive iron loading and provide additional 
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Previous studies, especially the work of Miller and Hutchins [37] and Pirart and Barbier [38], 
raised the possibility of a protective effect of hereditary hemochromatosis against 
atherosclerosis. An unknown “facteur constitutionnel” [38] linked to hemochromatosis that 
enhances resistance to vascular lesions was proposed. A mechanistic hypothesis to explain 
the findings [37;38] was not proposed as the studies were done prior to identification of 
either the principal iron overloading genotypes or the iron regulatory hormone hepcidin. 
More recent evidence supporting the hypothesis that hemochromatosis-associated hepcidin 
deficiency is protective against atherosclerosis has been reported [52]. Valenti et al [52] 
studied vascular disease, iron status, hepcidin levels and HFE mutations in 506 consecutive 
patients with nonalcholic fatty liver disease (NAFLD). None were homozygous for 
hereditary hemochromatosis. Serum ferritin was associated with common carotid intima-
media thickness (CC-IMT) (p = 0.048) and with prevalence of atherosclerotic carotid plaques 
(p = 0.0004), except in patients whose heterozygous HFE mutations lower hepcidin levels. 
Hyperferritinemia was associated with vascular damage only in patients with wild type 
HFE genotypes (p<0.0001). Hepcidin was elevated in those without such an HFE mutation 
and was found to be an independent predictor of the presence of carotid atherosclerosis. 
4. Iron, hepcidin, inflammation and vascular disease 
Inflammation accelerates atherogenesis [53]. The mechanism may involve iron- and 
hepcidin-mediated mechanisms [4;6]. Hepcidin is upregulated by interleukin-6 (IL-6), a 
cytokine induced by inflammatory processes. IL-6 has also been found to be a 
cardiovascular disease risk factor [54]. An important end result of any process that induces 
IL-6 is increased deposition of iron within reticuloendothelial cells, including atherosclerotic 
plaque macrophages, because of hepcidin upregulation. Continued inflammation-mediated 
hepcidin synthesis maintains iron in storage sites even in the face of a low hematocrit as in 
the anemia of inflammation (i.e. the “anemia of chronic disorders”). 
Hepatic hepcidin may be normally upregulated in inflammation even in hemochromatosis 
homozygotes who usually have markedly low hepcidin levels [55]. The effects of 
inflammatory processes in hemochromatosis patients on possible redistribution of iron from 
parenchymal cells to the reticuloendothelial compartment, including arterial plaque 
macrophages, are not currently known. Interactions between mutational effects and 
inflammation-induced effects on hepcidin level may result in complex epidemiological 
patterns in studies of cardiovascular disease expression in hemochromatosis patients.  
5. Blunted inflammatory responses in macrophages in hemochromatosis or 
induced iron depletion 
A recent study of macrophages in the Hfe knockout (Hfe -/-) mouse [56] is pertinent to the 
present discussion of iron, inflammation and atherosclerosis. Wang et al [56] found 
attenuated inflammatory responses in a mouse model of human hemochromatosis and 
reduced translation of cytokine mRNAs in Hfe -/-  macrophages in response to Salmonella 
and LPS exposure. Intramacrophage iron levels were decreased in the Hfe -/- mice in 
association with upregulation of macrophage iron exporter ferroportin (FPN). Salmonella- 
and LPS-induced inflammatory responses were diminished in the Hfe knockout animals. 
Less severe enterocolitis was observed in vivo and reduced macrophage TNF-  and IL-6 
secretion was observed in vitro.  
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Of special significance in the present discussion, the reduced translation of cytokine mRNAs 
of the mutant macrophages could be reproduced in wild-type cells by reducing the 
intracellular iron concentration with chelation. Atherosclerotic plaque macrophages in 
patients with hemochromatosis mutations associated with diminished hepcidin may display 
similar attenuated inflammatory responses such as those from Hfe -/- mice [56], and thereby 
a diminished tendency to form atherosclerotic foam cells. 
6. Iron, hemochromatosis and other cell types in vascular disease 
Iron plays a role in vascular disease in other cell types than the macrophage, e.g.  
endothelial cells [3;9;14;18;57-59] and vascular smooth muscle cells [60-62]. Patients with 
hemochromatosis have endothelial dysfunction that is improved by iron reduction therapy 
[63]. This suggests that iron overload itself rather than mutational effects of iron overload 
genes influences endothelial function.  Proliferaton of vascular smooth muscle cells [60-62] 
also requires iron. How hemochromatosis mutations might modifies iron-mediated 
atherogenic processes in these cell types will require additional studies. 
7. Serum cholesterol level, hemochromatosis, macrophage iron loss, and 
cardiovascular disease 
Adams et al [64] reported that hemochromatosis patients homzygous for C282Y have 
diminished serum cholesterol and low-density lipoprotein (LDL) levels. Systemically lower 
cholesterol and LDL could represent an additional mechanism by which hemochromatosis 
patients are relatively protected from atherosclerosis.  This could be associated with the iron 
retention deficit in mutant macrophages. A role for macrophage iron metabolism in 
regulation of cellular lipid level has been proposed [65]. As noted above, the most extreme 
reductions in hepcidin level are seen at the opposite extremes of total body iron load, i.e. in 
both iron deficiency anemia and in homozygous hemochromatosis. Consistent with a 
hepcidin level similar to that in hemochromatosis, iron deficiency is also associated with 
lower systemic levels of serum cholesterol and LDL [12;66;67]. Future studies are needed to 
determine if lower macrophage iron level in iron deficiency or inherited iron overload 
negatively regulates systemic cholesterol level. 
8. Mutational protection against atherogenesis: Epidemiological implications 
The literature on the role of iron in cardiovascular disease in the general population is 
contradictory and inconsistent, as has often been noted [8]. There have been misconceptions 
regarding the hypothesis leading to inadequate study designs [20;68]. Another key 
limitation of previous studies that has not been addressed is the possibility of a protective 
effect of hemochromatosis mutations against iron-mediated atherogenesis. If 
hemochromatosis mutations confer protection against atherogenesis, previous 
epidemiological studies of iron and atherosclerosis may be critically flawed. The highest 
serum ferritin levels in population groups whose hemochromatosis gene status has not been 
ascertained will select a disproportionate share of subjects who are heterozygous or 
homozygous for hemochromatosis. These high serum ferritin individuals may have less 
disease because of mutational protection against atherosclerosis and may confound 
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9. Penetrance and testing the hepcidin hypothesis 
This problem of clinical penetrance of the hemochromatosis mutations needs to be 
considered in the design of a study to test the hepcidin hypothesis. There is undoubtedy a 
variable impact of genotype on hepcidin expression. Genotype of subjects in a study to test 
the hypothesis shouldbe determined; however, testing the hypothesis would not rely 
directly on showing an association of genotype with disease. The hypothesis suggests that 
protection against atherogenesis is inversely proportional to hepcidin expression. In an 
epidemiological study, the hypothesis suggests that, among those with any one of a number 
of iron overloading genotypes, protection against atherogenesis would be seen in 
proportion to the degree of life long hepcidin downregulation. 
It would be inappropriate to simply look at a group of all subjects with hepcidin 
expression below some prespecified level. It would be necessary to exclude the iron 
deficient subjects from a group defined by such a criterion, as iron deficiency is associated 
with quite low hepcidin levels. A future interventional study of the effect of long term 
iron deficiency-induced reduction in hepcidin expression on atherogenesis would  be of 
interest. 
10. Conclusions and future directions 
The hypothesis that iron depletion protects against atherosclerosis may apply even in 
hemochromatosis homozygotes because of the mutational effect of selective iron depletion 
of the macrophage, a key cell type in atherogenesis. In homozygotes, a sea of tissue iron 
deposition surrounds islands of iron depleted cells of the reticuloendothelial system. Low 
hepcidin expression is a mutational feature of hemochromatosis and also of systemic iron 
deficiency that may protect against iron-mediated atherogenesis in both conditions. What is 
known at present about disease patterns in genetic iron overload is compatible with the 
hypothesis that iron depletion protects against atherosclerosis. Hereditary hemochromatosis 
may be a special case of selective cellular iron depletion that inhibits atherogenesis. 
More detailed investigations are needed on hepcidin as a risk factor for atherosclerosis 
including more studies of atherosclerotic disease in patients with hemochromatosis 
mutations. Work is also needed on the effects of the inflammatory response on iron 
metabolism, especially the impact of inflammatory processes on hepcidin and macrophage 
iron in patients with hemochromatosis mutations.  
It would be of interest to replicate the low hepcidin levels of those with hemochromatosis 
mutations in normal subjects and to assess the effects of low hepcidin levels on 
atherogenesis. A well established and safe method that would have the effect of reducing 
hepcidin production in normal subjects is induced iron depletion. Long-term modest 
reduction in storage iron can be  achieved in patients with established vascular disease and 
is associated with decreased cancer mortality [69] and, among younger participants, 
decreased cardiovascular mortality [7].  
In humans with intact hepcidin responses, atherosclerotic plaque has a substantially higher 
iron concentration than that in healthy arterial wall [15].  Increased lesional iron is also seen 
in cholesterol fed animals. In a series of studies with rabbits fed a 1% cholesterol diet, Watt 
and colleagues [70-74] used nuclear microscopy to show a 7-fold increase in iron 
concentration within newly formed atherosclerotic lesions compared to healthy arteries. 
Iron accumulation was seen at the onset of lesion formation.  
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A role for iron in foam cell formation and lesion progression has been implicated by 
numerous observations and experiments [4-6;75-83]. Recent work shows that iron can be 
mobilized out of atherosclerotic plaque by manipulation of body iron status, and that this 
process may be associated with reduction in lesion size. Animal experiments suggest that 
systemic lowering of stored iron levels reduces intralesional iron content and also the size of 
atherosclerotic plaques [70;84]. It is well known that iron-deficient erythropoiesis can 
mobilize and relocate almost all stored iron in the body to maturing erythroid precursors. In 
iron deficiency, mobilization is facilitated by extreme downregulation of hepcidin. Key 
questions in future human studies include the following: What duration and degree of iron 
reduction therapy is needed for restoring iron levels in atherosclerotic vessel segments to the 
much lower level seen in healthy vascular tissue? How much reduction in the level of 
hepcidin is required to facilitate the relocation of stored iron from intralesional macrophages 
to erythroid precursors? And, is it possible in normal subjects to inhibit the formation of 
atherosclerotic foam cells by rendering their macrophages as iron poor as in those with 
hemochromatosis mutations? 
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known at present about disease patterns in genetic iron overload is compatible with the 
hypothesis that iron depletion protects against atherosclerosis. Hereditary hemochromatosis 
may be a special case of selective cellular iron depletion that inhibits atherogenesis. 
More detailed investigations are needed on hepcidin as a risk factor for atherosclerosis 
including more studies of atherosclerotic disease in patients with hemochromatosis 
mutations. Work is also needed on the effects of the inflammatory response on iron 
metabolism, especially the impact of inflammatory processes on hepcidin and macrophage 
iron in patients with hemochromatosis mutations.  
It would be of interest to replicate the low hepcidin levels of those with hemochromatosis 
mutations in normal subjects and to assess the effects of low hepcidin levels on 
atherogenesis. A well established and safe method that would have the effect of reducing 
hepcidin production in normal subjects is induced iron depletion. Long-term modest 
reduction in storage iron can be  achieved in patients with established vascular disease and 
is associated with decreased cancer mortality [69] and, among younger participants, 
decreased cardiovascular mortality [7].  
In humans with intact hepcidin responses, atherosclerotic plaque has a substantially higher 
iron concentration than that in healthy arterial wall [15].  Increased lesional iron is also seen 
in cholesterol fed animals. In a series of studies with rabbits fed a 1% cholesterol diet, Watt 
and colleagues [70-74] used nuclear microscopy to show a 7-fold increase in iron 
concentration within newly formed atherosclerotic lesions compared to healthy arteries. 
Iron accumulation was seen at the onset of lesion formation.  
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A role for iron in foam cell formation and lesion progression has been implicated by 
numerous observations and experiments [4-6;75-83]. Recent work shows that iron can be 
mobilized out of atherosclerotic plaque by manipulation of body iron status, and that this 
process may be associated with reduction in lesion size. Animal experiments suggest that 
systemic lowering of stored iron levels reduces intralesional iron content and also the size of 
atherosclerotic plaques [70;84]. It is well known that iron-deficient erythropoiesis can 
mobilize and relocate almost all stored iron in the body to maturing erythroid precursors. In 
iron deficiency, mobilization is facilitated by extreme downregulation of hepcidin. Key 
questions in future human studies include the following: What duration and degree of iron 
reduction therapy is needed for restoring iron levels in atherosclerotic vessel segments to the 
much lower level seen in healthy vascular tissue? How much reduction in the level of 
hepcidin is required to facilitate the relocation of stored iron from intralesional macrophages 
to erythroid precursors? And, is it possible in normal subjects to inhibit the formation of 
atherosclerotic foam cells by rendering their macrophages as iron poor as in those with 
hemochromatosis mutations? 
11. Conflict of interest disclosures 
None. 
12. References 
[1] Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1(8233):1293-
1294. 
[2] Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117(5):1177-
1188. 
[3] Sullivan JL. Stored Iron and Vascular Reactivity. Arterioscler Thromb Vasc Biol 2005; 
25(8):1532-1535. 
[4] Sullivan J. Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability. Exp Biol 
Med 2007; 232(8):1014-1020. 
[5] Li W, XU LH, Forssell C, Sullivan JL, YUAN XM. Overexpression of Transferrin 
Receptor and Ferritin Related to Clinical Symptoms and Destabilization of Human 
Carotid Plaques. Proc Soc Exp Biol Med 2008; 233(7):818-826. 
[6] Sullivan JL. Iron in arterial plaque: A modifiable risk factor for atherosclerosis. 
Biochimica et Biophysica Acta (BBA) - General Subjects 2009; 1790(7):718-723. 
[7] Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, 
Ozaki CK, Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in 
Patients With Peripheral Arterial Disease: A Randomized Controlled Trial. JAMA 
2007; 297(6):603-610. 
[8] Hu FB. The Iron-Heart Hypothesis: Search for the Ironclad Evidence. JAMA 2007; 
297(6):639-641. 
[9] Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in 
voluntary blood donors. Arterioscler Thromb Vasc Biol 2005; 25(8):1577-1583. 
[10] Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High 
stored iron levels are associated with excess risk of myocardial infarction in eastern 





[11] Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann 
Med 2003; 35(8):578-591. 
[12] Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies 
in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967:342-351. 
[13] Kell DB. Iron behaving badly: inappropriate Iron chelation as a major contributor to 
the aetiology of vascular and other progressive inflammatory and degenerative 
diseases. BMC Med Genomics 2009; 2(1):2. 
[14] Kartikasari AE, Georgiou NA, Visseren FL, Kats-Renaud H, van Asbeck BS, Marx JJ. 
Intracellular labile iron modulates adhesion of human monocytes to human 
endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24(12):2257-2262. 
[15] Stadler N, Lindner RA, Davies MJ. Direct Detection and Quantification of Transition 
Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of 
Elevated Levels of Iron and Copper. Arterioscler Thromb Vasc Biol 2004; 24(5):949-
954. 
[16] Raman SV, Winner MW, III, Tran T, Velayutham M, Simonetti OP, Baker PB, Olesik J, 
McCarthy B, Ferketich AK, Zweier JL. In Vivo Atherosclerotic Plaque 
Characterization Using Magnetic Susceptibility Distinguishes Symptom-Producing 
Plaques. J Am Coll Cardiol Img 2008; 1(1):49-57. 
[17] You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, Topol EJ, Wang Q. 
Proteomic approach to coronary atherosclerosis shows ferritin light chain as a 
significant marker: evidence consistent with iron hypothesis in atherosclerosis. 
Physiol Genomics 2003; 13(1):25-30. 
[18] Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., Vita JA. Iron 
chelation improves endothelial function in patients with coronary artery disease. 
Circulation 2001; 103(23):2799-2804. 
[19] Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, 
Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron 
correlate with MCP-1 release and vascular damage in patients with metabolic 
syndrome alterations. Arterioscler Thromb Vasc Biol 2011; 31(3):683-690. 
[20] Sullivan JL. Misconceptions in the debate on the iron hypothesis. Journal of Nutritional 
Biochemistry 2001; 12:33-37. 
[21] Burt MJ, Halliday JW, Powell LW. Iron and coronary heart disease [editorial] [see 
comments]. BMJ 1993; 307(6904):575-576. 
[22] Sullivan JL. Heterozygous hemochromatosis as a risk factor for premature myocardial 
infarction. Medical Hypotheses 1990; 31:1-5. 
[23] Sullivan JL. Iron and the Genetics of Cardiovascular Disease. Circulation 1999; 
100(12):1260-1263. 
[24] Sullivan JL, Zacharski LR. Hereditary haemochromatosis and the hypothesis that iron 
depletion protects against ischemic heart disease. Eur J Clin Invest 2001; 31(5):375-
377. 
[25] Kramer JH, Lightfoot FG, Weglicki WB. Cardiac tissue iron: effects on post-ischemic 
function and free radical production, and its possible role during preconditioning. 
Cell Mol Biol (Noisy -Le-Grand) 2000; 46(8):1313-1327. 
[26] Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, Das DK. HFE Mutation 
and Dietary Iron Content Interact to Increase Ischemia/Reperfusion Injury of the 
Heart in Mice. Circ Res 2003; 92(11):1240-1246. 
 
Hemochromatosis and Iron-Mediated Atherogenesis 
 
503 
[27] Kartikasari AER, Georgiou NA, Visseren FLJ, Kats-Renaud H, Sweder van Asbeck B, 
Marx JJM. Endothelial activation and induction of monocyte adhesion by 
nontransferrin-bound iron present in human sera. FASEB J 2005;05-4700fje. 
[28] Lekakis J, Papamicheal C, Stamatelopoulos K, Cimponeriu A, Voutsas A, Vemmos K, 
Mavrikakis M, Stamatelopoulos S. Hemochromatosis associated with endothelial 
dysfunction: evidence for the role of iron stores in early atherogenesis. Vasc Med 
1999; 4(3):147-148. 
[29] Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, 
Domingo R, Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, 
Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, 
Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman 
RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-
like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 
1996; 13(4):399-408. 
[30] Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma 
JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated 
with cardiovascular death in women [see comments]. Circulation 1999; 
100(12):1268-1273. 
[31] Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased 
risk of acute myocardial infarction in carriers of the hemochromatosis gene 
Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see 
comments]. Circulation 1999; 100(12):1274-1279. 
[32] Franco RF, Zago MA, Trip MD, ten Cate H, van den EA, Prins MH, Kastelein JJ, 
Reitsma PH. Prevalence of hereditary haemochromatosis in premature 
atherosclerotic vascular disease. Br J Haematol 1998; 102(5):1172-1175. 
[33] Ellervik C, Tybjaerg-Hansen A, Grande P, Appleyard M, Nordestgaard BG. Hereditary 
hemochromatosis and risk of ischemic heart disease: a prospective study and a 
case-control study. Circulation 2005; 112(2):185-193. 
[34] van der A, Peeters PHM, Grobbee DE, Roest M, Marx JJM, Voorbij HM, van der 
Schouw YT. HFE mutations and risk of coronary heart disease in middle-aged 
women. European Journal of Clinical Investigation 2006; 36(10):682-690. 
[35] van der A, Rovers MM, Grobbee DE, Marx JJM, Waalen J, Ellervik C, Nordestgaard 
BG, Olynyk JK, Mills PR, Shepherd J, Grandchamp B, Boer JMA, Caruso C, Arca M, 
Meyer BJ, van der Schouw YT. Mutations in the HFE Gene and Cardiovascular 
Disease Risk: An Individual Patient Data Meta-Analysis of 53 880 Subjects. Circ 
Cardiovasc Genet 2008; 1(1):43-50. 
[36] Njajou OT, Hollander M, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, van 
Duijn CM. Mutations in the hemochromatosis gene (HFE) and stroke. Stroke 2002; 
33(10):2363-2366. 
[37] Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary 
artery disease. JAMA 1994; 272(3):231-233. 
[38] Pirart J, Barbier P. [Protective effects of hemochromatosis against senile and diabetic 
angiopathies]. Diabetologia 1971; 7(4):227-236. 






[11] Yuan XM, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann 
Med 2003; 35(8):578-591. 
[12] Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies 
in carbohydrate-intolerant patients. Ann N Y Acad Sci 2002; 967:342-351. 
[13] Kell DB. Iron behaving badly: inappropriate Iron chelation as a major contributor to 
the aetiology of vascular and other progressive inflammatory and degenerative 
diseases. BMC Med Genomics 2009; 2(1):2. 
[14] Kartikasari AE, Georgiou NA, Visseren FL, Kats-Renaud H, van Asbeck BS, Marx JJ. 
Intracellular labile iron modulates adhesion of human monocytes to human 
endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24(12):2257-2262. 
[15] Stadler N, Lindner RA, Davies MJ. Direct Detection and Quantification of Transition 
Metal Ions in Human Atherosclerotic Plaques: Evidence for the Presence of 
Elevated Levels of Iron and Copper. Arterioscler Thromb Vasc Biol 2004; 24(5):949-
954. 
[16] Raman SV, Winner MW, III, Tran T, Velayutham M, Simonetti OP, Baker PB, Olesik J, 
McCarthy B, Ferketich AK, Zweier JL. In Vivo Atherosclerotic Plaque 
Characterization Using Magnetic Susceptibility Distinguishes Symptom-Producing 
Plaques. J Am Coll Cardiol Img 2008; 1(1):49-57. 
[17] You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, Topol EJ, Wang Q. 
Proteomic approach to coronary atherosclerosis shows ferritin light chain as a 
significant marker: evidence consistent with iron hypothesis in atherosclerosis. 
Physiol Genomics 2003; 13(1):25-30. 
[18] Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., Vita JA. Iron 
chelation improves endothelial function in patients with coronary artery disease. 
Circulation 2001; 103(23):2799-2804. 
[19] Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, 
Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron 
correlate with MCP-1 release and vascular damage in patients with metabolic 
syndrome alterations. Arterioscler Thromb Vasc Biol 2011; 31(3):683-690. 
[20] Sullivan JL. Misconceptions in the debate on the iron hypothesis. Journal of Nutritional 
Biochemistry 2001; 12:33-37. 
[21] Burt MJ, Halliday JW, Powell LW. Iron and coronary heart disease [editorial] [see 
comments]. BMJ 1993; 307(6904):575-576. 
[22] Sullivan JL. Heterozygous hemochromatosis as a risk factor for premature myocardial 
infarction. Medical Hypotheses 1990; 31:1-5. 
[23] Sullivan JL. Iron and the Genetics of Cardiovascular Disease. Circulation 1999; 
100(12):1260-1263. 
[24] Sullivan JL, Zacharski LR. Hereditary haemochromatosis and the hypothesis that iron 
depletion protects against ischemic heart disease. Eur J Clin Invest 2001; 31(5):375-
377. 
[25] Kramer JH, Lightfoot FG, Weglicki WB. Cardiac tissue iron: effects on post-ischemic 
function and free radical production, and its possible role during preconditioning. 
Cell Mol Biol (Noisy -Le-Grand) 2000; 46(8):1313-1327. 
[26] Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, Das DK. HFE Mutation 
and Dietary Iron Content Interact to Increase Ischemia/Reperfusion Injury of the 
Heart in Mice. Circ Res 2003; 92(11):1240-1246. 
 
Hemochromatosis and Iron-Mediated Atherogenesis 
 
503 
[27] Kartikasari AER, Georgiou NA, Visseren FLJ, Kats-Renaud H, Sweder van Asbeck B, 
Marx JJM. Endothelial activation and induction of monocyte adhesion by 
nontransferrin-bound iron present in human sera. FASEB J 2005;05-4700fje. 
[28] Lekakis J, Papamicheal C, Stamatelopoulos K, Cimponeriu A, Voutsas A, Vemmos K, 
Mavrikakis M, Stamatelopoulos S. Hemochromatosis associated with endothelial 
dysfunction: evidence for the role of iron stores in early atherogenesis. Vasc Med 
1999; 4(3):147-148. 
[29] Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, 
Domingo R, Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, 
Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, 
Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman 
RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-
like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 
1996; 13(4):399-408. 
[30] Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma 
JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated 
with cardiovascular death in women [see comments]. Circulation 1999; 
100(12):1268-1273. 
[31] Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased 
risk of acute myocardial infarction in carriers of the hemochromatosis gene 
Cys282Tyr mutation : a prospective cohort study in men in eastern Finland [see 
comments]. Circulation 1999; 100(12):1274-1279. 
[32] Franco RF, Zago MA, Trip MD, ten Cate H, van den EA, Prins MH, Kastelein JJ, 
Reitsma PH. Prevalence of hereditary haemochromatosis in premature 
atherosclerotic vascular disease. Br J Haematol 1998; 102(5):1172-1175. 
[33] Ellervik C, Tybjaerg-Hansen A, Grande P, Appleyard M, Nordestgaard BG. Hereditary 
hemochromatosis and risk of ischemic heart disease: a prospective study and a 
case-control study. Circulation 2005; 112(2):185-193. 
[34] van der A, Peeters PHM, Grobbee DE, Roest M, Marx JJM, Voorbij HM, van der 
Schouw YT. HFE mutations and risk of coronary heart disease in middle-aged 
women. European Journal of Clinical Investigation 2006; 36(10):682-690. 
[35] van der A, Rovers MM, Grobbee DE, Marx JJM, Waalen J, Ellervik C, Nordestgaard 
BG, Olynyk JK, Mills PR, Shepherd J, Grandchamp B, Boer JMA, Caruso C, Arca M, 
Meyer BJ, van der Schouw YT. Mutations in the HFE Gene and Cardiovascular 
Disease Risk: An Individual Patient Data Meta-Analysis of 53 880 Subjects. Circ 
Cardiovasc Genet 2008; 1(1):43-50. 
[36] Njajou OT, Hollander M, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, van 
Duijn CM. Mutations in the hemochromatosis gene (HFE) and stroke. Stroke 2002; 
33(10):2363-2366. 
[37] Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary 
artery disease. JAMA 1994; 272(3):231-233. 
[38] Pirart J, Barbier P. [Protective effects of hemochromatosis against senile and diabetic 
angiopathies]. Diabetologia 1971; 7(4):227-236. 






[40] JAMES TN. Pathology of the cardiac conduction system in hemochromatosis. N Engl J 
Med 1964; 271:92-94. 
[41] Moura E, Noordermeer MA, Verhoeven N, Verheul AFM, Marx JJM. Iron Release 
From Human Monocytes After Erythrophagocytosis In Vitro: An Investigation in 
Normal Subjects and Hereditary Hemochromatosis Patients. Blood 1998; 
92(7):2511-2519. 
[42] Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse 
liver-specific gene, encoding a protein homologous to human antimicrobial peptide 
hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276(11):7811-
7819. 
[43] Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide 
Synthesized in the Liver. J Biol Chem 2001; 276(11):7806-7810. 
[44] Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. 
Lack of hepcidin gene expression and severe tissue iron overload in upstream 
stimulatory factor 2 (USF2) knockout mice. Proceedings of the National Academy 
of Sciences of the United States of America 2001; 98(15):8780-8785. 
[45] Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a 
putative mediator of anemia of inflammation, is a type II acute-phase protein. 
Blood 2003; 101(7):2461-2463. 
[46] Nemeth E, Ganz T. Regulation of Iron Metabolism by Hepcidin. Annual Review of 
Nutrition 2006; 26(1):323-342. 
[47] Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 
mediates hypoferremia of inflammation by inducing the synthesis of the iron 
regulatory hormone hepcidin. J Clin Invest 2004; 113(9):1271-1276. 
[48] Nguyen NB, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron 
transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 
291(3):L417-L425. 
[49] Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. 
Am J Physiol Gastrointest Liver Physiol 2006; 290(2):G199-G203. 
[50] Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine 
hepcidin assay by mass spectrometry. Blood 2005; 106(9):3268-3270. 
[51] Lee PL, Beutler E. Regulation of Hepcidin and Iron-Overload Disease. Annual Review 
of Pathology: Mechanisms of Disease 2009; 4(1):489-515. 
[52] Valenti L, Swinkels DW, Burdick L, Tjalsma H, Bertelli C, Fatta C, Bignamini D, 
DONGIOVANNI P, Rametta R, Motta BM, Fargion S, Fracanzani AL. Serum 
ferritin and hepcidin levels predict vascular damage in patients with nonalcoholic 
fatty liver disease. Poster session presented at: International BioIron Society 2009 
Meeting; 2009 Jun 7-11; Porto, Portugal.  2009. Ref Type: Abstract 
[53] Paoletti R, Gotto AM, Jr., Hajjar DP. Inflammation in Atherosclerosis and Implications 
for Therapy. Circulation 2004; 109(23_suppl_1):III-20. 
[54] Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma Concentration of 
Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently 
Healthy Men. Circulation 2000; 101(15):1767-1772. 
[55] van Deuren M, Kroot JJ, Swinkels DW. Time-course analysis of serum hepcidin, iron 
and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated 
with IL-1 receptor antagonist. Haematologica 2009. 
 
Hemochromatosis and Iron-Mediated Atherogenesis 
 
505 
[56] Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. 
Attenuated Inflammatory Responses in Hemochromatosis Reveal a Role for Iron in 
the Regulation of Macrophage Cytokine Translation. J Immunol 2008; 181(4):2723-
2731. 
[57] Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-
induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 
2002; 22(7):E15-E18. 
[58] Li L, Frei B. Prolonged Exposure to LPS Increases Iron, Heme, and p22phox Levels and 
NADPH Oxidase Activity in Human Aortic Endothelial Cells: Inhibition by 
Desferrioxamine. Arterioscler Thromb Vasc Biol 2009; 29(5):732-738. 
[59] Kartikasari AE, Georgiou NA, de Geest M, Kats-Renaud JH, Bouwman JJ, van Asbeck 
BS, Marx JJ, Visseren FL. Iron enhances endothelial cell activation in response to 
Cytomegalovirus or Chlamydia pneumoniae infection. Eur J Clin Invest 2006; 
36(10):743-752. 
[60] Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, 
Mezzetti A, Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular 
smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14(2):299-304. 
[61] Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, Horwitz LD. An exochelin 
of Mycobacterium tuberculosis reversibly arrests growth of human vascular 
smooth muscle cells in vitro. J Biol Chem 2000; 275(23):17821-17826. 
[62] Pang JH, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, Chau LY. Increased ferritin 
gene expression in atherosclerotic lesions. J Clin Invest 1996; 97(10):2204-2212. 
[63] Gaenzer H, Marschang P, Sturm W, Neumayr Gu, Vogel W, Patsch J, Weiss Gu. 
Association between increased iron stores and impaired endothelial function in 
patients with hereditary hemochromatosis*1. Journal of the American College of 
Cardiology 2002; 40(12):2189-2194. 
[64] Adams PC, Pankow JS, Barton JC, Acton RT, Leiendecker-Foster C, McLaren GD, 
Speechley M, Eckfeldt JH. HFE C282Y Homozygosity Is Associated With Lower 
Total and Low-Density Lipoprotein Cholesterol: The Hemochromatosis and Iron 
Overload Screening Study. Circ Cardiovasc Genet 2009; 2(1):34-37. 
[65] Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases 
cholesterol accumulation and macrophage scavenger receptor I expression in THP-
1 mononuclear phagocytes. Metabolism 2005; 54(4):453-459. 
[66] Choi JW, Kim SK, Pai SH. Changes in Serum Lipid Concentrations during Iron 
Depletion and after Iron Supplementation. Ann Clin Lab Sci 2001; 31(2):151-156. 
[67] Ozdemir A, Sevinc C, Selamet U, Turkmen F. The relationship between iron deficiency 
anemia and lipid metabolism in premenopausal women. Am J Med Sci 2007; 
334(5):331-333. 
[68] Sullivan JL. Iron versus cholesterol--perspectives on the iron and heart disease debate. 
J Clin Epidemiol 1996; 49(12):1345-1352. 
[69] Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, 
Ozaki CK, Lavori PW. Decreased Cancer Risk After Iron Reduction in Patients 
With Peripheral Arterial Disease: Results From a Randomized Trial. J Natl Cancer 
Inst 2008;djn209. 
[70] Minqin R, Rajendran R, Pan N, Kwong-Huat TB, Ong WY, Watt F, Halliwell B. The 





[40] JAMES TN. Pathology of the cardiac conduction system in hemochromatosis. N Engl J 
Med 1964; 271:92-94. 
[41] Moura E, Noordermeer MA, Verhoeven N, Verheul AFM, Marx JJM. Iron Release 
From Human Monocytes After Erythrophagocytosis In Vitro: An Investigation in 
Normal Subjects and Hereditary Hemochromatosis Patients. Blood 1998; 
92(7):2511-2519. 
[42] Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse 
liver-specific gene, encoding a protein homologous to human antimicrobial peptide 
hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276(11):7811-
7819. 
[43] Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide 
Synthesized in the Liver. J Biol Chem 2001; 276(11):7806-7810. 
[44] Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. 
Lack of hepcidin gene expression and severe tissue iron overload in upstream 
stimulatory factor 2 (USF2) knockout mice. Proceedings of the National Academy 
of Sciences of the United States of America 2001; 98(15):8780-8785. 
[45] Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a 
putative mediator of anemia of inflammation, is a type II acute-phase protein. 
Blood 2003; 101(7):2461-2463. 
[46] Nemeth E, Ganz T. Regulation of Iron Metabolism by Hepcidin. Annual Review of 
Nutrition 2006; 26(1):323-342. 
[47] Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 
mediates hypoferremia of inflammation by inducing the synthesis of the iron 
regulatory hormone hepcidin. J Clin Invest 2004; 113(9):1271-1276. 
[48] Nguyen NB, Callaghan KD, Ghio AJ, Haile DJ, Yang F. Hepcidin expression and iron 
transport in alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 
291(3):L417-L425. 
[49] Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. 
Am J Physiol Gastrointest Liver Physiol 2006; 290(2):G199-G203. 
[50] Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine 
hepcidin assay by mass spectrometry. Blood 2005; 106(9):3268-3270. 
[51] Lee PL, Beutler E. Regulation of Hepcidin and Iron-Overload Disease. Annual Review 
of Pathology: Mechanisms of Disease 2009; 4(1):489-515. 
[52] Valenti L, Swinkels DW, Burdick L, Tjalsma H, Bertelli C, Fatta C, Bignamini D, 
DONGIOVANNI P, Rametta R, Motta BM, Fargion S, Fracanzani AL. Serum 
ferritin and hepcidin levels predict vascular damage in patients with nonalcoholic 
fatty liver disease. Poster session presented at: International BioIron Society 2009 
Meeting; 2009 Jun 7-11; Porto, Portugal.  2009. Ref Type: Abstract 
[53] Paoletti R, Gotto AM, Jr., Hajjar DP. Inflammation in Atherosclerosis and Implications 
for Therapy. Circulation 2004; 109(23_suppl_1):III-20. 
[54] Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma Concentration of 
Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently 
Healthy Men. Circulation 2000; 101(15):1767-1772. 
[55] van Deuren M, Kroot JJ, Swinkels DW. Time-course analysis of serum hepcidin, iron 
and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated 
with IL-1 receptor antagonist. Haematologica 2009. 
 
Hemochromatosis and Iron-Mediated Atherogenesis 
 
505 
[56] Wang L, Johnson EE, Shi HN, Walker WA, Wessling-Resnick M, Cherayil BJ. 
Attenuated Inflammatory Responses in Hemochromatosis Reveal a Role for Iron in 
the Regulation of Macrophage Cytokine Translation. J Immunol 2008; 181(4):2723-
2731. 
[57] Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-
induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol 
2002; 22(7):E15-E18. 
[58] Li L, Frei B. Prolonged Exposure to LPS Increases Iron, Heme, and p22phox Levels and 
NADPH Oxidase Activity in Human Aortic Endothelial Cells: Inhibition by 
Desferrioxamine. Arterioscler Thromb Vasc Biol 2009; 29(5):732-738. 
[59] Kartikasari AE, Georgiou NA, de Geest M, Kats-Renaud JH, Bouwman JJ, van Asbeck 
BS, Marx JJ, Visseren FL. Iron enhances endothelial cell activation in response to 
Cytomegalovirus or Chlamydia pneumoniae infection. Eur J Clin Invest 2006; 
36(10):743-752. 
[60] Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, 
Mezzetti A, Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular 
smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14(2):299-304. 
[61] Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, Horwitz LD. An exochelin 
of Mycobacterium tuberculosis reversibly arrests growth of human vascular 
smooth muscle cells in vitro. J Biol Chem 2000; 275(23):17821-17826. 
[62] Pang JH, Jiang MJ, Chen YL, Wang FW, Wang DL, Chu SH, Chau LY. Increased ferritin 
gene expression in atherosclerotic lesions. J Clin Invest 1996; 97(10):2204-2212. 
[63] Gaenzer H, Marschang P, Sturm W, Neumayr Gu, Vogel W, Patsch J, Weiss Gu. 
Association between increased iron stores and impaired endothelial function in 
patients with hereditary hemochromatosis*1. Journal of the American College of 
Cardiology 2002; 40(12):2189-2194. 
[64] Adams PC, Pankow JS, Barton JC, Acton RT, Leiendecker-Foster C, McLaren GD, 
Speechley M, Eckfeldt JH. HFE C282Y Homozygosity Is Associated With Lower 
Total and Low-Density Lipoprotein Cholesterol: The Hemochromatosis and Iron 
Overload Screening Study. Circ Cardiovasc Genet 2009; 2(1):34-37. 
[65] Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases 
cholesterol accumulation and macrophage scavenger receptor I expression in THP-
1 mononuclear phagocytes. Metabolism 2005; 54(4):453-459. 
[66] Choi JW, Kim SK, Pai SH. Changes in Serum Lipid Concentrations during Iron 
Depletion and after Iron Supplementation. Ann Clin Lab Sci 2001; 31(2):151-156. 
[67] Ozdemir A, Sevinc C, Selamet U, Turkmen F. The relationship between iron deficiency 
anemia and lipid metabolism in premenopausal women. Am J Med Sci 2007; 
334(5):331-333. 
[68] Sullivan JL. Iron versus cholesterol--perspectives on the iron and heart disease debate. 
J Clin Epidemiol 1996; 49(12):1345-1352. 
[69] Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, 
Ozaki CK, Lavori PW. Decreased Cancer Risk After Iron Reduction in Patients 
With Peripheral Arterial Disease: Results From a Randomized Trial. J Natl Cancer 
Inst 2008;djn209. 
[70] Minqin R, Rajendran R, Pan N, Kwong-Huat TB, Ong WY, Watt F, Halliwell B. The 





decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol 
Med 2005; 38(9):1206-1211. 
[71] Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F. The onset of atherosclerotic lesion 
formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 
1999; 459(2):218-222. 
[72] Minqin R, Watt F, Huat BT, Halliwell B. Correlation of iron and zinc levels with lesion 
depth in newly formed atherosclerotic lesions. Free Radic Biol Med 2003; 34(6):746-
752. 
[73] Ren M, Rajendran R, Ning P, Tan Kwong Huat B, Choon Nam O, Watt F, Jenner A, 
Halliwell B. Zinc supplementation decreases the development of atherosclerosis in 
rabbits. Free Radical Biology and Medicine 2006; 41(2):222-225. 
[74] Watt F, Rajendran R, Ren MQ, Tan BKH, Halliwell B. A nuclear microscopy study of 
trace elements Ca, Fe, Zn and Cu in atherosclerosis. Nuclear Instruments and 
Methods in Physics Research Section B: Beam Interactions with Materials and 
Atoms 2006; 249(1-2):646-652. 
[75] Yuan XM, Anders WL, Olsson AG, Brunk UT. Iron in human atheroma and LDL 
oxidation by macrophages following erythrophagocytosis. Atherosclerosis 1996; 
124(1):61-73. 
[76] Lee FY, Lee TS, Pan CC, Huang AL, Chau LY. Colocalization of iron and ceroid in 
human atherosclerotic lesions. Atherosclerosis 1998; 138(2):281-288. 
[77] Lee TS, Lee FY, Pang JH, Chau LY. Erythrophagocytosis and iron deposition in 
atherosclerotic lesions. Chin J Physiol 1999; 42(1):17-23. 
[78] Li W, Hellsten A, XU LH, Zhuang DM, Jansson K, Brunk UT, YUAN XM. Foam cell 
death induced by 7[beta]-hydroxycholesterol is mediated by labile iron-driven 
oxidative injury: Mechanisms underlying induction of ferritin in human atheroma. 
Free Radical Biology and Medicine 2005; 39(7):864-875. 
[79] Tavora F, Ripple M, Li L, Burke A. Monocytes and neutrophils expressing 
myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. 
BMC Cardiovascular Disorders 2009; 9(1):27. 
[80] Yuan XM, Li W, Baird SK, Carlsson M, Melefors O. Secretion of ferritin by iron-laden 
macrophages and influence of lipoproteins. Free Radic Res 2004; 38(10):1133-1142. 
[81] Li W, Xu LH, Yuan XM. Macrophage hemoglobin scavenger receptor and ferritin 
accumulation in human atherosclerotic lesions. Ann N Y Acad Sci 2004; 1030:196-
201. 
[82] Li W, Hellsten A, Nyhalah JD, Yuan XM. Enhanced expression of natural resistance-
associated macrophage protein 1 in atherosclerotic lesions may be associated with 
oxidized lipid-induced apoptosis. Ann N Y Acad Sci 2004; 1030:202-207. 
[83] Li W, Ostblom M, XU LH, Hellsten A, Leanderson P, Liedberg B, Brunk UT, Eaton JW, 
YUAN XM. Cytocidal effects of atheromatous plaque components: the death zone 
revisited. FASEB J 2006; 20(13):2281-2290. 
[84] Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions 
in apoE-deficient mice. Circulation 1999; 99(9):1222-1229 
24 
Paraoxonase Polymorphisms and Platelet 
Activating Factor Acetylhydrolase Activity  
as a Genetic Risk Factors in Cerebral 
Atherosclerosis 
Zlata Flegar-Meštrić1, Mirjana Mariana Kardum Paro1,  
Sonja Perkov1, Vinko Vidjak2 and Marija Grdić Rajković3 
1Institute of Clinical Chemistry and Laboratory Medicine,  
2Clinical Department for Diagnostic and Clinical Radiology,  
Merkur University Hospital, Zagreb 
3Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and 
Biochemistry, University of Zagreb, Zagreb,  
Croatia 
1. Introduction 
Atherosclerosis is a progressive disease characterized by the accumulation of lipids and 
fibrous elements in the large arteries (Lusis, JA. 2000). Investigations into the genetics of 
atherosclerosis, along with biochemical approaches, have greatly advanced today 
knowledge of the mechanisms of this complex multifactorial disease (Lusis et al., 2004a, 
2004b; Lusis &Weiss , 2010). According to the oxidation hypothesis, oxidative stress is a key 
mechanism through which atherosclerosis as a chronic inflammatory disease develops. It is 
mediated by reactive oxygen species that alter the fundamental properties of cholesterol, 
cholesterol esters, and phospholipids on lipoproteins, as well as other proteins, to make 
them dysfunctional, immunogenic, and pro-atherogenic (Tsimikas et. al., 2009). Oxidative 
stress can be enhanced by non-enzymatic pathways, such as by copper and iron cations, as 
well as by enzymatic pathways, such as by lipoxygenases, myeloperoxidase, and NADPH 
oxidase. These pro-oxidant pathways are balanced by anti-oxidant mechanisms, such as 
anti-oxidant vitamins (alpha-tocopherol and carotenoids) present within lipoproteins, and 
anti-oxidant enzymes, such as superoxide dismutase and glutathione peroxidase. Many of 
these enzymes and products of oxidation can be measured in the circulation, including 
oxidized low-density lipoprotein, oxidized phospholipids, isoprostanes, and 
myeloperoxidase, and have been shown to predict the presence of cardiovascular disease 
(CVD) and incident cardiovascular events (Tsimikas et al., 2007, 2009).  
Human serum paraoxonase [(PON1); aryldialkylphosphatase (EC 3.1.8.1)] is associated with 
high density lipoprotein particles (HDL) responsible in part for the ability of HDL to prevent 
lipid peroxidation. The decreased serum paraoxonase (PON1) activity in patients with 
atherosclerosis disease may cause decreased HDL antioxidant capacity and therefore 
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1. Introduction 
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atherosclerosis, along with biochemical approaches, have greatly advanced today 
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mechanism through which atherosclerosis as a chronic inflammatory disease develops. It is 
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cholesterol esters, and phospholipids on lipoproteins, as well as other proteins, to make 
them dysfunctional, immunogenic, and pro-atherogenic (Tsimikas et. al., 2009). Oxidative 
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well as by enzymatic pathways, such as by lipoxygenases, myeloperoxidase, and NADPH 
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these enzymes and products of oxidation can be measured in the circulation, including 
oxidized low-density lipoprotein, oxidized phospholipids, isoprostanes, and 
myeloperoxidase, and have been shown to predict the presence of cardiovascular disease 
(CVD) and incident cardiovascular events (Tsimikas et al., 2007, 2009).  
Human serum paraoxonase [(PON1); aryldialkylphosphatase (EC 3.1.8.1)] is associated with 
high density lipoprotein particles (HDL) responsible in part for the ability of HDL to prevent 
lipid peroxidation. The decreased serum paraoxonase (PON1) activity in patients with 
atherosclerosis disease may cause decreased HDL antioxidant capacity and therefore 





Nieminen et al., 2006; Shih DM. & Lusis AJ. 2009). The enormous between-individual 
biological variability in serum PON1 activity seems to be regulated mainly by genetic 
determinants. The paraoxonase gene family includes pon1, pon2 and pon3 genes which produce 
three enzyme paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3). 
These genes are located on the long arm of chromosome 7 and they are structurally similar. 
They share about 70% of identity in nucleotide sequences and about 60% of identity in amino 
acid sequences. PON1 mRNA is expressed in the liver, and PON3 mRNA is expressed 
primarily in the liver but also in the kidneys. On the other hand PON2 mRNA is ubiquitously 
expressed in different kinds of tissues like kidneys, liver, lungs, small intestine, placenta, 
spleen, stomach and testicles and in the cells of the artery wall (including endothelial cell, 
smooth muscle cell and macrophages) (Draganov, DI.  La Du, BN. 2004; Ng et al., 2005). 
PON1 is a 354 amino acid long glycosylated protein and has an apparent mass of 43-47 kDa. 
The enzyme is synthesized in the liver and is secreted into plasma. In the plasma, PON1 is 
mainly bounded to high density lipoproteins (HDL) but also small amount of this enzyme 
was detected in very low-density lipoprotein (VLDL), and postprandial chylomicrons. 
PON1 has hydrophobic signal sequence on the N-terminal region, from which only the 
initiator methionine residue is removed, and this region is for the association of PON1 with 
HDL (Draganov, DI.  La Du, BN. 2004; Fuhrman et al., 2005.) PON1 possesses 
organophosphatase, arylesterase and lactonase activities and hydrolyzes different kinds of 
substrates (like paraoxon, chlorpyrifos oxon, diazoxon, sarin, soman, phenylacetate, 
tiophenylacetate homogentisic acid lactone, dihydrocoumarin, γ-butyrolactone and 
homocysteine thiolactone) (Draganov, DI.  La Du, BN. 2004; Ng et al., 2005).  PON1 is also 
well known to possess antioxidative and antiatherogenic activity, to protect HDL and low-
density lipoprotein (LDL) from oxidation, and to destroy biologically active oxidized lipids 
on lipoproteins and in arterial cells (Draganov, DI.  La Du, BN. 2004; Aviram, M. 2004). 
More than 160 polymorphisms of pon1 gene are known, and some of them have been 
recognized to affect PON1 concentration and activity (Deakin, SP.  James, RW. 2004; Costa 
et al., 2005). Two polymorphisms in the coding region of pon1 gene result in the substitution of 
amino acid glutamine with arginine at the position 192 (Q192R polymorphism, the exchange 
of codon CAA to CGA in exon 6) and in the substitution of amino acid leucine to methionine 
at the position 55 (L55M polymorphism, the exchange of codon TTG to ATG in exon 3) 
(Adkins et al., 1993). Q192 and R192 alloenzymes have a different affinity and catalytic activity 
towards numerous substrates, the R192 alloenzyme hydrolyzes paraoxon six times faster than 
Q192 alloenzyme while Q192 alloenzyme hydrolyzes sarin, soman and diazoxon faster than 
R192 alloenzyme (Deakin, SP.  James, RW. 2004). These two alloenzymes are also different 
in their ability to protect LDL from oxidation in vitro, Q192 alloenzyme is more efficient than 
R192 alloenzyme (Deakin, SP.  James, RW. 2004; Mackness et al., 1999). L55M 
polymorphism affects PON1 mRNA levels, concentration and enzyme activity. M55 
alloenzyme is associated with a lower level of PON1 mRNA, concentration and activity 
(Deakin, SP.  James, RW. 2004). These two alloenzymes are also different in protection of 
LDL against oxidation, where M55 alloenzyme shows to be more protective (Mackness et al., 
1999). In the promoter region of pon1 gene at least five polymorphisms were detected and -
108C>T polymorphism is one of them. This polymorphism affects pon1 gene expression, and 
enzyme concentration and activity. It is believed that -108C>T polymorphism is the main 
contributor to serum PON1 variation (accounting for 23-24% of total variation), while other 
polymorphisms in pon1 promoter region made little or no difference to serum PON1 levels 
(Deakin, SP.  James, RW. 2004; Leviev, I.  James, RW. 2000; Suehiro et al., 2000). 
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As it was mentioned earlier, PON2 is a ubiquitously expressed intracellular protein with a 
relative molecular mass of approximately 44 kDa (Ng et al., 2005; Li et al., 2003). PON2 has 
antioxidant properties, lowers the intracellular oxidative stress and prevents the cell-
mediated oxidation of LDL (Ng at al., 2005; Li et al., 2003). In the pon2 gene two common 
polymorphisms were identified. Alanine or glycine could be at the position 148 (A148G), 
and serine or cysteine could be at the position 311 (S311C). S311C polymorphism has been 
related with eg. coronary artery disease, ischemic stroke in patients with type 2 diabetes 
mellitus, Alzheimer’s disease and reduced bone mass in postmenopausal women (Ng at al., 
2005; Li et al., 2003). The mechanisms by which PON2 exerts its atheroprotective effects 
remain to be clarified. Large-scale epidemiologic studies are needed to further examine the 
relationship between PON2 genetic polymorphisms and risk for CVD (Shih, DM.  Lusius, 
AJ. 2009). 
Human PON3 is a '40-kDa protein primarily synthesized in the liver with biological activity 
similar to PON1. PON3 is a secreted protein associated with HDL in the plasma and can 
participate in the prevention of LDL oxidation. The PON3 protein may play a role, distinct 
from that of PON1, in the lipoprotein metabolism of the kidney. These characteristics link 
PON3 with a group of enzymes, such as PON1, platelet-activating factor–acetylhydrolase, 
and lecithin-cholesterol acyltransferase, which together may contribute to the 
antiatherogenic properties of HDL, but the role of PON3 in atherosclerosis needs further 
investigation (Reddy et al., 2001; Getz, GS.  Resardon, CA. 2004). 
Another lipoprotein-associated enzyme, the platelet-activating factor acetylhydrolase (PAF-
AH), also referred to as lipoprotein-associated phospholipase A2 (Lp-PLA2), is an enzyme (EC 
3.1.1.47) recently described as a potentially useful plasma biomarker associated with 
cardiovascular disease (Srinivasan, B.  Bahson, BJ. 2010; Koenig et al., 2004; Yamada et al., 
2000; Karasawa, K. 2006; Mallat et al., 2010). The biological role of Lp-PLA2 (PAF-AH) has 
been controversial, with contradictory antiatherogenic and proatherogenic functions. The 
antiatherogenic properties of Lp-PLA2 were first suggested because plasma PAF-AH might 
play an anti-inflammatory role in human diseases by preventing the accumulation of PAF (1-
O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and PAF-like oxidized phospholipids 
(Karasawa, K. 2006; Mallat et al., 2010; Mitsios et al., 2006). PAF is a biologically active 
phospholipid involved in diverse pathologies such as inflammation and atherosclerosis. PAF 
can activate various cell types including platelets. In the presence of PAF, platelets aggregate 
and degranulate, releasing biologically potent agents. PAF is hydrolyzed and converted to 
lysoPAF by the catalytic reaction of PAF-AH (Mitsios et al., 2006). The atherogenic role of Lp-
PLA2 comes from the observation that this enzyme can also produce lysophosphatidylcholine 
and oxidatively modified nonesterified fatty acids which could promote the pathogenesis of 
atherosclerosis (Karasawa, K. 2006; Mallat et al., 2010). Lysophosphatidylcholine is an 
important chemoattractant for macrophages and T cells, it induces migration of vascular 
smooth muscle cells, affects endothelial function, and increases the expression of adhesion 
molecules and cytokines (Garza et al., 2007; Tsimikas et al., 2009). 
Phospholipases A2 (PLA2s) comprise distinct sets of enzymes with different localizations:  
the intracellular (cytosolic) enzymes that are Ca2+ dependent (cPLA2), Ca2+ independent 
(iPLA2), or specific for PAF (intracellular PAF acetylhydrolase) and extracellular (plasma) 
enzymes, either associated with lipoproteins (Lp-PLA2) or secreted PLA2s (sPLA2) (Mallat et 
al., 2010). Extracellular (plasma) PAF-AH shares 41% sequence identity with intracellular 
(cytosolic) Type II PAFAH, whereas both enzymes show less structural similarity to Type I 
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As it was mentioned earlier, PON2 is a ubiquitously expressed intracellular protein with a 
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AJ. 2009). 
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O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and PAF-like oxidized phospholipids 
(Karasawa, K. 2006; Mallat et al., 2010; Mitsios et al., 2006). PAF is a biologically active 
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and degranulate, releasing biologically potent agents. PAF is hydrolyzed and converted to 
lysoPAF by the catalytic reaction of PAF-AH (Mitsios et al., 2006). The atherogenic role of Lp-
PLA2 comes from the observation that this enzyme can also produce lysophosphatidylcholine 
and oxidatively modified nonesterified fatty acids which could promote the pathogenesis of 
atherosclerosis (Karasawa, K. 2006; Mallat et al., 2010). Lysophosphatidylcholine is an 
important chemoattractant for macrophages and T cells, it induces migration of vascular 
smooth muscle cells, affects endothelial function, and increases the expression of adhesion 
molecules and cytokines (Garza et al., 2007; Tsimikas et al., 2009). 
Phospholipases A2 (PLA2s) comprise distinct sets of enzymes with different localizations:  
the intracellular (cytosolic) enzymes that are Ca2+ dependent (cPLA2), Ca2+ independent 
(iPLA2), or specific for PAF (intracellular PAF acetylhydrolase) and extracellular (plasma) 
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(cytosolic) Type II PAFAH, whereas both enzymes show less structural similarity to Type I 





diverse family of structurally related, disulfide-rich calcium-dependent secreted enzymes 
that hydrolyze the sn-2 position of glycerophospholipids generating potent lipid mediators: 
lysophospholipids and free fatty acids, including the precursor of eicosanoids, arachidonic 
acid. Extracellular levels of secreted PLA2s are increased in both plasma and inflammatory 
fluids in various inflammatory diseases ( Karabina et al., 2010; Mallat et al., 2010 ).  
The extracellular (plasma) enzyme Lp-PLA2 is a single polypeptide that originates mostly from 
cells of the hematopoietic lineage, primarily from monocytes/macrophages (Karabina et al., 
2010; Stafforini, DM. 2009). Lp-PLA2 (PAF-AH) exhibits unique substrate specificity toward 
PAF and oxidized phospholipids. In human plasma, PAF-AH activity is associated mainly 
with the apolipoprotein B (apoB)-containing lipoproteins and primarily with low-density 
lipoprotein (LDL). A small proportion of the circulating enzyme activity is also associated with 
high density lipoprotein and lipoprotein(a), an atherogenic lipoprotein particle that appears to 
be a preferential carrier of oxidized phospholipids in human plasma (Mallat et al., 2010; 
Wolfert et al., 2004; Karasawa, K. 2006). In plasma, approximately 80% of Lp-PLA2 is attached 
to low-density lipoproteins (LDLs), and the remaining 20% is linked to high-density 
lipoproteins (HDLs) and lipoprotein (a) (Garza et al., 2007). HDL protects LDL from oxidation 
and HDL-associated PAF-AH might be involved in this effect together with other HDL-
associated enzymes, including PON1 and lecithin-cholesterol acyltransferase (LCAT) . 
Dyslipidemia-induced decrease in the ratio of HDL-associated PAF-AH to the plasma PAF-
AH levels might thus lead to the promotion of atherosclerosis (Karasawa, K. 2006 ; Garza et al., 
2007). Many studies appeared on the role of lipoprotein–associated PLA2 and secreted PLA2s 
in atherosclerosis at the level of biology and epidemiology. It is still unclear whether these 
PLA2s act as true biological effectors of cardiovascular diseases in humans and whether they 
have proven utility as biomarkers of disease severity (Mallat et al., 2010). 
We explored relations between serum PON1 and PAF-AH activities as well as the 
distribution of polymorphisms of pon1 and pon2 genes and cerebral atherosclerosis in well-
characterized groups of patients with angiografically assessed severe stenosis of cerebral 
arteries and matched control no-stenosis group.  
2. Patients and methods  
2.1 Patients 
The study comprised 119 patients, 35 women and 84 men with symptoms of cerebrovascular 
insufficiency and stenosis of carotid artery more than 50% of the lumen. Among them, 87 
(73.1%) had transitory ischemic attacks, 19 (16.0%) had suffered a cerebrovascular insult 
with motor deficit 5-9 months previously, and 13 patients (10.9%) had headache and vertigo 
with carotid bruit. All patients were examined by neurologists and referred to Doppler 
examination. At the Doppler examination, all of them had stenosis of one or both carotid 
arteries more than 50% of the arterial lumen and were preceded to digital subtraction 
angiography (DSA) and possible endovascular carotid PTA/stent treatment. Based on the 
angiographic findings, for the purpose of present investigation they were divided in two 
groups. The first group consisted of 73 patients, 25 female, median age 67 years (range, 41-79 
years) and 48 male, median age 65 years (range, 46-83 years) with a moderate degree of 
carotid extra cranial stenosis between 50% and 69% of the arterial lumen. In this group there 
was no intracranial stenosis of cerebral arteries. The second group consisted of 46 patients, 
10 female, median age 67 years (range, 46-78 years) and 36 male, median age 68 years 
(range, 54-78 years) in whom stenosis between 70-99% or obliteration of the carotid artery 
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was angiographically determined. In this group, intracranial stenosis less than 50% of the 
lumen of carotid arteries in three patients were found. 
The control no-stenosis group consisted of 90 patients, 46 female, median age 60 years 
(range, 44-76 years) and 44 male, median age 63 years (range, 46-82 years) with suspected 
cerebrovascular symptoms, but with normal Doppler examination of the carotid arteries. 
Vertigo, headache and transitory vision problems were indications for Doppler examination 
for 72 patients (80%). Twelve out of 90 (13.3%) patients had had nonischemic 
cerebrovascular insult a few months or years priorly with new symptoms like headache, 
suspected motor deficit or vertigo. The remaining six patients (6.7%) had the same 
symptoms combined with the carotid bruit. All of them had normal appearance and normal 
hemodynamic results at Doppler examination of carotid arteries. The third group of 
patients, with Doppler established carotid stenosis between 1-49% of cerebral arteries, was 
not included in the present investigation. They were proceeded to other non-invasive 
carotid investigations like MR angiography or multislice CT angiography. 
All Doppler and DSA procedures were performed at the Institute for Diagnostic and 
Interventional Radiology of the Merkur University Hospital. Doppler examinations were 
performed at the center of excellence with more than 3,000 examinations per year. DSA was 
performed by the interventional radiologists skilled in neurovascular interventions.  
Smokers were defined as those reporting daily smoking. Obesity was defined in terms of the 
patient’s body mass index (BMI) calculated as weight in kg/height in m2 . 
The patients with the BMI  25 were considered overweight. Written informed consent was 
obtained from all subjects according to the guidelines of our Ethics Committee. 
This study was approved by the Ethics Committee of the Merkur University Hospital, 
Zagreb, Croatia.  
2.2 Samples  
Blood samples were collected by venopuncture after overnight fasting and under controlled 
pre-analytical conditions. Serum was prepared 30 min after blood collection into vacutainer 
tubes (Becton Dickinson) without additives by centrifugation at 3000 rpm for 15 minutes. 
Blood collected in EDTA-coated tubes was used for determination of pon1 and pon2 
genotypes while sera were analyzed for triacylglycerol, total cholesterol, LDL and HDL-
cholesterol concentrations and PON1 and PAF-AH activities.  
2.3 Methods 
2.3.1 Serum triacylglycerol, total cholesterol, LDL and HDL cholesterol assays 
Serum triacylglycerol and total cholesterol were measured by enzymatic PAP- method. HDL-
cholesterol was measured with direct method based on selective inhibition of the non-HDL 
fractions by means of polyanions. A homogeneous assay for the selective measurement of LDL-
cholesterol in serum was used. All measurements were performed on fresh sera on the day of 
blood collection using standard commercial kits (Olympus Diagnostic GmbH, Hamburg, 
Germany) on the Olympus AU 600 analyzer (Olympus Mishima Co., Ltd., Shizuoka, Japan).  
2.3.2 Paraoxonase activity measurement 
PON1 paraoxonase activity was assessed by using paraoxon as the substrate in the presence 
of NaCl (NaCl stimulated activity) (Juretić et al., 2006). The assay was performed on 
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37°C, as previously described, with a minor modification (Grdić et al., 2008). Briefly, 15 μL 
of serum was added to 300 μL of reaction mixture containing 2.5 mmol/L paraoxon of ~90% 
purity, 2.2 mmol/L CaCl2 and 1.0 mol/L NaCl in 0.1 mol/L Tris– HCl buffer, pH 8.0. The 
release of p-nitrophenol from paraoxon was measured at 410/480 nm (ε410/480=17900 L/ 
mol cm) and the enzyme activity is expressed in international units per 1 L of serum and 
standardized against concentration of HDL-cholesterol . Serum samples were kept frozen at 
-80°C until the day of analysis. 
2.3.3 Paraoxonase polymorphisms determinations 
Polymorphisms of pon1 and pon2 genes were determined by the polymerase chain reaction 
(PCR) followed by restriction fragment length polymorphism analysis (PCR-RFLP) (Table 
1). The PCR reaction was performed in a Gene Amp PCR System 2720 (Applied Biosystems) 
PCR machine. Pon1 gene polymorphisms (Q192R, L55M and -108C>T) were determined by 
the method described by Campo et al., (Campo et al., 2004). with some modifications 
concerning the sequence of 1CT primer, annealing temperature and restriction enzyme for  
-108C>T polymorphism (Grdić et al., 2008; Grdić Rajković et al., 2011).  
Pon2 gene polymorphism (S311C) was determined by the method described by Sanghera et 
al. (Sangera et al., 1998) with a few modifications including the sequence of 2SC primer and 
annealing temperature (Grdić et al., 2011). Briefly, the amplification mixture (total volume 
25 μL) for each pon1 gene polymorphism and for pon2 gene polymorphism contained 250 ng 
of genomic DNA, 0.4 μmol/L of each primer, 0.2 mmol/L of each dNTP, 2mmol/LMgCl2, 
0.5 units of PlatinumTaqDNA Polymerase and 2.5 μL of reaction buffer (200mmol/L Tris–
HCl, pH 8.4 and 500mmol/L KCl). PCR reaction was carried out using the following 
procedure: the first step of predenaturation at 95 °C for 12 min, 35 cycles of amplification (30 
seconds at 94 °C followed by 30 seconds at specific primers annealing temperature and 60 
seconds at 72 °C), and the last cycle of final extension at 72 °C for 7 min. PCR was attenuated 
by lowering the temperature to 4 °C for at least 6 min. The primers, annealing temperatures 
and lengths of PCR fragments are given in Table 1. Endonuclease mixture for each 
polymorphism explored in this study (total volume 15 μL) contained 9 μL of amplified 
fragment, an appropriate buffer for each restriction enzyme and 4 units of BspPI (for pon1 
Q192R), 5 units of Hin1II (for pon1 L55M), 3 units of BsrBI (for pon1 -108C>T) and 3 units of 
DdeI (for pon2 S311C). For separation of restriction products electrophoresis on 4% agarose 
gel in TAE buffer (0.04 mol/L Tris–HCl, 5 mmol/L Na-acetate, 0.04 mmol/L EDTA, pH 7.9) 
and stained with ethidium bromide (final concentration was 0.5 μg/mL) were used. The 
length of RFLP fragments is given in Table 1.  
Determination of pon1 Q192R, pon1 L55M and pon1 -108C>T polymorphisms by the PCR-
RFLP procedure using specific restriction enzymes were described in details previously 
(Grdić et al., 2008, 2011). Briefly, for pon1 Q192R polymorphism undigested fragment (238 
bp) was detected in genotype QQ, digested fragments (175 and 63 bp) were detected in 
genotype RR, and both digested and undigested fragments (238, 175 and 63 bp) were 
detected in genotype QR. For pon1 L55M polymorphism undigested fragment (172 bp) was 
detected in genotype LL, digested fragments (103 and 69 bp) were detected in genotype 
MM, and digested and undigested fragments (172, 103 and 69 bp) were detected in genotype 
LM. For pon1-108C>T polymorphism undigested fragment (240 bp) was detected in 
genotype TT, digested fragment (212 bp) was detected in genotype CC, and both undigested 
and digested fragments (240 and 212 bp) were detected in genotype CT .  
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Q192R 1QR: 5′ TATTGTTGCTGTGGGACCTGAG 3′ 60  BspPI 238 bp 
Q allele:  
238 bp 
 2QR: 5′ CCTGAGAATCTGAGTAAATCCACT 3′    
R allele:  
175+63 bp 
pon1  
L55M 1LM: 5′ CCTGCAATAATATGAAACAACCTG 3′ 63  Hin1II 172 bp 
L allele:  
172 bp 




AGCTAGCTGCCGACCCGGCGGGGAGGaG 3′ 68  BsrBI 240 bp 
C allele: 
 212+28 bp 
 2CT: 5′ GGCTGCAGCCCTCACCACAACCC 3′    T allele:  240 bp 
pon2 
 S311C 1SC: 5′ ACATGCATGTACGGTGGTCTTATA 3′ 55  DdeI 265 bp 
S allele:  
123+75+67 bp 
 2SC: 5′ AGCAATTCATAGAAAATTAATTGTTA 3′    
C allele:  
142+123 bp 
Table 1. Conditions for PCR-RFLP method. The lower case base “a” in pon1 -108CNT 1CT 
primer indicates a mismatch, introducing a restriction site for restriction enzyme BsrBI. 
Determination of pon2 S311C polymorphism by PCR-RFLP procedure using DdeI restriction 
enzyme was carried out as follows. The exchange of the nucleotide C with G results in 
substitution of codon TCT to TGT (exon 9 of pon2 gene), and with substitution of serine to 
cystein at position 311 (S311C, SNP ID rs7493). S and C alleles have a restriction site for DdeI 
restriction enzyme but the presence of codon TCT in S allele introduces an additional 
restriction site for this enzyme. The amplified fragment of 265 bp was digested in two 
fragments (142 and 123 bp) in both S and C allele. In the case of S allele 142 bp fragment is 
additionally digested in two fragments (75 and 67 bp). Fragments of 123, 75 and 67 bp were 
detected in genotype SS, fragments of 142 and 123 bp were detected in genotype CC, and 
fragments of 142, 123, 75 and 67 bp were detected in genotype SC.  
2.3.4 PAF-AH activity assay 
Platelet-activating factor acetylhydrolase (PAF-AH) activity was measured in plain serum 
with the new automated spectrophotometric assay (Azwell Inc., Auto PAF-AH, Osaka, 
Japan) at 37C (Kosaka et al., 2000). In the first phase, 2µL of serum was added to 240 µL of 
200 mmol/L HEPES (N-2-hydroxyethylpiperazine–N´-2-ethanesulfonic acid) buffer 
(Reagent 1), pH 7.6 and pre-incubated at 37ºC for 5 min. The reaction was started by adding 
80 µL of 20 mmol/L citric acid monohydrate buffer, pH 4.5 containing 90 mmol/L 1-
myristoyl-2-(4-nitrophenylsuccinyl)phosphatidylcholine (Reagent 2). The liberation of p-
nitrophenol was monitored at 405 and 505 nm at 1 and 3 min after the addition of Reagent 2 
using the automatic biochemical analyzer OlympusAU600 (Olympus Mishima Co., Ltd., 
Shizuoka, Japan). Enzyme activities are expressed in international units per liter of serum 
and standardized against concentration of LDL-cholesterol. Serum samples were kept 
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Q192R 1QR: 5′ TATTGTTGCTGTGGGACCTGAG 3′ 60  BspPI 238 bp 
Q allele:  
238 bp 
 2QR: 5′ CCTGAGAATCTGAGTAAATCCACT 3′    
R allele:  
175+63 bp 
pon1  
L55M 1LM: 5′ CCTGCAATAATATGAAACAACCTG 3′ 63  Hin1II 172 bp 
L allele:  
172 bp 




AGCTAGCTGCCGACCCGGCGGGGAGGaG 3′ 68  BsrBI 240 bp 
C allele: 
 212+28 bp 
 2CT: 5′ GGCTGCAGCCCTCACCACAACCC 3′    T allele:  240 bp 
pon2 
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Table 1. Conditions for PCR-RFLP method. The lower case base “a” in pon1 -108CNT 1CT 
primer indicates a mismatch, introducing a restriction site for restriction enzyme BsrBI. 
Determination of pon2 S311C polymorphism by PCR-RFLP procedure using DdeI restriction 
enzyme was carried out as follows. The exchange of the nucleotide C with G results in 
substitution of codon TCT to TGT (exon 9 of pon2 gene), and with substitution of serine to 
cystein at position 311 (S311C, SNP ID rs7493). S and C alleles have a restriction site for DdeI 
restriction enzyme but the presence of codon TCT in S allele introduces an additional 
restriction site for this enzyme. The amplified fragment of 265 bp was digested in two 
fragments (142 and 123 bp) in both S and C allele. In the case of S allele 142 bp fragment is 
additionally digested in two fragments (75 and 67 bp). Fragments of 123, 75 and 67 bp were 
detected in genotype SS, fragments of 142 and 123 bp were detected in genotype CC, and 
fragments of 142, 123, 75 and 67 bp were detected in genotype SC.  
2.3.4 PAF-AH activity assay 
Platelet-activating factor acetylhydrolase (PAF-AH) activity was measured in plain serum 
with the new automated spectrophotometric assay (Azwell Inc., Auto PAF-AH, Osaka, 
Japan) at 37C (Kosaka et al., 2000). In the first phase, 2µL of serum was added to 240 µL of 
200 mmol/L HEPES (N-2-hydroxyethylpiperazine–N´-2-ethanesulfonic acid) buffer 
(Reagent 1), pH 7.6 and pre-incubated at 37ºC for 5 min. The reaction was started by adding 
80 µL of 20 mmol/L citric acid monohydrate buffer, pH 4.5 containing 90 mmol/L 1-
myristoyl-2-(4-nitrophenylsuccinyl)phosphatidylcholine (Reagent 2). The liberation of p-
nitrophenol was monitored at 405 and 505 nm at 1 and 3 min after the addition of Reagent 2 
using the automatic biochemical analyzer OlympusAU600 (Olympus Mishima Co., Ltd., 
Shizuoka, Japan). Enzyme activities are expressed in international units per liter of serum 
and standardized against concentration of LDL-cholesterol. Serum samples were kept 





2.3.5 Quality control of measurements 
The Institute of Clinical Chemistry and Laboratory Medicine of the Merkur University 
Hospital has been accredited to ISO 15189, Medical laboratories - Particular requirements for 
quality and competence since 2007 (ISO 15189, 2008). Analytical methods for measurement of 
serum triacylglycerol, total cholesterol, LDL and HDL-cholesterol concentrations as well as for 
paraoxonase polymorphisms determinations used in this study have been accredited 
according to this norm (Flegar- Meštrić et al., 2010a).  Traceability of analytical methods is 
achieved through a manufacturer’s reference materials (calibrators) or reference methods for 
enzyme activities. Analyzer–based calibrations are routinely performed for compensation of 
systematic effects. Estimates of within-laboratory precision are provided by internal quality 
control data using commercial control sera (Olympus Diagnostic) for triacylglycerol, total 
cholesterol, LDL and HDL-cholesterol concentrations and pool serum samples for the 
paraoxonase and PAF-AH activities. Trueness estimates are based on the long-term results of 
external quality assessment (EQA) obtained by the participation of the Institute of Clinical 
Chemistry and Laboratory Medicine of the Merkur University Hospital in the National 
External Quality Assessment Scheme organized by the Croatian Society of Medical 
Biochemists and international EQA schemes for general and special medical biochemistry 
organized by Labquality - WHO Collaborating Centre for Education and Training in 
Laboratory Quality Assurance, FIN-00520 Helsinki, Finland (Flegar-Meštrić, Z. et al., 2010b). 
According to the requirements of the international standard ISO 15189, interlaboratory 
comparisons were performed for the paraoxonase polymorphisms determinations between the 
Institute of Clinical Chemistry and Laboratory Medicine of the Merkur University Hospital 
and Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia. Estimation of 
measurement uncertainties is done on the basis of the “Guide to the Expression of Uncertainty 
in Measurement” (GUM, 2005). The uncertainty components that we use are uncertainties 
related to calibrator, within-laboratory precision and trueness estimates based on the results of 
external quality assessment (EQA). The expanded measurement uncertainties (k=2) obtained 
for triacylglycerol, total cholesterol, LDL and HDL-cholesterol concentrations and pool serum 
samples for the paraoxonase and PAF-AH activities in the normal concentration range were 
4.8, 4.0, 8.0, 11.1, 4.2 and 3.8%, respectively. 
2.4 Statistical analysis 
The Mann-Whitney U-test was applied to evaluate the differences between the groups, with 
p< 0.05 considered statistically significant. The correlations between serum PAF-AH activity 
and concentrations of total and LDL cholesterol were estimated using Pearson's correlation. 
Chi-square test was used for comparisons of allele and genotype proportions. MedCalc 
statistical program (MedCalc Software Version 8.1.0.0, 2005 Frank Schoonjans for Windows, 
available at the website:www.medcalc.be/) was used. 
3. Results  
3.1 Patients 
The results of the Mann-Whitney U-test showed that, according to the demographic and 
lifestyle characteristics (age, body mass index), the control no-stenosis group matched the 
groups of patients with different degrees of cerebrovascular stenosis (Table 2). The chi-
squared test showed no significant differences between sex and cerebrovascular stenosis 
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subgroups (Yates corrected χ² =0.003, p=0.338 in the group with <70% of stenosis; Yates 
corrected χ² =0.023, p=0.638 in the group with >70% of stenosis) or smoking habits and 
cerebrovascular stenosis subgroups (Yates corrected χ² =0.001, p=0.478 in the group with 
<70% of stenosis; Yates corrected χ² =0.012, p=0.962 in the group with >70% of stenosis). The 
proportion of daily smokers in the group of patients with <70% of stenosis was 33.3% and 
32.6% in the group of patients with >70% of stenosis versus 25.8 % in control no-stenosis 
group. The mean values of the body mass index in all groups examined were more than 25 
kg/m2 , indicating overweight.  
3.2 Serum triacylglycerol, total cholesterol, LDL and HDL cholesterol concentrations  
Comparing the results obtained for the traditional risk factors (triacylglycerol, total 
cholesterol, HDL-cholesterol, LDL-cholesterol) between the groups of patients with 
cerebrovascular stenosis and control no-stenosis group using the Mann-Whitney univariate 
statistic method, significant differences were found for all serum lipid parameters (p<0.05) 
















Age (years) 61  (44-82) 
66  
(41 - 83) 0.068 
68  
(46 - 83) 0.160 
Body mass index 
(kg/m2 ) 
26.3  
(20.2 – 35.7) 
25.7  
(19.1 – 34.1) 0.143 
26.5 




(4.2 – 8.4) 
5.4 
 (3.4 – 11.5) 0.001 
5.7  




(0.34 – 4.14) 
1.75 
 (0.43 – 8.18) 0.003 
1.66  




 (1.0 – 3.1) 
1.3  
(0.7 – 2.3) 0.000 
1.1  




(2.6 – 5.9) 
3.6  
(1.8 – 6.3) 0.021 
3.5 
 (1.2 – 8.4) 0.001 
Table 2. Demographic and biochemical parameters for control no-stenosis group and 
patients with <70% and >70% of cerebrovascular stenosis. Results are given as medians, 
with ranges in parentheses. p values: significance level for difference between the group of 
patients with cerebrovascular stenosis and the control no-stenosis group tested by Mann-
Whitney test; p <0.05 was considered as statistically significant. 
3.3 Paraoxonase activity measurement 
Basal and stimulated PON1 activities differ significantly between patients group with stenosis 
and the control no-stenosis group, and HDL standardized basal and stimulated PON1 activity 
did not show statistical difference. Kolmogorov –Smirnov test for normal distribution reject 
normality for all examined data (Table 3) . There were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid and lipoprotein parameters 
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3.3 Paraoxonase activity measurement 
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normality for all examined data (Table 3) . There were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid and lipoprotein parameters 











stenosis (N=119) p 
 Median (IQR) Median (IQR) 
Basal PON1 activity (U/L) 187 (137) 103 (180) 0.0056  
NaCl –stimulated PON1 activity 
(U/L) 379 (326) 213
 (339) 0.0079 
HDL standardized  
basal PON1 activity (U/mmol) 110 (125) 93 (142) 0.9390 
HDL standardized  
NaCl –stimulated PON1 activity 
(U/mmol) 
228 (238) 189 (310) 0.9605 
Table 3. Serum paraoxonase (PON1) activity and HDL standardized paraoxonase activity in 
control no-stenosis group and patients with cerebrovascular stenosis. Abbreviation: IQR, 
Interquartile range; p values: significance level for difference between the group of patients 
with cerebrovascular stenosis and the control no-stenosis group tested by Mann-Whitney 
test; p <0.05 was considered as statistically significant. 
 
 Correlation coefficient 
Control no-stenosis 
group (N=90) 
Patients with cerebrovascular stenosis 
(N=119) 
Basal PON1 activity 
r p r p 
Tryacylglicerol 0.1638 0.1229 0.0754 0.4211 
Total cholesterol 0.0105 0.9219 0.1534 0.1003 
HDL cholesterol 0.1278 0.2301 0.1146 0.2205 
LDL cholesterol -0.3067 0.3182 0.1201 0.1992 
 NaCl stimulated PON1 activity 
Tryacylglicerol 0.1587 0.1358 0.0691 0.4606 
Total cholesterol -0.0140 0.8956 0.1589 0.0844 
HDL cholesterol 0.1283 0.2281 0.1154 0.2173 
LDL cholesterol -0.1262 0.2359 0.1306 0.1623 
Table 4. Relationships between paraoxonase activity and serum lipids and lipoproteins 
levels. p <0.05 was considered as statistically significant. 
3.4 Paraoxonase polymorphisms determinations 
Genotype frequencies of pon1 and pon2 polymorphisms found in the group of patients with 
angiografically assessed stenosis of cerebral arteries vs. control no-stenosis group are 
presented in Table 5 and Figures 1-4. Observed and expected genotype frequencies of all 
examined pon1 and pon2 genes polymorphisms were in Hardy-Weinberg equilibrium. There 
were no statistically significant differences between genotype frequencies of pon1 and pon2 
(Table 5) as well as for the alleles frequencies in patients group vs. control no-stenosis group 
(p>0,05) (Table 6).  
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n % n %  
pon1 L55M      
LL 33 40 32 45 P = 0,910 
LM 41 51 25 35  
MM 7 9 14 20  
pon1 Q192R      
QQ 38 47 33 47 P = 0,995 
QR 39 48 32 45  
RR 4 5 6 8  
pon1 -108C>T      
CC 22 27 18 25 P = 0,912 
CT 47 58 32 45  
TT 12 15 21 30  
pon2 S311C      
SS 44 54 45 63 P = 0,981 
CS 37 46 24 34  
CC 0 0 2 3  
Table 5. Genotype frequencies of pon1 and pon2 polymorphisms in control no-stenosis group 
and patients with cerebrovascular stenosis. Data are shown as number (n) and percentage 
(%) of individuals having a certain genotype; checked by Chi-square test.  
 
 
Fig. 1. Determination of L55M pon1 gene polymorphism by the PCR-RFLP procedure using 
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Fig. 1. Determination of L55M pon1 gene polymorphism by the PCR-RFLP procedure using 






Fig. 2. Determination of Q192R pon1 gene polymorphism by the PCR-RFLP procedure using 




Fig. 3. Determination of -108C>T pon1 gene polymorphism by the PCR-RFLP procedure 
using BsrBI restriction enzyme. Line 1 CT, line 2 CC, lines 3, 4 CT, line 5 TT and line 6 CT 
genotype. 
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Fig. 4. Determination of S311C pon2 gene polymorphism by the PCR-RFLP procedure 







cerebrovascular stenosis p 
n % n %  
pon1 L55M      
L 107 62 89 63 P = 0,9744 
M 65 38 53 37  
pon1 Q192R      
Q 115 66 139 70 P = 0,8477 
R 47 34 61 30  
pon1 -108C>T      
C 91 56 95 48 P = 0,1246 
T 71 44 105 52  
pon2 S311C      
S 125 77 160 80 P = 0,5980 
C 37 23 40 20  
Table 6. Allele frequencies of pon1 and pon2 polymorphisms in control no-stenosis group 
and patients with cerebrovascular stenosis. Data are shown as number (n) and 






Fig. 2. Determination of Q192R pon1 gene polymorphism by the PCR-RFLP procedure using 




Fig. 3. Determination of -108C>T pon1 gene polymorphism by the PCR-RFLP procedure 
using BsrBI restriction enzyme. Line 1 CT, line 2 CC, lines 3, 4 CT, line 5 TT and line 6 CT 
genotype. 
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Fig. 4. Determination of S311C pon2 gene polymorphism by the PCR-RFLP procedure 
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3.5 PAF-AH activity assay 
The values of PAF-AH activity did not differ significantly between control no-stenosis 
group and group of patients with cerebrovascular stenosis (Table 7) while LDL standardized 
PAF-AH activity (U/mmol) showed significant difference. The PAF-AH activity showed 






cerebrovascular stenosis  
Median (IQR) Median (IQR) p 
PAF-AH activity 
(U/L) 405 (134) 414 (171) 0.769 
LDL standardized  
PAF-AH activity 
(U/mmol) 
99 (30) 119 (41) <0.0001 
Table 7. Serum Platelet-activating factor acetylhydrolase (PAF-AH) activity in groups 
studied. p values: significance level for difference between the group of patients with 
cerebrovascular stenosis and the control no-stenosis group tested by Mann-Whitney test; p 




Control no-stenosis group Patients with cerebrovascular stenosis 
r p r p 
Tryacylglicerol 0.353 0.0006 0.153 0.1018 
Total cholesterol 0.417 <0.0001 0.591 <0.0001 
HDL cholesterol -0.360 0.0005 -0.006 0.9495 
LDL cholesterol 0.459 <0.0001 0.5879 <0.0001 
Table 8. Relationships between platelet-activating factor acetylhydrolase (PAF-AH) activity 
and serum lipids and lipoproteins levels. p <0.05 was considered as statistically significant. 
4. Discussion  
Atherosclerosis, a disease of large arteries, is the primary cause of heart disease and stroke 
(Lusis, JA. 2000). Epidemiological studies over the past 50 years have revealed various risk 
factors for atherosclerosis and cardiovascular disease, which can be grouped into factors 
with an important genetic component and those that are largely environmental (Gupta et al., 
2009; Lusis, JA. 2000). The results of our study indicated that significant changes associated 
with cerebrovascular stenosis could be the result of the environmental factors and 
demographic characteristics of the examined population, which is in accordance with 
previous studies that have investigated the atherosclerosis and the severity and extent of 
cardiovascular disease (Mallat et al., 2010; Costa et al., 2005; Granér et al., 2006). All groups 
examined in our study were characterized by a high frequency of cigarette smoking and 
overweight, which is consistent with the results of a previous large cross-sectional 
epidemiological study of Croatian population (Turek et al., 2001), and could be considered 
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as the possible risk factors that contribute to the increased risk of cerebrovascular stenosis 
(Flegar-Meštrić et al., 2007; Vrhovski-Hebrang et al., 2002).  
It has been reported that raised levels of atherogenic lipoproteins are a prerequisite for most 
forms of atherosclerotic disease (Mallat et al., 2010; Tsimikas et al., 2009; Lusis, JA. 2000). 
In our study, the median values obtained in the groups of patients with different degrees of 
cerebrovascular stenosis were for total cholesterol, LDL-cholesterol and tryacilglycerols 
higher and for HDL-cholesterol lower than the recommended values for prevention of 
atherosclerotic disease (De Backer et al., 2004), indicating a possible contribution of 
dyslipidemia to the risk of developing future stenosis of cerebral arteries.  
Today, the aim of cardiovascular risk prevention is to determine atherosclerotic disease 
activity and shift the present focus from identification of stenosis, which is a focal disease, to 
identification of patients with inflamed and rupture-prone plaque (Karabina et al., 2010). 
Numerous biomarkers have been proposed to better discern the vulnerability of plaque 
rupture, pathogenesis, or cardiovascular risk. Epidemiologic, genetic, and biochemical 
studies support an antiatherogenic role for paraoxonase (PON) 1. The two other members of 
the PON gene family, namely, PON2 and PON3, have also been reported to possess 
antioxidant properties and may exhibit antiatherogenic capacities as well (Shih, DM  Lusis, 
AJ. 2009). Previous studies have demonstrated that PON1 expression is down regulated by 
oxidative stress. In contrast, more recent studies have shown that PON2 expression is up 
regulated in response to oxidative stress-inducing agents, while PON3 expression remains 
unchanged (Ng et al., 2005). Although PON1 activity is determined genetically, various 
factors, such as diet, lifestyle and environmental factors, can influence PON1 activity (Ng et 
al., 2005; Gupta et al., 2009). Between individuals, there is an approximately 10- to 40-fold 
variation in PON1 activity (Gupta et al., 2009).  
Only a few studies have examined the relationship between PON1 activity and 
angiographically proven cardiovascular disease (Graner et al., 2006; Mackness et al., 2001). 
Our results indicated that basal and stimulated PON1 activities were significantly decreased 
in patients group with angiographically proven cerebrovascular stenosis (>50%) versus 
control no-stenosis group (p<0.05), and there were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid parameters (total 
cholesterol, LDL-cholesterol, HDL-cholesterol and tryacilglycerols), p>0.05. Those results 
are in line with previous studies, indicating that PON1 activities toward paraoxon are lower 
in subjects with cardiovascular disease than in control subjects regardless of the PON1 
genotype. This would suggest that the quality of the PON1 enzyme is a more important 
factor in cardiovascular disease than the PON1 gene (Mackness et al., 2001).  
Polymorphisms in pon1 and pon2 genes (L55M and Q192R in pon1, and S311C in pon2) have 
been reported to be associated with the risk for the development of atherosclerosis as well as 
polymorphism in pon1 promoter region (-108C>T) (Pasdar et al., 2006; Granér et al., 2006).  
Paraoxonase-1 has several genetic polymorphisms that modify its activity and mass 
concentration. Hypothesized differences in the ability of the polymorphic forms to protect 
oxidation of LDL have led to numerous studies attempting to determine the relationship 
between PON1 polymorphisms and cardiovascular disease. The results of meta-analysis of 
88 studies on 4 PON polymorphisms [Q192R, L55M, and T(−107)C in the PON1 and the 
S311C in the PON2] suggested an overall weak association between the R192 polymorphism 
and CHD risk. Despite these limitations, this meta-analysis suggests that Q192R 





3.5 PAF-AH activity assay 
The values of PAF-AH activity did not differ significantly between control no-stenosis 
group and group of patients with cerebrovascular stenosis (Table 7) while LDL standardized 
PAF-AH activity (U/mmol) showed significant difference. The PAF-AH activity showed 






cerebrovascular stenosis  
Median (IQR) Median (IQR) p 
PAF-AH activity 
(U/L) 405 (134) 414 (171) 0.769 
LDL standardized  
PAF-AH activity 
(U/mmol) 
99 (30) 119 (41) <0.0001 
Table 7. Serum Platelet-activating factor acetylhydrolase (PAF-AH) activity in groups 
studied. p values: significance level for difference between the group of patients with 
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Control no-stenosis group Patients with cerebrovascular stenosis 
r p r p 
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as the possible risk factors that contribute to the increased risk of cerebrovascular stenosis 
(Flegar-Meštrić et al., 2007; Vrhovski-Hebrang et al., 2002).  
It has been reported that raised levels of atherogenic lipoproteins are a prerequisite for most 
forms of atherosclerotic disease (Mallat et al., 2010; Tsimikas et al., 2009; Lusis, JA. 2000). 
In our study, the median values obtained in the groups of patients with different degrees of 
cerebrovascular stenosis were for total cholesterol, LDL-cholesterol and tryacilglycerols 
higher and for HDL-cholesterol lower than the recommended values for prevention of 
atherosclerotic disease (De Backer et al., 2004), indicating a possible contribution of 
dyslipidemia to the risk of developing future stenosis of cerebral arteries.  
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regulated in response to oxidative stress-inducing agents, while PON3 expression remains 
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al., 2005; Gupta et al., 2009). Between individuals, there is an approximately 10- to 40-fold 
variation in PON1 activity (Gupta et al., 2009).  
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angiographically proven cardiovascular disease (Graner et al., 2006; Mackness et al., 2001). 
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in patients group with angiographically proven cerebrovascular stenosis (>50%) versus 
control no-stenosis group (p<0.05), and there were no statistically significant relationships 
between basal and stimulated PON1 activity and examined lipid parameters (total 
cholesterol, LDL-cholesterol, HDL-cholesterol and tryacilglycerols), p>0.05. Those results 
are in line with previous studies, indicating that PON1 activities toward paraoxon are lower 
in subjects with cardiovascular disease than in control subjects regardless of the PON1 
genotype. This would suggest that the quality of the PON1 enzyme is a more important 
factor in cardiovascular disease than the PON1 gene (Mackness et al., 2001).  
Polymorphisms in pon1 and pon2 genes (L55M and Q192R in pon1, and S311C in pon2) have 
been reported to be associated with the risk for the development of atherosclerosis as well as 
polymorphism in pon1 promoter region (-108C>T) (Pasdar et al., 2006; Granér et al., 2006).  
Paraoxonase-1 has several genetic polymorphisms that modify its activity and mass 
concentration. Hypothesized differences in the ability of the polymorphic forms to protect 
oxidation of LDL have led to numerous studies attempting to determine the relationship 
between PON1 polymorphisms and cardiovascular disease. The results of meta-analysis of 
88 studies on 4 PON polymorphisms [Q192R, L55M, and T(−107)C in the PON1 and the 
S311C in the PON2] suggested an overall weak association between the R192 polymorphism 
and CHD risk. Despite these limitations, this meta-analysis suggests that Q192R 





and S311C polymorphisms (Wang et al., 2011). Additionally, it has been reported that no 
significant genotypic or allelic frequency differences between stroke cases and controls for 
any of the structural polymorphisms of the PON genes tested were found (Pasdar et al., 
2006).  
In our study, there were no significant differences in genotype or allele frequencies of pon1 
and pon2 genes between patients with stenosis of cerebral arteries and controls, indicating 
that there is no relationship between examined polymorphisms and reduced paraoxonase 
activity in patients group with angiographically proven cerebrovascular stenosis.  
The platelet-activating factor acetylhydrolase (PAF-AH) or lipoprotein-associated 
phospholipase A2 (Lp-PLA2) is among the multiple biomarkers that have been associated 
with an increased CHD risk (Karabina et al., 2010; Garza et al., 2007; Tsimikas et al., 2009; 
Reddy et al., 2009; Wolfert et al., 2004). A recent meta-analysis of 14 prospective 
epidemiologic studies involving more than 20,000 patients established a high relative risk 
for cardiovascular events with high Lp-PLA2.( Garza et. al., 2007; Ballantyne et al., 2007). 
The LDL-associated PAF-AH activity increases in parallel with the severity of 
hypercholesterolemia, thus one of the major factors that determines plasma levels of PAF-
AH is the rate of removal of LDL from the circulation (Karabina et al., 2010; Tsimikas et al., 
2009). In our study, the PAF-AH activity shows the most significant linear relationship with 
total cholesterol and LDL cholesterol in the control no-stenosis group and the group of 
patients with cerebrovascular stenosis. It has been reported that increased Lp-PLA2 activity 
is significantly related to incident cardiovascular disease (cardiovascular death, myocardial 
infarction, stroke, and transient ischemic attack) (Tsimikas et al., 2009; Mallat et al., 2010). In 
our study, the median serum PAF-AH activity did not differ significantly between patients 
with cerebrovascular stenosis and control no-stenosis group (median values 414 U/L versus 
405 U/L, p>0,05), which is consistent with results of our previous study (Flegar-Meštrić et 
al., 2003), while LDL standardized PAF-AH activity a showed significant difference between 
the patients with cerebrovascular stenosis and control group (median values 119 U/mmol 
versus 99 U/mmol, p<0,0001).  
Previous studies show that Lp-PLA2 is a unique inflammatory biomarker that plays a critical 
role in the development of atherosclerosis and may be involved in the causal pathway of 
plaque inflammation and plaque rupture (Munzel, T.  Gori, T. 2009; Cariquist et al., 2007). 
The association of Lp-PLA2 with cardiovascular risk among different population studies 
independent of classical risk factors makes the premise even stronger that Lp-PLA2 is 
involved in progression of atherosclerosis to advanced rupture-prone unstable plaques 
(Reddy et al., 2009) . As Lp-PLA2 is produced by macrophages and foam cells of 
atherosclerotic plaques that are numerous in unstable plaque, the differentiation between 
stable versus unstable plaque could be established by the presence of elevated Lp-PLA2 
(Reddy et al., 2009; Munzel, T.  Gori, T. 2009; Hiramoto et al., 1997; Zalewski, A.  
Macphee, C. 2005). However, the clinical utility of Lp-PLA2 activity for prediction of 
cardiovascular risk has to be explored in future studies. 
5. Conclusion 
The results of the present study show that basal and stimulated PON1 activities were 
significantly decreased in the patients group with cerebrovascular stenosis (group of 
patients with symptoms of cerebrovascular insufficiency and stenosis of carotid artery more 
than 50% of the lumen) versus control no-stenosis group (p<0.05). There were no statistically 
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significant relationships between PON1 activity and lipid parameters (total cholesterol, 
LDL-cholesterol, HDL-cholesterol and tryacilglycerols), p>0.05. According to the results 
obtained, we assume that decreased PON1 activities in patients with cerebrovascular 
stenosis may cause a decreased HDL antioxidant capacity and therefore contribute to the 
increased risk of the development of cerebrovascular atherosclerosis. However, there were 
no significant differences in genotype or allele frequencies of pon1 and pon2 genes between 
patients with stenosis of cerebral arteries and no-stenosis control group, indicating that 
changes in paraoxonase activity are determined by both genetic and environmental factors.  
Our results show the most significant linear relationship between PAF-AH activity and total 
cholesterol and LDL-cholesterol ( p<0.001) in the control no-stenosis group, as well as in the 
group of patients with cerebrovascular stenosis. The median serum PAF-AH activity did not 
differ significantly between the patients with cerebrovascular stenosis and control no-
stenosis group (p>0,05), while LDL standardized PAF-AH activity showed significant 
difference between both examined groups (p<0.0001). According to our results, the LDL-
standardized PAF-AH activity could be used as an additional discriminating biochemical 
indicator of cerebrovascular stenosis.  
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1. Introduction  
Over the past decade we have witnessed an explosion of information regarding the 
molecular mechanisms underlying atherogenesis. While at one time atherosclerosis was 
viewed as a passive process of lipid deposition within muscular arteries, resulting in 
progressive luminal stenosis, we now understand that the process is much more complex. In 
particular, there is a growing appreciation for the role of both adaptive and innate immunity 
in atherogenesis, and for the contribution of other, non-traditional inflammatory stimuli. 
Indeed, atherogenesis is now understood primarily as an inflammatory disorder and much 
of the therapeutic focus has turned to devising approaches for reducing systemic levels of 
pro-inflammatory mediators and/or preventing these mediators from altering the 
biochemistry and physiology of the cells that make up the vessel wall. The inflammatory 
component of atherogenesis is particularly important from a clinical standpoint since it 
appears that atherosclerotic lesions characterized by on-going inflammation are those that 
are most unstable and susceptible to rupture, possibly leading to luminal thrombosis and 
acute myocardial infarction. 
In this chapter, we provide a brief overview of the mechanisms underlying atherogenesis, 
highlighting known pro-inflammatory influences. We then focus on activation of the NF-B 
family of transcription factors as a major molecular mediator of inflammation and 
summarize recent work that has provided new insights into how a diverse set of G protein-
coupled receptors (GPCRs) may use a common mechanism to communicate NF-B 
activation in cells native to the vessel wall, particularly endothelial cells. These discoveries 
may provide novel avenues for therapeutic intervention as we refine our approach to 
treating patients at risk for atherosclerosis. 
2. Basic concepts and mechanisms in atherogenesis 
Atherosclerosis is a chronic, progressive process through which lipid deposition, extracellular 
matrix production, immune cell infiltration, and smooth muscle cell proliferation all conspire 
to produce arterial obstruction and to disrupt normal arterial vasoreactivity (Hansson, 2005). 
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Fig. 1. The role of the endothelium through the stages of plaque formation. It should be 
noted that while endothelial dysfunction represents the first stage of plaque formation, it 
continues through all other stages as well. See text for a detailed description of each stage. 
2.1 Endothelial dysfunction 
The earliest recognizable stage in the development of atherosclerosis is characterized by 
changes in the cellular physiology of endothelial cells, referred to as endothelial dysfunction 
(Sitia et al., 2010). Endothelial cells form a single cell-thick, selectively permeable barrier, 
separating circulating blood components from the vessel wall. Aside from their barrier 
function, these cells also influence overall vessel function, in particular by regulating levels 
of nitric oxide (NO) which influences vascular contractility and tone (Jin and Loscalzo, 
2010). Endothelial dysfunction ensues when these cells are exposed to injurious stimuli, 
resulting in a disruption in their ability to maintain a proper barrier and to promote vascular 
relaxation. As will be discussed, many features of endothelial dysfunction can be linked to 
the stimulation of signal transduction pathways culminating in NF-B activation (de 
Winther et al., 2005). In particular, NF-B activation induces expression of chemokines such 
as monocyte chemotactic factor (MCP-1), and adhesion molecules such as vascular and 
intercellular adhesion molecules (VCAM-1 and ICAM-1), which serve to recruit circulating 
monocytes and facilitate their process of transmigration through the endothelial barrier into 
the subendothelial space (de Winther et al., 2005) (Fig. 1). In addition, NF-B activation 
plays a role in reorganizing tight and adherens junctions, which represent the glue 
connecting one endothelial cell to the next (Aveleira et al., 2010). Alteration in tight junctions 
can then influence the permeability of the endothelial layer to serum proteins and lipids. 
Finally, NF-B activation has a complex role in controlling various aspects of NO 
production, and vice versa (Csiszar et al., 2008; Farmer and Kennedy, 2009; Laroux et al., 
2001). As such, factors that act on endothelial cells to induce NF-B represent important 
players in the initiation of atherogenesis. 
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2.2 Fatty streak 
The fatty streak is a waxy yellow deposit in the subendothelial space that represents the first 
grossly visual evidence of atherogenesis (Packard and Libby, 2008). The fatty streak is 
formed by the accumulation of lipid and lipid-laden macrophages, also known as foam cells, 
which are recruited during endothelial dysfunction to the intimal space. While these streaks 
typically develop into more advanced lesions, they do have the potential to involute and 
resolve, so that at least at this stage, the process of atherogenesis is a reversible one. Lipid 
residing in the intima, particularly when in an oxidized form (Ox-LDL), can act to further 
endothelial dysfunction, initiating a vicious cycle that perpetuates fatty streak formation 
and can lead to more advanced lesions (Packard and Libby, 2008). This occurs in part 
through activation of scavenger receptors on the basolateral surface of endothelial cells, 
including the lectin-like oxidized LDL receptor-1 (LOX-1) (Mitra et al., 2011). Among other 
effects, LOX-1 activation upregulates VCAM-1 and ICAM-1 leading to further monocyte 
recruitment, upregulates the receptor for Angiotensin II (AGTR1), and increases release of 
reactive oxygen species (ROS) which cause further oxidation of LDL particles (Mitra et al., 
2011). 
2.3 Intermediate lesion 
As the plaque progresses, there is further expansion of the intimal space with lipid and 
macrophages. Other leukocytes, including lymphocytes and mast cells, begin to accumulate 
and play key regulatory roles (Hansson, 2005; Packard and Libby, 2008). In this stage, 
vascular smooth muscle cells (VSMCs) begin to proliferate and some migrate into the 
superficial intima, leaving their usual position in the media. This occurs in response to 
increasing concentrations of growth factors released from endothelial cells and 
inflammatory cells in the developing lesion. The VSMCs in turn contribute to plaque size 
through their proliferation and through production of extracellular matrix proteins 
(collagen, elastin, proteoglycans). However, it is these matrix proteins and VSMCs that 
together form a protective fibrous cap separating the inflammatory core of the plaque from 
the endothelial layer (Libby et al., 2011). Thus, the integrity of the fibrous cap is essential for 
maintaining a stable lesion. Also during this stage, the vessel undergoes compensatory 
remodelling in an effort to maintain luminal patency, although there is invariably a 
progressive stenosis (Rader and Daugherty, 2008). Part of the remodelling process includes 
the ingrowth of a neovascular network, extending from the vasa vasorum of the outer 
adventitial layer of the vessel into the central portion of plaque (Libby et al., 2011) (Fig. 1). 
While this neovascularization serves a stabilizing function by providing for adequate blood 
supply to the plaque, and preventing cellular hypoxia in this region, these newly formed 
vessels are also leaky, delicate, and prone to rupture. In this way, neovascularization 
represents a double-edged sword, simultaneously promoting and risking lesion stability. 
2.4 Advanced/vulnerable lesion 
With increasing cycles of lipid deposition and inflammation, the plaque becomes 
progressively unstable and prone to rupture due to a multitude of factors. The lipid core 
may become necrotic, leading to release of cytotoxic substances and cellular debris. 
Hemorrhage of the lipid core microvasculature may occur, leading to intra-lesional 
thrombosis and production of pro-inflammatory molecules including thrombin. These 
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Ultimately, it is the integrity of the surface endothelial lining of the plaque that represents 
the greatest clinical concern. Any damage to these endothelial cells may then lead to 
exposure of the extracellular matrix to circulating blood. This includes the exposure of tissue 
factor (TF), which triggers the coagulation cascade and can lead to life-threatening local 
thrombosis. Damage to the endothelium may occur via processes occurring in the vessel 
lumen, for example as a consequence of shear stresses induced by hypertension and plasma 
turbulence. Alternatively, damage may come from below, as a consequence of inflammation 
in the plaque. Ongoing inflammation within the lipid core weakens the fibrous cap, in part 
because inflammatory cells release proteases that degrade the extracellular matrix. For 
example, macrophages release matrix metalloproteinase 9 (MMP-9), which alone is 
sufficient to induce rupture of advanced lesions in mice (Gough et al., 2006). T lymphocytes 
uniquely contribute to plaque instability via the production of IFN- which then 
downregulates VSMC matrix production (Packard and Libby, 2008). Thus, lesions that are 
most susceptible to rupture are those that have been weakened over time by the action of 
matrix-degrading proteases and have a paucity of VSMCs to provide a protective barrier 
separating the lipid core from surface endothelial cells (Libby et al., 2011).  
3. Specific GPCR agonists as contributors to vascular inflammation 
The GPCR family represents the largest family of cell surface receptors, and includes over 800 
known members (Dorsam and Gutkind, 2007; Lappano and Maggiolini, 2011). GPCRs are 
structurally defined by an extracellular N-terminal tail, seven trans-membrane domains linked 
together by 6 alternating intracellular and extracellular loops, and a C-terminal tail (Strader et 
al., 1994). Members of this receptor family respond to a diverse array of ligands including 
peptides, amines, glycoproteins and enzymes. The receptors relay extracellular signals by 
activating multiple intracellular signaling pathways which include those for ERK, Akt, JNK, 
p38MAPK, STAT, and NF-B activation, to name only a few (Dorsam and Gutkind, 2007; 
Lappano and Maggiolini, 2011). Several GPCR agonists have been identified as key regulators 
of both endothelial cell function and atherogenesis. Below we discuss three such agonists that 
play particularly prominent roles in the pathophysiologic stages of atherogenesis. 
3.1 Angiotensin II 
Angiotensin II (Ang II) is a GPCR agonist, long known for its classic role in controlling blood 
pressure through regulating vascular smooth muscle tension, influencing renal reabsorption of 
sodium and water, and through stimulating aldosterone release from the adrenal. However, in 
recent years our understanding of this peptide hormone has broadened, and it is now 
appreciated that Ang II exerts a much wider spectrum of responses (Luft, 2001). In particular, 
Ang II is now appreciated for its profound pro-inflammatory effects, exerted on both 
endothelial and smooth muscle cells of the vasculature (Phillips and Kagiyama, 2002). 
Through this role, Ang II is thought to promote atherogenesis via mechanisms that are 
independent from its impact on blood pressure. Consistent with this notion, animal models of 
Ang II-dependent atherosclerosis, as well as large clinical trials investigating angiotensin 
converting enzyme (ACE) inhibitors or AGTR1 blockers (eg, HOPE, EUROPA, and LIFE), 
have demonstrated that the contribution of Ang II to atherogenesis cannot be explained solely 
by its ability to promote hypertension (Bertrand, 2004; Ferrario and Strawn, 2006; Kintscher et 
al., 2004). Instead, there is emerging evidence that perhaps the greatest impact of Ang II lies in 
its ability to directly induce pro-inflammatory signal transduction.  
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AGTR1 is expressed on both endothelial cells and VSMCs (Brasier et al., 2002). In addition, 
all the components of a local renin-angiotensin system (RAS) exist within the vasculature, so 
that Ang II can be locally produced and act in an autocrine or paracrine fashion, 
supplementing the effects of systemically circulating Ang II (Sata and Fukuda, 2010). 
Although Ang II influences numerous aspects of endothelial cell physiology, at least four 
categories of genes are induced that contribute to atherogenesis (Fig. 2). These include 1) 
genes whose products promote recruitment and activation of monocytes and other 
inflammatory cells (eg, chemokines, cytokines, and adhesion molecules such as MCP-1, IL-6, 
IL-8, ICAM-1, VCAM-1, and E-selectin), 2) genes whose products destabilize plaque and 
promote both proliferation and migration of underlying VSMCs (eg, MMP-9, PAI-1, and 
IGF-1R), 3) genes whose products mediate endothelial dysfunction, particularly in the 
presence of oxidized LDL (eg, LOX-1), and 4) genes encoding secondary cytokines that can 
feed back to ECs and VSMCs, further enhancing the pro-inflammatory milieu (eg, TNFα, Il-
1β) (Fig. 2) (Brasier et al., 2002; de Winther et al., 2005; Pober and Sessa, 2007). Importantly, 
activation of LOX-1 sets in motion a destructive feed-forward cycle, whereby it enhances the 
expression of both AGTR1 and angiotensin converting enzyme (ACE) (Li et al., 2000; Li et 
al., 2003). This in turn results in enhanced local production of Ang II (Fig. 2). As will be 
discussed, all the above are NF-B regulated genes, highlighting NF-B activation as a key 
pro-atherogenic signaling event.  
 
 
Fig. 2. Pleiotropic effects of Ang II on vascular pathophysiology.  
Ang II, either made locally within the vessel wall or present following diffusion from the 
vessel lumen, can also act on VSMCs. Here, AGTR1 activation results in many of the same 
pro-inflammatory responses that are seen in endothelial cells. Additionally, MAPK 
pathways are activated, partly through transactivation of EGF receptors, thereby promoting 
the hypertrophy and hyperplasia of VSMCs that is characteristic of atherosclerotic lesions 
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Thrombin is known historically for its role in the clotting cascade. Active thrombin is 
generated from the inactive precursor, prothrombin, via cleavage by a complex consisting of 
factor Xa and factor Va, assembled through the actions of tissue factor (TF) (Borissoff et al., 
2011). Thrombin then plays a role in generating a stable clot, in part through cleaving 
fibrinogen to produce fibrin, and through its actions on platelets. However, as is the case for 
Ang II, there is increasing appreciation for the receptor-mediated, pro-inflammatory effects 
of thrombin. Unlike most GPCR agonists, thrombin is a serine protease and acts on its 
cognate receptors through an unusual mechanism. The best studied thrombin receptor on 
endothelial cells is perhaps the protease activated receptor-1 (PAR-1) (Borissoff et al., 2009). 
In this case, thrombin binds to an extracellular hirudin-like domain on PAR-1 and cleaves 
the receptor at a specific site, exposing a cryptic ligand, SFLLRN, present near the N-
terminal tail of the receptor. The newly exposed amino acid sequence acts as a tethered 
ligand by binding to a pocket on extracellular loop 2 and permanently activating the 
receptor (Borissoff et al., 2009). A synthetic peptide with the same SFLLRN sequence, also 
known as TRAP-6, can be used to induce the same response from PAR-1 as thrombin 
(Coughlin, 2005). 
Both PAR-1 and its agonist thrombin are major participants in the regulation of 
endothelial cell biology and atherogenesis, affecting cell signaling, gene expression, 
endothelial permeability, angiogenesis, and vascular tone (Hirano, 2007). Indeed, the 
importance of direct pro-atherogenic effects of thrombin on cells of the vessel wall were 
recently highlighted by a study in mice showing that atherosclerosis can proceed 
independently of thrombin-induced platelet activation (Hamilton et al., 2009). As with 
Ang II, many of the effects of thrombin on endothelial cells can be mechanistically linked 
to NF-B activation. 
3.3 IL-8 
A vast array of chemokines and associated GPCRs exist that influence vascular biology 
(Rosenkilde and Schwartz, 2004). For the purposes of this review, we highlight only one, 
IL-8 (CXCL8), because of the recent work demonstrating parallels between the molecular 
signaling pathways activated by IL-8 and those activated by both Ang II and thrombin 
(Martin et al., 2009). IL-8 is a CXC chemokine with many immunomodulatory functions 
and a broad range of biological effects. The effects of IL-8 are mediated primarily 
through CXCR2, a GPCR that is expressed on a broad range of cells, including 
endothelial cells (Rosenkilde and Schwartz, 2004). IL-8 is upregulated within developing 
atherosclerotic lesions, in part due to the stimulatory effect of Ox-LDL (Braunersreuther 
et al., 2007). Among its many effects, IL-8 induces expression of vascular endothelial 
growth factor (VEGF), which is synthesized and released by endothelial cells and can act 
in an autocrine/paracrine fashion to induce angiogenesis within the lipid core and to 
increase vascular permeability (Gavard et al., 2009). As with Ang II and thrombin, many 
of the pro-inflammatory effects of IL-8 can be attributed to the activation of NF-B. In 
particular, IL-8 induction of the VEGF gene occurs through NF-B binding sites in its 
promoter (Martin et al., 2009). See Table 1 for a summary of several pro- 
atherogenic effects of IL-8, and other GPCR agonists, that have been ascribed to NF-B 
activation. 
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GPCR Affected cell type in plaque NF-κB related pro-atherogenic effects 
Angiotensin II 
Type 1 receptor 
Endothelial cells 
 Release of pro-inflammatory cytokines 
 Recruitment and activation of 
inflammatory cells 
 Destabilization of plaque 
VSMCs  Proliferation and migration into plaque 
CXCR2 (IL-8 
receptor) Endothelial cells 
 Expression of VEGF 
 Promotion of plaque 
neovascularization 






 Recruitment of inflammatory cells 
 Enhancement of vascular permeability 
 Promotion of plaque 
neovascularization 
 Stimulation of vasoconstriction 
Table 1. Selected effects of three GPCRs and their ligands on atherogenesis. 
4. GPCR connectivity to NF-κB  
For ligand activated GPCRs, many, but not all, signaling events are initiated through the 
activation of heterotrimeric G proteins (Dorsam and Gutkind, 2007; Lappano and 
Maggiolini, 2011). The cytoplasmic loops within GPCRs serve to recruit these G proteins, 
consisting of , , and  subunits. Upon agonist binding, the receptors promote exchange of 
GDP for GTP on the G subunit, leading to its dissociation from the G subunits. Both 
GTP-bound G and G subunits are then able to stimulate a range of downstream 
effectors. At least part of the specificity in receptor signaling stems from the fact that there 
are numerous G subtypes, broadly grouped into four classes (Gs, Gi, Gq/11, and 
G12/13), and GPCRs will preferentially couple to certain subtypes (Dorsam and Gutkind, 
2007; Lappano and Maggiolini, 2011). 
Receptors that couple to Gq/11 are known to activate protein kinase C (PKC) isoforms 
through G protein-dependent stimulation of phospholipase C, Ca2+ mobilization, and DAG 
generation. These include receptors for agonists described above (Ang II, thrombin, IL-8) as 
well as others that potentially influence endothelial biology in the context of atherogenesis, 
including endothelin-1, lysophosphatidic acid (LPA), and SDF-1/CXCL12 . For some time, it 
has been clear that PKC activation by select GPCRs is a prerequisite for subsequent NF-B 
activation, but we are only now beginning to unravel the specific mechanistic links between 
PKC and the NF-B machinery. In order to discuss these links, we will first briefly review 
the salient features of the NF-B family of transcription factors, and their regulation. For a 
more nuanced treatment, the reader is referred to one of the more complete reviews of the 
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GPCR Affected cell type in plaque NF-κB related pro-atherogenic effects 
Angiotensin II 
Type 1 receptor 
Endothelial cells 
 Release of pro-inflammatory cytokines 
 Recruitment and activation of 
inflammatory cells 
 Destabilization of plaque 
VSMCs  Proliferation and migration into plaque 
CXCR2 (IL-8 
receptor) Endothelial cells 
 Expression of VEGF 
 Promotion of plaque 
neovascularization 






 Recruitment of inflammatory cells 
 Enhancement of vascular permeability 
 Promotion of plaque 
neovascularization 
 Stimulation of vasoconstriction 
Table 1. Selected effects of three GPCRs and their ligands on atherogenesis. 
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more nuanced treatment, the reader is referred to one of the more complete reviews of the 






4.1 The NF-κB family 
The NF-B family denotes a group of five transcription factors and includes the proteins 
RelA (p65), RelB, c-Rel, NF-B1 (p105/50), and NF-B2 (p100/52) (Oeckinghaus and Ghosh, 
2009). All share a highly conserved Rel homology domain (RHD) which directs their 
dimerization, nuclear localization, and DNA binding activities (Oeckinghaus and Ghosh, 
2009). Upon entering the nucleus, NF-B subunits bind to the NF-B consensus sequence, 
GGPuNNPyPyCC, present within the regulatory regions of target genes. Along with an 
array of co-factors, NF-B transcription factors are able to induce or repress transcription of 
a wide variety of genes. Several pathways exist for activating NF-B, depending upon the 
specific cellular stimulus, and this affects which NF-B subunits are recruited into action. 
4.2 The canonical NF-κB signaling pathway 
In the unstimulated cell, the canonical NF-B subunits, RelA and p50, stand at the ready in 
the cytoplasm, retained there by a family of regulatory proteins termed inhibitors of B 
(IBs). These IB proteins conceal the nuclear localization sequences on RelA and p50, 
preventing their nuclear translocation. Various stimuli, including ligands for the TNF, 
interleukin, Toll-like, and antigen receptor families, act to induce intracellular signaling 
pathways that culminate in activation of the chief canonical regulatory complex, termed the 
IB kinase (IKK) complex (Fig. 3A). The IKK complex is composed of three principal 
subunits, one regulatory subunit (NEMO/IKK), and two catalytic subunits (IKK and 
IKK) (Oeckinghaus and Ghosh, 2009). Once activated, the catalytic subunits, particularly 
IKK, phosphorylate IBs, leading to their ubiquitination and proteosomal degradation. 
This frees the RelA/p50 complex for nuclear translocation and transcriptional regulation. 
While the steps leading from IKK activation to IB phosphorylation and degradation are 
well-conserved, no matter what the stimulus, specificity is built into the system in that 
different receptors use vastly different signaling mechanisms for communicating with the 
IKK complex (dotted lines in Fig. 3A). It is in dissecting these “private pathways” for IKK 
activation that much of the recent progress in NF-B research has been made. This is a 
crucial area of discovery, since identifying molecules that specifically mediate IKK 
activation in response to selected receptor ligands may allow for development of 
pharmaceuticals that interrupt (or enhance) the response to those ligands and not others. 
This could be a critically important area of discovery since general inhibition of NF-B can 
have substantial negative side-effects including the initiation of a generalized state of 
immunodeficiency, or impairment of growth/development. 
4.3 The non-canonical (alternative) NF-κB signaling pathway 
A distinct set of stimuli, including CD40 ligand, BAFF, and lymphotoxin-, work to 
activate a second set of NF-B subunits (Oeckinghaus and Ghosh, 2009). Activation of 
their cognate receptors causes phosphorylation of p100, in complex with its partner, RelB 
(Fig. 3B). This occurs through the kinase activity of IKK, but does not require the other 
components of the IKK complex. Instead, IKK activation requires the upstream 
activation of NF-B inducing kinase (NIK), which serves not only to phosphorylate and 
activate IKK, but also appears to assist in recruiting p100. Once phosphorylated, p100 
undergoes partial proteolysis, producing p52, and it is the RelB/p52 complex that is active 
as a regulator of transcription. Thus, in essence the p100 precursor acts much the same as 
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an IB, preventing non-canonical NF-B activity. An area of intense interest relates to the 
question of whether the non-canonical NF-B complex of RelB/p52 regulates a distinct set 
of genes from those regulated by RelA/p50. Importantly, while GPCRs are known to 
stimulate the canonical pathway, their potential for activating non-canonical signaling 




Fig. 3. Distinct pathways for canonical and non-canonical NF-B activation. 
4.4 Unique/emerging NF-κB signaling pathways 
Although the canonical and non-canonical pathways for NF-B activation have 
historically received the most attention, it is clear that several other mechanisms are in 
place for activating NF-B subunits. Bearing in mind that several different NF-B 
heterodimer complexes have been identified, it is likely that our understanding of 
alternative routes for NF-B activation will only grow as the regulation of these 
complexes is explored in more detail. For example, recent work in B cells has 
demonstrated that c-Rel/p50 heterodimers can be regulated by a unique, non-proteosome 
dependent pathway for IB degradation (O'Connor et al., 2004). Further, kinases other 
than IKK have been identified that can act to phosphorylate IB proteins, leading to their 
degradation (McElhinny et al., 1996; Schwarz et al., 1996). Finally, other levels of control 
exist beyond the simple degradation of IB proteins. Several groups have shown that NF-
B subunits are targets of secondary modification, including phosphorylation and 
acetylation, alterations that can affect their ability to interact with both DNA consensus 
sites and transcriptional co-regulators. Thus, as the body of experimental data grows, it 
will no doubt become obvious that the concepts of canonical and non-canonical activation, 
outlined above and in Fig. 3, represent only a framework for a much more complicated 
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4.5 GPCR dependent NF-κB signaling 
Activation of certain GPCRs expressed on vascular cells, including the receptors for Ang II, 
thrombin, and IL-8, leads to all the hallmarks of canonical NF-B activation. Although the 
precise mechanisms underlying this response have been unclear, it has long been 
appreciated that canonical activation requires proximal stimulation of PKC (Fraser, 2008). 
For example, Ang II induction of NF-B in both endothelial cells, VSMCs, and 
cardiomyocytes is tightly linked to activation of PKC, although the specific PKC isoform 
responsible may differ depending on the cell type (Brasier et al., 2000; Hiroki et al., 2004; 
Kalra et al., 2002; Liao et al., 1997; Parmentier et al., 2006; Rouet-Benzineb et al., 2000). For 
PAR-1, PKC is known as the primary PKC mediating NF-B activation in endothelial cells 
(Minami et al., 2004; Rahman et al., 2001). PKC and  have both been implicated in LPA-
dependent NF-B activation, in ovarian cancer cells and in airway epithelial cells, 
respectively (Cummings et al., 2004; Mahanivong et al., 2008). Finally, several PKC isoforms, 
including PKC and PKC, have been shown to mediate IL-8/CXCR2-dependent signaling, 
but these studies have not been performed in endothelial cells or VSMCs (Waugh and 
Wilson, 2008). 
In that upstream PKC activation is a prerequisite for GPCR-responsive NF-B signaling, we 
and others recognized a parallel theme with the antigen-responsive activation of NF-B in 
lymphocytes. In B lymphocytes, antigen receptor ligation induces PKC, and this is critical 
for subsequent NF-B activation, while in T lymphocytes it is PKC that is crucial (Lucas et 
al., 2004). Over the past decade, a tremendous volume of data has been generated to define 
the precise molecular steps linking PKC activation with the NF-B machinery in 
lymphocytes. This work revealed that a multi-protein signaling complex, termed the 
CARMA1/Bcl10/MALT1 (CBM) signalosome serves as a molecular bridge between the two, 
and is necessary for lymphocytes to mount a normal, NF-B-dependent immune response to 
antigenic challenge (Lucas et al., 2004; Thome, 2004; Wegener and Krappmann, 2007). 
Taking cues from the lymphocyte field, we and others worked to define a novel molecular 
pathway that explains how GPCR-dependent PKC activation can result in NF-B signaling. 
This pathway utilizes an analogous CBM signalosome, present in cells outside of the 
immune system, and is detailed in the next section. 
It is important to note, however, that the discovery of a GPCR-responsive CBM signalosome 
must be viewed in the larger context of GPCR signaling, with the realization that other 
signaling pathways are active, some of which may influence NF-B through independent 
mechanisms. For example, Brasier and colleagues have uncovered a distinct mechanism by 
which ligand-activated AGTR1 induces RelA in VSMCs (Brasier, 2010). In these cells, 
substantial levels of RelA are found inactive in the nucleus under resting conditions. Ang II 
stimulation induces a pathway of RhoA and NIK activation, culminating in NIK-dependent 
phosphorylation of the nuclear RelA species on serine 536 (Choudhary et al., 2007; Cui et al., 
2006). This phosphorylated pool of RelA is free from IB regulation and dynamically cycles 
through the nucleus, interacting with target genes (Bosisio et al., 2006; Sasaki et al., 2005). 
This mechanism of regulation has been shown to impact the NF-B responsive, IL-6 gene. 
Consistent with this observation, we have seen only a partial effect of blocking the CBM 
signalosome on Ang II-dependent IL-6 induction, underscoring the concept that different 
NF-B responsive genes may respond to different NF-B transcription factor complexes 
and/or different modes of NF-B regulation. 
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5. The CARMA3/Bcl10/MALT1 signalosome; missing link for GPCR activity 
5.1 Lessons learned from lymphocytes 
CARMA1 (also known as Bimp3/CARD11) is a member of the membrane-associated 
guanylate kinase (MAGUK) superfamily of molecular scaffolds that each utilize multiple 
discrete protein interaction domains to cluster receptors and cytosolic signaling molecules 
at the cell membrane (Dimitratos et al., 1999; Fanning and Anderson, 1999). As such, all 
MAGUKS contain three defining interactions domains: the PSD-95/Dlg/ZO-1 
homologous (PDZ) domain, the Src-homology (SH3) domain, and the guanylate kinase 
(GUK)-like domain (Fig. 4A). CARMA1 is expressed exclusively in lymphocytes, and a 
few related cells of the immune system, and is one of three known members of the 
CARMA subfamily. This subfamily is distinguished from members of other MAGUK 
subfamilies by the presence of additional coiled-coil and caspase recruitment (CARD) 
domains.  
Numerous biochemical and genetic studies have now definitively established that 
CARMA1 is an essential component of the antigen-induced NF-B signaling pathway in T 
cells. Data indicate that CARMA1 acts as a molecular bridge, linking PKC activation with 
stimulation of the downstream signaling proteins, Bcl10 and MALT1 (Fig. 4B) (Lucas et 
al., 2004). Together, CARMA1, Bcl10, and MALT1 form a complex (referred to as the CBM 
signalosome) that is recruited to the lymphocyte immunological synapse following 
receptor engagement. In this complex, the small Bcl10 protein appears to function as an 
adaptor, capable of oligomerizing MALT1. Finally, MALT1 acts as an effector subunit by 
stimulating IKK, the IKK regulatory subunit, in part through promoting its K63-linked 
ubiquitination (Sun et al., 2004; Zhou et al., 2004). This subsequently leads to activation of 
the catalytic subunits, IKK and IKK, thereby allowing them to phosphorylate IB and 
free NF-B for nuclear transport. The details as to how MALT1 achieves regulation of the 
IKK complex are still unfolding, with the current dogma suggesting that the process 
includes a coordinated series of K63-linked ubiquitination events, not only of IKK but of 
several other proteins in the complex, as well as IKK phosphorylation, probably via the 
kinase TAK1. 
A second mechanism of action for MALT1 has recently emerged and gained considerable 
attention. This relates to the discovery that MALT1 is a substrate-specific protease 
(McAllister-Lucas and Lucas, 2008). Although such enzymatic activity has long been 
postulated, based on recognition of a “caspase-like” active site in the C-terminus of MALT1 
(Uren et al., 2000), it wasn’t until only recently that substrates for MALT1 cleavage were 
identified. So far, three have been identified, and their cleavage sites mapped (Coornaert et 
al., 2008; Rebeaud et al., 2008; Staal et al., 2011). Two of the substrates, A20 and CYLD, are 
deubiquitinases, known for their ability to dampen NF-B signaling through their ubiquitin 
editing functions, affecting various players in the NF-B machinery. Thus, by targeting these 
two proteins for cleavage, it is thought that MALT1 proteolytic activity serves to maximize 
the level of NF-B activation, following antigen stimulation of lymphocytes. Indeed, 
cleavage of A20 leads to loss of its inhibitory effect and magnified antigen-dependent NF-B 
activation (Coornaert et al., 2008). In theory, the same could occur with cleavage of CYLD, 
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Fig. 4. A, Schematic diagram of proteins that make up the CBM signalosome. B and C, 
Similarities and differences exist between the mechanisms through which the CARMA1- 
and CARMA3-containing signalosomes act to stimulate the IKK complex; see text for 
description.  
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Many of the details concerning how the CBM complex is recruited and activated at the T cell 
immunological synapse have become clear only recently. First, Ghosh and co-workers 
demonstrated that, following T cell receptor stimulation, the enzyme 3-phosphoinositide-
dependent kinase 1 (PDK1) serves to anchor both activated PKC and CARMA1 within 
close proximity to one another, at the immunological synapse (Fig. 4B) (Lee et al., 2005). 
PDK1 is a kinase known to phosphorylate PKC at a specific site within its “activation loop” 
(Belham et al., 1999; Mora et al., 2004; Newton, 2001, 2003). This phosphorylation appears to 
serve as a priming reaction, allowing PKC to then respond to activating signals, such as Ca2+ 
or DAG, depending on the specific isoform. However, the ability of PDK1 to interact with 
CARMA1 represents a newly defined role for this kinase. Although PDK1 plays a key role in 
recruiting the CBM signalosome to the T cell receptor, it may not represent the only 
molecular link; for example, recent work has demonstrated that the protein ADAP is also 
crucial in this regard (Medeiros et al., 2007). 
A second major finding was that PKC acts to phosphorylate specific sites within the linker 
region of CARMA1, which resides between the CARD/coiled-coil domains and the domains 
present in all MAGUK proteins (PDZ/SH3/GUK) (Matsumoto et al., 2005; Sommer et al., 
2005). This appears to result in a conformational change in CARMA1, allowing for exposure 
of the CARD domain (Sommer et al., 2005). Consequently, Bcl10 and MALT1 can then be 
effectively recruited to the immunological synapse because their recruitment depends 
primarily on a CARD-CARD interaction between CARMA1 and Bcl10. Finally, the IKK 
complex is recruited and can thereby be activated by the fully assembled CBM complex 
(Shinohara et al., 2005; Stilo et al., 2004; Weil et al., 2003). It should be noted that the majority 
of the work defining the mechanism of action of the CBM signalosome has been carried out 
using T cell models. Interestingly, not all of the concepts are likely to hold true for B cells. In 
particular, based on phenotypic differences between MALT1-/- mice and BCL10-/- or 
CARMA1-/- mice, there is some debate as to whether MALT1 is an obligate player in B cell 
receptor-dependent NF-B activation. 
5.2 CARMA3, a CARMA homologue expressed in cells outside the immune system 
Except for CARMA1, the key molecules mediating antigen-dependent NF-B activation in 
lymphocytes are ubiquitously expressed in a diverse array of cells. However, we and others 
had noted that a highly related protein, CARMA3 (Bimp1/CARD10), is expressed more 
broadly than the immune cell-specific CARMA1 (McAllister-Lucas et al., 2001; Wang et al., 
2001b). The CARMA1 and CARMA3 genes encode proteins that are highly similar; the 
CARDS and coiled-coil domains share approximately 60% and 50% sequence identity with 
one another, respectively, while the PDZ, SH3 and GUK domains share approximately 20-
30% identity. The functional similarities between CARMA3 and CARMA1 are illustrated by 
the fact that CARMA3 can rescue antigen-induced NF-B activation in CARMA1-deficient T 
cells (Matsumoto et al., 2005). Of potential importance to cardiovascular pathophysiology, 
all three proteins of a putative CARMA3-containing CBM complex are abundant in heart 
and aorta, and western blotting confirms their presence in those tissues at the protein level 
(McAllister-Lucas et al., 2010; McAllister-Lucas et al., 2007). As a result, we wondered if 
CARMA3 might scaffold an analogous CBM signalosome in cells outside the immune 
system. The known dependence on PKC activation for GPCR-responsive NF-B stimulation 
led to the hypothesis that specific GPCRs might represent candidates for receptors that 
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Using distinct systems and approaches, we and two other groups simultaneously 
demonstrated that two GPCRs could harness a CARMA3-containing CBM signalosome for 
the purposes of NF-B activation (Klemm et al., 2007; McAllister-Lucas et al., 2007; Wang et 
al., 2007) (Fig. 4C). Our group demonstrated the essential role of CARMA3, Bcl10, and 
MALT1 in the Ang II-dependent activation of canonical NF-B (McAllister-Lucas et al., 
2007). This initial work focused on hepatocytes as a model, but subsequent work 
demonstrated that the same CBM machinery is active in endothelial cells following Ang II 
stimulation (McAllister-Lucas et al., 2010). Individually knocking down each component of 
the putative CARMA3/Bcl10/MALT1 complex completely blocked Ang II-dependent IB 
phosphorylation, a marker of canonical NF-B activation, or induction of an NF-B 
responsive reporter gene. In addition, expression of a dominant negative mutant of 
CARMA3 was sufficient to impair Ang II-dependent K63-linked IKK polyubiquitination. 
The other two studies focused on mouse embryonic fibroblasts (MEFs) from BCL10-/- and 
MALT1-/- mouse strains. In contrast to wild-type MEFs, these knockout cells showed a 
complete lack of NF-B activation when stimulated with lysophosphatidic acid (LPA) 
(Klemm et al., 2007; Wang et al., 2007). Follow-up work revealed the same phenomenon 
with CARMA3-/- MEFs (Grabiner et al., 2007). Like the receptor for Ang II (AGTR1), 
receptors for LPA (LPA1-4) are prototypical GPCRs, coupled primarily with Gq/11 subunits. 
With regard to pathophysiology, LPA receptor-induced NF-B activation has been linked to 
a variety of consequences, depending upon the cell type affected, which include the 
promotion of carcinoma cell survival and spread, as well as endothelial dysfunction. 
However, despite the potential importance of the CBM complex in mediating LPA-
dependent effects in endothelial cells or VSMCs, studies have yet to be published that 
specifically link LPA receptors to the CBM components in the vasculature. 
Following these initial studies, several groups have added to the list of GPCRs capable of 
harnessing the CARMA3-containing CBM signalosome. To date, however, the only 
receptors that have been specifically shown to utilize the signalosome in endothelial cells are 
those for Ang II (AGTR1), thrombin (PAR-1) and IL-8 (CXCR2) (Delekta et al., 2010; Martin 
et al., 2009; McAllister-Lucas et al., 2010). 
5.3 Distinct mechanisms for recruiting CARMA1- and CARMA3-containing 
signalosomes 
Although there are strong parallels between the mechanisms underlying recruitment and 
activation of the CARMA1-containing CBM signalosome of lymphocytes and the CARMA3-
containing CBM signalosome of endothelial cells, there are also notable differences. Most 
striking are the differences in how the signalosomes communicate with their cognate 
receptors. We have already described work demonstrating a crucial role for PDK1 in 
scaffolding an interaction with antigen receptors in the T cell. In contrast, PDK1 may have 
no role in coordinating GPCR-dependent CBM assembly; at least for PAR-1, knockdown of 
PDK1 in endothelial cells has no effect on thrombin-dependent NF-B activation (Delekta et 
al., 2010). Instead, we and others have implicated -arrestin 2 as a protein that could serve 
the function of scaffolding CARMA3 to select GPCRs (Delekta et al., 2010; Sun and Lin, 
2008). 
Traditionally, the -arrestin proteins have been known for their role in down-regulating 
activated GPCRs through receptor endocytosis, leading to their recycling or degradation. 
Activated GPCRs are phosphorylated by various G protein receptor kinases (GRKs), 
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which then allows recruitment of arrestins to the receptors. This helps to uncouple G 
proteins from the receptors and assists in receptor internalization through clathrin-coated 
pits. But more recently, arrestins have become known as scaffold proteins that facilitate 
the recruitment and activation of a number of distinct secondary signaling molecules 
(DeFea, 2011). In this way, arrestins are now appreciated not just for their ability to 
terminate GPCR signaling, but also for their ability to promote a second layer of GPCR-
dependent responses. 
Lin and colleagues originally showed that -arrestin 2 deficient MEFs were unable to 
respond to LPA treatment with an NF-B signal (Sun and Lin, 2008). They then determined 
that -arrestin 2 bound to CARMA3. Further, co-immunoprecipitation experiments 
demonstrated that CARMA3 could interact with the LPA receptor only when -arrestin 2 
was present to act as a bridge. Subsequent work showed that -arrestin 2 deficient MEFs are 
also defective in thrombin-dependent NF-B activation (Delekta et al., 2010). Thus, it is 
likely that for GPCR signaling, -arrestin 2 serves a scaffolding role, analogous to what has 
been shown for PDK1 in the lymphocyte system (Fig. 4C). 
Despite the progress that has been made in understanding the regulation of CARMA3-
containing CBM signalosomes, much remains to be learned. The CARMA1-containing 
complex has been studied for a much longer period of time, and many of the finer details 
have been explored in more detail. For example, the sites of PKC-dependent CARMA1 
phosphorylation, which allow for unfolding of CARMA1 and exposure of the CARD 
domain, have been mapped (Matsumoto et al., 2005; Sommer et al., 2005). In addition, other 
kinases have been identified that can positively or negatively regulate CARMA1 (Bidere et 
al., 2009; Brenner et al., 2009; Ishiguro et al., 2006; Shinohara et al., 2007). In contrast, 
mechanisms for regulation of CARMA3 remain mostly speculative at this time. 
5.4 Distinct mechanisms for CARMA1- and CARMA3-dependent IKK activation 
Another area of potential distinction, differentiating CARMA1- and CARMA3-containing 
signalosomes, relates to their ability to facilitate IKK complex phosphorylation, a necessary 
step for full IKK activation. As described previously, MALT1 is thought to play a major role 
as an “effector” protein in the CBM complex, coordinating the activation of the IKK 
complex. This occurs at least in part through the ability of MALT1 to direct multiple K63-
linked ubiquitin modifications, targeting IKK, Bcl10, and even MALT1 itself. In the 
lymphocyte, these ubiquitin chains may then serve as a scaffold to recruit the kinase, TAK1, 
which completes the activation of the IKK complex through phosphorylation of IKK at 
specific residues within its activation loop (Shinohara et al., 2005; Wang et al., 2001a). As for 
the activation of TAK1, this appears to occur through a parallel pathway, initiated by the 
antigen receptor, that does not depend upon the CBM complex (Shambharkar et al., 2007) 
(Fig. 4B).  
Interestingly, recent work has shown that TAK1 is dispensable for LPA-dependent NF-B 
activation. Instead, another mitogen-activated protein kinase, MEKK3, takes its place (Sun et 
al., 2009). Thus, the ligand-activated LPA receptor induces a parallel pathway, independent 
of the CARMA3-containing CBM complex, that causes MEKK3 activation, subsequently 
leading to IKK phosphorylation (Fig. 4C). It remains an open question as to whether 
MEKK3 will be involved in IKK complex activation downstream of all GPCRs, or whether 
distinct kinases will act in concert with the CARMA3-containing CBM complex, depending 





Using distinct systems and approaches, we and two other groups simultaneously 
demonstrated that two GPCRs could harness a CARMA3-containing CBM signalosome for 
the purposes of NF-B activation (Klemm et al., 2007; McAllister-Lucas et al., 2007; Wang et 
al., 2007) (Fig. 4C). Our group demonstrated the essential role of CARMA3, Bcl10, and 
MALT1 in the Ang II-dependent activation of canonical NF-B (McAllister-Lucas et al., 
2007). This initial work focused on hepatocytes as a model, but subsequent work 
demonstrated that the same CBM machinery is active in endothelial cells following Ang II 
stimulation (McAllister-Lucas et al., 2010). Individually knocking down each component of 
the putative CARMA3/Bcl10/MALT1 complex completely blocked Ang II-dependent IB 
phosphorylation, a marker of canonical NF-B activation, or induction of an NF-B 
responsive reporter gene. In addition, expression of a dominant negative mutant of 
CARMA3 was sufficient to impair Ang II-dependent K63-linked IKK polyubiquitination. 
The other two studies focused on mouse embryonic fibroblasts (MEFs) from BCL10-/- and 
MALT1-/- mouse strains. In contrast to wild-type MEFs, these knockout cells showed a 
complete lack of NF-B activation when stimulated with lysophosphatidic acid (LPA) 
(Klemm et al., 2007; Wang et al., 2007). Follow-up work revealed the same phenomenon 
with CARMA3-/- MEFs (Grabiner et al., 2007). Like the receptor for Ang II (AGTR1), 
receptors for LPA (LPA1-4) are prototypical GPCRs, coupled primarily with Gq/11 subunits. 
With regard to pathophysiology, LPA receptor-induced NF-B activation has been linked to 
a variety of consequences, depending upon the cell type affected, which include the 
promotion of carcinoma cell survival and spread, as well as endothelial dysfunction. 
However, despite the potential importance of the CBM complex in mediating LPA-
dependent effects in endothelial cells or VSMCs, studies have yet to be published that 
specifically link LPA receptors to the CBM components in the vasculature. 
Following these initial studies, several groups have added to the list of GPCRs capable of 
harnessing the CARMA3-containing CBM signalosome. To date, however, the only 
receptors that have been specifically shown to utilize the signalosome in endothelial cells are 
those for Ang II (AGTR1), thrombin (PAR-1) and IL-8 (CXCR2) (Delekta et al., 2010; Martin 
et al., 2009; McAllister-Lucas et al., 2010). 
5.3 Distinct mechanisms for recruiting CARMA1- and CARMA3-containing 
signalosomes 
Although there are strong parallels between the mechanisms underlying recruitment and 
activation of the CARMA1-containing CBM signalosome of lymphocytes and the CARMA3-
containing CBM signalosome of endothelial cells, there are also notable differences. Most 
striking are the differences in how the signalosomes communicate with their cognate 
receptors. We have already described work demonstrating a crucial role for PDK1 in 
scaffolding an interaction with antigen receptors in the T cell. In contrast, PDK1 may have 
no role in coordinating GPCR-dependent CBM assembly; at least for PAR-1, knockdown of 
PDK1 in endothelial cells has no effect on thrombin-dependent NF-B activation (Delekta et 
al., 2010). Instead, we and others have implicated -arrestin 2 as a protein that could serve 
the function of scaffolding CARMA3 to select GPCRs (Delekta et al., 2010; Sun and Lin, 
2008). 
Traditionally, the -arrestin proteins have been known for their role in down-regulating 
activated GPCRs through receptor endocytosis, leading to their recycling or degradation. 
Activated GPCRs are phosphorylated by various G protein receptor kinases (GRKs), 
 
G Protein-Coupled Receptor Dependent NF-κB Signaling in Atherogenesis 
 
543 
which then allows recruitment of arrestins to the receptors. This helps to uncouple G 
proteins from the receptors and assists in receptor internalization through clathrin-coated 
pits. But more recently, arrestins have become known as scaffold proteins that facilitate 
the recruitment and activation of a number of distinct secondary signaling molecules 
(DeFea, 2011). In this way, arrestins are now appreciated not just for their ability to 
terminate GPCR signaling, but also for their ability to promote a second layer of GPCR-
dependent responses. 
Lin and colleagues originally showed that -arrestin 2 deficient MEFs were unable to 
respond to LPA treatment with an NF-B signal (Sun and Lin, 2008). They then determined 
that -arrestin 2 bound to CARMA3. Further, co-immunoprecipitation experiments 
demonstrated that CARMA3 could interact with the LPA receptor only when -arrestin 2 
was present to act as a bridge. Subsequent work showed that -arrestin 2 deficient MEFs are 
also defective in thrombin-dependent NF-B activation (Delekta et al., 2010). Thus, it is 
likely that for GPCR signaling, -arrestin 2 serves a scaffolding role, analogous to what has 
been shown for PDK1 in the lymphocyte system (Fig. 4C). 
Despite the progress that has been made in understanding the regulation of CARMA3-
containing CBM signalosomes, much remains to be learned. The CARMA1-containing 
complex has been studied for a much longer period of time, and many of the finer details 
have been explored in more detail. For example, the sites of PKC-dependent CARMA1 
phosphorylation, which allow for unfolding of CARMA1 and exposure of the CARD 
domain, have been mapped (Matsumoto et al., 2005; Sommer et al., 2005). In addition, other 
kinases have been identified that can positively or negatively regulate CARMA1 (Bidere et 
al., 2009; Brenner et al., 2009; Ishiguro et al., 2006; Shinohara et al., 2007). In contrast, 
mechanisms for regulation of CARMA3 remain mostly speculative at this time. 
5.4 Distinct mechanisms for CARMA1- and CARMA3-dependent IKK activation 
Another area of potential distinction, differentiating CARMA1- and CARMA3-containing 
signalosomes, relates to their ability to facilitate IKK complex phosphorylation, a necessary 
step for full IKK activation. As described previously, MALT1 is thought to play a major role 
as an “effector” protein in the CBM complex, coordinating the activation of the IKK 
complex. This occurs at least in part through the ability of MALT1 to direct multiple K63-
linked ubiquitin modifications, targeting IKK, Bcl10, and even MALT1 itself. In the 
lymphocyte, these ubiquitin chains may then serve as a scaffold to recruit the kinase, TAK1, 
which completes the activation of the IKK complex through phosphorylation of IKK at 
specific residues within its activation loop (Shinohara et al., 2005; Wang et al., 2001a). As for 
the activation of TAK1, this appears to occur through a parallel pathway, initiated by the 
antigen receptor, that does not depend upon the CBM complex (Shambharkar et al., 2007) 
(Fig. 4B).  
Interestingly, recent work has shown that TAK1 is dispensable for LPA-dependent NF-B 
activation. Instead, another mitogen-activated protein kinase, MEKK3, takes its place (Sun et 
al., 2009). Thus, the ligand-activated LPA receptor induces a parallel pathway, independent 
of the CARMA3-containing CBM complex, that causes MEKK3 activation, subsequently 
leading to IKK phosphorylation (Fig. 4C). It remains an open question as to whether 
MEKK3 will be involved in IKK complex activation downstream of all GPCRs, or whether 
distinct kinases will act in concert with the CARMA3-containing CBM complex, depending 





6. The CARMA3/Bcl10/MALT1 signalosome and endothelial phenotype 
6.1 Role for endothelial NF-κB activation in atherogenesis 
As discussed earlier, many pieces of evidence implicate endothelial cell NF-B activation as 
an important GPCR-mediated signaling event favoring atherogenesis. Recently, this concept 
was reinforced by elegant studies using two related mouse models (Gareus et al., 2008). 
These researchers first generated an endothelial-specific IKK-/- mouse, to disrupt any NF-B 
signaling in this cell type. These IKK-/- mice were crossed with a mouse model of 
atherosclerosis (ApoE-/-) and fed a cholesterol-rich diet. After ten weeks, these mice showed a 
30% reduction in plaque size, 40% reduction of T cells in plaques, and an overall retardation 
in the progression to advanced plaques as compared to IKK+/+/ApoE-/- mice under the same 
diet. To further demonstrate the specific role of endothelial NF-B in atherogenesis, an 
additional transgenic mouse model was created, expressing dominant negative IB (IB-
SR) under control of the Tie2 promoter. This effectively targeted expression of the dominant 
negative mutant to endothelial cells. Since the dominant negative mutant lacks 
phosphorylation acceptor sites for IKK, its expression effectively keeps NF-B subunits 
sequestered in an inactive state, regardless of whether or not the cell is being stimulated by 
any of the classic NF-B inducers. These mice were once again backcrossed with ApoE-/- mice 
and placed on a high cholesterol diet for ten weeks, after which they showed a 60% 
reduction in plaque size and a significant reduction in plaque progression as compared to 
ApoE-/- mice with normally functioning NF-B (Gareus et al., 2008). The endothelium of IB-
SR/ApoE-/- mice was almost completely free from expression of most cytokines, chemokines 
and adhesion molecules. Taken together, this study provides exceptionally strong evidence 
that NF-B activation within the endothelium alone is necessary to drive a significant 
atherogenesis response. 
6.2 The GPCR-CBM-NF-κB axis in endothelial dysfunction and atherogenesis 
To date, three GPCRs have been linked to the CBM signalosome and NF-B activation, 
specifically in endothelial cells. These are the receptors for Ang II, thrombin, and IL-8. 
Others are sure to follow; for example, clear evidence exists for an important role for LPA 
receptor-dependent NF-B activation in endothelial biology, but to date the connections 
between this receptor and the CBM signalosome have been explored only in cell models 
outside vascular biology. In the following sections, we describe the specific work that has 
been done to investigate the GPCR-CBM-NF-B signaling axis in endothelial cells, 
focusing on the cellular and pathophysiologic consequences of activating this signaling 
axis. 
6.2.1 IL-8 and VEGF induction 
Vascular endothelial growth factor (VEGF) is a key endothelial-specific growth factor 
that is induced in response to tissue damage. VEGF modulates endothelial cell 
phenotypes by inducing cell proliferation, promoting cell migration, and inhibiting 
apoptosis, and is regarded as a key regulator of angiogenesis (Ferrara et al., 2003). In 
atherogenesis, VEGF may play a role in promoting the pathologic ingrowth of the 
neovascular network from the vasa vasorum, into plaque developing in the subintimal 
space. These effects are mediated through VEGF binding to its own receptors, VEGFR-
1/2 (Ferrara et al., 2003).  
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Under certain conditions such as tissue hypoxia, VEGF synthesis and secretion is regulated 
via activation of the transcription factor, hypoxia inducible factor-1 (HIF-1) (Semenza, 2007). 
Although hypoxia is a potent stimulus for VEGF expression, inflammatory cytokines have 
also been reported to stimulate VEGF expression through mechanisms that have not been 
fully delineated. One recent study, however, revealed that regulation of VEGF expression in 
endothelial cells can occur via CBM signalosome-mediated activation of NF-B (Martin et 
al., 2009). These investigators showed that the pro-inflammatory cytokine IL-8 (CXCL8) 
stimulated VEGF production and secretion through activation of its cognate GPCR, CXCR2. 
This receptor, in turn, was linked to the CBM signaling complex and NF-B activation. 
Importantly, the effect of IL-8 on VEGF induction was independent of HIF-1 but entirely 
dependent on NF-B. Inhibition of any of the CBM components by siRNA was effective at 
reducing NF-B activation and resulted in a marked inhibition of VEGF mRNA expression 
and protein secretion. Further, this was accompanied by decreased autocrine VEGFR2 
activation. These results suggest that the CBM signalosome is necessary for regulating VEGF 
production in endothelial cells in response to certain inflammatory cytokines, and might 
indirectly contribute to the VEGF-dependent transition of the endothelium into a pro-
angiogenic phenotype. 
6.2.2 Thrombin and endothelial cell/monocyte adhesion 
As discussed earlier, thrombin and its receptor, PAR-1, are thought to induce a variety of 
pro-inflammatory responses that may also contribute to endothelial phenotype changes 
(Hirano, 2007). Thrombin levels are increased at sites of vascular injury and thrombosis, 
where the persistent stimulation of its receptor leads to endothelial dysfunction, thereby 
increasing inflammatory responses leading to further vessel wall damage and 
atherosclerotic lesion progression. One of the key responses to local thrombin production is 
the increase in endothelial cell expression of adhesion molecules, allowing for firm adhesion 
of circulating monocytes and other leukocytes (Minami et al., 2004). Our lab has specifically 
shown that thrombin-dependent activation of the CBM-NF-B signaling axis in endothelial 
cells results in upregulation of two such adhesion molecules, VCAM-1 and ICAM-1, at both 
the mRNA and protein levels (Delekta et al., 2010). Further, we showed that thrombin-
induced adhesion of monocytes to endothelial cells requires the intact CBM signalosome; 
siRNA-mediated knockdown of Bcl10 in endothelial cells altered their phenotype to 
completely abolish thrombin-dependent monocyte adherence. Further work will be 
required to test the role of the CBM proteins in modulating other aspects of thrombin-
dependent endothelial dysfunction. 
6.2.3 Ang II and in vivo atherogenesis 
Similar to thrombin, Ang II produced locally in the vasculature has been reported to induce 
a number of inflammatory responses, including the expression of NF-B-sensitive adhesion 
molecules and cytokines in endothelial cells, and the recruitment of inflammatory cells to 
the vessel wall (Daugherty and Cassis, 2004). Our group recently showed that Ang II 
activation of its receptor, present on endothelial cells and on VSMCs, stimulates NF-B 
through the CBM signalosome (McAllister-Lucas et al., 2010).  
Further, we tested the effects of manipulating the signalosome in vivo. In these studies, we 
utilized the ApoE-/- mouse strain described earlier, which is hyperlipidemic and prone to 
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Under certain conditions such as tissue hypoxia, VEGF synthesis and secretion is regulated 
via activation of the transcription factor, hypoxia inducible factor-1 (HIF-1) (Semenza, 2007). 
Although hypoxia is a potent stimulus for VEGF expression, inflammatory cytokines have 
also been reported to stimulate VEGF expression through mechanisms that have not been 
fully delineated. One recent study, however, revealed that regulation of VEGF expression in 
endothelial cells can occur via CBM signalosome-mediated activation of NF-B (Martin et 
al., 2009). These investigators showed that the pro-inflammatory cytokine IL-8 (CXCL8) 
stimulated VEGF production and secretion through activation of its cognate GPCR, CXCR2. 
This receptor, in turn, was linked to the CBM signaling complex and NF-B activation. 
Importantly, the effect of IL-8 on VEGF induction was independent of HIF-1 but entirely 
dependent on NF-B. Inhibition of any of the CBM components by siRNA was effective at 
reducing NF-B activation and resulted in a marked inhibition of VEGF mRNA expression 
and protein secretion. Further, this was accompanied by decreased autocrine VEGFR2 
activation. These results suggest that the CBM signalosome is necessary for regulating VEGF 
production in endothelial cells in response to certain inflammatory cytokines, and might 
indirectly contribute to the VEGF-dependent transition of the endothelium into a pro-
angiogenic phenotype. 
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cells results in upregulation of two such adhesion molecules, VCAM-1 and ICAM-1, at both 
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6.2.3 Ang II and in vivo atherogenesis 
Similar to thrombin, Ang II produced locally in the vasculature has been reported to induce 
a number of inflammatory responses, including the expression of NF-B-sensitive adhesion 
molecules and cytokines in endothelial cells, and the recruitment of inflammatory cells to 
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through the CBM signalosome (McAllister-Lucas et al., 2010).  
Further, we tested the effects of manipulating the signalosome in vivo. In these studies, we 
utilized the ApoE-/- mouse strain described earlier, which is hyperlipidemic and prone to 





accelerated through infusion with Ang II, even at subpressor doses. When infusions are 
carried out for as little as 4 weeks, the mice develop prominent and premature 
atherosclerotic lesions, even in the absence of a high-fat diet; these can be visualized grossly 
by staining the intimal surfaces of the aorta with Oil-red-O, a stain that reacts to lipid-laden 
lesions (Fig. 5). This effect of Ang II infusion is generally accepted to be the result of its 
direct pro-inflammatory effects on the vessel wall, which conspires with hyperlipidemia to 
cause accelerated atherogenesis. We tested the role of the CBM signalosome by crossing 
ApoE-/- and Bcl10-/- mice to generate a double knock-out line (McAllister-Lucas et al., 2010). 
The absence of Bcl10 in the ApoE-deficient strain revealed a dramatic phenotype in which 
the mice were protected from developing Ang II-induced atherosclerosis and aortic 
aneurysms (Fig. 5). Additionally, the reduction in atherosclerotic lesions in aortas from 
ApoE-/-/Bcl10-/- mice was associated with reduced aortic gene expression of several pro-
inflammatory molecules, as compared to ApoE-/- mice infused with Ang II in the same way. 
 
 
Fig. 5. Representative aortic arches from mice infused with Ang II for 4 weeks. Genotypes 
are as indicated. Aortas are stained with Oil-red-O to highlight lipid-laden intimal lesions 
(fatty streaks-advanced lesions). See text and McAllister-Lucas et al., 2010 for details. 
6.2.4 LPA and the CBM signalosome in atherogenesis? 
As mentioned, it is likely that other GPCRs will be linked to the CBM-NF-B signaling axis 
in endothelial cells, since several have already been linked in this way through work on 
other cell types. In particular, the receptors for LPA are likely to harness the CBM proteins 
in endothelial cells, considering their prominent role in affecting endothelial cell biology. A 
new study by Schober and colleagues demonstrates that LPA, produced via oxidation of 
LDL particles, enhances atherosclerotic lesion formation in ApoE-/- mice (Zhou et al., 2011). 
This effect is mediated largely via LPA receptor-dependent elaboration of CXCL1 (GRO-) 
on the surface of endothelial cells. CXCL1 is a chemokine that acts to promote monocyte 
recruitment to the endothelial wall, and thus plays a role in promoting atherogenesis. The 
authors showed that CXCL1 expression was in part NF-B dependent. Thus, since LPA-
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stimulated NF-B activation has been shown to require the CBM complex in MEFs and in 
ovarian cancer cells (Grabiner et al., 2007; Klemm et al., 2007; Mahanivong et al., 2008; Wang 
et al., 2007), it is likely that the same will hold true for endothelial cells. 
7. Therapeutic opportunities 
Identification of the CBM signalosome as a critical mediator of GPCR-dependent pro-
inflammatory effects suggests that pharmaceutical targeting of the CBM proteins could 
represent a new strategy for preventing or treating atherosclerosis. Since disruption of the 
CBM signalosome blocks NF-B activation and inflammatory signaling downstream of 
AGTR1, PAR-1, CXCR2 and probably other GPCRs within the vessel wall that contribute to 
endothelial dysfunction and atherogenesis, inhibiting vascular CBM activity may prove 
beneficial. Potential pharmaceutical approaches include: 1) preventing specific upstream 
events that link GPCR stimulation to CBM activation, 2) blocking key post-translational 
modifications of CBM components, and 3) directly targeting the activity of CBM 
components themselves.  
7.1 Upstream targets 
The specific upstream molecular mechanisms by which GPCR stimulation promotes 
assembly and activation of the CBM have not yet been extensively investigated, and these 
mechanisms likely vary significantly depending on ligand, GPCR and cell type. However, 
there are some clues to potential therapeutic targets that could be critical for GPCR-induced 
CBM activation in the vasculature. For example, arrestin 2 associates with CARMA3, and 
studies thus far demonstrate that arrestin 2 is required for both LPA and thrombin to 
induce GPCR-dependent NF-B activation (Delekta et al., 2010; Sun and Lin, 2008). 
Intriguingly, recent studies demonstrate that in VSMCs, arrestin 2 mediates AGTR1-
dependent prevention of apoptosis and is required for both LPA and thrombin-induced 
vascular smooth muscle cell proliferation (Ahn et al., 2009; Kim et al., 2008). Furthermore, 
deficiency of arrestin 2 protects LDL receptor knockout (ldlr-/-) mice from aortic 
atherosclerosis (Kim et al., 2008). Together, these studies suggest that somehow targeting 
arrestin 2 could represent a rational therapeutic strategy for preventing GPCR-dependent 
CBM activation and combating atherosclerosis. Precisely how to inhibit arrestin 2-
dependent CBM activation remains to be investigated, but one potential approach would be 
to block GRK-mediated phosphorylation of GPCRs, thus preventing phosphorylation-
dependent recruitment of arrestin 2 to the GPCR (DeFea, 2011). In addition, "G-protein-
biased ligands" which selectively activate G-protein-mediated signaling downstream of 
specific GPCRs, while inhibiting arrestin-mediated signaling, are currently under 
development, and such agents may prove to be useful in modulating arrestin 2/CBM-
dependent vascular inflammatory disease (Whalen et al., 2011).  
7.2 Targets involved in CBM modification 
In addition to arrestin 2-mediated recruitment of CARMA3, another critical step in GPCR-
induced CBM activation that represents a potential therapeutic target is the PKC-mediated 
phosphorylation of CARMA3. As discussed above, T-cell receptor (TCR) or B-cell receptor 
(BCR) stimulation induces PKC-dependent phosphorylation of CARMA1, thus causing a 
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form the CARMA1-Bcl10-MALT1 (CBM) complex (Matsumoto et al., 2005; Sommer et al., 
2005). It is not yet known if a similar mechanism of PKC-induced CARMA3 
phosphorylation occurs downstream of GPCRs, although it is well established that GPCR 
stimulation leads to phosphorylation and activation of various PKC isoforms and treatment 
with broad-spectrum PKC inhibitors can block GPCR-dependent NF-B activation. 
However, a pharmaceutical approach targeting PKC in atherogenesis is likely to be complex 
(Ding et al., 2011), since as we described earlier, each GPCR may utilize distinct PKC 
isoforms to communicate with the CBM complex. Nevertheless, progress is being made on 
this front; a recent report demonstrated that treatment with the DAG/calcium-dependent 
PKC inhibitor, Go6976, and siRNA-mediated silencing of PKC�both blocked AGTR1-
dependent NF-B signaling in VSMCs (Doyon and Servant, 2010). Likewise, PKC inhibitors 
RO318220 and GF109203X have been shown to abrogate thrombin-dependent pro-
inflammatory signaling in human aortic VSMCs (Chung et al., 2010). Perhaps the PKC 
isoform has been most thoroughly studied in the context of atherosclerosis. For example, 
genetic knockdown of PKC�or treatment with the PKC inhibitor, ruboxistaurin, results in 
decreased atherosclerosis in ApoE-deficient mice (Harja et al., 2009), and this same PKC 
inhibitor has also been shown to reduce endothelial dysfunction in human patients (Mehta 
et al., 2009). Because there is much evidence supporting a critical role for PKCs in 
atherogenesis and there are multiple isoform-specific PKC inhibitors already available, it 
will be of great interest to determine whether inhibition of particular PKCs blocks CBM 
activation by specific GPCRs within the vasculature and whether these effects are associated 
with a pharmaceutical benefit in the setting of atherosclerosis. 
Like PKC-mediated phosphorylation of CARMA3, other post-translational modifications of 
CBM components may be critical to GPCR-induced CBM activity and could therefore 
represent potential targets for pharmaceutical intervention in GPCR-driven atherosclerosis. 
In lymphocytes, several kinases and phosphatases have been implicated in regulating the 
phosphorylation status of CARMA1 and Bcl10, and similarly, several ubiquitin ligases and 
deubiquitinases have been implicated in regulating the ubiquitination status of all three 
components of the CBM complex. In contrast to antigen receptor-dependent CBM activation 
in lymphocytes, GPCR-dependent regulation of the phosphorylation and ubiquitination of 
CARMA3, Bcl10 and MALT1 has not yet been investigated, although it seems likely that at 
least some of the same processes that regulate CBM activity in response to antigen receptor 
stimulation will also play a role in GPCR-dependent CBM regulation. Future studies may 
identify specific kinases, phosphatases, ubiquitin ligases and/or deubiquitinases that could 
be targeted in an effort to treat atherosclerosis by inhibiting GPCR/CBM pro-inflammatory 
activity in the vasculature. 
7.3 Targeting the enzymatic activity of the CBM signalosome itself 
MALT1, recently discovered to be a protease, is the only component of the CBM complex 
that is known to possess intrinsic enzymatic activity, and inhibition of MALT1 proteolytic 
activity may indeed represent a promising new therapeutic target for the treatment of 
atherosclerosis. As described in section 5.1, three proteolytic substrates for MALT1 have 
been identified so far: the MALT1 binding partner Bcl10, and the NF-B-inhibiting 
deubiquitinases A20 and CYLD (Coornaert et al., 2008; Rebeaud et al., 2008; Staal et al., 
2011). In T-cells, MALT1-dependent cleavage of Bcl10 is induced by TCR stimulation and 
may play a role in integrin-mediated T-cell adhesion (Rebeaud et al., 2008). Whether 
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GPCR stimulation can induce MALT1-dependent cleavage of Bcl10 has not yet been 
investigated, and how Bcl10 cleavage might impact endothelial or VSMC function is 
totally unknown. TCR stimulation also induces the cleavage of A20 by MALT1, and this 
results in loss of A20's ability to inhibit TCR-dependent NF-B activation. It is speculated 
that A20 cleavage, which separates the N-terminal deubiquitination domain from the C-
terminal substrate interaction domain, prevents the removal of activating K63-linked 
polyubiquitin from A20's substrates, which include TRAFs 2 and 6, Bcl10, IKK and 
MALT1 itself, and that preserving these activating ubiquitination events promotes NF-B 
activity. In this way, MALT1-dependent A20 cleavage can amplify the degree of NF-B 
dependent gene expression (Coornaert et al., 2008). Whether GPCRs within the 
vasculature such as AGTR1, PAR-1, CXCR2 or LPA receptors induce MALT1-dependent 
A20 cleavage is not known. Intriguingly, A20 appears to have a protective effect against 
atherosclerosis in both mice and humans. In ApoE-/- mice, A20 haploinsufficiency results 
in a significant increase in atherosclerosis compared to normal A20 controls, whereas 
transgenic overexpression of A20 results in decreased atherosclerosis (Wolfrum et al., 
2007). Moreover, in human diabetic patients, polymorphisms at the A20 locus leading to 
reduced levels of A20 expression are associated with increased coronary artery disease 
(Boonyasrisawat et al., 2007). Whether inhibition of MALT1-mediated cleavage of A20 
might impact GPCR-driven atherogenesis remains to be investigated, but based on these 
studies, one might predict that preventing A20 cleavage could be protective. Initial 
studies suggest that MALT1-induced cleavage of CYLD is required for TCR-induced JNK 
activation (Staal et al., 2011), but MALT1-dependent CYLD cleavage has not been studied 
in the vasculature. Interestingly, CYLD overexpression attenuates neointimal formation in 
a rat model of carotid artery injury (Takami et al., 2008). How these studies of CYLD 
relate to GPCR/CBM-mediated atherogenesis remain to be investigated. Clearly much 
remains to be learned about the role of MALT1 proteolytic activity and its biologic affects. 
Future studies will hopefully elucidate whether MALT1 proteolytic activity contributes to 
vascular pathobiology and whether inhibiting this activity represents a rational 
therapeutic approach to atherogenesis. 
8. Conclusion 
There is a pressing need to understand the molecular mechanisms underlying 
cardiovascular disease, as it is the leading cause of disease-related deaths worldwide. 
Atherosclerosis is a chronic inflammatory disease of the vasculature in which the pro-
inflammatory transcription factor, NF-B, is a chief driving force. NF-B-dependent plaque 
formation is mediated via the expression of cytokines, chemokines, and adhesion molecules, 
and via changes in endothelial biology including a reduction in NO production. While many 
inducers of NF-B have been identified that act on endothelial cells, selective GPCR ligands 
clearly represent major players in the process of atherogenesis. Up until recently, little was 
known about the precise molecular mechanisms through which GPCRs communicate NF-B 
activation in endothelial cells. However, dramatic progress has now been made in 
understanding this process, and we have outlined much of this work here in this chapter. It 
is hoped that delineating the molecules mediating GPCR-dependent NF-B activation will 
provide new avenues for pharmaceutical development, adding a new layer of therapeutic 
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activation in endothelial cells. However, dramatic progress has now been made in 
understanding this process, and we have outlined much of this work here in this chapter. It 
is hoped that delineating the molecules mediating GPCR-dependent NF-B activation will 
provide new avenues for pharmaceutical development, adding a new layer of therapeutic 
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1. Introduction 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. Recently, collagen peptides have 
been used as foods that take advantage of their tertiary functions. We have been focusing on 
the vasoprotective effect of collagen peptides. 
Chicken collagen hydrolysate (CCH) is obtained by treating chicken feet with enzymes to 
produce an angiotensin-converting enzyme (ACE) inhibitory peptide. Administration of this 
CCH for 12 weeks reduces blood pressure in humans. We therefore investigated the 
mechanism of the vasoprotective effect of CCH. We tested whether prolonged CCH 
treatment of rats or mice would restore endothelial cell function and improve 
proinflammatory cytokine levels. We found that CCH treatment improved the 
vasorelaxation of rat aorta damaged with L-NG-nitroarginine methyl ester , an NO synthesis 
inhibitor. CCH treatment also reduced the serum levels of IL-6, sICAM-1, and TNF-α in an 
atherosclerotic mouse model, C57BL/6.KOR-ApoEsh1.  
These findings indicate the usefulness of collagen peptides as foods promoting anti-
atherogenesis via a vasoprotective effect. 
Years have passed since functional foods and their tertiary function first attracted attention. The 
primary function of foods is to supply the nutrients required to sustain life, and the secondary 
function is to satisfy taste preferences. The tertiary function of foods is to exert biological 
regulatory effects, such as biophylaxis, homeostatic maintenance, and disease prevention, 
which are activated upon food intake. Purified food ingredients that have tertiary functions are 
widely consumed as supplements. Multitudes of supplements are available on today’s market: 
besides common vitamins, minerals, and amino acids, there are catechins, which are antioxidant 
constituents of tea (Katiyar, 2003), soy isoflavones, which have female hormone–like actions 
(Weijer, 2002), and docosahexaenoic acids and eicosapentaenoic acids, which decrease 
triglyceride levels (Tamai, 2004). Collagen is being used widely, not only in supplements but 
also as an ingredient of common food products such as beverages, yogurts, and breads. 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. It forms an extracellular matrix 
that plays a role in the formation of connective tissues and acts as a scaffold for cells, but its 
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1. Introduction 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. Recently, collagen peptides have 
been used as foods that take advantage of their tertiary functions. We have been focusing on 
the vasoprotective effect of collagen peptides. 
Chicken collagen hydrolysate (CCH) is obtained by treating chicken feet with enzymes to 
produce an angiotensin-converting enzyme (ACE) inhibitory peptide. Administration of this 
CCH for 12 weeks reduces blood pressure in humans. We therefore investigated the 
mechanism of the vasoprotective effect of CCH. We tested whether prolonged CCH 
treatment of rats or mice would restore endothelial cell function and improve 
proinflammatory cytokine levels. We found that CCH treatment improved the 
vasorelaxation of rat aorta damaged with L-NG-nitroarginine methyl ester , an NO synthesis 
inhibitor. CCH treatment also reduced the serum levels of IL-6, sICAM-1, and TNF-α in an 
atherosclerotic mouse model, C57BL/6.KOR-ApoEsh1.  
These findings indicate the usefulness of collagen peptides as foods promoting anti-
atherogenesis via a vasoprotective effect. 
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function is to satisfy taste preferences. The tertiary function of foods is to exert biological 
regulatory effects, such as biophylaxis, homeostatic maintenance, and disease prevention, 
which are activated upon food intake. Purified food ingredients that have tertiary functions are 
widely consumed as supplements. Multitudes of supplements are available on today’s market: 
besides common vitamins, minerals, and amino acids, there are catechins, which are antioxidant 
constituents of tea (Katiyar, 2003), soy isoflavones, which have female hormone–like actions 
(Weijer, 2002), and docosahexaenoic acids and eicosapentaenoic acids, which decrease 
triglyceride levels (Tamai, 2004). Collagen is being used widely, not only in supplements but 
also as an ingredient of common food products such as beverages, yogurts, and breads. 
Collagen is a major protein in living organisms and accounts for about one-third of all 
protein in mammalian bodies, including the human body. It forms an extracellular matrix 
that plays a role in the formation of connective tissues and acts as a scaffold for cells, but its 





helix structure; with heating, this structure is lost and the collagen becomes gelatin like. 
Moreover, as a result of enzymatic degradation that eliminates its gelation ability, the 
gelatin increases in solubility and becomes collagen peptides (Fig. 1), which are frequently 
consumed by women, in particular. Collagen peptides are consumed as a food product to 
supply the collagen lost from the body with age, and a substantial number of reports have 
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Fig. 1. Collagen in the body exhibits a triple helix structure but is denatured and becomes 
gelatin-like if heated. Enzyme treatment of denatured collagen produces collagen peptides, 
which are composed of atypical repetitions of -Gly-X-Y-Gly-X-Y- and are consumed as 
functional foods.  
1.1 The tertiary function of collagen peptides 
In recent years, vigorous research has been conducted to elucidate both the mechanism by 
which collagen peptides are absorbed from food into the body and the tertiary functions of 
this protein. Orally administered collagen peptides are transferred to the blood in the form 
of dipeptides or tripeptides, without being completely degraded to amino acids (Iwai, 2009 
and Shigemura,2009). A double-blind placebo-controlled trial has confirmed that collagen 
peptide treatment increases the skin’s moisture content (Ohara, 2009). The primary structure 
of collagen consists of atypical repetitions of -Gly-X-Y- and characteristically includes 
hydroxyproline, which is produced by posttranslational modification. Many studies have 
suggested that this particular sequence enables collagen to exert multiple bioactivities, not 
only in skin and bones, but also in blood vessels, which contain large amounts of collagen 
(Arborelius, 1999). Accordingly, collagen peptides are expected to have tertiary functions 
additional to those already known. 
1.2 Targeting blood vessels 
The blood vessels are referred to as the largest organ in the body, because the vascular 
endothelial cells, which line the vessel lumens, cover an area as large as six tennis courts and 
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weigh 1.5 kg; they are therefore as heavy as the liver. Although blood vessels were once seen 
as simply the “pipes” that circulate blood, it has become increasingly clear that the vascular 
endothelial cells receive signals from organs and control blood supply and the secretion of 
various cytokines on demand (Kato, 2004). 
There are many diseases caused by vascular abnormalities, especially in Japan. According to 
the cause-specific death rates reported by the Ministry of Health, Labor, and Welfare of 
Japan in 2006, death rates due to circulatory system diseases are extremely high: after 
malignant neoplasms (30.4%), cardiovascular diseases account for 15.9% of all deaths and 
cerebrovascular diseases account for 11.8%. From this perspective, protecting the blood 
vessels from disease should increase the quality of life of many people. We therefore took 
advantage of the absorbability of collagen peptides and aimed to develop ones targeting the 
protection of blood vessels. 
1.3 Development of a low-molecular-weight chicken collagen hydrolysate 
Collagen peptides are generally extracted from pig skin or fish scales. However, here we 
used chicken legs as sources of the new collagen peptides. This was because, although 
gelatin is known to be allergenic, our previous study showed that the allergenicity of 
chicken-derived gelatin is the lowest among a number of types (Taguchi, 2002). 
Chicken legs were solubilized by acid treatment and the extracted collagen was processed 
by proteases. The resulting low-molecular-weight collagen peptides were then dried and 
powdered for subsequent use as low-molecular-weight chicken collagen hydrolysate (CCH) 
(Saiga, 2008) (Fig. 2). Our preliminary in vitro experiments showed that CCH strongly 
inhibits angiotensin-converting enzyme (ACE). Production of angiotensin II, a vasopressor, 
is suppressed by the inhibition of ACE in the blood and organs, thereby resulting in a 
hypotensive effect (Gupta, 2010). Because hypertension is closely related to arteriosclerosis, 
the inhibition of blood pressure elevation is expected to have a protective effect on the blood 
vessels. In addition, ACE serves as a kininase II (Sharma, 2009). Because kininase II 
degrades bradykinin, a vasodilator, inhibition of ACE (or kininase II) by CCH causes 
bradykinin accumulation in the body. Bradykinin activates endothelial nitric oxide synthase 
(eNOS) and increases the production of nitric oxide (NO), a vasodilator. In this manner, 
CCH was expected to have a vasoprotective function—a novel tertiary function of foods— 
through its ACE inhibitory activity. 
2. Hypotensive effects of chicken collagen hydrolysate in subjects with 
hypertension 
Arteriosclerosis and hypertension are closely associated with each other. If strong 
pressure is applied continuously to an artery because of hypertension, the arterial walls 
are damaged and blood cholesterols infiltrate the walls through the damaged areas and 
cause arteriosclerosis. In addition, advanced arteriosclerosis narrows the blood vessels 
and causes blood flow to deteriorate. The heartbeat is then enhanced to improve blood 
flow, and this causes the blood pressure to increase. In this manner, hypertension 
accelerates arteriosclerosis and produces a vicious cycle. If we could alleviate 
hypertension, we would thus also be able to ameliorate arteriosclerosis. We therefore 
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Fig. 2. Process of production of chicken collagen hydrolysate (CCH). Chicken legs are used 
as the basic ingredient and are treated with acid and then hot water to extract collagen, 
which was then processed with proteases. The resulting low-molecular-weight collagen 
peptides are then dried and powered for subsequent use as CCH.  
2.1 Subjects 
Subjects for the test were 120 healthy, antihypertensive drug–free, adult males and females 
with mild hypertension or high-normal blood pressure. The subjects (males, 59; females, 61) 
were randomly assigned to two groups. No significant differences in subject characteristics, 
including sex, age, height, body weight, body mass index, systolic blood pressure, diastolic 
blood pressure, and pulse rate, were observed between the two groups (P > 0.2). 
The study was approved by the institutional review board and was performed under the 
close supervision of the study investigators. The subjects were well informed about the 
test contents and methods by the study investigators, and they provided written 
informed consent to protect their rights in accordance with the spirit of the Declaration 
of Helsinki. 
2.2 Experimental diets 
A drink containing CCH (hereafter, referred to as the test food) or its counterpart without 
CCH (hereafter, referred to as the placebo) was used in the experiment. The test food 
contained 2.9 g of CCH; for the placebo, the raw material composition was the same as that 
of the test food, but without the CCH. 
2.3 Trial design 
The trial was designed as a placebo-controlled, double-blind, parallel-group comparison 
study. The study ran for a total of 18 weeks: 2 observational weeks before the treatment 
(pre-treatment observation period), a 12-week treatment period, and 4 weeks for post-
treatment observation (post-treatment observation period). All subjects were given a bottle 
of drink daily during the treatment period. All subjects were directed not to change their 
daily diets and exercise regimens (Fig.3). They were advised strongly not to overeat, over-
drink, or over-exercise. 
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Fig. 3. Clinical trial schedule for CCH administration. The 120 subjects were assigned to two 
groups and given the experimental or placebo diet for 12 weeks. Blood pressure was 
measured a total of 11 times in the course of the experiment: twice in the pre-treatment 
observation period, 7 times in the treatment period, and twice in the post-treatment 
observation period.  
2.4 Measurement of blood pressure 
Blood pressure was measured a total of 11 times in the course of the experiment: twice in the 
pre-treatment observation period, 7 times in the treatment period, and twice in the post-
treatment observation period. The subjects were kept at rest for at least 10 min before the 
measurement. Blood pressure in the left cubital fossa was measured while the subjects were 
seated. Blood pressure was measured more than once with a mercury manometer. The 
average value of 2 stable measurements (i.e. when the difference of the values was less than 
5 mmHg) was recorded as the value recorded. Pulse rate was measured once at each visit. 
The subjects’ condition was also interviewed by a doctor at the time of measurement of 
blood pressure. 
2.5 Results 
Systolic blood pressures in the test food group were non-significantly lower (P < 0.1) than 
those of the placebo group after 2 weeks of treatment and were significantly lower (P < 0.05) 
than in the placebo group after 12 weeks of treatment (Fig. 4). In the test food group, in 
comparison with the mean pre-treatment blood pressure (139.7 mm Hg), the blood pressure 
was significantly lower after 2 weeks (133.9 mm Hg; P < 0.001), 4 weeks (135.7 mm Hg; P < 
0.01), 6 weeks (134.6 mm Hg; P < 0.001), 8 weeks (134.4 mm Hg; P < 0.01), 10 weeks (134.6 
mm Hg; P < 0.001), and 12 weeks (133.5 mm Hg; P < 0.001). After 2 weeks of treatment, the 
blood pressure in the test food group was 135.5 mm Hg; this was non-significantly lower 
than the pre-treatment blood pressure (P < 0.1). In the placebo group, blood pressure after 6 
weeks of treatment (135.9 mm Hg) was significantly lower than the pre-treatment blood 
pressure (139.8 mm Hg) (P < 0.05). 
2.6 Discussion 
Blood pressures in the test food group decreased continuously during the treatment period. 
Because the compositional difference between the test food and placebo in this experiment 
was only the presence or the absence of CCH, the observed antihypertensive effect was 
considered to be due to CCH treatment. We had previously confirmed that CCH exhibits 
ACE inhibitory activity and antihypertensive effects in rats (Saiga, 2008). The results of this 
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medical examination some subjects reported a dry cough. Dry cough is typically observed 
with ACE inhibitor administration and is attributed to bradykinin accumulation in the body. 
This raises the possibility that the CCH inhibited kininase II and thus caused accumulation 
of bradykinin, a vasoprotector, which then induced NO production via the stimulation of 
eNOS. The results suggest that CCH exerts vasoprotective effects by ameliorating blood 






















Fig. 4. Time-course of changes in systolic blood pressure in the subjects. Systolic blood 
pressures in the test food group were non-significantly lower than those in the placebo 
group after 2 weeks of treatment and were significantly lower than in the placebo group 
after 12 weeks of treatment. In comparison with the pre-treatment blood pressure (mean of 
the values at −2, −1, and 0 weeks), the blood pressure in the test food group was 
consistently  and significantly lower throughout the treatment period. Data are mean ± SE 
values . + P< 0.1, # P< 0.05 versus placebo group. † P< 0.1, ＊P< 0.05, ＊＊ P< 0.01, ＊＊＊ 
P< 0.001 versus pre-treatment blood pressure.  
In our previous in vitro studies, we found that CCH treatment of human umbilical vein 
endothelial cells directly increased eNOS activation (data not shown). When eNOS 
expressed in vascular endothelial cells is activated, the cells produce NO. The NO 
functions as a signal to relax adjacent vascular smooth muscle cells; consequently, this 
dilates arteries and increases blood flow. Other than NO, vascular endothelial cells excrete 
vasoactive substances such as endothelin, a vasopressor, and maintain the balance of 
constriction and dilation of blood vessels. NO production via eNOS is particularly 
important in maintaining the homeostasis of blood vessels. Taken together, these findings 
indicate that oral administration of CCH improves blood pressure by inhibiting ACE and 
protects blood vessels by inducing NO production, thereby inhibiting the development of 
arteriosclerosis. 
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3. CCH treatment improves vascular endothelial function in rats and thus 
exerts protective effects on organs 
The clinical trial described in the preceding section suggested that CCH protects the blood 
vessels by inducing NO production. Therefore, we next directly investigated the 
vasodilatory effect of CCH ex vivo by using rat blood vessels. We administered L-NG-
nitroarginine methyl ester (L-NAME), an NO synthesis inhibitor, to rats to trigger vascular 
endothelial dysfunction. We then tested whether prolonged CCH treatment of the rats 
would restore their endothelial function (Zhang, 2010). 
3.1 Experimental animals 
Thirty-six male WKY rats (10 weeks old) were randomly allocated to three groups. The first 
group (control group) received untreated chow and drinking water. The second group (L-
NAME group) received L-NAME in their drinking water (0.5 g/L) for 8 weeks. The third 
group (L-NAME＋CCH group) received L-NAME in their drinking water and CCH (2.0 
g/kg daily) via a metal oral Zonde needle. All animal procedures were performed in 
accordance with the Animal Experimentation Guidelines of the Japanese Association for 
Laboratory Animal Science and were approved by the Animal Use and Care Committee of 
Nippon Meat Packers, Inc. 
3.2 Vasorelaxation assay 
A vasorelaxation assay was performed on the tissue of eight or nine rats from each group 
after 8 weeks of treatment. The rats were anesthetized with diethyl ether and the thoracic 
aorta was removed. The surrounding connective tissue and fat were carefully removed from 
the thoracic aorta, which was then cut into 2- to 3-mm-wide rings. Segments of thoracic 
aorta were mounted between two steel hooks in isolated tissue chambers containing Krebs-
Henseleit solution at 37 °C. The isometric tension was recorded with an isometric force-
displacement transducer. After an equilibration period, L-norepinephrine bitartrate was 
added to cause contraction. This was followed by the addition of cumulative doses of 
acetylcholine chloride to the bath solution to produce relaxation. Vascular relaxation was 
expressed as a percentage of tension development (Fig.5). 
3.3 Results 
After 8 weeks of treatment, the survival rate of the L-NAME group rats, which had received 
L-NAME in their drinking water, was 66.7% of that of the control rats. However, rats that 
had ingested CCH (L-NAME＋CCH group) had a significantly better survival rate (91.7% of 
that of the control group) than the L-NAME rats (P < 0.05) (Fig.6). During all of the 
experiments, monitoring revealed that the rats drank 17 to 30 mL of water and ate 16 to 30 g 
of chow every day, confirming that their drinking and eating patterns were unaffected by 
the treatment protocols. Body weight gains did not differ among groups (data not shown). 
We measured the vasorelaxant effects of CCH treatment after 8 weeks of treatment (Fig. 7). 
Treatment with acetylcholine chloride caused concentration-dependent relaxation of the 
thoracic aorta preparations from all groups after the preparations had been caused to 
contract by the addition of L-norepinephrine bitartrate. The acetylcholine chloride induced a 
relaxation response in the thoracic aortas from the L-NAME group (12.7% vasorelaxation); 
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Compared with that of the L-NAME group, vasorelaxation of the thoracic aortas from the L-
NAME＋CCH group (36.0%) was significantly improved by long-term administration of 
CCH (P < 0.05). 
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Fig. 5. Schematic of the Magnus apparatus. The excised rat thoracic aorta was cut into 2- to 
3-mm-wide rings and the segments were mounted between two steel hooks in isolated 
tissue chambers containing Krebs-Henseleit solution at 37C. Drops of L-norepinephrine 
bitartrate were then added to the tissue chamber to cause the aorta to contract. This was 
followed by the addition of various doses of acetylcholine chloride to trigger aortic 
relaxation. The electrical signals for this contraction–relaxation reaction were amplified via a 


















Fig. 6. Survival rates of rats during the test period. Eight weeks into the test period, the 
survival rate of the L-NAME + CCH group was significantly higher than that of the L-
NAME group. Data are mean ± SE values (n=12 rats). ＊ P< 0.05 versus L-NAME group.  
 























Fig. 7. Vasorelaxation of rat thoracic aortas over the 8 weeks of the test period . Treatment 
with acetylcholine chloride caused concentration-dependent relaxation of the thoracic aorta 
preparations from all groups.  Especially at high acetylcholine concentrations,  
vasorelaxation  was significantly higher in the L-NAME + CCH group than in the L-NAME 
group. Data are mean ± SE values (n=8-9 rats). ＊ P< 0.05 versus L-NAME group.  
3.4 Discussion 
We found that CCH treatment improved vascular endothelial function. Acetylcholine 
activates eNOS expressed in vascular endothelial cells and induces NO production, thereby 
dilating blood vessels. In L-NAME-treated rats, the vasodilation response associated with 
NO production induced by an acetylcholine stimulus was inhibited; however, CCH 
treatment improved this response. As stated earlier, our previous studies have confirmed 
that CCH activates eNOS in vascular endothelial cells in vitro; this result was again 
supported by our study. In essence, therefore, CCH treatment strongly activated eNOS, 
promoted NO production, and thus triggered a vasodilatory response. 
Moreover, the survival curves showed that the survival rate of L-NAME-treated rats was 
significantly enhanced by CCH administration. This may have been because CCH treatment 
alleviated the various organ failures caused by L-NAME-induced vascular disorders. We 
previously conducted the same experiment by using a higher concentration of L-NAME (1 
g/L) and prepared tissue sections for observation. We identified substantial tissue damage 
associated with L-NAME treatment in the blood vessels, kidney, and heart ; this damage 
was alleviated by CCH treatment (Fig. 8). The substantial fibrosis observed, especially in the 
heart and liver, was relieved by CCH treatment. Although further investigations of this 
attenuation effect of CCH treatment on tissue damage are required, we consider that it 
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Fig. 8. Tissue sections of  blood vessels (A, ×160), kidney (B, ×80) and heart (C, ×80) after 
treatment with L-NAME at a high concentration (1 g/L). Tissues were stained with Masson 
trichrome. These sections are from a similarly designed previous experiment of ours. 
Significant tissue damage caused by L-NAME was observed in the blood vessels, kidneys, 
and heart tissues, whereas CCH treatment alleviated these damages. Arrows indicate signs 
of fibrosis.  
4. CCH treatment inhibits proinflammatory cytokine expression in a mouse 
model of arteriosclerosis 
Previous studies have indicated that CCH exerts vasoprotective effects and thus organ 
protective effects. We therefore investigated the effects of CCH in an atherosclerosis mouse 
model, C57BL/6.KOR-ApoEsh1. This mouse is spontaneously hyperlipidemic and 
characteristically has high total cholesterol (TC) levels and arteriosclerotic lesions. Using this 
mouse model, we examined the changes in blood cholesterol levels and proinflammatory 
cytokine expression in response to prolonged CCH treatment (Zhang, 2010). 
4.1 Experimental animals 
Eighteen male C57BL/6.KOR-ApoEshl mice (7 weeks old) were randomly allocated to two 
groups (n = 9) and fed on a normal diet or a diet supplemented with 10% CCH for 12 weeks. 
At the end of the 12-week experiment, the mice were sacrificed, blood was obtained from 
their veins, and tissues were collected for further analysis. All animal procedures were 
performed in accordance with the Animal Experimentation Guidelines of the Japanese 
Association for Laboratory Animal Science and were approved by the Animal Use and Care 
Committee of Nippon Meat Packers, Inc. 
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4.2 Measurement of plasma and hepatic lipids 
Levels of TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-
density lipoprotein cholesterol (HDL-C) in the plasma and liver were determined. Total 
lipids extracted from the liver were also analyzed. 
In addition, plasma levels of interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 
(sICAM-1), and tumor necrosis factor-α (TNF-α) were measured by ELISA. 
4.3 Observation of tissue sections 
At the end of the 12-week test period, the thoracic aorta and liver were excised from the 
dissected rats and were fixed in formalin, paraffin-embedded, and sliced with a microtome 
to prepare thin sections, which were then stained with Oil Red O or hematoxylin-eosin for 
histological observation. 
4.4 Results 
The mice were treated with CCH for 12 weeks and then sacrificed for analysis. Compared 
with those in the controls, the amounts of plasma TC and hepatic lipid and TG in the CCH 
group were reduced by 14.4%, 24.7%, and 42.8%, respectively (Table 1). However, CCH 
administration had no obvious influence on the concentrations of TG, LDL-C, and HDL-C in 
the plasma or of TC in the liver. 
 
 
Plasma (mg/100ml) Liver (mg/g)
TC TG LDL-C HDL-C Lipid TC TG
Control 1208±93 308±72 678±68 10.2±1.5 75.3±6.6 0.31±0.11 4.9±2.4




Table 1. Effect of CCH treatment on plasma concentrations of TC, TG, LDL-C, and HDL-C 
and on hepatic total lipid, TC, and TG in C57BL/6.KOR-ApoEsh1 mice at the end of the 12-
week test period. Plasma TC, hepatic total lipid, and hepatic TG concentrations were 
significantly lower in the 10% CCH group than in the control group. Data are mean ± SE 
values (n=9 mice). ＊ P< 0.05 versus L-NAME group.  
We also investigated the effects of CCH treatment on plasma proinflammatory cytokine 
levels in C57BL/6.KOR-ApoEshl mice. Administration of CCH resulted in decreases in 
plasma levels of IL-6 (by 43.4%, P < 0.01), sICAM-1 (by 17.9%, P < 0.05), and TNF-α (by 
24.1%, P < 0.01) (Fig.9). 
To investigate whether CCH had a preventive and therapeutic effect on arteriosclerosis, 
atherosclerotic lesions in the aorta were observed by microscopy with Oil Red O staining 
(Fig.10). There were no obvious differences in the aortas of the CCH and control groups. 
We then tested whether CCH treatment had alleviated liver damage in the C57BL/6.KOR-
ApoEshl mouse model. Sections of paraffin-embedded liver were stained with 
hematoxylin-eosin or Oil Red O. Treatment with 10% CCH for 12 weeks decreased the 
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Fig. 9. Effect of CCH treatment on plasma proinflammatory cytokine levels in 
C57BL/6.KOR-ApoEsh1 mice at the end of the 12-week test period. Interleukin-6 (IL-6) (A), 
soluble intercellular adhesion molecule-1 (sICAM-1 ) (B), tumor necrosis factor alpha (TNF-
α) (C). The levels of all plasma proinflammatory cytokines were significantly lower in the 
10% CCH group than in the control group. Data are mean ± SE values (n=9 mice). ＊ P< 
0.05, ＊＊ P< 0.01 versus control group.  
 








Fig. 10. Tissue sections of aortic root (A) and liver (B and C) at the end of the 12-week test 
period. Tissues were stained with Oil Red O (A, ×80; C, ×140) or hematoxylin-eosin (B , 
×140). No obvious change was observed in the aortic root of the 10% CCH group; however, 
diffuse lipid droplets and fat vacuoles in the livers of the treatment group were less 
abundant than in those of the control group.  
 




Our results suggested that, as well as lowering plasma TC, CCH had a lipid-lowering effect 
through regulation of hepatic lipid biosynthesis to suppress TG levels. In humans, collagen-
specific peptides are absorbed into the blood as a result of CCH treatment  (Iwai, 2009). 
Once absorbed into the body, the CCH peptides function as regulatory factors to influence 
cholesterol homeostasis. This effect may have contributed to the decrease in the abundance 
of lipid droplets and fat vacuoles observed in the liver tissues. 
Because inflammation plays an important role in the development of arteriosclerosis, 
inflammatory markers were also examined to investigate the anti-inflammatory function of 
dietary intervention. IL-6, sICAM-1, and TNF-α are the major proinflammatory cytokines 
secreted by adipocytes. At the same time, NO inhibits the expression of these 
proinflammatory cytokines in the vascular endothelium. Our previous studies indicate that 
orally ingested CCH induces NO production in the body. Hence, the results imply that CCH 
treatment downregulates several proinflammatory cytokines via NO production, thereby 
having beneficial effects on the fat tissues. Further detailed investigations are, however, 
necessary to elucidate more of the direct effects of CCH on fat cells. 
Unfortunately, no direct therapeutic effect of CCH on arteriosclerotic plaques was 
observed in this study. Nevertheless, the data demonstrated that CCH treatment 
substantially reduced both the total lipid content in the liver and the production of 
proinflammatory cytokines such as IL-6, TNF-α, and sICAM-1 in a mouse model highly 
susceptible to arteriosclerosis. High levels of expression of these factors lead to the 
progression of arteriosclerosis. From this perspective, long-term CCH treatment may  
be effective as a simple dietary, rather than drug, treatment for preventing 
arteriosclerosis. 
5. Conclusion: The availability of collagen peptides as a food providing anti-
atherogenesis via a vasoprotective effect 
It has been frequently reported that externally applied collagen peptides help to  increase 
water retention owing to their high water retentivity. On the other hand, the functionality of 
orally ingested collagen is not fully understood. However, much of the evidence reported in 
recent years, including the results of this study, supports the specific physiological activities 
of collagen absorbed by the body. 
In this study, we examined the impacts of collagen peptides on blood vessels from various 
perspectives. We demonstrated that collagen peptides exhibit vasoprotective functions via 
NO production and effectively protect against atherogenesis. 
Functional foods will not replace pharmaceuticals. However, what humans continue to do 
regularly for survival is to eat. Whereas a balanced diet obviously supports healthy life, 
elucidation of the tertiary function of food ingredients by precisely following their 
mechanisms is a long-term mission for food researchers. We focused on collagen and 
analyzed the whole process from development of, to research into, novel chicken-derived 
collagen peptides. We clarified the efficacy of vasoprotection, which is a novel tertiary 
function of collagen peptides. We intend to continue our efforts to demonstrate the 
beneficial functionalities of collagen in the hope of improving the global quality of life 
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α) (C). The levels of all plasma proinflammatory cytokines were significantly lower in the 
10% CCH group than in the control group. Data are mean ± SE values (n=9 mice). ＊ P< 
0.05, ＊＊ P< 0.01 versus control group.  
 








Fig. 10. Tissue sections of aortic root (A) and liver (B and C) at the end of the 12-week test 
period. Tissues were stained with Oil Red O (A, ×80; C, ×140) or hematoxylin-eosin (B , 
×140). No obvious change was observed in the aortic root of the 10% CCH group; however, 
diffuse lipid droplets and fat vacuoles in the livers of the treatment group were less 
abundant than in those of the control group.  
 




Our results suggested that, as well as lowering plasma TC, CCH had a lipid-lowering effect 
through regulation of hepatic lipid biosynthesis to suppress TG levels. In humans, collagen-
specific peptides are absorbed into the blood as a result of CCH treatment  (Iwai, 2009). 
Once absorbed into the body, the CCH peptides function as regulatory factors to influence 
cholesterol homeostasis. This effect may have contributed to the decrease in the abundance 
of lipid droplets and fat vacuoles observed in the liver tissues. 
Because inflammation plays an important role in the development of arteriosclerosis, 
inflammatory markers were also examined to investigate the anti-inflammatory function of 
dietary intervention. IL-6, sICAM-1, and TNF-α are the major proinflammatory cytokines 
secreted by adipocytes. At the same time, NO inhibits the expression of these 
proinflammatory cytokines in the vascular endothelium. Our previous studies indicate that 
orally ingested CCH induces NO production in the body. Hence, the results imply that CCH 
treatment downregulates several proinflammatory cytokines via NO production, thereby 
having beneficial effects on the fat tissues. Further detailed investigations are, however, 
necessary to elucidate more of the direct effects of CCH on fat cells. 
Unfortunately, no direct therapeutic effect of CCH on arteriosclerotic plaques was 
observed in this study. Nevertheless, the data demonstrated that CCH treatment 
substantially reduced both the total lipid content in the liver and the production of 
proinflammatory cytokines such as IL-6, TNF-α, and sICAM-1 in a mouse model highly 
susceptible to arteriosclerosis. High levels of expression of these factors lead to the 
progression of arteriosclerosis. From this perspective, long-term CCH treatment may  
be effective as a simple dietary, rather than drug, treatment for preventing 
arteriosclerosis. 
5. Conclusion: The availability of collagen peptides as a food providing anti-
atherogenesis via a vasoprotective effect 
It has been frequently reported that externally applied collagen peptides help to  increase 
water retention owing to their high water retentivity. On the other hand, the functionality of 
orally ingested collagen is not fully understood. However, much of the evidence reported in 
recent years, including the results of this study, supports the specific physiological activities 
of collagen absorbed by the body. 
In this study, we examined the impacts of collagen peptides on blood vessels from various 
perspectives. We demonstrated that collagen peptides exhibit vasoprotective functions via 
NO production and effectively protect against atherogenesis. 
Functional foods will not replace pharmaceuticals. However, what humans continue to do 
regularly for survival is to eat. Whereas a balanced diet obviously supports healthy life, 
elucidation of the tertiary function of food ingredients by precisely following their 
mechanisms is a long-term mission for food researchers. We focused on collagen and 
analyzed the whole process from development of, to research into, novel chicken-derived 
collagen peptides. We clarified the efficacy of vasoprotection, which is a novel tertiary 
function of collagen peptides. We intend to continue our efforts to demonstrate the 
beneficial functionalities of collagen in the hope of improving the global quality of life 






Katiyar SK. 2003. Skin photoprotection by green tea: antioxidant and immunomodulatory 
effects. Curr Drug Targets Immune Endocr Metabol Disord 3(3):234-42.  
Weijer P, Barentsen R. 2002. Isoflavones from red clover (Promensil) significantly reduce 
menopausal hot flush symptoms compared with placebo. Maturitas 25;42(3):187-93. 
Tamai T, Ikematsu H, Shionoya K, Murota I, Baba T, Hiura N, Sato R. 2004. Effect of fish 
sausage enriched with DHA (docosahexaenoic acid) on serum lpids (II): effect of 
three month-long intake on serum lipids, and safety evaluation. J Jpn Soc Clin Nutr 
25(4):293-302. 
Iwai K, Zhang Y, Kouguchi T, Saiga Egusa A, Shimizu M, Ohmori T, Takahata Y, Morimatsu 
F. 2009. Blood concentration of food-derived peptides following oral intake of 
chicken collagen hydrolysate and its angiotensin-converting enzyme inhibitory 
activity in healthy volunteers. Nippon Shokuhin Kagaku Kogaku Kaishi 56(6):326–
30. 
Shigemura Y, Iwai K, Morimatsu F, Iwamoto T, Mori T, Oda C, Taira T, Park E, Nakamura 
Y, Sato K. 2009. Effect of Prolyl-hydroxyproline (Pro-Hyp), a food-derived collagen 
peptide in human blood, on growth of fibroblasts from mouse skin. J Agric Food 
Chem 57(2):444–9. 
Ohara H, Ito K, Iida H, Matsumoto H. 2009. Improvement in the moisture content of the 
stratum corneum following 4 weeks of collagen hydrolysate ingestion. Nippon 
Shokuhin Kagaku Kogaku Kaishi 56:137–45.  
Arborelius M, Konttinen Y, Nordström D, Solovieva S. 1999. Gly-X-Y repeat sequences in 
the treatment of active rheumatoid arthritis. Rheumatol Int 18(4):129-35. 
Kato T, Node K. 2004. Frontier of vascular failure. Node K. (Eds.). Concept of vasucular 
failure. 21-2. Tokyo. Medical review. 
Taguchi Y. 2002. Development of a low allergic chicken gelatin. Packaging of foodstuff. 
33(2): 35-40. 
Saiga A, Iwai K, Hayakawa T, Takahata Y, Kitamura S, Nishimura T, Morimatsu F. 2008. 
Angiotensin I-converting enzyme inhibitory peptides obtained from chicken 
collagen hydrolysate. J Agric Food Chem 56:9586–91. 
Gupta R, Guptha S. 2010. Strategies for initial management of hypertension. Indian J Med 
Res. 132(5):531-42. 
Sharma JN. 2009. Hypertension and the bradykinin system. Curr Hypertens Rep 11(3):178-
81. 
Kouguchi T, Ohmori T, Hayakawa T, Takahata Y, Maeyama Y, Kajimoto Y, Kitakaze M, 
Morimatsu F. 2008. Hypotensive effects and safety of intake of lactic acid beverage 
containing chicken collagen hydrolysate in subjects with mild hypertension or 
high-normal blood pressure. Jpn Pharmacol Ther 36(6):561–75. 
Zhang Y, Kouguchi T, Shimizu M, Ohmori T, Takahata Y, Morimatsu F. 2010. Chiken 
collagen hydrolysate protects rats from hypertension and cardiovascular damage. J 
Med Food 13(2):399-405. 
Zhang Y, Kouguchi T, Shimizu K, Sato M, Takahata Y, Morimatsu F. 2010. Chicken collagen 
hydrolysate reduces proinflammatory cytokine production in C57BL/6.KOR-






Katiyar SK. 2003. Skin photoprotection by green tea: antioxidant and immunomodulatory 
effects. Curr Drug Targets Immune Endocr Metabol Disord 3(3):234-42.  
Weijer P, Barentsen R. 2002. Isoflavones from red clover (Promensil) significantly reduce 
menopausal hot flush symptoms compared with placebo. Maturitas 25;42(3):187-93. 
Tamai T, Ikematsu H, Shionoya K, Murota I, Baba T, Hiura N, Sato R. 2004. Effect of fish 
sausage enriched with DHA (docosahexaenoic acid) on serum lpids (II): effect of 
three month-long intake on serum lipids, and safety evaluation. J Jpn Soc Clin Nutr 
25(4):293-302. 
Iwai K, Zhang Y, Kouguchi T, Saiga Egusa A, Shimizu M, Ohmori T, Takahata Y, Morimatsu 
F. 2009. Blood concentration of food-derived peptides following oral intake of 
chicken collagen hydrolysate and its angiotensin-converting enzyme inhibitory 
activity in healthy volunteers. Nippon Shokuhin Kagaku Kogaku Kaishi 56(6):326–
30. 
Shigemura Y, Iwai K, Morimatsu F, Iwamoto T, Mori T, Oda C, Taira T, Park E, Nakamura 
Y, Sato K. 2009. Effect of Prolyl-hydroxyproline (Pro-Hyp), a food-derived collagen 
peptide in human blood, on growth of fibroblasts from mouse skin. J Agric Food 
Chem 57(2):444–9. 
Ohara H, Ito K, Iida H, Matsumoto H. 2009. Improvement in the moisture content of the 
stratum corneum following 4 weeks of collagen hydrolysate ingestion. Nippon 
Shokuhin Kagaku Kogaku Kaishi 56:137–45.  
Arborelius M, Konttinen Y, Nordström D, Solovieva S. 1999. Gly-X-Y repeat sequences in 
the treatment of active rheumatoid arthritis. Rheumatol Int 18(4):129-35. 
Kato T, Node K. 2004. Frontier of vascular failure. Node K. (Eds.). Concept of vasucular 
failure. 21-2. Tokyo. Medical review. 
Taguchi Y. 2002. Development of a low allergic chicken gelatin. Packaging of foodstuff. 
33(2): 35-40. 
Saiga A, Iwai K, Hayakawa T, Takahata Y, Kitamura S, Nishimura T, Morimatsu F. 2008. 
Angiotensin I-converting enzyme inhibitory peptides obtained from chicken 
collagen hydrolysate. J Agric Food Chem 56:9586–91. 
Gupta R, Guptha S. 2010. Strategies for initial management of hypertension. Indian J Med 
Res. 132(5):531-42. 
Sharma JN. 2009. Hypertension and the bradykinin system. Curr Hypertens Rep 11(3):178-
81. 
Kouguchi T, Ohmori T, Hayakawa T, Takahata Y, Maeyama Y, Kajimoto Y, Kitakaze M, 
Morimatsu F. 2008. Hypotensive effects and safety of intake of lactic acid beverage 
containing chicken collagen hydrolysate in subjects with mild hypertension or 
high-normal blood pressure. Jpn Pharmacol Ther 36(6):561–75. 
Zhang Y, Kouguchi T, Shimizu M, Ohmori T, Takahata Y, Morimatsu F. 2010. Chiken 
collagen hydrolysate protects rats from hypertension and cardiovascular damage. J 
Med Food 13(2):399-405. 
Zhang Y, Kouguchi T, Shimizu K, Sato M, Takahata Y, Morimatsu F. 2010. Chicken collagen 
hydrolysate reduces proinflammatory cytokine production in C57BL/6.KOR-
ApoEshl mice. J Nutr Sci Vitaminol 56(3):208-10. 
Atherogenesis
Edited by Sampath Parthasarathy
Edited by Sampath Parthasarathy
This monograph will bring out the state-of-the-art advances in the dynamics of 
cholesterol transport and will address several important issues that pertain to 
oxidative stress and inflammation. The book is divided into three major sections. 
The book will offer insights into the roles of specific cytokines, inflammation, and 
oxidative stress in atherosclerosis and is intended for new researchers who are curious 
about atherosclerosis as well as for established senior researchers and clinicians who 
would be interested in novel findings that may link various aspects of the disease.
Photo by Ugreen / iStock
ISBN 978-953-307-992-9
A
therogenesis
ISBN 978-953-51-6784-6
